

AACR Annual Meeting 2023: Abstract Presentations

List of scheduled abstract presentations as of April 1, 2023. Additional abstracts may be withdrawn or rescheduled before the start of the meeting.

Abstract presentation information is also available in the [online program planner](#) and the [meeting app](#).

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
1	Mouse models of cancer available from The Jackson Laboratory	Jason	Beckwith	Poster	Mouse Models of Human Cancer	4/16/23	1:30 PM	Section 1	1
2	Vertical MAPK pathway targeting in novel genetically engineered mouse and cell line models of NF1-altered melanoma: the mSK-Mel murine cohort	Alexis	Jones	Poster	Mouse Models of Human Cancer	4/16/23	1:30 PM	Section 1	2
3	In vivo CRISPR activation screening identifies tissue-specific oncogene selection	Fredrik	Thege	Poster	Mouse Models of Human Cancer	4/16/23	1:30 PM	Section 1	3
4	A novel humanized mouse model for study of T cells and NK cells in the tumor microenvironment	Jyoti	Arora	Poster	Mouse Models of Human Cancer	4/16/23	1:30 PM	Section 1	4
5	Alveolar epithelial type 1 cells can serve as a cell of origin for lung adenocarcinoma with distinct molecular and phenotypic presentation	Crystal	Marconett	Poster	Mouse Models of Human Cancer	4/16/23	1:30 PM	Section 1	5
6	Comprehensive single-cell transcriptomic analysis of a mouse model of bladder cancer identifies endothelial cells as a principal target of interferon gamma during response to combined PD-1, CTLA-4 immune checkpoint inhibitor treatment	Sharon	Freshour	Poster	Mouse Models of Human Cancer	4/16/23	1:30 PM	Section 1	6
7	AGS3 depletion promotes tumorigenesis in a murine model of lung cancer	Timothy	Adekoya	Poster	Mouse Models of Human Cancer	4/16/23	1:30 PM	Section 1	7
8	Differential flt3 mutational status in acute myeloid leukemia predicts sensitivity to flt3 inhibitor gilteritinib in vitro and in vivo	Bincy	John	Poster	Mouse Models of Human Cancer	4/16/23	1:30 PM	Section 1	8
9	Histological characterization of two genetically engineered mouse models of non-small cell lung cancer	Nicole	Leon	Poster	Mouse Models of Human Cancer	4/16/23	1:30 PM	Section 1	9
10	Orthotopic nGEM glioma growth rates in allogenic hosts associate with hypoxia and proximity to host cells	Angela	Baker	Poster	Mouse Models of Human Cancer	4/16/23	1:30 PM	Section 1	10
12	Distinct Nrf2 signaling thresholds mediate lung tumor initiation and progression	Janine	DeBlasi	Poster	Mouse Models of Human Cancer	4/16/23	1:30 PM	Section 1	12
13	A non-surgical approach to develop an orthotopic colorectal cancer mouse model	Samantha	Sharma	Poster	Mouse Models of Human Cancer	4/16/23	1:30 PM	Section 1	13
14	The impact of genetic background on cancer phenotypes of mouse models	Carol	Bult	Poster	Mouse Models of Human Cancer	4/16/23	1:30 PM	Section 1	14
15	Investigating the spectrum of brain tumors associated with Adgrb3 and Tp53 loss in a mouse model of Li-Fraumeni syndrome	Alex	Torrelli-Diljohn	Poster	Mouse Models of Human Cancer	4/16/23	1:30 PM	Section 1	15
16	The role of innate and adaptive immunity in the sex bias of LKB1-mutant lung adenocarcinoma	Yijian	Fan	Poster	Mouse Models of Human Cancer	4/16/23	1:30 PM	Section 1	16

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
17	Sex disparities in a murine model of BBN-induced bladder cancer	Gabrielle	Kennelley	Poster	Mouse Models of Human Cancer	4/16/23	1:30 PM	Section 1	17
18	Transcriptomic analysis of mucinous adenocarcinoma in genetically-engineered mouse model	Haruki	Sada	Poster	Mouse Models of Human Cancer	4/16/23	1:30 PM	Section 1	18
19	Braf(v600e) mutation together with loss of trp53 or pten drives the origination of hairy cell leukemia from b-lymphocyte	Jiancheng	Hu	Poster	Mouse Models of Human Cancer	4/16/23	1:30 PM	Section 1	19
20	In vitro and in vivo investigation of tumor treating fields for treatment of spinal metastasis	Claudio	Tatsui	Poster	Mouse Models of Human Cancer	4/16/23	1:30 PM	Section 1	20
21	A novel bladder cancer syngeneic mouse model using gene-edited organoids derived from bladder urothelium	Akihiro	Hamada	Poster	Mouse Models of Human Cancer	4/16/23	1:30 PM	Section 1	21
22	A new transgenic mouse model to explore the role of Cripto signaling in lethal prostate cancer	Elisa	Rodrigues Sousa	Poster	Mouse Models of Human Cancer	4/16/23	1:30 PM	Section 1	22
23	Development of a biallelicDicer1mutant mouse strain for studying the pathogenesis of DICER1 syndrome-associated cancer	Yemin	Wang	Poster	Mouse Models of Human Cancer	4/16/23	1:30 PM	Section 1	23
24	Oncogenic KrasG12D and Cdkn2a/p16 knockout in LGR5 expressing progenitor cells synergize to advance adenoma and adenocarcinoma phenotypes in murine small intestine	Tyler	Seckar	Poster	Mouse Models of Human Cancer	4/16/23	1:30 PM	Section 1	24
25	MIF and NR3C2 interactively regulate glucose metabolism in pancreatic cancer	Shouhui	Yang	Poster	Mouse Models of Human Cancer	4/16/23	1:30 PM	Section 1	25
26	BaF3 RAS cell panel, a powerful cell model for Ras inhibitor discovery and development	Feng	Hao	Poster	Mouse Models of Human Cancer	4/16/23	1:30 PM	Section 1	26
27	Characterizing 3q26 copy number gain in lung squamous cell carcinoma through a novel genetically engineered mouse model	Kayleah	Meneses	Poster	Mouse Models of Human Cancer	4/16/23	1:30 PM	Section 1	27
28	In vivoscreening platform based on BaF3 kinase engineered cell lines for discovery of next-generation kinase inhibitors	Feng	Hao	Poster	Mouse Models of Human Cancer	4/16/23	1:30 PM	Section 1	28
29	Characterization of a murine intestinal cancer homograft model for therapeutic evaluation	Jinxi	Wang	Poster	Mouse Models of Human Cancer	4/16/23	1:30 PM	Section 1	29
33	Humanized MOLM-13 AML model as a versatile tool to study immune-activating agents	Holger	Weber	Poster	Novel Models of Human Cancer	4/16/23	1:30 PM	Section 2	1
34	A clinically-relevant orthotopic endometrial carcinosarcoma mouse model using human patient-derived organoids	Arielle	Katcher	Poster	Novel Models of Human Cancer	4/16/23	1:30 PM	Section 2	2
35	Development of novel human hepatocellular carcinoma models using genetically modified human hepatocytes in FSRG humanized liver mice	Marisa	Carbonaro	Poster	Novel Models of Human Cancer	4/16/23	1:30 PM	Section 2	3
36	Comparing twenty-two matched patient-derived cell lines developed from either patient, PDX, or organoid tumor cell material	Cindy	Timme	Poster	Novel Models of Human Cancer	4/16/23	1:30 PM	Section 2	4

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
37	A novel technique to preclinically assess the ability of targeted therapies to inhibit both primary and metastatic non small cell lung carcinoma	Erin	Trachet	Poster	Novel Models of Human Cancer	4/16/23	1:30 PM	Section 2	5
38	PBMC donor selection affects engraftment rates and onset of graft versus host disease in humanized NCG mice for use in cancer studies	Steven	Bronson	Poster	Novel Models of Human Cancer	4/16/23	1:30 PM	Section 2	6
39	Assessment of a novel method using adult healthy donor mobilized human CD34+hematopoietic stem cells in NCG mice for use in tumor modeling	Steven	Bronson	Poster	Novel Models of Human Cancer	4/16/23	1:30 PM	Section 2	7
40	NCI patient derived models repository: PDX, organoid and cell lines from the same patient - bridging the translational pipeline	Yvonne	Evrard	Poster	Novel Models of Human Cancer	4/16/23	1:30 PM	Section 2	8
41	Subcutaneous growth and immune cell profiling of BT-474 human breast carcinoma in four strains of triple immunodeficient mice	Justin	Snider	Poster	Novel Models of Human Cancer	4/16/23	1:30 PM	Section 2	9
42	In vivo subcutaneous and orthotopic cancer xenograft modeling in the SRG immunodeficient rat	R. Grace	Walton	Poster	Novel Models of Human Cancer	4/16/23	1:30 PM	Section 2	10
43	Application of MiniPDX® in clinical indication identification and anti-tumor drug development	Danyi	Wen	Poster	Novel Models of Human Cancer	4/16/23	1:30 PM	Section 2	11
44	An in vivo platform of pre-characterized renal cell carcinoma (RCC) patient-derived xenograft models allows the preclinical evaluation of patient-tailored intervention strategies	Dennis	Kobelt	Poster	Novel Models of Human Cancer	4/16/23	1:30 PM	Section 2	12
45	Elephant p53 protects mice from carcinogen induced death	Lisa	Abegglen	Poster	Novel Models of Human Cancer	4/16/23	1:30 PM	Section 2	13
46	High-plex spatial transcriptomic characterization of canine tumor tissue	Sarah	Church	Poster	Novel Models of Human Cancer	4/16/23	1:30 PM	Section 2	14
47	A cell culture model of resistant cells in solid cancers that opportunistically switch between proliferation and quiescence	Balraj	Singh	Poster	Novel Models of Human Cancer	4/16/23	1:30 PM	Section 2	15
48	Increasing the racial diversity of lung adenocarcinoma cell lines	Christopher	Leon	Poster	Novel Models of Human Cancer	4/16/23	1:30 PM	Section 2	16
49	Comparison of subcutaneous and orthotopic tumor growth in syngeneic mouse models of ovarian and renal cancer	Mari	Suominen	Poster	Novel Models of Human Cancer	4/16/23	1:30 PM	Section 2	17
50	Tumorigenic properties of uveal melanoma cancer cells cultured in 3D or on a reconstructed extracellular matrix	Olivier	Chancy	Poster	Novel Models of Human Cancer	4/16/23	1:30 PM	Section 2	18
51	The SRG immunodeficient rat demonstrates utility across multiple tumor types of different organ origins	Koh Meng	Aw Yong	Poster	Novel Models of Human Cancer	4/16/23	1:30 PM	Section 2	19
52	Characterization of murine intrahepatic cholangiocarcinoma homograft models for therapeutic evaluation	Jinxi	Wang	Poster	Novel Models of Human Cancer	4/16/23	1:30 PM	Section 2	20
53	Zebrafish tp53 mutants recapitulate Li-Fraumeni syndrome phenotypes and provide a preclinical platform for evaluating tumor preventive compounds	Kim	Kobar	Poster	Novel Models of Human Cancer	4/16/23	1:30 PM	Section 2	21

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
54	Regulation of luminal epithelial cell identity in the pre-tumorigenic mammary gland	Jerrica	Breindel	Poster	Novel Models of Human Cancer	4/16/23	1:30 PM	Section 2	22
55	High frequency of TP53 mutations in canine skin tumors recapitulates solar induced human lesions representing an important research model of spontaneous diseases	Lucas	Rodrigues	Poster	Novel Models of Human Cancer	4/16/23	1:30 PM	Section 2	23
56	Unlocking primary cell culture for more relevant in vitro models	Benjamin	Theek	Poster	Novel Models of Human Cancer	4/16/23	1:30 PM	Section 2	24
60	An emerging paradigm of Cxcl12 & Cxcr4 involvement in breast cancer metastasis	Dimitra	Anastasiadou	Poster	Tumor Dormancy and Metastasis	4/16/23	1:30 PM	Section 3	1
61	PRDM16 is key for promoting bone metastatic prostate cancer cell survival during entry into dormancy	Mostafa	Nasr	Poster	Tumor Dormancy and Metastasis	4/16/23	1:30 PM	Section 3	2
62	Untangling the connection between stress and metastatic breast cancer	Xue-Yan	He	Poster	Tumor Dormancy and Metastasis	4/16/23	1:30 PM	Section 3	3
63	Machine learning identifies experimental brain metastasis subtypes based on their influence on neural circuits	Mariam	Masmudi-Martín	Poster	Tumor Dormancy and Metastasis	4/16/23	1:30 PM	Section 3	4
64	Tumor-tumor cooperation during osteosarcoma lung metastasis is driven by interactions between lung epithelia and niche-initiating anchor cells	Ryan	Roberts	Poster	Tumor Dormancy and Metastasis	4/16/23	1:30 PM	Section 3	5
65	HIRA is a master regulator of the proliferation-to-dormancy switch in breast cancer	Stanislav	Drapela	Poster	Tumor Dormancy and Metastasis	4/16/23	1:30 PM	Section 3	6
66	Galectin-1 mediated chronic tumoral-STING activation promotes metastasisthrough MDSC recruitment	Dhanya	Nambiar	Poster	Tumor Dormancy and Metastasis	4/16/23	1:30 PM	Section 3	7
67	Blockade of VEGF-A signaling by Bevacizumab did not affect significantly in vivo metastatic dissemination of three colorectal cancer cells with different metastatic potential	Julia	Schueler	Poster	Tumor Dormancy and Metastasis	4/16/23	1:30 PM	Section 3	8
68	Dissecting cellular and molecular alterations in pre-invasive to invasive lung cancer progression at single-cell resolution	Liron	Yoffe	Poster	Tumor Dormancy and Metastasis	4/16/23	1:30 PM	Section 3	9
69	Minimally invasive brain metastases are characterized by elevated immune cell infiltrate	Sarah	Maritan	Poster	Tumor Dormancy and Metastasis	4/16/23	1:30 PM	Section 3	10
70	Mechanisms of tumor dormancy induction mediated by abrogation of myeloid tgfb signaling	Abdul	Ahad	Poster	Tumor Dormancy and Metastasis	4/16/23	1:30 PM	Section 3	11
71	Melanoma alters the bone marrow immune composition in an age-related manner	Alexis	Carey	Poster	Tumor Dormancy and Metastasis	4/16/23	1:30 PM	Section 3	12
72	Ablation of WNT10B alters the tumor microenvironment in highly metastatic breast cancer, altering paclitaxel response	Hannah	Kelso	Poster	Tumor Dormancy and Metastasis	4/16/23	1:30 PM	Section 3	13
73	Blockade of p38 MAPK reduces the tumor-induced immune suppressive microenvironment in metastatic breast cancer	Priyanka	Rajan	Poster	Tumor Dormancy and Metastasis	4/16/23	1:30 PM	Section 3	14

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
75	Impaired metastatic seeding underlies concomitant tumor resistance	Akshita	Bhatt	Poster	Tumor Dormancy and Metastasis	4/16/23	1:30 PM	Section 3	16
76	Reprogramming of the preinvasive breast microenvironment identified by spatial nucleus barcoding	Zhenna	Xiao	Poster	Tumor Dormancy and Metastasis	4/16/23	1:30 PM	Section 3	17
77	Recapitulating metastatic colorectal cancer in somatic mutation models for investigating the tumor immune microenvironment in minimal residual disease	Alaa	Mohamed	Poster	Tumor Dormancy and Metastasis	4/16/23	1:30 PM	Section 3	18
78	Microenvironmental cues that regulate breast cancer cellular dormancy in the bone marrow niche	Pulkit	Datt	Poster	Tumor Dormancy and Metastasis	4/16/23	1:30 PM	Section 3	19
79	Study of tumor microenvironment of ovarian clear cell carcinoma	Tanja	Pejovic	Poster	Tumor Dormancy and Metastasis	4/16/23	1:30 PM	Section 3	20
80	Change in B cell lymphocyte expression from the pre- to post-malignant prostate predicts disease aggressiveness	Sudha	Sadasivan	Poster	Tumor Dormancy and Metastasis	4/16/23	1:30 PM	Section 3	21
81	The association between melanoma liver metastases (mets) and the systemic anti-tumor immune profile	Jordan	Conway	Poster	Tumor Dormancy and Metastasis	4/16/23	1:30 PM	Section 3	22
82	Role of MSC-derived CXCL1 in bone-metastatic prostate cancer	Catherine	Johnson	Poster	Tumor Dormancy and Metastasis	4/16/23	1:30 PM	Section 3	23
84	Single-cell transcriptional analysis of multiple myeloma bone marrow aspirates using particle-templated instant partition sequencing (PIPseq)	Robert	Meltzer	Poster	Tumor Dormancy and Metastasis	4/16/23	1:30 PM	Section 3	25
85	Senescent cells promote breast cancer tumorigenesis	Jiayu (Jennifer)	Ye	Poster	Tumor Dormancy and Metastasis	4/16/23	1:30 PM	Section 3	26
86	Chemotherapy-induced microenvironmental changes promote dormant breast cancer cell outgrowth in adipose tissue	Qihao	Ren	Poster	Tumor Dormancy and Metastasis	4/16/23	1:30 PM	Section 3	27
87	The role of miro1-mediated mitochondrial positioning in the development and metastasis of breast cancer	Randi	Gravelle	Poster	Tumor Dormancy and Metastasis	4/16/23	1:30 PM	Section 3	28
90	Exploring the role of common circulating tumor cell-associated genes in estrogen receptor-positive breast cancer recurrence	Martin	Rotbauer	Poster	Tumor Heterogeneity 1	4/16/23	1:30 PM	Section 4	1
91	Multi-omic single-cell approach reveals transcriptional and epigenetic plasticity in breast cancer	Hisham	Mohammed	Poster	Tumor Heterogeneity 1	4/16/23	1:30 PM	Section 4	2
92	Deploying spatial transcriptomics to inform intratumoral heterogeneity in late-stage uveal melanoma leveraging advanced preclinical modeling and clinical samples	Sanjana	Srinivasan	Poster	Tumor Heterogeneity 1	4/16/23	1:30 PM	Section 4	3
93	An endogenous molecular brake preventing APOBEC-driven tumor mutational burden, heterogeneity and therapy resistance	Ping	Mu	Poster	Tumor Heterogeneity 1	4/16/23	1:30 PM	Section 4	4
94	Advanced preclinical modeling reveals unique monosomy 3 associated biology in late-stage uveal melanoma	Johnathon	Rose	Poster	Tumor Heterogeneity 1	4/16/23	1:30 PM	Section 4	5

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
95	Uncommitted cells and phenotypic plasticity elucidate the complexity of the epithelial-mesenchymal molecular gradient of pleural mesothelioma	David	Severson	Poster	Tumor Heterogeneity 1	4/16/23	1:30 PM	Section 4	6
96	Integrated molecular analysis of human dedifferentiated liposarcoma identifies a population of liposarcoma progenitors vulnerable to TGF beta inhibition	Sarah	Watson	Poster	Tumor Heterogeneity 1	4/16/23	1:30 PM	Section 4	7
97	Multiregional profiling revealed intra-tumor transcriptomic heterogeneity associated with the prognosis in non-small cell lung cancer	Chenyang	Li	Poster	Tumor Heterogeneity 1	4/16/23	1:30 PM	Section 4	8
99	Apoptotic DNase DFFB mediates cancer persister cell mutagenesis and acquired drug resistance	August	Williams	Poster	Tumor Heterogeneity 1	4/16/23	1:30 PM	Section 4	10
101	Convergent genomic diversity and novel oncogenic metabolism in intrahepatic cholangiocarcinoma	Yusuke	Nakano	Poster	Tumor Heterogeneity 1	4/16/23	1:30 PM	Section 4	12
102	Transient chromosomal instability as a driver of ovarian cancer genome evolution	Ignacio	Vazquez-Garcia	Poster	Tumor Heterogeneity 1	4/16/23	1:30 PM	Section 4	13
103	Dissecting cell state diversity during melanoma growth and metastasis	Panagiotis	Karras	Poster	Tumor Heterogeneity 1	4/16/23	1:30 PM	Section 4	14
104	The role of APOBEC3A in ovarian cancer progression	Jessica	Devenport	Poster	Tumor Heterogeneity 1	4/16/23	1:30 PM	Section 4	15
105	Gene expression heterogeneity reveals therapeutic targets and novel regulators of metastasis	Dongbo	Yang	Poster	Tumor Heterogeneity 1	4/16/23	1:30 PM	Section 4	16
106	Intratumoral heterogeneity of glioblastoma is attributed to precancerous cells derived from neural stem cells	Jeong Ho	Lee	Poster	Tumor Heterogeneity 1	4/16/23	1:30 PM	Section 4	17
107	EML4-ALK fusions drive lung adeno-to-squamous transdifferentiation through phase separation-mediated JAK-STAT activation	Zhen	Qin	Poster	Tumor Heterogeneity 1	4/16/23	1:30 PM	Section 4	18
108	Spatio-temporal view of malignant histogenesis and cancer evolution via formation of polyploid giant cancer cell	Jinsong	Liu	Poster	Tumor Heterogeneity 1	4/16/23	1:30 PM	Section 4	19
109	Multi-modal single-cell analysis of immunotherapy-experienced cutaneous and mucosal melanoma	Jana	Biermann	Poster	Tumor Heterogeneity 1	4/16/23	1:30 PM	Section 4	20
111	Characterizing subpopulation response to doxorubicin in a barcode-labeled triple negative breast carcinoma cell line	Daylin	Morgan	Poster	Tumor Heterogeneity 1	4/16/23	1:30 PM	Section 4	22
112	Multi-omics analysis of molecular landscape and heterogeneity in fetal adenocarcinoma of the lung	Wei	Guo	Poster	Tumor Heterogeneity 1	4/16/23	1:30 PM	Section 4	23
113	An atlas of epithelial cell states and plasticity in lung adenocarcinoma	Guangchun	Han	Poster	Tumor Heterogeneity 1	4/16/23	1:30 PM	Section 4	24
116	A novel murine model for interrogating tumor heterogeneity in non-small cell lung cancer	Michael	Oh	Poster	Tumor Heterogeneity 1	4/16/23	1:30 PM	Section 4	27

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
121	In situ mutational mapping of tumor cells and tissues at subcellular resolution	Jessica	Östlin	Poster	Tumor Heterogeneity 2	4/16/23	1:30 PM	Section 5	2
122	The subclonal dynamics of gross ploidy alterations in TNBC cells under chemotherapeutic pressure	Andrea	Gardner	Poster	Tumor Heterogeneity 2	4/16/23	1:30 PM	Section 5	3
123	Molecular mechanisms of RNA and DNA editing in leukemic transformation of hemopoietic stem and progenitor cells	Jane	Isquith	Poster	Tumor Heterogeneity 2	4/16/23	1:30 PM	Section 5	4
124	Autocrine signaling extends PD-L1 expression in NSCLC following an active immune response	Taylor	Bursell	Poster	Tumor Heterogeneity 2	4/16/23	1:30 PM	Section 5	5
125	Archival single cell sequencing reveals persistent subclones over years to decades of DCIS progression	Kaile	Wang	Poster	Tumor Heterogeneity 2	4/16/23	1:30 PM	Section 5	6
126	Extreme selection constrains ability of EGFR-driven lung adenocarcinoma to diversify in response to erlotinib therapy	J Nicholas	Fisk	Poster	Tumor Heterogeneity 2	4/16/23	1:30 PM	Section 5	7
127	Single-cell methylation sequencing data reveals succinct metastatic migration histories and tumor progression models	Xuan	Li	Poster	Tumor Heterogeneity 2	4/16/23	1:30 PM	Section 5	8
128	Clonal expansion with driver mutations in normal human endometrium	Koichi	Watanabe	Poster	Tumor Heterogeneity 2	4/16/23	1:30 PM	Section 5	9
129	Determine the genetic similarity of synchronous endometrial and ovarian cancers with variants in polyguanine sequences	Yu-Yi	Huang	Poster	Tumor Heterogeneity 2	4/16/23	1:30 PM	Section 5	10
130	Distinct mutational drivers and evolutionary pathways in stage IA non-myoinvasive endometrioid endometrial cancer	Sara	Moufarrij	Poster	Tumor Heterogeneity 2	4/16/23	1:30 PM	Section 5	11
131	Clonal expansion in bile duct associated with chronic inflammation	Hirona	Maeda	Poster	Tumor Heterogeneity 2	4/16/23	1:30 PM	Section 5	12
132	The molecular basis of an evolutionary arms race between cancer cells and their host	Arig	Ibrahim-Hashim	Poster	Tumor Heterogeneity 2	4/16/23	1:30 PM	Section 5	13
133	Rewinding the tape of life: somatic profiling in Von Hippel-Lindau (VHL) disease reveals evolutionary contingency and constraints	Scott	Shepherd	Poster	Tumor Heterogeneity 2	4/16/23	1:30 PM	Section 5	14
134	Lymph node metastases are seeded via two distinct ways in phylogenetic study of gastric cancer	Pei-Chi	Cheng	Poster	Tumor Heterogeneity 2	4/16/23	1:30 PM	Section 5	15
135	Elucidating tumor evolution in pediatric cancers using stochastic models and mutation accumulation experiments	Seung-Hwan	Kim	Poster	Tumor Heterogeneity 2	4/16/23	1:30 PM	Section 5	16
136	Single cell lineage analysis reveals clonal evolution and dynamic intra-clonal gene expression states during colorectal cancer progression	M Haidar	Kasem	Poster	Tumor Heterogeneity 2	4/16/23	1:30 PM	Section 5	17
137	Epigenetic regulation of APOBEC3A mutagenesis and tumor evolution during targeted therapy in non-small cell lung cancer	Hideko	Isozaki	Poster	Tumor Heterogeneity 2	4/16/23	1:30 PM	Section 5	18

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
138	Establishment of monoclonal cell subpopulations as model systems for functionally exploring resistance mechanisms in EGFR mutant non-small cell cancers	Claire	Blanchard	Poster	Tumor Heterogeneity 2	4/16/23	1:30 PM	Section 5	19
139	Exploiting interactions between ploidy and host physiology	Noemi	Andor	Poster	Tumor Heterogeneity 2	4/16/23	1:30 PM	Section 5	20
140	Clonal evaluation of ERG/SPINK1 status to determine disease progression using whole mount prostatectomy specimens	Joonyoung	Cho	Poster	Tumor Heterogeneity 2	4/16/23	1:30 PM	Section 5	21
141	Interrogating subclonal mechanisms of immune evasion and immunotherapy resistance in melanoma	Isabella	Church	Poster	Tumor Heterogeneity 2	4/16/23	1:30 PM	Section 5	22
142	Candidate measures of lineage plasticity in aggressive phenotypes of prostate cancer	Souzana	Logotheti	Poster	Tumor Heterogeneity 2	4/16/23	1:30 PM	Section 5	23
143	A platform for deep evolutionary profiling of cancer resistance	Arvind	Ravi	Poster	Tumor Heterogeneity 2	4/16/23	1:30 PM	Section 5	24
144	Spatial transcriptomic landscape of the primary and recurrent glioblastoma tumor microenvironment	Jean	Clemenceau	Poster	Tumor Heterogeneity 2	4/16/23	1:30 PM	Section 5	25
145	Giant cells: A new paradigm to understand tumor origins and decode their complexity at the organismal level	Jinsong	Liu	Poster	Tumor Heterogeneity 2	4/16/23	1:30 PM	Section 5	26
149	An organoid model for understanding the pathogenesis of Lynch syndrome	Caroline	Guild	Poster	Tumor Organoids for Cancer Research	4/16/23	1:30 PM	Section 6	1
150	A 515 tumor specimens collection from surgery to benchtop: the WFORCE organoid experience in personalized research	Steven	Forsythe	Poster	Tumor Organoids for Cancer Research	4/16/23	1:30 PM	Section 6	2
151	Optimization of screening conditions using patient-derived organoids for diagnostic purposes	Carla	Verissimo	Poster	Tumor Organoids for Cancer Research	4/16/23	1:30 PM	Section 6	3
152	Robust establishment and expansion of human fallopian tube organoids in serum-free culture	Victor	Ho	Poster	Tumor Organoids for Cancer Research	4/16/23	1:30 PM	Section 6	4
153	Identification of a gastrointestinal (GI) toxicity gene signature that predicts GI-toxicity induction in small intestinal organoids	Aude	Marine-Bonavita	Poster	Tumor Organoids for Cancer Research	4/16/23	1:30 PM	Section 6	5
154	Establishment and characterization of a novel clear cell sarcoma organoid model derived from a human biopsy	Petreena	Campbell	Poster	Tumor Organoids for Cancer Research	4/16/23	1:30 PM	Section 6	6
155	Towards the development of an in vitro human vascularized immunocompetent metastatic melanoma-on-chip model	Pierre	Gaudriault	Poster	Tumor Organoids for Cancer Research	4/16/23	1:30 PM	Section 6	7
156	An ascitic fluid-derived organoid platform for Hispanic ovarian cancer patients to capture heterogeneity and disparity	Md Mynul	Hassan	Poster	Tumor Organoids for Cancer Research	4/16/23	1:30 PM	Section 6	8
157	Patient in the lab: Down-scaling patient-derived organoid screening for diagnostic purposes	Sylvia	Boj	Poster	Tumor Organoids for Cancer Research	4/16/23	1:30 PM	Section 6	9
158	How low can you go: Maintenance of tumoroid phenotype with a highly scalable and automation-compatible reduced-ECM suspension culture method	Brittany	Balhouse	Poster	Tumor Organoids for Cancer Research	4/16/23	1:30 PM	Section 6	10

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
159	Vascularized 3D cancer organoid research platform using surface acoustic waves	Hyoyoung	Kim	Poster	Tumor Organoids for Cancer Research	4/16/23	1:30 PM	Section 6	11
160	Derivation and long-term maintenance of patient-derived tumoroid lines in a defined, serum-free medium	Chris	Yankaskas	Poster	Tumor Organoids for Cancer Research	4/16/23	1:30 PM	Section 6	12
161	Patient-derived organoids (PDOs) hub of National Cancer Center, Korea: pre-clinical model for drug screening	Yebeen	Yu	Poster	Tumor Organoids for Cancer Research	4/16/23	1:30 PM	Section 6	13
162	Individualizing treatment using patient derived organoids, BH3 profiling and microfluidics: A proof of concept in a patient with low-grade serous ovarian carcinoma	Elena	Ivanova	Poster	Tumor Organoids for Cancer Research	4/16/23	1:30 PM	Section 6	14
163	Establishment of pancreatic ductal adenocarcinoma organoids model using endoscopic ultrasonography-guided fine needle biopsy: a new window into understanding pancreatic ductal adenocarcinoma tumor biology	Hyemin	Kim	Poster	Tumor Organoids for Cancer Research	4/16/23	1:30 PM	Section 6	15
164	Development of a living biobank of breast cancer organoids	Nadeem	Wajih	Poster	Tumor Organoids for Cancer Research	4/16/23	1:30 PM	Section 6	16
165	Establishment and characterization of Vogelgram-mimic colorectal cancer organoids as a laboratory tool	Lindsey	Carlsen	Poster	Tumor Organoids for Cancer Research	4/16/23	1:30 PM	Section 6	17
167	Assessment of homologous recombination deficiency cancer signatures with patient-derived tumor organoid models	Hui-Hsuan	Kuo	Poster	Tumor Organoids for Cancer Research	4/16/23	1:30 PM	Section 6	19
168	Esophageal adenocarcinoma-on-a-chip; modeling patient specific disease progression and a step towards functional precision oncology	Sanjima	Pal	Poster	Tumor Organoids for Cancer Research	4/16/23	1:30 PM	Section 6	20
169	Leveraging space to advance terrestrial cancer research	Jessica	Pham	Poster	Tumor Organoids for Cancer Research	4/16/23	1:30 PM	Section 6	21
170	Glioblastoma patient-derived organoids as a model for discovering novel markers of therapy resistance in the context of tumor microenvironment: potential role of melanoma antigens	Barbara	Breznik	Poster	Tumor Organoids for Cancer Research	4/16/23	1:30 PM	Section 6	22
171	Prostate cancer organoids from KUCaP patient-derived xenograft(PDX) series enables us to genetic engineering human-derived cellular models	Takuro	Sunada	Poster	Tumor Organoids for Cancer Research	4/16/23	1:30 PM	Section 6	23
172	The impact of extracellular matrix modulation and cancer-associated fibroblast presence on patient-derived tumor organoid growth rate, morphology, and chemoresistance	Scott	Valena	Poster	Tumor Organoids for Cancer Research	4/16/23	1:30 PM	Section 6	24
173	Genomic characterization of patient-derived pancreatic cancer organoids	Irene	Xie	Poster	Tumor Organoids for Cancer Research	4/16/23	1:30 PM	Section 6	25
174	Organoids developed from synovial sarcoma patient-derived xenografts	Lore	De Cock	Poster	Tumor Organoids for Cancer Research	4/16/23	1:30 PM	Section 6	26

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
175	Determining the genetic alterations in initiation and progression of high-grade serous ovarian carcinoma	Daryl	Phuong	Poster	Tumor Organoids for Cancer Research	4/16/23	1:30 PM	Section 6	27
176	Generation and maintenance of anaplastic thyroid cancer spheroids from human cancer cells	Jiangnan	Hu	Poster	Tumor Organoids for Cancer Research	4/16/23	1:30 PM	Section 6	28
177	Expansion of established patient-derived tumoroids in a novel serum-free, Wnt-free media system	Colin	Paul	Poster	Tumor Organoids for Cancer Research	4/16/23	1:30 PM	Section 6	29
178	Establishment of patient-derived organoid of breast cancer	Won-Ji	Ryu	Poster	Tumor Organoids for Cancer Research	4/16/23	1:30 PM	Section 6	30
182	Bladder cancer organoids as a functional system to model different disease stages and therapy response	Martina	Minoli	Poster	Tumor Organoids for Therapeutic Testing	4/16/23	1:30 PM	Section 7	1
183	Evaluating targeted therapy combination for refractory colorectal cancer using MicroOrganoSpheres (MOS)	Shengli	Ding	Poster	Tumor Organoids for Therapeutic Testing	4/16/23	1:30 PM	Section 7	2
184	Multiple Myeloma 3D model: A platform for testing drug effects on myeloma in conjunction with the bone marrow niche	Hanadi	Rashad	Poster	Tumor Organoids for Therapeutic Testing	4/16/23	1:30 PM	Section 7	3
185	Global mapping of pathway modules and phosphorylation networks in PDX and corresponding organoid (PDXO) models treated with targeted therapies	Yuehan	Feng	Poster	Tumor Organoids for Therapeutic Testing	4/16/23	1:30 PM	Section 7	4
186	Cellos: High-throughput deconvolution of 3D organoid dynamics at cellular resolution for cancer pharmacology	Patience	Mukashyaka	Poster	Tumor Organoids for Therapeutic Testing	4/16/23	1:30 PM	Section 7	5
187	Let's get physiological! Impact of media conditions on drug response to targeted therapies in CRC organoids	Gerrit	Erdmann	Poster	Tumor Organoids for Therapeutic Testing	4/16/23	1:30 PM	Section 7	6
188	Autologous organoids and T cell co-cultures as a powerful personalized platform for immunotherapy development	Claudia	Beaurivage	Poster	Tumor Organoids for Therapeutic Testing	4/16/23	1:30 PM	Section 7	7
189	Developing a patient-derived organoid biobank, suitable for large scale drug screenings	Daniele	Mori	Poster	Tumor Organoids for Therapeutic Testing	4/16/23	1:30 PM	Section 7	8
190	Personalized identification of cancer treatments in real-time: TumOC - a tumor organoid-on-chip platform for online cell vitality measurements	Lena	Wedeken	Poster	Tumor Organoids for Therapeutic Testing	4/16/23	1:30 PM	Section 7	9
191	CTC-derived organoids from liver and pancreatic cancer patients for personalized therapy	Catalina	Galeano-Garces	Poster	Tumor Organoids for Therapeutic Testing	4/16/23	1:30 PM	Section 7	10
192	A novel and rapid patient-derived organoid breast cancer platform for precision medicine	David	Graham	Poster	Tumor Organoids for Therapeutic Testing	4/16/23	1:30 PM	Section 7	11
193	A high throughput vascularized immunocompetent tumoroids model in a standard multiwell plate for precision oncology	Pierre	Gaudriault	Poster	Tumor Organoids for Therapeutic Testing	4/16/23	1:30 PM	Section 7	12
194	Ovarian cancer patient-derived organoids and tumor xenografts as preclinical models for precision medicine	Yebeen	Yu	Poster	Tumor Organoids for Therapeutic Testing	4/16/23	1:30 PM	Section 7	13

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
195	Establishment and validation of pheochromocytoma organoids for high-throughput drug screening	Maite	Calucho	Poster	Tumor Organoids for Therapeutic Testing	4/16/23	1:30 PM	Section 7	14
196	A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening	Huyen	Nguyen	Poster	Tumor Organoids for Therapeutic Testing	4/16/23	1:30 PM	Section 7	15
197	Novel 3D bioprinted pancreatic tumor models for anti-cancer drug assessment	Shreyas	Gaikwad	Poster	Tumor Organoids for Therapeutic Testing	4/16/23	1:30 PM	Section 7	16
198	Pan-cancer assay-ready organoid drug screening with robust, reproducible and clinically-relevant output	Marrit	Putker	Poster	Tumor Organoids for Therapeutic Testing	4/16/23	1:30 PM	Section 7	17
199	Novel platform for automation of high throughput drug discovery using patient derived colorectal cancer organoids	Angeline	Lim	Poster	Tumor Organoids for Therapeutic Testing	4/16/23	1:30 PM	Section 7	18
201	Establishment of 3D co-culture spheroid model for in- vitro drug screening	Christella	Nelson	Poster	Tumor Organoids for Therapeutic Testing	4/16/23	1:30 PM	Section 7	20
202	Perfused patient-derived tumor organoid models with autologous immune cells for preclinical drug development	Melissa	Millard	Poster	Tumor Organoids for Therapeutic Testing	4/16/23	1:30 PM	Section 7	21
203	A characterization of drug sensitivity and resistance in sarcoma	Ahmad	Al Shihabi	Poster	Tumor Organoids for Therapeutic Testing	4/16/23	1:30 PM	Section 7	22
205	Patient-derived organoids from surgically treated, localized non-small cell lung cancer as high-throughput drug testing platforms for conventional and repurposed drugs	Yariswamy	Manjunath	Poster	Tumor Organoids for Therapeutic Testing	4/16/23	1:30 PM	Section 7	24
206	Organoid models for predicting drug response in high grade serous and triple negative breast cancer	Helen	MacKay	Poster	Tumor Organoids for Therapeutic Testing	4/16/23	1:30 PM	Section 7	25
207	Ex vivo modeling of multiple myeloma: A novel drug sensitivity screening platform	Vaishnavi	Sambandam	Poster	Tumor Organoids for Therapeutic Testing	4/16/23	1:30 PM	Section 7	26
211	The performance characteristic of the low input tagmentation-based whole genome sequencing in high quality somatic variant calling	Liqun	Jiang	Poster	Innovative Approaches for Tumor Profiling and Data Analysis 1	4/16/23	1:30 PM	Section 8	1
212	True2 duplex sequencing reveals a diverse landscape of unique somatic mutations beyond the surgical margins of high- and low-grade diffuse gliomas	Hunter	Underhill	Poster	Innovative Approaches for Tumor Profiling and Data Analysis 1	4/16/23	1:30 PM	Section 8	2
213	Phylogenetic reconstruction across 303 metastatic tumor samples using Ultima whole-genome sequencing dramatically increases subclonal resolution	Julian	Hess	Poster	Innovative Approaches for Tumor Profiling and Data Analysis 1	4/16/23	1:30 PM	Section 8	3
214	Patient-specific mapping of oncogenic structural changes in pediatric osteosarcoma	Andrew	Clugston	Poster	Innovative Approaches for Tumor Profiling and Data Analysis 1	4/16/23	1:30 PM	Section 8	4
215	A novel enzymatic library preparation workflow that dramatically reduces artifacts associated with damaged FFPE samples	Giulia	Corbet	Poster	Innovative Approaches for Tumor Profiling and Data Analysis 1	4/16/23	1:30 PM	Section 8	5

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
216	Profiling single cell and spatial transcriptomes in FFPE archived tissues	Jasmine Ying-Jiun	Chen	Poster	Innovative Approaches for Tumor Profiling and Data Analysis 1	4/16/23	1:30 PM	Section 8	6
218	Somatic mutations in single-cell derived alveolar organoids	Moritz	Przybilla	Poster	Innovative Approaches for Tumor Profiling and Data Analysis 1	4/16/23	1:30 PM	Section 8	8
219	Single-tube NGS profiling allows identification of molecular signature in ALL patients	Lina	Zelinger	Poster	Innovative Approaches for Tumor Profiling and Data Analysis 1	4/16/23	1:30 PM	Section 8	9
220	Performance assessment of the novel G4 sequencing platform for cancer research applications	Timothy	Looney	Poster	Innovative Approaches for Tumor Profiling and Data Analysis 1	4/16/23	1:30 PM	Section 8	10
221	Development of a rapid, highly sensitive cell-free RNA NGS assay for the detection of gene fusion and splicing variants in cancers	shujun	luo	Poster	Innovative Approaches for Tumor Profiling and Data Analysis 1	4/16/23	1:30 PM	Section 8	11
222	High frequency of structural variants in FFPE colorectal cancer tissue detected by targeting selected common fragile site genes and LINE transposable elements	Carmen	Rubio-Alarcon	Poster	Innovative Approaches for Tumor Profiling and Data Analysis 1	4/16/23	1:30 PM	Section 8	12
223	Identifying gene amplifications in p53 abnormal endometrial carcinomas by shallow whole genome sequencing	Juliana	Sobral de Barros	Poster	Innovative Approaches for Tumor Profiling and Data Analysis 1	4/16/23	1:30 PM	Section 8	13
224	Establishing de novo platform for whole genome sequencing of pancreatic cyst fluid for early detection and diagnosis of pancreatic cancer	Adenike	Adekeye	Poster	Innovative Approaches for Tumor Profiling and Data Analysis 1	4/16/23	1:30 PM	Section 8	14
226	Targeted transcriptome sequencing enables exponential scaling of combinatorial barcoding in AML samples	Grace	Kim	Poster	Innovative Approaches for Tumor Profiling and Data Analysis 1	4/16/23	1:30 PM	Section 8	16
227	In vivo functional genomics screen to uncover tumor intrinsic negative regulators of NK cell-mediated tumor cell killing	Kayla	Duval	Poster	Innovative Approaches for Tumor Profiling and Data Analysis 1	4/16/23	1:30 PM	Section 8	17
228	Recurrent mitochondrial mutations in thyroid cancer	Julia	Hopkins	Poster	Innovative Approaches for Tumor Profiling and Data Analysis 1	4/16/23	1:30 PM	Section 8	18
229	Methylation as a surrogate for mutations to identify therapeutic targets	Robert	Seitz	Poster	Innovative Approaches for Tumor Profiling and Data Analysis 1	4/16/23	1:30 PM	Section 8	19
230	Characterizing pathogenic germline variants in a large Chinese lung cancer cohort	Haimeng	Tang	Poster	Innovative Approaches for Tumor Profiling and Data Analysis 1	4/16/23	1:30 PM	Section 8	20
231	Evaluation of a 293 gene oncology-focused exome sequencing panel for screening of ovarian cancer patients for BRCA mutations as a prerequisite for autologous cellular immunotherapy manufacturing	David	Willoughby	Poster	Innovative Approaches for Tumor Profiling and Data Analysis 1	4/16/23	1:30 PM	Section 8	21
232	Fully automated comprehensive genomic profiling for detection of cancer variants, gene fusions, and complex oncology endpoints	Seth	Sadis	Poster	Innovative Approaches for Tumor Profiling and Data Analysis 1	4/16/23	1:30 PM	Section 8	22
233	Inter-site performance comparison of a next generation sequencing (NGS) assay for minimal residual disease detection	Bowdoin	Su	Poster	Innovative Approaches for Tumor Profiling and Data Analysis 1	4/16/23	1:30 PM	Section 8	23

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
	research in diffuse large B-Cell lymphoma (DLBCL) using plasma circulating tumor DNA (ctDNA)								
234	ITCC-P4: Genomic profiling and analyses of pediatric patient tumor and patient-derived xenograft (PDX) models for high throughput in vivo testing	Apurva	Gopisetty	Poster	Innovative Approaches for Tumor Profiling and Data Analysis 1	4/16/23	1:30 PM	Section 8	24
235	Establishing clinical utility for genomic profiling with plasma cell free DNA in urothelial carcinoma	Yuki	Kita	Poster	Innovative Approaches for Tumor Profiling and Data Analysis 1	4/16/23	1:30 PM	Section 8	25
237	Coincidence of InDels with missense mutations: 0, 1 or 2 artifacts?	James	Eshleman	Poster	Innovative Approaches for Tumor Profiling and Data Analysis 2	4/16/23	1:30 PM	Section 9	1
238	Comprehensive study of gene expression outliers and their regulation mechanisms in pan-cancer	Jee Yun	Han	Poster	Innovative Approaches for Tumor Profiling and Data Analysis 2	4/16/23	1:30 PM	Section 9	2
239	Whole-genome sequencing based homologous recombination deficiency testing for precision oncology of breast cancers	Ryul	Kim	Poster	Innovative Approaches for Tumor Profiling and Data Analysis 2	4/16/23	1:30 PM	Section 9	3
240	Comprehensive analytical solution to measure HRD genomic scars from SNP arrays, pan-cancer NGS panels, and optical genome mapping (OGM)	Daniel	Saul	Poster	Innovative Approaches for Tumor Profiling and Data Analysis 2	4/16/23	1:30 PM	Section 9	4
241	Evaluation of single cell RNA sequencing from FFPE tissue using 10x Genomics Chromium Fixed RNA Profiling	Joseph	Modarelli	Poster	Innovative Approaches for Tumor Profiling and Data Analysis 2	4/16/23	1:30 PM	Section 9	5
242	Improving whole transcriptome library preparation workflow and data quality for oncology-relevant samples and applications	Travis	Sanders	Poster	Innovative Approaches for Tumor Profiling and Data Analysis 2	4/16/23	1:30 PM	Section 9	6
243	Long-read sequencing of pediatric cancer genomes identifies multiple clinically relevant variants	Byunggil	Yoo	Poster	Innovative Approaches for Tumor Profiling and Data Analysis 2	4/16/23	1:30 PM	Section 9	7
244	Use of comprehensive molecular profiling to identify additional clinically-relevant alterations compared to targeted gene panels	Sandrine	Degryse	Poster	Innovative Approaches for Tumor Profiling and Data Analysis 2	4/16/23	1:30 PM	Section 9	8
245	Development of a novel urine cell-free DNA preservation method for molecular profiling in genitourinary tumors	shujun	luo	Poster	Innovative Approaches for Tumor Profiling and Data Analysis 2	4/16/23	1:30 PM	Section 9	9
246	Evaluation of a comprehensive genomic profiling assay for characterization of biomarkers in FFPE tissue	Xinyan	Li	Poster	Innovative Approaches for Tumor Profiling and Data Analysis 2	4/16/23	1:30 PM	Section 9	10
247	Twist pan-cancer synthetic RNA fusion control for assay development	Patrick	Cherry	Poster	Innovative Approaches for Tumor Profiling and Data Analysis 2	4/16/23	1:30 PM	Section 9	11
248	Using combinatorial barcoding to simultaneously profile the transcriptome and immune repertoire of 1 million T cells	Efthymia	Papalexi	Poster	Innovative Approaches for Tumor Profiling and Data Analysis 2	4/16/23	1:30 PM	Section 9	12
249	A novel suite of enzyme mixes enable robust hybrid capture sequencing from low quality FFPE DNA	Margaret	Heider	Poster	Innovative Approaches for Tumor Profiling and Data Analysis 2	4/16/23	1:30 PM	Section 9	13
250	Identifying drivers of liver cancer using CRISPR activation screening in vivo	Alexandra	Vázquez Salgado	Poster	Innovative Approaches for Tumor Profiling and Data Analysis 2	4/16/23	1:30 PM	Section 9	14

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
251	Identification of therapeutic vulnerabilities by genome-wide CRISPR knockout library screening of colon cancer organoids	Phillip	Buckhaults	Poster	Innovative Approaches for Tumor Profiling and Data Analysis 2	4/16/23	1:30 PM	Section 9	15
252	A single-tube approach for detection of circulating tumor DNA using customized panels	Tony	Godfrey	Poster	Innovative Approaches for Tumor Profiling and Data Analysis 2	4/16/23	1:30 PM	Section 9	16
255	Isolation of unaltered sub-populations of immune cells using magnetic levitation	Kevin	Travers	Poster	Innovative Approaches for Tumor Profiling and Data Analysis 2	4/16/23	1:30 PM	Section 9	19
256	Detection of METexon 14 skipping and fusions in non-small cell lung cancer by comprehensive genomic profiling using a dual targeted DNA/RNA panel	Hidenori	Kage	Poster	Innovative Approaches for Tumor Profiling and Data Analysis 2	4/16/23	1:30 PM	Section 9	20
257	CDX model based genome-scale CRISPR KO screens for modulators of KRAS (G12C) inhibitor sensitivity	Haixin	Zhao	Poster	Innovative Approaches for Tumor Profiling and Data Analysis 2	4/16/23	1:30 PM	Section 9	21
258	Whole genome analysis of hereditary leiomyomatosis and renal cell cancer identifies role of localized hypermutational events	Selina	Wu	Poster	Innovative Approaches for Tumor Profiling and Data Analysis 2	4/16/23	1:30 PM	Section 9	22
259	Fully automated targeted sequencing sample prep on open platform liquid handlers	Grace	Zhao	Poster	Innovative Approaches for Tumor Profiling and Data Analysis 2	4/16/23	1:30 PM	Section 9	23
260	Long RNA and DNA sequencing reveals HEK293 diversity between commercial sources	Bradley	Langhorst	Poster	Innovative Approaches for Tumor Profiling and Data Analysis 2	4/16/23	1:30 PM	Section 9	24
261	Whole genome sequencing provides a more comprehensive genetic characterization of lung cancer compared to a targeted panel sequencing	Ji-Hyung	Park	Poster	Innovative Approaches for Tumor Profiling and Data Analysis 2	4/16/23	1:30 PM	Section 9	25
262	Heat Map Analysis, a new integrated pathway scoring system for cancer genome profiling	Chiho	Nakashima	Poster	Innovative Approaches for Tumor Profiling and Data Analysis 2	4/16/23	1:30 PM	Section 9	26
263	Automating next generation sequencing workflows for custom hyb panels: high quality library preparation and target enrichment on the Biomek NGenius System	Nicole	Roseman	Poster	Innovative Approaches for Tumor Profiling and Data Analysis 2	4/16/23	1:30 PM	Section 9	27
264	Framework to determine fusion junction of novel RNA fusions and their actionability for personalized therapy of lung cancer patients	Prisha	Verma	Poster	Innovative Approaches for Tumor Profiling and Data Analysis 2	4/16/23	1:30 PM	Section 9	28
268	Antitumor CD4+ T cells reprogram tumor metabolism to drive progressive tumor regression	Caitlin	Brandle	Poster	Signaling Pathways in Cancer Metabolism	4/16/23	1:30 PM	Section 10	1
269	New metabolic biomarker of ALDOA induces tumor aggressiveness in breast cancer and nicotinamide as a potential anti-tumor agent targeting ALDOA	Da Sol	Kim	Poster	Signaling Pathways in Cancer Metabolism	4/16/23	1:30 PM	Section 10	2
270	Metabolic rewiring and metastatic potential in STK11-null lung adenocarcinoma	Shannon	Prior	Poster	Signaling Pathways in Cancer Metabolism	4/16/23	1:30 PM	Section 10	3
271	MYC mediates enhanced lactate reutilization and resistance to anti-angiogenesis therapy in preclinical models of LKB1-deficient NSCLC	Yu	Qian	Poster	Signaling Pathways in Cancer Metabolism	4/16/23	1:30 PM	Section 10	4

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
272	Autophagy and MEK inhibition promotes ferroptosis in liver kinase B1 (Lkb1)-deficient Kras-driven lung tumors	Vrushank	Bhatt	Poster	Signaling Pathways in Cancer Metabolism	4/16/23	1:30 PM	Section 10	5
273	Synergistically suppressive effects by combination of glycolytic inhibitor with TRAP1-depletion in colorectal cancer	Ru	Chen	Poster	Signaling Pathways in Cancer Metabolism	4/16/23	1:30 PM	Section 10	6
274	Functional coupling between the amino acid transporters SLC38A5 and SLC7A11 in TNBC via selenomethionine	Marilyn	Mathew	Poster	Signaling Pathways in Cancer Metabolism	4/16/23	1:30 PM	Section 10	7
275	Harnessing chemerin signaling as a novel therapeutic vulnerability in ccRCC	Dazhi	Wang	Poster	Signaling Pathways in Cancer Metabolism	4/16/23	1:30 PM	Section 10	8
276	Delineating the role of vesicular glutamate transporter SLC17A7 in osteosarcoma	Niveditha	Nerlakanti	Poster	Signaling Pathways in Cancer Metabolism	4/16/23	1:30 PM	Section 10	9
277	NUC-7738 promotes alternative polyadenylation site usage and reduces glutaminase GAC isoform	Mustafa	Elshani	Poster	Signaling Pathways in Cancer Metabolism	4/16/23	1:30 PM	Section 10	10
278	Role of ATP1F1 in glioblastoma cell survival and metabolism	Maheedhara Reddy	Guda	Poster	Signaling Pathways in Cancer Metabolism	4/16/23	1:30 PM	Section 10	11
279	Lysosomal cyst(e)ine regulates melanoma de-differentiation and sensitivity to ferroptosis	Deyang	Yu	Poster	Signaling Pathways in Cancer Metabolism	4/16/23	1:30 PM	Section 10	12
280	Targeting mRNA pseudouridylation to suppress neuroblastoma metabolism	Anamika	Gupta	Poster	Signaling Pathways in Cancer Metabolism	4/16/23	1:30 PM	Section 10	13
281	Phosphodiesterase 8/9 inhibition to sensitize squamous non-small cell lung cancer (NSCLC) to pemetrexed (PMX): A double-edge strategy	Anna	Ivanina Foureau	Poster	Signaling Pathways in Cancer Metabolism	4/16/23	1:30 PM	Section 10	14
282	Differential metabolic adaptations define responses of winner and loser oncogenic mutant cells in skin epidermis in vivo	Anupama	Hemalatha	Poster	Signaling Pathways in Cancer Metabolism	4/16/23	1:30 PM	Section 10	15
283	AHCYL1 is crucial for NRAS mutant-expressing melanoma tumor growth by governing ER calcium homeostasis	Chufan	Cai	Poster	Signaling Pathways in Cancer Metabolism	4/16/23	1:30 PM	Section 10	16
284	Sigma1 regulates lipid droplet mediated redox homeostasis required for prostate cancer proliferation	Felix	Kim	Poster	Signaling Pathways in Cancer Metabolism	4/16/23	1:30 PM	Section 10	17
285	Dichloroacetate as a novel pharmaceutical treatment for cancer-related fatigue in melanoma	xinyi	zhang	Poster	Signaling Pathways in Cancer Metabolism	4/16/23	1:30 PM	Section 10	18
286	Targeting metabolic vulnerabilities in acute myeloid leukemia	Kanwal	Hameed	Poster	Signaling Pathways in Cancer Metabolism	4/16/23	1:30 PM	Section 10	19
287	Novel p62 interaction suggests novel role in glutamate metabolism	Haley	Dahl	Poster	Signaling Pathways in Cancer Metabolism	4/16/23	1:30 PM	Section 10	20
288	Glycolysis is enriched to propagating waves in cell cortex as a new mechanism for cancer progression	Huiwang	Zhan	Poster	Signaling Pathways in Cancer Metabolism	4/16/23	1:30 PM	Section 10	21
289	B7-H3 mediated metabolic reprogramming promotes small cell lung cancer progression	Mahek	Fatima	Poster	Signaling Pathways in Cancer Metabolism	4/16/23	1:30 PM	Section 10	22

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
291	A ketogenic diet rewires pancreatic cancer metabolism towards an actionable metabolic	Omid	Hajihassani	Poster	Signaling Pathways in Cancer Metabolism	4/16/23	1:30 PM	Section 10	24
292	Effects of aqueous cinnamon extract on activity of SIRT1	William	Hrivnak	Poster	Signaling Pathways in Cancer Metabolism	4/16/23	1:30 PM	Section 10	25
293	Non-metabolic regulatory functions of nuclear pyruvate kinase M2 induce a MAPK mediated phenotypic switch in invasive cancers	Maria	Apostolidi	Poster	Signaling Pathways in Cancer Metabolism	4/16/23	1:30 PM	Section 10	26
294	Tumor concentration of metformin is a determinant factor of its regulation of fatty acid β -oxidation and c-Src pathway in triple-negative breast cancer	Junhyoung	Park	Poster	Signaling Pathways in Cancer Metabolism	4/16/23	1:30 PM	Section 10	27
295	Targeting spermine synthase triggers lipid metabolism reprogramming as a new therapeutic option to combat colorectal cancer	Murong	Ma	Poster	Signaling Pathways in Cancer Metabolism	4/16/23	1:30 PM	Section 10	28
296	Clinical significance of glycolytic metabolic activity in liver cancer and its implication to immunotherapy	Ju-Seog	Lee	Poster	Signaling Pathways in Cancer Metabolism	4/16/23	1:30 PM	Section 10	29
299	Large tandem duplications in cancer resulting from transcription and DNA replication collisions	Lixing	Yang	Poster	Targeting Replication Stress and the Immune Microenvironment	4/16/23	1:30 PM	Section 11	1
300	Mechanisms of growth hormone action in the aging tissue microenvironment	Vera	Chesnokova	Poster	Targeting Replication Stress and the Immune Microenvironment	4/16/23	1:30 PM	Section 11	2
301	CENP-E inhibitors activate cGAS-STING pathway by inducing chromosome misalignment and micronucleation after mitotic slippage	Akihiro	Ohashi	Poster	Targeting Replication Stress and the Immune Microenvironment	4/16/23	1:30 PM	Section 11	3
302	Loss of head and neck squamous cell carcinoma MK2 increases STING activation through increased micronuclei formation	Deri	Morgan	Poster	Targeting Replication Stress and the Immune Microenvironment	4/16/23	1:30 PM	Section 11	4
303	DPY30 loss leads to DNA re-replication and immunoediting in pancreatic ductal adenocarcinoma	Francesca	Citron	Poster	Targeting Replication Stress and the Immune Microenvironment	4/16/23	1:30 PM	Section 11	5
304	Micronuclei in circulating stromal cells correlates with PD-L1 expression and predicts progression in metastatic breast cancer	Daniel	Adams	Poster	Targeting Replication Stress and the Immune Microenvironment	4/16/23	1:30 PM	Section 11	6
305	POLE-specific variant classification strategy is critical for identifying patients who may benefit from immunotherapy	Brennan	Decker	Poster	Targeting Replication Stress and the Immune Microenvironment	4/16/23	1:30 PM	Section 11	7
306	Alternatively activated macrophages induce bystander effects via arginase 1	Ram	Undi	Poster	Targeting Replication Stress and the Immune Microenvironment	4/16/23	1:30 PM	Section 11	8
307	Blocking LBH overexpression sensitizes triple negative breast cancer cells to ATR inhibition therapy	Koteswararao	Garikapati	Poster	Targeting Replication Stress and the Immune Microenvironment	4/16/23	1:30 PM	Section 11	9
308	Low molecular weight cyclin E deregulates DNA replication and damage repair to promote genomic instability in breast cancer	Mi	Li	Poster	Targeting Replication Stress and the Immune Microenvironment	4/16/23	1:30 PM	Section 11	10

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
309	ATM phosphorylation of NRF2 promotes DNA damage repair	Cheyenne	Schneider	Poster	Targeting Replication Stress and the Immune Microenvironment	4/16/23	1:30 PM	Section 11	11
310	CHAF1A promotes the translesion DNA synthesis pathway in response to DNA replication stress	Bing	Wen	Poster	Targeting Replication Stress and the Immune Microenvironment	4/16/23	1:30 PM	Section 11	12
311	Optimization of treatment schedule for the combination therapy of ATR inhibitor elimusertib and PARP inhibitor niraparib in preclinical tumor models	Antje	Wengner	Poster	Targeting Replication Stress and the Immune Microenvironment	4/16/23	1:30 PM	Section 11	13
312	The ATR inhibitor ART0380 shows preclinical efficacy in monotherapy or in combination with gemcitabine, aPD1, PARP inhibitors and topoisomerase 1 poisons	Jayesh	Majithiya	Poster	Targeting Replication Stress and the Immune Microenvironment	4/16/23	1:30 PM	Section 11	14
313	Mechanisms of oncogenic tyrosine kinase fusion formation and selection in human cancers	Taek-Chin	Cheong	Poster	Targeting Replication Stress and the Immune Microenvironment	4/16/23	1:30 PM	Section 11	15
314	Intratumor genetic heterogeneity dictates metastatic subclones in stage II colon cancer	Sanam	Yaghoubi	Poster	Targeting Replication Stress and the Immune Microenvironment	4/16/23	1:30 PM	Section 11	16
315	HPV-related genome rearrangements in head and neck cancer cell lines	Vera	Mukhina	Poster	Targeting Replication Stress and the Immune Microenvironment	4/16/23	1:30 PM	Section 11	17
316	Engineering large chromosomal deletions to advance precision oncology for prostate cancer	Jinjin	Wu	Poster	Targeting Replication Stress and the Immune Microenvironment	4/16/23	1:30 PM	Section 11	18
317	Particulate matter accumulates chromosomal instability during mitosis	Jaewook	Ryu	Poster	Targeting Replication Stress and the Immune Microenvironment	4/16/23	1:30 PM	Section 11	19
321	Metformin enhances the efficacy of enzalutamide treatment in castration-resistant prostate cancer	Kendall	Simpson	Poster	Tumor Signaling	4/16/23	1:30 PM	Section 12	1
322	Electron microscopy using electron dense genetic tag elucidates novel extracellular vesicle biogenesis in non-small cell lung cancer	Ikjot	Sohal	Poster	Tumor Signaling	4/16/23	1:30 PM	Section 12	2
323	CHI3L1 secreting PMN-MDSCs promote IFN- γ signaling in triple negative breast cancer	Ukjin	Kim	Poster	Tumor Signaling	4/16/23	1:30 PM	Section 12	3
324	Nickel exposure alters extracellular vesicles biogenesis to carry NUPR1 and mediate cancer progression	Shan	Liu	Poster	Tumor Signaling	4/16/23	1:30 PM	Section 12	4
325	The cellular prion protein is involved in the modulation of Wnt signaling in glioblastoma	Barbara	Coelho	Poster	Tumor Signaling	4/16/23	1:30 PM	Section 12	5
326	Identification of novel substrates of the UBR5 E3 ubiquitin ligase in ovarian cancer	Scott	Eblen	Poster	Tumor Signaling	4/16/23	1:30 PM	Section 12	6
327	Knockdown of VRK1 inhibits the proliferation of small cell neuroendocrine carcinoma of the uterine cervix	Mariya	Kobayashi	Poster	Tumor Signaling	4/16/23	1:30 PM	Section 12	7
328	Acetylation regulates the oncogenic functions of PRMT5	Ji Hae	Seo	Poster	Tumor Signaling	4/16/23	1:30 PM	Section 12	8
329	Vascular endothelial zinc finger 1 promotes stemness by regulating key signaling pathways	Isaiah	Mensah	Poster	Tumor Signaling	4/16/23	1:30 PM	Section 12	9

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
330	EP300 loss drives tumorigenesis in bladder cancer via activation of IL-6/JAK/STAT3 signaling	Sizhi	Gao	Poster	Tumor Signaling	4/16/23	1:30 PM	Section 12	10
331	Mitochondrial transfer from astrocytes drives glioblastoma tumorigenicity	Dionysios	Watson	Poster	Tumor Signaling	4/16/23	1:30 PM	Section 12	11
332	Simultaneous inhibition of EZH2 and activation of dopamine D1 in an isotropic triple-negative breast cancer microgel model	Xilal	Rima	Poster	Tumor Signaling	4/16/23	1:30 PM	Section 12	12
333	Interleukin 23 receptor is a critical regulator of the mitotic spindle and necessary for AML viability	Nathan	Duong	Poster	Tumor Signaling	4/16/23	1:30 PM	Section 12	13
334	ASAP1's role in regulating myogenic differentiation in fusion negative rhabdomyosarcoma	Angela	Kim	Poster	Tumor Signaling	4/16/23	1:30 PM	Section 12	14
335	Ubiquitin Specific Peptidase 37promotes Osteosarcoma oncogenesis by interacting with PCNA and impacting constitutive replication fork movement.	Mayank	Singh	Poster	Tumor Signaling	4/16/23	1:30 PM	Section 12	15
336	Role of ST6GAL1 sialyltransferase in early stages of pancreatic cancer development	Susan	Bellis	Poster	Tumor Signaling	4/16/23	1:30 PM	Section 12	16
337	Antitumor effect of oncomagnetic therapy in glioblastoma	Arvind	Pandey	Poster	Tumor Signaling	4/16/23	1:30 PM	Section 12	17
338	Regulation of gap junction intercellular communication in pancreatic cancer cells	Annelise	Nguyen	Poster	Tumor Signaling	4/16/23	1:30 PM	Section 12	18
339	Exploring the roles of GSDMD in mammary tumorigenesis	Derek	Zhang	Poster	Tumor Signaling	4/16/23	1:30 PM	Section 12	19
340	Investigating the role of HMGA2 and AR crosstalk in prostate cancer cell proliferation	Mojisoluwa	Awolowo	Poster	Tumor Signaling	4/16/23	1:30 PM	Section 12	20
341	Critical role of defensins in respiratory viral infection induced breast cancer progression	Umer	Ali	Poster	Tumor Signaling	4/16/23	1:30 PM	Section 12	21
342	Differential CD45 isoform expression and function in AML versus healthy leukocytes	Evan	Ales	Poster	Tumor Signaling	4/16/23	1:30 PM	Section 12	22
343	Cooperation between PRMT1 and PRMT6 drives lung cancer health disparities among Black/African American men	Ching-Yi	Chen	Poster	Tumor Signaling	4/16/23	1:30 PM	Section 12	23
344	PKC- ι is a simultaneous modulator of the sonic hedgehog and the FAK/paxillin pathways in medulloblastoma	Luke	Lajmi	Poster	Tumor Signaling	4/16/23	1:30 PM	Section 12	24
345	Cutaneous T-cell lymphoma: ectopic expression of gametocyte specific factor 1 (GTSF1) stimulates the Th phenotype	Amelia	Martínez Villarreal	Poster	Tumor Signaling	4/16/23	1:30 PM	Section 12	25
346	Downregulating KIF4A inhibited growth of uterine leiomyosarcoma by regulating cell cycle	Satoshi	Nakagawa	Poster	Tumor Signaling	4/16/23	1:30 PM	Section 12	26
347	Revealing the intracellular cytomatrix, immobilized biocatalysis, and concept of the operating cell	Tattym	Shaiken	Poster	Tumor Signaling	4/16/23	1:30 PM	Section 12	27
348	Elucidation of SUMOylation machinery in human cancer cells and naked mole-rat tissues	Mohammed	Salih	Poster	Tumor Signaling	4/16/23	1:30 PM	Section 12	28

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
349	LncRNA Myca controls hepatocellular carcinoma growth and progression	Hsin-Yi	Chen	Poster	Tumor Signaling	4/16/23	1:30 PM	Section 12	29
350	Study of A3 adenosine receptor interactions and identification of novel ant-/agonist using a specific fluorescent probe	Katerina	Jecmenova	Poster	Tumor Signaling	4/16/23	1:30 PM	Section 12	30
354	The progression of changes in cardiac structure and function in mice with epithelial ovarian cancer	Bridget	Coyle-Asbil	Poster	Cancer Cachexia	4/16/23	1:30 PM	Section 13	1
355	Examination of systemic myokine concentrations with risk of cachexia in non-metastatic colorectal cancer patients - Results from the ColoCare Study	Jennifer	Ose	Poster	Cancer Cachexia	4/16/23	1:30 PM	Section 13	2
356	Targeting differential metabolism in an aged model of cancer cachexia	Aneesha	Dasgupta	Poster	Cancer Cachexia	4/16/23	1:30 PM	Section 13	3
359	Pancreatic cancer cachexia is associated with infiltration of immune cells into sympathetic ganglia	Parham	Diba	Poster	Cancer Cachexia	4/16/23	1:30 PM	Section 13	6
360	Changes in adipose tissue microenvironment occurs early in murine models of pancreatic cancer cachexia	Sephora	Jean	Poster	Cancer Cachexia	4/16/23	1:30 PM	Section 13	7
361	PDK4 is dispensable for PDAC chachexia	Omnia	Gaafer	Poster	Cancer Cachexia	4/16/23	1:30 PM	Section 13	8
362	Development of PEP3-IR750 probe to identify adipose tissue and cachexia in murine models	Sophia	Chakrabarty	Poster	Cancer Cachexia	4/16/23	1:30 PM	Section 13	9
363	Modelling cancer cachexia using a comprehensive panel of heterogeneous esophageal squamous cell carcinoma xenografts for therapeutic application	Bryan Chee-chad	Lung	Poster	Cancer Cachexia	4/16/23	1:30 PM	Section 13	10
364	Multi-omics approaches revealed the involvement of immune cells in skeletal muscles of lung cancer cachexia mouse model	Se-Young	Park	Poster	Cancer Cachexia	4/16/23	1:30 PM	Section 13	11
365	Targeting FGF21 inhibits tumor growth and attenuates cachexia in experimental colorectal cancer	Joshua	Huot	Poster	Cancer Cachexia	4/16/23	1:30 PM	Section 13	12
366	Utilizing epicardial fat thickness as an indicator of cardiac cachexia in resectable pancreatic ductal adenocarcinoma	Vignesh	Vudatha	Poster	Cancer Cachexia	4/16/23	1:30 PM	Section 13	13
367	The heparan sulfate mimetic PG545 inhibits tumor growth in both male and female mouse model of pancreatic ductal adenocarcinoma (PDAC) with sex difference in the effect on cachexia	Xiaoling	Zhong	Poster	Cancer Cachexia	4/16/23	1:30 PM	Section 13	14
368	Neutralizing antibody against GDF-15 restores cachexia	Hao	Peng	Poster	Cancer Cachexia	4/16/23	1:30 PM	Section 13	15
369	Gemcitabine nab-paclitaxel combination with DMAPT in PDAC cachexia	Brittany	Counts	Poster	Cancer Cachexia	4/16/23	1:30 PM	Section 13	16
370	Potential of inflammation pro-resolving lipid mediators in controlling cancer cachexia	Ahmed	Attaya	Poster	Cancer Cachexia	4/16/23	1:30 PM	Section 13	17

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
371	Integrin-mediated lipolysis by pancreatic cancer-derived extracellular vesicles in cancer-associated cachexia	Chikako	Shibata	Poster	Cancer Cachexia	4/16/23	1:30 PM	Section 13	18
375	Smoking induces Wee1 expression through miRNA deregulation, promoting docetaxel resistance in esophageal adenocarcinoma	Krishnapriya	Thangaretnam	Poster	Drug Resistance in Molecular Targeted Therapies 1	4/16/23	1:30 PM	Section 14	1
376	DKK1 inhibition can overcome sorafenib resistance in hepatocellular carcinoma cells through beta-catenin suppression	Lin	Li	Poster	Drug Resistance in Molecular Targeted Therapies 1	4/16/23	1:30 PM	Section 14	2
377	RON receptor tyrosine kinase in head and neck cancer: a potential target for overcoming resistance to anti-EGFR therapy	Zhixin	Lu	Poster	Drug Resistance in Molecular Targeted Therapies 1	4/16/23	1:30 PM	Section 14	3
378	Ferritin regulates oxaliplatin sensitivity and immunosuppression in pancreatic ductal adenocarcinoma	Ching-Feng	Chiu	Poster	Drug Resistance in Molecular Targeted Therapies 1	4/16/23	1:30 PM	Section 14	4
379	Circumvention of gefitinib resistance by repurposing flunarizine via histone deacetylase inhibition in lung cancer	William	Cho	Poster	Drug Resistance in Molecular Targeted Therapies 1	4/16/23	1:30 PM	Section 14	5
380	BaF3-BTK engineering cell lines as a useful platform for novel BTK inhibitor discovery	Feng	Hao	Poster	Drug Resistance in Molecular Targeted Therapies 1	4/16/23	1:30 PM	Section 14	6
381	Inhibition of CCR6-CCL20 axis enhances cytotoxic effect of chemotherapeutics in colon cancer	Hina	Mir	Poster	Drug Resistance in Molecular Targeted Therapies 1	4/16/23	1:30 PM	Section 14	7
382	Synergistic anti-tumor effect of ABN401 in combination with KRAS inhibitor in a c-MET-altered KRASG12C non-small cell lung cancer model	Saehyung	Lee	Poster	Drug Resistance in Molecular Targeted Therapies 1	4/16/23	1:30 PM	Section 14	8
383	Trastuzumab deruxtecan resistance is associated with reduced responsiveness to topoisomerase inhibitors (payload resistance) but no reduction in sensitivity to HER2 tyrosine kinase inhibitors	Monique	Nilsson	Poster	Drug Resistance in Molecular Targeted Therapies 1	4/16/23	1:30 PM	Section 14	9
384	Secondhand smoke exposure alters cisplatin-induced cell death and alters cell death and survival pathway in HNSCC	Balaji	Sadhasivam	Poster	Drug Resistance in Molecular Targeted Therapies 1	4/16/23	1:30 PM	Section 14	10
385	Synergistic effects of MIA-602 and its potential for use in ATRA/ATO Resistant APL	Ravinder	Chale	Poster	Drug Resistance in Molecular Targeted Therapies 1	4/16/23	1:30 PM	Section 14	11
386	Metastatic models of resistance to next generation tyrosine kinase inhibitors (TKIs) in HER2-positive breast cancer (BC)	Fu-Tien	Liao	Poster	Drug Resistance in Molecular Targeted Therapies 1	4/16/23	1:30 PM	Section 14	12
387	Enolase-1 as a candidate theranostics target for neuroendocrine prostate cancer	Krystal	Santiago Torres	Poster	Drug Resistance in Molecular Targeted Therapies 1	4/16/23	1:30 PM	Section 14	13
388	Acquired sensitivity to ONC201/TIC10 in ER+ breast cancer progressing on the mTOR inhibitor everolimus	Eleni	Farmaki	Poster	Drug Resistance in Molecular Targeted Therapies 1	4/16/23	1:30 PM	Section 14	14
389	Focal adhesion kinase (FAK) confers lenvatinib resistance in hepatocellular carcinoma via regulation of lysine deficient protein kinase 1(WNK1)	Shaimaa	Gad	Poster	Drug Resistance in Molecular Targeted Therapies 1	4/16/23	1:30 PM	Section 14	15

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
390	A comparison of the activity of the quadruplex-targeting experimental drugs QN-302 and CX-5461 (pidnarulex) in wild-type and gemcitabine-resistant pancreatic cancer cell lines	Stephen	Neidle	Poster	Drug Resistance in Molecular Targeted Therapies 1	4/16/23	1:30 PM	Section 14	16
391	Adenylosuccinate lyase enzyme is essential for growth of endocrine therapy resistant ER+ breast cancer cells	Surojeet	Sengupta	Poster	Drug Resistance in Molecular Targeted Therapies 1	4/16/23	1:30 PM	Section 14	17
392	Targeting drug-resistant acute myeloid leukemia (AML) clone using casein kinase II inhibitor	Katherine	Mercer	Poster	Drug Resistance in Molecular Targeted Therapies 1	4/16/23	1:30 PM	Section 14	18
393	Determinants of birinapant efficacy in triple negative breast cancer	Elisabeth	Brown	Poster	Drug Resistance in Molecular Targeted Therapies 1	4/16/23	1:30 PM	Section 14	19
394	ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms	Francesco	Bertoni	Poster	Drug Resistance in Molecular Targeted Therapies 1	4/16/23	1:30 PM	Section 14	20
395	Resistance to tyrosine kinase inhibitor confers an immunosuppressive microenvironment and cross-resistance to immunotherapy through AXL/PDPK1 axis in liver cancer	Man	Tong	Poster	Drug Resistance in Molecular Targeted Therapies 1	4/16/23	1:30 PM	Section 14	21
396	Role of PHF8 in resistance to melanoma targeted therapies	María de los Ángeles	Gómez-Muñoz	Poster	Drug Resistance in Molecular Targeted Therapies 1	4/16/23	1:30 PM	Section 14	22
397	The role of heparan sulfate in enhancing the chemotherapeutic response in triple-negative breast cancer	Jasmine	Manouchehri	Poster	Drug Resistance in Molecular Targeted Therapies 1	4/16/23	1:30 PM	Section 14	23
398	The inhibition of sulfation of heparan sulfate augments the chemotherapeutic response in triple-negative breast cancer	Jasmine	Manouchehri	Poster	Drug Resistance in Molecular Targeted Therapies 1	4/16/23	1:30 PM	Section 14	24
399	Molecular mechanism of ormeloxifene mediated chemosensitivity in hepatocellular carcinoma	Mohammed	Sikander	Poster	Drug Resistance in Molecular Targeted Therapies 1	4/16/23	1:30 PM	Section 14	25
400	TIP60-mediated regulation of DNp63a is associated with cisplatin resistance	Akshay	Hira	Poster	Drug Resistance in Molecular Targeted Therapies 1	4/16/23	1:30 PM	Section 14	26
401	Developing KRAS G12C inhibitor-resistant tumor models for efficacy evaluation of next-generation anticancer therapies	Jun	Zhou	Poster	Drug Resistance in Molecular Targeted Therapies 1	4/16/23	1:30 PM	Section 14	27
406	Novel therapeutic combination targets the growth of letrozole resistant breast cancer through decreased cyclin B1	Syreeta	Tilghman	Poster	Drug Resistance in Molecular Targeted Therapies 2	4/16/23	1:30 PM	Section 15	1
408	Novel growth hormone receptor antagonist with discrete PEGylations markedly improve response to therapy in human pancreatic and bile duct cancers in mice	Reetobrata	Basu	Poster	Drug Resistance in Molecular Targeted Therapies 2	4/16/23	1:30 PM	Section 15	3
410	Tumor heterogeneity via AXL activation on primary resistance to EGFR tyrosine kinase inhibitors in EGFR mutated lung cancer	Tadaaki	Yamada	Poster	Drug Resistance in Molecular Targeted Therapies 2	4/16/23	1:30 PM	Section 15	5
411	PHI-501, a novel pan-RAF/DDRs dual kinase inhibitor, overcomes BRAF or MEK inhibitor resistance in melanoma	Sue Min	Kim	Poster	Drug Resistance in Molecular Targeted Therapies 2	4/16/23	1:30 PM	Section 15	6

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
412	Drug combination screen identifies pemigatinib, an FGFR inhibitor, as a mechanism to overcome KRASG12C inhibitor resistance in lung cancer	Angela	Abdollahi	Poster	Drug Resistance in Molecular Targeted Therapies 2	4/16/23	1:30 PM	Section 15	7
414	Targeting lipid metabolism to improve efficacy of braf-targeted therapy in colorectal cancer	Mariah	Geisen	Poster	Drug Resistance in Molecular Targeted Therapies 2	4/16/23	1:30 PM	Section 15	9
415	Metabolic reprogramming driven by IGF2BP3-COX6B2 axis promotes acquired resistance to EGFR-TKIs in non-small lung cancer	Xiaolei	Zhang	Poster	Drug Resistance in Molecular Targeted Therapies 2	4/16/23	1:30 PM	Section 15	10
416	Phosphorylation of CDK9 transduces ALK signaling to promote resistance to PARP inhibitors via RNA Pol II activated homologous recombination repair	Yu-Yi	Chu	Poster	Drug Resistance in Molecular Targeted Therapies 2	4/16/23	1:30 PM	Section 15	11
417	Targeting aurora kinase b overcomes acquired resistance to met-tyrosine kinase inhibitor in met-amplified lung cancer	Yura	Choi	Poster	Drug Resistance in Molecular Targeted Therapies 2	4/16/23	1:30 PM	Section 15	12
418	Elacridar potentiates sunitinib efficacy in colorectal cancer models	Dennis	Poel	Poster	Drug Resistance in Molecular Targeted Therapies 2	4/16/23	1:30 PM	Section 15	13
419	Elevated Akt/mTOR signaling drives therapy resistance in ALM	Jeremy	Bravo Narula	Poster	Drug Resistance in Molecular Targeted Therapies 2	4/16/23	1:30 PM	Section 15	14
420	Dicer-dependent of ERK activation promotes the acquired oxaliplatin resistance in colorectal cancer	Yu-Heng	Kuan	Poster	Drug Resistance in Molecular Targeted Therapies 2	4/16/23	1:30 PM	Section 15	15
422	Cell intrinsic determinants of response to mTOR based therapy	Milica	Momcilovic	Poster	Drug Resistance in Molecular Targeted Therapies 2	4/16/23	1:30 PM	Section 15	17
423	β -Escin eradicates cancer stem-like population in HER2-positive breast cancer with trastuzumab resistance	Soeun	Park	Poster	Drug Resistance in Molecular Targeted Therapies 2	4/16/23	1:30 PM	Section 15	18
424	RTK inhibitor resistance in NSCLC harboring MED12 mutation is overcome by only blocking MEK signaling, not AKT due to mutated MED12-induced YAP-PTEN dysregulation	Hyun-Min	Ryu	Poster	Drug Resistance in Molecular Targeted Therapies 2	4/16/23	1:30 PM	Section 15	19
425	Characterization of TKI-induced drug-tolerant persister cells from a patient-derived cell line	Floriane	Brayé	Poster	Drug Resistance in Molecular Targeted Therapies 2	4/16/23	1:30 PM	Section 15	20
426	Ongoing TCR β VDJ rearrangement in pre-T LBL cell lines	Dengchao	Cao	Poster	Drug Resistance in Molecular Targeted Therapies 2	4/16/23	1:30 PM	Section 15	21
427	Newer generation mTOR inhibition represents effective therapeutic strategy for BRAF-mutant melanoma	Gennie	Parkman	Poster	Drug Resistance in Molecular Targeted Therapies 2	4/16/23	1:30 PM	Section 15	22
428	The role of sphingosine kinase 2 in overcoming EGFR-tyrosine kinase inhibitor resistance, EMT and NSCLC tumor progression	S M	Nasifuzzaman	Poster	Drug Resistance in Molecular Targeted Therapies 2	4/16/23	1:30 PM	Section 15	23
429	Efficacy of JSI-1187 or VIC-1911 in combination with KRAS G12C inhibitors for the treatment of KRAS G12C-mutated non-small cell lung cancer and colorectal cancer	Lei	Zhang	Poster	Drug Resistance in Molecular Targeted Therapies 2	4/16/23	1:30 PM	Section 15	24

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
430	Pemigatinib, an FGFR inhibitor, overcomes resistance to KRASG12C inhibitors in mesenchymal-like NSCLC tumors	Margaret	Favata	Poster	Drug Resistance in Molecular Targeted Therapies 2	4/16/23	1:30 PM	Section 15	25
431	FOXD1 promotes dedifferentiation and targeted therapy resistance in melanoma by regulating the expression of connective tissue growth factor	Qian	Sun	Poster	Drug Resistance in Molecular Targeted Therapies 2	4/16/23	1:30 PM	Section 15	26
432	Mechanisms of acquired resistance to ARV-471, a novel PROTAC [®] estrogen receptor degrader	Jessica	Teh	Poster	Drug Resistance in Molecular Targeted Therapies 2	4/16/23	1:30 PM	Section 15	27
433	Mechanisms of resistance to BAY 2927088, the first reversible inhibitor targeting EGFR exon 20 insertion mutations in non-small cell lung cancer	Gizem	Karsli Uzunbas	Poster	Drug Resistance in Molecular Targeted Therapies 2	4/16/23	1:30 PM	Section 15	28
437	Computational discovery and preclinical validation of therapeutic leads with novel MOAs for Glioblastoma	Isaac	Hakim	Poster	New Drug Targets	4/16/23	1:30 PM	Section 16	1
438	Antibody drug conjugate using a novel anti-CDCP1 antibody with low hematopoietic stem-cell binding and rapid internalization showed high efficacy for solid cancer	Shu-ichi	Hashimoto	Poster	New Drug Targets	4/16/23	1:30 PM	Section 16	2
439	From foe to friend: In vivo reprogramming of tumor-associated macrophages to an anti-cancer phenotype by modulating N-myristoyltransferase activity.	Wouter	Kallemeijn	Poster	New Drug Targets	4/16/23	1:30 PM	Section 16	3
440	The role of PELP1 inhibitor SMIP34 in the treatment of endometrial cancer	Xue	Yang	Poster	New Drug Targets	4/16/23	1:30 PM	Section 16	4
441	Targeting MKK3-MYC complex to reduce racial survival disparity in breast cancer	Andrey	Ivanov	Poster	New Drug Targets	4/16/23	1:30 PM	Section 16	5
442	Developing a lipogenesis inhibitor for prostate cancer	Dallin	Lowder	Poster	New Drug Targets	4/16/23	1:30 PM	Section 16	6
443	Therapeutic targeting of GPR68 activated by acidic extracellular microenvironment induces ferroptosis in glioblastoma cells	Charles	Hong	Poster	New Drug Targets	4/16/23	1:30 PM	Section 16	7
444	Inhibition of GPR68 signaling activated downstream of the Warburg effect induces cell death and enhances radiosensitivity in diverse cancer cell types	Charles	Hong	Poster	New Drug Targets	4/16/23	1:30 PM	Section 16	8
445	A next generation TEAD inhibitor with refined isoform specificity for superior safety & efficacy	Florian	Muller	Poster	New Drug Targets	4/16/23	1:30 PM	Section 16	9
446	LONP1 inhibition induces mitochondrial proteotoxic stress and is cytotoxic to acute myeloid leukemia cells	Matthew	Tcheng	Poster	New Drug Targets	4/16/23	1:30 PM	Section 16	10
447	Genetic and pharmacological inhibition of TUT4 and TUT7 sensitizes AML cells to BCL-2 inhibition	Corey	Fyfe	Poster	New Drug Targets	4/16/23	1:30 PM	Section 16	11
448	Computational discovery and experimental validation of splicing-derived neoantigens	Hasan Ekrem	Zumrut	Poster	New Drug Targets	4/16/23	1:30 PM	Section 16	12

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
449	Discovery of novel MTA-cooperative PRMT5 inhibitors as targeted therapeutics for MTAP-deleted cancers	Mateusz	Nowak	Poster	New Drug Targets	4/16/23	1:30 PM	Section 16	13
450	Preclinical development of FTX-001: first in class inhibitor of the long non-coding RNA MALAT1	Marie-Aline	Neveu	Poster	New Drug Targets	4/16/23	1:30 PM	Section 16	14
451	AICAR targets oncogenic signaling pathways of MUC1-CT	Wen Cai	Zhang	Poster	New Drug Targets	4/16/23	1:30 PM	Section 16	15
452	Novel autophagy inhibitory strategies to overcome chemotherapy resistance in multiple myeloma	Marilena	Tauro	Poster	New Drug Targets	4/16/23	1:30 PM	Section 16	16
453	Targeting FOXL2C402Gvulnerabilities in adult type ovarian granulosa cell tumors	Thomas	Welte	Poster	New Drug Targets	4/16/23	1:30 PM	Section 16	17
454	Validation of GPR35 as a novel cancer target in digestive tract cancers and discovery of potent, selective GPR35 inverse agonists	James	Westcott	Poster	New Drug Targets	4/16/23	1:30 PM	Section 16	18
455	Development of an antibody-drug conjugate panel targeting high grade serous ovarian cancer	Haonan	Lu	Poster	New Drug Targets	4/16/23	1:30 PM	Section 16	19
456	Raptamer-drug conjugates as molecularly targeted cancer therapeutics	Stephanie	Vega	Poster	New Drug Targets	4/16/23	1:30 PM	Section 16	20
457	Characterization of novel NQO1-targeted therapeutic and theranostic compounds for tumor selective chemotherapy	Kalkunte	Srivenugopal	Poster	New Drug Targets	4/16/23	1:30 PM	Section 16	21
458	Targeting p27Kip1 to inhibit CDK4/6/2 as a novel therapeutic strategy to treat pancreatic ductal adenocarcinoma	Carolina	Guido	Poster	New Drug Targets	4/16/23	1:30 PM	Section 16	22
459	Targeting the non-junctional tumorigenic function of connexin43 in cancer cell plasticity	Samy	Lamouille	Poster	New Drug Targets	4/16/23	1:30 PM	Section 16	23
461	Targeting glucose metabolism in lung cancer	Sucheta	Telang	Poster	New Drug Targets	4/16/23	1:30 PM	Section 16	25
462	A novel and potent Cblb inhibitor demonstrates robust immunological profile and anti-tumor efficacy	Pravin	Iyer	Poster	New Drug Targets	4/16/23	1:30 PM	Section 16	26
463	GRC 54276, a novel small molecule inhibitor of HPK1 has entered phase 1/2 clinical trial insolid malignancies and Hodgkin's/non Hodgkin's lymphoma	Pravin	Iyer	Poster	New Drug Targets	4/16/23	1:30 PM	Section 16	27
464	AAC-11 survival pathways as therapeutic target in cancer: AAC-11 leucine-zipper domain derived peptides exert potent antitumor effects and exhibit favorable stability, pharmacokinetic and toxicology profiles	Jean-Luc	Poyet	Poster	New Drug Targets	4/16/23	1:30 PM	Section 16	28
465	The preclinical characterization of TST003, a first-in-class mAb targeting gremlin-1 overexpressed by cancer-associated fibroblasts and tumor cells	Yi	Gu	Poster	New Drug Targets	4/16/23	1:30 PM	Section 16	29
466	A potential pro-oncogenic role of SERPINB4 in melanoma	Gagan	Chhabra	Poster	New Drug Targets	4/16/23	1:30 PM	Section 16	30
470	A MDM2 degrader inhibits cell proliferation and growth of MDM2-overexpressing acute lymphoblastic leukemia in SCID mice	tao	Liu	Poster	Novel Antitumor Agents 1	4/16/23	1:30 PM	Section 17	1

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
471	A new synthetic peptide DS-2 enhanced anti-tumor activity by targeting human telomerase reverse transcriptase (hTERT) in prostate cancer cells	Jae Hyeon	Park	Poster	Novel Antitumor Agents 1	4/16/23	1:30 PM	Section 17	2
472	HER2 as a therapeutic target in bladder cancer	Xinran	Tang	Poster	Novel Antitumor Agents 1	4/16/23	1:30 PM	Section 17	3
473	Covalent menin inhibitor, BMF-219, impacts key gene signatures and molecular pathways in chronic lymphocytic leukemia patient-derived models	Priyanka	Somanath	Poster	Novel Antitumor Agents 1	4/16/23	1:30 PM	Section 17	4
474	Preclinical development of an oral selective estrogen receptor degrader (SERD) TFX06 for the treatment of ER+HER2- breast cancer	Douglas	Fang	Poster	Novel Antitumor Agents 1	4/16/23	1:30 PM	Section 17	5
475	Preclinical development of ABM-168, a novel MEK Inhibitor to treat cancer with brain tumors	Yong	Hu	Poster	Novel Antitumor Agents 1	4/16/23	1:30 PM	Section 17	6
476	ABM-1310 has significant improved BBB-penetration and intracranial tumor growth inhibition compared to FDA approved BRAF inhibitors	Yong	Hu	Poster	Novel Antitumor Agents 1	4/16/23	1:30 PM	Section 17	7
477	Discovery of RGT-018: A potent, selective and orally bioavailable SOS1 inhibitor for mutant KRAS-driven cancers	Fei	Xiao	Poster	Novel Antitumor Agents 1	4/16/23	1:30 PM	Section 17	8
478	A novel dual-acting RAS/ β -catenin inhibitor activates antitumor immunity to potentiate cancer immunotherapy	Md	Gazi	Poster	Novel Antitumor Agents 1	4/16/23	1:30 PM	Section 17	9
479	Novel specific PKM2 inhibitor, compound 3h, induces apoptotic and autophagic cell death through Akt/mTOR signaling pathway in prostate cancer cells	Chunxue	Jiang	Poster	Novel Antitumor Agents 1	4/16/23	1:30 PM	Section 17	10
480	Enhancing chemotherapy response by telotristat ethyl, an inhibitor of tryptophan hydroxylase involved in serotonin synthesis, in cholangiocarcinoma	Niranjan	Awasthi	Poster	Novel Antitumor Agents 1	4/16/23	1:30 PM	Section 17	11
481	Investigating molecular glues as a new therapeutic approach to high-risk neuroblastoma	Ian	Delahunty	Poster	Novel Antitumor Agents 1	4/16/23	1:30 PM	Section 17	12
482	Discovery of a novel and oral CHK1 inhibitor for the treatment of solid tumors	Xiaohong	Yu	Poster	Novel Antitumor Agents 1	4/16/23	1:30 PM	Section 17	13
483	Hederacolchiside A1 inhibits autophagy via CTSC inhibition and inhibits growth in colon cancer	Solbi	Kim	Poster	Novel Antitumor Agents 1	4/16/23	1:30 PM	Section 17	14
484	VIP236: A small molecule drug conjugate with an optimized camptothecin payload has significant activity in patient-derived and metastatic cancer models	Beatrix	Stelte-Ludwig	Poster	Novel Antitumor Agents 1	4/16/23	1:30 PM	Section 17	15
485	Hypoxia inducible factor (HIF) inhibitor 64B has superior anti-tumor effects compared to two different tyrosine kinase inhibitors when tested in mouse models of uveal melanoma	Margaret	Offermann	Poster	Novel Antitumor Agents 1	4/16/23	1:30 PM	Section 17	16

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
486	Characterization of a novel series of highly selective PARP7 inhibitors	Alan	Wise	Poster	Novel Antitumor Agents 1	4/16/23	1:30 PM	Section 17	17
487	ITI-1020, a novel PDE type 1 inhibitor, reduces tumor growth in triple negative breast cancer (TNBC) mouse models	Maud	Voisin	Poster	Novel Antitumor Agents 1	4/16/23	1:30 PM	Section 17	18
488	New therapeutic strategies suppressing NAD ⁺ and ATP production in cancer metabolism specific to 3D cultured ovarian cancer cells	Kei	Kudo	Poster	Novel Antitumor Agents 1	4/16/23	1:30 PM	Section 17	19
490	Discovery of novel, potent and orally available MAT2A inhibitors	Xuxing	Chen	Poster	Novel Antitumor Agents 1	4/16/23	1:30 PM	Section 17	21
491	Tankyrase-selective inhibitor STP1002 reverses resistance to MEK inhibitors in colorectal cancer with KRAS mutations	Kyungjin	Kim	Poster	Novel Antitumor Agents 1	4/16/23	1:30 PM	Section 17	22
492	Pharmacological inhibition of CXCR4 increases the anti-tumor activity of conventional and targeted therapies in B cell lymphoma models	Francesco	Bertoni	Poster	Novel Antitumor Agents 1	4/16/23	1:30 PM	Section 17	23
494	BPI-452080: A potent and selective HIF-2 α inhibitor for the treatment of clear cell renal cell carcinoma, von Hippel-Lindau disease, and other solid tumors	Jiabing	Wang	Poster	Novel Antitumor Agents 1	4/16/23	1:30 PM	Section 17	25
495	Discovery of BPI-221351, a potent, selective, orally available, and brain penetrating dual inhibitor of mutant IDH1/2	Jiabing	Wang	Poster	Novel Antitumor Agents 1	4/16/23	1:30 PM	Section 17	26
496	Targeting CD73-adenosine axis for the treatment of multiple myeloma	Bing	Hou	Poster	Novel Antitumor Agents 1	4/16/23	1:30 PM	Section 17	27
497	HX301, a first-in-class ARK5i, demonstrates antitumor activity in preclinical HCC models with high ARK5/Myc expression	Zhihua	Jiao	Poster	Novel Antitumor Agents 1	4/16/23	1:30 PM	Section 17	28
498	p53-dependent treatment response to DNA-PK inhibition in combination with irradiation in head and neck squamous cell carcinoma (HNSCC) models	Liana	Hayrapetyan	Poster	Novel Antitumor Agents 1	4/16/23	1:30 PM	Section 17	29
501	Discovery of BPI-460372, a potent and selective inhibitor of TEAD for the treatment of solid tumors harboring Hippo pathway aberrations	Jiabing	Wang	Poster	Novel Antitumor Agents 2	4/16/23	1:30 PM	Section 18	1
502	ISM3091, a novel selective USP1 inhibitor as a targeted anticancer therapy	Sujata	Rao	Poster	Novel Antitumor Agents 2	4/16/23	1:30 PM	Section 18	2
503	ISM3412, a novel and selective MAT2A inhibitor for the treatment of cancer	Sujata	Rao	Poster	Novel Antitumor Agents 2	4/16/23	1:30 PM	Section 18	3
504	BPI-472372: a potent and orally bioavailable small molecule inhibitor of CD73 for cancer immunotherapy	Jiabing	Wang	Poster	Novel Antitumor Agents 2	4/16/23	1:30 PM	Section 18	4
505	Small molecule circadian clock compounds display therapeutic potential in targeting glioblastoma stem cells	Priscilla	Chan	Poster	Novel Antitumor Agents 2	4/16/23	1:30 PM	Section 18	5

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
506	ANJ810 is a highly selective novel MCL1 inhibitor with optimized in vivo clearance showing robust efficacy in preclinical solid and hematological tumor models	Ulrike	Rauh	Poster	Novel Antitumor Agents 2	4/16/23	1:30 PM	Section 18	6
509	DM5167, a novel selective PARP1 inhibitor, efficiently reduces growth of triple-negative breast cancers	Sujin	Nam	Poster	Novel Antitumor Agents 2	4/16/23	1:30 PM	Section 18	9
510	Targeting metabolic vulnerabilities to reduce triple negative breast cancer health disparities	Diana	Márquez-Garban	Poster	Novel Antitumor Agents 2	4/16/23	1:30 PM	Section 18	10
511	A small molecule CET019 inhibits progression of triple negative breast cancer	Arpit	Dheeraj	Poster	Novel Antitumor Agents 2	4/16/23	1:30 PM	Section 18	11
512	Identification of SS008871, a novel Polθ inhibitor that effectively inhibits tumors with homologous recombination deficiency in vitro and in vivo	Renhong	Tang	Poster	Novel Antitumor Agents 2	4/16/23	1:30 PM	Section 18	12
513	Suppressing YBX1 with a small molecule inhibitor sensitizes lung cancer to chemotherapy	Jee Min	Lee	Poster	Novel Antitumor Agents 2	4/16/23	1:30 PM	Section 18	13
514	Novel potent azetidine-based inhibitors bind irreversibly to Stat3 DNA-binding domain (DBD) and are efficacious against tumor growth in mice	Francisco	Lopez-Tapia	Poster	Novel Antitumor Agents 2	4/16/23	1:30 PM	Section 18	14
515	Discovery of potent and orally available small molecule inhibitors of the SOS1-KRAS interaction	Ha Na	Yu	Poster	Novel Antitumor Agents 2	4/16/23	1:30 PM	Section 18	15
516	Discovery and preclinical characterization of AMG 650, a first-in-class inhibitor of kinesin KIF18A motor protein with potent activity against chromosomally unstable cancers	Marc	Payton	Poster	Novel Antitumor Agents 2	4/16/23	1:30 PM	Section 18	16
517	Targeting chromosomally unstable tumors with a selective KIF18A inhibitor	Aaron	Phillips	Poster	Novel Antitumor Agents 2	4/16/23	1:30 PM	Section 18	17
518	AB801 is a highly potent and selective AXL kinase inhibitor that demonstrates significant anti-tumor activity	Ester	Fernandez-Salas	Poster	Novel Antitumor Agents 2	4/16/23	1:30 PM	Section 18	18
519	A novel Skp1 inhibitor has potent preclinical efficacy against metastatic castration-resistant prostate cancer	Xin	Li	Poster	Novel Antitumor Agents 2	4/16/23	1:30 PM	Section 18	19
520	Investigation the function and application of spermine in castration-resistant prostate cancer	Jingkai	Sun	Poster	Novel Antitumor Agents 2	4/16/23	1:30 PM	Section 18	20
521	Discovery of novel TNKS inhibitors through structure-based virtual screening	Jiyeon	Ahn	Poster	Novel Antitumor Agents 2	4/16/23	1:30 PM	Section 18	21
522	Selective estrogen receptor a-UPR activators (SERA): a novel class of small molecules that eradicate estrogen receptor positive tumors	Michael	Mulligan	Poster	Novel Antitumor Agents 2	4/16/23	1:30 PM	Section 18	22
523	Targeting myc-amplified cancers with a novel prodrug inhibiting aurora A kinase	Ya-Hui	Chi	Poster	Novel Antitumor Agents 2	4/16/23	1:30 PM	Section 18	23

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
524	SP-3164, a novel ikaros and aiolos molecular glue degrader with preclinical activity in non-Hodgkin lymphomas	Daniela	Santiesteban	Poster	Novel Antitumor Agents 2	4/16/23	1:30 PM	Section 18	24
525	Targeting interleukin-1 receptor-associated kinase 1/4 in acute myeloid leukemia stem cells	Tzu-Chieh	Ho	Poster	Novel Antitumor Agents 2	4/16/23	1:30 PM	Section 18	25
526	RMC-9805, a first-in-class, mutant-selective, covalent and oral KRASG12D(ON) inhibitor that induces apoptosis and drives tumor regression in preclinical models of KRASG12D cancers	Jingjing	Jiang	Poster	Novel Antitumor Agents 2	4/16/23	1:30 PM	Section 18	26
527	Targeting citric acid cycle anaplerosis reverses the immunosuppressive phenotype of CD11b+Gr1+ myeloid cells in ovarian cancer	Mary Priyanka	Udumula	Poster	Novel Antitumor Agents 2	4/16/23	1:30 PM	Section 18	27
528	Mechanisms and rational combinations with gp-2250, a novel oxathiazine derivative, in ovarian cancer	Mark	Kim	Poster	Novel Antitumor Agents 2	4/16/23	1:30 PM	Section 18	28
529	Novel inhibitors of the NRF2 pathway also arrest lung cancer cells in G2/M	Christopher	Occhiuto	Poster	Novel Antitumor Agents 2	4/16/23	1:30 PM	Section 18	29
530	Preclinical evaluation of avutometinib (VS-6766; RAF/MEK clamp) in combination with EGFR inhibition in colorectal cancer patient-derived xenograft (PDX) models harboring KRAS mutations	Chongkai	Wang	Poster	Novel Antitumor Agents 2	4/16/23	1:30 PM	Section 18	30
534	PRMT5 inhibition as a therapeutic strategy for KRAS mutant CRC: downstream mediators of the PRMT5-KRAS crosstalk	David	Shifteh	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 1	4/16/23	1:30 PM	Section 19	1
536	The role of CCN1 in mutant K-RAS addiction in pancreatic ductal adenocarcinoma	Archana	De	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 1	4/16/23	1:30 PM	Section 19	3
537	Validating USP27X as a drug target in lung cancer	Shamshad	Alam	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 1	4/16/23	1:30 PM	Section 19	4
538	Inhibition of progression of malignant melanomas in B16F10 murine model by recombinant N-acetylgalactosamine-4-Sulfatase (arylsulfatase B)	Joanne	Tobacman	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 1	4/16/23	1:30 PM	Section 19	5
539	Furin predicts prognosis and promotes PTC progression and metastasis via MEK-ERK axis	Pratheeshkumar	Poyil	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 1	4/16/23	1:30 PM	Section 19	6
542	Synthetic lethal targeting of AURKA in head and neck squamous cell carcinoma	Flaviane	Silva	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 1	4/16/23	1:30 PM	Section 19	9
543	Preclinical characteristic of HMPL-306, a CNS-penetrable dual inhibitor of mutant IDH1 and IDH2	Na	Yang	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 1	4/16/23	1:30 PM	Section 19	10
544	Dissecting the functional impairment of wild-type Tp53 in human glioblastoma	Leopoldo	García-Montaña	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 1	4/16/23	1:30 PM	Section 19	11
546	Targeting BRAF mutations in head and neck cancer	Chun Ho	Law	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 1	4/16/23	1:30 PM	Section 19	13

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
547	Role of KDM4A in bladder cancer	Neveen	Said	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 1	4/16/23	1:30 PM	Section 19	14
548	The microRNA-10b targeted therapeutic, TTX-MC138, is effective in preclinical pancreatic adenocarcinoma	Zdravka	Medarova	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 1	4/16/23	1:30 PM	Section 19	15
549	Characterization of the selective inhibitory effect of KRas inhibitors in different cellular assay formats	Franziska	Fimm-Todt	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 1	4/16/23	1:30 PM	Section 19	16
550	p53 rescue of tumor suppressor function with ADGN-531 causes tumor regression both as single agent and in combination with PARPi and KRASG12Cinhibitors	Gilles	Divita	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 1	4/16/23	1:30 PM	Section 19	17
551	MDM2 inhibition in combination with imipridone ONC201 treatment as a synergistic combination in solid tumors	Andrew	George	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 1	4/16/23	1:30 PM	Section 19	18
552	Stromal facilitated multifactorial resistance to tumor cells against targeted therapies in ALK+ NSCLC	Bina	Desai	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 1	4/16/23	1:30 PM	Section 19	19
553	SKP2 knockout induces macrophage infiltration in p53/Rb1 null transgenic mouse models of osteosarcoma and drives gene expression correlated with improved survival in patients	Alexander	Ferrena	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 1	4/16/23	1:30 PM	Section 19	20
554	The role of Mycobacterium w as a novel treatment for osteosarcoma	Kirsten	Stefan	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 1	4/16/23	1:30 PM	Section 19	21
555	Gene expression profiling in recurrence of oral cancer involved in tumor microenvironment change and cancer stem cells	Mitomu	Kioi	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 1	4/16/23	1:30 PM	Section 19	22
556	Bystander effects of EGFR-targeting 40H3 antibody-drug conjugates in glioblastoma with heterogeneous EGFR expression	Sonia	Jain	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 1	4/16/23	1:30 PM	Section 19	23
557	EGFR-targeted mesenchymal stem cells for enhanced tumor retention and inhibition	Shubhmita	Bhatnagar	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 1	4/16/23	1:30 PM	Section 19	24
558	EGFR inhibition in lung adenocarcinoma upregulates cell surface expression of the placental antigen ALPP and enhances efficacy of ALPP-ADC therapy	Yihui	Chen	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 1	4/16/23	1:30 PM	Section 19	25
559	Expression of molecular targets for antibody-drug conjugates in patients with NSCLC and RET fusions	Arianna	Marinello	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 1	4/16/23	1:30 PM	Section 19	26
560	Disitamab vedotin, an investigational HER2-directed antibody-drug conjugate, shows potent antitumor activity as a monotherapy and in combination with tucatinib in preclinical cancer models	Anita	Kulukian	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 1	4/16/23	1:30 PM	Section 19	27
561	Development of competing and non-competing fully human internalizing anti-Her2 monoclonal antibodies	Ginette	Serrero	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 1	4/16/23	1:30 PM	Section 19	28

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
562	Anti-tumor efficacy of GMF-1A3, an MMAE-based antibody drug conjugate targeting cell surface cleaved Amphiregulin in breast cancer	Paraic	Kenny	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 1	4/16/23	1:30 PM	Section 19	29
563	Preclinical development of YL202, a novel HER3-targeting antibody-drug conjugate (ADC) with novel DNA topoisomerase I inhibitor for treatment of solid tumors	Jian	Xu	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 1	4/16/23	1:30 PM	Section 19	30
568	Activation of the RXR nuclear receptor regulates CD4 T cell activity in a murine model of HER2+ breast cancer	Ana	Leal	Poster	Targeting the Tumor Microenvironment	4/16/23	1:30 PM	Section 20	2
569	BIO-PROTAC: New treatment modality to treat undruggable KRAS mutants by application of cell penetrating scFv	Gookjin	Yoon	Poster	Targeting the Tumor Microenvironment	4/16/23	1:30 PM	Section 20	3
570	Dual acting bone defender agents inhibit prostate cancer-mediated bone destruction	Fangfang	Qiao	Poster	Targeting the Tumor Microenvironment	4/16/23	1:30 PM	Section 20	4
571	Angiopoietin-like 4 as a potential therapeutic target for clear cell renal carcinoma	Zeng	Jin	Poster	Targeting the Tumor Microenvironment	4/16/23	1:30 PM	Section 20	5
572	Tumor-activated PD1-directed IL-2 increased antigen specific T cells in tumors and demonstrated anti-tumor activity in mice	Ertan	Eryilmaz	Poster	Targeting the Tumor Microenvironment	4/16/23	1:30 PM	Section 20	6
574	Depletion of regulatory T cells without interruption of IL-2 signaling by antibody against CD25 for enhancing antitumor immunity	Feng	Hao	Poster	Targeting the Tumor Microenvironment	4/16/23	1:30 PM	Section 20	8
575	Brain delivery of clinically suitable nanobioconjugates to inhibit glioblastoma growth through extracellular matrix-immune cell crosstalk	Alexander	Ljubimov	Poster	Targeting the Tumor Microenvironment	4/16/23	1:30 PM	Section 20	9
576	ACTM-838, a novel immunotherapy that enriches in solid tumors after IV dosing and comprehensively reverses the immunosuppressive TME to promote durable anti-tumor immunity	Akshata	Udyavar	Poster	Targeting the Tumor Microenvironment	4/16/23	1:30 PM	Section 20	10
577	ENPP1 inhibitor ZX-8177 in combination with chemotherapy or radiation exhibits synergistic anti-tumor effects via STING-mediated response	Xiaoli	Qin	Poster	Targeting the Tumor Microenvironment	4/16/23	1:30 PM	Section 20	11
578	Novel bi-thiazole LOX inhibitors to overcome chemotherapy resistance in triple negative breast cancer	Metin	Cetin	Poster	Targeting the Tumor Microenvironment	4/16/23	1:30 PM	Section 20	12
579	Mini-tumors: Pre-clinical HCl assays to screen anti-cancer drugs in the context of organoids, cancer-associated fibroblasts and immune cells	Marrit	Putker	Poster	Targeting the Tumor Microenvironment	4/16/23	1:30 PM	Section 20	13
580	A novel drug suppresses pancreatic cancer growth through immunomodulation	Shreyas	Gaikwad	Poster	Targeting the Tumor Microenvironment	4/16/23	1:30 PM	Section 20	14

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
581	Peptide-based theranostics targeting ANTXR1 in cancer stroma	Shengjun	Li	Poster	Targeting the Tumor Microenvironment	4/16/23	1:30 PM	Section 20	15
582	IDO1 inhibition sensitizes metastatic lung tumors to hypoxia/ER stress targeting agent-induced cell death	Shih-Chun	Shen	Poster	Targeting the Tumor Microenvironment	4/16/23	1:30 PM	Section 20	16
583	AVA3996, a novel pre CISION™ medicine, targeted to the tumor microenvironment via fibroblast activation protein (FAP) mediated cleavage	David	Jones	Poster	Targeting the Tumor Microenvironment	4/16/23	1:30 PM	Section 20	17
584	Doppel, an exosome mediated biomarker specific to tumor endothelial cells	Byoungmo	Kim	Poster	Targeting the Tumor Microenvironment	4/16/23	1:30 PM	Section 20	18
585	Pretargeted radioimmunotherapy with a novel anti-oxMIF/HSG bispecific antibody and a Lu177-loaded HSG radioligand results in significant tumor regression in murine models of cancer	Alexander	Schinagl	Poster	Targeting the Tumor Microenvironment	4/16/23	1:30 PM	Section 20	19
586	Development of a novel pan-chemokine receptor inhibitor as therapeutic for breast cancer	Mariana	Grigoruta	Poster	Targeting the Tumor Microenvironment	4/16/23	1:30 PM	Section 20	20
587	A half-life extended, tumor-activated IL-12 increased the infiltration of effector immune cells into the tumor microenvironment and demonstrated anti-tumor activity in syngeneic mouse models	Jennifer	O'Neil	Poster	Targeting the Tumor Microenvironment	4/16/23	1:30 PM	Section 20	21
589	Long-term acclimation of target cell lines to tumor microenvironment culture condition provides mechanistic insights into cell therapy effectiveness	James	Lim	Poster	Targeting the Tumor Microenvironment	4/16/23	1:30 PM	Section 20	23
592	Therapeutical antibody against LILRB2 enhances antitumor immunity by reprogramming M2 macrophage	Guojin	Wu	Poster	Targeting the Tumor Microenvironment	4/16/23	1:30 PM	Section 20	26
593	Bispecific antibody against TIGIT and PVRIG enhances antitumor immunity	Guojin	Wu	Poster	Targeting the Tumor Microenvironment	4/16/23	1:30 PM	Section 20	27
594	Effects of interstitial pressure on lung cancer cells	Shinsaku	Tokuda	Poster	Targeting the Tumor Microenvironment	4/16/23	1:30 PM	Section 20	28
595	Targeting metabolic vulnerability in brain-metastatic HER2+ breast cancer	Habib	Serhan	Poster	Targeting the Tumor Microenvironment	4/16/23	1:30 PM	Section 20	29
596	Development and assessment of a novel tumor microenvironment activable linker (TMALIN) ADC platform for solid tumor treatments	Jian	Xu	Poster	Targeting the Tumor Microenvironment	4/16/23	1:30 PM	Section 20	30
600	Tumour and local lymphoid tissue interaction determines prognosis in high grade serous ovarian cancer	Haonan	Lu	Poster	Adaptive Immunity to Tumors	4/16/23	1:30 PM	Section 21	1
601	Serological responses to tumor-associated adducts in pancreatic cancer	Talita	Aguiar	Poster	Adaptive Immunity to Tumors	4/16/23	1:30 PM	Section 21	2

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
602	Single cell evaluation of intratumoral B cells across solid tumor indications	Shawn	Fahl	Poster	Adaptive Immunity to Tumors	4/16/23	1:30 PM	Section 21	3
603	Deficiency of metabolic regulator PKM2 activates the pentose phosphate pathway to generate TCF1+ progenitor CD8+ T cells to improve checkpoint blockade	Geoffrey	Markowitz	Poster	Adaptive Immunity to Tumors	4/16/23	1:30 PM	Section 21	4
604	Hybrid quantification of SILAC-barcoded interacting tumor and T cells	Sofia	Ibáñez Molero	Poster	Adaptive Immunity to Tumors	4/16/23	1:30 PM	Section 21	5
605	Single cell RNA sequencing reveals tumor immune microenvironment and T cell receptor diversity in epidermal growth factor receptor (EGFR) mutated lung cancer	Turja	Chakrabarti	Poster	Adaptive Immunity to Tumors	4/16/23	1:30 PM	Section 21	6
606	Cis-B7:CD28 interactions at invaginated synaptic membranes activate CD28 and promote T cell function	Yunlong	Zhao	Poster	Adaptive Immunity to Tumors	4/16/23	1:30 PM	Section 21	7
607	CD8+ T cell clones maintain a pool of memory-like Ly108+ cells in the tumor during their contraction phase	Munetomo	Takahashi	Poster	Adaptive Immunity to Tumors	4/16/23	1:30 PM	Section 21	8
608	Low avidity neopeptide-specific CD8+ tumor infiltrating lymphocytes are less exhausted and more effective than their high avidity counterparts in a BALB/c murine fibrosarcoma	Summit	Singhviranon	Poster	Adaptive Immunity to Tumors	4/16/23	1:30 PM	Section 21	9
609	The predictive power of tertiary lymphoid structures in assessing response to trimodal therapy in muscle invasive bladder cancer	Nour	Hassan	Poster	Adaptive Immunity to Tumors	4/16/23	1:30 PM	Section 21	10
610	Modeling tumor immunoediting coupled with T-cell repertoire dynamic	Jayon	Lihm	Poster	Adaptive Immunity to Tumors	4/16/23	1:30 PM	Section 21	11
611	Sex disparities in cancer immunoediting	Elise	Alspach	Poster	Adaptive Immunity to Tumors	4/16/23	1:30 PM	Section 21	12
612	Control of the Basal Molecular Subtype of Murine Bladder Cancer by Adaptive Immunity	Burles	Johnson	Poster	Adaptive Immunity to Tumors	4/16/23	1:30 PM	Section 21	13
613	T cell antitumor function requires potassium transport	Robert	Eil	Poster	Adaptive Immunity to Tumors	4/16/23	1:30 PM	Section 21	14
614	CD137 (4-1BB) requires physically associated cIAPs for signal transduction and antitumor effects	Ignacio	Melero	Poster	Adaptive Immunity to Tumors	4/16/23	1:30 PM	Section 21	15
615	Spatially resolved expression of T cell receptors elucidates spatial relationships between T cells, immune infiltration, and cancer-associated pathways	Katrina	van Raay	Poster	Adaptive Immunity to Tumors	4/16/23	1:30 PM	Section 21	16
617	Oncogenic CXCL10 triggers CD8+ T cell exhaustion in ovarian cancer	Runying	Long	Poster	Adaptive Immunity to Tumors	4/16/23	1:30 PM	Section 21	18
618	CRISPR screening identifies the deubiquitylase ATXN3 as a PD-L1 positive regulator for tumor immune evasion	Deyu	Fang	Poster	Adaptive Immunity to Tumors	4/16/23	1:30 PM	Section 21	19
619	TP53 gain-of-function mutation modulates the immunosuppressive microenvironment in non-HPV associated oral squamous cell carcinoma	Yewen	Shi	Poster	Adaptive Immunity to Tumors	4/16/23	1:30 PM	Section 21	20

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
620	Regulation of anti-tumor immune response by EphA2 receptor tyrosine kinase	Bingcheng	Wang	Poster	Adaptive Immunity to Tumors	4/16/23	1:30 PM	Section 21	21
621	Aging dampens lymphoma-provoked phenotypic and epigenomic changes to the adaptive immune system	Rebecca	Hesterberg	Poster	Adaptive Immunity to Tumors	4/16/23	1:30 PM	Section 21	22
622	Progesterone promotes immunosuppression in the mammary gland through regulatory T cell activity	Eilidh	Chowanec	Poster	Adaptive Immunity to Tumors	4/16/23	1:30 PM	Section 21	23
623	Immunological aging slows triple-negative breast cancer progression and impedes response to therapy	Milos	Spasic	Poster	Adaptive Immunity to Tumors	4/16/23	1:30 PM	Section 21	24
624	The role of draining lymph nodes in the post-transplant recurrence of liver cancer: Examining immune response using spatial proteomics	Peyton	Hickman	Poster	Adaptive Immunity to Tumors	4/16/23	1:30 PM	Section 21	25
625	PARP14 inhibition restores PD-1 immune checkpoint inhibitor response following IFN γ -driven adaptive resistance	Chun Wai	Wong	Poster	Adaptive Immunity to Tumors	4/16/23	1:30 PM	Section 21	26
628	Liver macrophages promote breast cancer liver metastasis through migrating neutrophils and initiating NETosis	Erwei	Song	Poster	Cancer-associated Inflammation and Microbiome	4/16/23	1:30 PM	Section 22	1
629	Characterization of the molecular mechanism of APOC1 in anti-ferroptosis and lymph node microenvironment remodeling in ESCC metastasis process	Beilei	Liu	Poster	Cancer-associated Inflammation and Microbiome	4/16/23	1:30 PM	Section 22	2
631	Single-cell analysis of immune and stroma cell remodeling in renal cell carcinoma primary tumors and bone metastatic lesions	Shenglin	Mei	Poster	Cancer-associated Inflammation and Microbiome	4/16/23	1:30 PM	Section 22	4
632	Exploiting pyroptosis in melanoma brain metastasis	Maria	Cavallo	Poster	Cancer-associated Inflammation and Microbiome	4/16/23	1:30 PM	Section 22	5
634	The impact of IL-4 on migration in triple negative breast cancer cell lines	Portia	Andrews	Poster	Cancer-associated Inflammation and Microbiome	4/16/23	1:30 PM	Section 22	7
635	Effects of vagus nerve signals on the development of peritoneal metastasis of murine gastric cancer	Yurie	Futoh	Poster	Cancer-associated Inflammation and Microbiome	4/16/23	1:30 PM	Section 22	8
636	Role of Apobec3a in pancreatitis and inflammation triggered carcinogenesis	Sonja	Woermann	Poster	Cancer-associated Inflammation and Microbiome	4/16/23	1:30 PM	Section 22	9
637	Cytokine CCL9 mediates oncogenic Kras-induced pancreatic acinar-to-ductal metaplasia through ROS	Geou-Yarh	Liou	Poster	Cancer-associated Inflammation and Microbiome	4/16/23	1:30 PM	Section 22	10
638	EPB-53 prevents NASH-HCC transition via regulation of SPHK1-S1P-HIPPO signaling and immune modulation in a murine model	Yan	Li	Poster	Cancer-associated Inflammation and Microbiome	4/16/23	1:30 PM	Section 22	11
639	Prevention of pancreatitis and subsequent pancreatic cancer and fibrosis development by PI3K γ inhibition	Anghesom	Ghebremedhin	Poster	Cancer-associated Inflammation and Microbiome	4/16/23	1:30 PM	Section 22	12
640	Exploring the relationships between prostate cancer, colorectal cancer, and ulcerative colitis	Marco	De Velasco	Poster	Cancer-associated Inflammation and Microbiome	4/16/23	1:30 PM	Section 22	13

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
641	VirMAP for cancer: Characterization of the intratumoral virome in virally-associated cancers and a resource for investigators	Yongwoo	Seo	Poster	Cancer-associated Inflammation and Microbiome	4/16/23	1:30 PM	Section 22	14
642	CSF-1R+ macrophages control the gut microbiome-enhanced liver NKT function through IL-18	Chi	Ma	Poster	Cancer-associated Inflammation and Microbiome	4/16/23	1:30 PM	Section 22	15
643	Correlations of dietary fiber with intestinal microbiome and outcomes in allogeneic hematopoietic cell transplantation	Jenny	Paredes	Poster	Cancer-associated Inflammation and Microbiome	4/16/23	1:30 PM	Section 22	16
644	Gut microbiota-derived metabolites as regulators of immunity in pre-cancer	Amir	Mohseni	Poster	Cancer-associated Inflammation and Microbiome	4/16/23	1:30 PM	Section 22	17
645	Impact of sex differences on cross-talk between the gut microbiome, CEACAMs, and TGF- β signaling in cancers	Krishanu	Bhowmick	Poster	Cancer-associated Inflammation and Microbiome	4/16/23	1:30 PM	Section 22	18
646	Characteristics of skin microbiome in immune related cutaneous adverse events	Lukas	Kraehenbuehl	Poster	Cancer-associated Inflammation and Microbiome	4/16/23	1:30 PM	Section 22	19
647	Landscapes of intra-tumoral and intra-cellular microbiome in gastric cancer progression and correlation with oncogenic and immunological features	Fuduan	Peng	Poster	Cancer-associated Inflammation and Microbiome	4/16/23	1:30 PM	Section 22	20
648	Oral microbiome reprograms oral cancer stem cells to the highly immunosuppressive tumor stemness defense (TSD) phenotype	Partha	Saikia	Poster	Cancer-associated Inflammation and Microbiome	4/16/23	1:30 PM	Section 22	21
649	Comparative effects of combustible cigarette versus electronic cigarette exposures on K-ras mutant lung cancer	Maria	Grimaldo	Poster	Cancer-associated Inflammation and Microbiome	4/16/23	1:30 PM	Section 22	22
650	A machine learning model accurately predicts response to immune checkpoint inhibitors in colorectal cancer using the gut microbiome	Ayah	Al-Bzour	Poster	Cancer-associated Inflammation and Microbiome	4/16/23	1:30 PM	Section 22	23
651	Revealing the role of lung cancer microbiota in the tumor progression	Erick	Riquelme	Poster	Cancer-associated Inflammation and Microbiome	4/16/23	1:30 PM	Section 22	24
652	Tumor cell-specific IL-1/IL-1R signaling promotes KRAS mutant lung tumorigenesis	Avantika	Krishna	Poster	Cancer-associated Inflammation and Microbiome	4/16/23	1:30 PM	Section 22	25
653	Tumor cell-macrophage crosstalk drives immune suppression in pancreatic cancer	Siddharth	Mehra	Poster	Cancer-associated Inflammation and Microbiome	4/16/23	1:30 PM	Section 22	26
654	Ovarian cancer-cell glucocorticoid receptor activity modulates cytokine secretion promoting infiltration of immunosuppressive cells into the tumor microenvironment	Manisha	Taya	Poster	Cancer-associated Inflammation and Microbiome	4/16/23	1:30 PM	Section 22	27
655	Necroptosis promotes tumor growth through IL1-alpha release and recruitment of immunosuppressive myeloid cells	Kay	Hänggi	Poster	Cancer-associated Inflammation and Microbiome	4/16/23	1:30 PM	Section 22	28
656	Suppression of pyruvate carboxylase drives tumor microenvironment immunosuppression	Michael	Coleman	Poster	Cancer-associated Inflammation and Microbiome	4/16/23	1:30 PM	Section 22	29

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
657	IRAK1 regulated inflammatory signal from the leukemia cells modulates tumor microenvironment and promote leukemogenesis	Ting	Zhang	Poster	Cancer-associated Inflammation and Microbiome	4/16/23	1:30 PM	Section 22	30
662	Local and systemic effects of Dickkopf-1 during breast cancer progression by limiting NK cell-mediated killing	Seunghyun	Lee	Poster	Innate Immunity to Tumors	4/16/23	1:30 PM	Section 23	2
663	Resistin mediates the immunoediting activity exerted by primary human macrophages towards mesothelioma cells	Malik	Hamaidia	Poster	Innate Immunity to Tumors	4/16/23	1:30 PM	Section 23	3
664	Characterization of double-negative B cells within the NPC microenvironment	Michael	Chung	Poster	Innate Immunity to Tumors	4/16/23	1:30 PM	Section 23	4
665	Repetitive elements and viral mimicry co-evolve with the immune microenvironment in pancreatic ductal adenocarcinoma	Siyu	Sun	Poster	Innate Immunity to Tumors	4/16/23	1:30 PM	Section 23	5
666	Targeting the CD47/SIRP α "Do not eat me" phagocytic pathway in macrophages to improve anti-CD47 immune therapy	Nithya	Gajendran	Poster	Innate Immunity to Tumors	4/16/23	1:30 PM	Section 23	6
667	Single-cell functional genomics of natural killer cell evasion by tumor cells	Olli	Dufva	Poster	Innate Immunity to Tumors	4/16/23	1:30 PM	Section 23	7
668	The translational biology of small molecule GPR65 inhibitors: shared effects between mouse models and human primary tumors highlight the unique transformative potential of targeting a genetically validated innate immune checkpoint	Barbara	Cipriani	Poster	Innate Immunity to Tumors	4/16/23	1:30 PM	Section 23	8
669	Immunophenotyping of human brain tumors reveals myeloid cell mediated anti-glioma axis	Pravesh	Gupta	Poster	Innate Immunity to Tumors	4/16/23	1:30 PM	Section 23	9
670	Sex differences in the innate immune response to lung cancer	Lauren	May	Poster	Innate Immunity to Tumors	4/16/23	1:30 PM	Section 23	10
671	Exploiting macrophage differentiation and plasticity as an immunomodulating strategy	Carla	Castro	Poster	Innate Immunity to Tumors	4/16/23	1:30 PM	Section 23	11
672	A genetic defect in phenylalanine hydroxylase (PAH) affects the immune system in kidney	Seojeong	Kim	Poster	Innate Immunity to Tumors	4/16/23	1:30 PM	Section 23	12
673	p38 γ MAPK remodels tumor microenvironment facilitating breast cancer progression and brain metastasis	Xiangliang	Yuan	Poster	Innate Immunity to Tumors	4/16/23	1:30 PM	Section 23	13
674	CRISPR and drug screens identify ERK as the mediator of IFN γ -induced melanoma growth inhibition	Ameya	Champhekar	Poster	Innate Immunity to Tumors	4/16/23	1:30 PM	Section 23	14
675	Understanding SETDB1-mediated tumor immune evasion mechanism in endometrial cancer	Kiarash	Salari	Poster	Innate Immunity to Tumors	4/16/23	1:30 PM	Section 23	15
676	Neuro-oncology imaging mass cytometry panels enable spatial investigation of brain tumor microenvironment	Nick	Zabinyakov	Poster	Innate Immunity to Tumors	4/16/23	1:30 PM	Section 23	16
677	Increasing plexity of imaging mass cytometry for tumor tissue analysis	Nick	Zabinyakov	Poster	Innate Immunity to Tumors	4/16/23	1:30 PM	Section 23	17

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
678	Investigating the mechanisms involved in HMGB1-dependent DNA uptake and STING activation in dendritic cells	Daiana	Celias	Poster	Innate Immunity to Tumors	4/16/23	1:30 PM	Section 23	18
681	ICVB-1042, an oncolytic adenovirus, infects and kills bladder, breast, and glioblastoma human dissociated tumor cells	Michael	Pokrass	Poster	Oncolytic Viruses, Anticancer Vaccines, and Other Immunomodulatory Therapies	4/16/23	1:30 PM	Section 24	1
682	Heterologous prime-boost viral vector vaccines for the treatment of a P1A-expressing BGL-1 glioblastoma model	Emily	Steffke	Poster	Oncolytic Viruses, Anticancer Vaccines, and Other Immunomodulatory Therapies	4/16/23	1:30 PM	Section 24	2
683	Vaccination against androgen receptor splice variant induces anti-tumor adaptive immune responses	Robert	Marek	Poster	Oncolytic Viruses, Anticancer Vaccines, and Other Immunomodulatory Therapies	4/16/23	1:30 PM	Section 24	3
684	Nanovaccine displaying immunodominant T cell epitopes of fibroblast activation protein is effective against desmoplastic tumors	Hocheol	Shin	Poster	Oncolytic Viruses, Anticancer Vaccines, and Other Immunomodulatory Therapies	4/16/23	1:30 PM	Section 24	4
685	Engineering semi-allogeneic whole cancer vaccines with enhanced immunogenicity for the treatment of advanced solid tumors	Miguel	Lopez-Lago	Poster	Oncolytic Viruses, Anticancer Vaccines, and Other Immunomodulatory Therapies	4/16/23	1:30 PM	Section 24	5
686	Immunostimulatory gene therapy with oncolytic viruses potentiates the effect of paclitaxel and cisplatin in ovarian cancer	Jonas	Härdin	Poster	Oncolytic Viruses, Anticancer Vaccines, and Other Immunomodulatory Therapies	4/16/23	1:30 PM	Section 24	6
687	Preclinical activity of ES2B-C001, a human candidate HER-2 virus-like particle (VLP) vaccine, against mammary carcinoma onset and metastasis	Francesca	Ruzzi	Poster	Oncolytic Viruses, Anticancer Vaccines, and Other Immunomodulatory Therapies	4/16/23	1:30 PM	Section 24	7
688	Oncolytic VSV with retargeted glycoprotein and genetic ON switch for precise targeting of liver cancer using a synthetic virology platform	Chad	Moles	Poster	Oncolytic Viruses, Anticancer Vaccines, and Other Immunomodulatory Therapies	4/16/23	1:30 PM	Section 24	8
689	The codon-modified influenza virus CodaLytic™ rescues immunostimulatory activity and anti-tumor efficacy in PD-1-refractory tumor models	Johanna	Kaufmann	Poster	Oncolytic Viruses, Anticancer Vaccines, and Other Immunomodulatory Therapies	4/16/23	1:30 PM	Section 24	9
690	Modification of mRNA-encoded HPV16 antigens to include endolysosomal trafficking domains drives cross-presentation and results in superior in vivo and ex vivo antigen-specific responses	Ole Audun	Haabeth	Poster	Oncolytic Viruses, Anticancer Vaccines, and Other Immunomodulatory Therapies	4/16/23	1:30 PM	Section 24	10
691	Irradiated whole tumor cells pulsed with mannan-BAM, TLR ligands and anti-CD40 antibody serve as a potent tumor cell vaccine against glioblastoma	Herui	Wang	Poster	Oncolytic Viruses, Anticancer Vaccines, and Other Immunomodulatory Therapies	4/16/23	1:30 PM	Section 24	11

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
692	OAd-mediated SA-4-1BBL fused to HPV-16 E7 elicits specific antitumor efficacy in syngeneic mouse lung cancer model	Jorge	Gomez-Gutierrez	Poster	Oncolytic Viruses, Anticancer Vaccines, and Other Immunomodulatory Therapies	4/16/23	1:30 PM	Section 24	12
693	A novel multi-subset dendritic cell vaccine derived from hematopoietic progenitor cells	Richard	Barrett	Poster	Oncolytic Viruses, Anticancer Vaccines, and Other Immunomodulatory Therapies	4/16/23	1:30 PM	Section 24	13
694	TG6050 an oncolytic vaccinia virus armed with interleukin 12 and anti-CTLA4 antibody induces TME remodeling and strong anti-tumoral responses	Jean-Baptiste	Marchand	Poster	Oncolytic Viruses, Anticancer Vaccines, and Other Immunomodulatory Therapies	4/16/23	1:30 PM	Section 24	14
695	Immunostimulatory gene therapy with an oncolytic virus expressing TMZ-CD40L and 4-1BBL induces oncolysis and show immunomodulatory capacity in soft tissue sarcoma	Ahmed	Calandigary	Poster	Oncolytic Viruses, Anticancer Vaccines, and Other Immunomodulatory Therapies	4/16/23	1:30 PM	Section 24	15
696	Sensitizing breast cancers to immune checkpoint inhibitors through CD27 agonism and vaccination against tumor-associated antigen	Bin-Jin	Hwang	Poster	Oncolytic Viruses, Anticancer Vaccines, and Other Immunomodulatory Therapies	4/16/23	1:30 PM	Section 24	16
697	Extracellular vesicles (EV) - mediators of therapeutic vaccination? In vivo and in vitro characterization of EVs generated after infection of human and murine cells with therapeutic poxviruses	Karola	Rittner	Poster	Oncolytic Viruses, Anticancer Vaccines, and Other Immunomodulatory Therapies	4/16/23	1:30 PM	Section 24	17
698	Developing a self-targeted cancer immunotherapy using engineered whole tumor cell-based vaccine	Kok-Siong	Chen	Poster	Oncolytic Viruses, Anticancer Vaccines, and Other Immunomodulatory Therapies	4/16/23	1:30 PM	Section 24	18
700	Induction of cancer-specific T-cell responses in patients immunized with P10s-PADRE vaccine	Behjatolah	Monzavi-Karbassi	Poster	Oncolytic Viruses, Anticancer Vaccines, and Other Immunomodulatory Therapies	4/16/23	1:30 PM	Section 24	20
701	Evaluation of an AKT-1 antisense oligonucleotide in combination with Lenvatinib and Everolimus in Renca-luciferase syngeneic orthotopic murine tumor model	Fengyang	Xie	Poster	Oncolytic Viruses, Anticancer Vaccines, and Other Immunomodulatory Therapies	4/16/23	1:30 PM	Section 24	21
702	A novel small molecule inhibitor of ENPP1 promotes T and NK cell activation and enhances anti-tumor efficacy in combination with immune checkpoint blockade therapy	Pyoung Oh	Yoon	Poster	Oncolytic Viruses, Anticancer Vaccines, and Other Immunomodulatory Therapies	4/16/23	1:30 PM	Section 24	22
704	MDSC-targeted TFF2-MSA suppresses tumor growth and increases survival in anti-PD-1 treated MC38 and CT26.wt murine colorectal cancer models	Bruce	Daugherty	Poster	Oncolytic Viruses, Anticancer Vaccines, and Other Immunomodulatory Therapies	4/16/23	1:30 PM	Section 24	24
705	Potential of immunotherapy by LSD1 modulation	Konrad	Koehler	Poster	Oncolytic Viruses, Anticancer Vaccines, and Other Immunomodulatory Therapies	4/16/23	1:30 PM	Section 24	25

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
706	CRB-601, an avβ8 blocking antibody, prevents activation of TGFβ and exhibits anti-tumor activity associated with immune cell remodeling of the tumor microenvironment	Daqing	Wang	Poster	Oncolytic Viruses, Anticancer Vaccines, and Other Immunomodulatory Therapies	4/16/23	1:30 PM	Section 24	26
707	High major histocompatibility complex class I expression overcomes cancer immunotherapy resistance due to interferon gamma signaling pathway defects	Katsushige	Kawase	Poster	Oncolytic Viruses, Anticancer Vaccines, and Other Immunomodulatory Therapies	4/16/23	1:30 PM	Section 24	27
708	Characterization of MDNA132, an IL-13 decoy receptor selective superkine for targeted delivery of immunotherapies to the tumor microenvironment	Aanchal	Sharma	Poster	Oncolytic Viruses, Anticancer Vaccines, and Other Immunomodulatory Therapies	4/16/23	1:30 PM	Section 24	28
709	AST-301, a pDNA-based therapeutic cancer vaccine encoding HER2 ICD, improves the efficacy of checkpoint blockade therapy in CD34+ humanized gastric cancer mouse model	Hyo-Hyun	Park	Poster	Oncolytic Viruses, Anticancer Vaccines, and Other Immunomodulatory Therapies	4/16/23	1:30 PM	Section 24	29
710	Preclinical development of ALD2510, a Next-Gen Fc-enhanced, TREG-selective and IL-2-sparing anti-CD25 antibody for the treatment of solid tumors	Arnaud	Foussat	Poster	Oncolytic Viruses, Anticancer Vaccines, and Other Immunomodulatory Therapies	4/16/23	1:30 PM	Section 24	30
714	Using empathy-driven instructional design to reimagine cancer research	Janet	Brishke	Poster	Science and Health Policy / Regulatory Science and Policy	4/16/23	1:30 PM	Section 26	1
716	Trends in Medicare reimbursements within the first year of cervical cancer diagnosis, 2007-2015	Lakshmi	Kodali	Poster	Science and Health Policy / Regulatory Science and Policy	4/16/23	1:30 PM	Section 26	3
717	Racial and ethnic disparities in presentations and survival rates of hepatocellular carcinoma	Jingwei	Song	Poster	Science and Health Policy / Regulatory Science and Policy	4/16/23	1:30 PM	Section 26	4
718	Stomach cancer patient advocacy and education: Bridging the gap in disparity	Aki	Smith	Poster	Science and Health Policy / Regulatory Science and Policy	4/16/23	1:30 PM	Section 26	5
719	Advocacy organizations as critical players in the research ecosystem: A case study in the value and use of real world evidence	Kimberly	Newcomer	Poster	Science and Health Policy / Regulatory Science and Policy	4/16/23	1:30 PM	Section 26	6
720	Implementation and evaluation of a mental health app with comedy content for women living with advanced cancer	Saranne	Rothberg, MS	Poster	Science and Health Policy / Regulatory Science and Policy	4/16/23	1:30 PM	Section 26	7
721	Vaccination barriers for HPV vaccine initiation and completion: A perception analysis using the Association of Immunization Managers annual survey	Alondra	Mercado-Andino	Poster	Science and Health Policy / Regulatory Science and Policy	4/16/23	1:30 PM	Section 26	8
722	Epidemiological characterization of renal cell carcinoma in Hispanics: A single US center cohort study	Abner	Murray	Poster	Science and Health Policy / Regulatory Science and Policy	4/16/23	1:30 PM	Section 26	9
723	Who reconstitutes my chemotherapy? Examining the educational needs of oncology pharmacy practitioners in Nigeria	Runcie	Chidebe	Poster	Science and Health Policy / Regulatory Science and Policy	4/16/23	1:30 PM	Section 26	10
724	Leaving cancer patients behind for greener pastures: The clinical oncology workforce in Nigeria	Runcie	Chidebe	Poster	Science and Health Policy / Regulatory Science and Policy	4/16/23	1:30 PM	Section 26	11

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
725	Prostate cancer risk disparities and sociocultural factors in men of African ancestry	Joan	Brown	Poster	Science and Health Policy / Regulatory Science and Policy	4/16/23	1:30 PM	Section 26	12
726	Machine learning prediction of financial toxicity in patients with resected lung cancer	Nathaniel	Deboever	Poster	Science and Health Policy / Regulatory Science and Policy	4/16/23	1:30 PM	Section 26	13
727	Early detection saves lives: I survived, and you can too— Any day above ground is a good day	AJ	Merriweather	Poster	Science and Health Policy / Regulatory Science and Policy	4/16/23	1:30 PM	Section 26	14
728	Socio-economic and health disparity determinants of breast cancer prevalence in low-income counties in Alabama and Mississippi: An analysis of Deep South cancer epidemic	Ram	Alagan	Poster	Science and Health Policy / Regulatory Science and Policy	4/16/23	1:30 PM	Section 26	15
729	The economic and healthcare resource utilization of metastatic non-small cell lung cancer	Cloe	Koh	Poster	Science and Health Policy / Regulatory Science and Policy	4/16/23	1:30 PM	Section 26	16
733	Relationship between pre-diagnostic biomarkers and sarcopenia in colorectal cancer patients	Johannes	Färdeman	Poster	Cancer Survivorship	4/16/23	1:30 PM	Section 27	1
734	Comprehensive validation of high-risk clinicopathologic features in early-stage, node-negative non-small cell lung cancer	Brendan	Heiden	Poster	Cancer Survivorship	4/16/23	1:30 PM	Section 27	2
735	The associations between the use of GLP-1 receptor agonists, cancer recurrence and all-cause mortality among cancer survivors	Po-Hua	Chen	Poster	Cancer Survivorship	4/16/23	1:30 PM	Section 27	3
736	Treatment with immune checkpoint inhibitors (ICIs) and the occurrence of colitis among patients with melanoma in the United States	Xianying	Pan	Poster	Cancer Survivorship	4/16/23	1:30 PM	Section 27	4
737	Variation in prognostic value of Gleason score for lethal prostate cancer using time-varying area under the curve	Zhike	Lin	Poster	Cancer Survivorship	4/16/23	1:30 PM	Section 27	5
738	Long-term survivorship between gastrectomy and endoscopic resection for gastric cancer using a nationwide real-world database: 15 years of follow-up	Hyeong-taek	Woo	Poster	Cancer Survivorship	4/16/23	1:30 PM	Section 27	6
739	Alcohol consumption patterns among US cancer survivors: A cross-sectional study of the All of Us Research Program	Mengyao	Shi	Poster	Cancer Survivorship	4/16/23	1:30 PM	Section 27	7
740	Prevalence and cancer-specific patterns of cannabis use among US cancer survivors, 2016-2021	Ce	Shang	Poster	Cancer Survivorship	4/16/23	1:30 PM	Section 27	8
741	Incident diabetes by obesity-related cancer status and cancer treatment type	Maci	Winn	Poster	Cancer Survivorship	4/16/23	1:30 PM	Section 27	9
742	Trial in progress: Comprehensive outcomes for after cancer health (COACH), a randomized trial assessing health outcomes following primary cancer therapy	Marilyn	Hammer	Poster	Cancer Survivorship	4/16/23	1:30 PM	Section 27	10
743	Association between physical activity and lipid profile among breast cancer survivors	Hyun Jeong	Cho	Poster	Cancer Survivorship	4/16/23	1:30 PM	Section 27	11

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
744	Treatment inequities among patients diagnosed with Hodgkin's lymphoma with and without HIV (2018-2019): an analysis of the US National Cancer Database	Jessica	Islam	Poster	Cancer Survivorship	4/16/23	1:30 PM	Section 27	12
745	Burden of potential HIV and cancer-related treatment drug-drug interactions: An analysis of SEER-Medicare	Jessica	Islam	Poster	Cancer Survivorship	4/16/23	1:30 PM	Section 27	13
746	Disparities in factors affecting access to palliative care in patients with stage IV breast cancer	Mira	Itani	Poster	Cancer Survivorship	4/16/23	1:30 PM	Section 27	14
747	Racial differences in clinical outcome in patients treated for clinically localized prostate cancer by radical prostatectomy	Pin	Li	Poster	Cancer Survivorship	4/16/23	1:30 PM	Section 27	15
748	Accuracy of self reported chemotherapy usage in annual follow up surveys for a breast cancer registry	Nicole	Larson	Poster	Cancer Survivorship	4/16/23	1:30 PM	Section 27	16
749	The impact of multimorbidity on the relationship between breast cancer tumor characteristics and survivorship care experiences among older women: A SEER-CAHPS analysis	Avonne	Connor	Poster	Cancer Survivorship	4/16/23	1:30 PM	Section 27	17
750	Quality of life among anal cancer patients in Puerto Rico	Jeslie	Ramos-Cartagena	Poster	Cancer Survivorship	4/16/23	1:30 PM	Section 27	18
751	Disparities in physician office visit wait time among US cancer survivors	Onyema	Chido-Amajuoyi	Poster	Cancer Survivorship	4/16/23	1:30 PM	Section 27	19
752	Increasing cancer patient acceptance of tobacco cessation by an innovative patient-centric personal pathway to success (PPS) program	Cary	Presant	Poster	Cancer Survivorship	4/16/23	1:30 PM	Section 27	20
753	HPV vaccine uptake in survivors of childhood and adolescent and young adult (AYA) cancer	Mrudula	Nair	Poster	Cancer Survivorship	4/16/23	1:30 PM	Section 27	21
754	Exploring racial and ethnic disparities in pain medication use in patients with colorectal cancer	John	Allen	Poster	Cancer Survivorship	4/16/23	1:30 PM	Section 27	22
755	The impact of cancer treatment on cognitive function and quality of life in patients undergoing treatment at a tertiary care hospital in New Delhi, India	Delfin Lovelina	Francis	Poster	Cancer Survivorship	4/16/23	1:30 PM	Section 27	23
759	Genome-wide cell-free DNA fragmentation in early detection and disease monitoring of hepatocellular carcinoma	Shifeng	Lian	Poster	Omics and Imaging Approaches in Cancer Risk, Early Detection, and Response Assessment	4/16/23	1:30 PM	Section 28	1
760	Characteristics of fatty liver disease-related hepatocellular carcinoma and genetic background in Japan	Tomomi	Kogiso	Poster	Omics and Imaging Approaches in Cancer Risk, Early Detection, and Response Assessment	4/16/23	1:30 PM	Section 28	2
762	Organo-on-pillar based anticancer drug screening platform for ovarian cancer	Hye Ryeong	Jun	Poster	Omics and Imaging Approaches in Cancer Risk, Early Detection, and Response Assessment	4/16/23	1:30 PM	Section 28	4

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
763	Minimally invasive colorectal resection is associated with significantly elevated plasma levels of extracellular cold inducible RNA binding protein for a month after colorectal resection & may promote the growth of residual metastases	Chandana	Herath Mudiyansele	Poster	Omics and Imaging Approaches in Cancer Risk, Early Detection, and Response Assessment	4/16/23	1:30 PM	Section 28	5
764	Automated walk away NGS sample preparation for constructing in-line molecular barcoded RNA libraries from Fresh Frozen and FFPE samples	Bahram	Arezi	Poster	Omics and Imaging Approaches in Cancer Risk, Early Detection, and Response Assessment	4/16/23	1:30 PM	Section 28	6
765	Early diagnosis of brain metastases using cerebrospinal fluid cell-free DNA-based breakpoint motif and mutational features in lung cancer	Haimeng	Tang	Poster	Omics and Imaging Approaches in Cancer Risk, Early Detection, and Response Assessment	4/16/23	1:30 PM	Section 28	7
766	A genome-wide association study identifies the association of common variants in the major histocompatibility complex with cervical cancer in black South African women	Abram	Kamiza	Poster	Omics and Imaging Approaches in Cancer Risk, Early Detection, and Response Assessment	4/16/23	1:30 PM	Section 28	8
767	Genomics and transcriptomics profiling of BRCA mutation carriers revealed the landscape of early pathogenesis of BRCA1/2-associated breast cancer	Po-Han	Lin	Poster	Omics and Imaging Approaches in Cancer Risk, Early Detection, and Response Assessment	4/16/23	1:30 PM	Section 28	9
768	Immunohistochemistry analysis of the molecular subtypes of muscle invasive bladder cancer in association with prognosis	QuocThang	Pham	Poster	Omics and Imaging Approaches in Cancer Risk, Early Detection, and Response Assessment	4/16/23	1:30 PM	Section 28	10
769	Evaluating the diagnostic burden of tumor localization strategies for multi-cancer early detection tests	Tomasz	Beer	Poster	Omics and Imaging Approaches in Cancer Risk, Early Detection, and Response Assessment	4/16/23	1:30 PM	Section 28	11
770	Provider communication contributes to colorectal cancer screening intention through improving screening outcome expectancies and perceived behavioral control	Xuan	Zhu	Poster	Omics and Imaging Approaches in Cancer Risk, Early Detection, and Response Assessment	4/16/23	1:30 PM	Section 28	12
771	Mechanisms of genetic predisposition to multifocal lung cancer	Risa	Burr	Poster	Omics and Imaging Approaches in Cancer Risk, Early Detection, and Response Assessment	4/16/23	1:30 PM	Section 28	13
772	Using chromosomal-scale length variation to predict breast cancer occurrence and recurrence with machine learning	Yasaman	Fatapour	Poster	Omics and Imaging Approaches in Cancer Risk, Early Detection, and Response Assessment	4/16/23	1:30 PM	Section 28	14
773	Early detection of ovarian cancer using cell-free DNA fragmentomes	Akshaya	Annapragada	Poster	Omics and Imaging Approaches in Cancer Risk, Early Detection, and Response Assessment	4/16/23	1:30 PM	Section 28	15
774	Detection of intraductal carcinoma of the prostate (IDCP) cases focusing on high-grade prostatic intraepithelial neoplasia (PIN) findings regarding invasive carcinoma of the prostate	Ryuta	Watanabe	Poster	Omics and Imaging Approaches in Cancer Risk, Early Detection, and Response Assessment	4/16/23	1:30 PM	Section 28	16

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
775	Integrative genomic and transcriptomic profiling of myeloma precursors in a prospective longitudinal observational study (ORIGIN)	Minghao	Dang	Poster	Omics and Imaging Approaches in Cancer Risk, Early Detection, and Response Assessment	4/16/23	1:30 PM	Section 28	17
776	Temporal changes in mammographic breast density and breast cancer risk among women with benign breast disease	Maeve	Mullooly	Poster	Omics and Imaging Approaches in Cancer Risk, Early Detection, and Response Assessment	4/16/23	1:30 PM	Section 28	18
777	Super-resolution imaging of heterochromatin structure detects early events in lung cancer	Laura	Stabile	Poster	Omics and Imaging Approaches in Cancer Risk, Early Detection, and Response Assessment	4/16/23	1:30 PM	Section 28	19
779	Clonal B-cell expansion and the potential challenges to blood-based early cancer detection	Jing	Xiang	Poster	Omics and Imaging Approaches in Cancer Risk, Early Detection, and Response Assessment	4/16/23	1:30 PM	Section 28	21
780	Digital PCR-based EGFR T790M mutation detection from human blood samples collected in PAXgene Blood ccfDNA Tubes	Christian	Neander	Poster	Omics and Imaging Approaches in Cancer Risk, Early Detection, and Response Assessment	4/16/23	1:30 PM	Section 28	22
781	Clinical implications for returning polygenic risk information for skin cancer to ultra-high risk organ transplant recipients.	Mathias	Seviiri	Poster	Omics and Imaging Approaches in Cancer Risk, Early Detection, and Response Assessment	4/16/23	1:30 PM	Section 28	23
782	Circulating tumour DNA-based molecular response predicts treatment outcome in multiple myeloma	Sridurga	Mithraprabhu	Poster	Omics and Imaging Approaches in Cancer Risk, Early Detection, and Response Assessment	4/16/23	1:30 PM	Section 28	24
783	Systematic review and meta-analysis of the accuracy and applicability of blood-based multi-cancer early detection (MCED) in the general population	Youjin	Oh	Poster	Omics and Imaging Approaches in Cancer Risk, Early Detection, and Response Assessment	4/16/23	1:30 PM	Section 28	25
784	Systematic review and meta-analysis of the accuracy of tumor origin detection in blood-based multi-cancer early detection (MCED) in the general population	Youjin	Oh	Poster	Omics and Imaging Approaches in Cancer Risk, Early Detection, and Response Assessment	4/16/23	1:30 PM	Section 28	26
785	A smart cytopathology risk-assessment platform for oral potentially malignant disorders and oral squamous cell carcinoma at the point-of-care	Kritika	Srinivasan Rajsri	Poster	Omics and Imaging Approaches in Cancer Risk, Early Detection, and Response Assessment	4/16/23	1:30 PM	Section 28	27
786	Single molecule methylation sequencing of circulating DNA identifies individuals with breast cancer	Hanlee	Ji	Poster	Omics and Imaging Approaches in Cancer Risk, Early Detection, and Response Assessment	4/16/23	1:30 PM	Section 28	28
787	Lung cancer screening use before & during the COVID-19 pandemic in the US: Population-based evidence from 2019-2021	Hermine	Poghosyan	Poster	Omics and Imaging Approaches in Cancer Risk, Early Detection, and Response Assessment	4/16/23	1:30 PM	Section 28	29

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
788	Novel multiplex methylation-specific qPCR strategy for early CRC detection	Yun	Bao	Poster	Omics and Imaging Approaches in Cancer Risk, Early Detection, and Response Assessment	4/16/23	1:30 PM	Section 28	30
792	SARS-CoV-2 spike S1 mediated lung tumor regression in a mouse model	Monica	Sheinin	Poster	COVID-19 and Cancer	4/16/23	1:30 PM	Section 29	1
793	Mechanism of interferon induction by cannabidiol (CBD) and analogues in lung cancer cells	Leticia	Stock	Poster	COVID-19 and Cancer	4/16/23	1:30 PM	Section 29	2
794	Repurposing of poly- γ -glutamic acid, immunotherapeutic drug for cervical intraepithelial neoplasia 1, as covid-19 treatment	Jae Chul	Choi	Poster	COVID-19 and Cancer	4/16/23	1:30 PM	Section 29	3
795	T-cell mediated response to emerging COVID-19 strains in patients with cancer studied via deep learning	Olga	Lyudovyk	Poster	COVID-19 and Cancer	4/16/23	1:30 PM	Section 29	4
796	Altered immune response to vaccination in patients with plasma cell premalignancy	Yoshinobu	Konishi	Poster	COVID-19 and Cancer	4/16/23	1:30 PM	Section 29	5
797	COVID-19 vaccines in patients with solid tumor cancers receiving immune checkpoint inhibitors	Danielle	Gilbert	Poster	COVID-19 and Cancer	4/16/23	1:30 PM	Section 29	6
798	SeroNet Pooling Project of immunocompromised populations	Elham	Kazemain	Poster	COVID-19 and Cancer	4/16/23	1:30 PM	Section 29	7
799	Measuring the impact of the COVID-19 pandemic on breast cancer screening in Puerto Rico	Hermilis	Berrios Ortiz	Poster	COVID-19 and Cancer	4/16/23	1:30 PM	Section 29	8
800	Participation in COVID-19 clinical trials, willingness to participate, and trust in sources of information among persons with and without cancer in Puerto Rico.	Fabiola	Rivera-Gastón	Poster	COVID-19 and Cancer	4/16/23	1:30 PM	Section 29	9
801	The impact of COVID-19 on colorectal screening in Puerto Rico	Héctor	Contreras-Mora	Poster	COVID-19 and Cancer	4/16/23	1:30 PM	Section 29	10
802	Identifying factors that affect barriers to lymphoma treatment during the COVID - 19 pandemic	Amanda	Watson	Poster	COVID-19 and Cancer	4/16/23	1:30 PM	Section 29	11
804	The temporal evolution in disease phenotype of COVID-19 hospitalisation, intensive care and case fatality rates in cancer patients across the United Kingdom (UKCCP)	Thomas	Starkey	Poster	COVID-19 and Cancer	4/16/23	1:30 PM	Section 29	13
805	Association of state-level COVID-19 mortality rates with real-world progression and real-world overall survival among patients with advanced non-small cell lung cancer, 2020-2022	Maneet	Kaur	Poster	COVID-19 and Cancer	4/16/23	1:30 PM	Section 29	14
806	Enhancer deregulation in TET2-mutant clonal hematopoiesis is associated with increased COVID-19 severity and mortality	Moritz	Binder	Poster	COVID-19 and Cancer	4/16/23	1:30 PM	Section 29	15
807	Inflammatory biomarkers: Breast cancer survival and possible role in COVID-19 associated comorbidity	Hai	Hu	Poster	COVID-19 and Cancer	4/16/23	1:30 PM	Section 29	16
811	Development of a NOX-ROS nanoinhibitor for enhancing response to radiotherapy in lung cancer cells while mitigation radiation-induced inflammation and injury in the normal lung tissue	Lei	Zhu	Poster	Basic and Applied Nanotechnology and Nano-based Therapeutics and Drug Delivery	4/16/23	1:30 PM	Section 30	1

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
812	Treatment of metastatic cancers using immunotherapeutic cowpea mosaic virus nanoparticles	Young Hun	Chung	Poster	Basic and Applied Nanotechnology and Nano-based Therapeutics and Drug Delivery	4/16/23	1:30 PM	Section 30	2
813	The protein-like polymer (PLP): A tunable proteomimetic nanoplatform for the development of rationally designed cancer vaccines	Max	Wang	Poster	Basic and Applied Nanotechnology and Nano-based Therapeutics and Drug Delivery	4/16/23	1:30 PM	Section 30	3
814	Novel strategy for aptamer-directed nanovesicle targeting in cholangiocarcinoma	Jennifer	Tomlinson	Poster	Basic and Applied Nanotechnology and Nano-based Therapeutics and Drug Delivery	4/16/23	1:30 PM	Section 30	4
815	Improved tolerability and tumor specific delivery of a therapeutic bispecific T cell engager using a pH-sensitive nanoparticle platform	Qingtai	Su	Poster	Basic and Applied Nanotechnology and Nano-based Therapeutics and Drug Delivery	4/16/23	1:30 PM	Section 30	5
816	Biological evaluation of novel stearyl gemcitabine nanoparticles in primary pancreatic cancer cells and PDX mice tumor models	Esther	Frimpong	Poster	Basic and Applied Nanotechnology and Nano-based Therapeutics and Drug Delivery	4/16/23	1:30 PM	Section 30	6
817	Effective near infrared laser-induced photothermal therapy for cancer using indocyanine green/methyl-B-cyclodextrin compound loaded liposomal nanoparticle	MinKyu	Kim	Poster	Basic and Applied Nanotechnology and Nano-based Therapeutics and Drug Delivery	4/16/23	1:30 PM	Section 30	7
818	Preclinical studies of the cabazitaxel nanoformulation MPB-1734 support therapeutic application in chemo-resistant solid tumors and synergistic benefit in combination with immune checkpoint inhibitor	Yuan Hung	Hsu	Poster	Basic and Applied Nanotechnology and Nano-based Therapeutics and Drug Delivery	4/16/23	1:30 PM	Section 30	8
819	Investigating the impacts of membrane potential on nano-electroporation efficacy	Max	Shotbolt	Poster	Basic and Applied Nanotechnology and Nano-based Therapeutics and Drug Delivery	4/16/23	1:30 PM	Section 30	9
820	Photo-activatable ON-OFF microparticles for on-demand pulsatile drug delivery in a breast cancer model	Neelkanth	Bardhan	Poster	Basic and Applied Nanotechnology and Nano-based Therapeutics and Drug Delivery	4/16/23	1:30 PM	Section 30	10
821	Targeting metastatic prostate cancer using planetary ball-milled (PBM) nanoparticles	Santosh	Singh	Poster	Basic and Applied Nanotechnology and Nano-based Therapeutics and Drug Delivery	4/16/23	1:30 PM	Section 30	11
822	Target-specific nanoparticle-based strategy for improved therapeutic efficacy to treat pancreatic cancer	Juan	Vivero-Escoto	Poster	Basic and Applied Nanotechnology and Nano-based Therapeutics and Drug Delivery	4/16/23	1:30 PM	Section 30	12
823	Piperlongumine nanoformulation enhances gemcitabine therapeutic response in pancreatic cancer	Vivek	Kashyap	Poster	Basic and Applied Nanotechnology and Nano-based Therapeutics and Drug Delivery	4/16/23	1:30 PM	Section 30	13

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
825	Targeted nanospheres for the treatment of cancer	HyungGyoo	Kang	Poster	Basic and Applied Nanotechnology and Nano-based Therapeutics and Drug Delivery	4/16/23	1:30 PM	Section 30	15
826	Illuminating cancer cells with a novel nano fluorescent NIR probe for bioimaging	Neeraj	Chauhan	Poster	Basic and Applied Nanotechnology and Nano-based Therapeutics and Drug Delivery	4/16/23	1:30 PM	Section 30	16
827	Comparative study of calcein encapsulation into nanoparticles using three different micromixers as a model for small drug molecules	Armen	Erzingatzian	Poster	Basic and Applied Nanotechnology and Nano-based Therapeutics and Drug Delivery	4/16/23	1:30 PM	Section 30	17
828	DNA origami nanostructures as a targeted payload delivery system	Carlos	Castro	Poster	Basic and Applied Nanotechnology and Nano-based Therapeutics and Drug Delivery	4/16/23	1:30 PM	Section 30	18
829	Evaluation of SK-N-DZ CLENs as a potential drug delivery system for selective targeting of neuroblastoma cells	Kevin	Bumanglag	Poster	Basic and Applied Nanotechnology and Nano-based Therapeutics and Drug Delivery	4/16/23	1:30 PM	Section 30	19
830	Optimized retinoblastoma treatment approach using a Y79 retinoblastoma cellular model and CCK-8 in vitro assay protocol	Ashley	Varela Martinez	Poster	Basic and Applied Nanotechnology and Nano-based Therapeutics and Drug Delivery	4/16/23	1:30 PM	Section 30	20
831	Selective targeting of pediatric rhabdoid tumor using G401-CLENs: Cytotoxicity studies	Varun	Kudchadker	Poster	Basic and Applied Nanotechnology and Nano-based Therapeutics and Drug Delivery	4/16/23	1:30 PM	Section 30	21
832	Exosome-based hybrid nanosystem for targeted TNBC therapy	Amalendu	Ranjan	Poster	Basic and Applied Nanotechnology and Nano-based Therapeutics and Drug Delivery	4/16/23	1:30 PM	Section 30	22
833	Exosomes isolation via lyophilization for Philadelphia-positive leukemia therapy	Afsar Ali	Mian	Poster	Basic and Applied Nanotechnology and Nano-based Therapeutics and Drug Delivery	4/16/23	1:30 PM	Section 30	23
834	Synergistic effect of bacterial ghosts loaded with belinostat and betaine nano-emulsion: A potential treatment strategy for breast cancer	Sara	Deghedy	Poster	Basic and Applied Nanotechnology and Nano-based Therapeutics and Drug Delivery	4/16/23	1:30 PM	Section 30	24
835	Translational nanotechnology-based cancer vaccine to re-educate host immune response against metastatic cancers	Helena	Florindo	Poster	Basic and Applied Nanotechnology and Nano-based Therapeutics and Drug Delivery	4/16/23	1:30 PM	Section 30	25
836	Enabling mRNA medicine for brain tumors	Saigopalakrishna	Yerneni	Poster	Basic and Applied Nanotechnology and Nano-based Therapeutics and Drug Delivery	4/16/23	1:30 PM	Section 30	26

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
837	Preclinical development of ELU001: A folate receptor alpha (FR α)-targeted C'Dot drug conjugate (CDC) for the treatment of brain metastases	Gregory	Adams	Poster	Basic and Applied Nanotechnology and Nano-based Therapeutics and Drug Delivery	4/16/23	1:30 PM	Section 30	27
838	Development of cationic polypeptide-based adjuvants for cancer immunotherapy	DaeYong	Lee	Poster	Basic and Applied Nanotechnology and Nano-based Therapeutics and Drug Delivery	4/16/23	1:30 PM	Section 30	28
839	Characterization and evaluation of modified 5-fluorouracil loaded liposomal nanoparticle on pancreatic and colorectal cancer cell lines	Raviteja	Bulusu	Poster	Basic and Applied Nanotechnology and Nano-based Therapeutics and Drug Delivery	4/16/23	1:30 PM	Section 30	29
843	Development of a quantitative systems pharmacology model for clinical dose and schedule optimization of RG6234, a T-cell engaging antibody targeting GPRC5D in multiple myeloma	Cristina	Santini	Poster	Mathematical Modeling of Tumor Growth and Treatment Response	4/16/23	1:30 PM	Section 31	1
845	Developing MRI-based digital-twins via mathematical modeling and deep learning to predict the response of triple-negative breast cancer to neoadjuvant therapy	Casey	Stowers	Poster	Mathematical Modeling of Tumor Growth and Treatment Response	4/16/23	1:30 PM	Section 31	3
846	Utilizing quantitative systems pharmacology (QSP) model to understand cytokine release syndrome (CRS) following administration of epcoritamab in DLBCL patients	Nasrin	Afzal	Poster	Mathematical Modeling of Tumor Growth and Treatment Response	4/16/23	1:30 PM	Section 31	4
847	Applying the principles of convexity and concavity to guide treatment scheduling of ALK inhibitors in non-small cell lung cancer	Jeffrey	West	Poster	Mathematical Modeling of Tumor Growth and Treatment Response	4/16/23	1:30 PM	Section 31	5
849	Evaluation of a transcriptomics-based precision oncology platform for patient-therapy alignment in treatment resistant malignancies	Prabhjot	Mundi	Poster	Mathematical Modeling of Tumor Growth and Treatment Response	4/16/23	1:30 PM	Section 31	7
850	Patient-specific, organ-scale forecasting of prostate cancer growth in active surveillance	Guillermo	Lorenzo Gomez	Poster	Mathematical Modeling of Tumor Growth and Treatment Response	4/16/23	1:30 PM	Section 31	8
851	Machine learning (ML) model for prediction of pneumonitis using real-world data (RWD) on immune checkpoint inhibitor (ICI)-treated advanced non-small cell lung cancer (aNSCLC)	Deep	Hathi	Poster	Mathematical Modeling of Tumor Growth and Treatment Response	4/16/23	1:30 PM	Section 31	9
852	Predicting progression in metastatic castrate-sensitive prostate cancer by coupling PSA and testosterone dynamics to a mechanistic mathematical model	Jill	Gallaher	Poster	Mathematical Modeling of Tumor Growth and Treatment Response	4/16/23	1:30 PM	Section 31	10
853	The impact of normal tissue density on tumor growth and evolution in a 3D whole-tumor model of lung cancer	Rafael	Bravo	Poster	Mathematical Modeling of Tumor Growth and Treatment Response	4/16/23	1:30 PM	Section 31	11
854	A pharmaco-pheno-multiomic integration analysis of pancreatic cancer: A highly predictive biomarker model of biomarkers of Gemcitabine/Abraxane sensitivity and resistance	Gilad	Silberberg	Poster	Mathematical Modeling of Tumor Growth and Treatment Response	4/16/23	1:30 PM	Section 31	12

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
855	Model-informed drug design (MIDD) exploration of a theoretical CD47xTAA bispecific antibody using available data from magrolimab, an anti-CD47 monoclonal antibody	Emily	Pace	Poster	Mathematical Modeling of Tumor Growth and Treatment Response	4/16/23	1:30 PM	Section 31	13
856	Comparison of the effect of two EGFR-TKI in patients with EGFR-mutant lung adenocarcinoma using in silico clinical trials	Hippolyte	Darré	Poster	Mathematical Modeling of Tumor Growth and Treatment Response	4/16/23	1:30 PM	Section 31	14
857	Assuming tumors have a spherical shape in modeling EGFR mutant lung adenocarcinoma: Impact on modeled clinical outcome	Julie	Kleine-Schultjann	Poster	Mathematical Modeling of Tumor Growth and Treatment Response	4/16/23	1:30 PM	Section 31	15
858	Predicting cancer patient treatment outcomes from recurrent somatic mutations: identifying and mitigating some critical data biases	Jonathan	Friedman	Poster	Mathematical Modeling of Tumor Growth and Treatment Response	4/16/23	1:30 PM	Section 31	16
859	Simulations of tumor heterogeneity impact on treatment response using a mechanistic model of EGFR-mutant lung adenocarcinoma	Perrine	Masson	Poster	Mathematical Modeling of Tumor Growth and Treatment Response	4/16/23	1:30 PM	Section 31	17
860	The dynamics of LINE-1 retrotransposition in cellular populations	Stephen	Martis	Poster	Mathematical Modeling of Tumor Growth and Treatment Response	4/16/23	1:30 PM	Section 31	18
861	Modelling the role of EGFR mutation in the initiation of never-smoker lung cancer	Helena	Coggan	Poster	Mathematical Modeling of Tumor Growth and Treatment Response	4/16/23	1:30 PM	Section 31	19
862	Pairwise and higher-order epistatic effects among somatic cancer mutations across oncogenesis of lung adenocarcinoma	Jorge	Alfaro-Murillo	Poster	Mathematical Modeling of Tumor Growth and Treatment Response	4/16/23	1:30 PM	Section 31	20
863	Predictive value of baseline inter-sites heterogeneity measured by radiomics in metastatic lung adenocarcinomas	Sophie	Cousin	Poster	Mathematical Modeling of Tumor Growth and Treatment Response	4/16/23	1:30 PM	Section 31	21
867	Identifying plasma exosomal small non-coding RNAs as potential biomarkers for lung cancer early detection	Yuanyuan	Fu	Poster	Molecular Modeling, Sequence, and Integrative Analysis	4/16/23	1:30 PM	Section 32	1
869	Molecular genetic positioning of small intestine and papilla of Vater carcinomas including clinicopathological classification	Yukiyasu	Okamura	Poster	Molecular Modeling, Sequence, and Integrative Analysis	4/16/23	1:30 PM	Section 32	3
870	Glutamine metabolism drives some mechanisms of PARP inhibitor persistence in ovarian cancer	Adriana	Del Pino Herrera	Poster	Molecular Modeling, Sequence, and Integrative Analysis	4/16/23	1:30 PM	Section 32	4
871	Accurate estimation of open chromatin and intrinsic biases in bulk and single-cell CUT&Tag data	Sheng'en	Hu	Poster	Molecular Modeling, Sequence, and Integrative Analysis	4/16/23	1:30 PM	Section 32	5
872	Deciphering the activation mechanism of CDK4/cyclin-D complex that differs from the CDK2/cyclin-E complex	Wengang	Zhang	Poster	Molecular Modeling, Sequence, and Integrative Analysis	4/16/23	1:30 PM	Section 32	6
873	The mechanisms of SHP2 activation in cancer and neurodevelopmental disorder	Yonglan	Liu	Poster	Molecular Modeling, Sequence, and Integrative Analysis	4/16/23	1:30 PM	Section 32	7
875	Breast cancer bioinformatics: Untangling the roles of nucleolin and BRCA1 in dysregulated DNA repair	Nitu	Farhin	Poster	Molecular Modeling, Sequence, and Integrative Analysis	4/16/23	1:30 PM	Section 32	9

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
876	Sequencing a new broadly-consented tumor/normal cell line for a Genome in a Bottle Benchmark	Gail	Rosen	Poster	Molecular Modeling, Sequence, and Integrative Analysis	4/16/23	1:30 PM	Section 32	10
877	Protein-protein interactions in cancer: An in-silico analysis of Cdc6 interactions	Andriele	Silva Eichner	Poster	Molecular Modeling, Sequence, and Integrative Analysis	4/16/23	1:30 PM	Section 32	11
878	In silico insights from NEK10 modeling, its interactome, and protein-protein interactions	Andriele	Silva Eichner	Poster	Molecular Modeling, Sequence, and Integrative Analysis	4/16/23	1:30 PM	Section 32	12
879	Exosomal mRNAs secreted from pancreatic cancer (PC) cell lines might include good candidates of biomarkers of PC patients	Yuhan	Rong	Poster	Molecular Modeling, Sequence, and Integrative Analysis	4/16/23	1:30 PM	Section 32	13
880	Activation of the Wnt pathway is associated with GNASR201 mutant appendiceal cancer in the peritoneum	Saikat	Chowdhury	Poster	Molecular Modeling, Sequence, and Integrative Analysis	4/16/23	1:30 PM	Section 32	14
881	Desmocollin-3 and tumor immune microenvironment: Bioinformatics evaluation	Arpit	Dheeraj	Poster	Molecular Modeling, Sequence, and Integrative Analysis	4/16/23	1:30 PM	Section 32	15
882	Functional enrichment analysis of somatic mutations identifies novel risk factors for pediatric neuroblastoma	Nolan	Middleton	Poster	Molecular Modeling, Sequence, and Integrative Analysis	4/16/23	1:30 PM	Section 32	16
883	Glutaminases expression and viral infection as potential prognostic factors in cervical, head and neck and liver cancers	Claudia	Machicado Rivero	Poster	Molecular Modeling, Sequence, and Integrative Analysis	4/16/23	1:30 PM	Section 32	17
886	Fine-tuned CAIX targeted CAR-T cells exhibit superior efficacy and mitigate on-target off-tumor side effects	Yufei	Wang	Poster	Adoptive Cell Therapy 1	4/16/23	1:30 PM	Section 37	1
887	Killer cell immunoglobulin-like receptor 2DL2 (KIR2DL2) immune checkpoint modulates CAR-T cell effector function.	Miguel	Gomez Fontela	Poster	Adoptive Cell Therapy 1	4/16/23	1:30 PM	Section 37	2
889	The efficacy and safety of PD-L1-specific CAR-T in advanced gastric cancer	Mihwa	Kim	Poster	Adoptive Cell Therapy 1	4/16/23	1:30 PM	Section 37	4
890	ADAM17 knockout NK or CAR NK cells augment antibody dependent cellular cytotoxicity (ADCC) and anti-tumor activity	Chao	Guo	Poster	Adoptive Cell Therapy 1	4/16/23	1:30 PM	Section 37	5
891	CD70-targeting CAR-T and CAR-NK cells demonstrate potent activity against NSCLC drug-tolerant persister cells	Yan	Yang	Poster	Adoptive Cell Therapy 1	4/16/23	1:30 PM	Section 37	6
892	Afamitresgene autoleucel (afami-cel; formerly ADP-A2M4) demonstrates durable clinical responses by inducing broad immune engagement with anti-tumor activity	Martin	Isabelle	Poster	Adoptive Cell Therapy 1	4/16/23	1:30 PM	Section 37	7
893	Memory like differentiation enhances in vitro and in vivo NK cell responses against colorectal cancer	Nancy D.	Marin	Poster	Adoptive Cell Therapy 1	4/16/23	1:30 PM	Section 37	8
894	The race is on: BiTE vs CART targeting FLT3 in AML	Lisa	Rohrbacher	Poster	Adoptive Cell Therapy 1	4/16/23	1:30 PM	Section 37	9
895	Tumor-wide neoantigen-specific T-cells infiltrating mutant IDH1 low-grade gliomas and persisting in peripheral blood allow for personalized TCR-based immunotherapies	Darwin	Kwok	Poster	Adoptive Cell Therapy 1	4/16/23	1:30 PM	Section 37	10
896	Investigating tissue-resident memory T cell differentiation of CAR T cells reveals an unexpected role for CD69	Menglin	Cheng	Poster	Adoptive Cell Therapy 1	4/16/23	1:30 PM	Section 37	11

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
898	Generation and validation of anti-linker monoclonal antibodies for the detection of surface expressed scFv-based CARs	Amrik	Singh	Poster	Adoptive Cell Therapy 1	4/16/23	1:30 PM	Section 37	13
899	Deciphering the benefits of variable delivery routes and molecular armoring to enhance efficacy of MUC1-CAR T-cells in targeting triple-negative breast cancer	Piril	Erlor	Poster	Adoptive Cell Therapy 1	4/16/23	1:30 PM	Section 37	14
900	Reprogramming macrophages with HDAC6 inhibitors for anti-cancer macrophage-based cell therapy	Satish Kumar	Noonpalle	Poster	Adoptive Cell Therapy 1	4/16/23	1:30 PM	Section 37	15
901	Monitoring of neoantigens and adoptively transferred personalized neoTCR T cell populations in the tumor and PBMCs of patients with solid tumors	Susan	Foy	Poster	Adoptive Cell Therapy 1	4/16/23	1:30 PM	Section 37	16
902	Harnessing CD39 for the treatment of colorectal cancer and liver metastases by engineered T cells	Alessia	Potenza	Poster	Adoptive Cell Therapy 1	4/16/23	1:30 PM	Section 37	17
903	Engineered iPSC-derived NK cells as next-generation immunotherapies for cancer	Robert	Hollingsworth	Poster	Adoptive Cell Therapy 1	4/16/23	1:30 PM	Section 37	18
904	Optimizing CAR T therapy via metabolic engineering for the treatment of glioblastoma	Loic	Deleyrolle	Poster	Adoptive Cell Therapy 1	4/16/23	1:30 PM	Section 37	19
905	A novel bioluminescent bioassay platform for the discovery and development of engineered T cell therapies for cancer	Jamison	Grailer	Poster	Adoptive Cell Therapy 1	4/16/23	1:30 PM	Section 37	20
906	Development of a repeated challenge potency assay for evaluation of immune cell-mediated cytotoxicity in vitro	Stacie	Chvatal	Poster	Adoptive Cell Therapy 1	4/16/23	1:30 PM	Section 37	21
907	Evaluation of the anti-GPC1 scFv-Fc fusion protein as a detection tool of GPC1 expression in human cancers	Takeshi	Sawada	Poster	Adoptive Cell Therapy 1	4/16/23	1:30 PM	Section 37	22
908	Tumour organoid-t cell co-culture assay to evaluate CAR t cell cytotoxicity	Sylvia	Boj	Poster	Adoptive Cell Therapy 1	4/16/23	1:30 PM	Section 37	23
909	Single-cell multi-omics reveals type-2 function and metabolic fitness in maintaining CAR T cell longevity associated with 8-year leukemia remission	Zhiliang	Bai	Poster	Adoptive Cell Therapy 1	4/16/23	1:30 PM	Section 37	24
911	Butyrophilin 3A2 expression plays a critical role in phosphoantigen-mediated $\gamma\delta$ T cell cytotoxicity of neuroblastoma cells	Hunter	Jonus	Poster	Adoptive Cell Therapy 1	4/16/23	1:30 PM	Section 37	26
912	Single cell analysis reveals tumor evolution and CAR T cell dysfunction associated with tumor resistance	Yanping	Yang	Poster	Adoptive Cell Therapy 1	4/16/23	1:30 PM	Section 37	27
913	Engineering allogeneic off-the-shelf CD19-directed CAR-iNKT cells without additional genetic manipulations for the treatment of hematological malignancies	Kanagaraju	Ponnusamy	Poster	Adoptive Cell Therapy 1	4/16/23	1:30 PM	Section 37	28

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
914	Preinfusion polyfunctional profiles and cytokine secretion activity of transgenic TCR-T cells, and serum cytokine profiles, are associated with clinical outcomes in sarcoma and melanoma	Theodore	Nowicki	Poster	Adoptive Cell Therapy 1	4/16/23	1:30 PM	Section 37	29
918	Real-world clinical characteristics and treatment (tx) outcomes by co-mutation status in patients (pts) with KRAS G12C-mutated non-small cell lung cancer (NSCLC)	Marcelo	Negrao	Poster	Analyses Using Clinical and Genomic Databases	4/16/23	1:30 PM	Section 38	1
919	Benefit of chemotherapy in early-stage breast cancer with variant histology	Arya Mariam	Roy	Poster	Analyses Using Clinical and Genomic Databases	4/16/23	1:30 PM	Section 38	2
920	Real-world biomarker testing patterns in metastatic castration-resistant prostate cancer patients	Simon	Blanc, MD	Poster	Analyses Using Clinical and Genomic Databases	4/16/23	1:30 PM	Section 38	3
921	Identification of NRG1 fusions in patients with solid tumors: analysis from a real-world community oncology network	Emma	Sturgill	Poster	Analyses Using Clinical and Genomic Databases	4/16/23	1:30 PM	Section 38	4
922	Body composition and metabolic dysfunction really matter for the achievement of better outcomes in high-grade serous ovarian cancer	Mauricio	Cuello-Fredes	Poster	Analyses Using Clinical and Genomic Databases	4/16/23	1:30 PM	Section 38	5
923	Genomic landscape of patients with non-small cell lung cancer (NSCLC)	neeraj	singh	Poster	Analyses Using Clinical and Genomic Databases	4/16/23	1:30 PM	Section 38	6
924	The prognostic impact of the KRAS G12C-mutation in non-small cell lung cancer (NSCLC): a real-world analysis	Lova	Sun	Poster	Analyses Using Clinical and Genomic Databases	4/16/23	1:30 PM	Section 38	7
925	NTRK gene fusion in adults and pediatrics with solid tumors: a record linkage study of expression frequency and patient characteristics using the Auria Biobank in Finland	Wei	Zhang	Poster	Analyses Using Clinical and Genomic Databases	4/16/23	1:30 PM	Section 38	8
926	Genomics-based personalized oncology of advanced thymic epithelial tumors	Lino	Möhrmann	Poster	Analyses Using Clinical and Genomic Databases	4/16/23	1:30 PM	Section 38	9
927	Studying novel patient population using integrated real-world data	Sivakumar	Gowrisankar	Poster	Analyses Using Clinical and Genomic Databases	4/16/23	1:30 PM	Section 38	10
928	Correlation among actionable gene mutations, microsatellite instability and tumor mutational burden in advanced colorectal cancer and association with survival	Hirota	Miyashita	Poster	Analyses Using Clinical and Genomic Databases	4/16/23	1:30 PM	Section 38	11
929	The molecular landscape of premenopausal versus postmenopausal breast cancer in patients without inherited predisposition mutations	Ahmad	Charifa	Poster	Analyses Using Clinical and Genomic Databases	4/16/23	1:30 PM	Section 38	12
930	Treatment patterns and overall survival among men with metastatic castration-resistant prostate cancer harboring DDR mutations	Alexander	Niyazov	Poster	Analyses Using Clinical and Genomic Databases	4/16/23	1:30 PM	Section 38	13

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
931	Comprehensive analysis of 3,600 small cell lung cancer cases reveals rare genetic subtypes and multiple mechanisms of histological transformation	Smruthy	Sivakumar	Poster	Analyses Using Clinical and Genomic Databases	4/16/23	1:30 PM	Section 38	14
932	Snapshot! Exploring sample diversity of sarcoma cancers across common data repositories	Alfredo	Gonzalez	Poster	Analyses Using Clinical and Genomic Databases	4/16/23	1:30 PM	Section 38	15
933	Real world treatment patterns and outcomes in patients with advanced non-small cell lung cancer (aNSCLC) post-EGFR tyrosine kinase inhibitor (TKI) therapy	Ericka	Ebot	Poster	Analyses Using Clinical and Genomic Databases	4/16/23	1:30 PM	Section 38	16
934	Use of real-world data of dogs with cancer to drive drug development strategy and inform human clinical trials	Chase	Schwalbach	Poster	Analyses Using Clinical and Genomic Databases	4/16/23	1:30 PM	Section 38	17
935	The real-world data of the cancer genome profiling testing for pancreatic ductal adenocarcinoma from a nationwide database in Japan	Toshifumi	Doi	Poster	Analyses Using Clinical and Genomic Databases	4/16/23	1:30 PM	Section 38	18
936	Clinicogenomic predictors for the pattern of failure in high-grade glioma	Joo Ho	Lee	Poster	Analyses Using Clinical and Genomic Databases	4/16/23	1:30 PM	Section 38	19
937	Opposing roles of SPOP mutations in human prostate and endometrial cancers	Ludimila	Cavalcante	Poster	Analyses Using Clinical and Genomic Databases	4/16/23	1:30 PM	Section 38	20
938	Outcomes of molecular tumor board recommendations for cancer patients with progression on standard of care therapies in Saudi Arabia	Faizah	Alotaibi	Poster	Analyses Using Clinical and Genomic Databases	4/16/23	1:30 PM	Section 38	21
939	Genomic characterization of PMBCL, cHL and DLBCL utilizing tissue and liquid biopsies	Haimeng	Tang	Poster	Analyses Using Clinical and Genomic Databases	4/16/23	1:30 PM	Section 38	22
940	Comprehensive characterization of MET exon 14 skipping mutations in non-small cell lung cancer	Haimeng	Tang	Poster	Analyses Using Clinical and Genomic Databases	4/16/23	1:30 PM	Section 38	23
941	Assessment of the completeness, accuracy, and scalability of commercial abstraction for a large prostate cancer biospecimen repository	Emily	Carbone	Poster	Analyses Using Clinical and Genomic Databases	4/16/23	1:30 PM	Section 38	24
942	Real-world demographics, baseline characteristics, healthcare resource utilization and costs amongst non-small cell lung cancer (NSCLC) patients tested with a Host Immune Classifier (HIC)	Wade	Iams	Poster	Analyses Using Clinical and Genomic Databases	4/16/23	1:30 PM	Section 38	25
943	Informatics-based and other approaches to estimate real world disease progression in lung cancer	Rosyabelle	Amorrortu	Poster	Analyses Using Clinical and Genomic Databases	4/16/23	1:30 PM	Section 38	26
945	Early detection of high-grade IPMN using extracellular vesicles - a successful patient story	Harmeet	Dhani	Poster	Analyses Using Clinical and Genomic Databases	4/16/23	1:30 PM	Section 38	28
946	A silver jubilee for synthetic lethality in cancer treatment: where do we stand?	Joo Sang	Lee	Poster	Analyses Using Clinical and Genomic Databases	4/16/23	1:30 PM	Section 38	29

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
950	Targeting PKMYT1 kinase is an effective treatment strategy in triple negative breast cancers with low molecular weight cyclin E (LMW-E) expression	Khandan	Keyomarsi	Poster	Biomarkers of Therapeutic Benefit 1	4/16/23	1:30 PM	Section 39	1
951	Clinical model for predicting pathological complete response in patients with esophageal and gastroesophageal junction adenocarcinoma after trimodality therapy	Kohei	Yamashita	Poster	Biomarkers of Therapeutic Benefit 1	4/16/23	1:30 PM	Section 39	2
952	Prioritizing mutations associated with smoking as a variable in lung cancer precision medicine with immunotherapies	Margaret	Smith	Poster	Biomarkers of Therapeutic Benefit 1	4/16/23	1:30 PM	Section 39	3
953	Development of a predictive biomarker signature for the highly potent SIK3 inhibitor OMX-0407	Ilona-Petra	Maser	Poster	Biomarkers of Therapeutic Benefit 1	4/16/23	1:30 PM	Section 39	4
954	PIK3CA mutation induces immunogenicity and increases the immune checkpoint inhibitor response in urothelial carcinoma	Harvey	Su	Poster	Biomarkers of Therapeutic Benefit 1	4/16/23	1:30 PM	Section 39	5
955	Proteogenomic insights suggest druggable pathways in endometrial cancer	Lizabeth	Katsnelson	Poster	Biomarkers of Therapeutic Benefit 1	4/16/23	1:30 PM	Section 39	6
956	FBXW7 regulates imatinib chemoresistance through targeting MCL1 for apoptotic regulation in gastrointestinal stromal tumors	Xiyu	Wu	Poster	Biomarkers of Therapeutic Benefit 1	4/16/23	1:30 PM	Section 39	7
957	Prediction of patient response to targeted and immunotherapies from the tumor transcriptome in a wide set of indications and clinical trials	Gal	Dinstag	Poster	Biomarkers of Therapeutic Benefit 1	4/16/23	1:30 PM	Section 39	8
958	Signal transduction pathway activity of TGF- β and Hedgehog as possible response predictors to checkpoint inhibition in patients with advanced melanoma; a retrospective cohort study	Stefan	vanRavensteijn	Poster	Biomarkers of Therapeutic Benefit 1	4/16/23	1:30 PM	Section 39	9
959	Immune signatures of GD2 CAR T cell activity in H3K27M+ diffuse midline glioma patients	Sneha	Ramakrishna	Poster	Biomarkers of Therapeutic Benefit 1	4/16/23	1:30 PM	Section 39	10
960	Overlapping expression landscape of antibody drug conjugate targets, trophoblast cell surface antigen 2 (Trop-2) & human epidermal growth factor receptor 2 (HER2), in breast cancer	Arielle	Medford	Poster	Biomarkers of Therapeutic Benefit 1	4/16/23	1:30 PM	Section 39	11
961	HER2-low expression in patients with advanced or metastatic solid tumors	Burak	Uzunparmak	Poster	Biomarkers of Therapeutic Benefit 1	4/16/23	1:30 PM	Section 39	12
962	Oncodrivens expression analysis in primary tumors: potential for development of targeted immunotherapies for triple negative breast cancer (TNBC)	Saurabh	Garg	Poster	Biomarkers of Therapeutic Benefit 1	4/16/23	1:30 PM	Section 39	13
963	Clinical impact of MTAP status in advanced cholangiocarcinoma: Genomic profile and response to treatment	Cátia	Gaspar	Poster	Biomarkers of Therapeutic Benefit 1	4/16/23	1:30 PM	Section 39	14
964	Genomic and clinical predictors of early disease progression and chemoimmunotherapy benefit in advanced NSCLC	Lingzhi	Hong	Poster	Biomarkers of Therapeutic Benefit 1	4/16/23	1:30 PM	Section 39	15

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
965	Genomic heterogeneity and ploidy identify patients with intrinsic resistance to PD-1 blockade in metastatic melanoma	Giuseppe	Tarantino	Poster	Biomarkers of Therapeutic Benefit 1	4/16/23	1:30 PM	Section 39	16
966	Exploration of a novel HRD signature (HRDsig) as a biomarker for rucaparib benefit in ARIEL2	Ethan	Sokol	Poster	Biomarkers of Therapeutic Benefit 1	4/16/23	1:30 PM	Section 39	17
967	Real-world transcriptomic biomarkers as replacement for immunohistochemistry and FISH studies in breast cancer	Maher	Albitar	Poster	Biomarkers of Therapeutic Benefit 1	4/16/23	1:30 PM	Section 39	18
968	Evaluation of Her2 RNA expression as a potential predictive biomarker for anti-Her2 therapy	Laura	Lamb	Poster	Biomarkers of Therapeutic Benefit 1	4/16/23	1:30 PM	Section 39	19
969	Non-invasive detection of plasma proteins in immune checkpoint inhibitor-treated patients with advanced non-small cell lung cancer	Simone	Stensgaard	Poster	Biomarkers of Therapeutic Benefit 1	4/16/23	1:30 PM	Section 39	20
970	Clinical analysis of patients (pts) with lung cancer treated with anti-PD1/PDL1 therapy	Xin	Zhao	Poster	Biomarkers of Therapeutic Benefit 1	4/16/23	1:30 PM	Section 39	21
971	Thymidine Kinase activity - A liquid biomarker reflecting proliferation rate and treatment efficacy in solid tumors provides unique guidance in oncology trials and drug development	Mattias	Bergqvist	Poster	Biomarkers of Therapeutic Benefit 1	4/16/23	1:30 PM	Section 39	22
972	VISTA expression in patients with advanced solid tumors: A potential biomarker in VISTA-101 clinical trial	Thierry	Guillaudeux	Poster	Biomarkers of Therapeutic Benefit 1	4/16/23	1:30 PM	Section 39	23
973	Uncovering gene signatures of Ewings sarcoma drug sensitivity during the evolution of resistance	Kristi	Lin-Rahardja	Poster	Biomarkers of Therapeutic Benefit 1	4/16/23	1:30 PM	Section 39	24
974	Fully customizable multiplex immunofluorescent (mIF) assay as proof-of-concept lab-developed test (LDT) for cancer immunotherapy: Using direct conjugation of antibodies with commercially-available dyes	Jeffrey Chun Tatt	Lim	Poster	Biomarkers of Therapeutic Benefit 1	4/16/23	1:30 PM	Section 39	25
975	Treatment prognostic signature of patients with non-small cell lung cancer: a retrospective single-institutional study	Yuezhu	Wang	Poster	Biomarkers of Therapeutic Benefit 1	4/16/23	1:30 PM	Section 39	26
976	The regulation of FOLH1/PSMA in prostate cancer	Margaret	White	Poster	Biomarkers of Therapeutic Benefit 1	4/16/23	1:30 PM	Section 39	27
978	Genomic characterization and risk stratification of colorectal cancer	Yoshikage	Inoue	Poster	Biomarkers of Therapeutic Benefit 1	4/16/23	1:30 PM	Section 39	29
979	Development of a methylation-based classifier to identify pancreatic adenocarcinoma subtype	Zachary	Schrank	Poster	Biomarkers of Therapeutic Benefit 1	4/16/23	1:30 PM	Section 39	30
983	Design and methodology of LAPIS, an ongoing, phase III trial of neoadjuvant pamrevlumab (pam) with chemotherapy (CT) in patients (pts) with unresectable, locally advanced pancreatic cancer (LAPC)	Vincent	Picozzi	Poster	Biostatistics in Clinical Trials / Surgical Oncology	4/16/23	1:30 PM	Section 40	1

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
984	Race- and ancestry-related metabolites and SNPs associated with response to secondary hormonal therapy in metastatic castration-resistant prostate cancer	Sean	Piawski	Poster	Biostatistics in Clinical Trials / Surgical Oncology	4/16/23	1:30 PM	Section 40	2
985	An innovative spatial biology biomarker discovery approach to enable acceleration of drug development	Jason	Reeves	Poster	Biostatistics in Clinical Trials / Surgical Oncology	4/16/23	1:30 PM	Section 40	3
986	A BioPharma best practices framework to enable successful morphology guided spatial biology studies using NanoString GeoMx® Digital Spatial Profiler	Maxine	McClain	Poster	Biostatistics in Clinical Trials / Surgical Oncology	4/16/23	1:30 PM	Section 40	4
987	Seamless statistical analysis of adverse event data for clinical association	Dung-Tsa	Chen	Poster	Biostatistics in Clinical Trials / Surgical Oncology	4/16/23	1:30 PM	Section 40	5
988	Long-term health outcomes of bilateral salpingo-oophorectomy in women with personal history of breast cancer	Hend	Hassan	Poster	Biostatistics in Clinical Trials / Surgical Oncology	4/16/23	1:30 PM	Section 40	6
989	Ascites in colorectal peritoneal carcinomatosis supersedes mutational status and other clinical variables as negative prognostic factor for CRS-HIPEC via EMT pathway	Josephine	Hendrikson	Poster	Biostatistics in Clinical Trials / Surgical Oncology	4/16/23	1:30 PM	Section 40	7
990	Immune-suppressive tumor microenvironment leads to poor survival following curative intent surgical resection in soft-tissue sarcomas	Nathan	Seligson	Poster	Biostatistics in Clinical Trials / Surgical Oncology	4/16/23	1:30 PM	Section 40	8
991	Leveraging sequences missing from the human genome to detect cancer	Ofer	Yizhar Barnea	Poster	Diagnostic and Prognostic Biomarkers 1	4/16/23	1:30 PM	Section 41	1
993	Epigenetic immune cell profiling in B-non-Hodgkin lymphoma biopsies	Jeannette	Werner	Poster	Diagnostic and Prognostic Biomarkers 1	4/16/23	1:30 PM	Section 41	3
994	Chiroptical detection and mutation analysis of cancer-associated extracellular vesicles in microfluidic devices with oriented chiral nanoparticles	Abha	Kumari	Poster	Diagnostic and Prognostic Biomarkers 1	4/16/23	1:30 PM	Section 41	4
995	Evaluation of plasma cytokines and chemokines as potential biomarkers for colorectal cancer detection	Hilmaris	Centeno-Girona	Poster	Diagnostic and Prognostic Biomarkers 1	4/16/23	1:30 PM	Section 41	5
996	Identification of molecular biomarkers differentiating malignant uterine leiomyosarcoma from benign leiomyoma	Sara	Khamaiseh	Poster	Diagnostic and Prognostic Biomarkers 1	4/16/23	1:30 PM	Section 41	6
997	Cell-free DNA fragmentomics distinguish between benign, pre-malignant and malignant peripheral nerve sheath tumors in neurofibromatosis type 1.	Alex	Pan	Poster	Diagnostic and Prognostic Biomarkers 1	4/16/23	1:30 PM	Section 41	7
998	A blood-based extracellular vesicles DNA methylation signature for colorectal cancer screening	Mengrou	Lu	Poster	Diagnostic and Prognostic Biomarkers 1	4/16/23	1:30 PM	Section 41	8
999	Colocalization of MAGE-A3 and MAGE-A4 in bladder cancer	Bailey	Gilmore	Poster	Diagnostic and Prognostic Biomarkers 1	4/16/23	1:30 PM	Section 41	9

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
1000	Associations of parity and body mass index with NanoString digital spatial protein profiling in early onset breast cancer	Robert	Vierkant	Poster	Diagnostic and Prognostic Biomarkers 1	4/16/23	1:30 PM	Section 41	10
1001	Urinary metabolite diagnostic and prognostic liquid biopsy biomarkers of lung cancer - never smokers versus tobacco smokers	Bhavik	Dalal	Poster	Diagnostic and Prognostic Biomarkers 1	4/16/23	1:30 PM	Section 41	11
1002	Epigenetic and genetic characteristics and their association with prognosis of follicular lymphoma: Analysis at a Japanese single institution	Mizuki	Watanabe	Poster	Diagnostic and Prognostic Biomarkers 1	4/16/23	1:30 PM	Section 41	12
1003	The prognostic significance of prolyl 4-hydroxylase subunit alpha 1 and the therapeutic efficacy of diethyl-pythiDC, its small molecule inhibitor, in pancreatic ductal adenocarcinoma	Moh'd	Khushman	Poster	Diagnostic and Prognostic Biomarkers 1	4/16/23	1:30 PM	Section 41	13
1004	Higher circulating tryptophan metabolites are associated with improved survival among patients with stage I-III colorectal cancer: results from the FOCUS consortium	Victoria	Damerell	Poster	Diagnostic and Prognostic Biomarkers 1	4/16/23	1:30 PM	Section 41	14
1005	LINE-1 hypomethylation is associated with poor outcomes in locoregionally advanced oropharyngeal cancer	Elisabetta	Fratta	Poster	Diagnostic and Prognostic Biomarkers 1	4/16/23	1:30 PM	Section 41	15
1006	Assessment of expression of microRNA-23b as a prognostic marker in cancer	Ahmed	Wadaaallah	Poster	Diagnostic and Prognostic Biomarkers 1	4/16/23	1:30 PM	Section 41	16
1008	A novel biomarker and therapeutic target for early pancreatic cancer	Min Seok	Park	Poster	Diagnostic and Prognostic Biomarkers 1	4/16/23	1:30 PM	Section 41	18
1010	Circulating biomarkers of vitamin B1, B2, and B3 status and their associations with clinical outcomes among non-metastatic colorectal cancer patients: results from the FOCUS Consortium	Biljana	Gigic	Poster	Diagnostic and Prognostic Biomarkers 1	4/16/23	1:30 PM	Section 41	20
1011	Hsa_circ_0116796 as a novel biomarker for predicting prognosis of human hepatocellular carcinoma	Huiwon	Do	Poster	Diagnostic and Prognostic Biomarkers 1	4/16/23	1:30 PM	Section 41	21
1012	Detecting and intervening on rare pre-existing resistant subclones to BRAF/MEK inhibitors in metastatic melanoma	Michael	Nakazawa	Poster	Diagnostic and Prognostic Biomarkers 1	4/16/23	1:30 PM	Section 41	22
1013	Circulating H3K27 methylated nucleosome concentration in lung cancer improves the contributive value of ctDNA molecular profiling result at diagnosis	Lea	Payen-Gay	Poster	Diagnostic and Prognostic Biomarkers 1	4/16/23	1:30 PM	Section 41	23
1014	High tumor mutational burden in patients with mismatch repair proficient metastatic colorectal cancer: Single institution cohort	Giulia	Maddalena	Poster	Diagnostic and Prognostic Biomarkers 1	4/16/23	1:30 PM	Section 41	24
1015	VEGFR-3 expression profiling by histology to classify patient population for the selective VEGFR-3 inhibitor EVT801	Pierre	Fons	Poster	Diagnostic and Prognostic Biomarkers 1	4/16/23	1:30 PM	Section 41	25
1016	Prognostic factors for overall survival, recurrence-free survival, and metastasis-free survival of colon cancer in Morocco	Fatima	El Agy	Poster	Diagnostic and Prognostic Biomarkers 1	4/16/23	1:30 PM	Section 41	26

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
1018	Multiplex immunofluorescence and image analysis to investigate the role of the immune contexture and fibroblast activation for tumor cell budding in colorectal cancer	Dirk	Zielinski	Poster	Diagnostic and Prognostic Biomarkers 1	4/16/23	1:30 PM	Section 41	28
1019	Altona regression model: a new prognostic model for breast cancer patients after neoadjuvant treatment	Anne-Sophie	Wegscheider	Poster	Diagnostic and Prognostic Biomarkers 1	4/16/23	1:30 PM	Section 41	29
1020	Tissue-informed ctDNA MRD assay detects post-surgery minimal residual disease in HCC patients	Haoran	Tang	Poster	Diagnostic and Prognostic Biomarkers 1	4/16/23	1:30 PM	Section 41	30
1024	Improved cfDNA methylation profiling through correction of misrepaired jagged-ends	Rui	Wang	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 1	4/16/23	1:30 PM	Section 42	1
1025	OvaPrint - a novel cfDNA methylation liquid biopsy for cancer risk assessment in high grade serous ovarian carcinoma	David	Buckley	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 1	4/16/23	1:30 PM	Section 42	2
1026	A novel detection system of circulating tumor cells based on size-dependent enrichment with immunofluorescent staining of CK8/18 in advanced non-small cell lung cancer	Tetsuya	Sakai	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 1	4/16/23	1:30 PM	Section 42	3
1027	Assessment of tumor mutation burden (TMB) based on whole exome sequencing using extracellular vesicles-derived DNA obtained from bronchoalveolar lavage fluid (BALF) in advanced NSCLC patients treated with pembrolizumab	Heejoung	Kim	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 1	4/16/23	1:30 PM	Section 42	4
1030	Development of a genome-wide methylome enrichment platform for multi-cancer early detection (MCED)	Ben	Park	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 1	4/16/23	1:30 PM	Section 42	7
1031	Specific gene alterations of HER2 positive single circulating tumor cell (CTC) compared to autologous leukocytes in metastatic breast cancer (MBC)	Qiang	Zhang	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 1	4/16/23	1:30 PM	Section 42	8
1032	Development of a plasma circRNA signature for the discrimination of malign lung nodules using the nCounter platform	Carlos	Pedraz Valdunciel	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 1	4/16/23	1:30 PM	Section 42	9
1033	Evaluation of HER2 status in circulating tumor cells isolated using the Parsortix® system	Nerea	Borreguero-Munoz	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 1	4/16/23	1:30 PM	Section 42	10
1034	Clinical utility of liquid biopsy for molecular characterization and resistance detection in patients with advanced NSCLC and ALK, ROS1 or RET fusions	Mihaela	Aldea	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 1	4/16/23	1:30 PM	Section 42	11
1035	Early ctDNA reduction is associated with better overall survival in the Ph 3 trial of tebentafusp in previously untreated metastatic uveal melanoma	Ryan	Sullivan	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 1	4/16/23	1:30 PM	Section 42	12
1036	Detection of circulating tumor DNA by whole genome sequencing enables prediction of recurrence in stage III colorectal cancer patients with great inter-lab reproducibility	Amanda	Frydendahl	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 1	4/16/23	1:30 PM	Section 42	13

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
1037	Circulating tumor DNA-based molecular residual disease predicts relapse in patients with resectable gastric cancer	Jing	Sun	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 1	4/16/23	1:30 PM	Section 42	14
1039	Individualized tumor-informed circulating tumor DNA (ctDNA) analysis for postoperative monitoring of non-small cell lung cancer (NSCLC) - the MEDAL study	Zhihong	Zhang	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 1	4/16/23	1:30 PM	Section 42	16
1040	Evaluation of blood collection tube's performance for analysis of liquid biopsies by flow and mass cytometry	Anne-Florence	Blandin	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 1	4/16/23	1:30 PM	Section 42	17
1041	Circulating tumor (ct)DNA molecular response rate (MRR) as a potential surrogate for radiologic objective response rate (ORR): A meta-analysis of immunotherapy studies	Qu	Zhang	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 1	4/16/23	1:30 PM	Section 42	18
1042	Analytical validation of a liquid biopsy test using cell-free circulating tumor DNA for mutational profiling	Anastasiya	Yudina	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 1	4/16/23	1:30 PM	Section 42	19
1043	Liquid biopsy signature combining copy number instability and mutant KRAS detection is associated with survival for patients with metastatic pancreatic cancer	Samuele	Cannas	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 1	4/16/23	1:30 PM	Section 42	20
1044	Cell-free DNA concentration as a prognostic biomarker in patients with non-small cell lung cancer under immunotherapy treatment	Isabel	Barragan	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 1	4/16/23	1:30 PM	Section 42	21
1045	RePhyNER: Overcoming limitations of access to matched germline for serial liquid biopsy applications	Mohammad	Shahrokh Esfahani	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 1	4/16/23	1:30 PM	Section 42	22
1046	Tracking tumor mutations in ctDNA through repetitive plasma samples in patients with newly diagnosed brain cancer	Dorte	Schou Nørøxe	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 1	4/16/23	1:30 PM	Section 42	23
1047	Plasma KRAS mutations as predictive biomarkers for pancreatic cancer in high-risk group	Klara	Cervena	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 1	4/16/23	1:30 PM	Section 42	24
1048	Enabling higher sensitivity liquid biopsies with multiplex digital PCR NSCLC-relevant drug resistance panels	Michael	Granitsiotis	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 1	4/16/23	1:30 PM	Section 42	25
1049	Liquid biopsy-based comprehensive genomic profiling reveal mutational landscape in advanced breast cancer	Haoran	Tang	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 1	4/16/23	1:30 PM	Section 42	26
1050	Non-invasive detection of circulating mRNA markers in diseases of the colon and rectum	Veronika	Vymetalkova	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 1	4/16/23	1:30 PM	Section 42	27
1051	Liquid biopsy in the detection of genetic biomarkers in gastrointestinal cancer	Luciana	Bastos-Rodrigues	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 1	4/16/23	1:30 PM	Section 42	28
1052	Background variability in plasma ctDNA levels in patients with advanced lung cancer in the absence of treatment	Diana	Vega	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 1	4/16/23	1:30 PM	Section 42	29
1053	Circulating tumor DNA from cerebrospinal fluid (CSF) allows for characterization and monitoring of glioma patients	Subhiksha	Nandakumar	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 1	4/16/23	1:30 PM	Section 42	30

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
1057	Development/validation of a molecular and clinical evidence-based algorithm for selecting optimal precision therapeutic strategy for cancer patients	Yuliang	Sun	Poster	Precision Molecular Subtyping and Therapeutic Development	4/16/23	1:30 PM	Section 43	1
1058	Establishment of patient-derived organoid models of primary liver cancer and enable clinical personalized oncology	Chao	Song	Poster	Precision Molecular Subtyping and Therapeutic Development	4/16/23	1:30 PM	Section 43	2
1059	Precision medicine in a community cancer center: pan-cancer DNA/RNA sequencing of tumors reveals clinically relevant gene fusions	Sourat	Darabi	Poster	Precision Molecular Subtyping and Therapeutic Development	4/16/23	1:30 PM	Section 43	3
1060	Phosphoproteomic subtyping of gastric cancer reveals dynamic transformation with chemotherapy	Jun	Adachi	Poster	Precision Molecular Subtyping and Therapeutic Development	4/16/23	1:30 PM	Section 43	4
1061	Digital phenotyping in pediatric oncology: the development of a mobile application for outpatients follow up	Abeer	Abd Elmoneim	Poster	Precision Molecular Subtyping and Therapeutic Development	4/16/23	1:30 PM	Section 43	5
1062	A comprehensive CRISPR-enabled functional genomics profiling platform in acute myeloid leukemia (AML): Pilot study and validation of Fx Heme	Stephane	Corbel	Poster	Precision Molecular Subtyping and Therapeutic Development	4/16/23	1:30 PM	Section 43	6
1063	Precision medicine and cancer drug repurposing in the management of vascular anomalies	Petra	Pokorna	Poster	Precision Molecular Subtyping and Therapeutic Development	4/16/23	1:30 PM	Section 43	7
1064	Cancer-specific molecular subtypes of pancreatic cancer reveal clinically relevant molecular dependency	Sung Hwan	Lee	Poster	Precision Molecular Subtyping and Therapeutic Development	4/16/23	1:30 PM	Section 43	8
1065	Cancer-specific molecular subtypes of cholangiocarcinoma reveal unique molecular dependency with clinical relevance	Woo Young	Kwon	Poster	Precision Molecular Subtyping and Therapeutic Development	4/16/23	1:30 PM	Section 43	9
1066	PARP inhibitor rucaparib in combination with imipridones ONC201 or ONC212 demonstrates preclinical synergy against BRCA1/2-deficient breast, ovarian, and prostate cancer cells	Maryam	Ghandali	Poster	Precision Molecular Subtyping and Therapeutic Development	4/16/23	1:30 PM	Section 43	10
1067	MatchMiner: An open-source AI precision medicine trial matching platform	Harry	Klein	Poster	Precision Molecular Subtyping and Therapeutic Development	4/16/23	1:30 PM	Section 43	11
1068	A precision CRISPR approach to target structural variant junctions in cancer	Radhika Suhas	Hulbatte	Poster	Precision Molecular Subtyping and Therapeutic Development	4/16/23	1:30 PM	Section 43	12
1069	A novel PATHway based RNA and DNA Integration with Tumor Organoid Testing (PATRIOTTM) platform predicts therapeutic options in cohorts with MET overexpression and CDKN2A downregulation in patients with colon and pancreatic cancers	Anna	Larson	Poster	Precision Molecular Subtyping and Therapeutic Development	4/16/23	1:30 PM	Section 43	13
1070	The anti-tumor efficacy of combining oral ATR kinase inhibitor ceralasertib with TIC10/ONC201, an oral Akt/ERK inhibitor, TRAIL pathway and integrated stress response inducer, in prostate cancer treatment	Yutong	Xia	Poster	Precision Molecular Subtyping and Therapeutic Development	4/16/23	1:30 PM	Section 43	14

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
1071	Tipifarnib synergizes with TKIs in clear cell renal cell carcinoma models	Jovylyn	Gatchalian	Poster	Precision Molecular Subtyping and Therapeutic Development	4/16/23	1:30 PM	Section 43	15
1072	Combination of 5-Fluorouracil or ONC212 plus KRAS G12D inhibitor MRTX1133 against colorectal and pancreatic cancer cells results in immune-stimulatory cytokine patterns and unexpected synergies independent of G12D mutation	Vida	Tajiknia	Poster	Precision Molecular Subtyping and Therapeutic Development	4/16/23	1:30 PM	Section 43	16
1073	PRMT5 inhibition synergizes with a natural small molecule compound to kill MTAP-deleted cells and suppress tumor growth	Yasaman	Barekataan	Poster	Precision Molecular Subtyping and Therapeutic Development	4/16/23	1:30 PM	Section 43	17
1074	The potential of 18 β -glycyrrhetic acid benefit lenvatinib induced cytotoxicity on hepatocellular carcinoma	Yeh	Pei-Wen	Poster	Precision Molecular Subtyping and Therapeutic Development	4/16/23	1:30 PM	Section 43	18
1075	Identification of resistance mechanisms to direct KRAS inhibition in pancreatic cancer	Andrew	Waters	Poster	Precision Molecular Subtyping and Therapeutic Development	4/16/23	1:30 PM	Section 43	19
1076	Targeting EGFR and PI3K pathways with KRASG12D inhibitor overcomes oncogenic dependence in pancreatic cancer	Prashant	Bhavar	Poster	Precision Molecular Subtyping and Therapeutic Development	4/16/23	1:30 PM	Section 43	20
1077	Porcupine inhibition enhances enzalutamide efficacy in drug resistant prostate cancer	Katelyn	Jones	Poster	Precision Molecular Subtyping and Therapeutic Development	4/16/23	1:30 PM	Section 43	21
1078	Sotorasib and metformin combination enhances cytotoxicity and apoptosis in KRAS mutant lung cancer cell lines	Norma	Hernandez-Pedro	Poster	Precision Molecular Subtyping and Therapeutic Development	4/16/23	1:30 PM	Section 43	22
1079	Combination of tipifarnib with KRAS G12C inhibitors to prevent adaptive resistance	Hetika	Patel	Poster	Precision Molecular Subtyping and Therapeutic Development	4/16/23	1:30 PM	Section 43	23
1080	JAK inhibition as a therapeutic approach to enhance radiation response in rectal cancer	Kathryn	Pennel	Poster	Precision Molecular Subtyping and Therapeutic Development	4/16/23	1:30 PM	Section 43	24
1081	Co-targeting CK1epsilon and PIK3CB/p110beta to treat glioblastoma	Eileen	Xu	Poster	Precision Molecular Subtyping and Therapeutic Development	4/16/23	1:30 PM	Section 43	25
1082	Effect of doublet treatment versus single-agent treatment in gastric cancers with/without MET amplification or a MET exon 14 skipping mutation	sung-hwa	sohn	Poster	Precision Molecular Subtyping and Therapeutic Development	4/16/23	1:30 PM	Section 43	26
1083	MEKi and SOS1i as a combination treatment option for KRAS mutant endometrial cancer	Kaja	Kostyrko	Poster	Precision Molecular Subtyping and Therapeutic Development	4/16/23	1:30 PM	Section 43	27
1084	AI-aided drug development for disconnecting glioma tumor microtubule networks	Daniel	Azorín	Poster	Precision Molecular Subtyping and Therapeutic Development	4/16/23	1:30 PM	Section 43	28
1088	Acquired radiation resistance induces thiol-dependent cisplatin cross-resistance	Ruud	Dings	Poster	Radiation Oncology / Radiation Science	4/16/23	1:30 PM	Section 44	1
1089	High grade serous ovarian cancer: Detecting stemness and EMT levels in response to chemo and radiation therapy	Yeonkyu	Jung	Poster	Radiation Oncology / Radiation Science	4/16/23	1:30 PM	Section 44	2
1090	Dominant-negative TP53 variants confer radiation resistance in endometrial cancer	Aaron	Petty	Poster	Radiation Oncology / Radiation Science	4/16/23	1:30 PM	Section 44	3

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
1091	MDM2 inhibition as a novel radio-sensitizing strategy for endometrial cancer	Aaron	Petty	Poster	Radiation Oncology / Radiation Science	4/16/23	1:30 PM	Section 44	4
1092	Targeting one-carbon metabolism radiosensitizes pancreatic ductal adenocarcinoma cells (PDAC)	Minal	Nenwani	Poster	Radiation Oncology / Radiation Science	4/16/23	1:30 PM	Section 44	5
1093	Measuring and inhibiting purine metabolism in patients with glioblastoma	Daniel	Wahl	Poster	Radiation Oncology / Radiation Science	4/16/23	1:30 PM	Section 44	6
1094	3-Bromopyruvate reduces pancreatic tumor growth by damaging mitochondria and inhibiting glucose metabolism in both cell culture and mouse model.	Sanjit	Roy	Poster	Radiation Oncology / Radiation Science	4/16/23	1:30 PM	Section 44	7
1095	Exploiting altered methionine metabolism to overcome treatment resistance in glioblastoma	Navyateja	Korimerla	Poster	Radiation Oncology / Radiation Science	4/16/23	1:30 PM	Section 44	8
1096	Single cell transcriptomic sequencing of pancreatic ductal adenocarcinoma reveals an enrichment of immunosuppressive pathways in patients at high risk for early local progression following stereotactic body radiation therapy	Vincent	Bernard	Poster	Radiation Oncology / Radiation Science	4/16/23	1:30 PM	Section 44	9
1097	Surufatinib improved the radiation sensitivity of biliary cancer growth by reprogramming of TAM and anti-angiogenesis	Hong	Ma	Poster	Radiation Oncology / Radiation Science	4/16/23	1:30 PM	Section 44	10
1098	Combination of a DNA vaccine-induced immune checkpoint blockade and radiation therapy induces anti-tumor immunity	Keng-Hsueh	Lan	Poster	Radiation Oncology / Radiation Science	4/16/23	1:30 PM	Section 44	11
1099	Combined treatment with direct hydrogen peroxide administration and irradiation promotes an abscopal effect in mouse models	Naoya	Kemmotsu	Poster	Radiation Oncology / Radiation Science	4/16/23	1:30 PM	Section 44	12
1100	4-1BBL agonist targeted to fibroblast activation protein α synergizes with radiotherapy in murine breast tumor	Maria E.	Rodriguez-Ruiz	Poster	Radiation Oncology / Radiation Science	4/16/23	1:30 PM	Section 44	13
1101	Combination therapy to overcome radiotherapy induced immunosuppression and improve tumor control	Shruti	Bansal	Poster	Radiation Oncology / Radiation Science	4/16/23	1:30 PM	Section 44	14
1102	Establishing the cytotoxic benefit of Tumor Treating Fields on radiation sensitive and acquired radiation resistant glioblastoma patient derived xenograft pairs	Taylor	Schanel	Poster	Radiation Oncology / Radiation Science	4/16/23	1:30 PM	Section 44	15
1103	Theoretical basis and formula for tumor-treating fields dose-response curves	Kristen	Carlson	Poster	Radiation Oncology / Radiation Science	4/16/23	1:30 PM	Section 44	16
1104	Gene expression profile analysis of hyperthermia-induced radiosensitivity in breast cancer	Kevin	Tu	Poster	Radiation Oncology / Radiation Science	4/16/23	1:30 PM	Section 44	17
1105	Carbon ion radiotherapy eradicates glioblastoma via tumor immune environment reprogramming	Federica	Ciamarone	Poster	Radiation Oncology / Radiation Science	4/16/23	1:30 PM	Section 44	18
1106	A novel cancer therapy using proton beam; an integrated proton dynamic therapy, iPDT	Hlrofumi	Matsui	Poster	Radiation Oncology / Radiation Science	4/16/23	1:30 PM	Section 44	19

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
1107	Exploring the hypoxia pathway for gastrointestinal radioprotection in human minigut model	Neeraj	Kumari	Poster	Radiation Oncology / Radiation Science	4/16/23	1:30 PM	Section 44	20
1108	Comparative analysis of hypofractionated and conventional fractionated radiotherapy on acute skin toxicity in a multiracial/ethnic breast cancer population	Veronica	Zhang	Poster	Radiation Oncology / Radiation Science	4/16/23	1:30 PM	Section 44	21
1109	Effects of radiation therapy on the hardness of enamel and dentin	Rachel	Kulchar	Poster	Radiation Oncology / Radiation Science	4/16/23	1:30 PM	Section 44	22
1111	The status of Government-funded radiotherapy centres in Nigeria	Simeon	Aruah	Poster	Radiation Oncology / Radiation Science	4/16/23	1:30 PM	Section 44	24
1116	Identifying neuroendocrine prostate cancer drivers using in vivo forward genetics	Alessandro	Vasciaveo	Oral	Cutting-edge Computational Approaches for Precision Oncology and Cancer Biology	4/16/23	3:00 PM	Room W240	
1117	Rapid label-free imaging-based evaluation of cancer dependencies in zero-passage primary cells	Mushriq	Al-Jazrawe	Oral	Cutting-edge Computational Approaches for Precision Oncology and Cancer Biology	4/16/23	3:00 PM	Room W240	
1118	High-dimensional deconstruction of pancreatic cancer identifies co-occurring TME features associated with survival	Prathamesh	Chati	Oral	Cutting-edge Computational Approaches for Precision Oncology and Cancer Biology	4/16/23	3:00 PM	Room W240	
1119	Systems pharmacology approaches to study tumor drug mechanism of action	Lucas Zhongming	Hu	Oral	Cutting-edge Computational Approaches for Precision Oncology and Cancer Biology	4/16/23	3:00 PM	Room W240	
1120	Dissecting tumor cell programs through group biology estimation in clinical single-cell transcriptomics	Shreya	Johri	Oral	Cutting-edge Computational Approaches for Precision Oncology and Cancer Biology	4/16/23	3:00 PM	Room W240	
1121	Patient-centric Discovery by Active Learning (PeDAL) platform to predict drug response in a heterogeneous patient population	Robert	Montgomery	Oral	Cutting-edge Computational Approaches for Precision Oncology and Cancer Biology	4/16/23	3:00 PM	Room W240	
1122	Pan-cancer analysis reveals roles of retrotransposon-fusion RNAs	E. Alice	Lee	Oral	Cutting-edge Computational Approaches for Precision Oncology and Cancer Biology	4/16/23	3:00 PM	Room W240	
1124	PTEN loss confers resistance to anti-PD-1 therapy in NSCLC by increasing tumor infiltration of T regulatory cells	Francisco	Exposito	Oral	Immunotherapy	4/16/23	3:00 PM	Room W414	
1125	Neoantigen immunogenicity landscapes and evolution of tumor ecosystems during immunotherapy with nivolumab	Tyler	Alban	Oral	Immunotherapy	4/16/23	3:00 PM	Room W414	
1126	Disease monitoring with comprehensive genomics provides evidence of mechanism of action and immune evasion in patients receiving an individualized neoantigen cancer vaccine	Matthew	Davis	Oral	Immunotherapy	4/16/23	3:00 PM	Room W414	

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
1127	Preclinical development of safe and effective T cell receptors specific for mutant KRAS G12D peptide	Loïc	Vincent	Oral	Immunotherapy	4/16/23	3:00 PM	Room W414	
1128	Lineage tracing of CAR T cells in patients with B cell malignancies	Zinaida	Good	Oral	Immunotherapy	4/16/23	3:00 PM	Room W414	
1129	Targeting tissue-resident macrophage progenitors restores anti-tumor immunity and suppresses tumor growth	Hui	Chen	Oral	Immunotherapy	4/16/23	3:00 PM	Room W414	
1130	A phase 1 dose escalation study of GCC19CART - a novel CoupledCAR therapy for subjects with metastatic colorectal cancer	Lei	Xiao	Oral	Immunotherapy	4/16/23	3:00 PM	Room W414	
1132	Exploiting MGMT loss using a new class of DNA modifiers which selectively target tumor DNA and overcome therapy resistance mechanisms across multiple tumor types	Kyle	Tarantino	Oral	Innovative Therapeutic Approaches	4/16/23	3:00 PM	Room W331	
1133	A B7-H4 targeting antibody-drug conjugate shows anti-tumor activity in PARPi and platinum resistant cancers with B7-H4 expression	Sarah	Gitto	Oral	Innovative Therapeutic Approaches	4/16/23	3:00 PM	Room W331	
1134	Therapeutic potential of an antibody-drug conjugate directed against a tumor-specific epitope on podocalyxin	Pamela	Austin Dean	Oral	Innovative Therapeutic Approaches	4/16/23	3:00 PM	Room W331	
1135	TP317, a first-in-class resolvin E1 small molecule, potentiates the efficacy of immune checkpoint (ICI) inhibitors in ICI-resistant and ICI-sensitive tumors	Franciele	Kipper	Oral	Innovative Therapeutic Approaches	4/16/23	3:00 PM	Room W331	
1136	Targeting DHX9 inhibition as a novel therapeutic modality in microsatellite instable colorectal cancer	Jennifer	Castro	Oral	Innovative Therapeutic Approaches	4/16/23	3:00 PM	Room W331	
1137	Identification of a high selective SMARCA2 degrader which effectively suppresses the SMARCA4-deficient tumors in vitro and in vivo	Renhong	Tang	Oral	Innovative Therapeutic Approaches	4/16/23	3:00 PM	Room W331	
1138	Novel SMARCA2 degrading bifunctional molecules as therapeutics in SMARCA4 mutant lung cancer	Yonathan	Lissanu	Oral	Innovative Therapeutic Approaches	4/16/23	3:00 PM	Room W331	
1140	Pre-clinical efficacy of targeting BAF complexes through inhibition of the dual ATPases BRG1 and BRM by FHD-286 in cellular models of AML	Warren	Fiskus	Oral	Small Molecule Therapeutic Agents	4/16/23	3:00 PM	Room W224	
1141	The CoREST complex as a novel target to disrupt AT/RT's abnormal epigenetic landscape	Anupa	Geethadevi	Oral	Small Molecule Therapeutic Agents	4/16/23	3:00 PM	Room W224	
1142	Discovery of FMC-376 a novel orally bioavailable inhibitor of activated KRASG12C	Kevin	Webster	Oral	Small Molecule Therapeutic Agents	4/16/23	3:00 PM	Room W224	
1143	Development of a CDK2-selective small molecule inhibitor INCB123667 for the treatment of CCNE1hi breast cancers	Saswati	Chand	Oral	Small Molecule Therapeutic Agents	4/16/23	3:00 PM	Room W224	

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
1144	Dynamic changes in circulating tumor DNA (ctDNA) in patients treated with sotorasib for KRAS G12C mutant non-small cell lung cancer	Yonina	Murciano-Goroff	Oral	Small Molecule Therapeutic Agents	4/16/23	3:00 PM	Room W224	
1145	PH020-803: an MTA-cooperative and brain-penetrable PRMT5 inhibitor that selectively targets MTAP-deleted tumors	Feng	Gao	Oral	Small Molecule Therapeutic Agents	4/16/23	3:00 PM	Room W224	
1146	Tepotinib treatment inhibits tumor growth and affects tumor permeability in an intracranial PDX model of MET-amplified NSCLC brain metastasis	Joachim	Albers	Oral	Small Molecule Therapeutic Agents	4/16/23	3:00 PM	Room W224	
1148	1XX mutations slow CAR T cell signaling and increase in vivo persistence	Cynthia	Bamdad	Oral	Genetically Engineered Anticancer T Cells	4/16/23	3:00 PM	Valencia BC	
1149	Universal redirection of chimeric antigen receptor T cells against solid tumors via tumor cell membrane-inserting CAR ligands	Angela	Zhang	Oral	Genetically Engineered Anticancer T Cells	4/16/23	3:00 PM	Valencia BC	
1150	CD70 HIT T cells overcome tumor antigen heterogeneity in renal cell carcinoma	Sophie	Hanina	Oral	Genetically Engineered Anticancer T Cells	4/16/23	3:00 PM	Valencia BC	
1151	CD6 isoforms improve CAR T cell fitness	Jessica	Morris	Oral	Genetically Engineered Anticancer T Cells	4/16/23	3:00 PM	Valencia BC	
1152	NKTR-255, a polymer-conjugated IL-15, dramatically improves ROR1 CAR-T cell persistence and anti-tumor efficacy in an autochthonous model of ROR1+ lung cancer	W.	Nutt	Oral	Genetically Engineered Anticancer T Cells	4/16/23	3:00 PM	Valencia BC	
1153	IL-4 depletion leads to the improvement of CART cell therapy	Carli	Stewart	Oral	Genetically Engineered Anticancer T Cells	4/16/23	3:00 PM	Valencia BC	
1154	Investigating the functional role of GPNMB in glioblastoma and the tumor immune microenvironment and its targeted elimination using CAR-Ts	Neil	Savage	Oral	Genetically Engineered Anticancer T Cells	4/16/23	3:00 PM	Valencia BC	
1156	GUK1 is a novel metabolic liability in oncogene-driven lung cancer	Jaime	Schneider	Oral	Metabolism and Cancer	4/16/23	3:00 PM	Room W304 A-D	
1157	Uncovering a novel role of peroxisomal β -oxidation in advanced, treatment-resistant prostate cancer	Chui Yan	Mah	Oral	Metabolism and Cancer	4/16/23	3:00 PM	Room W304 A-D	
1158	Inosine endows CAR T cells with features of increased stemness and anti-tumor potency	Dorota	Klysz	Oral	Metabolism and Cancer	4/16/23	3:00 PM	Room W304 A-D	
1159	BRAF- mediated PHGDH induction establishes a metabolic vulnerability in melanoma	Neel	Jasani	Oral	Metabolism and Cancer	4/16/23	3:00 PM	Room W304 A-D	
1160	A machine learning based method for in-vivo metabolic flux analysis of patient tumors	Anjali	Mittal	Oral	Metabolism and Cancer	4/16/23	3:00 PM	Room W304 A-D	
1161	Primary and metastatic tumors exhibit systems-level differences in dependence on mitochondrial respiratory function	Neal	Bennett	Oral	Metabolism and Cancer	4/16/23	3:00 PM	Room W304 A-D	

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
1162	Ketogenic diet promotes tumor ferroptosis but induces relative corticosterone deficiency that accelerates cachexia	Miriam	Ferrer	Oral	Metabolism and Cancer	4/16/23	3:00 PM	Room W304 A-D	
1164	Spatiotemporal profiling defines persister and resistance signatures in targeted treatment of melanoma	Jill	Rubinstein	Oral	Tumor Heterogeneity at Single-cell Resolution in Space and Time	4/16/23	3:00 PM	Tangerine Ballroom 1 (WF1)	
1165	Mechanisms of therapeutic resistance in pancreatic cancer identified by single-cell spatial transcriptomics and genetically-engineered stromal tumoroids	Carina	Shiau	Oral	Tumor Heterogeneity at Single-cell Resolution in Space and Time	4/16/23	3:00 PM	Tangerine Ballroom 1 (WF1)	
1166	APOBEC deaminases compete with tobacco smoking mutagenesis and affect age at onset of lung cancer	Tongwu	Zhang	Oral	Tumor Heterogeneity at Single-cell Resolution in Space and Time	4/16/23	3:00 PM	Tangerine Ballroom 1 (WF1)	
1167	Single-cell transcriptomic profiling of SCLC transformation reveals increased intratumoral diversity of variant and non-neuroendocrine subtypes	Joseph	Chan	Oral	Tumor Heterogeneity at Single-cell Resolution in Space and Time	4/16/23	3:00 PM	Tangerine Ballroom 1 (WF1)	
1168	Mutational processes in tumor-adjacent normal kidneys across countries with varying cancer incidence rates	Yichen	Wang	Oral	Tumor Heterogeneity at Single-cell Resolution in Space and Time	4/16/23	3:00 PM	Tangerine Ballroom 1 (WF1)	
1169	Genomic evolution of pancreatic cancer at single-cell resolution	Haochen	Zhang	Oral	Tumor Heterogeneity at Single-cell Resolution in Space and Time	4/16/23	3:00 PM	Tangerine Ballroom 1 (WF1)	
1170	Scalable co-sequencing of RNA and DNA from individual nuclei	Timothy	Olsen	Oral	Tumor Heterogeneity at Single-cell Resolution in Space and Time	4/16/23	3:00 PM	Tangerine Ballroom 1 (WF1)	
1172	Oncogenic context shapes the fitness landscape of tumor suppression	Lily	Blair	Oral	Advancing Cancer Research Through an International Cancer Registry: AACR Project GENIE Use Cases	4/16/23	3:00 PM	Room W230	
1173	Landscape of 4,506 pan-cancer samples harboring BRAFV600E mutations, and NTRK/RET Fusions from 137,401 adult patients with cancer: Clinical implications for tissue agnostic therapies	Mohamed	Gouda	Oral	Advancing Cancer Research Through an International Cancer Registry: AACR Project GENIE Use Cases	4/16/23	3:00 PM	Room W230	
1174	Enhancing the utilization of deep learning to predict patient response in small immunotherapy cohorts using real-world data	Gustavo	Arango-Argoty	Oral	Advancing Cancer Research Through an International Cancer Registry: AACR Project GENIE Use Cases	4/16/23	3:00 PM	Room W230	
1175	Systematic profiling of conditional pathway activation as a new class of cancer dependency	Liang	Chang	Oral	Advancing Cancer Research Through an International Cancer	4/16/23	3:00 PM	Room W230	

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
					Registry: AACR Project GENIE Use Cases				
1176	Quantitative integration of PIK3CA hotspots and paralogy identifies occult oncogenic mutants in PIK3CD	Aphrothiti	Hanrahan	Oral	Advancing Cancer Research Through an International Cancer Registry: AACR Project GENIE Use Cases	4/16/23	3:00 PM	Room W230	
1177	Genomic characteristics and clinical outcomes of early onset colorectal cancer (EOCRC): Findings from AACR Project GENIE Biopharma Collaborative registry	Enrique	Sanz Garcia	Oral	Advancing Cancer Research Through an International Cancer Registry: AACR Project GENIE Use Cases	4/16/23	3:00 PM	Room W230	
1180	Identification of target proteins for breast cancer genetic risk loci and blood risk biomarkers in a large study by integrating genomic and proteomic data	Guochong	Jia	Oral	Beyond GWAS: Understanding Etiologic Heterogeneity	4/16/23	3:00 PM	Room W304 E-H	
1181	Etiologic heterogeneity of genetic risk for DLBCL cell-of-origin molecular subtypes	Rosalie	Griffin Waller	Oral	Beyond GWAS: Understanding Etiologic Heterogeneity	4/16/23	3:00 PM	Room W304 E-H	
1182	Association of prostate cancer candidate genes with overall and aggressive prostate cancer in men of African ancestry	Fei	Chen	Oral	Beyond GWAS: Understanding Etiologic Heterogeneity	4/16/23	3:00 PM	Room W304 E-H	
1183	Mutation type and location in breast cancer susceptibility genes are associated with differential risk in the general population	Mwangala	Akamandisa	Oral	Beyond GWAS: Understanding Etiologic Heterogeneity	4/16/23	3:00 PM	Room W304 E-H	
1184	Impact of individual level uncertainty of lung cancer polygenic risk score on risk stratification and prediction	Xinan	Wang	Oral	Beyond GWAS: Understanding Etiologic Heterogeneity	4/16/23	3:00 PM	Room W304 E-H	
1185	Mosaic chromosomal alterations are independent predictors of chronic lymphocytic leukemia risk	Aubrey	Hubbard	Oral	Beyond GWAS: Understanding Etiologic Heterogeneity	4/16/23	3:00 PM	Room W304 E-H	
1186	Contraception and ovarian cancer risk by tumor immune profiles	Jennifer	Mongioli	Oral	Beyond GWAS: Understanding Etiologic Heterogeneity	4/16/23	3:00 PM	Room W304 E-H	
1188	IL-17/IL-17RA signaling in the pancreatic epithelium upregulates B7-H4 to promote tumorigenesis	Susana	Castro Pando	Oral	Interactions between Tumor Cells and Immune Cells, Neurons, and Fibroblasts in the Tumor Microenvironment	4/16/23	3:00 PM	Room W311 A-D	
1189	MERTK is a target in the microenvironment of osteolytic bone metastasis	Janik	Engelmann	Oral	Interactions between Tumor Cells and Immune Cells, Neurons, and Fibroblasts in the Tumor Microenvironment	4/16/23	3:00 PM	Room W311 A-D	
1190	Mimicking CAFs, pial cells support leptomeningeal metastasis	Jenna	Snyder	Oral	Interactions between Tumor Cells and Immune Cells, Neurons, and Fibroblasts in the Tumor Microenvironment	4/16/23	3:00 PM	Room W311 A-D	

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
1191	Targeting the tumor extracellular matrix to enhance therapeutic interventions in glioblastoma	Sara	Pedron-Haba	Oral	Interactions between Tumor Cells and Immune Cells, Neurons, and Fibroblasts in the Tumor Microenvironment	4/16/23	3:00 PM	Room W311 A-D	
1192	Branched-chain keto acids exert an immune-suppressive and neurodegenerative microenvironment in CNS leptomenigeal lymphoma	Mariam	Khaled	Oral	Interactions between Tumor Cells and Immune Cells, Neurons, and Fibroblasts in the Tumor Microenvironment	4/16/23	3:00 PM	Room W311 A-D	
1193	Sensory innervation directly promotes gastric cancer and modulates the tumor microenvironment	Xiaofei	Zhi	Oral	Interactions between Tumor Cells and Immune Cells, Neurons, and Fibroblasts in the Tumor Microenvironment	4/16/23	3:00 PM	Room W311 A-D	
1194	Evolution of immune and stromal cell states during the gastric cancer continuum	Ruiping	Wang	Oral	Interactions between Tumor Cells and Immune Cells, Neurons, and Fibroblasts in the Tumor Microenvironment	4/16/23	3:00 PM	Room W311 A-D	
1196	The epigenetic impact and therapeutic opportunity of AR-directed therapy for DSRCT	Danh	Truong	Oral	Pediatric Cancer 1: Genomics and Biology Inform Innovative Diagnostic and Treatment Approaches	4/16/23	3:00 PM	Room W307	
1197	B7-H3-CAR T cells for the treatment of pediatric adrenocortical carcinoma	Rebecca	Epperly	Oral	Pediatric Cancer 1: Genomics and Biology Inform Innovative Diagnostic and Treatment Approaches	4/16/23	3:00 PM	Room W307	
1198	T cell receptor (TCR) landscape of childhood brain tumors	Itay	Raphael	Oral	Pediatric Cancer 1: Genomics and Biology Inform Innovative Diagnostic and Treatment Approaches	4/16/23	3:00 PM	Room W307	
1199	Discovery of subtype-specific and therapy associated effects on the tumor immune microenvironment in pediatric neuroblastoma	Katherine	Masih	Oral	Pediatric Cancer 1: Genomics and Biology Inform Innovative Diagnostic and Treatment Approaches	4/16/23	3:00 PM	Room W307	
1200	Aurora kinase A is a potential therapeutic target regulated by the MYCN oncogene in human retinoblastoma	Naheed	Borah	Oral	Pediatric Cancer 1: Genomics and Biology Inform Innovative Diagnostic and Treatment Approaches	4/16/23	3:00 PM	Room W307	

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
1201	ALK amplification and rearrangements are recurrent targetable events in congenital and adult glioblastoma	Anne-Florence	Blandin	Oral	Pediatric Cancer 1: Genomics and Biology Inform Innovative Diagnostic and Treatment Approaches	4/16/23	3:00 PM	Room W307	
1202	Targeting cell adhesion molecule 1 (CADM1) with an antibody drug conjugate for the treatment of osteosarcoma	Yifei	Wang	Oral	Pediatric Cancer 1: Genomics and Biology Inform Innovative Diagnostic and Treatment Approaches	4/16/23	3:00 PM	Room W307	
1212	Horizontal transfer of functional human papillomavirus genes in head and neck squamous cell carcinoma	Jason	Tasoulas	Poster	Carcinogenesis and Mutagenesis	4/17/23	9:00 AM	Section 1	1
1213	Impact of pesticide exposure in West African Black men within the United States, Cameroon, and Nigeria	Emelina	Asto-Flores	Poster	Carcinogenesis and Mutagenesis	4/17/23	9:00 AM	Section 1	2
1214	Establishment and characterization of reversibly immortalized endometrial and ovarian epithelial cell lines using Sendai virus.	Masayo	Okawa	Poster	Carcinogenesis and Mutagenesis	4/17/23	9:00 AM	Section 1	3
1215	Synthetic colibactins reveal the structural and biological mode-of-action of a microbial carcinogen	Michael	Dougherty	Poster	Carcinogenesis and Mutagenesis	4/17/23	9:00 AM	Section 1	4
1216	Virome characterization in different types of non-Hodgkin lymphoma	Juliana	Siqueira	Poster	Carcinogenesis and Mutagenesis	4/17/23	9:00 AM	Section 1	5
1217	The FAM72 gene family promotes cancer development by disabling the base excision repair system	Rossanna	Pezo	Poster	Carcinogenesis and Mutagenesis	4/17/23	9:00 AM	Section 1	6
1218	Mercury(II)-induced abnormalities in processing of topoisomerase I-mediated DNA damage	Giorgiana	Ursu	Poster	Carcinogenesis and Mutagenesis	4/17/23	9:00 AM	Section 1	7
1219	Establishment and characterization of amitrole-induced mouse thyroid adenoma-derived cell lines	Yo-Taro	Shirai	Poster	Carcinogenesis and Mutagenesis	4/17/23	9:00 AM	Section 1	8
1220	Carcinogenic nickel(II) is a replication stressor causing genotoxicity via DNA incorporation of rNMPs	Casey	Krawic	Poster	Carcinogenesis and Mutagenesis	4/17/23	9:00 AM	Section 1	9
1224	Quaking overexpression downregulates epithelial-mesenchymal transition in lung cancer cells	Jung-Jyh	Hung	Poster	EMT and Plasticity	4/17/23	9:00 AM	Section 2	1
1225	the existence, characteristics and underlying regulators of spontaneous epithelial-mesenchymal transition from a monophasic metaplastic squamous carcinoma patient-derived cancer cell model	Yen-Shen	Lu	Poster	EMT and Plasticity	4/17/23	9:00 AM	Section 2	2
1226	SETD2 loss in renal epithelial cells induces epithelial to mesenchymal transition in a TGFβ-independent manner	Tianchu	Wang	Poster	EMT and Plasticity	4/17/23	9:00 AM	Section 2	3
1227	Esophageal cancer shows spontaneous plasticity between epithelial and mesenchymal status	Kenji	Tsuchihashi	Poster	EMT and Plasticity	4/17/23	9:00 AM	Section 2	4

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
1228	TCF1 orchestrates the epithelial/mesenchymal hybrid phenotype in basal breast cancer via upregulation of FOXC2 leading to stemness and metastasis	Huizhi	Liang	Poster	EMT and Plasticity	4/17/23	9:00 AM	Section 2	5
1229	Deciphering molecular mechanisms of metastasis in renal cell carcinoma	Emily	Arner	Poster	EMT and Plasticity	4/17/23	9:00 AM	Section 2	6
1230	The pre-metastatic niche establishment through the induction of the epithelial-to-mesenchymal transition by circulating exosomes in lymphangi leiomyomatosis (LAM): implication of the complement cascade	Amina	Jouida	Poster	EMT and Plasticity	4/17/23	9:00 AM	Section 2	7
1231	A stochastic data-driven model predicts the timing and distribution of the epithelial-mesenchymal transition	Annice	Najafi	Poster	EMT and Plasticity	4/17/23	9:00 AM	Section 2	8
1232	Gastroesophageal reflux disease promotes E-cadherin cleavage and activates EMT via APE1-redox function in esophageal adenocarcinoma	Heng	Lu	Poster	EMT and Plasticity	4/17/23	9:00 AM	Section 2	9
1233	Depletion of Apc gene in Cdx2 gastro-intestinal cells facilitates metastasis of colorectal adenocarcinoma Lgr5 cells to distant organs	Xiaonan	Han	Poster	EMT and Plasticity	4/17/23	9:00 AM	Section 2	10
1234	Tumor cell-intrinsic PD-L1 promotes epithelial-to-mesenchymal transition in non-small cell lung cancer in interferon-g-independent and dependent way	Hyein	Jeong	Poster	EMT and Plasticity	4/17/23	9:00 AM	Section 2	11
1235	Quantitative high-content imaging reveals novel modulators of the metastatic hybrid state during epithelial-mesenchymal transition	Daniel	Purcell	Poster	EMT and Plasticity	4/17/23	9:00 AM	Section 2	12
1236	Direct interaction between cancer cells and fibroblasts drives epithelial-to-mesenchymal plasticity (EMP)	Nilu	Dhungel	Poster	EMT and Plasticity	4/17/23	9:00 AM	Section 2	13
1237	Zeb1-mediated autophagy enhances resistance of breast cancer cells to genotoxic drugs	Nick	Barlev	Poster	EMT and Plasticity	4/17/23	9:00 AM	Section 2	14
1238	Loss of HSPD1 induces cellular plasticity in triple-negative breast cancer cells	Muhammad	Khodary	Poster	EMT and Plasticity	4/17/23	9:00 AM	Section 2	15
1239	Intracellular effects of blocking MDM2 and HMG-CoA reductase in metastatic prostate cancer cells	Samia	Alsubhi	Poster	EMT and Plasticity	4/17/23	9:00 AM	Section 2	16
1240	mSin1 regulates epithelial-mesenchymal transition	Shile	Huang	Poster	EMT and Plasticity	4/17/23	9:00 AM	Section 2	17
1241	A single cell landscape of malignant pancreas cancer ascites	Shigeaki	Umeda	Poster	EMT and Plasticity	4/17/23	9:00 AM	Section 2	18
1242	Single cell multiomic map reveals regulatory landscape of human brain metastases	Remi	Klotz	Poster	EMT and Plasticity	4/17/23	9:00 AM	Section 2	19
1243	RON receptor signaling enhances prostate cancer metastasis in Hi-Myc mice	Angelle	Jones	Poster	EMT and Plasticity	4/17/23	9:00 AM	Section 2	20

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
1244	Examining the differential roles of OSM and IL-6 in varying subtypes of breast cancer for novel therapeutic treatment	Cody	Wolf	Poster	EMT and Plasticity	4/17/23	9:00 AM	Section 2	21
1245	A novel, immune-competent, Myc-dependent model of rapid metastatic recurrence of pancreatic cancer after resection	Jackie	Phipps	Poster	EMT and Plasticity	4/17/23	9:00 AM	Section 2	22
1246	Single-cell profiles of multiplexed in vivo models facilitate the characterization of phenotypic plasticity and invasion in glioblastoma	Toshiro	Hara	Poster	EMT and Plasticity	4/17/23	9:00 AM	Section 2	23
1250	Aberrant polyunsaturated fatty acids desaturation impairs survival and anti-tumor immunity of tumor resident memory CD8+ T cell in hepatocellular carcinoma	Tao	Ding	Poster	Metabolic Influences on the Tumor Microenvironment	4/17/23	9:00 AM	Section 3	1
1251	Novel potential role of m6A-demethylase FTO (fat mass and obesity) protein in colorectal cancer	Glauben	Landskron-Ramos	Poster	Metabolic Influences on the Tumor Microenvironment	4/17/23	9:00 AM	Section 3	2
1252	Role of purine and pyrimidine metabolism in CLL B cell survival and drug resistance mediated via interaction with bone marrow microenvironment	Sutapa	Sinha	Poster	Metabolic Influences on the Tumor Microenvironment	4/17/23	9:00 AM	Section 3	3
1253	Dietary tryptophan catabolite released by intratumoral Lactobacillus reuteri facilitates aPD-L1 therapy	Marlies	Meisel	Poster	Metabolic Influences on the Tumor Microenvironment	4/17/23	9:00 AM	Section 3	4
1254	Acetyl-coA distribution devotes STAT3 related neuronal methylation phenotype and pro-inflammatory niche in gastric cancer	Jie-Ting	Low	Poster	Metabolic Influences on the Tumor Microenvironment	4/17/23	9:00 AM	Section 3	5
1255	Glucose dependent CD73+ CAFs enforce a tumor metabolic barrier that promotes T cell exclusion	Marina	Broz	Poster	Metabolic Influences on the Tumor Microenvironment	4/17/23	9:00 AM	Section 3	6
1256	Transglutaminase-2 is elevated in the invasive cell state and modulates the tumor immune microenvironment in cutaneous melanoma	Signe	Caksa	Poster	Metabolic Influences on the Tumor Microenvironment	4/17/23	9:00 AM	Section 3	7
1257	Ursolic acid modulates T Cell compartment of hepatocellular carcinoma	Patricia	Da Costa Lopez	Poster	Metabolic Influences on the Tumor Microenvironment	4/17/23	9:00 AM	Section 3	8
1258	27-Hydroxycholesterol impairs lysosomal integrity in myeloid immune cells, resulting in enhanced secretion of cancer promoting extracellular vesicles	Anasuya	Das Gupta	Poster	Metabolic Influences on the Tumor Microenvironment	4/17/23	9:00 AM	Section 3	9
1259	Disturbing the Siglec-Sialoglycan axis to target myeloid-derived suppressor cells in the tumor microenvironment	Ronja	Wieboldt	Poster	Metabolic Influences on the Tumor Microenvironment	4/17/23	9:00 AM	Section 3	10
1261	Mutant IDH-mediated suppression of the Th17 lineage in glioma: Biologic impact and therapeutic potential	Christopher	Pirozzi	Poster	Metabolic Influences on the Tumor Microenvironment	4/17/23	9:00 AM	Section 3	12
1263	Hypoxia induces down-regulation of stimulator of interferon genes (STING) that is synergized with oncometabolites	Yuhong	Lu	Poster	Metabolic Influences on the Tumor Microenvironment	4/17/23	9:00 AM	Section 3	14

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
1265	Pan-cancer study of glycosylation-related gene expression: The emerging role of galectin-2 in tumor progression	Montana	Manselle Cocco	Poster	Metabolic Influences on the Tumor Microenvironment	4/17/23	9:00 AM	Section 3	16
1266	MYC mediated HIF-2 α modulates the altruistic stemness reprogramming in leukemia stem cells	Shirsajit	Mitra	Poster	Metabolic Influences on the Tumor Microenvironment	4/17/23	9:00 AM	Section 3	17
1267	Suppression of pyruvate carboxylase drives PDL1 expression in mouse models of TNBC	Numair	Attaar	Poster	Metabolic Influences on the Tumor Microenvironment	4/17/23	9:00 AM	Section 3	18
1268	The effect of metformin for neutrophil extracellular traps (NETs) on tumor immune microenvironment of colorectal cancer with type 2 diabetes mellitus	Akira	Saito	Poster	Metabolic Influences on the Tumor Microenvironment	4/17/23	9:00 AM	Section 3	19
1269	Evaluating the effect of metformin on components of extracellular matrix in colorectal cancer	Amar	Kaur	Poster	Metabolic Influences on the Tumor Microenvironment	4/17/23	9:00 AM	Section 3	20
1270	ECHS1 mediates metabolic disruption in hormone receptor-positive breast tumor microenvironment	Tina	Bharani	Poster	Metabolic Influences on the Tumor Microenvironment	4/17/23	9:00 AM	Section 3	21
1272	Aberrantly exposed phosphatidylserine as a drug delivery target in pancreatic cancer	Natalie	Phinney	Poster	Metabolic Influences on the Tumor Microenvironment	4/17/23	9:00 AM	Section 3	23
1273	Glioblastoma brain tumor-initiating cells are protected from hypoxia when co-cultured with normal human astrocytes revealing a potential role for mitochondrial transfer via tunneling nanotubes	Lauren	Nassour-Caswell	Poster	Metabolic Influences on the Tumor Microenvironment	4/17/23	9:00 AM	Section 3	24
1274	Extrinsic photoaging vs intrinsic aging in dermal fibroblasts: Its impact on the microenvironment and melanoma progression	Vania	Wang	Poster	Metabolic Influences on the Tumor Microenvironment	4/17/23	9:00 AM	Section 3	25
1278	ID3 controlled dynamic Pyk2 localization is important for the mobility of cancer stem cells	Quentin	Felty	Poster	Metastasis Promoting and Suppressing Genes	4/17/23	9:00 AM	Section 4	1
1279	Investigating the impact of PGC-1 α -coupled metabolic reprogramming on breast cancer metastasis	Emma	Ciccolini	Poster	Metastasis Promoting and Suppressing Genes	4/17/23	9:00 AM	Section 4	2
1280	Role of soluble mesothelin in peritoneal metastasis	Neel	Panchwagh	Poster	Metastasis Promoting and Suppressing Genes	4/17/23	9:00 AM	Section 4	3
1281	Oncoprotein YB-1 modulation of Lyn-MAPK-NF-kB pathway, a potential therapeutic strategy combined with sorafenib for advanced stage HCC	Ana	Ayala Pazzi	Poster	Metastasis Promoting and Suppressing Genes	4/17/23	9:00 AM	Section 4	4
1283	MUC5AC promotes brain metastases and colonization in non small cell lung cancer	Imayavaramban	Lakshmanan	Poster	Metastasis Promoting and Suppressing Genes	4/17/23	9:00 AM	Section 4	6
1284	The effect of Semaphorin 7A on breast cancer metastases and chemoresistance in young women	Kelsey	Kines	Poster	Metastasis Promoting and Suppressing Genes	4/17/23	9:00 AM	Section 4	7
1285	The pro-metastatic role of long-noncoding RNA LOXL1-AS1 in sonic-hedgehog medulloblastoma	Anh Duy	Do	Poster	Metastasis Promoting and Suppressing Genes	4/17/23	9:00 AM	Section 4	8

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
1286	UNC5B promotes EMT and metastasis of pancreatic adenocarcinomas and expresses different isoforms that impact sensitivity to Netrin-1 blockade	Chris	Harris	Poster	Metastasis Promoting and Suppressing Genes	4/17/23	9:00 AM	Section 4	9
1287	DEC2, a circadian rhythm transcription factor, promotes growth, metastasis and dormancy by facilitating immune cell invasion through decreasing cell surface expression of MHC-1 in a novel model of pancreatic cancer dormancy	Chris	Harris	Poster	Metastasis Promoting and Suppressing Genes	4/17/23	9:00 AM	Section 4	10
1288	NRP1 exon 4-skipping variant promotes colorectal cancer metastasis by secreted exosomes and activated endosomal signals	Yiwei	Gu	Poster	Metastasis Promoting and Suppressing Genes	4/17/23	9:00 AM	Section 4	11
1289	The role of mutant p53-mediated mechanisms in modulating the tumor microenvironment and promoting lung metastasis	Gizem	Efe	Poster	Metastasis Promoting and Suppressing Genes	4/17/23	9:00 AM	Section 4	12
1290	PTEN loss-mediated cell surface translocation of Annexin A2 promotes prostate cancer metastasis	Pankaj	Chaudhary	Poster	Metastasis Promoting and Suppressing Genes	4/17/23	9:00 AM	Section 4	13
1291	Signaling pathways modulated by lncRNA UCA1 during anchorage-independent growth in colorectal cancer	Sophia	Leslie	Poster	Metastasis Promoting and Suppressing Genes	4/17/23	9:00 AM	Section 4	14
1292	CX3CR1 surface expression and phenotypic plasticity in metastasis-initiating cells	Jieyi	Zhang	Poster	Metastasis Promoting and Suppressing Genes	4/17/23	9:00 AM	Section 4	15
1293	GPRC5A drives an implantation-like phenotype in early-stage lung disseminated cancer cells of esophageal squamous carcinoma	Hongyu	Zhou	Poster	Metastasis Promoting and Suppressing Genes	4/17/23	9:00 AM	Section 4	16
1294	Loss of bromodomain-7 (BRD7) promotes breast cancer lung metastasis by reprogramming the tumor immune microenvironment	Jayanta	Mondal	Poster	Metastasis Promoting and Suppressing Genes	4/17/23	9:00 AM	Section 4	17
1295	RAI2 is a novel bone metastasis-associated gene, mediating a vicious cross talk between breast cancer cells and osteoclasts	Thais	Pereira Veiga	Poster	Metastasis Promoting and Suppressing Genes	4/17/23	9:00 AM	Section 4	18
1296	Targeting nuclear AURKA and hypoxia signaling pathway attenuates metastatic burden in triple negative breast cancer	Abha	Maskey	Poster	Metastasis Promoting and Suppressing Genes	4/17/23	9:00 AM	Section 4	19
1297	BZW2 a potential target to inhibit colorectal cancer growth and metastasis	Prachi	Bajpai	Poster	Metastasis Promoting and Suppressing Genes	4/17/23	9:00 AM	Section 4	20
1298	Single cell analysis of breast cancer progression and metastasis to lymph nodes reveals cancer cell plasticity and MHC class II-mediated immune regulation	Pin-Ji	Lei	Poster	Metastasis Promoting and Suppressing Genes	4/17/23	9:00 AM	Section 4	21
1299	Transcriptomic analysis to unveil alveolar rhabdomyosarcoma metastatic process	Sara	Sanchez-Serra	Poster	Metastasis Promoting and Suppressing Genes	4/17/23	9:00 AM	Section 4	22
1300	Single-cell and spatial transcriptomic profiling reveal the cascade of immune events during progression and metastasis of non-small cell lung cancer	Yanhua	Tian	Poster	Metastasis Promoting and Suppressing Genes	4/17/23	9:00 AM	Section 4	23

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
1301	Evolution of heterogenous BRAFi/MEKi+CDK4/6i resistance mechanisms and targeting site-specific resistant populations in metastatic cutaneous melanoma	Haley	Wilson	Poster	Metastasis Promoting and Suppressing Genes	4/17/23	9:00 AM	Section 4	24
1302	BDNF methylation and expression is associated with stage and CMS classification in colorectal cancer	Jaime	Lopez	Poster	Metastasis Promoting and Suppressing Genes	4/17/23	9:00 AM	Section 4	25
1304	Multiomic approaches to illuminate molecular drivers of breast cancer metastasis to the liver	Mara	Gilardi	Poster	Metastasis Promoting and Suppressing Genes	4/17/23	9:00 AM	Section 4	27
1305	Cellular and molecular landscape of metastatic gastric cancer	Enyu	Dai	Poster	Metastasis Promoting and Suppressing Genes	4/17/23	9:00 AM	Section 4	28
1306	New therapeutic approach for triple negative breast cancer: soluble TNF α blockade and MUC4 expression as a prognostic biomarker	Florencia	Mauro	Poster	Metastasis Promoting and Suppressing Genes	4/17/23	9:00 AM	Section 4	29
1307	The effect of circulating CXCL10 on osteosarcoma metastasis using orthotopic xenograft mouse models	Tsz Kwong	Man	Poster	Metastasis Promoting and Suppressing Genes	4/17/23	9:00 AM	Section 4	30
1311	PCSK9 expression in liver sinusoidal endothelial cells during liver metastasis	Ander	Martin-San Sebastian	Poster	Metastatic and Premetastatic Microenvironments	4/17/23	9:00 AM	Section 5	1
1312	Oncogenic mutant p53 proteins are selectively shuttled by cancer extracellular vesicles to educate the tumor microenvironment	Bibek	Bhatta	Poster	Metastatic and Premetastatic Microenvironments	4/17/23	9:00 AM	Section 5	2
1313	Hepatic pre-metastatic niche formation by uveal melanoma extracellular vesicles	Kelly	Coutant	Poster	Metastatic and Premetastatic Microenvironments	4/17/23	9:00 AM	Section 5	3
1314	Molecular contribution of Annexin A2 in triple negative breast cancer metastasis via tumor-derived extracellular vesicles	Rucha	Trivedi	Poster	Metastatic and Premetastatic Microenvironments	4/17/23	9:00 AM	Section 5	4
1315	NETs act as immunosuppressive agents within lymph nodes during cancer	Ariane	Brassard	Poster	Metastatic and Premetastatic Microenvironments	4/17/23	9:00 AM	Section 5	5
1316	Immune cell dysfunction is enhanced in a mouse model of obesity-associated breast cancer lung metastasis	Abbey	Williams	Poster	Metastatic and Premetastatic Microenvironments	4/17/23	9:00 AM	Section 5	6
1317	Exercise training prevents exosome mediated pre-metastatic niche formation in the liver	Ruiqi	Yang	Poster	Metastatic and Premetastatic Microenvironments	4/17/23	9:00 AM	Section 5	7
1318	Potential mechanism of re-dissemination from lung metastases to tertiary sites in breast carcinoma: Tumor microenvironment of metastasis doorways and related pro-metastatic tumor phenotypes	Burcu	Karadal-Ferrena	Poster	Metastatic and Premetastatic Microenvironments	4/17/23	9:00 AM	Section 5	8
1319	Saffron (<i>Crocus sativus</i>) extract inhibits migration and invasion of cancer cells through modulation of MMP-3 and MMP-9 expression	Tyler	King	Poster	Metastatic and Premetastatic Microenvironments	4/17/23	9:00 AM	Section 5	9

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
1320	Hypoxic extracellular vesicles induce a pro-metastatic phenotype in neuroblastoma: from the delivery of miR-210-3p to the preconditioning of a metastatic niche	Anna	Fietta	Poster	Metastatic and Premetastatic Microenvironments	4/17/23	9:00 AM	Section 5	10
1321	New mouse models of metastatic lung cancer	Paige	Ramkissoon	Poster	Metastatic and Premetastatic Microenvironments	4/17/23	9:00 AM	Section 5	11
1322	Comparison of brain extracellular matrices in a blood brain barrier organ on a chip model	Ehsanul	Hoque Apu	Poster	Metastatic and Premetastatic Microenvironments	4/17/23	9:00 AM	Section 5	12
1323	Peristalsis based modulation of colorectal cancer cells leads to changes in stemness and invasiveness in an organ on chip model	Curran	Shah	Poster	Metastatic and Premetastatic Microenvironments	4/17/23	9:00 AM	Section 5	13
1324	EphA2 Expression in Breast Cancer Mediates Osteoclast Expansion and Promotes Osteolytic Bone Metastasis	Dominique	Parker	Poster	Metastatic and Premetastatic Microenvironments	4/17/23	9:00 AM	Section 5	14
1325	Novel recombinant rabbit monoclonal antibodies for cancer biology research	Alexander	Ball	Poster	Metastatic and Premetastatic Microenvironments	4/17/23	9:00 AM	Section 5	15
1326	Perineural invasion and bone metastases in prostate cancer - is there a link?	Dawid	Sigorski	Poster	Metastatic and Premetastatic Microenvironments	4/17/23	9:00 AM	Section 5	16
1327	Mechanism of tumor microenvironment remodeling and progression based on FAM20C-mediated extracellular kinome network in oral squamous cell carcinoma	Mi Rim	Lee	Poster	Metastatic and Premetastatic Microenvironments	4/17/23	9:00 AM	Section 5	17
1328	Building a 3D co-culture model for metastatic pancreatic ductal cancer using Curiochips microphysiological system	Jan	Pencik	Poster	Metastatic and Premetastatic Microenvironments	4/17/23	9:00 AM	Section 5	18
1329	Aging increases malignant peritoneal mesothelioma metastasis	Mykayla	Miller	Poster	Metastatic and Premetastatic Microenvironments	4/17/23	9:00 AM	Section 5	19
1330	Golgi disorganization and ER stress: the mechanism underlying alcohol-mediated prostate cancer progression	Amanda	Macke	Poster	Metastatic and Premetastatic Microenvironments	4/17/23	9:00 AM	Section 5	20
1331	"								
									A novel approach to treating hormonal breast cancer using

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
									clinical database and 3D ex vivo model
								"	Chaun (Christine)
Song	Poster	Metastatic and Premetastatic Microenvironments	4/17/23	9:00 AM	Section 5	21			
1332	Extracted mRNA from frozen buffy coat samples shows promise for use in downstream sequencing analyses	Erik	Bovinder Ylitalo	Poster	Metastatic and Premetastatic Microenvironments	4/17/23	9:00 AM	Section 5	22
1333	A novel and highly efficient biomimetic capture approach for the isolation and characterization of circulating metastatic cancer cell clusters from lung cancer patients	Peter	Teriete	Poster	Metastatic and Premetastatic Microenvironments	4/17/23	9:00 AM	Section 5	23
1337	Aged pancreatic fibroblasts enhance pancreatic cancer growth and progression	Daniel	Zabransky	Poster	Tumor Cell Interactions with Fibroblasts, Neuronal Cells, and Immune Cells	4/17/23	9:00 AM	Section 6	1
1338	Subpopulations of cancer associated fibroblasts serve as cancer stem cell niche in ovarian cancer via activation of non-canonical Wnt signaling	Xue	Xiao	Poster	Tumor Cell Interactions with Fibroblasts, Neuronal Cells, and Immune Cells	4/17/23	9:00 AM	Section 6	2
1339	Targeting specific extracellular matrix proteins to reactivate T cell trafficking in triple-negative breast cancer	Valentine	Gauthier	Poster	Tumor Cell Interactions with Fibroblasts, Neuronal Cells, and Immune Cells	4/17/23	9:00 AM	Section 6	3
1340	Type XVII collagen biology is central in the fibro-immune axis of tumor fibrosis: serological assessment of type XVII collagen	Marina	Crespo-Bravo	Poster	Tumor Cell Interactions with Fibroblasts, Neuronal Cells, and Immune Cells	4/17/23	9:00 AM	Section 6	4

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
1341	Non-invasive biomarkers quantifying collagens essential for embryogenesis are elevated in the circulation of solid tumor patients and may guide drug development	Jeppe	Thorlacius-Ussing	Poster	Tumor Cell Interactions with Fibroblasts, Neuronal Cells, and Immune Cells	4/17/23	9:00 AM	Section 6	5
1342	Roles of mesenchymal-like tumour cells and myofibroblastic cancer-associated fibroblasts in progression and therapeutic response of clear-cell renal cell carcinoma	Alexandra	Helleux	Poster	Tumor Cell Interactions with Fibroblasts, Neuronal Cells, and Immune Cells	4/17/23	9:00 AM	Section 6	6
1343	Mesenchymal cell populations associated with different stages of prostate cancer progression in mice and human	Mohamed	Omar	Poster	Tumor Cell Interactions with Fibroblasts, Neuronal Cells, and Immune Cells	4/17/23	9:00 AM	Section 6	7
1344	myCAFs and iCAFs have similar lineage	Thomas	Walter	Poster	Tumor Cell Interactions with Fibroblasts, Neuronal Cells, and Immune Cells	4/17/23	9:00 AM	Section 6	8
1345	p21 (WAF1/CIP1) drives a secretory phenotype in senescent fibroblasts and promotes bystander cancer cell growth in the tumor microenvironment	Shengliang	Zhang	Poster	Tumor Cell Interactions with Fibroblasts, Neuronal Cells, and Immune Cells	4/17/23	9:00 AM	Section 6	9
1346	Phagocytosis of solid tumors favors macrophage clusters and cooperativity in tumor elimination	Dennis	Discher	Poster	Tumor Cell Interactions with Fibroblasts, Neuronal Cells, and Immune Cells	4/17/23	9:00 AM	Section 6	10
1347	PAUF stimulates monocytes and induces their differentiation into tumor-associated macrophages	Fen	Jiang	Poster	Tumor Cell Interactions with Fibroblasts, Neuronal Cells, and Immune Cells	4/17/23	9:00 AM	Section 6	11
1348	Neutrophil pro-tumorigenic role in progression and therapy resistance in pancreatic ductal adenocarcinoma	Reegan	Sturgeon	Poster	Tumor Cell Interactions with Fibroblasts, Neuronal Cells, and Immune Cells	4/17/23	9:00 AM	Section 6	12
1349	Exploring CD63 as a targetable mediator of the pro-tumorigenic tissue microenvironment in HNSCC	Elisabeth	Dingendorf	Poster	Tumor Cell Interactions with Fibroblasts, Neuronal Cells, and Immune Cells	4/17/23	9:00 AM	Section 6	13
1350	Kupffer cells secrete CXCL5 to promote liver cancer	Taojian	Tu	Poster	Tumor Cell Interactions with Fibroblasts, Neuronal Cells, and Immune Cells	4/17/23	9:00 AM	Section 6	14
1351	Uterine natural killer cells display a unique functional dichotomy in human endometrial cancer	Caprice	Eisele	Poster	Tumor Cell Interactions with Fibroblasts, Neuronal Cells, and Immune Cells	4/17/23	9:00 AM	Section 6	15
1352	SOX17 plays a critical role in immune evasion of colorectal cancer	Norihiro	Goto	Poster	Tumor Cell Interactions with Fibroblasts, Neuronal Cells, and Immune Cells	4/17/23	9:00 AM	Section 6	16

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
1353	CD71 and CD117 identifies an early cancer associated macrophage progenitor population in leukemic mouse bone marrow	Xiaocui	Lu	Poster	Tumor Cell Interactions with Fibroblasts, Neuronal Cells, and Immune Cells	4/17/23	9:00 AM	Section 6	17
1354	Proteasome activation prevents T cell exhaustion and improves antitumor activity	Asis	Palazon	Poster	Tumor Cell Interactions with Fibroblasts, Neuronal Cells, and Immune Cells	4/17/23	9:00 AM	Section 6	18
1355	Evolution of immune tumor microenvironment (TME) from esophageal dysplasia to esophageal squamous cell carcinoma (ESCC)	Jhe-Cyuan	Guo	Poster	Tumor Cell Interactions with Fibroblasts, Neuronal Cells, and Immune Cells	4/17/23	9:00 AM	Section 6	19
1356	The tumor immune microenvironment of recurrent nasopharyngeal carcinoma	Jingyi	Ma	Poster	Tumor Cell Interactions with Fibroblasts, Neuronal Cells, and Immune Cells	4/17/23	9:00 AM	Section 6	20
1357	Alpha-synuclein may promote melanoma progression by modulating the levels of tetraspanin proteins	Nirjhar	Aloy	Poster	Tumor Cell Interactions with Fibroblasts, Neuronal Cells, and Immune Cells	4/17/23	9:00 AM	Section 6	21
1358	Prognostic value of genetic aberrations and tumor immune microenvironment in primary acral melanoma	Haimeng	Tang	Poster	Tumor Cell Interactions with Fibroblasts, Neuronal Cells, and Immune Cells	4/17/23	9:00 AM	Section 6	22
1359	Characterisation of heterogeneity of esophageal squamous cell carcinoma ecosystem by single-cell transcriptomics analysis	Carissa Wing-Yan	Wong	Poster	Tumor Cell Interactions with Fibroblasts, Neuronal Cells, and Immune Cells	4/17/23	9:00 AM	Section 6	23
1360	Spatial image analysis of tumor-infiltrating lymphocytes on gastric cancer to predict anti-PD1 inhibitor response	Sanghoon	Lee	Poster	Tumor Cell Interactions with Fibroblasts, Neuronal Cells, and Immune Cells	4/17/23	9:00 AM	Section 6	24
1361	Astrocytes activate neuronal programming in melanoma brain metastases	Julia	Farnan	Poster	Tumor Cell Interactions with Fibroblasts, Neuronal Cells, and Immune Cells	4/17/23	9:00 AM	Section 6	25
1362	Impact of chemotherapy on functional and biochemical characteristics of cancer-associated fibroblasts	Olivier	De Wever	Poster	Tumor Cell Interactions with Fibroblasts, Neuronal Cells, and Immune Cells	4/17/23	9:00 AM	Section 6	26
1363	Breast pericytes: A newly identified driver of tumor cell proliferation	Katelyn	Del Toro	Poster	Tumor Cell Interactions with Fibroblasts, Neuronal Cells, and Immune Cells	4/17/23	9:00 AM	Section 6	27
1364	Profiling tumor microenvironment for therapeutic intervention to soft-tissue sarcomas	Jin-Fen	Xiao	Poster	Tumor Cell Interactions with Fibroblasts, Neuronal Cells, and Immune Cells	4/17/23	9:00 AM	Section 6	28

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
1365	The spatially resolved host-microbiome sequencing platform reveals the interaction between bacteria and cancer stem cell microinches	Gyeongjun	Kim	Poster	Tumor Cell Interactions with Fibroblasts, Neuronal Cells, and Immune Cells	4/17/23	9:00 AM	Section 6	29
1366	HMGB1 localization and its effect on the immune response in the lung tumor microenvironment	Glenn	Simmons	Poster	Tumor Cell Interactions with Fibroblasts, Neuronal Cells, and Immune Cells	4/17/23	9:00 AM	Section 6	30
1370	Overexpression of the small GTPase Rab27B regulates autophagy flux and contributes to tumor growth in colorectal cancer	Sahida	Afroz	Poster	Autophagy, Mitochondrial Function, and Ferroptosis	4/17/23	9:00 AM	Section 8	1
1371	Tumor treating fields exposure causes an imbalance of reactive oxygen homeostasis likely through the cytosolic function of the fanconi's anemia genes	Narasimha Kumar	Karanam	Poster	Autophagy, Mitochondrial Function, and Ferroptosis	4/17/23	9:00 AM	Section 8	2
1372	NUDT16L1 promotes colon cancer progression via inhibition of ferroptosis	Yi-Syuan	Lin	Poster	Autophagy, Mitochondrial Function, and Ferroptosis	4/17/23	9:00 AM	Section 8	3
1373	Cell-in-cell mediated entosis reveals a progression mechanism in pancreatic cancer	Jianlu	Song	Poster	Autophagy, Mitochondrial Function, and Ferroptosis	4/17/23	9:00 AM	Section 8	4
1374	Small cell lung cancer predominantly expressing ASCL1 shows a distinct oxidative phenotype	Karin	Schelch	Poster	Autophagy, Mitochondrial Function, and Ferroptosis	4/17/23	9:00 AM	Section 8	5
1375	Paranuclear retention of c-KIT by Merkel cell polyomavirus large T-antigen suppresses autophagy through interaction with Beclin 1 essential for Merkel cell carcinoma cell survival	Hao	Shi	Poster	Autophagy, Mitochondrial Function, and Ferroptosis	4/17/23	9:00 AM	Section 8	6
1376	Prx4 depletion enhances ferroptosis susceptibility in colorectal cancer	Aziza	alshahrani	Poster	Autophagy, Mitochondrial Function, and Ferroptosis	4/17/23	9:00 AM	Section 8	7
1377	DCC-3116, a first-in-class selective inhibitor of ULK1/2 kinases and autophagy, synergizes with encorafenib and cetuximab in BRAF V600E mutant colorectal cancer models	Madhumita	Bogdan	Poster	Autophagy, Mitochondrial Function, and Ferroptosis	4/17/23	9:00 AM	Section 8	8
1378	Proguanil inhibits breast cancer in vitro and in vivo through mitochondrial dysfunction	Marina	Curcic	Poster	Autophagy, Mitochondrial Function, and Ferroptosis	4/17/23	9:00 AM	Section 8	9
1379	Studying the autophagic flux in response to hypoxia in BAP1-mutated pleural mesothelioma cells linked to asbestos exposure	Chloe	Michaud	Poster	Autophagy, Mitochondrial Function, and Ferroptosis	4/17/23	9:00 AM	Section 8	10
1380	Blocking autophagy ameliorates the severity of ConA induced autoimmune hepatitis in mice	Ruiqing	Yan	Poster	Autophagy, Mitochondrial Function, and Ferroptosis	4/17/23	9:00 AM	Section 8	11
1381	Reprogramming of iron metabolism confers ferroptosis resistance in ECM-detached cells	Jianping	He	Poster	Autophagy, Mitochondrial Function, and Ferroptosis	4/17/23	9:00 AM	Section 8	12
1382	Expression and intracellular translocation of cancer biomarkers in hepatocarcinoma cells induced by changes in mitochondrial metabolism	Bradley	Larson	Poster	Autophagy, Mitochondrial Function, and Ferroptosis	4/17/23	9:00 AM	Section 8	13

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
1383	Mechanisms of ATG9 mediated aggrephagy initiation	Deshan	Madhusanka	Poster	Autophagy, Mitochondrial Function, and Ferroptosis	4/17/23	9:00 AM	Section 8	14
1384	Stearoyl-CoA desaturase confers cell density-dependent resistance to ferroptosis induced by inhibition of glutathione peroxidase 4 in melanoma cells	Hitomi	Shirahama	Poster	Autophagy, Mitochondrial Function, and Ferroptosis	4/17/23	9:00 AM	Section 8	15
1385	Oncogenic regulation of autophagy and DNA emission	Thupten	Tsering	Poster	Autophagy, Mitochondrial Function, and Ferroptosis	4/17/23	9:00 AM	Section 8	16
1386	Ag5 is highly potent, mitochondrially targeted agent with a differentiated mechanism of action that promises to be efficacious in solid cancers	Martin	Treder	Poster	Autophagy, Mitochondrial Function, and Ferroptosis	4/17/23	9:00 AM	Section 8	17
1387	Novel thienopyrimidine-hydrazinyl analog, TPH104m inhibits mitochondrial respiration and induces caspase-independent cell death in triple-negative breast cancer cells	Saloni	Malla	Poster	Autophagy, Mitochondrial Function, and Ferroptosis	4/17/23	9:00 AM	Section 8	18
1388	Non-thermal plasma-activated medium induces ferroptotic cell death by intracellular ferrous iron overload in head and neck cancer	Quockhanh	Nguyen	Poster	Autophagy, Mitochondrial Function, and Ferroptosis	4/17/23	9:00 AM	Section 8	19
1392	Integrative biomarker analysis of regorafenib plus nivolumab (RegoNivo) in unresectable hepatocellular carcinoma (uHCC): A multicenter phase 2 RENOBATE trial	Jeong Seok	Lee	Poster	Biomarker Discovery	4/17/23	9:00 AM	Section 9	1
1393	Persistent mutation burden drives sustained anti-tumor immune responses in human cancers	Valsamo	Anagnostou	Poster	Biomarker Discovery	4/17/23	9:00 AM	Section 9	2
1394	Comprehensive clinical and genomic analysis for patients with MYC, MYCN, and MYCL amplified solid tumors	Monica	Chen	Poster	Biomarker Discovery	4/17/23	9:00 AM	Section 9	3
1395	Genomic and transcriptomic analyses identify distinct features of triple-negative inflammatory breast cancer	Xiaoping	Wang	Poster	Biomarker Discovery	4/17/23	9:00 AM	Section 9	4
1396	The HOX family gene signature predicts prognosis and indicates immune infiltrates in pediatric gliomas	Qianhao	Zhao	Poster	Biomarker Discovery	4/17/23	9:00 AM	Section 9	5
1397	Collagen COL26A1 promotes papillary thyroid cancer invasion and metastasis and correlates with poor survival and clinical outcomes	Michelle	Carnazza	Poster	Biomarker Discovery	4/17/23	9:00 AM	Section 9	6
1398	Clinical and transcriptomic analysis demonstrates improved survival and unique gene expression signatures among SCLC arising in patients with minimal tobacco use	Kyle	Concannon	Poster	Biomarker Discovery	4/17/23	9:00 AM	Section 9	7
1399	Genomic profiling of gastric cancer with peritoneal metastasis identifies molecular subtypes and a potential molecular-guided therapeutic strategy for intractable gastric cancer	Juin	Park	Poster	Biomarker Discovery	4/17/23	9:00 AM	Section 9	8
1400	Novel expression biomarkers via prediction of response to FOLFIRINOX (FFX) treatment for PDAC	Hosseini	Asghari	Poster	Biomarker Discovery	4/17/23	9:00 AM	Section 9	9

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
1401	Landscape of known and novel myeloid neoplasia fusions identified by a multimodal comprehensive genomic profiling test in 789 patients	Michal	Krawczyk	Poster	Biomarker Discovery	4/17/23	9:00 AM	Section 9	10
1402	Comparative analysis of clinicopathologic features and tumor immune-microenvironment of primary diffuse large B cell lymphoma of the central nervous system according to molecular classification	Sehui	Kim	Poster	Biomarker Discovery	4/17/23	9:00 AM	Section 9	11
1404	A functional genetic polymorphism of mitochondrion-associated DNAJA3 in nonalcoholic steatohepatitis-related hepatocellular carcinoma	Yuto	Shiode	Poster	Biomarker Discovery	4/17/23	9:00 AM	Section 9	13
1405	Long non-coding RNA LINC01614 augments papillary thyroid cancer cell phenotype	Danielle	Quaranto	Poster	Biomarker Discovery	4/17/23	9:00 AM	Section 9	14
1406	Long non-coding RNA DUXAP10 is a putative determinant of anaplastic thyroid cancer	Nicole	DeSouza	Poster	Biomarker Discovery	4/17/23	9:00 AM	Section 9	15
1407	Refining endometrial carcinoma of no-specific molecular subtype by sources of estrogen signaling	Clarissa	Lam	Poster	Biomarker Discovery	4/17/23	9:00 AM	Section 9	16
1408	Increased infiltrating class-switched memory B cell in breast cancer tumors were associated with favorable prognostic outcome	Mariko	Asaoka	Poster	Biomarker Discovery	4/17/23	9:00 AM	Section 9	17
1409	RNA sequencing reveals that African Americans carrying wild-type CYP3A5 differentially express genes known to promote aggressive prostate cancer	Ranjana	Mitra	Poster	Biomarker Discovery	4/17/23	9:00 AM	Section 9	18
1411	Different treatment response in several head and neck squamous cell carcinoma (HNSCC) cell lines reflecting underlying genomic and molecular signatures	Jo-Pai	Chen	Poster	Biomarker Discovery	4/17/23	9:00 AM	Section 9	20
1412	Co-existence of TP53 mutation confers endocrine resistance in PIK3CA-mutated ER+HER2- breast cancer	Yoonwon	Kook	Poster	Biomarker Discovery	4/17/23	9:00 AM	Section 9	21
1413	Chromosome arm aneuploidies as genetic vulnerabilities of triple-negative breast cancer	Rohan	Dandage	Poster	Biomarker Discovery	4/17/23	9:00 AM	Section 9	22
1414	The role of chromosome arm 3p and human papillomavirus on proliferation, differentiation, and metastasis in squamous cancers	Samyukta	Mallick	Poster	Biomarker Discovery	4/17/23	9:00 AM	Section 9	23
1415	The search for molecular biomarkers of relapse in early stage lung adenocarcinoma	Honggang	Ke	Poster	Biomarker Discovery	4/17/23	9:00 AM	Section 9	24
1416	Genomic features of renal cell carcinoma developed during end-stage renal disease and dialysis	Shigekatsu	Maekawa	Poster	Biomarker Discovery	4/17/23	9:00 AM	Section 9	25
1420	The non-canonical role of Rb in enhancers and insulators	Hanjun	Lee	Poster	Cell Cycle Progression, Checkpoint, and Telomeres	4/17/23	9:00 AM	Section 10	1

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
1421	Targeting ASPM suppresses the tumorigenicity of human hepatocellular carcinoma cells via ASPM-TPX2 axis disruption and result in increased chromosome segregation error	Hung-Wei	Pan	Poster	Cell Cycle Progression, Checkpoint, and Telomeres	4/17/23	9:00 AM	Section 10	2
1422	Fibroblast growth factor receptor-1 is a novel therapeutic target in mantle cell Lymphoma	Anuvrat	Sircar	Poster	Cell Cycle Progression, Checkpoint, and Telomeres	4/17/23	9:00 AM	Section 10	3
1423	Regulation of SKP2 expression by methyltransferase-independent function of EZH2 in tumor growth and progression	Tania Marlyn	Colon	Poster	Cell Cycle Progression, Checkpoint, and Telomeres	4/17/23	9:00 AM	Section 10	4
1424	Selective blockade of neuropeptide Y receptor 1 induces cell cycle arrest and promotes apoptosis in colon cancer cells	Sooraj	Kakkat	Poster	Cell Cycle Progression, Checkpoint, and Telomeres	4/17/23	9:00 AM	Section 10	5
1425	TTFields reduce sensitivity in glioblastoma is associated with the functional expression of the chloride intracellular channel 1 and with voltage dependent sodium channel	Michele	Mazzanti	Poster	Cell Cycle Progression, Checkpoint, and Telomeres	4/17/23	9:00 AM	Section 10	6
1426	Sox-based sensor phosphopeptides for continuous, homogeneous and quantitative monitoring of protein phosphatase activity	Susan	Cornell-Kennon	Poster	Cell Cycle Progression, Checkpoint, and Telomeres	4/17/23	9:00 AM	Section 10	7
1427	NQO1/c-Fos/CKS1 signaling pathway regulates cell cycle progression at the G2/M phase	Eun-Taex	Oh	Poster	Cell Cycle Progression, Checkpoint, and Telomeres	4/17/23	9:00 AM	Section 10	8
1428	Luminescent immunoassays for homogeneous determination of cell proliferation and senescence	Dan	Lazar	Poster	Cell Cycle Progression, Checkpoint, and Telomeres	4/17/23	9:00 AM	Section 10	9
1429	C-terminal phosphorylation of p27 promotes cell cycle dependent changes through transcriptional coregulation of cJun and STAT3	Amir	Bagheri	Poster	Cell Cycle Progression, Checkpoint, and Telomeres	4/17/23	9:00 AM	Section 10	10
1431	Sprouty 2 expression attenuates proliferation in nras-driven acute myeloid leukemia cell lines	Michael	Roberts	Poster	Cell Cycle Progression, Checkpoint, and Telomeres	4/17/23	9:00 AM	Section 10	12
1433	Targeting the mitotic kinase NEK2 potentiates CDK4/6 inhibitor efficacy in breast cancer	Jessica	Bobbitt	Poster	Cell Cycle Progression, Checkpoint, and Telomeres	4/17/23	9:00 AM	Section 10	14
1434	Co-occurrence of alterations impacting telomere elongation	Radwa	Sharaf	Poster	Cell Cycle Progression, Checkpoint, and Telomeres	4/17/23	9:00 AM	Section 10	15
1435	A GABP dominant negative approach to targeting tumor cell immortality	Nicholas	Stevens	Poster	Cell Cycle Progression, Checkpoint, and Telomeres	4/17/23	9:00 AM	Section 10	16
1436	T-oligo's mechanism of action in melanoma cells	Archit	Agnihotri	Poster	Cell Cycle Progression, Checkpoint, and Telomeres	4/17/23	9:00 AM	Section 10	17
1437	E-cigarette vape promotes cell cycle progression and inflammation in 3D pre-clinical oral spheroid models	Jasmine	Almeda	Poster	Cell Cycle Progression, Checkpoint, and Telomeres	4/17/23	9:00 AM	Section 10	18
1439	In vivo characterization of a selective FGFR2 inhibitor with potency against gatekeeper and molecular brake mutations	John	Fischer	Poster	Cell Cycle Progression, Checkpoint, and Telomeres	4/17/23	9:00 AM	Section 10	20
1440	Identification of a novel EGFR sparing brain penetrant ErbB2 inhibitor with activity against oncogenic ErbB2 mutations	Mark J	Chicarelli	Poster	Cell Cycle Progression, Checkpoint, and Telomeres	4/17/23	9:00 AM	Section 10	21

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
1441	p27Kip1 is upregulated in UMSCV-4 cells corresponding to entering a state of quiescence when treated with clobetasol	Jani	Lewis	Poster	Cell Cycle Progression, Checkpoint, and Telomeres	4/17/23	9:00 AM	Section 10	22
1445	TBX2 acts as a molecular switch to downregulate androgen receptor and upregulate glucocorticoid receptor signaling in castrate resistant prostate cancer	Sayanika	Dutta	Poster	Gene Regulation in Hormonal and Pediatric Cancers	4/17/23	9:00 AM	Section 11	1
1446	The elevated expression of INSM1 is correlated with EZH2 in neuroendocrine prostate cancer	Lin	Li	Poster	Gene Regulation in Hormonal and Pediatric Cancers	4/17/23	9:00 AM	Section 11	2
1447	Retinoic acid-induced 2 driven polymerization of c-terminal binding proteins sustains epithelial differentiation in castration-resistant prostate cancer	Stefan	Werner	Poster	Gene Regulation in Hormonal and Pediatric Cancers	4/17/23	9:00 AM	Section 11	3
1448	The YAP1/TEAD and NF-Kappa B transcription factors may cooperate to mediate prostate cancer progression	Bekir	Cinar	Poster	Gene Regulation in Hormonal and Pediatric Cancers	4/17/23	9:00 AM	Section 11	4
1449	Targeting CBP/p300 and its downstream transcriptional machinery in advanced prostate cancer	Ayesha	Shafi	Poster	Gene Regulation in Hormonal and Pediatric Cancers	4/17/23	9:00 AM	Section 11	5
1450	Global changes in RBPs and mRNA interactions during prostate cancer progression	Abdulrahman	Dwead	Poster	Gene Regulation in Hormonal and Pediatric Cancers	4/17/23	9:00 AM	Section 11	6
1451	Cognition-mediated transcriptomic signature associated with androgen deprivation therapy in prostate cancer	Shiv	Verma	Poster	Gene Regulation in Hormonal and Pediatric Cancers	4/17/23	9:00 AM	Section 11	7
1452	Big data analysis revealed signalling activity and key regulators in human prostate cancer cell lines	Siyuan	Cheng	Poster	Gene Regulation in Hormonal and Pediatric Cancers	4/17/23	9:00 AM	Section 11	8
1454	SMAD3 promotes expression and activity of the androgen receptor in prostate cancer	Jianfei	Qi	Poster	Gene Regulation in Hormonal and Pediatric Cancers	4/17/23	9:00 AM	Section 11	10
1455	The glucocorticoid receptor-LEDGFp75 interaction in prostate cancer therapy cross-resistance	Evelyn	Sanchez-Hernandez	Poster	Gene Regulation in Hormonal and Pediatric Cancers	4/17/23	9:00 AM	Section 11	11
1456	An expression study of circadian clock-associated transcription factors and nuclear receptors in mouse prostate gland and tumor	Ria	Chopra	Poster	Gene Regulation in Hormonal and Pediatric Cancers	4/17/23	9:00 AM	Section 11	12
1457	PDEF restricts prostate cancer cellular plasticity in part by modulating YAP1/TAZ-TEAD transcriptional network	Hari	Koul	Poster	Gene Regulation in Hormonal and Pediatric Cancers	4/17/23	9:00 AM	Section 11	13
1458	The PAX5 transcription factor is a suppressor of NFAT-mediated breast cancer aggressivity	Félix	Després	Poster	Gene Regulation in Hormonal and Pediatric Cancers	4/17/23	9:00 AM	Section 11	14
1459	Nanocage delivered engineered destabilized 3UTR ARE of cMYC inhibits triple negative breast cancer growth and metastasis in vivo by targeting cMYC and downregulating STAT5A5B	Chidiebere	Awah	Poster	Gene Regulation in Hormonal and Pediatric Cancers	4/17/23	9:00 AM	Section 11	15
1460	Co-expression network analysis reveals male breast cancer specific transcriptional module	Meenakshi	Anurag	Poster	Gene Regulation in Hormonal and Pediatric Cancers	4/17/23	9:00 AM	Section 11	16
1461	C-terminally phosphorylated p27 modulates chromatin remodeling in breast cancer	Seyedeh Fatemeh	Razavipour	Poster	Gene Regulation in Hormonal and Pediatric Cancers	4/17/23	9:00 AM	Section 11	17

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
1462	Oncogenic Foxl2 is a chromatin-remodeling pioneer transcription factor in adult-type ovarian granulosa cell tumors	Veena	Vuttaradhi	Poster	Gene Regulation in Hormonal and Pediatric Cancers	4/17/23	9:00 AM	Section 11	18
1463	Fxr1 is an oncogenic driver in ovarian cancer	Jasmine	George	Poster	Gene Regulation in Hormonal and Pediatric Cancers	4/17/23	9:00 AM	Section 11	19
1464	Exosomal delivery of tumor suppressive microRNA-7 as a novel approach to regulating cervical cancer cell growth	Gabriella	McWilliams	Poster	Gene Regulation in Hormonal and Pediatric Cancers	4/17/23	9:00 AM	Section 11	20
1465	A SNAI2/CDKN1A pathway protects rhabdomyosarcoma tumors from radiation	Paulomi	Modi	Poster	Gene Regulation in Hormonal and Pediatric Cancers	4/17/23	9:00 AM	Section 11	21
1466	Heterogeneity of the EWS-FLI1 transcriptome drives differences in the cellular phenotype of Ewing sarcoma cell lines	Seneca	Kinn-Gurzo	Poster	Gene Regulation in Hormonal and Pediatric Cancers	4/17/23	9:00 AM	Section 11	22
1467	A novel screening model to identify EWS::FLI1 regulators and their consequences on Ewing sarcoma plasticity	Veveeyan	Suresh	Poster	Gene Regulation in Hormonal and Pediatric Cancers	4/17/23	9:00 AM	Section 11	23
1468	MYC-C interacts with Aurora kinase A in Ewing sarcoma cells	Molly	McNae	Poster	Gene Regulation in Hormonal and Pediatric Cancers	4/17/23	9:00 AM	Section 11	24
1469	Visualization of endogenous EWSR1 in Ewing sarcoma cells reveals a regular nucleoplasmic organization that includes concentration at regions of active transcription	Soumya	Sundara Rajan	Poster	Gene Regulation in Hormonal and Pediatric Cancers	4/17/23	9:00 AM	Section 11	25
1470	ASCL1 dimerizes with TCF12 protein and activates BMP-SMAD1 pathway during subtype switching from mesenchymal towards adrenergic neuroblastoma	Lu	Wang	Poster	Gene Regulation in Hormonal and Pediatric Cancers	4/17/23	9:00 AM	Section 11	26
1474	Hippo-mediated control of the mutant TERT promoter via MYC and GABP	Nicholas	Stevens	Poster	Gene Regulation in Solid Tumors	4/17/23	9:00 AM	Section 12	1
1475	FOXO transcription factors regulate WNT pathway gene expression in GBM	Megan	Keniry	Poster	Gene Regulation in Solid Tumors	4/17/23	9:00 AM	Section 12	2
1476	FOXM1 inhibition: A novel therapeutic approach for small cell lung cancer	Md Arafat	Khan	Poster	Gene Regulation in Solid Tumors	4/17/23	9:00 AM	Section 12	3
1477	TICRR is a prognosis biomarker associated with RNA epigenetic modification, DDR pathway, and RNA metabolism of lung adenocarcinoma	Xunbo	Zheng	Poster	Gene Regulation in Solid Tumors	4/17/23	9:00 AM	Section 12	4
1478	Broad downregulation of normal-specific super-enhancer associated genes in lung adenocarcinoma	Guoshuai	Cai	Poster	Gene Regulation in Solid Tumors	4/17/23	9:00 AM	Section 12	5
1479	FOXA2 induces invasive mucinous adenocarcinoma of the lung in the presence of mutant KRAS	Yutaka	Maeda	Poster	Gene Regulation in Solid Tumors	4/17/23	9:00 AM	Section 12	6
1480	ZEB1 dimerization is regulated by acetylation and promotes protein stability, interactions, EMT, and NSCLC metastasis	Mabel	Perez-Oquendo	Poster	Gene Regulation in Solid Tumors	4/17/23	9:00 AM	Section 12	7

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
1481	MAPK and NF-kappaB signaling converge on the epigenome to transcriptionally activate genes involved in pancreatic cancer metastasis	Joana	Aggrey-Fynn	Poster	Gene Regulation in Solid Tumors	4/17/23	9:00 AM	Section 12	8
1482	Critical role of OGT-mediated novel NF-κB o-glcNAcylation in pancreatic cancer	Aishat	Motolani	Poster	Gene Regulation in Solid Tumors	4/17/23	9:00 AM	Section 12	9
1483	Development of FUBP1 inhibitors to reprogram pancreatic cancer cells into an anti-cancer phenotype	Alexandra	Bunea	Poster	Gene Regulation in Solid Tumors	4/17/23	9:00 AM	Section 12	10
1484	Identification of the critical active enhancer and regulated transcripts contributing to the refractory nature of pancreatic cancer	Tadashi	Abe	Poster	Gene Regulation in Solid Tumors	4/17/23	9:00 AM	Section 12	11
1485	Elucidating the role of VGLL1 in pancreatic cancer tumorigenesis	Heather	Sonnemann	Poster	Gene Regulation in Solid Tumors	4/17/23	9:00 AM	Section 12	12
1486	The regulatory mechanism of LncRNA CCAT1 via three-dimensional genome structure in colorectal cancer cells	Yuhki	Yokoyama	Poster	Gene Regulation in Solid Tumors	4/17/23	9:00 AM	Section 12	13
1487	TPM4 overexpression promotes colon epithelial cell tumorigenesis	Michael	Papetti	Poster	Gene Regulation in Solid Tumors	4/17/23	9:00 AM	Section 12	14
1488	The FOXA2 contributes to tumor proliferation and invasion via HGF mediated ERK signaling pathway in human gastric cancer	Jiyoon	Jung	Poster	Gene Regulation in Solid Tumors	4/17/23	9:00 AM	Section 12	15
1489	Overexpression of ribosomal L22-like1 (RPL22L1) enhances cancer stem cell properties and promotes tumor progression in hepatocellular carcinoma (HCC)	JinLin	Huang	Poster	Gene Regulation in Solid Tumors	4/17/23	9:00 AM	Section 12	16
1490	Exon exclusion of NELF-E produces an anti-tumorigenic truncated isoform in hepatocellular carcinoma	Laura	Reynolds	Poster	Gene Regulation in Solid Tumors	4/17/23	9:00 AM	Section 12	17
1491	Delineating the oncogenic mechanisms of NAT10 in hepatocellular carcinoma	Daniel	Arango	Poster	Gene Regulation in Solid Tumors	4/17/23	9:00 AM	Section 12	18
1492	Interaction between Argonaute-2 and Negative Elongation Factor-E in hepatocellular carcinoma	Brittany	Ruiz	Poster	Gene Regulation in Solid Tumors	4/17/23	9:00 AM	Section 12	19
1493	ROS inhibits enzymatic activation of PRMT5 and increases the protein stability of tumor suppressors as non-histone substrates in liver cancer	Ji Min	Lee	Poster	Gene Regulation in Solid Tumors	4/17/23	9:00 AM	Section 12	20
1494	PBRM1-deficient PBAF complexes target de novo genomic loci to activate NF-κB pathway in clear cell renal cell carcinoma	Xiaosai	Yao	Poster	Gene Regulation in Solid Tumors	4/17/23	9:00 AM	Section 12	21
1495	Developing a model to investigate the roles of biomolecular condensates in papillary renal cell carcinoma	Choon Leng	So	Poster	Gene Regulation in Solid Tumors	4/17/23	9:00 AM	Section 12	22
1498	Melanoma antigen gene A6 and androgen receptor interaction in bladder cancer	Sanjay	Gupta	Poster	Gene Regulation in Solid Tumors	4/17/23	9:00 AM	Section 12	25
1499	HOXC6 gene functions as an oncogenic driver in HPV+ head and neck squamous cell carcinoma (HNSCC)	Subhendu	Roy Choudhury	Poster	Gene Regulation in Solid Tumors	4/17/23	9:00 AM	Section 12	26

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
1501	Epigenetic dedifferentiation as a therapeutic strategy in adrenal cancer	Dipika	Mohan	Poster	Gene Regulation in Solid Tumors	4/17/23	9:00 AM	Section 12	28
1502	PRAME modulates the effect of retinoids on keratinocyte differentiation and cell cycle progression in basal cell carcinoma and cutaneous squamous cell carcinoma	Brandon	Ramchatesingh	Poster	Gene Regulation in Solid Tumors	4/17/23	9:00 AM	Section 12	29
1506	Decoding multi-omics genetic profiling reveals heterogeneity in adult pan-gliomas	Takuma	Nakashima	Poster	Tumor Heterogeneity and Clonal Evolution	4/17/23	9:00 AM	Section 13	1
1507	Multiregional sampling of high grade glioma identifies regional biologic signatures	Mylan	Blomquist	Poster	Tumor Heterogeneity and Clonal Evolution	4/17/23	9:00 AM	Section 13	2
1509	Longitudinal profiling of high-risk pediatric malignancies using a multiomics approach	Henry	Martell	Poster	Tumor Heterogeneity and Clonal Evolution	4/17/23	9:00 AM	Section 13	4
1510	Clonal hematopoiesis in Down syndrome and its potential impact on hematopoietic lineages	Edward	Evans	Poster	Tumor Heterogeneity and Clonal Evolution	4/17/23	9:00 AM	Section 13	5
1511	Origin of synchronous or metachronous multiple pancreatic cancers	Tomonori	Hirano	Poster	Tumor Heterogeneity and Clonal Evolution	4/17/23	9:00 AM	Section 13	6
1512	Evolution of large copy number variants in breast cancer through genetic network rewiring	Elena	Kuzmin	Poster	Tumor Heterogeneity and Clonal Evolution	4/17/23	9:00 AM	Section 13	7
1513	A multi-sample study reveals the evolution and heterogeneity in high-grade serous ovarian cancer	Siao-Han	Wong	Poster	Tumor Heterogeneity and Clonal Evolution	4/17/23	9:00 AM	Section 13	8
1515	Tumor molecular profiling and spatial transcriptomics to assess colorectal cancer heterogeneity and microenvironment	Enrique	Velazquez Villarreal	Poster	Tumor Heterogeneity and Clonal Evolution	4/17/23	9:00 AM	Section 13	10
1516	Bulk and spatial single-cell transcriptomic characterization of fibrolamellar hepatocellular carcinoma	David	Requena	Poster	Tumor Heterogeneity and Clonal Evolution	4/17/23	9:00 AM	Section 13	11
1517	Genetic characterization of normal pancreas tissue using single-cell technology	Elias-Ramzey	Karnoub	Poster	Tumor Heterogeneity and Clonal Evolution	4/17/23	9:00 AM	Section 13	12
1518	Benign oncocytic tumors in the setting of HLRCC syndrome	Dilara	Akbulut	Poster	Tumor Heterogeneity and Clonal Evolution	4/17/23	9:00 AM	Section 13	13
1521	Unlocking the therapeutic index of highly potent site-specific ADCs in solid tumors	James	Italia	Poster	Antibody Drug Conjugates	4/17/23	9:00 AM	Section 14	1
1522	SGN-B6A induces immunogenic cell death as an additional mechanism of action	Vivian	Trang	Poster	Antibody Drug Conjugates	4/17/23	9:00 AM	Section 14	2
1523	Subcutaneous dosing of amatoxin-based ADCs increases the therapeutic index	Kristin	Decker	Poster	Antibody Drug Conjugates	4/17/23	9:00 AM	Section 14	3
1524	Effect of a chimeric antibody targeting CXCL1 in bladder cancer	Nari	Kim	Poster	Antibody Drug Conjugates	4/17/23	9:00 AM	Section 14	4
1525	A novel platform for protein engineering and modification to expand the therapeutic index of anti-tumor therapeutics	Amy	Twite	Poster	Antibody Drug Conjugates	4/17/23	9:00 AM	Section 14	5

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
1527	KY-CLC-mouse, a common light chain bi-specific antibody discovery platform	Guojin	Wu	Poster	Antibody Drug Conjugates	4/17/23	9:00 AM	Section 14	7
1528	6B5, an anti-human B7-H3 therapeutic antibody that enhances antibody-dependent cellular cytotoxicity and inhibits tumor growth in B7-H3-humanized mice	W. Frank	An	Poster	Antibody Drug Conjugates	4/17/23	9:00 AM	Section 14	8
1529	Characterizing antibody internalization for rational selection of ADC linker design	Zekun	Shao	Poster	Antibody Drug Conjugates	4/17/23	9:00 AM	Section 14	9
1530	Gastric cancer antibody fragment drug-conjugates (FDCs): Applying a successful concept to solid tumours	Mahendra	Deonarain	Poster	Antibody Drug Conjugates	4/17/23	9:00 AM	Section 14	10
1531	Human anti-CD40 agonistic antibodies with enhanced FcγR engagement activate immune cell and promote anti-tumor efficacy	Linya	Wang	Poster	Antibody Drug Conjugates	4/17/23	9:00 AM	Section 14	11
1532	Next generation IgM antibody based multimeric platform: ePENDY (engineered pentamer body)	Sungmuk	Kang	Poster	Antibody Drug Conjugates	4/17/23	9:00 AM	Section 14	12
1533	ZW220, a novel NaPi2b-targeting antibody drug conjugate bearing a topoisomerase 1 inhibitor payload	Andrea	Hernandez Rojas	Poster	Antibody Drug Conjugates	4/17/23	9:00 AM	Section 14	13
1535	A novel ELISA Kit: highly accuracy and sensitivity for GDF-15 detection	Feng	Hao	Poster	Antibody Drug Conjugates	4/17/23	9:00 AM	Section 14	15
1536	Machine learning guided engineering of nivolumab for superior physicochemical properties for subcutaneous injection	Norio	Hamamatsu	Poster	Antibody Drug Conjugates	4/17/23	9:00 AM	Section 14	16
1537	DRIVE-Biologics: All the steps from discovery to development of novel biological entities	Francis	Bichat	Poster	Antibody Drug Conjugates	4/17/23	9:00 AM	Section 14	17
1538	Revisiting the dogma of antibody drug conjugates (ADCs): Emerging data challenge the benefit of linker stability and the primacy of payload delivery	Raffaele	Colombo	Poster	Antibody Drug Conjugates	4/17/23	9:00 AM	Section 14	18
1540	A click chemistry-activated auristatin protodrug (TCO-MMAE) demonstrates potency and safety with antibody and intratumoral tumor-targeting agents	Jesse	McFarland	Poster	Antibody Drug Conjugates	4/17/23	9:00 AM	Section 14	20
1541	NextGen conditionally active biologic (CAB) anti-Nectin-4-ADC with improved stability and safety	Jing	Wang	Poster	Antibody Drug Conjugates	4/17/23	9:00 AM	Section 14	21
1542	Generation of an antibody-drug conjugate-optimized TLR 7/8 agonist payload	Kung-Pern	Wang	Poster	Antibody Drug Conjugates	4/17/23	9:00 AM	Section 14	22
1543	Discovery of CCR8 antibodies targeting regulatory T cells to enable tumor sensitization	Brad	Screnci	Poster	Antibody Drug Conjugates	4/17/23	9:00 AM	Section 14	23
1544	MBK-103, a potent novel conjugation platform-based antibody-drug conjugate, changing therapeutic options in folate receptor alpha positive cancer patients	Lenka	Kyrych Sadilkova	Poster	Antibody Drug Conjugates	4/17/23	9:00 AM	Section 14	24

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
1545	Targeting anticancer agents to the tumor microenvironment with cathepsin B cleavable drug-linker conjugates of phosphatidylserine-binding proteins	Yuling	Deng	Poster	Antibody Drug Conjugates	4/17/23	9:00 AM	Section 14	25
1546	ADCC enhanced anti-CD25 mAb (TST010) demonstrated antitumor activity via depleting Treg cells and increasing CD8+T/Treg ratio in preclinical tumor models	Yi	Gu	Poster	Antibody Drug Conjugates	4/17/23	9:00 AM	Section 14	26
1547	The urokinase plasminogen activator receptor-associated protein (uPARAP) is an attractive target for the development of antibody-drug conjugates (ADCs) for treatment of mesenchymal malignancies	Pernille	Barkholt	Poster	Antibody Drug Conjugates	4/17/23	9:00 AM	Section 14	27
1548	CO-1008, an ADC program targeting leukemic progenitor and blast AML cells, but not normal hematopoietic progenitor cells	Garima	Kaushik	Poster	Antibody Drug Conjugates	4/17/23	9:00 AM	Section 14	28
1549	Preclinical characterization of GQ1010, a next generation Trop2 ADC with the best-in-class potential against diverse Trop2+ solid tumors	Paul	Song	Poster	Antibody Drug Conjugates	4/17/23	9:00 AM	Section 14	29
1553	Discovery of CDK4/6 bifunctional degraders for ER+/HER2- breast cancer and triple negative breast cancer	Hannah	Majeski	Poster	Cell Cycle/Cell Proliferation Inhibitors for Cancer Therapy	4/17/23	9:00 AM	Section 15	1
1554	IpY.20, a first-in-class inhibitor of p27Kip1, inhibits CDK4/6 and CDK2 to kill tumor cells	Grace	Chen	Poster	Cell Cycle/Cell Proliferation Inhibitors for Cancer Therapy	4/17/23	9:00 AM	Section 15	2
1555	CDK2 inhibition & disruption of centrosome stoichiometry: a clinically tractable death program for aneuploid cancer cells	Zibo	Chen	Poster	Cell Cycle/Cell Proliferation Inhibitors for Cancer Therapy	4/17/23	9:00 AM	Section 15	3
1556	CDKN3 inhibition enhances the antitumor effect of paclitaxel by promoting abnormal mitosis of cancer cells	Shigeki	Kataoka	Poster	Cell Cycle/Cell Proliferation Inhibitors for Cancer Therapy	4/17/23	9:00 AM	Section 15	4
1557	Defining modulators of response to samuraciclib, a CDK7 inhibitor for breast cancer	Kaste	Jurgaityte	Poster	Cell Cycle/Cell Proliferation Inhibitors for Cancer Therapy	4/17/23	9:00 AM	Section 15	5
1558	Targeting CDK9 via the small-molecule inhibitor enitociclib as a therapeutic strategy to treat MYCN-amplified rhabdomyosarcoma and neuroblastoma in children	Son	Tran	Poster	Cell Cycle/Cell Proliferation Inhibitors for Cancer Therapy	4/17/23	9:00 AM	Section 15	6
1559	Mechanisms responsible for hypersensitivity of small cell lung cancers to novel cyclin A and B RxL macrocyclic peptide inhibitors	Matthew	Oser	Poster	Cell Cycle/Cell Proliferation Inhibitors for Cancer Therapy	4/17/23	9:00 AM	Section 15	7
1560	Orally bioavailable macrocycles that target cyclins A and B RxL motifs cause tumor regression in xenograft models and in vitro show activity across multiple cancer types	Catherine	Gleason	Poster	Cell Cycle/Cell Proliferation Inhibitors for Cancer Therapy	4/17/23	9:00 AM	Section 15	8
1561	Preclinical examination of PLK1 inhibitors for the treatment of diffuse midline gliomas	Elisha	Hayden	Poster	Cell Cycle/Cell Proliferation Inhibitors for Cancer Therapy	4/17/23	9:00 AM	Section 15	9
1562	Correlative biomarker analysis of the phase II study of prexasertib, a cell cycle checkpoint kinase 1 (CHK1) inhibitor, in BRCA wild-type	Elena	Giudice	Poster	Cell Cycle/Cell Proliferation Inhibitors for Cancer Therapy	4/17/23	9:00 AM	Section 15	10

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
	(BRCAwt), platinum-resistant recurrent, high-grade serous ovarian cancer (PR-HGSOC)								
1563	Concomitant inhibition of Aurora kinase A and WEE1 kinases results in synergistic tumor control and heightens DNA replication stress in head and neck and lung carcinomas.	Jong Woo	Lee	Poster	Cell Cycle/Cell Proliferation Inhibitors for Cancer Therapy	4/17/23	9:00 AM	Section 15	11
1564	Novel combination of TRIP13 and Aurora kinase A inhibition demonstrated extensive DNA damage and immunogenic cell death in RB-deficient cancers	Soma	Ghosh	Poster	Cell Cycle/Cell Proliferation Inhibitors for Cancer Therapy	4/17/23	9:00 AM	Section 15	12
1565	Targeting of KIF11 and AURKA to improve outcomes in Ewing sarcoma	Soumya	Turaga	Poster	Cell Cycle/Cell Proliferation Inhibitors for Cancer Therapy	4/17/23	9:00 AM	Section 15	13
1566	DNA damage generated by transcription-replication conflicts explains the synthetic lethality of PARP inhibitors with homologous recombination deficiency	Thanos	Halazonetis	Poster	Cell Cycle/Cell Proliferation Inhibitors for Cancer Therapy	4/17/23	9:00 AM	Section 15	14
1567	Anti-cancer effect of Mps1 inhibitor in gastric cancer	Kim	Eun Seo	Poster	Cell Cycle/Cell Proliferation Inhibitors for Cancer Therapy	4/17/23	9:00 AM	Section 15	15
1568	Mechanistic studies of KL-50, a novel imidazotetrazine for the treatment of MGMT-/MMR- gliomas and glioblastoma	Eric	Huseman	Poster	Cell Cycle/Cell Proliferation Inhibitors for Cancer Therapy	4/17/23	9:00 AM	Section 15	16
1569	OXC-101 kills cancer by disturbing microtubule polymerization and inhibiting MTH1	Ulrika	Warpman Berglund	Poster	Cell Cycle/Cell Proliferation Inhibitors for Cancer Therapy	4/17/23	9:00 AM	Section 15	17
1570	Novel Myc-dependent compound DL78 selectively induces mitotic catastrophe and cell death in high grade serous ovarian cancer	Jessica	Teitel	Poster	Cell Cycle/Cell Proliferation Inhibitors for Cancer Therapy	4/17/23	9:00 AM	Section 15	18
1571	The feasibility and pharmacological mechanism of cucurbitacin E for the treatment of EGFR-TKI-primary resistant NSCLC	Chun-Han	Chen	Poster	Cell Cycle/Cell Proliferation Inhibitors for Cancer Therapy	4/17/23	9:00 AM	Section 15	19
1572	Antiproliferative activity of enzalutamide and alisertib in prostate cancer cells overexpressing HMGA2	Yusuf	Liadi	Poster	Cell Cycle/Cell Proliferation Inhibitors for Cancer Therapy	4/17/23	9:00 AM	Section 15	20
1573	Inhibition of acetyl-CoA carboxylase induced spindle abnormalities	Ling-Huei	Yih	Poster	Cell Cycle/Cell Proliferation Inhibitors for Cancer Therapy	4/17/23	9:00 AM	Section 15	21
1574	Homoharringtonine is effective in treating acute lymphoblastic leukaemia via modulation of apoptotic pathway	Anan	Jiao	Poster	Cell Cycle/Cell Proliferation Inhibitors for Cancer Therapy	4/17/23	9:00 AM	Section 15	22
1578	Novel Cereblon mediated bifunctional degraders of SOS1 for treatment of pan-KRAS mutant tumors	Kyle	Begovich	Poster	New Therapeutic Targeted Agents	4/17/23	9:00 AM	Section 16	1
1580	LCN2 is a therapeutic target against inflammatory breast cancer	Mariened	Flores-Colon	Poster	New Therapeutic Targeted Agents	4/17/23	9:00 AM	Section 16	3
1581	KSQ-4279, a first-in-class USP1 inhibitor shows strong combination activity with multiple PARP inhibitors in BRCA mutant cancers	Erica	Tobin	Poster	New Therapeutic Targeted Agents	4/17/23	9:00 AM	Section 16	4
1582	Inhibition of autophagy by CAGE targeting peptide retard tumor growth in non-small cell lung cancer of EGFR TKI resistance	Jung-Young	Shin	Poster	New Therapeutic Targeted Agents	4/17/23	9:00 AM	Section 16	5

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
1583	Bcl-6 as a potential therapeutic target for bladder cancer	Hideki	Furuuya	Poster	New Therapeutic Targeted Agents	4/17/23	9:00 AM	Section 16	6
1585	Targeting acid ceramidase-1 to inhibit sphingolipid metabolism and tumor growth in pancreatic ductal carcinoma	Krishan	Jain	Poster	New Therapeutic Targeted Agents	4/17/23	9:00 AM	Section 16	8
1586	The potential therapeutic effect of the Rac/Cdc42 inhibitor MBQ-167 in glioblastomain vitro	Derealise	Garcia Almedina	Poster	New Therapeutic Targeted Agents	4/17/23	9:00 AM	Section 16	9
1587	Breast cancer treatment: Exploring bazedoxifene, a known SERM, SERD and indirect STAT3 inhibitor	Juliette	Bherer	Poster	New Therapeutic Targeted Agents	4/17/23	9:00 AM	Section 16	10
1588	Using glyco-engineered cells with flexible expression of tumor-associated carbohydrates for the generation of highly tumor-specific antibodies	Patrik	Kehler	Poster	New Therapeutic Targeted Agents	4/17/23	9:00 AM	Section 16	11
1589	Characterization of polyaminohydroxamic acids and polyaminobenzamides as inhibitors of HDAC10	Tracy	Stewart	Poster	New Therapeutic Targeted Agents	4/17/23	9:00 AM	Section 16	12
1590	Identification and characterization of a first-generation inhibitor of claudin-1 to inhibit colon cancer progression and metastasis	Iram	Fatima	Poster	New Therapeutic Targeted Agents	4/17/23	9:00 AM	Section 16	13
1591	Integrating protein hydroxylase inhibition into cancer therapeutics: From orbital interactions at hydroxylase active sites to misfolded protein-driven cancer cell death and immunogenic cancer cell apoptosis.	Spencer	Goering	Poster	New Therapeutic Targeted Agents	4/17/23	9:00 AM	Section 16	14
1592	The role of beta-adrenergic receptor agonists and inhibitors on the efficacy of Doxorubicin in TNBC cell lines	Alanna	Burwell	Poster	New Therapeutic Targeted Agents	4/17/23	9:00 AM	Section 16	15
1593	Synergistic effect of SH003 and Docetaxel by targeting a metabolic pathway in non-small cell lung cancer cells	Yu-Jeong	Choi	Poster	New Therapeutic Targeted Agents	4/17/23	9:00 AM	Section 16	16
1594	SMARCA2 (BRM) degraders promotes differentiation and inhibit proliferation in AML models	Anjana	Agarwal	Poster	New Therapeutic Targeted Agents	4/17/23	9:00 AM	Section 16	17
1595	Thyroid hormone drives the terminal differentiation of tumor cells in medulloblastoma	Zeng-Jie	Yang	Poster	New Therapeutic Targeted Agents	4/17/23	9:00 AM	Section 16	18
1597	Sensitivity of gastric cancer cells to all-trans retinoic acid, a new agent in the personalized treatment of this heterogeneous tumor: Definition of a predictive gene-expression model that may be used for the selection of patients who may benefit from retinoid-based treatments	Enrico	Garattini	Poster	New Therapeutic Targeted Agents	4/17/23	9:00 AM	Section 16	20
1598	RM-046, a first-in-class, mutant-selective, and oral KRASQ61H(ON) inhibitor that drives tumor regression in preclinical models and validates KRASQ61H as a therapeutic target	Yu	Yang	Poster	New Therapeutic Targeted Agents	4/17/23	9:00 AM	Section 16	21
1599	Targeting tumor synthetic vulnerabilities and immune evasion mechanisms with CO-1002	Daniel	Ciznadija	Poster	New Therapeutic Targeted Agents	4/17/23	9:00 AM	Section 16	22
1600	Phase I trial of intravenous mistletoe extract in advanced cancer	Channing	Paller	Poster	New Therapeutic Targeted Agents	4/17/23	9:00 AM	Section 16	23

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
1601	Potentialiation of arsenic trioxide in glioblastoma	Charles	Shaffer	Poster	New Therapeutic Targeted Agents	4/17/23	9:00 AM	Section 16	24
1602	Co-targeting mitochondria and nucleotide metabolism in T315I-BCR-ABL myeloid leukemia for therapy	Chang-Yu	Huang	Poster	New Therapeutic Targeted Agents	4/17/23	9:00 AM	Section 16	25
1603	The effect of dickkopf-1 (DKK-1) on prostate cancer growth and bone metastasis using the canine osteoblastic Probasco cell line	Shiyu	Yuan	Poster	New Therapeutic Targeted Agents	4/17/23	9:00 AM	Section 16	26
1604	Preclinical development of ADCT-211, a novel pyrrolobenzodiazepine dimer-based antibody-drug conjugate targeting solid tumors expressing IL13RA2	Francesca	Zammarchi	Poster	New Therapeutic Targeted Agents	4/17/23	9:00 AM	Section 16	27
1611	Statins inhibit the collaborative metastasis mediated by VHL heterogeneity in clear cell renal cell carcinoma (ccRCC) via a non-cholesterol pathway	Moe	Ishihara	Poster	Novel Antitumor Agents 3	4/17/23	9:00 AM	Section 17	1
1612	Therapeutic co-targeting YAP1 and TAZ using antisense oligos (ASOs) suppress gastric cancer progression and peritoneal metastases	Jingjing	Wu	Poster	Novel Antitumor Agents 3	4/17/23	9:00 AM	Section 17	2
1613	Dimerization-induced activation of the integrated stress response kinase PERK by an investigational small molecule modulator, DP-9024	Aaron	Rudeen	Poster	Novel Antitumor Agents 3	4/17/23	9:00 AM	Section 17	3
1614	Antitumor activity of novel and potent YAP/TAZ-TEAD inhibitors targeting the Hippo pathway in solid tumors	Heesun	Moon	Poster	Novel Antitumor Agents 3	4/17/23	9:00 AM	Section 17	4
1615	NMS-812, a novel potent PERK inhibitor that also inhibits GCN2, exhibits strong anti-tumor activity as single agent and in combination in preclinical models	Claudia	Perrera	Poster	Novel Antitumor Agents 3	4/17/23	9:00 AM	Section 17	5
1616	Preclinical characterization of KSHN001126, a novel, differentiated and steroidal oral selective estrogen receptor degrader (SERD)	Ganesh	Sangle	Poster	Novel Antitumor Agents 3	4/17/23	9:00 AM	Section 17	6
1617	TGFBR1 as a novel therapeutic target in adult granulosa cell tumors	Curtis	Allred	Poster	Novel Antitumor Agents 3	4/17/23	9:00 AM	Section 17	7
1618	A highly selective and potent TLR8 agonist ZG0895 in preclinical studies of anti-tumor activities	Bing	Zhu	Poster	Novel Antitumor Agents 3	4/17/23	9:00 AM	Section 17	8
1619	Generation of a novel estrogen receptor degrader	Bill	Chen	Poster	Novel Antitumor Agents 3	4/17/23	9:00 AM	Section 17	9
1620	Identification of a molecular degrader targeting the AR-V7 splice variant	Bill	Chen	Poster	Novel Antitumor Agents 3	4/17/23	9:00 AM	Section 17	10
1621	L105, a next generation of Bcl-2 inhibitor, overcomes Bcl-2 mutation and exhibits superior antitumor activity	Li	Zhong	Poster	Novel Antitumor Agents 3	4/17/23	9:00 AM	Section 17	11
1622	Ecubectedin is a novel transcriptional inhibitor that displays potent antitumor effects in vitro and in vivo	Eva Maria	Garrido-Martin	Poster	Novel Antitumor Agents 3	4/17/23	9:00 AM	Section 17	12

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
1624	eIF4E allosteric regulators cause rapid commitment to apoptosis in cancer cells while sparing immune cells	Lisa-Marie	Sturla	Poster	Novel Antitumor Agents 3	4/17/23	9:00 AM	Section 17	14
1625	A novel SOS1 inhibitor, HM99462 demonstrates antitumor activity against KRAS-mutant cancers	Hyunjin	Park	Poster	Novel Antitumor Agents 3	4/17/23	9:00 AM	Section 17	15
1626	Tumors driven by oncogene amplified extrachromosomal DNA (ecDNA) demonstrate enhanced sensitivity to cell cycle checkpoint kinase 1 (CHK1) inhibition	Sudhir	Chowdhry	Poster	Novel Antitumor Agents 3	4/17/23	9:00 AM	Section 17	16
1627	PHI-501, a novel and potent pan-RAF inhibitor in metastatic melanoma	Jung Hee	Park	Poster	Novel Antitumor Agents 3	4/17/23	9:00 AM	Section 17	17
1628	A small-molecule inhibitor of WRN selectively kills MSI-H cancer cells and phenocopies WRN genetic defects	Josh	Taygerly	Poster	Novel Antitumor Agents 3	4/17/23	9:00 AM	Section 17	18
1629	Prostate cancer RIPTAC™ therapeutics demonstrate activity in preclinical models of Enzalutamide-resistant prostate cancer	Xinheng	Yu	Poster	Novel Antitumor Agents 3	4/17/23	9:00 AM	Section 17	19
1630	Development of a prodrug for treating renal cancer carcinoma	Ross	Hamilton	Poster	Novel Antitumor Agents 3	4/17/23	9:00 AM	Section 17	20
1631	Combination of olverembatinib (HQP1351) with BCL-2 inhibitor lisaftoclax (APG-2575) overcomes resistance in gastrointestinal stromal tumors (GISTs)	Eric	Liang	Poster	Novel Antitumor Agents 3	4/17/23	9:00 AM	Section 17	21
1632	MDM2 inhibitor alrizomadlin (APG-115) promotes antitumor activity of mitogen-activated protein kinase (MAPK) inhibitors in uveal melanoma	Eric	Liang	Poster	Novel Antitumor Agents 3	4/17/23	9:00 AM	Section 17	22
1633	ADT-030, a novel dual-acting RAS and β -catenin inhibitor with robust antitumor activity	Veronica	Ramirez-Alcantara	Poster	Novel Antitumor Agents 3	4/17/23	9:00 AM	Section 17	23
1634	Novel autophagy inhibitor ESK981 potentiates MEK inhibition cytotoxicity in pancreatic cancer	Caleb	Cheng	Poster	Novel Antitumor Agents 3	4/17/23	9:00 AM	Section 17	24
1635	OKI-1546 is a selective, orally bioavailable inhibitor of CDK12 that causes tumor regression in multiple preclinical cancer models	Alexander	Strait	Poster	Novel Antitumor Agents 3	4/17/23	9:00 AM	Section 17	25
1636	Generation of novel potent human TREX1 inhibitors facilitated by crystallography	Valerie	Chen	Poster	Novel Antitumor Agents 3	4/17/23	9:00 AM	Section 17	26
1637	MAT2A inhibition in MTAP-/- tumors confers mechanistic vulnerabilities to multiple clinically actionable synthetic lethal drug combinations	Kimberline	Gerrick	Poster	Novel Antitumor Agents 3	4/17/23	9:00 AM	Section 17	27
1638	Validation of a novel pan-Ras inhibitor, ADT-007, against lethal variants of prostate cancer	Amit	Mitra	Poster	Novel Antitumor Agents 3	4/17/23	9:00 AM	Section 17	28
1639	DP-9149, an investigational small molecule modulator of the Integrated Stress Response kinase GCN2, pre-clinically causes solid tumor growth inhibition as a single agent and regression in combination with standard of care agents	Gada	Al-Ani	Poster	Novel Antitumor Agents 3	4/17/23	9:00 AM	Section 17	29

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
1640	DP-9024, an investigational small molecule modulator of the Integrated Stress Response kinase PERK, causes B-cell cancer growth inhibition as single agent and in combination with standard-of-care agents	Gada	Al-Ani	Poster	Novel Antitumor Agents 3	4/17/23	9:00 AM	Section 17	30
1644	Dual inhibition of MAT2A and PRMT5 delivers synergistic anti-tumor responses in preclinical models of MTAP-deleted cancer	Marcus	Fischer	Poster	Novel Antitumor Agents 4	4/17/23	9:00 AM	Section 18	1
1645	JAB-2485: A potent, highly selective small-molecule Aurora kinase A inhibitor that targets cell division	Guiqun	Yang	Poster	Novel Antitumor Agents 4	4/17/23	9:00 AM	Section 18	2
1646	IK-930, a paralog-selective TEAD inhibitor for treating YAP/TAZ-TEAD dependent cancers	Nathan	Young	Poster	Novel Antitumor Agents 4	4/17/23	9:00 AM	Section 18	3
1647	In vivo efficacy and metabolism of a new synthesized dual EGFR-DNA targeting combi-molecule in a human stem cells-derived model of glioblastoma implanted intracranially in mice	Caterina	Facchin	Poster	Novel Antitumor Agents 4	4/17/23	9:00 AM	Section 18	4
1648	Discovery of a potent and selective PARP1 inhibitor and trapper with anti-tumor activities in HRD tumors	Mingming	Gao	Poster	Novel Antitumor Agents 4	4/17/23	9:00 AM	Section 18	5
1649	Chemically induced chaperone-mediated protein degradation (CHAMP) of KRAS(G12C)	Kevin	Foley	Poster	Novel Antitumor Agents 4	4/17/23	9:00 AM	Section 18	6
1650	Discovery of a novel Kevetrin analog as a potential therapeutic for ovarian cancer	Asif	Raza	Poster	Novel Antitumor Agents 4	4/17/23	9:00 AM	Section 18	7
1651	Discovery of oridonin-based proteolysis targeting chimera (PROTAC) compounds as putative protein degraders and potent anticancer agents for triple-negative breast cancer	Ruixia	Ma	Poster	Novel Antitumor Agents 4	4/17/23	9:00 AM	Section 18	8
1652	A novel reversible inhibitor of XPO1 with potent efficacy in multiple preclinical mouse models	Dirk	Daelemans	Poster	Novel Antitumor Agents 4	4/17/23	9:00 AM	Section 18	9
1653	Heme sequestration modulates the tumor immune microenvironment in KRAS mutation/LKB1 inactivation non-small cell lung cancer	Maria del Carmen	Chacon Castro	Poster	Novel Antitumor Agents 4	4/17/23	9:00 AM	Section 18	10
1654	Pre-clinical activity of the Wnt/Beta-catenin pathway inhibitor RXC004 in models of biliary tract cancer	Dorottya	Keppel	Poster	Novel Antitumor Agents 4	4/17/23	9:00 AM	Section 18	11
1655	Discovery of a novel PP2A activator as a potential therapeutic for FOLFOX resistant colon cancer	Hannah	Johnson	Poster	Novel Antitumor Agents 4	4/17/23	9:00 AM	Section 18	12
1656	Evexomostat: A novel therapeutic in development for the treatment of prostate cancer	Peter	Cornelius	Poster	Novel Antitumor Agents 4	4/17/23	9:00 AM	Section 18	13
1657	Discovery of a first-in-class multifunctional TYMS non-classical antifolate inhibitors with potent in vivo activity that prolongs survival	Maria	Guijarro	Poster	Novel Antitumor Agents 4	4/17/23	9:00 AM	Section 18	14
1658	ADT-007 binds RAS and inhibits RAS signaling	Adam	Keeton	Poster	Novel Antitumor Agents 4	4/17/23	9:00 AM	Section 18	15

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
1659	Development of HJC0152, its analogs and protein degraders to modulate STAT3 for triple-negative breast cancer therapy	Gabrielle	Vontz	Poster	Novel Antitumor Agents 4	4/17/23	9:00 AM	Section 18	16
1660	Preclinical investigation of orally bioavailable, potent KRASMulti inhibitor JAB-23425	Peng	Wang	Poster	Novel Antitumor Agents 4	4/17/23	9:00 AM	Section 18	17
1661	Heart-sparing ALK5 inhibitor for treatment of gastrointestinal and liver cancers	Andrew	Miller	Poster	Novel Antitumor Agents 4	4/17/23	9:00 AM	Section 18	18
1662	Understanding the sensitivity of cancer cells to myristoylation inhibitors for oncology applications	Erwan	Beauchamp	Poster	Novel Antitumor Agents 4	4/17/23	9:00 AM	Section 18	19
1663	Development of a novel oral microtubule targeting agent with pan-cancer efficacy	Maria-Dorothea	Nastke	Poster	Novel Antitumor Agents 4	4/17/23	9:00 AM	Section 18	20
1664	Discovery of a novel and potent TACC3 protein-protein interaction inhibitor targeting highly aggressive cancers	Sridhar	Vempati	Poster	Novel Antitumor Agents 4	4/17/23	9:00 AM	Section 18	21
1665	Imipramine enhances the efficacy of lomustine by regulating WNT- β -catenin signaling in glioblastoma	Prabhakar	Pitta Venkata	Poster	Novel Antitumor Agents 4	4/17/23	9:00 AM	Section 18	22
1666	Novel peptides target the β -catenin/TBL1 complex to competitively inhibit dysregulated Wnt signaling in cancer	Shelby	Rheinschmidt	Poster	Novel Antitumor Agents 4	4/17/23	9:00 AM	Section 18	23
1667	Elimusertib shows stronger antitumor activity than standard of care chemotherapy in pediatric solid tumor models	Fabian Fadi	Pusch	Poster	Novel Antitumor Agents 4	4/17/23	9:00 AM	Section 18	24
1668	Targeting drug-induced tolerant & resistant cell populations by novel ferroptosis inducer	Nadia	Gurvich	Poster	Novel Antitumor Agents 4	4/17/23	9:00 AM	Section 18	25
1669	In vitro and in vivo synthetic lethality: Potent tumor suppression by a novel FLT3/cKIT/CSF1R/CDK19 inhibitor	Hui	Chen	Poster	Novel Antitumor Agents 4	4/17/23	9:00 AM	Section 18	26
1670	Sabizabulin shows anti-cancer efficacy in HER2+ breast cancer and novel sabizabulin derivatives overcome paclitaxel-resistance in triple negative breast cancer	Kelli	Hartman	Poster	Novel Antitumor Agents 4	4/17/23	9:00 AM	Section 18	27
1671	Discovery of ETS-003, a potent and selective YAP/TAZ-TEAD PPI inhibitor with broad anti-tumor activity in Hippo-YAP aberrant cancers	Xin	Guo	Poster	Novel Antitumor Agents 4	4/17/23	9:00 AM	Section 18	28
1672	Synergistic combination therapy with ONC201/TIC10, Enzalutamide and Darolutamide in castration-resistant prostate cancer	Jinxuan Laura	Wu	Poster	Novel Antitumor Agents 4	4/17/23	9:00 AM	Section 18	29
1673	Discovery of potent, selective, and orally bioavailable GSPT1 degraders and their pre-clinical anti-tumor activity in acute myeloid leukemia and solid tumors	Min Sung	Joo	Poster	Novel Antitumor Agents 4	4/17/23	9:00 AM	Section 18	30
1676	PRMT5 regulates the chemoresistance of ovarian cancer cells	Ji Hae	Seo	Poster	Novel Mechanisms / Drug Transport and Metabolism	4/17/23	9:00 AM	Section 19	1

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
1677	ASPC-1-MRTX-1133R as a useful cell line model for KRAS-G12D inhibitor development	Feng	Hao	Poster	Novel Mechanisms / Drug Transport and Metabolism	4/17/23	9:00 AM	Section 19	2
1678	Overcoming treatment resistance in advanced bladder cancers using a neo-adjuvant combination with a natural product analog	Juliette	Seremak	Poster	Novel Mechanisms / Drug Transport and Metabolism	4/17/23	9:00 AM	Section 19	3
1679	Unraveling the function of TRAF2 and NCK interacting kinase (TNIK) in high-grade serous ovarian cancer	Noah	Puleo	Poster	Novel Mechanisms / Drug Transport and Metabolism	4/17/23	9:00 AM	Section 19	4
1680	Characterization of sensitivity to single agents and combination treatments (VAC and VI) and development of acquired resistance in childhood rhabdomyosarcoma xenograft models	Peter	Houghton	Poster	Novel Mechanisms / Drug Transport and Metabolism	4/17/23	9:00 AM	Section 19	5
1681	The alternative mechanism of Src inhibition in colon cancer cells	Yi-Wen	Lu	Poster	Novel Mechanisms / Drug Transport and Metabolism	4/17/23	9:00 AM	Section 19	6
1682	Bridging gaps in treatment resistance 2D models with the incorporation of 3D models	Manasa	Gadde	Poster	Novel Mechanisms / Drug Transport and Metabolism	4/17/23	9:00 AM	Section 19	7
1683	Ether phospholipids metabolism is a latent vulnerability for pancreatic cancer resistance	Ziheng	Chen	Poster	Novel Mechanisms / Drug Transport and Metabolism	4/17/23	9:00 AM	Section 19	8
1684	Plasminogen activator inhibitor-1 (PAI-1) promotes cisplatin resistance in ovarian cancer cells by inhibiting ROS-mediated apoptosis and ferroptosis	Mi Jeong	Kwon	Poster	Novel Mechanisms / Drug Transport and Metabolism	4/17/23	9:00 AM	Section 19	9
1685	Overcoming acquired resistance to PROTAC degraders	Tongchen	He	Poster	Novel Mechanisms / Drug Transport and Metabolism	4/17/23	9:00 AM	Section 19	10
1686	Leiomyosarcoma poly-aneuploid cancer cells form in response to chemotherapy and contribute to chemoresistance	Lisa	Abegglen	Poster	Novel Mechanisms / Drug Transport and Metabolism	4/17/23	9:00 AM	Section 19	11
1687	ATPase copper transporting beta (ATP7B) contributes to acquired docetaxel resistance in human prostate cancer	Liankun	Song	Poster	Novel Mechanisms / Drug Transport and Metabolism	4/17/23	9:00 AM	Section 19	12
1688	Proton pump inhibitors as a potential combination therapy with existing chemotherapy for esophageal cancer	Ryuichi	Morita	Poster	Novel Mechanisms / Drug Transport and Metabolism	4/17/23	9:00 AM	Section 19	13
1689	The role of circular RNAs in triple negative breast cancer and chemotherapy resistance	Xiyin	Wang	Poster	Novel Mechanisms / Drug Transport and Metabolism	4/17/23	9:00 AM	Section 19	14
1690	Myc suppression permits entry into the cancer endocycle to evade toxic effects of chemotherapy	Michael	Loycano	Poster	Novel Mechanisms / Drug Transport and Metabolism	4/17/23	9:00 AM	Section 19	15
1692	mTOR inhibition attenuates chemosensitivity through induction of a persister state	Yulin	Li	Poster	Novel Mechanisms / Drug Transport and Metabolism	4/17/23	9:00 AM	Section 19	17
1693	Drug-tolerant persister cells contain heterogeneous subpopulations that utilize lung lineage pathways as drug resistance mechanism	Yang	Tian	Poster	Novel Mechanisms / Drug Transport and Metabolism	4/17/23	9:00 AM	Section 19	18
1694	Loss of ZNF251 stimulates NHEJ resulting in PARP inhibitor resistance in BRCA1-mutated cancer cells	Jian	Huang	Poster	Novel Mechanisms / Drug Transport and Metabolism	4/17/23	9:00 AM	Section 19	19

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
1695	Guanylate binding protein 1 modulate the proteasomal machinery and causes the cytochrome C degradation	Dhanir	Tailor	Poster	Novel Mechanisms / Drug Transport and Metabolism	4/17/23	9:00 AM	Section 19	20
1696	Systematic identification of pathways associated with antibody drug conjugate sensitivity in breast cancer	Bogang	Wu	Poster	Novel Mechanisms / Drug Transport and Metabolism	4/17/23	9:00 AM	Section 19	21
1697	Role of intra-tumoral bacteria in EGFR-tyrosine kinase inhibitor resistance	Wendong	Li	Poster	Novel Mechanisms / Drug Transport and Metabolism	4/17/23	9:00 AM	Section 19	22
1698	Novel role of Tribbles 2 driving treatment-emergent neuroendocrine differentiation in prostate cancer	Jitender	Monga	Poster	Novel Mechanisms / Drug Transport and Metabolism	4/17/23	9:00 AM	Section 19	23
1699	Targeting mercapturic acid pathway transporter in chemoradiotherapy resistant ovarian cancer	Sharad	Singhal	Poster	Novel Mechanisms / Drug Transport and Metabolism	4/17/23	9:00 AM	Section 19	24
1700	Clonal emergence of resistance to methotrexate in osteosarcoma barcoded PDX cells	Zhongting	Zhang	Poster	Novel Mechanisms / Drug Transport and Metabolism	4/17/23	9:00 AM	Section 19	25
1704	Interferon inducible ADAR1 is essential for the survival of oral squamous cell carcinoma	Sok Ching	Cheong	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 2	4/17/23	9:00 AM	Section 20	1
1705	SPOP: An essential gene for normal and prostate tumor cells	Kinza	Rizwan	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 2	4/17/23	9:00 AM	Section 20	2
1706	A non-canonical MiT/TFE-dependent NRF2 program is a druggable vulnerability in multiple cancer types	Rizwan	Haq	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 2	4/17/23	9:00 AM	Section 20	3
1707	Establishment of a targeted exosome drug delivery system containing natural bacterial toxins and antitoxins	Shiran	Shapira	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 2	4/17/23	9:00 AM	Section 20	4
1708	Sex-biased function of an oncogene, YAP1, regulates medulloblastoma stem cells and immune evasion	Kyuson	Yun	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 2	4/17/23	9:00 AM	Section 20	5
1709	MAPK pathway alterations are a targetable vulnerability in bladder cancer	Raie	Bekele	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 2	4/17/23	9:00 AM	Section 20	6
1710	Pharmacologic targeting or silencing of TRIP13 reduces progression of pancreatic ductal adenocarcinoma	Farrukh	Afaq	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 2	4/17/23	9:00 AM	Section 20	7
1712	Targeting asparagine dependency as a therapy for TP53-mutated castration-resistant prostate cancer	Young A	Yoo	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 2	4/17/23	9:00 AM	Section 20	9
1713	TRMT6-mediated N1-methyladenosine methylation promotes tumorigenesis in colorectal cancer	SILEI	SUI	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 2	4/17/23	9:00 AM	Section 20	10
1714	CRACD/KIAA1211 loss drives cell plasticity and immune evasion of small cell lung cancer	Shengzhe	Zhang	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 2	4/17/23	9:00 AM	Section 20	11
1715	SOS1 inhibition is an effective therapeutic strategy in SOS1-mutant cancer	Matthew	Sale	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 2	4/17/23	9:00 AM	Section 20	12
1716	A small molecule corrector for p53 mutants found in cancer	Maryam	Fallatah	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 2	4/17/23	9:00 AM	Section 20	13

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
1717	KRAS mutant gene editing prevents tumor growth in vivo and overcomes acquired resistance to KRASG12C inhibitor	Gilles	Divita	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 2	4/17/23	9:00 AM	Section 20	14
1718	Development of potent estrogen receptor beta agonists for treating glioblastoma	Uday	Pratap	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 2	4/17/23	9:00 AM	Section 20	15
1719	VHLloss enables immune checkpoint blockade therapy by boosting interferon response	Meng	Jiao	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 2	4/17/23	9:00 AM	Section 20	16
1720	Examining mechanistic underpinnings of chemoresistance in triple negative breast cancer	Qitong	Wu	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 2	4/17/23	9:00 AM	Section 20	17
1721	Dual targeting of JAK2 and TrkA inhibits breast cancer cell stemness, enhances apoptosis, and delays tumor growth of triple-negative and HER2-enriched breast cancers	Angelina	Regua	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 2	4/17/23	9:00 AM	Section 20	18
1722	KRAS, BRAF, BRCA1 and EGFR mutation-specific panels using hydrogel-based 3D in vitro tumor models	Kolin	Hribar	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 2	4/17/23	9:00 AM	Section 20	19
1723	Ferroptosis is a novel therapeutic target for RB1 deficient lethal prostate cancer	Mu-En	Wang	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 2	4/17/23	9:00 AM	Section 20	20
1724	SCR-8388, a potent and selective SOS1::KRAS inhibitor, is effective in KRAS-addicted cancers	Renhong	Tang	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 2	4/17/23	9:00 AM	Section 20	21
1725	Preclinical evaluation of RM-042, an orally bioavailable inhibitor of GTP-RAS, in models of pancreatic ductal adenocarcinoma	Urszula	Wasko	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 2	4/17/23	9:00 AM	Section 20	22
1726	Loss of NF1 drives hormone dependent mammary carcinogenesis in a rat model with intact immune system	Deeann	Wallis	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 2	4/17/23	9:00 AM	Section 20	23
1727	Cytoplasmic EZH2 and the DLC1 tumor suppressor are regulated by the CRM1 nuclear export protein and by specific complex formation between mutant KRAS and RAN-GAP	Brajendra	Tripathi	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 2	4/17/23	9:00 AM	Section 20	24
1728	Exosomal delivery of Fas-associated factor 1 (FAF1), a multifunctional tumor suppressor and genuine exosome cargo, effectively antagonizes tumor growth	Jeong-Hoon	Han	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 2	4/17/23	9:00 AM	Section 20	25
1729	MG53 suppresses the tumor growth via transcriptional inhibiting the expression of KIF11 in pancreatic cancer	Chuanxi	Cai	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 2	4/17/23	9:00 AM	Section 20	26
1730	A novel chimeric virus-like drug conjugate (VDC) for the potential treatment of HPV-positive tumors	Rhonda	Kines	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 2	4/17/23	9:00 AM	Section 20	27
1731	Aurora-a mediated phosphorylation of Maf1 is essential for maintaining protein stability and regulating tRNA biosynthesis in HCC	Liang-Yi	Hung	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 2	4/17/23	9:00 AM	Section 20	28
1732	Functional characterization of the impact of CD36 deletion on normal hematopoiesis and the leukemia microenvironment	Yiting	Meng	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 2	4/17/23	9:00 AM	Section 20	29

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
1736	Role of brain fatty acid binding protein in glioblastoma microtubule formation	Won-Shik	Choi	Poster	Reversal of Drug Resistance	4/17/23	9:00 AM	Section 21	1
1737	Genome-scale metabolic modeling reveals a metabolic switch that restores sensitivity to anticancer chemotherapy in drug-resistant breast cancer cells	JinA	Lim	Poster	Reversal of Drug Resistance	4/17/23	9:00 AM	Section 21	2
1738	Sensitizing cancer cell to doxorubicin by tumor treating fields (TTFields)-induced, elevated membrane permeability	Bella	Koltun	Poster	Reversal of Drug Resistance	4/17/23	9:00 AM	Section 21	3
1739	Reversal of lenvatinib resistance by curcumin via EGFR signaling pathway in hepatocellular carcinoma	Katsuki	Miyazaki	Poster	Reversal of Drug Resistance	4/17/23	9:00 AM	Section 21	4
1740	CCR5/CCL5 axis inhibition reverses cisplatin-chemoresistance phenotype in gastric cancer cells	Priscilla	Brebi	Poster	Reversal of Drug Resistance	4/17/23	9:00 AM	Section 21	5
1741	Inhibition of pcsk9 impairs the development of vessel co-option and potentiates anti-angiogenic therapy in colorectal cancer liver metastases	Miran	Rada	Poster	Reversal of Drug Resistance	4/17/23	9:00 AM	Section 21	6
1743	miR-1307-5p reverses cisplatin resistance in oral squamous cell carcinomas (OSCC) by targeting EHF, a modulator of stemness genes	Aditi	Patel	Poster	Reversal of Drug Resistance	4/17/23	9:00 AM	Section 21	8
1744	Chemoresistant non-small cell lung cancer: A resensitizing strategy utilizing antimuscarinics	Tyler	Bland	Poster	Reversal of Drug Resistance	4/17/23	9:00 AM	Section 21	9
1745	Targeting therapeutic resistance of esophageal adenocarcinoma through modulating the epithelial-to-mesenchymal transition via NFkB-mediated signaling	Yun	Zhang	Poster	Reversal of Drug Resistance	4/17/23	9:00 AM	Section 21	10
1746	Broad-spectrum kinome profiling identifies CDK6 upregulation as a driver of lenvatinib resistance in hepatocellular carcinoma	Carmen	Leung	Poster	Reversal of Drug Resistance	4/17/23	9:00 AM	Section 21	11
1747	Targeting metabolic and epigenetic programs to re-sensitize glioblastoma to chemotherapy	Emma	Rowland	Poster	Reversal of Drug Resistance	4/17/23	9:00 AM	Section 21	12
1748	Mcl-1 inhibitor KS18 overcomes bortezomib, venetoclax, and ABT-737 resistance in multiple myeloma	Omar	Al Odat	Poster	Reversal of Drug Resistance	4/17/23	9:00 AM	Section 21	13
1749	The synergic effect of cisplatin and a chemokine receptor antagonist sensitizes drug resistant gastric cancer cells and inhibits tumoroid formation	Bárbara	Mora-Lagos	Poster	Reversal of Drug Resistance	4/17/23	9:00 AM	Section 21	14
1750	Removal of mucin glycans by Bifidobacterium bifidum enhances chemotherapy-mediated cell death in mucinous adenocarcinomas	Mindy	Engevik	Poster	Reversal of Drug Resistance	4/17/23	9:00 AM	Section 21	15
1751	Prognostic value of CD20/CD73 ratio in sensitive and relapsed/refractory diffuse large B-cell lymphoma cell lines	Juan	Gu	Poster	Reversal of Drug Resistance	4/17/23	9:00 AM	Section 21	16
1752	Darolutamide reverses osimertinib resistance in non-small cell lung cancer	John	Schmitz	Poster	Reversal of Drug Resistance	4/17/23	9:00 AM	Section 21	17

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
1753	Functional inhibition of the RNA-binding protein HuR sensitizes triple-negative breast cancer to chemotherapy	Lanjing	Wei	Poster	Reversal of Drug Resistance	4/17/23	9:00 AM	Section 21	18
1754	Targeting the mitochondrial protein MAGMAS increases sensitivity to docetaxel in neuroendocrine prostate cancer cells	Alfonso	Durán	Poster	Reversal of Drug Resistance	4/17/23	9:00 AM	Section 21	19
1755	ADAR1-mediated RNA editing of SCD1 links lipid metabolism to gastric cancer drug resistance and self-renewal	Jia Jian	Loh	Poster	Reversal of Drug Resistance	4/17/23	9:00 AM	Section 21	20
1756	Targeting LIFR/c-Myc Axis to Overcome Docetaxel Resistance in Prostate Cancer	Sushanta	Halder	Poster	Reversal of Drug Resistance	4/17/23	9:00 AM	Section 21	21
1757	Characterizing novel immunomodulating interactions for potentiating HDAC3 inhibition in non-Hodgkin lymphoma	Michael	He	Poster	Reversal of Drug Resistance	4/17/23	9:00 AM	Section 21	22
1758	Resistance to cancer therapy via upregulation of the NRP2/VEGF-C axis can be neutralized by ATYR2810	Alison	Barber	Poster	Reversal of Drug Resistance	4/17/23	9:00 AM	Section 21	23
1759	Targeting adaptation to cancer treatment by drug combinations	Augustin	Luna	Poster	Reversal of Drug Resistance	4/17/23	9:00 AM	Section 21	24
1760	ADI-PEG20 and GC7 as a novel anti-metabolite strategy for the treatment of malignant pleural mesothelioma	Joséphine	Carpentier	Poster	Reversal of Drug Resistance	4/17/23	9:00 AM	Section 21	25
1761	Dual inhibition of HSP27 and FAO as a novel therapeutic strategy for cisplatin-resistant ovarian cancer	James	Heiserman	Poster	Reversal of Drug Resistance	4/17/23	9:00 AM	Section 21	26
1762	MALT1 is activated by doxorubicin and mediates therapy resistance in triple-negative breast cancer	Maria	Beecher	Poster	Reversal of Drug Resistance	4/17/23	9:00 AM	Section 21	27
1767	Biodistribution of zoledronate and effects on gd PSCA-CAR T cells in a model of bone metastatic prostate cancer	Leticia	Tordesillas	Poster	CAR T-cell Therapy 1	4/17/23	9:00 AM	Section 22	1
1768	Multiplexed shRNA cassettes targeting orthogonal pathways (FAS/PTPN2/TGFBR) enhance the potency of integrated circuit T cells (ICTs) in multiple solid tumor models	Thomas	Gardner	Poster	CAR T-cell Therapy 1	4/17/23	9:00 AM	Section 22	2
1769	A combination approach of a cellular library and single cell microfluidics analysis for the rapid selection of CAR-T cells	Eren	Boga	Poster	CAR T-cell Therapy 1	4/17/23	9:00 AM	Section 22	3
1770	CD28-Y218 phosphorylation in CAR-T cells is mediated by the IL-2-inducible T-cell kinase (ITK)	Elena	Martinez-Planes	Poster	CAR T-cell Therapy 1	4/17/23	9:00 AM	Section 22	4
1771	Characterization of RHOA inactivation as a driver of CAR-T therapy resistance in diffuse large B-cell lymphoma	Austin	Newsam	Poster	CAR T-cell Therapy 1	4/17/23	9:00 AM	Section 22	5
1772	Development of a novel L1CAM-targeted CAR-T, CX804, and its therapeutic efficacy in ovarian and gastric cancer	Xiumei	Che	Poster	CAR T-cell Therapy 1	4/17/23	9:00 AM	Section 22	6
1773	Preclinical characterization of allogeneic Vγ9Vδ2 HER2-TAC T cells for the treatment of HER2-positive solid tumors	Suzanna	Prosser	Poster	CAR T-cell Therapy 1	4/17/23	9:00 AM	Section 22	7
1774	Pre-treatment of CAR-T cells with met+rap improves the mitochondrial function and anti-tumor efficacy in a hypoxic glioma microenvironment	Ryusuke	Hatae	Poster	CAR T-cell Therapy 1	4/17/23	9:00 AM	Section 22	8

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
1775	Expansion of human T cells using xenogeneic free and gamma irradiated human platelet lysate	Vanesa	Alonso-Camino	Poster	CAR T-cell Therapy 1	4/17/23	9:00 AM	Section 22	9
1777	A non-signaling CAR for gamma-delta ($\gamma\delta$) T cells to preserve healthy tissues	Lei	Ding	Poster	CAR T-cell Therapy 1	4/17/23	9:00 AM	Section 22	11
1778	B7-H3-CAR T-cell therapy in immune-competent osteosarcoma models: Regnase-1 KO overcomes limited CAR T-cell expansion	Adeleye	Adeshakin	Poster	CAR T-cell Therapy 1	4/17/23	9:00 AM	Section 22	12
1779	Fourth-generation chimeric antigen receptor T cells targeting mucin 1 against breast cancer	Kamonlapat	Supimon	Poster	CAR T-cell Therapy 1	4/17/23	9:00 AM	Section 22	13
1780	TCR-T and CAR-T cells targeting HLA-A2/MAGEA4 demonstrate differential tumor control, reflecting co-stimulatory signaling requirements	Corinne	Decker	Poster	CAR T-cell Therapy 1	4/17/23	9:00 AM	Section 22	14
1781	G9a/GLP inhibition during ex vivo lymphocyte expansion increases in vivo cytotoxicity of engineered T cells against hepatocellular carcinoma	Andrea	Pavesi	Poster	CAR T-cell Therapy 1	4/17/23	9:00 AM	Section 22	15
1782	Functional potency assay predicts CAR-T effectiveness in tumor microenvironment	Yelena	Bronevetsky	Poster	CAR T-cell Therapy 1	4/17/23	9:00 AM	Section 22	16
1783	High-throughput arrayed screening of logic-gated CARs enables the selection of candidates for ccRCC with optimal potency and fidelity traits	Nishant	Mehta	Poster	CAR T-cell Therapy 1	4/17/23	9:00 AM	Section 22	17
1784	FGFR4 and CD276 dual targeting CAR T cells demonstrate synergistic antitumor activity in childhood rhabdomyosarcoma	Meijie	Tian	Poster	CAR T-cell Therapy 1	4/17/23	9:00 AM	Section 22	18
1785	Multi-step engineering of gene-edited CAR T cells using RNA lipid nanoparticles	Samuel	Clarke	Poster	CAR T-cell Therapy 1	4/17/23	9:00 AM	Section 22	19
1786	Mesothelin-targeting, nanobody-based CAR T cells effectively target solid tumors in fully immunocompetent hosts	Chaido	Stathopoulou	Poster	CAR T-cell Therapy 1	4/17/23	9:00 AM	Section 22	20
1787	Design of bispecific adapters for universal CAR T cell therapies of solid tumors	Suilan	Zheng	Poster	CAR T-cell Therapy 1	4/17/23	9:00 AM	Section 22	21
1788	A novel costimulatory signaling domain for chimeric antigen receptor-engineering	Hyun-Il	Cho	Poster	CAR T-cell Therapy 1	4/17/23	9:00 AM	Section 22	22
1789	Pre-clinical studies to advance anti-ROR1 CAR-T cell therapy for metastatic prostate cancer	Christina	Jamieson	Poster	CAR T-cell Therapy 1	4/17/23	9:00 AM	Section 22	23
1790	Exploring the efficacy of allogeneic gamma delta T cell adoptive cell therapy against the pediatric brain tumor medulloblastoma	Hunter	Jonus	Poster	CAR T-cell Therapy 1	4/17/23	9:00 AM	Section 22	24
1791	Next generation UltraCAR-T [®] cells with intrinsic checkpoint inhibition and overnight manufacturing overcome suppressive tumor microenvironment leading to sustained antitumor activity	Tim	Chan	Poster	CAR T-cell Therapy 1	4/17/23	9:00 AM	Section 22	25

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
1792	Engineering TAG72-CAR T cells as a therapeutic strategy in the hen - a spontaneous, preclinical model for ovarian cancer	Lindsey	Treviño	Poster	CAR T-cell Therapy 1	4/17/23	9:00 AM	Section 22	26
1793	Single-cell RNA analysis reveal effector-like CD8+ CAR-T cell subpopulations associated with response in lymphoma patients	Tina	Sarén	Poster	CAR T-cell Therapy 1	4/17/23	9:00 AM	Section 22	27
1794	Targeting mammalian SWI/SNF chromatin remodeling complexes to improve T cell-based cancer immunotherapies	Elena	Battistello	Poster	CAR T-cell Therapy 1	4/17/23	9:00 AM	Section 22	28
1797	Impact of estrogen depletion using an aromatase inhibitor (AI) on EGFR-mutated non-small cell lung cancer (NSCLC) in a murine model	J. Nicholas	Bodor	Poster	Immunomodulatory Agents and Interventions 1	4/17/23	9:00 AM	Section 23	1
1798	ALDH inhibition as modulator of ovarian tumor associated immune cells	Julia	Knight	Poster	Immunomodulatory Agents and Interventions 1	4/17/23	9:00 AM	Section 23	2
1799	BH3120, a bispecific antibody targeting 4-1BB and PD-L1 simultaneously, stimulates T cells in tumor tissue preferred manner	Jiangcheng	Xu	Poster	Immunomodulatory Agents and Interventions 1	4/17/23	9:00 AM	Section 23	3
1800	An oral triple inhibitor of PI3K δ/γ and DNA-PK elicits anticancer immunity and potentiates therapeutic efficacy of immune checkpoint blockade	Won Suk	Lee	Poster	Immunomodulatory Agents and Interventions 1	4/17/23	9:00 AM	Section 23	4
1801	STK-012, an α/β -selective IL-2 activates tumor antigen specific CD25+ CD8 T cells to reject tumors without acute vascular toxicity	Martin	Oft	Poster	Immunomodulatory Agents and Interventions 1	4/17/23	9:00 AM	Section 23	5
1802	Personalization of oncolytic virus therapy: Heterogenous anti-tumor responses in preclinical prostate and bladder cancer models	Thijs	Janssen	Poster	Immunomodulatory Agents and Interventions 1	4/17/23	9:00 AM	Section 23	6
1803	GNP101, anti-HER2-IFN- β mutein immunocytokine, for the treatment of Trastuzumab deruxtecan-resistant HER2-positive cancers	Chan Gyu	Lee	Poster	Immunomodulatory Agents and Interventions 1	4/17/23	9:00 AM	Section 23	7
1804	Durable eradication of tumors by single injections of a pHLP-STING agonist	Donald	Engelman	Poster	Immunomodulatory Agents and Interventions 1	4/17/23	9:00 AM	Section 23	8
1805	Identification of a small molecule that induces targeted protein degradation of ADAR1	Bill	Chen	Poster	Immunomodulatory Agents and Interventions 1	4/17/23	9:00 AM	Section 23	9
1806	Modulation of natural killer cell immune response to tumor with novel synthetic tumor -immune cell agonist, NK-TICA(r)	Fay	Dufort	Poster	Immunomodulatory Agents and Interventions 1	4/17/23	9:00 AM	Section 23	10
1807	CB307: a novel targeted CD137 agonist for enhancement of immune cell responses to PSMA+ tumors	Andrew	Pierce	Poster	Immunomodulatory Agents and Interventions 1	4/17/23	9:00 AM	Section 23	11
1808	Role of natural killer (NK) cells in glycoasminoglycan-mediated anti-cancer immunity	Pavani	Pingali	Poster	Immunomodulatory Agents and Interventions 1	4/17/23	9:00 AM	Section 23	12
1809	ACT-1002-4391 - A novel potent antagonist of the prostaglandin E2 receptors EP2 and EP4 with excellent duality	Imke	Renz	Poster	Immunomodulatory Agents and Interventions 1	4/17/23	9:00 AM	Section 23	13

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
1810	Enhanced anti-breast tumor cancer activity using nano-formulated TLR 7/8 agonist and PI3K inhibitor	Mostafa	Yazdimamaghan i	Poster	Immunomodulatory Agents and Interventions 1	4/17/23	9:00 AM	Section 23	14
1811	AFVT-2101: A FR α \times CD16A bispecific innate cell engager for the treatment of solid tumors	Peter	Sandy	Poster	Immunomodulatory Agents and Interventions 1	4/17/23	9:00 AM	Section 23	15
1812	ROS-dependent activation of immunogenic glioblastoma cell death & release of immunogenic particles by an autologous cell-based immunotherapeutic platform	Christopher	Cultrara	Poster	Immunomodulatory Agents and Interventions 1	4/17/23	9:00 AM	Section 23	16
1813	Selective ITK blockade induces antitumor responses and enhances efficacy to immune checkpoint inhibitors in preclinical models	Lih-Yun	Hsu	Poster	Immunomodulatory Agents and Interventions 1	4/17/23	9:00 AM	Section 23	17
1814	A long-acting and CD122-enhanced IL-2 analog, HM16390, shows a potent and durable anti-tumor effect in both syngeneic B16F10 or CT26 mouse models	Jinyoung	Kim	Poster	Immunomodulatory Agents and Interventions 1	4/17/23	9:00 AM	Section 23	18
1815	Rapid serial killing of target cells by V γ 9V δ 2 T Cells in cynomolgus macaques and humanized mice treated with a CD20-directed heterodimeric butyrophilin 2A1/3A1 fusion protein	Anne	Lai	Poster	Immunomodulatory Agents and Interventions 1	4/17/23	9:00 AM	Section 23	19
1816	Locoregional delivery with gene edited and engineered stem cells modulates unique immune profiling in leptomeningeal metastasis	Nobuhiko	Kanaya	Poster	Immunomodulatory Agents and Interventions 1	4/17/23	9:00 AM	Section 23	20
1817	WTX-613, (JZP898) a selectively activated IFN α INDUKINE™ molecule, reprograms the tumor microenvironment and generates robust anti-tumor immunity as a monotherapy and in combination with checkpoint inhibitors	Christopher	Nirschl	Poster	Immunomodulatory Agents and Interventions 1	4/17/23	9:00 AM	Section 23	21
1818	Developing an autologous humanized mouse model to assess responses to novel immunotherapeutics	Yee	Peng Phoon	Poster	Immunomodulatory Agents and Interventions 1	4/17/23	9:00 AM	Section 23	22
1819	Integrin inhibitor GLPG-0187 promotes T-cell killing of mismatch repair-deficient colorectal cancer cells by suppression of SMAD/TGF- β signaling	Brooke	Verschleiser	Poster	Immunomodulatory Agents and Interventions 1	4/17/23	9:00 AM	Section 23	23
1820	Efficacy and safety of the TLR7 agonist micelles MBS8(1V270) tested in pre-clinical models	Simon	Jensen	Poster	Immunomodulatory Agents and Interventions 1	4/17/23	9:00 AM	Section 23	24
1821	Discovery of XNW21015, a novel, potent HPK1 inhibitor with excellent immune modulatory activity	Yuchuan	Wu	Poster	Immunomodulatory Agents and Interventions 1	4/17/23	9:00 AM	Section 23	25
1822	IFN- γ and TRAIL involvement in androgen signaling-mediated NK cell killing of prostate cancer cells and further enhancement by NKG2A checkpoint inhibition with monalizumab	Maximilian	Schwermann	Poster	Immunomodulatory Agents and Interventions 1	4/17/23	9:00 AM	Section 23	26
1823	Overcoming siglec-9-mediated immunosuppression by using glycomimetics that block the binding of this receptor with its natural ligands	Manish	Patankar	Poster	Immunomodulatory Agents and Interventions 1	4/17/23	9:00 AM	Section 23	27

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
1824	Discovery and evaluation of an anti-IL18BP antibody to enhance anti-tumor immunity	H. Toni	Jun	Poster	Immunomodulatory Agents and Interventions 1	4/17/23	9:00 AM	Section 23	28
1825	A bacterial consortium engineered from feces of patients responding to anti-PD1 treatment mediates tumor response through IFN γ in non-small cell lung cancer	Rachel	Newsome	Poster	Immunomodulatory Agents and Interventions 1	4/17/23	9:00 AM	Section 23	29
1826	In vivo evaluation of NK-TICA [®] , a novel Bicycle [®] tumor-targeted immune cell agonist (TICA) designed to engage NK cells	Lukas	Stanczuk	Poster	Immunomodulatory Agents and Interventions 1	4/17/23	9:00 AM	Section 23	30
1829	Generation of IL-21 INDUKINETM molecules for the treatment of cancer	Jenna	Sullivan	Poster	Immunomodulatory Agents and Interventions 2	4/17/23	9:00 AM	Section 24	1
1830	E7386, a selective inhibitor of the interaction between β -catenin and CREB-binding protein (CBP), in combination with lenvatinib (LEN), exerts antitumor activity in preclinical tumor models with prior immune checkpoint inhibitor (ICI)-based combination treatment	Satoshi	Kawano	Poster	Immunomodulatory Agents and Interventions 2	4/17/23	9:00 AM	Section 24	2
1831	A long-acting and CD122-enhanced IL-2 analog, HM16390, synergizes with immune checkpoint inhibitor by remodeling an immune cell profile in tumor microenvironment	Jaehyuk	Choi	Poster	Immunomodulatory Agents and Interventions 2	4/17/23	9:00 AM	Section 24	3
1832	EphA2-dependent CD137 agonism and anti-tumor efficacy by BT7455, a Bicycle tumor-targeted immune cell agonist [®]	Lia	Luus	Poster	Immunomodulatory Agents and Interventions 2	4/17/23	9:00 AM	Section 24	4
1833	Novel IL-12 Partial Agonist For Cancer Immunotherapy Avoids NK-cell Mediated Toxicity	Ievgen	Koliesnik	Poster	Immunomodulatory Agents and Interventions 2	4/17/23	9:00 AM	Section 24	5
1834	Cholinergic nerve release of CGRP increases tumor growth in HNSCC by suppressing TILs	Laurel	Darragh	Poster	Immunomodulatory Agents and Interventions 2	4/17/23	9:00 AM	Section 24	6
1835	A synergistic antitumor effect of PLAG with aPD-1 by modulating the adenosine signaling pathway in ICI low-sensitivity CRC model	Jae Sam	Lee	Poster	Immunomodulatory Agents and Interventions 2	4/17/23	9:00 AM	Section 24	7
1836	Combining a novel retinoic acid receptor- γ agonist with immune checkpoint blockade represses lung cancer growth in vivo	Xi	Liu	Poster	Immunomodulatory Agents and Interventions 2	4/17/23	9:00 AM	Section 24	8
1837	E7386, a selective inhibitor of the interaction between β -catenin and CREB-binding protein (CBP), enhances antitumor activity in combination with lenvatinib (LEN), and LEN + anti-PD-1 antibody in a preclinical tumor model	Yusuke	Adachi	Poster	Immunomodulatory Agents and Interventions 2	4/17/23	9:00 AM	Section 24	9
1838	Immunomodulatory effects of curcumin monoglucuronide on PD1 immune checkpoint blockade in mouse Pten-null prostate cancer	Marco	De Velasco	Poster	Immunomodulatory Agents and Interventions 2	4/17/23	9:00 AM	Section 24	10
1839	CLN-617 is a first-in-class fusion protein that retains IL-2 and IL-12 in the injected tumor and potently triggers systemic anti-tumor immunity	Naveen	Mehta	Poster	Immunomodulatory Agents and Interventions 2	4/17/23	9:00 AM	Section 24	11

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
1840	Methylmalonic acid accumulation suppresses CD8+ T cell activation and contributes to age-induced immunosuppression	Joanne	Tejero	Poster	Immunomodulatory Agents and Interventions 2	4/17/23	9:00 AM	Section 24	12
1841	TAK-500 is a clinical stage immune-cell directed antibody drug conjugate (iADC) inducing STING activation in CCR2-expressing intratumor myeloid cells and favorable immunomodulation	Kurt	Schalper	Poster	Immunomodulatory Agents and Interventions 2	4/17/23	9:00 AM	Section 24	13
1842	The safety assessment and the pharmacodynamics evaluation of therapeutic cytokine in non-human primates	Wei	Li	Poster	Immunomodulatory Agents and Interventions 2	4/17/23	9:00 AM	Section 24	14
1843	Androgen signaling blockade enhances NK cell-mediated killing of prostate cancer cells (PC) and promotes NK cell tumor infiltration in vivo	Maximilian	Schwermann	Poster	Immunomodulatory Agents and Interventions 2	4/17/23	9:00 AM	Section 24	15
1844	Development of a high content screening (HCS) platform for novel cancer immunotherapeutics	Louise	Brackenbury	Poster	Immunomodulatory Agents and Interventions 2	4/17/23	9:00 AM	Section 24	16
1845	Mammalian orthoreoviruses R124 and jin-3 demonstrate oncolytic and immune-stimulatory effects in human preclinical bladder cancer models	Arjanneke	Van De Merbel	Poster	Immunomodulatory Agents and Interventions 2	4/17/23	9:00 AM	Section 24	17
1846	Intratumoral mPH-762, a self-delivering RNAi therapeutic (INTASYL™) targeting mouse PD-1, generates systemic tumor-specific memory CD8 T cells, providing a mechanism for abscopal efficacy toward untreated tumors in a murine hepatocarcinoma model	Benjamin	Cuiffo	Poster	Immunomodulatory Agents and Interventions 2	4/17/23	9:00 AM	Section 24	18
1847	Engineered cell surface tag-targeted IL-2 and IL-21 selectively and safely enhance CAR-T anti-tumor activity via different mechanisms	Nathan	Mathewson	Poster	Immunomodulatory Agents and Interventions 2	4/17/23	9:00 AM	Section 24	19
1848	A novel murine tumor model for assessing the efficacy of neoadjuvant dosing regimens for immunotherapies	Sara	Prijic	Poster	Immunomodulatory Agents and Interventions 2	4/17/23	9:00 AM	Section 24	20
1849	Superiority of dual IDO1/TDO2 inhibition versus IDO1 selective inhibition in reducing immunosuppressive KYN levels in tumors co-expressing IDO1 and TDO2	Carina	Lotz-Jenne	Poster	Immunomodulatory Agents and Interventions 2	4/17/23	9:00 AM	Section 24	21
1850	A first-in-class PD1-IL18 immunocytokine (BPT567) targets PD-1+ IL18R+ CD8+ T effector cells enriched in the tumor microenvironment and exhibits potent antitumor efficacy with excellent tolerability	Jean-Philippe	Carralot	Poster	Immunomodulatory Agents and Interventions 2	4/17/23	9:00 AM	Section 24	22
1851	Mechanisms underlying focused ultrasound-induced immunogenicity in melanoma	Sandra	Pelka	Poster	Immunomodulatory Agents and Interventions 2	4/17/23	9:00 AM	Section 24	23
1852	Systemic delivery of ST317, a cell penetrating STING pathway sensitizer, results in strong anti-tumor activity	Claus Elsborg	Olesen	Poster	Immunomodulatory Agents and Interventions 2	4/17/23	9:00 AM	Section 24	24
1853	Microparticle-delivered Cxcl9 prolongs Braf inhibitor efficacy in melanoma	Gabriele	Romano	Poster	Immunomodulatory Agents and Interventions 2	4/17/23	9:00 AM	Section 24	25

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
1854	Cancer treatment utilizing virus-inspired particles for the redirection of immune memory	Cayce	Dorrier	Poster	Immunomodulatory Agents and Interventions 2	4/17/23	9:00 AM	Section 24	26
1855	Targeting DGKA for immuno-oncology therapy: ISM4312A, a novel DGKA inhibitor with robust anti-tumor activity	Sujata	Rao	Poster	Immunomodulatory Agents and Interventions 2	4/17/23	9:00 AM	Section 24	27
1856	Pemetrexed-cisplatin-bevacizumab combo in lung cancer models: impact on tumor immunity	Joseph	Ciccolini	Poster	Immunomodulatory Agents and Interventions 2	4/17/23	9:00 AM	Section 24	28
1857	Nanoliposomes harness tumor immunity in breast cancer models	Joseph	Ciccolini	Poster	Immunomodulatory Agents and Interventions 2	4/17/23	9:00 AM	Section 24	29
1858	Enhanced delivery of anti PD-1 antibody to liver tumors in oncopig using pressure enabled drug delivery (PEDD) versus a systemic delivery	David	Jaroch	Poster	Immunomodulatory Agents and Interventions 2	4/17/23	9:00 AM	Section 24	30
1862	Synergistic and long-lasing anti-tumor efficacy of CBA-1205, a novel glycoengineered humanized antibody targeting DLK-1, in combination with lenvatinib in human HCC xenograft models.	Koji	Nakamura	Poster	Therapeutic Antibodies 1	4/17/23	9:00 AM	Section 25	1
1863	Evaluation of BDB101, a first-in-class TLR7/8 dual agonist conjugated to an anti-PD-L1 mAb, in cancer treatment	Lixin	Li	Poster	Therapeutic Antibodies 1	4/17/23	9:00 AM	Section 25	2
1864	An improved trispecific antibody (TsAb) platform for optimally engaging T cells for the treatment of solid tumor malignancies	Avanish	Varshney	Poster	Therapeutic Antibodies 1	4/17/23	9:00 AM	Section 25	3
1865	Development of CTIM-76, a highly specific Claudin 6 bispecific antibody for treatment of ovarian cancer	Joseph	Rucker	Poster	Therapeutic Antibodies 1	4/17/23	9:00 AM	Section 25	4
1866	D02, a novel, non-blocking antibody targeting IL2RA, exhibits significant anti-tumor activity in IL2RA-humanized mice	Qingcong	Lin	Poster	Therapeutic Antibodies 1	4/17/23	9:00 AM	Section 25	5
1867	Pre-clinical characterization of anti-CEACAM1 antibody	Jinyu	Dong	Poster	Therapeutic Antibodies 1	4/17/23	9:00 AM	Section 25	6
1868	Novel immune checkpoint inhibitor: In vivo and in vitro efficacy of anti-CNTN4 antibody, GENA-104A16 in the models with increased CNTN4 expression	Mi Young	Cha	Poster	Therapeutic Antibodies 1	4/17/23	9:00 AM	Section 25	7
1869	Preclinical evaluation of mosunetuzumab for the treatment of relapsed/refractory chronic lymphocytic leukemia	Kathy	Barrett	Poster	Therapeutic Antibodies 1	4/17/23	9:00 AM	Section 25	8
1870	VBI-003, a CD47xEpCAM bispecific antibody as a potential treatment for colorectal and small cell lung cancers	Oi Kwan	Wong	Poster	Therapeutic Antibodies 1	4/17/23	9:00 AM	Section 25	9
1871	Novel conditionally active bispecific HER2 x CD3 T cell engager targeting solid tumors	Ana Paula	Cugnetti	Poster	Therapeutic Antibodies 1	4/17/23	9:00 AM	Section 25	10
1872	A DLL3/CD3/CD137 trispecific T cell engager shows potent antitumor activity in small cell lung cancer models	Hirofumi	Mikami	Poster	Therapeutic Antibodies 1	4/17/23	9:00 AM	Section 25	11
1873	D3L-001, a novel bispecific antibody targeting HER2 and CD47, demonstrates potent preclinical efficacy in solid tumors.	Haopeng	Rui	Poster	Therapeutic Antibodies 1	4/17/23	9:00 AM	Section 25	12

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
1874	Preclinical characterization of MBS307, a CD40/PD-L1 trispecific antibody with increased therapeutic window and efficacy	Feng	Li	Poster	Therapeutic Antibodies 1	4/17/23	9:00 AM	Section 25	13
1875	A novel T-cell-engaging therapeutical antibody against GPRC5D&BCMA for multiple myeloma treatment	Feng	Li	Poster	Therapeutic Antibodies 1	4/17/23	9:00 AM	Section 25	14
1876	NAV-001, a high-efficacy antibody-drug conjugate targeting mesothelin with improved delivery of potent payload by counteracting MUC16/CA125 effects	Luigi	Grasso	Poster	Therapeutic Antibodies 1	4/17/23	9:00 AM	Section 25	15
1877	Tripokin: potential best-in-class for tumor targeted interleukin-2 (IL2) potentiated by tumor necrosis factor (TNF)	Eleonora	Prodi	Poster	Therapeutic Antibodies 1	4/17/23	9:00 AM	Section 25	16
1878	Preclinical development of a novel bispecific mAb-Trap fusion protein, IMM2520, targeting both PD-L1 and CD47 as cancer immunotherapy	Frank	Gan	Poster	Therapeutic Antibodies 1	4/17/23	9:00 AM	Section 25	17
1879	A novel dual CAB nectin-4 x CD3 bispecific antibody targeting solid tumors	Matthew	Lucas	Poster	Therapeutic Antibodies 1	4/17/23	9:00 AM	Section 25	18
1880	A novel CD137 agonist exhibits potent antitumor efficacy with a good safety profile	Yang	Huang	Poster	Therapeutic Antibodies 1	4/17/23	9:00 AM	Section 25	19
1881	Pre-clinical evaluation of a novel antibody drug conjugate (ADC) LM-306 targeting IL-13R α 2 in immuno-oncology	Runsheng	Li	Poster	Therapeutic Antibodies 1	4/17/23	9:00 AM	Section 25	20
1882	SCR-9171, a MUC17-targeted bispecific T cell engager molecule for gastrointestinal cancer	Renhong	Tang	Poster	Therapeutic Antibodies 1	4/17/23	9:00 AM	Section 25	21
1883	A novel T cell engager targeting BCMA and GPRC5D showed promising preclinical activity with low toxic risk for multiple myeloma treatment	Renhong	Tang	Poster	Therapeutic Antibodies 1	4/17/23	9:00 AM	Section 25	22
1884	DB-1310, a novel Her3 targeting antibody-drug conjugate, exhibits therapeutic efficacy for solid tumors	Rong	Shi	Poster	Therapeutic Antibodies 1	4/17/23	9:00 AM	Section 25	23
1885	Selection of an optimal anti-PD-L1 single domain antibody format for the vectorization into oncolytic vaccinia virus and the generation of bispecific immunomodulators.	Jean-Baptiste	Marchand	Poster	Therapeutic Antibodies 1	4/17/23	9:00 AM	Section 25	24
1886	Identifying T-cell engagers with optimal potency and cytokine-release profiles with a diverse panel of CD3-binding antibodies	Bryan	Barnhart	Poster	Therapeutic Antibodies 1	4/17/23	9:00 AM	Section 25	25
1887	Preclinical development of BB-1701, a HER2-tageting eribulin-containing ADC with potent bystander effect and ICD activity	Yang	Wang	Poster	Therapeutic Antibodies 1	4/17/23	9:00 AM	Section 25	26
1888	IAE0972, A novel EGFR/IL10 immunocytokine of monovalent anti-EGFR antibody fused with IL10 homodimer	Liusong	Yin	Poster	Therapeutic Antibodies 1	4/17/23	9:00 AM	Section 25	27
1889	IAP0971, A novel PD1/IL15 immunocytokine that binds specifically to PD1 and fuses IL15/IL15R α complex	Liusong	Yin	Poster	Therapeutic Antibodies 1	4/17/23	9:00 AM	Section 25	28
1890	Bispecific T cell engagers targeting TrkB	Jetta	Bijlsma	Poster	Therapeutic Antibodies 1	4/17/23	9:00 AM	Section 25	29

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
1891	Breaking barriers to access intracellular targets with T-cell engagers: Discovery of diverse, developable, and ultra-specific antibodies against a MAGE-A4 pMHC	Raffi	Tonikian	Poster	Therapeutic Antibodies 1	4/17/23	9:00 AM	Section 25	30
1895	Molecular characterization of prostate cancer between Hispanic American and Non-Hispanic Whites: Implications for cancer ethnic health disparities	Alejandro	Recio-Boiles	Poster	Cancer Disparities 1	4/17/23	9:00 AM	Section 26	1
1896	Dysregulation of DNA methylation in prostate cancer among African American men	Jong	Park	Poster	Cancer Disparities 1	4/17/23	9:00 AM	Section 26	2
1897	RNA expression markers with differential expression by race/ancestry are associated with prostate tumor aggressiveness among African American men	Kathryn	Barry	Poster	Cancer Disparities 1	4/17/23	9:00 AM	Section 26	3
1898	Racial/ethnic disparities in stage at diagnosis among women with cervical cancer in Texas: Mediating effects of neighborhood-level socioeconomic deprivation	Itunu	Sokale	Poster	Cancer Disparities 1	4/17/23	9:00 AM	Section 26	4
1899	Breast density comparison of Hispanic versus Non-Hispanic patients undergoing screening mammograms: Influence of age, parity and breast-feeding	Sangeetha	Prabhakaran	Poster	Cancer Disparities 1	4/17/23	9:00 AM	Section 26	5
1900	Radiotherapy-induced early adverse skin reactions: Comparative analysis of clinician- and patient-reported outcomes in a multi-racial/ethnic breast cancer population (WF-97609)	Jennifer	Hu	Poster	Cancer Disparities 1	4/17/23	9:00 AM	Section 26	6
1901	Analysis of the survivin expression in breast tumor tissue from black and white cancer patients	Kerrie	Brown	Poster	Cancer Disparities 1	4/17/23	9:00 AM	Section 26	7
1902	Lung cancer incidence by detailed race-ethnicity	Hannah	Cranford	Poster	Cancer Disparities 1	4/17/23	9:00 AM	Section 26	8
1903	Esophageal cancer clinical and socioeconomic aspects in Brazil: Inequalities affect patients from diagnosis to prognosis	Sheila	Soares-Lima	Poster	Cancer Disparities 1	4/17/23	9:00 AM	Section 26	9
1904	Somatic copy number alterations and gene expression signatures are associated with aggressive tumor biology in African Americans and European Americans with renal cell carcinoma	Khadijah	Mitchell	Poster	Cancer Disparities 1	4/17/23	9:00 AM	Section 26	10
1905	Genes and pathways related to Hispanic colorectal cancer disparities	Sourav	Roy	Poster	Cancer Disparities 1	4/17/23	9:00 AM	Section 26	11
1906	MSH3: An underestimated DNA MMR gene in colorectal carcinogenesis and its potential role in disparity	Mudasir	Rashid	Poster	Cancer Disparities 1	4/17/23	9:00 AM	Section 26	12
1907	Unique and novel deleterious MSH6 mutation among African American patients with colorectal cancer	Hassan	Ashktorab	Poster	Cancer Disparities 1	4/17/23	9:00 AM	Section 26	13
1908	Clinical genomic profiling identifies lower frequency of therapeutically actionable alterations and lower prognostic value	Henry	Walch	Poster	Cancer Disparities 1	4/17/23	9:00 AM	Section 26	14

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
	of APC inactivation in colorectal cancer patients of African ancestry								
1909	Pre-diagnostic vitamin D in association with colorectal cancer- and all-cause mortality: a prospective study among a non-Hispanic Black cohort	Shaneda	Warren Andersen	Poster	Cancer Disparities 1	4/17/23	9:00 AM	Section 26	15
1910	Patient race and ethnicity, experiences with care, and guideline concordant treatment for colorectal cancer among those with multimorbidity	Stephanie	Navarro	Poster	Cancer Disparities 1	4/17/23	9:00 AM	Section 26	16
1911	Racial and ethnic disparities in comorbidity burden among ovarian cancer patients	Lindsay	Collin	Poster	Cancer Disparities 1	4/17/23	9:00 AM	Section 26	17
1913	Population-based analysis of primary mediastinal B-cell lymphoma: a look at Hispanic outcomes	Lauren	Diaz Boyle	Poster	Cancer Disparities 1	4/17/23	9:00 AM	Section 26	19
1914	Pancreatic cancer and racial disparity in Hampton Roads	Zakary	Kolkey	Poster	Cancer Disparities 1	4/17/23	9:00 AM	Section 26	20
1915	Cancer disparities in the University of Chicago Comprehensive Cancer Center Catchment Area	Joel	Ssepuyya	Poster	Cancer Disparities 1	4/17/23	9:00 AM	Section 26	21
1916	Cancer disparities among sexual and gender minority patients at a National Cancer Institute-Designated Comprehensive Cancer Center	Shahrzad	Zamani	Poster	Cancer Disparities 1	4/17/23	9:00 AM	Section 26	22
1917	Socioeconomic barriers and their association with healthcare delays by nativity among cancer survivors from the All of Us Cohort	Angel	Arizpe	Poster	Cancer Disparities 1	4/17/23	9:00 AM	Section 26	23
1918	Reducing human papillomavirus associated cancers and disparities among Hispanics/Latinos through the adapted NCI NON CHE (National Outreach Network Community Health Education) program	Alejandra	Ramos	Poster	Cancer Disparities 1	4/17/23	9:00 AM	Section 26	24
1919	Cancer Wellness Hubs: A pop-up information model to reduce cancer disparities in medically-underserved, minority communities	Lourdes	Baezconde_Garbanati	Poster	Cancer Disparities 1	4/17/23	9:00 AM	Section 26	25
1920	Association of type 2 diabetes with overall and site-specific cancer among predominantly low-income Black and White Americans	Pranoti	Pradhan	Poster	Cancer Disparities 1	4/17/23	9:00 AM	Section 26	26
1921	Universal genetic testing for hereditary cancer syndromes in an under-represented minority population	Kevork	Khadarian	Poster	Cancer Disparities 1	4/17/23	9:00 AM	Section 26	27
1922	PhyloFrame: A machine learning framework for ancestry agnostic disease signatures	Leslie	Smith	Poster	Cancer Disparities 1	4/17/23	9:00 AM	Section 26	28
1923	Ancestry-associated differences in somatic mutation rates from tumor profiling data of a pan-cancer cohort of 100,000 patients	Brooke	Rhead	Poster	Cancer Disparities 1	4/17/23	9:00 AM	Section 26	29

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
1927	Differential effects of social isolation on cancer mortality by race/ethnicity and socioeconomic status among working age adults in the United States	Hyunjung	Lee	Poster	Cancer Disparities 2	4/17/23	9:00 AM	Section 27	1
1928	Racial/ethnic disparities in diabetes-related clinical care service use among cancer patients of cooccurring diabetes	Gaole	Song	Poster	Cancer Disparities 2	4/17/23	9:00 AM	Section 27	2
1929	Not just demographics: Urban and rural differences in skin cancer sun protection behaviors in the United States	Allison	Dona	Poster	Cancer Disparities 2	4/17/23	9:00 AM	Section 27	3
1930	Community outreach and engagement to increase colorectal cancer screening in ethnic minority communities	Kimlin	Ashing	Poster	Cancer Disparities 2	4/17/23	9:00 AM	Section 27	4
1931	Racialized economic segregation and late-stage colorectal cancer in the United States, 2009-2017	Eduardo	Santiago-Rodriguez	Poster	Cancer Disparities 2	4/17/23	9:00 AM	Section 27	5
1932	Evaluation of racial and ethnic psychotropic medication use among patients with colorectal cancer	MegCholack	Awunti	Poster	Cancer Disparities 2	4/17/23	9:00 AM	Section 27	6
1933	Transcriptomic profiling of Hispanic colorectal cancer disparities	Soumya	Nair	Poster	Cancer Disparities 2	4/17/23	9:00 AM	Section 27	7
1934	Incidence and survival outcomes of younger adults with colorectal cancers by age group: a SEER analysis	Sheeba	Ba Aqeel	Poster	Cancer Disparities 2	4/17/23	9:00 AM	Section 27	8
1935	Racial and ethnic disparities in survival among women with advanced-stage ovarian cancer who received systemic therapy: A National Cancer Database analysis	Caretia	Washington	Poster	Cancer Disparities 2	4/17/23	9:00 AM	Section 27	9
1936	Demographic and socioeconomic determinants to the access to multi-agent therapy in multiple myeloma: A National Cancer Database (NCDB) analysis of years 2004-2017	Ludovic	Saba	Poster	Cancer Disparities 2	4/17/23	9:00 AM	Section 27	10
1937	Racial differences of epigenome in normal breast tissue reveal biological pathways implicated in racial disparities in breast cancer	Chunyan	He	Poster	Cancer Disparities 2	4/17/23	9:00 AM	Section 27	11
1938	Germline mutations in breast cancer genes are associated with early age of diagnosis and triple negative disease in Guatemalan and US Hispanic women	Jesica	Godinez Paredes	Poster	Cancer Disparities 2	4/17/23	9:00 AM	Section 27	12
1939	Evaluating treatment data concordance among young Black women diagnosed with breast cancer	Mya	Roberson	Poster	Cancer Disparities 2	4/17/23	9:00 AM	Section 27	13
1940	Outcomes of patients treated with neoadjuvant chemotherapy for breast cancer at a safety net hospital	Prakriti	Srivastava	Poster	Cancer Disparities 2	4/17/23	9:00 AM	Section 27	14
1941	Barriers and effective interventions to engage Latinas' participation in breast cancer clinical trials	Monica	Padilla	Poster	Cancer Disparities 2	4/17/23	9:00 AM	Section 27	15
1942	Effectiveness of community outreach / engagement and faith-based strategies among African American & African Nationals to increase cancer clinical trials participation using a culturally tailored educational manual	Lourdes	Baezconde-Garbanati	Poster	Cancer Disparities 2	4/17/23	9:00 AM	Section 27	16

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
1943	Disparities in multinational phase III liver cancer clinical trials by regions of the world	J. Alberto	Maldonado	Poster	Cancer Disparities 2	4/17/23	9:00 AM	Section 27	17
1944	Racial and ethnic disparities in U.S. clinical trials in liver cancer in the last nineteen years	J. Alberto	Maldonado	Poster	Cancer Disparities 2	4/17/23	9:00 AM	Section 27	18
1945	Racial disparities in comprehensive cancer tumor profiling testing from real-world data of 100,000 cancer patient records	Francisco	De La Vega	Poster	Cancer Disparities 2	4/17/23	9:00 AM	Section 27	19
1946	Development and application of genetic ancestry reconstruction methods to study diversity of patient-derived models in the NCI PDXNet Consortium	Brian	Sanderson	Poster	Cancer Disparities 2	4/17/23	9:00 AM	Section 27	20
1947	Clinical and genomic correlates with genetic ancestry in lung squamous cell carcinoma	Sejal	Jain	Poster	Cancer Disparities 2	4/17/23	9:00 AM	Section 27	21
1948	Novel insights into lung cancer & chronic obstructive pulmonary disease racial disparities	Jose	Thomas Thaiparambil	Poster	Cancer Disparities 2	4/17/23	9:00 AM	Section 27	22
1949	KRAS G12C mutations in Hispanic and non-Hispanic patients with NSCLC: clinicopathologic characteristics and prognosis	Aysswarya	Manoharan	Poster	Cancer Disparities 2	4/17/23	9:00 AM	Section 27	23
1950	Socioeconomic status and lung cancer incidence: An analysis of data from 15 countries in the Lung Cancer Cohort Consortium	Justina	Onwuka	Poster	Cancer Disparities 2	4/17/23	9:00 AM	Section 27	24
1951	Combining diverse data sources to examine disparities in stage at diagnosis among adults with oral cancer in the United States	Sana	Chawla	Poster	Cancer Disparities 2	4/17/23	9:00 AM	Section 27	25
1952	Persistent poverty and oral and pharynx cancer incidence and relative survival rates	Shama	Karant	Poster	Cancer Disparities 2	4/17/23	9:00 AM	Section 27	26
1953	Association between genetic ancestry and all-cause mortality among Black and White ever-smokers in the PLCO cohort	Courtney	Dill	Poster	Cancer Disparities 2	4/17/23	9:00 AM	Section 27	27
1954	Black-White differences in prospective serum metabolites and biochemical pathways associated with prostate cancer risk in a COMETS consortium project	Jungeun	Lim	Poster	Cancer Disparities 2	4/17/23	9:00 AM	Section 27	28
1955	HER2 expression in African American men with prostate cancer	Nicole	Mavingire	Poster	Cancer Disparities 2	4/17/23	9:00 AM	Section 27	29
1956	Stress-mediated reactive oxygen species from mitochondria dysregulates the tumor microenvironment in prostate cancer of African American men	Asmaa	El-Kenawi	Poster	Cancer Disparities 2	4/17/23	9:00 AM	Section 27	30
1960	Racial differences in the association of metformin use with progression of monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans with diabetes mellitus	Lawrence	Liu	Poster	Cancer Disparities Research	4/17/23	9:00 AM	Section 28	1
1961	Stratifying high-risk patients, quantifying therapy efficacy, and detecting treatment/racial disparity in triple-negative breast cancer (TNBC) at Sentara-EVMS-VOA	Taylor	Drake	Poster	Cancer Disparities Research	4/17/23	9:00 AM	Section 28	2

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
1962	Oncologic anthropology-impact of Duffy adaptive trait on breast epithelial and tumor cell biology	Harikrishna	Nakshatri	Poster	Cancer Disparities Research	4/17/23	9:00 AM	Section 28	3
1963	Characterization of thyroid cancer among Hispanics in California	Robert	Hsu	Poster	Cancer Disparities Research	4/17/23	9:00 AM	Section 28	4
1964	Racial and ethnic trends in next-generation sequencing (NGS) utilization among adult patients with selected advanced tumor types: a large commercial database analysis	Gilbert	Ko	Poster	Cancer Disparities Research	4/17/23	9:00 AM	Section 28	5
1965	Racially divergent mitochondrial ND5 gene mutation promotes prostate cancer progression and confers therapeutic resistance	Kunwar Somesh	Vikramdeo	Poster	Cancer Disparities Research	4/17/23	9:00 AM	Section 28	6
1967	Addressing breast cancer disparities: knowledge and attitudes towards cancer prevention through breastfeeding among African American women in Georgia	Marlo	Vernon	Poster	Cancer Disparities Research	4/17/23	9:00 AM	Section 28	8
1968	A multiomic spatial atlas of breast cancer in women of African ancestry	Jasmine	Plummer	Poster	Cancer Disparities Research	4/17/23	9:00 AM	Section 28	9
1969	DNA methylation and mutation spectrum among pediatric acute lymphoblastic leukemia patients by Hispanic/Latinx ethnicity	Ernest	Amankwah	Poster	Cancer Disparities Research	4/17/23	9:00 AM	Section 28	10
1970	Protecting against algorithmic bias of AI-based clinical decision making tools in oncology	Benjamin	Ellis	Poster	Cancer Disparities Research	4/17/23	9:00 AM	Section 28	11
1971	Understanding the perspectives of Latino smokers on physical activity: A qualitative study	Francisco	Cartujano-Barrera	Poster	Cancer Disparities Research	4/17/23	9:00 AM	Section 28	12
1972	Potential predictors of prostate cancer screening: Findings from the MiCaP research digest study	Jessica	Otero Machuca	Poster	Cancer Disparities Research	4/17/23	9:00 AM	Section 28	13
1973	A geo inelegant approach to cancer disparity	Ahmed	Fadiel Metwaly	Poster	Cancer Disparities Research	4/17/23	9:00 AM	Section 28	14
1974	Predictors of correct recall of MC1R genetic risk among Hispanic individuals participating in a skin cancer precision prevention trial	John	Lacson	Poster	Cancer Disparities Research	4/17/23	9:00 AM	Section 28	15
1975	Community Engagement in Research and Clinical Trial (CERCT) program: The development of an inclusive clinical trials training program for community health workers (CHWs) and pharmacy technicians	Jennifer	Crook	Poster	Cancer Disparities Research	4/17/23	9:00 AM	Section 28	16
1976	Lung cancer screening disparities in Southeastern U.S.	Desiree	Rivers	Poster	Cancer Disparities Research	4/17/23	9:00 AM	Section 28	17
1977	Body mass index genetic risk score and obesity related cancer risk in Black and White adults	Peter	Katzmarzyk	Poster	Cancer Disparities Research	4/17/23	9:00 AM	Section 28	18
1978	Community Genomic Health Promotion Program evaluates precision DNA methylation biomarkers for use in self-testing and collection kits in urine, to increase cervical cancer screening rates among Latina women	Carmen	Ili	Poster	Cancer Disparities Research	4/17/23	9:00 AM	Section 28	19
1979	Examining stereotype perceptions of colorectal cancer in the Latino community	Bianca	Luna-Lupercio	Poster	Cancer Disparities Research	4/17/23	9:00 AM	Section 28	20

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
1980	Integrating common and rare genetic variants to predict cancer risks in diverse populations	Kuan-lin	Huang	Poster	Cancer Disparities Research	4/17/23	9:00 AM	Section 28	21
1981	Promotion of LDCT screening in Northern Illinois with focus on minority communities	Neelu	Puri	Poster	Cancer Disparities Research	4/17/23	9:00 AM	Section 28	22
1982	Exploring the impact of metastatic breast cancer support group in Nigeria	Runcie	Chidebe	Poster	Cancer Disparities Research	4/17/23	9:00 AM	Section 28	23
1983	Social /physical limitations and financial hardship among the US adult cancer survivors with multiple primary cancer	Jiazhang	Xing	Poster	Cancer Disparities Research	4/17/23	9:00 AM	Section 28	24
1987	Delivery of potent cytotoxic camptothecin derivatives to tumors by OncoFAP-based small molecule-drug conjugates	Matilde	Bocci	Poster	Drug Delivery	4/17/23	9:00 AM	Section 30	1
1988	FAP-targeted non-internalising drug conjugates: A comparative evaluation between small molecules, antibodies and peptides	Samuele	Cazzamalli	Poster	Drug Delivery	4/17/23	9:00 AM	Section 30	2
1989	DNA-encoded affinity maturation libraries enable the discovery of low picomolar fibroblast activation protein inhibitors suitable for radioligand therapy of solid tumors	Sara	Puglioli	Poster	Drug Delivery	4/17/23	9:00 AM	Section 30	3
1990	Targeting cancer stem cells is an answer to the curing lung cancer	Taisun	Kim	Poster	Drug Delivery	4/17/23	9:00 AM	Section 30	4
1991	Remodeling the microenvironment of osteosarcoma lung metastases with inhaled CSF-1Ri immunotherapy	Fatemah	Sunbul	Poster	Drug Delivery	4/17/23	9:00 AM	Section 30	5
1992	P-selectin-targeted delivery of intracranial therapeutics across an intact BBB in Sonic Hedgehog medulloblastoma	Daniel	Heller	Poster	Drug Delivery	4/17/23	9:00 AM	Section 30	6
1993	Sulfobutylether- β -cyclodextrin hydrogel microspheres delivering TLR 7/8 agonist for transarterial immunoembolization	Joel	Updyke	Poster	Drug Delivery	4/17/23	9:00 AM	Section 30	7
1994	Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA deficient ovarian cancer	Shicheng	Yang	Poster	Drug Delivery	4/17/23	9:00 AM	Section 30	8
1995	2C5-surface modified nanocarriers targeting neutrophil extracellular traps	Nina	Filipczak	Poster	Drug Delivery	4/17/23	9:00 AM	Section 30	9
1996	Prostate cancer androgen receptor signaling inhibition via romidepsin encapsulated lipid-polymer hybrid nanoparticle with PSMA617 targeting	Wendi	Ma	Poster	Drug Delivery	4/17/23	9:00 AM	Section 30	10
1997	2C5 antibody modified dendrimer-based mixed micelles for the treatment of multidrug resistant cancers	Satya Siva Kishan	Yalamarty	Poster	Drug Delivery	4/17/23	9:00 AM	Section 30	11
1998	Characterization of immunoliposomes for HER2-targeted delivery of the dual Rac/Cdc42 inhibitor MBQ-167	Luis	Velazquez	Poster	Drug Delivery	4/17/23	9:00 AM	Section 30	12
1999	Repurposing an antibiotic for breast cancer treatment using liposomes as a delivery system	Janaina Artem	Ataide	Poster	Drug Delivery	4/17/23	9:00 AM	Section 30	13
2000	Injectable alginate scaffolds for the delivery of minocycline for the treatment of glioblastoma	Kaitlyn	Ybáñez	Poster	Drug Delivery	4/17/23	9:00 AM	Section 30	14

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
2001	Engineering extracellular vesicle like liposomes with integrin $\alpha V\beta 5$ to study its role in cancer metastasis	Yunxi	Chen	Poster	Drug Delivery	4/17/23	9:00 AM	Section 30	15
2002	Intravenously administered STING agonist-loaded positively charged liposomes selectively target tumor microenvironments and reprogram tumor vasculature	Eun-Jin	Go	Poster	Drug Delivery	4/17/23	9:00 AM	Section 30	16
2003	Evaluation of liposome encapsulated sunitinib efficacy and immune modulation on renal cell carcinoma	Po-Fu	Yueh	Poster	Drug Delivery	4/17/23	9:00 AM	Section 30	17
2004	Selective cytotoxicity of multiple myeloma using novel cell membrane lipid-extracted nanoliposomes	Matthew	Amorin	Poster	Drug Delivery	4/17/23	9:00 AM	Section 30	18
2005	F5HR-mediated targeted delivery of paclitaxel immunoliposomes in receptor overexpressing ovarian cancer cells	Priyanka	Bhatt	Poster	Drug Delivery	4/17/23	9:00 AM	Section 30	19
2006	A novel macromolecular platinum drug with potent efficacy to overcome cross-resistance in cancer therapy	Yongbin	Liu	Poster	Drug Delivery	4/17/23	9:00 AM	Section 30	20
2007	Evaluation of the antitumor activity of ca102l, a hyaluronic acid and lenalidomide conjugate, in multiple myeloma	Eskouhie	Tchaparian	Poster	Drug Delivery	4/17/23	9:00 AM	Section 30	21
2008	Induced macropinocytosis by DNA-PK inhibitor for KRAS mutant cancer targeting of albumin-binding peptide drug conjugate	Ha Rin	Kim	Poster	Drug Delivery	4/17/23	9:00 AM	Section 30	22
2009	Gemcitabine-loaded EGFR aptamer for targeted therapy of lung cancer	Jun Young	Park	Poster	Drug Delivery	4/17/23	9:00 AM	Section 30	23
2010	The application of a PLGA scaffold for the dual delivery of Y15 and metformin for the treatment of platinum resistant ovarian cancer	Hannah	Obregon	Poster	Drug Delivery	4/17/23	9:00 AM	Section 30	24
2011	Polycondensate-epitope vaccine augments anti-cancer T lymphocyte responses and induces long-term immune memory	Xiaomeng	Hu	Poster	Drug Delivery	4/17/23	9:00 AM	Section 30	25
2012	A novel antibody-drug conjugate platform enabling high drug-to-antibody ratios and greater payload flexibility	Ludovic	Juen	Poster	Drug Delivery	4/17/23	9:00 AM	Section 30	26
2013	Oxidized anthracycline payloads induce anti-tumor immunogenic cell-death and show linker-dependent tolerability when delivered as ADCs	Joseph	Hamilton	Poster	Drug Delivery	4/17/23	9:00 AM	Section 30	27
2017	A liquid biopsy approach to gastric cancer reveals a signature reflective of epithelial to mesenchymal transition	Ali	Abdel Sater	Poster	Proteomics and Biomarker Discovery	4/17/23	9:00 AM	Section 31	1
2019	NCI's clinical proteomic tumor analysis consortium analysis tools and resources	Mehdi	Mesri	Poster	Proteomics and Biomarker Discovery	4/17/23	9:00 AM	Section 31	3
2020	Nascent proteome analysis of drug response in precision-cut tumor slices	Julia	Thiel	Poster	Proteomics and Biomarker Discovery	4/17/23	9:00 AM	Section 31	4
2021	Naveni TriFlex cell: An emerging method for simultaneous detection of free proteins and their interactions	Doroteya	Raykova	Poster	Proteomics and Biomarker Discovery	4/17/23	9:00 AM	Section 31	5

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
2022	What can we learn from phosphoproteomics compared to transcriptomics in DNA damage and other processes?	Gali	Arad	Poster	Proteomics and Biomarker Discovery	4/17/23	9:00 AM	Section 31	6
2023	CoPheeMap: a co-regulation map of 30,000 phosphosite illuminates the dark cancer phosphoproteome	Wen	Jiang	Poster	Proteomics and Biomarker Discovery	4/17/23	9:00 AM	Section 31	7
2024	High resolution limited proteolysis (HR-LiP), a novel structural proteomics approach for the prediction of small molecule-protein binding events	Nigel	Beaton	Poster	Proteomics and Biomarker Discovery	4/17/23	9:00 AM	Section 31	8
2025	Phosphoproteomic profiling following MAP3K1 kinase inhibition identifies NPM1 as a novel substrate	Lidia	Boghean	Poster	Proteomics and Biomarker Discovery	4/17/23	9:00 AM	Section 31	9
2026	Comprehensive metabolic flux analysis on triple-negative breast cancer shows potential collaterally lethal targets related to the serine pathway	Jin Heon	Jeon	Poster	Proteomics and Biomarker Discovery	4/17/23	9:00 AM	Section 31	10
2028	Using bioinformatic analysis of proteomic data to probe novel drug mechanism of action	Weining	Chen	Poster	Proteomics and Biomarker Discovery	4/17/23	9:00 AM	Section 31	12
2032	Intratumoral tumor infiltrating lymphocytes is associated with cell proliferation and better survival but not with response to chemotherapy	Rongrong	Wu	Poster	Bioinformatics Applications in Cancer Biology 1	4/17/23	9:00 AM	Section 32	1
2033	Assessment of human reference genomes on cancer somatic mutation detection in tumor-normal paired reference samples using whole genome short-read sequencing data	Chunlin	Xiao	Poster	Bioinformatics Applications in Cancer Biology 1	4/17/23	9:00 AM	Section 32	2
2034	Discovery of novel therapeutic targets using 3D chromatin conformation and patient-specific gene regulatory networks	Andre	Forbes	Poster	Bioinformatics Applications in Cancer Biology 1	4/17/23	9:00 AM	Section 32	3
2036	Distinct mutational processes shape selection of MHC class I and class II mutations across primary and metastatic tumors	Michael	Mumphrey	Poster	Bioinformatics Applications in Cancer Biology 1	4/17/23	9:00 AM	Section 32	5
2037	Tracking the emergence of immunotherapy resistance in lung cancer metastases	Sonya	Hessey	Poster	Bioinformatics Applications in Cancer Biology 1	4/17/23	9:00 AM	Section 32	6
2038	Epstein-Barr virus shapes the tumor microenvironment in classical Hodgkin lymphoma	Maryam	Pourmaleki	Poster	Bioinformatics Applications in Cancer Biology 1	4/17/23	9:00 AM	Section 32	7
2039	Predicting abundance and expression of immune cells in patients' head & neck tumor microenvironment from blood single-cell transcriptomics	Yingying	Cao	Poster	Bioinformatics Applications in Cancer Biology 1	4/17/23	9:00 AM	Section 32	8
2040	Molecular dynamic simulation of intermediates connecting KRAS and PRMT5 insight for targeting KRAS	Isaac	Silverman	Poster	Bioinformatics Applications in Cancer Biology 1	4/17/23	9:00 AM	Section 32	9
2041	Research strategies for rare germline variants and cancer study	Seokhyeon	Kim	Poster	Bioinformatics Applications in Cancer Biology 1	4/17/23	9:00 AM	Section 32	10

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
2042	Graph-based pathway analysis of T cell populations in hepatocellular carcinoma reveals novel metabolic regulators of tumor-infiltration lymphocyte activity	Divyansh	Agarwal	Poster	Bioinformatics Applications in Cancer Biology 1	4/17/23	9:00 AM	Section 32	11
2044	Using tumor immune microenvironment physiologic profiling to tailor immune checkpoint inhibitor diagnostic classification	Robert	Seitz	Poster	Bioinformatics Applications in Cancer Biology 1	4/17/23	9:00 AM	Section 32	13
2045	Analysis of the matrisome in malignant gliomas reveals architectural heterogeneity of the tumor microenvironment and discloses a prognostic signature of extracellular matrix targets	Minhein	Htet	Poster	Bioinformatics Applications in Cancer Biology 1	4/17/23	9:00 AM	Section 32	14
2046	Identification of the cuproptosis-related gene signature associated with the tumor environment and prognosis of patients with glioblastoma multiforme (GBM)	Yaman	Ahmed	Poster	Bioinformatics Applications in Cancer Biology 1	4/17/23	9:00 AM	Section 32	15
2047	Flux estimation analysis systematically characterizes the metabolic shifts of the central metabolism pathway in human cancer	Haiqi	Zhu	Poster	Bioinformatics Applications in Cancer Biology 1	4/17/23	9:00 AM	Section 32	16
2048	Mutations in FOXA1 alter chromatin remodeling and cell fate in prostate organoids	Erik	Ladewig	Poster	Bioinformatics Applications in Cancer Biology 1	4/17/23	9:00 AM	Section 32	17
2050	Molecular subclassification of NCI PDMR breast cancer models using PAM50 gene expression signature	Peter	Wu	Poster	Bioinformatics Applications in Cancer Biology 1	4/17/23	9:00 AM	Section 32	19
2051	MDN1, a novel potential early biomarker for endocrine resistant breast cancer	Syreeta	Tilghman	Poster	Bioinformatics Applications in Cancer Biology 1	4/17/23	9:00 AM	Section 32	20
2052	High-plex spatial multiomics of pediatric and adult diffuse midline glioma, H3 K27-altered	Alyssa	Rosenbloom	Poster	Bioinformatics Applications in Cancer Biology 1	4/17/23	9:00 AM	Section 32	21
2053	Structural variants detected by optical genome mapping in acute lymphoblastic leukemia patient-derived xenografts models	Yueying	Wang	Poster	Bioinformatics Applications in Cancer Biology 1	4/17/23	9:00 AM	Section 32	22
2054	Whole-genome sequencing based homologous recombination deficiency testing for precision oncology of breast cancers	Ryul	Kim	Poster	Bioinformatics Applications in Cancer Biology 1	4/17/23	9:00 AM	Section 32	23
2055	Prevalent focal amplification of oncogene in lung adenocarcinomas without canonical driver alterations	Joonoh	Lim	Poster	Bioinformatics Applications in Cancer Biology 1	4/17/23	9:00 AM	Section 32	24
2056	Large-scale whole genome sequencing of hepatocellular carcinoma reveals stepwise cancer evolution	Joonoh	Lim	Poster	Bioinformatics Applications in Cancer Biology 1	4/17/23	9:00 AM	Section 32	25
2057	Pan-cancer analysis of ion channel genes reveals patterns of large-scale transcriptional dysregulation and novel oncogenes with functions in cellular connectivity	Alexander	Bahcheli	Poster	Bioinformatics Applications in Cancer Biology 1	4/17/23	9:00 AM	Section 32	26
2058	Identifications of novel variants using system biology-based approaches in NT5C2, its association to relapse acute lymphoblastic leukaemia	Sugunakar	V	Poster	Bioinformatics Applications in Cancer Biology 1	4/17/23	9:00 AM	Section 32	27

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
2059	Machine learning integration of transcriptome-wide spatial sequencing data and ultra-high plex spatial proteomic data enables the prioritization of cancer drug targets	Quan	Nguyen	Poster	Bioinformatics Applications in Cancer Biology 1	4/17/23	9:00 AM	Section 32	28
2060	The exploratory analysis of dysregulated transcription factor FOXC1 in pan-cancer	Suhn	Rhie	Poster	Bioinformatics Applications in Cancer Biology 1	4/17/23	9:00 AM	Section 32	29
2061	Protein network analysis uncovers a poor-survival subtype in multiple myeloma	Anish	Simhal	Poster	Bioinformatics Applications in Cancer Biology 1	4/17/23	9:00 AM	Section 32	30
2065	A comprehensive online system for identifying tumor neoantigens	Chia-Yu	Sung	Poster	New Analysis Tools	4/17/23	9:00 AM	Section 33	1
2066	Visualization and analysis of cancer genomics data using UCSC Xena	Mary	Goldman	Poster	New Analysis Tools	4/17/23	9:00 AM	Section 33	2
2067	Rapid somatic and germline variant detection using the novel G4 sequencing platform and GPU acceleration	Timothy	Looney	Poster	New Analysis Tools	4/17/23	9:00 AM	Section 33	3
2068	MCAP Explore: A self-service data exploration and cohort building tool for oncologists	Rachel	Howard	Poster	New Analysis Tools	4/17/23	9:00 AM	Section 33	4
2069	ScNanoGPS: A robust tool for simultaneous calculation of same-cell genotypes and phenotypes from single cell long read transcriptomes	Cheng-Kai	Shiau	Poster	New Analysis Tools	4/17/23	9:00 AM	Section 33	5
2070	Accelerated somatic mutation calling tool for whole-genome and whole-exome sequencing data from heterogenous tumor samples	Shuangxi	Ji	Poster	New Analysis Tools	4/17/23	9:00 AM	Section 33	6
2071	Detecting somatic DNA copy number differences with DiNAMIC.Duo	Vonn	Walter	Poster	New Analysis Tools	4/17/23	9:00 AM	Section 33	7
2072	Computational modeling of metabolic variations in tumor microenvironment	Tingbo	Guo	Poster	New Analysis Tools	4/17/23	9:00 AM	Section 33	8
2073	Genomics to Notebook (g2nb): Extending the electronic notebook to address the needs of cancer bioinformatics	Michael	Reich	Poster	New Analysis Tools	4/17/23	9:00 AM	Section 33	9
2074	Genome Integrity assessment and verification by optical genome mapping for cell manufacturing/bioprocessing applications	Alex	Hastie	Poster	New Analysis Tools	4/17/23	9:00 AM	Section 33	10
2075	Highly customizable multi-sample single cell RNA-Seq pipeline on the CGC	Zelia	Worman	Poster	New Analysis Tools	4/17/23	9:00 AM	Section 33	11
2076	Novel framework for systematically detecting alternative transcript initiation by integrating ATAC-seq and RNA-seq	Hyo Young	Choi	Poster	New Analysis Tools	4/17/23	9:00 AM	Section 33	12
2077	Spatial analyses methods for visualization and interrogation of tumor immune micro-environment using multiplexed images	Vidhya	Kewale	Poster	New Analysis Tools	4/17/23	9:00 AM	Section 33	13
2078	VALIS: Virtual Alignment of pathoLogY Image Series for multi-gigapixel whole slide images	Chandler	Gatenbee	Poster	New Analysis Tools	4/17/23	9:00 AM	Section 33	14
2080	TimiGP: Dissect the tumor immune microenvironment and its association with survival and immunotherapy response	Chenyang	Li	Poster	New Analysis Tools	4/17/23	9:00 AM	Section 33	16

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
2081	Nano2NGS: A framework for converting nanopore sequencing data to NGS-like sequencing data for data analysis	Jidong	Lang	Poster	New Analysis Tools	4/17/23	9:00 AM	Section 33	17
2082	DNAfusion: An R/Bioconductor package for increased sensitivity of detecting EML4-ALK gene fusions in liquid biopsies from cancer patients	Christoffer	Maansson	Poster	New Analysis Tools	4/17/23	9:00 AM	Section 33	18
2083	Solving the problem of spatial informatics: Harnessing the power of the cloud and enabling the integration of open source tools for spatial 'omics analytics	Jason	Reeves	Poster	New Analysis Tools	4/17/23	9:00 AM	Section 33	19
2085	Structural principles of kinase-selectivity drug design	Mingzhen	Zhang	Poster	New Analysis Tools	4/17/23	9:00 AM	Section 33	21
2086	ISCVAM, an Interactive Single Cell Visual Analytics for Multiomics, accelerates the identification of novel rare cell populations	Thanh	Nguyen	Poster	New Analysis Tools	4/17/23	9:00 AM	Section 33	22
2087	Sherlock-Genome: a R shiny app for genomic analysis and visualization	Alyssa	Klein	Poster	New Analysis Tools	4/17/23	9:00 AM	Section 33	23
2088	gCNV-Seeker: A comprehensive germline CNV calling pipeline based on whole genome sequencing data	Jian	Sang	Poster	New Analysis Tools	4/17/23	9:00 AM	Section 33	24
2089	Vanishing deviance problem in high-dimensional penalized Cox regression	Sijie	Yao	Poster	New Analysis Tools	4/17/23	9:00 AM	Section 33	25
2090	Comprehensive interrogation of gene lists from genome-scale cancer screens with oncoEnrichR	Sigve	Nakken	Poster	New Analysis Tools	4/17/23	9:00 AM	Section 33	26
2091	Open-source single-cell spatial image analysis pipeline for ten-plex immunofluorescence of histological prostate cancer tissue sections	Jenni	Säilä	Poster	New Analysis Tools	4/17/23	9:00 AM	Section 33	27
2092	Consensus analysis of associated target-biomarker pairs in cancers	Sukjoon	Yoon	Poster	New Analysis Tools	4/17/23	9:00 AM	Section 33	28
2093	Introducing InMoose, an integrated open source Python package for multi-omic analyses	Akpéli	Nordor	Poster	New Analysis Tools	4/17/23	9:00 AM	Section 33	29
2094	A user-friendly R Shiny app for predicting drug response of cancer using deep learning	Li-Ju	Wang	Poster	New Analysis Tools	4/17/23	9:00 AM	Section 33	30
2098	Molecular based blood screening assay for metastatic adenoid cystic carcinoma	Acadia	Moeyersoms	Poster	Biomarkers for Elucidation of Tumor Biology and Metastasis	4/17/23	9:00 AM	Section 38	1
2100	Genomic profiles and immune cell infiltration landscapes for lymph node metastasis in T1 lung adenocarcinoma	Fang	Wu	Poster	Biomarkers for Elucidation of Tumor Biology and Metastasis	4/17/23	9:00 AM	Section 38	3
2101	Cancer-associated fibroblast activation predicts progression, metastasis, and prognosis of cutaneous squamous cell carcinoma	Veli-Matti	Kähäri	Poster	Biomarkers for Elucidation of Tumor Biology and Metastasis	4/17/23	9:00 AM	Section 38	4
2102	Metastatic-initiating signature-enriched subpopulation identified from single-cell transcriptomic sequencing of multi-timepoint esophageal squamous cell carcinoma pulmonary metastatic mice model	Ching Ngar	Wong	Poster	Biomarkers for Elucidation of Tumor Biology and Metastasis	4/17/23	9:00 AM	Section 38	5

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
2103	Immunophenotyping of extracellular vesicles isolated from lymphatic exudate identifies CD24 as a marker for lymph node metastases in oral cavity squamous cell carcinoma	Xinyu	Qu	Poster	Biomarkers for Elucidation of Tumor Biology and Metastasis	4/17/23	9:00 AM	Section 38	6
2105	Implications of metastatic stage at presentation in docetaxel naïve metastatic castrate resistant prostate cancer	Shawn	Malone	Poster	Biomarkers for Elucidation of Tumor Biology and Metastasis	4/17/23	9:00 AM	Section 38	8
2106	Importance of alveolar epithelial cell type 2 populations in non-small cell lung cancer progression from localized to metastatic disease	Kanve Nagaraj	Suvilesh	Poster	Biomarkers for Elucidation of Tumor Biology and Metastasis	4/17/23	9:00 AM	Section 38	9
2107	Development a customized panel with clinical application potential for transcriptome analyses in selected cancer types using FFPE specimens	Vittorio	D'Urso	Poster	Biomarkers for Elucidation of Tumor Biology and Metastasis	4/17/23	9:00 AM	Section 38	10
2108	High prevalence of immune exclusion in cancer as determined by pathologist assessment and image analysis	Laura	Dillon	Poster	Biomarkers for Elucidation of Tumor Biology and Metastasis	4/17/23	9:00 AM	Section 38	11
2109	Analytical characterization of a multiplex panel measuring 45 cytokines by proximity extension assay in plasma from subjects with NSCLC	Nicholas	Dupuis	Poster	Biomarkers for Elucidation of Tumor Biology and Metastasis	4/17/23	9:00 AM	Section 38	12
2110	Reprogramming of DNA methylation in NAFLD progression	Hanyong	Go	Poster	Biomarkers for Elucidation of Tumor Biology and Metastasis	4/17/23	9:00 AM	Section 38	13
2111	Identification of molecular markers of pseudomyxoma peritonei using integrative analysis of bulk and single cell RNA-seq data	Seong-Hwan	Park	Poster	Biomarkers for Elucidation of Tumor Biology and Metastasis	4/17/23	9:00 AM	Section 38	14
2112	Reporting recommendations for translational cancer genomic studies	Raffaella	Casolino	Poster	Biomarkers for Elucidation of Tumor Biology and Metastasis	4/17/23	9:00 AM	Section 38	15
2113	The age-dependent intratissue accumulation of cholesterol, resulting in reduced squalene epoxidase, is associated with a high colorectal cancer risk population.	Soo Young	Jun	Poster	Biomarkers for Elucidation of Tumor Biology and Metastasis	4/17/23	9:00 AM	Section 38	16
2114	Salivary glands shedding RNA into saliva: Challenges and opportunities	Laura	Palmieri	Poster	Biomarkers for Elucidation of Tumor Biology and Metastasis	4/17/23	9:00 AM	Section 38	17
2115	Zero-waste molecular diagnostics from biopsy needle wash water	Jack	Wadden	Poster	Biomarkers for Elucidation of Tumor Biology and Metastasis	4/17/23	9:00 AM	Section 38	18
2116	Phosphorylated extracellular signal-regulated kinase (pERK) activation in T effector cells as a target engagement biomarker for the DGKζ inhibitor BAY2965501 in clinical trials	Nicole	Schubert	Poster	Biomarkers for Elucidation of Tumor Biology and Metastasis	4/17/23	9:00 AM	Section 38	19
2117	Changes of the DNA methylation status in multiple myeloma patients experiencing chemotherapy induced peripheral neuropathy	Umamaheswari	Natarajan	Poster	Biomarkers for Elucidation of Tumor Biology and Metastasis	4/17/23	9:00 AM	Section 38	20
2118	Development of RNAscope multiplex-based assay for exploratory pharmacodynamic biomarkers assessment in breast cancer	Shikha	Saini	Poster	Biomarkers for Elucidation of Tumor Biology and Metastasis	4/17/23	9:00 AM	Section 38	21

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
	patients from Phase I clinical trial of ORM-5029, a potent GSPT1 degrader								
2119	Intravenous vitamin C therapy for cisplatin ineligible bladder cancer patients (CI-MIBC): Early investigation into potential pharmacodynamic biomarkers	Benjamin	Woolbright	Poster	Biomarkers for Elucidation of Tumor Biology and Metastasis	4/17/23	9:00 AM	Section 38	22
2120	Exploring the genomic landscape of colorectal cancer for enabling clinical genomics informed and real-world data based clinical development	Zheng	Feng	Poster	Biomarkers for Elucidation of Tumor Biology and Metastasis	4/17/23	9:00 AM	Section 38	23
2121	Saliva TCR repertoire as a tool for head and neck cancer immunophenotype monitoring	Dieila	De Lima	Poster	Biomarkers for Elucidation of Tumor Biology and Metastasis	4/17/23	9:00 AM	Section 38	24
2122	The dual BRM/BRG1 (SMARCA2/4) inhibitor FHD-286 induces differentiation in preclinical models of AML	Mike	Collins	Poster	Biomarkers for Elucidation of Tumor Biology and Metastasis	4/17/23	9:00 AM	Section 38	25
2123	Glycine decarboxylase regulates renal carcinoma progression via interferon stimulated gene factor 3-mediated pathway	Jin Young	Kim	Poster	Biomarkers for Elucidation of Tumor Biology and Metastasis	4/17/23	9:00 AM	Section 38	26
2127	TERT C228T and KDM6A alterations are potential predictive biomarkers in non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guérin instillation	Qi-Dong	Xia	Poster	Biomarkers of Therapeutic Benefit 2	4/17/23	9:00 AM	Section 39	1
2128	Genomic alterations in DNA mismatch repair (dMMR)	Vijaykumar	Holla	Poster	Biomarkers of Therapeutic Benefit 2	4/17/23	9:00 AM	Section 39	2
2129	Predictive response biomarkers from Phase I clinical trial of a SIRPalpha inhibitor BI765063, stand-alone and in combination with ezabenlimab, a PD1 inhibitor, in patients with advanced solid tumors	Stéphane	Champiat	Poster	Biomarkers of Therapeutic Benefit 2	4/17/23	9:00 AM	Section 39	3
2130	Lipid and immune-based biomarkers associated with clinical response to TPST-1120: A small molecule antagonist of peroxisome-proliferator activated receptor-alpha	Nathan	Standifer	Poster	Biomarkers of Therapeutic Benefit 2	4/17/23	9:00 AM	Section 39	4
2131	Immunoaffinity isolation of EpCAM expressing exosomes utilizing high throughput microfluidic chip with IEDDA chemistry (EpCAM-TCOOncoBean Chip)	Nna-Emeka	Onukwugha	Poster	Biomarkers of Therapeutic Benefit 2	4/17/23	9:00 AM	Section 39	5
2132	Tumor heterogeneity of CCNE1 copy number assessed by fluorescence in situ hybridization (FISH) in ovarian and uterine cancers and correlation with cyclin E protein expression	Adam	Petrone	Poster	Biomarkers of Therapeutic Benefit 2	4/17/23	9:00 AM	Section 39	6
2133	Next-generation sequencing-based MET focal amplification can predict treatment efficacy of MET inhibitors in lung cancer	Yuchen	Han	Poster	Biomarkers of Therapeutic Benefit 2	4/17/23	9:00 AM	Section 39	7
2134	Microsatellite instability status and high risk features in decision making for adjuvant chemotherapy in stage 2 colon cancer	Sung Uk	Bae	Poster	Biomarkers of Therapeutic Benefit 2	4/17/23	9:00 AM	Section 39	8

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
2135	Multi-omics characterization of chemo-refractory HGSC patients	Taru	Muranen	Poster	Biomarkers of Therapeutic Benefit 2	4/17/23	9:00 AM	Section 39	9
2136	Designing an immunofluorescence-based biomarker assay for detecting Rb and Phospho-Rb expression in HR+/HER2-breast cancer	Mantasha	Tabassum	Poster	Biomarkers of Therapeutic Benefit 2	4/17/23	9:00 AM	Section 39	10
2137	Clinical utility of circulating tumor DNA in patients with advanced KRAS G12C-mutated NSCLC treated with sotorasib	Sophie	Ernst	Poster	Biomarkers of Therapeutic Benefit 2	4/17/23	9:00 AM	Section 39	11
2138	Immune features of irAEs and aPD1 response in urothelial cancer patients of the RADIOHEAD study, as detected in blood by mass cytometry immune profiling	Johanna	Sweere	Poster	Biomarkers of Therapeutic Benefit 2	4/17/23	9:00 AM	Section 39	12
2140	DNA damage response in circulating tumor cells shows predictive value for metastatic breast cancer patients receiving CDK4/6 inhibitors	Corinna	Keup	Poster	Biomarkers of Therapeutic Benefit 2	4/17/23	9:00 AM	Section 39	14
2141	Claudin 18.2 (CLDN18.2) expression prevalence, prognostication and clinical variables in gastric and gastroesophageal junction adenocarcinoma patient samples	Matheus	Sewastjanow	Poster	Biomarkers of Therapeutic Benefit 2	4/17/23	9:00 AM	Section 39	15
2142	Immune determinants of CAR-T expansion in solid tumor patients receiving GD2 CAR-T cell therapy	Tara	Murty	Poster	Biomarkers of Therapeutic Benefit 2	4/17/23	9:00 AM	Section 39	16
2143	Cancer of unknown Primary (CUP): Beyond the identification of the site of origin by an integrative genomic approach	Majd	Al Assaad	Poster	Biomarkers of Therapeutic Benefit 2	4/17/23	9:00 AM	Section 39	17
2144	Proteomic study reveals predictive biomarkers of immune-related adverse events in melanoma	Muhammad Zaki	Fadlullah Wilmot	Poster	Biomarkers of Therapeutic Benefit 2	4/17/23	9:00 AM	Section 39	18
2145	High SLFN11 expression correlates with sensitivity to lurbinectedin in small cell lung cancer (SCLC) models	Aparna	Gupta	Poster	Biomarkers of Therapeutic Benefit 2	4/17/23	9:00 AM	Section 39	19
2146	LDH as a surrogate marker for both pCR and survival in breast cancer patient	In Hee	Lee	Poster	Biomarkers of Therapeutic Benefit 2	4/17/23	9:00 AM	Section 39	20
2147	Decoding the natural biology of triple-negative breast cancer and response to chemotherapy by single-cell transcriptomics	Yun	Yan	Poster	Biomarkers of Therapeutic Benefit 2	4/17/23	9:00 AM	Section 39	21
2148	Robust detection of somatic genetic alterations in pancreatic cancer ascites	Rajya	Kappagantula	Poster	Biomarkers of Therapeutic Benefit 2	4/17/23	9:00 AM	Section 39	22
2149	A whole genome sequencing classifier of homologous recombination deficiency	Kevin	Hadi	Poster	Biomarkers of Therapeutic Benefit 2	4/17/23	9:00 AM	Section 39	23
2150	CLDN18/ARHGAP26 fusions in gastric cancers	Deborah	Josefson	Poster	Biomarkers of Therapeutic Benefit 2	4/17/23	9:00 AM	Section 39	24
2151	Identification of transcript adenosine fingerprint to enrich for A2AR and PD-1 inhibition responders	Gregory	Vladimer	Poster	Biomarkers of Therapeutic Benefit 2	4/17/23	9:00 AM	Section 39	25

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
2152	Targetable oncogenic fusions and other alterations in bone and soft-tissue tumors assessed by RNA and DNA-based next-generation sequencing in real-world experience	Yi	Ding	Poster	Biomarkers of Therapeutic Benefit 2	4/17/23	9:00 AM	Section 39	26
2153	Cyclin E1 protein overexpression sensitizes ovarian cancer cells to ZN-c3, a novel, selective and oral bioavailable inhibitor of Wee1	Jianhui	Ma	Poster	Biomarkers of Therapeutic Benefit 2	4/17/23	9:00 AM	Section 39	27
2154	Differential expression of the PI3K-Akt signaling pathway pre and post chemotherapy in relation to hormonal profile in African women	Hurette Junie	Chansi Kengni	Poster	Biomarkers of Therapeutic Benefit 2	4/17/23	9:00 AM	Section 39	28
2155	Joint modeling of safety and peripheral mode-of-action (MoA) biomarkers to support RP2D identification in Phase 1 study of SAR444245 (SAR'245) as monotherapy (mono) or combined with pembrolizumab (pembro) in patients with advanced solid tumors	Wenting	Wang	Poster	Biomarkers of Therapeutic Benefit 2	4/17/23	9:00 AM	Section 39	29
2159	A pretreatment blood-based proteomic biomarker for enhanced decision-making in non-small cell lung cancer	Michal	Harel	Poster	Biomarkers of Therapeutic Benefit 3	4/17/23	9:00 AM	Section 40	1
2160	Quantitative proteomics of antibody-drug conjugates and chemotherapy targets in prostate cancer	Sheeno	Thyparambil	Poster	Biomarkers of Therapeutic Benefit 3	4/17/23	9:00 AM	Section 40	2
2161	Quinolinic acid phosphoribosyl transferase (QPRT) is an essential liability of non-small cell lung cancer	Hossein	Kashfi	Poster	Biomarkers of Therapeutic Benefit 3	4/17/23	9:00 AM	Section 40	3
2162	Preliminary analysis of circulating biomarkers of glioblastoma response during chemoradiotherapy	Paulo	Del Valle	Poster	Biomarkers of Therapeutic Benefit 3	4/17/23	9:00 AM	Section 40	4
2163	Circulating H3K27 nucleosomes to monitor lung cancer patients during treatment, a universal biomarker quantifying the molecular residual disease (MRD) in plasma samples	Lea	Payen-Gay	Poster	Biomarkers of Therapeutic Benefit 3	4/17/23	9:00 AM	Section 40	5
2164	Patterns of estrogen receptor expression across 18,500 tumor samples obtained from 149 cancer types	Maximilian	Lennartz	Poster	Biomarkers of Therapeutic Benefit 3	4/17/23	9:00 AM	Section 40	6
2165	Identification and characterization of Karyopherin α 2 (KPNA2), a member of the nucleocytoplasmic transporter family, in lung cancer	Seoree	Kim	Poster	Biomarkers of Therapeutic Benefit 3	4/17/23	9:00 AM	Section 40	7
2166	Analysis of ctDNA next generation sequencing (NGS) for predicting response to amivantamab and lazertinib among patients with EGFR-mutant NSCLC after progression on osimertinib and platinum-based chemotherapy (CHRYSALIS-2 Cohort A)	Rachel	Sanborn	Poster	Biomarkers of Therapeutic Benefit 3	4/17/23	9:00 AM	Section 40	8
2167	Immune-related biomarkers associated with pathologic complete response (pCR) to neoadjuvant cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer undergoing cystectomy	Maria	Ascierto	Poster	Biomarkers of Therapeutic Benefit 3	4/17/23	9:00 AM	Section 40	9

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
2168	Identifying a surrogate biomarker for neuropilin-2 axis in serum of prostate cancer patients	Sarah	Mullen	Poster	Biomarkers of Therapeutic Benefit 3	4/17/23	9:00 AM	Section 40	10
2169	NAD(P)H: quinone oxidoreductase 1 (NQO1)- A viable biomarker in colorectal cancer?	Chaithanya	Ganji	Poster	Biomarkers of Therapeutic Benefit 3	4/17/23	9:00 AM	Section 40	11
2170	Pre-treatment protein landscape in HER2-negative breast cancer treated with carboplatin in a neoadjuvant chemotherapy setting	Maria	Aanesland Dahle	Poster	Biomarkers of Therapeutic Benefit 3	4/17/23	9:00 AM	Section 40	12
2171	A multivariate biomarker predicts sacituzumab govitecan response in solid tumors	Nickolay	Khazanov	Poster	Biomarkers of Therapeutic Benefit 3	4/17/23	9:00 AM	Section 40	13
2172	Tumor IL1RAP levels and reduction in serum biomarkers correlate with response in PDAC patients treated with nadunolimab, an anti-IL1RAP monoclonal antibody, in combination with gemcitabine and nab-paclitaxel	David	Liberg	Poster	Biomarkers of Therapeutic Benefit 3	4/17/23	9:00 AM	Section 40	14
2173	A multi-institutional prospective biomarker study of durvalumab after concurrent chemoradiation therapy in patients with unresectable stage III non-small cell lung cancer (WJOG11518L/SUBMARINE)	Koji	Haratani	Poster	Biomarkers of Therapeutic Benefit 3	4/17/23	9:00 AM	Section 40	15
2174	Evaluation of extracellular vesicles (EVs) as potential predictors of response to immunotherapy (IO) in triple negative early and advanced breast cancer (BC): preliminary evidence from the IRIS project	Alessandra	Gennari	Poster	Biomarkers of Therapeutic Benefit 3	4/17/23	9:00 AM	Section 40	16
2175	Gene signature predicts pathological complete response in triple negative breast cancer patients: NACATRINE trial	Ana	Freitas	Poster	Biomarkers of Therapeutic Benefit 3	4/17/23	9:00 AM	Section 40	17
2176	A cell mass-based platform for characterizing immune cell function and response to checkpoint blockade in primary blood and malignant fluid samples	Robert	Kimmerling	Poster	Biomarkers of Therapeutic Benefit 3	4/17/23	9:00 AM	Section 40	18
2177	Roles of lactate dehydrogenase (LDH) in melanoma: an underestimated prognostic biomarker	Caroline	Robert	Poster	Biomarkers of Therapeutic Benefit 3	4/17/23	9:00 AM	Section 40	19
2178	Circulating tumor DNA (ctDNA) correlates closely with tumor necrosis and relapse-free survival (RFS) in hepatocellular carcinoma (HCC) patients treated with perioperative cemiplimab	Thomas	Marron	Poster	Biomarkers of Therapeutic Benefit 3	4/17/23	9:00 AM	Section 40	20
2179	The role of ATP-binding cassette transporter A5 in colorectal cancer progression	Khuloud	Bajbouj	Poster	Biomarkers of Therapeutic Benefit 3	4/17/23	9:00 AM	Section 40	21
2180	The PD-L1 protein expression in Chinese patients with advanced esophageal cancers: a multi-center retrospective study	Jianming	Ying	Poster	Biomarkers of Therapeutic Benefit 3	4/17/23	9:00 AM	Section 40	22
2181	Treatment-free remission after discontinuation of ALK tyrosine kinase inhibitors (TKIs) in patients with ALK-positive anaplastic large cell lymphoma (ALCL)	Jinyong	Kim	Poster	Biomarkers of Therapeutic Benefit 3	4/17/23	9:00 AM	Section 40	23

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
2182	The evolution of high grade serous ovarian cancer under the pressure of non-cytotoxic and cytotoxic treatment	Farhia	Kabeer	Poster	Biomarkers of Therapeutic Benefit 3	4/17/23	9:00 AM	Section 40	24
2183	Absolute quantification of PD-L1 gene expression in single cell on tissue for accurately predicting response to ICIs	Amandine	Gerstenberg	Poster	Biomarkers of Therapeutic Benefit 3	4/17/23	9:00 AM	Section 40	25
2184	Short Peptides derived from MIEN1 and their analogs exhibit anti-cancer activity in breast and prostate cancer cells	AMIT Kumar	Tripathi	Poster	Biomarkers of Therapeutic Benefit 3	4/17/23	9:00 AM	Section 40	26
2185	Septin isoform expression as a potential biomarker for differential response to microtubule targeted chemotherapy in breast cancer	Jacob	Essif	Poster	Biomarkers of Therapeutic Benefit 3	4/17/23	9:00 AM	Section 40	27
2186	An exploratory analysis of the intestinal microbiome in neoadjuvant chemotherapy for pancreatic cancer	Sherise	Rogers	Poster	Biomarkers of Therapeutic Benefit 3	4/17/23	9:00 AM	Section 40	28
2187	Epigenetic monitoring of gamma delta T-cells	Sven	Olek	Poster	Biomarkers of Therapeutic Benefit 3	4/17/23	9:00 AM	Section 40	29
2191	Detection of actionable lung cancer fusion genes with known and novel partners from highly degraded FFPE material	Bongyong	Lee	Poster	Diagnostic and Prognostic Biomarkers 2	4/17/23	9:00 AM	Section 41	1
2192	Potential of galectin-7 as differentiating biomarker of lung cancer subtypes	Avery	Funkhouser	Poster	Diagnostic and Prognostic Biomarkers 2	4/17/23	9:00 AM	Section 41	2
2194	Performance of a 24-hour turnaround, guideline-complete NSCLC assay, optimized for sparse samples	Kerri	Cabrera	Poster	Diagnostic and Prognostic Biomarkers 2	4/17/23	9:00 AM	Section 41	4
2196	Serum Filamin A is a prognostic biomarker for screening benign prostatic hyperplasia vs prostate cancer in Caucasian and African American men	Nischal Mahaveer	Chand	Poster	Diagnostic and Prognostic Biomarkers 2	4/17/23	9:00 AM	Section 41	6
2197	Comparative genomic profiling and disease monitoring in unresectable gastric and colon cancer	Haoran	Tang	Poster	Diagnostic and Prognostic Biomarkers 2	4/17/23	9:00 AM	Section 41	7
2199	Novel urinary marker for diagnosis and prognosis of neuroblastoma	Akinari	Hinoki	Poster	Diagnostic and Prognostic Biomarkers 2	4/17/23	9:00 AM	Section 41	9
2200	Transcriptomic profiling identifies an amino acid metabolism-related prognostic gene signature in lung adenocarcinoma patients	Huihui	Xiang	Poster	Diagnostic and Prognostic Biomarkers 2	4/17/23	9:00 AM	Section 41	10
2201	Effect of opioid and cannabinoid receptors gene expression on survival of patients with colorectal cancer	Monika	Vidlarova	Poster	Diagnostic and Prognostic Biomarkers 2	4/17/23	9:00 AM	Section 41	11
2202	Role of FadA secreting Fusobacterium nucleatum in initiation and progression of colorectal cancer	Angela	Huang	Poster	Diagnostic and Prognostic Biomarkers 2	4/17/23	9:00 AM	Section 41	12
2203	Circulating rare events inform disease progression in patients with upper tract urothelial carcinoma undergoing surgery	Salmaan	Sayeed	Poster	Diagnostic and Prognostic Biomarkers 2	4/17/23	9:00 AM	Section 41	13
2204	Predicting survival outcomes in patients with acute myeloid leukemia: medium-sized versus large next-generation sequencing panels	Yonghong	Li	Poster	Diagnostic and Prognostic Biomarkers 2	4/17/23	9:00 AM	Section 41	14

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
2205	KRTAP 2-3 is a novel potential biomarker of cells in the polyan euploid cancer cell (PACC) state to predict cancer recurrence	Sabrina	Mendez	Poster	Diagnostic and Prognostic Biomarkers 2	4/17/23	9:00 AM	Section 41	15
2207	The prognostic role of $\gamma\delta$ T cells in colorectal cancer and the establishment of related nomogram for predicting overall survival of the patients	Rulan	Ma	Poster	Diagnostic and Prognostic Biomarkers 2	4/17/23	9:00 AM	Section 41	17
2208	Rare neoplastic subpopulation predicts relapse in nasopharyngeal carcinoma	Ka Chun	Wu	Poster	Diagnostic and Prognostic Biomarkers 2	4/17/23	9:00 AM	Section 41	18
2209	A proteomic-based prognostic signature of pancreatic adenocarcinoma	Qing	Zhong	Poster	Diagnostic and Prognostic Biomarkers 2	4/17/23	9:00 AM	Section 41	19
2210	Importance of fibrillar collagen quality, not quantity, for patients with solid tumors	Neel	Nissen	Poster	Diagnostic and Prognostic Biomarkers 2	4/17/23	9:00 AM	Section 41	20
2211	The prognostic role of tertiary lymphoid structure (TLS) in locally advanced esophageal squamous cell carcinoma (ESCC)	Ta-Chen	Huang	Poster	Diagnostic and Prognostic Biomarkers 2	4/17/23	9:00 AM	Section 41	21
2212	Prevalence of PGP9.5 expression in human cancers: A TMA study of 14,900 tumors from 148 tumor types	Maximilian	Lennartz	Poster	Diagnostic and Prognostic Biomarkers 2	4/17/23	9:00 AM	Section 41	22
2213	Longitudinal tracking of circulating rare events in the liquid biopsy of stage III-IV NSCLC patients during treatment	Lily	Bai	Poster	Diagnostic and Prognostic Biomarkers 2	4/17/23	9:00 AM	Section 41	23
2214	NEDD9 as a prognostic biomarker and its immune landscape in lung adenocarcinoma	Leen	Al-Kraimeen	Poster	Diagnostic and Prognostic Biomarkers 2	4/17/23	9:00 AM	Section 41	24
2215	Periostin plays a crucial role in the recurrence of head and neck squamous cell carcinoma	Jung Je	Park	Poster	Diagnostic and Prognostic Biomarkers 2	4/17/23	9:00 AM	Section 41	25
2216	Construction of a prognostic 6-gene signature for breast cancer based on multi-omics data	Zeyu	Xing	Poster	Diagnostic and Prognostic Biomarkers 2	4/17/23	9:00 AM	Section 41	26
2217	Novel risk stratification utilizing NanoString for HPV+ head and neck cancer patients	Sulgi	kim	Poster	Diagnostic and Prognostic Biomarkers 2	4/17/23	9:00 AM	Section 41	27
2218	The molecular mechanism underlying KRAS regulation on STK31 expression in pancreatic ductal adenocarcinoma	Yuting	Liu	Poster	Diagnostic and Prognostic Biomarkers 2	4/17/23	9:00 AM	Section 41	28
2219	Urine cell-free DNA multi-omics to detect molecular residual disease and predict survival in bladder cancer patients	Pradeep	Chauhan	Poster	Diagnostic and Prognostic Biomarkers 2	4/17/23	9:00 AM	Section 41	29
2220	Dynamic development of ESR1 mutations in circulating tumor DNA (ctDNA) is associated with prognosis of patients with metastatic breast cancer (MBC)	Qiang	Zhang	Poster	Diagnostic and Prognostic Biomarkers 2	4/17/23	9:00 AM	Section 41	30
2224	Applying optical genome mapping to detect genomic biomarkers and use for residual disease monitoring in hematologic malignancies	Alex	Chitsazan	Poster	Genomic and Epigenomic Profiles for Response Prediction	4/17/23	9:00 AM	Section 42	1

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
2225	Describing the molecular landscape of extramedullary multiple myeloma using whole genome sequencing: Insights into pathology and therapeutic targets	Nicholas	Bingham	Poster	Genomic and Epigenomic Profiles for Response Prediction	4/17/23	9:00 AM	Section 42	2
2226	Modeling the role of Tet-deficiency and restoration in Bcl2-driven B cell lymphoma progression	Minh	Lam	Poster	Genomic and Epigenomic Profiles for Response Prediction	4/17/23	9:00 AM	Section 42	3
2227	Streamlined workflow for analyzing and reporting hematological malignancies in Bionano VIATM software	Benjamin	Clifford	Poster	Genomic and Epigenomic Profiles for Response Prediction	4/17/23	9:00 AM	Section 42	4
2228	Genome-wide mapping of SMYD3 in HPV-negative head and neck squamous cell carcinoma	Abbas	Saeed	Poster	Genomic and Epigenomic Profiles for Response Prediction	4/17/23	9:00 AM	Section 42	5
2229	Cell state transitions shape the intratumoral composition of small cell lung carcinoma	Priyanka	Gopal	Poster	Genomic and Epigenomic Profiles for Response Prediction	4/17/23	9:00 AM	Section 42	6
2230	Entinostat potentiates chemotherapeutic efficacy in small cell lung cancer cells	Anna	Schwendenwein	Poster	Genomic and Epigenomic Profiles for Response Prediction	4/17/23	9:00 AM	Section 42	7
2231	Epigenomic profiling uncovers distinct enrichment patterns of PBX1 super-enhancer among lung adenocarcinoma	Douglas	Mansell	Poster	Genomic and Epigenomic Profiles for Response Prediction	4/17/23	9:00 AM	Section 42	8
2232	The identification of novel autophagy flux-related molecules closely linked to the acquired resistance to EGFR TKIs in NSCLC patients harboring EGFR mutations	Jin-Hyoung	Kang	Poster	Genomic and Epigenomic Profiles for Response Prediction	4/17/23	9:00 AM	Section 42	9
2233	Clinical validation of a methylation array-based diagnostic assay for improved classification of CNS tumors	Melissa	Soucy	Poster	Genomic and Epigenomic Profiles for Response Prediction	4/17/23	9:00 AM	Section 42	10
2234	m6A RNA methylation as a therapeutic target in high grade glioma	Stuart	Smith	Poster	Genomic and Epigenomic Profiles for Response Prediction	4/17/23	9:00 AM	Section 42	11
2235	A treatment for glioblastoma with a novel epigenetic inhibitor and identification of its target.	Tokunaga	Kota	Poster	Genomic and Epigenomic Profiles for Response Prediction	4/17/23	9:00 AM	Section 42	12
2236	The role of CPI-613 in cholangiocarcinoma treatment	Fulei	Wuchu	Poster	Genomic and Epigenomic Profiles for Response Prediction	4/17/23	9:00 AM	Section 42	13
2237	Inhibition of HSF1 demonstrates therapeutic efficacy in preclinical models of cholangiocarcinoma	Danielle	Carlson	Poster	Genomic and Epigenomic Profiles for Response Prediction	4/17/23	9:00 AM	Section 42	14
2238	RAS activity-related features of metastatic pancreatic cancer	Shuichi	Mitsunaga	Poster	Genomic and Epigenomic Profiles for Response Prediction	4/17/23	9:00 AM	Section 42	15
2239	Investigation of the molecular biological significance of YAP/TAZ expression in PNEN	Yuta	Shiraishi	Poster	Genomic and Epigenomic Profiles for Response Prediction	4/17/23	9:00 AM	Section 42	16
2240	CK19 based molecular classification defined three distinct hepatocellular carcinoma subtypes with different cell lineage features and therapeutic vulnerabilities	Qiuyan	Wang	Poster	Genomic and Epigenomic Profiles for Response Prediction	4/17/23	9:00 AM	Section 42	17
2241	Transcriptomic analysis of tetraspanins in colorectal cancer	Thanawat	Suwatthanarak	Poster	Genomic and Epigenomic Profiles for Response Prediction	4/17/23	9:00 AM	Section 42	18

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
2242	KRAS mutations suppress the tumor immune microenvironment in colorectal cancer	Pariyada	Tanjak	Poster	Genomic and Epigenomic Profiles for Response Prediction	4/17/23	9:00 AM	Section 42	19
2243	Cyproheptadine exhibits anti-tumor activity by reversing the epigenetic silencing of IRF6 in urothelial carcinoma	Michael	Chan	Poster	Genomic and Epigenomic Profiles for Response Prediction	4/17/23	9:00 AM	Section 42	20
2244	Association of chromosomal instability with poor prognosis in metastatic hormone sensitive and castrate-resistant prostate cancer	Ryan	Rebernick	Poster	Genomic and Epigenomic Profiles for Response Prediction	4/17/23	9:00 AM	Section 42	21
2245	The transcriptomic profile of retroperitoneal primary well differentiated liposarcoma (WDLPS) and well differentiated (WD)/dedifferentiated (DD) components of DD liposarcoma (DDLPS) reveals the progression from WDLPS to DDLPS	Sandro	Pasquali	Poster	Genomic and Epigenomic Profiles for Response Prediction	4/17/23	9:00 AM	Section 42	22
2246	Prevalence of mycobacterium tuberculosis among PAP smear samples of cervical cancer suspects	Wondimu Ashagre	Awoke	Poster	Genomic and Epigenomic Profiles for Response Prediction	4/17/23	9:00 AM	Section 42	23
2247	Evaluation of multidrug resistant genes among breast cancer patients in Ghana	Gloria	Agyekum Boaitey	Poster	Genomic and Epigenomic Profiles for Response Prediction	4/17/23	9:00 AM	Section 42	24
2248	Activity of targeted agents in PIK3R1 mutated patient-derived xenografts	Abde	Abukhdeir	Poster	Genomic and Epigenomic Profiles for Response Prediction	4/17/23	9:00 AM	Section 42	25
2249	Development and validation of a pharmacodynamic (PD) assay for TOS-358, the first covalent inhibitor of PI3K α in clinical development	John	MacDougall	Poster	Genomic and Epigenomic Profiles for Response Prediction	4/17/23	9:00 AM	Section 42	26
2250	Immuno-oncology study to profile the tumor microenvironment in multiple human cancers using high-plex imaging mass cytometry	Thomas	Pfister	Poster	Genomic and Epigenomic Profiles for Response Prediction	4/17/23	9:00 AM	Section 42	27
2254	Immunotopography characterization after neoadjuvant therapy in the pancreatic cancer microenvironment	Pamela	Pulimeno	Poster	Immune Response to Therapies	4/17/23	9:00 AM	Section 43	1
2255	Patient pharmacodynamic biomarker and pk evaluation results from an ongoing phase I dose-escalation study of q702, an axl, mer and csf1r kinase inhibitor in patients with advanced solid tumors	Bae Jung	Choi	Poster	Immune Response to Therapies	4/17/23	9:00 AM	Section 43	2
2256	Cancer stem cells and exosomal PD-L1 suppress anti-tumor B cells	Ying	Xin	Poster	Immune Response to Therapies	4/17/23	9:00 AM	Section 43	3
2257	Activation and clonotypic expansion of the native T cell repertoire identifies durable response to CD19 CAR T cell therapy	Dimitra	Karagkouni	Poster	Immune Response to Therapies	4/17/23	9:00 AM	Section 43	4
2258	Starvation response to chemotherapy induces MHC class 1 upregulation in cancer cells	Reshma	Gurung	Poster	Immune Response to Therapies	4/17/23	9:00 AM	Section 43	5
2259	Novel metallotherapeutic BOLD-100 induces circulating cytokine changes when administered in combination with FOLFOX in advanced gastrointestinal cancer patients	Mark	Bazett	Poster	Immune Response to Therapies	4/17/23	9:00 AM	Section 43	6

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
2260	Characterizing tumor stromal evolution after neoadjuvant anti-PD-1 therapy in Merkel cell carcinoma	Joel	Sunshine	Poster	Immune Response to Therapies	4/17/23	9:00 AM	Section 43	7
2261	Deciphering cross-resistance mechanisms associated to targeted therapies and immunotherapy in BRAFmutmelanoma: The role of tumor-associated macrophages and galectin-1	Florencia	Veigas	Poster	Immune Response to Therapies	4/17/23	9:00 AM	Section 43	8
2262	Spatial architecture and cellular interactions of tumor immune microenvironment to discover biomarkers and predict immune checkpoint inhibitor response in gastric cancer	Sunho	Park	Poster	Immune Response to Therapies	4/17/23	9:00 AM	Section 43	9
2263	Complete remission of a patient with Merkel cell carcinoma treated with durvalumab	Saad	Sabbagh	Poster	Immune Response to Therapies	4/17/23	9:00 AM	Section 43	10
2264	Role of first-line immune checkpoint inhibitors monotherapy for oncogene-driven non-small cell lung cancer	Ying-Yin	Chen	Poster	Immune Response to Therapies	4/17/23	9:00 AM	Section 43	11
2265	STING pathway activation by ATR inhibition potentiates the antitumor immune response to anti-PD-L1 antibody in small cell lung cancer	Triparna	Sen	Poster	Immune Response to Therapies	4/17/23	9:00 AM	Section 43	12
2266	Tumor associated neutrophils (TAN) may produce neutrophil extracellular traps (NETs) which can suppress the infiltration of activated T cells in tumor tissue.	Kohei	Tamura	Poster	Immune Response to Therapies	4/17/23	9:00 AM	Section 43	13
2267	HLA-DR-restricted CD4 T cell responses to KRAS G12C in healthy donors linked to bacterial mimotope: lessons for KRAS neoantigen vaccines in cancer patients	Christine	Palmer	Poster	Immune Response to Therapies	4/17/23	9:00 AM	Section 43	14
2268	Single cell RNA sequencing defines dynamic immune cell subsets in serial colon and peripheral blood samples in a patient with checkpoint inhibitor-induced colitis	Jacqueline	Mann	Poster	Immune Response to Therapies	4/17/23	9:00 AM	Section 43	15
2269	Bexmarilimab induces B-cell activation and autoantibody production	Elisa	Vuorinen	Poster	Immune Response to Therapies	4/17/23	9:00 AM	Section 43	16
2270	Combination of CXCR4 antagonist and anti-PD1 therapy results in significant mobilization and increased infiltration of myeloid cells into the metastatic liver microenvironment of PDAC	Sarah	Shin	Poster	Immune Response to Therapies	4/17/23	9:00 AM	Section 43	17
2271	Characteristics of peripheral blood T cell receptor repertoire and correlation with response to chemotherapy in patients with breast cancer	Chun-Yu	Liu	Poster	Immune Response to Therapies	4/17/23	9:00 AM	Section 43	18
2272	Targeting the chaperone Hsp90 to activate the immune system and eradicate the triple negative breast cancer	Ahmed	Chadli	Poster	Immune Response to Therapies	4/17/23	9:00 AM	Section 43	19
2273	Soluble TNF α blockade improves effectiveness of trastuzumab deruxtecan and boosts antitumor potential of macrophages in a HER2+ tumor model	Sofia	Bruni	Poster	Immune Response to Therapies	4/17/23	9:00 AM	Section 43	20

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
2274	An immune-educating therapy, Maveropepimut-S, elicits a diverse and active anti-tumor T cell response in patients with advanced recurrent ovarian cancer	Kelcey	Patterson	Poster	Immune Response to Therapies	4/17/23	9:00 AM	Section 43	21
2275	Preclinical testing of therapeutic biologics using patient-derived 3D spheroids	Kathryn	Appleton	Poster	Immune Response to Therapies	4/17/23	9:00 AM	Section 43	22
2276	Spatiotemporal analysis of metastatic melanoma reveals mechanisms of resistance to immune checkpoint blockade	Gao	Zhang	Poster	Immune Response to Therapies	4/17/23	9:00 AM	Section 43	23
2277	Assessment of the response to STING agonist treatment and potentiation by manganese in glioblastoma cells and the tumor microenvironment	Andrea	Schmidt	Poster	Immune Response to Therapies	4/17/23	9:00 AM	Section 43	24
2278	Dissecting immuno-genomic pathways of response and resistance to immunotherapy in metastatic urothelial carcinoma in a real-world cohort	Nikhil	Pramod	Poster	Immune Response to Therapies	4/17/23	9:00 AM	Section 43	25
2279	Tumor treating fields induce immune modulation in non-small cell lung cancer	Suhe	Wang	Poster	Immune Response to Therapies	4/17/23	9:00 AM	Section 43	26
2280	BG34-200 immunotherapy of advanced melanoma	Veronique	Roche	Poster	Immune Response to Therapies	4/17/23	9:00 AM	Section 43	27
2281	Dual immune checkpoint blockade induces analogous alterations in the dysfunctional CD8+ T cell and activated Treg compartment	John	Haanen	Poster	Immune Response to Therapies	4/17/23	9:00 AM	Section 43	28
2282	Immune modulation of the T cell repertoire in mice following immunotherapy and chemotherapy combination treatments	Yuval	Elhanati	Poster	Immune Response to Therapies	4/17/23	9:00 AM	Section 43	29
2283	An immunosuppressive ectoenzyme-expressing T cell population is associated with non-responsiveness to immune checkpoint blockade in metastatic melanoma patients	Ankita	Mitra	Poster	Immune Response to Therapies	4/17/23	9:00 AM	Section 43	30
2288	Longitudinal measurement of HPV copy number in cell-free DNA predicts progression-free survival in HPV-positive oropharyngeal cancer patients	Martyna	Adamowicz	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 2	4/17/23	9:00 AM	Section 44	2
2289	Predicting tumor somatic versus clonal hematopoiesis origin for short variants in liquid assay	Chang	Xu	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 2	4/17/23	9:00 AM	Section 44	3
2290	DNA methylation markers for sensitive detection of circulating tumor DNA in plasma from patients with gastroesophageal adenocarcinomas	Cecilie Riis	Iden	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 2	4/17/23	9:00 AM	Section 44	4
2291	Dynamics of genomic instability of circulating tumor DNA in pancreatic cancer patients	SooBeen	Heo	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 2	4/17/23	9:00 AM	Section 44	5
2292	Novel method for the detection and evaluation of disease biomarkers on white blood cells from liquid biopsies	Erin	Bayer	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 2	4/17/23	9:00 AM	Section 44	6

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
2293	Tumor-informed fixed and patient-specific panels for minimal residual disease (MRD) detection in early-stage NSCLC:a head-to-head comparison	Pengpeng	Zhang	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 2	4/17/23	9:00 AM	Section 44	7
2294	The development of 3D deformable microfilter with a DNA aptamer for detecting circulating tumor cell	Masaaki	Iwatsuki	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 2	4/17/23	9:00 AM	Section 44	8
2295	Utility of circulating tumor DNA in lung cancer clinical research and practice: systematic review and meta-analysis	Solange	Peters	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 2	4/17/23	9:00 AM	Section 44	9
2296	Engineering and evaluation of a novel circulating tumor cell capture assay for urothelial carcinoma	Qinhan	Zhou	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 2	4/17/23	9:00 AM	Section 44	10
2297	Sensitive mutation detection by simultaneous targeted sequencing of the Watson and Crick strands	Weiwei	Bian	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 2	4/17/23	9:00 AM	Section 44	11
2298	Ultra-sensitive tumor-informed ctDNA assay predicts survival in advanced melanoma patients treated with immune checkpoint inhibition	Klaus	Pantel	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 2	4/17/23	9:00 AM	Section 44	12
2299	Misclassification of clonal hematopoietic mutations as tumor-derived confound accurate ctDNA-response assessment in patients with metastatic non-small-cell lung cancer: analyses from the phase 3 MYSTIC trial	Chris	Abbosh	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 2	4/17/23	9:00 AM	Section 44	13
2300	Non-invasive liquid biopsy assay for the detection of ASCL1 expression in CTCs of patients with lung cancer	Luisa	Fernandez	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 2	4/17/23	9:00 AM	Section 44	14
2301	Copy number profiling of circulating CD45+/cytokeratin+ cells in a patient with metastatic breast cancer	Nikki	Higa	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 2	4/17/23	9:00 AM	Section 44	15
2302	Detection of tumor-associated methylation and mutation signatures for early colorectal cancer diagnosis	Pushpinder	Bains	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 2	4/17/23	9:00 AM	Section 44	16
2303	Adverse clinical outcomes and distinct genomic phenotype of BRCA-deficient metastatic castration-resistant prostate cancer (mCRPC)	Heidi	Fettke	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 2	4/17/23	9:00 AM	Section 44	17
2304	Circulating tumor extracellular vesicles to monitor metastatic prostate cancer genomic and transcriptomic evolution	Irene	Casanova-Salas	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 2	4/17/23	9:00 AM	Section 44	18
2305	Ultra-sensitive detection of circulating tumor DNA by whole-genome sequencing of blood samples from locally advanced rectal cancer patients receiving neoadjuvant therapy and enrolled in watch-and-wait strategies for organ preservation	Francisco	Sanchez-Vega	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 2	4/17/23	9:00 AM	Section 44	19
2306	Potential clinical utility of circulating tumor DNA detected by digital PCR in a nationwide Danish cohort of high-risk colorectal cancer patients	Tenna	Henriksen	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 2	4/17/23	9:00 AM	Section 44	20

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
2307	Targeted cell-free DNA methylation signature in metastatic castration-resistant prostate cancer	Jodie	Wong	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 2	4/17/23	9:00 AM	Section 44	21
2308	Biomarkers of acquired resistance to sotorasib (soto) plus panitumumab (pani) in chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC)	David	Hong	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 2	4/17/23	9:00 AM	Section 44	22
2309	Unlocking the proteome of metastatic prostate cancer circulating tumor cells	Justin	Drake	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 2	4/17/23	9:00 AM	Section 44	23
2310	Tumor macrophage fusion cells detected in the circulation of metastatic breast cancer patients is prognostic for rapid progression and death	Daniel	Adams	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 2	4/17/23	9:00 AM	Section 44	24
2311	Extensive molecular heterogeneity in circulating tumor cells: A key player in oral squamous cell carcinoma prognosis	Anshika	Chauhan	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 2	4/17/23	9:00 AM	Section 44	25
2312	Single-cell low pass whole genome sequencing for copy-number profiling in circulating tumor cells from prostate, non-small cell lung and breast cancers	Danyi	Wang	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 2	4/17/23	9:00 AM	Section 44	26
2313	Real-world concordance between tumor mutation burden from blood and tissue	Leeseul	Kim	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 2	4/17/23	9:00 AM	Section 44	27
2314	Development of a 6-color multiplex Crystal Digital PCR assay for the detection of ESR1 and PIK3CA mutations in the plasma of metastatic breast cancer patients	Veronique	Quillien	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 2	4/17/23	9:00 AM	Section 44	28
2315	Temporal changes in circulating tumor cells and circulating tumor DNA in patients with resectable pancreatic ductal adenocarcinoma	Yang	Zhang	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 2	4/17/23	9:00 AM	Section 44	29
2316	Automating ctDNA liquid biopsy workflow for mutation testing: From sample extraction to dPCR analysis utilizing the Maxprep™ Liquid Handler, Maxwell® extraction system, and high-plex detection assays	Kimberly	Gutierrez	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 2	4/17/23	9:00 AM	Section 44	30
2320	Dissecting the effects of Smyd3 depletion in the tumor microenvironment of HPV-negative head and neck squamous cell carcinoma mouse models	Malhar	Patel	Poster	Modifiers of the Tumor Microenvironment	4/17/23	9:00 AM	Section 45	1
2321	Tumor-derived extracellular vesicles induce macrophages immunosuppressive polarization to promote ovarian cancer progression	Sonam	Mittal	Poster	Modifiers of the Tumor Microenvironment	4/17/23	9:00 AM	Section 45	2
2322	Precision immuno-oncology (IO) ISH/IF multiplex panel: Spatial detection of cytokines and IO biomarkers	Navi	Mehra	Poster	Modifiers of the Tumor Microenvironment	4/17/23	9:00 AM	Section 45	3

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
2323	ZGGS18, a bispecific drug candidate of anti-VEGF and TGFbeta-trap, inhibiting tumor proliferation and improving tumor microenvironment with I/O therapy	Bing	Zhu	Poster	Modifiers of the Tumor Microenvironment	4/17/23	9:00 AM	Section 45	4
2324	Characterizing the secretome of freshly dissociated gastroesophageal tumor biopsies to identify immune suppressive factors	Jasper	Sanders	Poster	Modifiers of the Tumor Microenvironment	4/17/23	9:00 AM	Section 45	5
2325	IRF1 displays opposing tumor cell-intrinsic and -extrinsic roles in anti-tumor immunity	Prabhat	Purbey	Poster	Modifiers of the Tumor Microenvironment	4/17/23	9:00 AM	Section 45	6
2326	Proteolysis-targeting chimera against NR4A1 for cancer immunotherapy	Lei	Wang	Poster	Modifiers of the Tumor Microenvironment	4/17/23	9:00 AM	Section 45	7
2327	Novel role of NAC1 in regulating tumor stem cells and their interaction with immune cells in triple-negative breast cancer	Chrispus	Ngule	Poster	Modifiers of the Tumor Microenvironment	4/17/23	9:00 AM	Section 45	8
2328	Macrophage-targeting immunotherapy for triple negative breast cancer	Matthew	Fernandez	Poster	Modifiers of the Tumor Microenvironment	4/17/23	9:00 AM	Section 45	9
2329	Disulfiram metabolite modulates NK and T cell cytotoxicity against metastatic colorectal cancer through tumor derived NKG2D ligands	Daciana	Dumut	Poster	Modifiers of the Tumor Microenvironment	4/17/23	9:00 AM	Section 45	10
2330	Discovery of EP4 receptor antagonist KF-0210 for the treatment of cancers	Yongqi	Deng	Poster	Modifiers of the Tumor Microenvironment	4/17/23	9:00 AM	Section 45	11
2331	Loss of LRRC15 in osteosarcoma cells disrupts extracellular matrix integration, intercellular communication, and differentiation	Sanjit	Mukherjee	Poster	Modifiers of the Tumor Microenvironment	4/17/23	9:00 AM	Section 45	12
2332	VSTM2A modulation of immune response in colorectal cancer through abrogating PD-L1 and PD-1 interaction	Yujuan	Dong	Poster	Modifiers of the Tumor Microenvironment	4/17/23	9:00 AM	Section 45	13
2333	Verteporfin demonstrates antitumoral effect in murine cholangiocarcinoma models	Xin	Wang	Poster	Modifiers of the Tumor Microenvironment	4/17/23	9:00 AM	Section 45	14
2334	Reprogramming M2-like tumor associated macrophages using a natural compound, glycyrrhizin, as a potential therapeutic strategy against prostate cancer	Amy	Thomas	Poster	Modifiers of the Tumor Microenvironment	4/17/23	9:00 AM	Section 45	15
2335	Targeting a positive feedback loop of MERTK and STAT3 during macrophage differentiation may provide anti-tumor immune function	Dan	Yan	Poster	Modifiers of the Tumor Microenvironment	4/17/23	9:00 AM	Section 45	16
2336	Extra-virgin olive oil prevented tumor immune escape and intratumoral metabolic reprogramming in a mouse model of colorectal cancer via promoting T-cell infiltration, DNA repair, attenuation of overexpression of immune checkpoint proteins, glutamine dependency, and the Warburg metabolic phenotype	Babajide	Ajayi	Poster	Modifiers of the Tumor Microenvironment	4/17/23	9:00 AM	Section 45	17

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
2337	Overcome solid tumor immunosuppression for T cells-mediated cancer elimination	Lei	Shi	Poster	Modifiers of the Tumor Microenvironment	4/17/23	9:00 AM	Section 45	18
2338	Age associated tumor microenvironment induces differential outcomes from immunomodulatory nanoparticles and therapeutic ultrasound in murine melanoma	Akansha	Singh	Poster	Modifiers of the Tumor Microenvironment	4/17/23	9:00 AM	Section 45	19
2339	Exploration of multiple immunotherapy modalities in osteosarcoma	Payal	Agarwal	Poster	Modifiers of the Tumor Microenvironment	4/17/23	9:00 AM	Section 45	20
2340	Development of a CCR8 monoclonal antibody which blocks CCR8 signaling and abolishes the immunosuppressive function of Treg for the treatment of cancer	Guohuang	Fan	Poster	Modifiers of the Tumor Microenvironment	4/17/23	9:00 AM	Section 45	21
2341	Group 2 innate lymphoid cells influence pancreatic stromal cell composition in homeostasis and pancreatic cancer	Thomas	Yip	Poster	Modifiers of the Tumor Microenvironment	4/17/23	9:00 AM	Section 45	22
2342	RO7119929, a TLR7 agonist prodrug, induces local inflammation of the tumor microenvironment (TME) by reprogramming myeloid cells in patients (pts) with advanced primary or metastatic liver cancers	Carles	Fabregat-Franco	Poster	Modifiers of the Tumor Microenvironment	4/17/23	9:00 AM	Section 45	23
2343	Targeting EPHB2/ABL1 restores anti-tumor immunity in a preclinical model of ependymoma	Jun	Ren	Poster	Modifiers of the Tumor Microenvironment	4/17/23	9:00 AM	Section 45	24
2347	Producing genetically defined CAFs for the study of hypoxia signaling in the pancreatic cancer TME	Sahar	Fattani	Poster	Fibrosis, the Extracellular Matrix, and Therapeutic Impact on Cancer Progression	4/17/23	1:30 PM	Section 1	1
2348	Mapping the interactome of matrisome targets using extracellular proximity labeling (ePL)	David	Peeney	Poster	Fibrosis, the Extracellular Matrix, and Therapeutic Impact on Cancer Progression	4/17/23	1:30 PM	Section 1	2
2349	Investigating the effect of ECM stiffness on macrophage-derived exosome secretion and PDAC organoid progression	Bayan	Mahgoub	Poster	Fibrosis, the Extracellular Matrix, and Therapeutic Impact on Cancer Progression	4/17/23	1:30 PM	Section 1	3
2350	Role of ECM hyaluronic acid in the tumor-promoting functions of TIMP-1	Nithyananda	Thorenoor	Poster	Fibrosis, the Extracellular Matrix, and Therapeutic Impact on Cancer Progression	4/17/23	1:30 PM	Section 1	4
2351	Cancer-associated fibroblasts modulate macrophage phenotype in PDAC through hypoxia inducible factor-2(HIF2)-dependent IGFBP3 secretion	Matthew	Cribb	Poster	Fibrosis, the Extracellular Matrix, and Therapeutic Impact on Cancer Progression	4/17/23	1:30 PM	Section 1	5
2352	ALDOC interplays with KIAA1409 to reduce m6A modifications and cancer-associated fibroblast characteristics in gliomas	Yu-Chan	Chang	Poster	Fibrosis, the Extracellular Matrix, and Therapeutic Impact on Cancer Progression	4/17/23	1:30 PM	Section 1	6

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
2353	PTGES is involved in the myofibroblast differentiation	Yi-Fang	Yang	Poster	Fibrosis, the Extracellular Matrix, and Therapeutic Impact on Cancer Progression	4/17/23	1:30 PM	Section 1	7
2354	Regulation of TIMPs through MMP dependent cleavage in breast cancer	Sasha	Coates-Park	Poster	Fibrosis, the Extracellular Matrix, and Therapeutic Impact on Cancer Progression	4/17/23	1:30 PM	Section 1	8
2355	Transcription factor EB modulates fibrotic response in pancreatic ductal adenocarcinoma	Alejandra	Diaz Alcalde	Poster	Fibrosis, the Extracellular Matrix, and Therapeutic Impact on Cancer Progression	4/17/23	1:30 PM	Section 1	9
2356	Aberrant TIMP-1 secretion by tumor-associated fibroblasts is a major contributor to the selective positive response to nintedanib in lung adenocarcinoma	Paula	Duch	Poster	Fibrosis, the Extracellular Matrix, and Therapeutic Impact on Cancer Progression	4/17/23	1:30 PM	Section 1	10
2357	Fibroblast activation protein (FAP) expression as a target for colorectal cancer treatment	Anna	Lippert	Poster	Fibrosis, the Extracellular Matrix, and Therapeutic Impact on Cancer Progression	4/17/23	1:30 PM	Section 1	11
2358	NROB2 re-educates myeloid cells within the tumor microenvironment: Potential novel strategy for breast cancer immunotherapy	Hashni Epa	Vidana Gamage	Poster	Fibrosis, the Extracellular Matrix, and Therapeutic Impact on Cancer Progression	4/17/23	1:30 PM	Section 1	12
2360	Digital spatial profiling of RNA and protein in the tumor microenvironment of invasive lobular breast cancer	Lynda	Bennett	Poster	Fibrosis, the Extracellular Matrix, and Therapeutic Impact on Cancer Progression	4/17/23	1:30 PM	Section 1	14
2361	Prevalence of mature tertiary lymphoid structures and association with tumor mutational burden in patients with solid tumors	Antoine	Italiano	Poster	Fibrosis, the Extracellular Matrix, and Therapeutic Impact on Cancer Progression	4/17/23	1:30 PM	Section 1	15
2362	Spatial transcriptomic landscape of primary and lymph node metastatic pancreatic cancer	Changjin	Hong	Poster	Fibrosis, the Extracellular Matrix, and Therapeutic Impact on Cancer Progression	4/17/23	1:30 PM	Section 1	16
2363	Ovarian tumor-intrinsic FAK-dependent regulation of the matrisome	Marjaana	Ojalill	Poster	Fibrosis, the Extracellular Matrix, and Therapeutic Impact on Cancer Progression	4/17/23	1:30 PM	Section 1	17
2364	Gut microbiome interacts with clinical characteristics on all-cause mortality of colorectal cancer patients	Tung	Hoang	Poster	Fibrosis, the Extracellular Matrix, and Therapeutic Impact on Cancer Progression	4/17/23	1:30 PM	Section 1	18
2365	Visualizing exosome structure in Dasatinib resistant colon cancer cells	Hui Min	Koo	Poster	Fibrosis, the Extracellular Matrix, and Therapeutic Impact on Cancer Progression	4/17/23	1:30 PM	Section 1	19

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
2366	Myeloma-derived circulating extracellular vesicles affect human stromal cell behaviour and promote tumor progression: A multi-omic approach	Nicholas	Bingham	Poster	Fibrosis, the Extracellular Matrix, and Therapeutic Impact on Cancer Progression	4/17/23	1:30 PM	Section 1	20
2367	Hedgehog signaling influences tumor immunogenicity by the modulation of T cell populations in breast cancer	Courtney	Swain	Poster	Fibrosis, the Extracellular Matrix, and Therapeutic Impact on Cancer Progression	4/17/23	1:30 PM	Section 1	21
2368	Pilot characterization of the salivary microbiome in pediatric cancer patients	Alejandra Beatriz	Cervantes Garduño	Poster	Fibrosis, the Extracellular Matrix, and Therapeutic Impact on Cancer Progression	4/17/23	1:30 PM	Section 1	22
2369	Spatial organization of the tumour immune microenvironment (TIME) in primary and metastatic melanoma is associated with patient outcome	Grace	Attrill	Poster	Fibrosis, the Extracellular Matrix, and Therapeutic Impact on Cancer Progression	4/17/23	1:30 PM	Section 1	23
2370	The role of extracellular vesicles in the glioblastoma tumor microenvironment	Marissa	Russo	Poster	Fibrosis, the Extracellular Matrix, and Therapeutic Impact on Cancer Progression	4/17/23	1:30 PM	Section 1	24
2371	Stromal androgen signaling acts as tumor niches to drive prostatic basal epithelial progenitor initiated oncogenesis through IGFBP3 mediated IGF1 induced Wnt activation	Alex	Hiroto	Poster	Fibrosis, the Extracellular Matrix, and Therapeutic Impact on Cancer Progression	4/17/23	1:30 PM	Section 1	25
2372	Does the ubiquitin E3 ligase glycoprotein 78 (gp78/amfr) link socioeconomic factors, race, and biology in breast cancer?	Myles	Ellis	Poster	Fibrosis, the Extracellular Matrix, and Therapeutic Impact on Cancer Progression	4/17/23	1:30 PM	Section 1	26
2373	Combination treatment with pH modulating drugs and immune checkpoint inhibitors increases TALL-104 cytotoxicity in preclinical co-culture experiments	Ryan	Malpass	Poster	Fibrosis, the Extracellular Matrix, and Therapeutic Impact on Cancer Progression	4/17/23	1:30 PM	Section 1	27
2374	Squamous cell carcinoma antigen regulates macrophage polarization, contributing to inhibition of T cell activity in cervical cancer chemo-radiotherapy	Liyun	Chen	Poster	Fibrosis, the Extracellular Matrix, and Therapeutic Impact on Cancer Progression	4/17/23	1:30 PM	Section 1	28
2375	Whole exome sequencing and immune profiling of cervical adenocarcinoma reveal a “cold” tumor-immune phenotype	Julianna	Bronk	Poster	Fibrosis, the Extracellular Matrix, and Therapeutic Impact on Cancer Progression	4/17/23	1:30 PM	Section 1	29
2379	Tunable squaraine dyes as contrast agents for image guided surgery with optoacoustic imaging	William	MacCuaig	Poster	Photoacoustic, Ultrasound, and Fluorescence Imaging	4/17/23	1:30 PM	Section 2	1
2380	Fluorescence labeling of human gastric cancer using novel tumor specific near infrared labeled antibodies	Kristin	Cox	Poster	Photoacoustic, Ultrasound, and Fluorescence Imaging	4/17/23	1:30 PM	Section 2	2
2381	Gold nanorods functionalized with an alpha5beta1 ligand: a simple and robust nanosystem for early bladder cancer detection	Flavio	Curnis	Poster	Photoacoustic, Ultrasound, and Fluorescence Imaging	4/17/23	1:30 PM	Section 2	3

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
2382	Three-dimensional spatial phenotyping of cellular landscapes in the bone microenvironment of spontaneous metastases	Daniel	Kermany	Poster	Photoacoustic, Ultrasound, and Fluorescence Imaging	4/17/23	1:30 PM	Section 2	4
2383	Fluorescence lifetime imaging microscopy to assess drug response in patient-derived colorectal cancer organoids	Emma	Fong	Poster	Photoacoustic, Ultrasound, and Fluorescence Imaging	4/17/23	1:30 PM	Section 2	5
2384	Quantitative phase imaging provides new insights into diverse morphologies in cell lines and their behavior in response to alternative cancer treatments	Rida	Khan	Poster	Photoacoustic, Ultrasound, and Fluorescence Imaging	4/17/23	1:30 PM	Section 2	6
2385	Targeting mannose receptor expression on macrophages for sentinel lymph node mapping in endometrial cancer: murine model	Sanghoon	Lee	Poster	Photoacoustic, Ultrasound, and Fluorescence Imaging	4/17/23	1:30 PM	Section 2	7
2386	Label free imaging for rapid assessment of tumor viability in live tumor fragments	Eric	Wait	Poster	Photoacoustic, Ultrasound, and Fluorescence Imaging	4/17/23	1:30 PM	Section 2	8
2387	Characterization of orthotopic bioluminescent patient-derived xenograft model of glioma for drug discovery	Jinxi	Wang	Poster	Photoacoustic, Ultrasound, and Fluorescence Imaging	4/17/23	1:30 PM	Section 2	9
2388	Non-invasive imaging of hypoxia as a biomarker of immunotherapeutic efficacy in head and neck cancer	Celia	DeJohn	Poster	Photoacoustic, Ultrasound, and Fluorescence Imaging	4/17/23	1:30 PM	Section 2	10
2389	In vivo multiphoton autofluorescence imaging is sensitive to CD8 T cell and tumor cell metabolic changes during immunotherapy in a murine melanoma model	Alexa	Heaton	Poster	Photoacoustic, Ultrasound, and Fluorescence Imaging	4/17/23	1:30 PM	Section 2	11
2390	Claudin-4 probe identifies triple negative breast cancer using multispectral optoacoustic tomography	Laycee	Parsons	Poster	Photoacoustic, Ultrasound, and Fluorescence Imaging	4/17/23	1:30 PM	Section 2	12
2391	Transdermal alkalinization treatment induces pH changes in a murine melanoma model as measured with MRI-CEST pH imaging	Pietro	Irrera	Poster	Photoacoustic, Ultrasound, and Fluorescence Imaging	4/17/23	1:30 PM	Section 2	13
2392	Multi-dimensional morphology analysis enables identification and label-free enrichment of heterogeneous tumor cell populations	Andreja	Jovic	Poster	Photoacoustic, Ultrasound, and Fluorescence Imaging	4/17/23	1:30 PM	Section 2	14
2393	Characterization and validation of a Smad3/TGF β pathway reporter mouse for analysis of TGF β signaling in normal homeostasis and cancer	Yuan	Yang	Poster	Photoacoustic, Ultrasound, and Fluorescence Imaging	4/17/23	1:30 PM	Section 2	15
2394	Activatable fluorogenic probe for two-photon imaging of heparanase in vivo	Zachary	Rabinowitz	Poster	Photoacoustic, Ultrasound, and Fluorescence Imaging	4/17/23	1:30 PM	Section 2	16
2395	A bioluminescent probe for detection and imaging of heparanase enzymatic activity	Johnathan	Somers	Poster	Photoacoustic, Ultrasound, and Fluorescence Imaging	4/17/23	1:30 PM	Section 2	17
2396	Longitudinal monitoring of stromal stiffness predicts immune escape in preclinical hepatocellular carcinoma	Kiyoyuki	Minamiguchi	Poster	Photoacoustic, Ultrasound, and Fluorescence Imaging	4/17/23	1:30 PM	Section 2	18
2397	An advanced approach technique for tracking point between immune check point inhibitor and cancer cell mechanism in immune response motility by infiltration a breast cancer cell	Hyunseok	Kim	Poster	Photoacoustic, Ultrasound, and Fluorescence Imaging	4/17/23	1:30 PM	Section 2	19

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
2401	Molecular mechanisms of intrinsic radioresistance in breast cancer	Breanna	McBean	Poster	Radiation Sciences	4/17/23	1:30 PM	Section 3	1
2402	Fractionated dosing: A more clinically relevant approach to radiotherapy in preclinical tumor models	Kerry-Ann	Bright	Poster	Radiation Sciences	4/17/23	1:30 PM	Section 3	2
2403	Divergent evolutionary response to multiple fractions of radiation (MF2) therapy in cervical cancer cell lines (CCCL)	Johanna	Kelley	Poster	Radiation Sciences	4/17/23	1:30 PM	Section 3	3
2404	Patient-derived organoid platform for the prediction of radiation response and modeling radiation resistance in oral cancer	Sumin	Kang	Poster	Radiation Sciences	4/17/23	1:30 PM	Section 3	4
2405	Delineating molecular vulnerabilities of ATM mutant prostate cancers	Mia	Hofstad	Poster	Radiation Sciences	4/17/23	1:30 PM	Section 3	5
2406	Targeting prmt5 inhibits DNA repair and enhances the radiosensitivity of GBM cells	Charlotte	Degorre	Poster	Radiation Sciences	4/17/23	1:30 PM	Section 3	6
2407	Targeting ribonucleotide reductase subunit 2 (RRM2) to radiosensitize glioblastoma	Sergio	Corrales-Guerrero	Poster	Radiation Sciences	4/17/23	1:30 PM	Section 3	7
2409	A synergistic effect of miR-21-5p inhibitor and PARP1 inhibitor to enhance the radiosensitivity of oral squamous cell carcinoma	Lin	Ma	Poster	Radiation Sciences	4/17/23	1:30 PM	Section 3	9
2410	Glutamine uptake inhibition as a strategy for radiosensitization in triple negative breast cancer	Bassel	Bashjawish	Poster	Radiation Sciences	4/17/23	1:30 PM	Section 3	10
2411	The pentose-phosphate pathway induces pancreatic cancer radioresistance, a preclinical study with clinical validation	Yaacov	Lawrence	Poster	Radiation Sciences	4/17/23	1:30 PM	Section 3	11
2412	MET inhibition enhances the effect of radiation in MET dysregulated non-small cell lung cancer models	Shrey	Ramesh	Poster	Radiation Sciences	4/17/23	1:30 PM	Section 3	12
2413	Glioblastoma stem-like cells are resistant to the negative effects of increased aneuploidy on in vitro survival and radiosensitivity	Ian	Sutton	Poster	Radiation Sciences	4/17/23	1:30 PM	Section 3	13
2414	Early biological impacts of radiotherapy-activated NBTXR3 nanoparticles	Jordan	Da silva	Poster	Radiation Sciences	4/17/23	1:30 PM	Section 3	14
2415	NBTXR3 radio-enhancing nanoparticle achieves a more robust antitumor immune response when combined with proton radiotherapy than photon radiotherapy	Yun	Hu	Poster	Radiation Sciences	4/17/23	1:30 PM	Section 3	15
2416	Uncovering the protective neurological mechanisms of hypofractionated FLASH radiotherapy	Charles	Limoli	Poster	Radiation Sciences	4/17/23	1:30 PM	Section 3	16
2417	Liver regeneration after radiation therapy: clinical observations and a new rat model	Tingshi	Su	Poster	Radiation Sciences	4/17/23	1:30 PM	Section 3	17
2419	A multimodel preclinical platform to evaluate photodynamic therapy as a strategy to reduce local recurrence in myxofibrosarcoma and osteosarcoma	Chiara	Spadazzi	Poster	Radiation Sciences	4/17/23	1:30 PM	Section 3	19

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
2420	Interstitial chemo-phototherapy for treatment of locally advanced hepatocellular carcinoma: A preclinical study	Emily	Oakley	Poster	Radiation Sciences	4/17/23	1:30 PM	Section 3	20
2421	WST-11 vascular-targeted photodynamic therapy induced immune modulation in upper tract urothelial cancer	Kwanghee	Kim	Poster	Radiation Sciences	4/17/23	1:30 PM	Section 3	21
2422	In vivo pilot study of the effect of EGCG in photodynamic therapy on non melanoma skin cancer	Carmen	Ili	Poster	Radiation Sciences	4/17/23	1:30 PM	Section 3	22
2423	Image-guided interstitial photodynamic therapy with palliative radiotherapy for ablating extrabronchial malignant central airway obstruction	Gal	Shafirstein	Poster	Radiation Sciences	4/17/23	1:30 PM	Section 3	23
2424	Development of radiation sensitivity evaluation platform in esophageal cancer patient derived organoids	Jung Eun	Kim	Poster	Radiation Sciences	4/17/23	1:30 PM	Section 3	24
2428	Cancer stem cells maintain stemness via autocrine activation of the IFN/JAK/STAT signaling pathway	Aidan	Li	Poster	Regulation of Stemness: Transformation, Differentiation, and Plasticity	4/17/23	1:30 PM	Section 4	1
2429	AGPAT4 as a novel metabolic driver of oncogenic stemness and dedifferentiation in hepatocellular carcinoma	Kai Yu	Ng	Poster	Regulation of Stemness: Transformation, Differentiation, and Plasticity	4/17/23	1:30 PM	Section 4	2
2430	The role of SOX2 in Barrett's esophagus development	Ramon	Jin	Poster	Regulation of Stemness: Transformation, Differentiation, and Plasticity	4/17/23	1:30 PM	Section 4	3
2431	The role and regulation of YAP1 in paligenosis, the cell program converting mature cells into precancerous metaplasia	Yongji	Zeng	Poster	Regulation of Stemness: Transformation, Differentiation, and Plasticity	4/17/23	1:30 PM	Section 4	4
2433	SERPINA12 promotes the tumorigenic capacity of hepatocellular carcinoma stem cells through hyperactivation of AKT/ β -catenin signaling	Huajian	Yu	Poster	Regulation of Stemness: Transformation, Differentiation, and Plasticity	4/17/23	1:30 PM	Section 4	6
2434	Regulation of initiation and establishment of ovarian cancer metastasis by metastasis initiating cells	Ji	Wang	Poster	Regulation of Stemness: Transformation, Differentiation, and Plasticity	4/17/23	1:30 PM	Section 4	7
2435	Single cell spatial analysis identifies regulators of brain tumor initiating cells	Reza	Mirzaei	Poster	Regulation of Stemness: Transformation, Differentiation, and Plasticity	4/17/23	1:30 PM	Section 4	8
2436	The multi-faceted Integrator complex in Notch-driven esophageal cancer	Elena	Shersher	Poster	Regulation of Stemness: Transformation, Differentiation, and Plasticity	4/17/23	1:30 PM	Section 4	9

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
2437	HMOX1 modulates tumor stemness and metastatic properties in prostate cancer	Agustina	Sabater	Poster	Regulation of Stemness: Transformation, Differentiation, and Plasticity	4/17/23	1:30 PM	Section 4	10
2438	Loss of galectin 3 reveals its potential roles in the aggressive pathology of uterine serous carcinoma	Yusuke	Matoba	Poster	Regulation of Stemness: Transformation, Differentiation, and Plasticity	4/17/23	1:30 PM	Section 4	11
2439	RPL27 augments growth and stemness properties in colorectal cancer through PLK1 signaling	Keon Uk	Park	Poster	Regulation of Stemness: Transformation, Differentiation, and Plasticity	4/17/23	1:30 PM	Section 4	12
2440	HOTAIR functionality and regulation in ovarian cancer stem cells	Yanchi	Zhou	Poster	Regulation of Stemness: Transformation, Differentiation, and Plasticity	4/17/23	1:30 PM	Section 4	13
2441	Identification and characterization of the role of KRT17 in the stemness regulation of hepatocellular carcinoma	Xiaona	Fang	Poster	Regulation of Stemness: Transformation, Differentiation, and Plasticity	4/17/23	1:30 PM	Section 4	14
2442	KLF8 and OGT/O-GlcNAcylation regulate stem-like cell properties in breast cancer	Giang	Le Minh	Poster	Regulation of Stemness: Transformation, Differentiation, and Plasticity	4/17/23	1:30 PM	Section 4	15
2443	Serine/threonine kinase 39 (STK39) regulates cancer stemness through regulating PARP-mediated SOX2/OCT4 expression in hepatocellular carcinoma	Terence Kin-Wah	Lee	Poster	Regulation of Stemness: Transformation, Differentiation, and Plasticity	4/17/23	1:30 PM	Section 4	16
2444	RAB27B drives a cancer stem cell phenotype in non-small cell lung cancer cells through enhanced extracellular vesicle secretion	Verline	Justilien	Poster	Regulation of Stemness: Transformation, Differentiation, and Plasticity	4/17/23	1:30 PM	Section 4	17
2445	PPM1G enhances hepatocellular carcinoma stemness via interacting with YBX1	Shan	Liu	Poster	Regulation of Stemness: Transformation, Differentiation, and Plasticity	4/17/23	1:30 PM	Section 4	18
2446	An investigation of HOX-regulatory mechanisms and their role in the SC origin of human CRC	Brian	Osmond	Poster	Regulation of Stemness: Transformation, Differentiation, and Plasticity	4/17/23	1:30 PM	Section 4	19
2447	XPC suppresses cancer stem cells via inhibiting STAT1-mediated expression of SOX2 in NSCLC	Na	Li	Poster	Regulation of Stemness: Transformation, Differentiation, and Plasticity	4/17/23	1:30 PM	Section 4	20
2448	Galectin-3 regulates stemness and cellular states in glioblastoma stem cells	Bedia	Akosman	Poster	Regulation of Stemness: Transformation, Differentiation, and Plasticity	4/17/23	1:30 PM	Section 4	21

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
2449	p38 β promotes cancer stemness and chemoresistance in hepatocellular carcinoma	Ianto	Huang	Poster	Regulation of Stemness: Transformation, Differentiation, and Plasticity	4/17/23	1:30 PM	Section 4	22
2450	Transforming intestinal stem cells into metastatic cancer Stem cells by aberrantly activated cytokine-STAT5A signaling	Xiaonan	Han	Poster	Regulation of Stemness: Transformation, Differentiation, and Plasticity	4/17/23	1:30 PM	Section 4	23
2451	KRAS activation in gastric cancer stem-like cells promotes tumor angiogenesis and metastasis	Changhwan	Yoon	Poster	Regulation of Stemness: Transformation, Differentiation, and Plasticity	4/17/23	1:30 PM	Section 4	24
2452	A study of AXIN2-regulatory mechanisms and their role in the stem cell origin of human CRC	Chi	Zhang	Poster	Regulation of Stemness: Transformation, Differentiation, and Plasticity	4/17/23	1:30 PM	Section 4	25
2453	Olfactomedin 4 downregulation enhances MYC-signaling in human benign prostate cells and the Olfm4 mouse models	Hongzhen	Li	Poster	Regulation of Stemness: Transformation, Differentiation, and Plasticity	4/17/23	1:30 PM	Section 4	26
2454	Identification of colorectal cancer stem cells from single cell RNA sequencing	Kangyu	Lin	Poster	Regulation of Stemness: Transformation, Differentiation, and Plasticity	4/17/23	1:30 PM	Section 4	27
2455	Investigating cancer stem cell plasticity in ovarian cancer	Tara	Metcalfe	Poster	Regulation of Stemness: Transformation, Differentiation, and Plasticity	4/17/23	1:30 PM	Section 4	28
2456	Transcriptional signatures of stem cell phenotypes in normal and clonal hematopoiesis	Ruslan	Soldatov	Poster	Regulation of Stemness: Transformation, Differentiation, and Plasticity	4/17/23	1:30 PM	Section 4	29
2457	Restoring the balance between WNT and retinoic acid signaling to promote differentiation of cancer stem cells in treatment of colorectal cancer	Caroline	Facey	Poster	Regulation of Stemness: Transformation, Differentiation, and Plasticity	4/17/23	1:30 PM	Section 4	30
2461	The cell migration inhibitor dihydromotuporamine C regulates actin-myosin contractility and actin polymerization	Laurence	von Kalm	Poster	Translational Metastasis Research	4/17/23	1:30 PM	Section 5	1
2462	AXL-WRNIP1 mediated replication stress response aids metastatic latency and relapse	Mauricio	Marquez-Palencia	Poster	Translational Metastasis Research	4/17/23	1:30 PM	Section 5	2
2463	Protein folding chaperonin as biological indicator for cancer progression and metastasis	Annette	Khaled	Poster	Translational Metastasis Research	4/17/23	1:30 PM	Section 5	3
2464	Novel models of breast cancer metastasis with different metastatic competence	Akshita	Bhatt	Poster	Translational Metastasis Research	4/17/23	1:30 PM	Section 5	4

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
2465	YKL-40 overexpression enhances metastatic potential and is a novel prognostic candidate and predictive biomarker for patients with colorectal cancer	Mariangela	De Robertis	Poster	Translational Metastasis Research	4/17/23	1:30 PM	Section 5	5
2466	Detection of extracellular vesicle-associated DNA in mouse metastatic breast cancer cells	Amélie	Nadeau	Poster	Translational Metastasis Research	4/17/23	1:30 PM	Section 5	6
2467	Novel biomarkers of metastasis-prone breast cancer revealed by high-throughput proteomics assay	Jiwon	Koh	Poster	Translational Metastasis Research	4/17/23	1:30 PM	Section 5	7
2468	Overcoming the leptomeningeal seeding of medulloblastoma by targeting HSP70	Seung Ah	Choi	Poster	Translational Metastasis Research	4/17/23	1:30 PM	Section 5	8
2470	ARG1 is potential prognostic biomarker for development of distant metastatic endometrial cancer in mice with Pten deficiency	Jae-Wook	Jeong	Poster	Translational Metastasis Research	4/17/23	1:30 PM	Section 5	10
2471	Novel Tetrazolo-pyridazine based MACC1 inhibitors are promising for anti-metastatic therapy	Ulrike	Stein	Poster	Translational Metastasis Research	4/17/23	1:30 PM	Section 5	11
2472	Interdisciplinary method to elucidate the interaction between brain microenvironment and cancer cells	Takahiro	Tsuji	Poster	Translational Metastasis Research	4/17/23	1:30 PM	Section 5	12
2473	Tissue factor-induced fibrinogenesis and cancer cell clustering contribute to polyclonal peritoneal metastasis in diffuse-type gastric carcinoma	Makoto	Miyazaki	Poster	Translational Metastasis Research	4/17/23	1:30 PM	Section 5	13
2474	Uncovering a new therapeutic vulnerability for preventing brain metastases	Sheila	Singh	Poster	Translational Metastasis Research	4/17/23	1:30 PM	Section 5	14
2475	Bromodomain inhibitor: MT1 and its potential role in modulation of prostate cancer progression	Mohammed	Al-Toubat	Poster	Translational Metastasis Research	4/17/23	1:30 PM	Section 5	15
2476	Nischarin is a potential druggable target in both epithelial and stromal compartments of pancreatic ductal adenocarcinoma	Jelena	Grahovac	Poster	Translational Metastasis Research	4/17/23	1:30 PM	Section 5	16
2477	Evaluating the effects of Bcl2 inhibitor, venetoclax, on cellular growth and clustering in triple-negative breast cancer cells	Alexis	Ruiz	Poster	Translational Metastasis Research	4/17/23	1:30 PM	Section 5	17
2478	The interplay between Apurinic/aprimidinic Endonuclease 1 (APE1) and DNA G-quadruplex (G4) in regulating triple-negative breast cancer (TNBC) metastasis	Yingling	Chen	Poster	Translational Metastasis Research	4/17/23	1:30 PM	Section 5	18
2480	Chemotherapy increases invasive cancer stem cells in breast cancer	Madeline	Friedman	Poster	Translational Metastasis Research	4/17/23	1:30 PM	Section 5	20
2481	Human osteoclast assays for studying the effects of bone metastasis treatments with different mechanisms of action	Jukka	Rissanen	Poster	Translational Metastasis Research	4/17/23	1:30 PM	Section 5	21
2482	On the verge of metastasis: CTH defines a cell-state-dependent adaptive response to microenvironmental stresses	Amal	El-Naggar	Poster	Translational Metastasis Research	4/17/23	1:30 PM	Section 5	22

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
2483	Attenuated Salmonella blocks cancer metastasis by activating NK cells in an IFN- γ -dependent manner	Jiandong	Huang	Poster	Translational Metastasis Research	4/17/23	1:30 PM	Section 5	23
2484	The role of the PI3K/Akt signaling pathway on LIN28B-mediated colorectal cancer metastasis	Alice	Shin	Poster	Translational Metastasis Research	4/17/23	1:30 PM	Section 5	24
2485	RAB31 interacts with AGR2 to respond to oxaliplatin resistance and epithelial-mesenchymal transition in colorectal cancer cells via the EGFR-independent pathway	Chi-Long	Chen	Poster	Translational Metastasis Research	4/17/23	1:30 PM	Section 5	25
2486	Dissecting the lineage specific roles of BCL-XL in breast cancer metastasis	Madison	Carelock	Poster	Translational Metastasis Research	4/17/23	1:30 PM	Section 5	26
2487	Metastasis: Cancer cells that have turned on a Yamanaka-like pluripotency program	Cynthia	Bamdad	Poster	Translational Metastasis Research	4/17/23	1:30 PM	Section 5	27
2489	Study the efficacy of hypomethylating agent in treating regular and brain metastasized HER2-positive breast cancer	Tuoen	Liu	Poster	Translational Metastasis Research	4/17/23	1:30 PM	Section 5	29
2493	Design and optimization of mouse markers for use in melanoma, cardiac applications	Danielle	Fails	Poster	Tumor-Host Interactions and Disease Progression	4/17/23	1:30 PM	Section 6	1
2494	Heterogeneous tumor-driven immune landscapes between lung adenocarcinomas in ever and never-smokers	Xiaozheng	Kang	Poster	Tumor-Host Interactions and Disease Progression	4/17/23	1:30 PM	Section 6	2
2495	Investigating pancreatic cancer-derived extracellular vesicle signaling in the tumor microenvironment	Jennifer	Finan	Poster	Tumor-Host Interactions and Disease Progression	4/17/23	1:30 PM	Section 6	3
2496	The landscape of the pre-leukemic bone marrow niche in acute myeloid leukemia	Chinmayee	Goda	Poster	Tumor-Host Interactions and Disease Progression	4/17/23	1:30 PM	Section 6	4
2497	Glioma-induced neuronal remodeling promotes regional immunosuppression	Takahide	Nejo	Poster	Tumor-Host Interactions and Disease Progression	4/17/23	1:30 PM	Section 6	5
2498	Melanoma cell -derived extracellular vesicles - immunomodulators of the tumor microenvironment	Sanna	Pasonen-Seppänen	Poster	Tumor-Host Interactions and Disease Progression	4/17/23	1:30 PM	Section 6	6
2499	Complement activation at the interface between cancer cells and adipocytes	Andres	Valdivia	Poster	Tumor-Host Interactions and Disease Progression	4/17/23	1:30 PM	Section 6	7
2500	EBV positive NPC-derived exosomes promote macrophage M2 polarization via activating MST1R and YAP1 signalings	Tzu-Tung	Liu	Poster	Tumor-Host Interactions and Disease Progression	4/17/23	1:30 PM	Section 6	8
2501	A glioblastoma and blood-brain barrier in vitro model to assess the tumor microenvironment and temozolomide resistance	Maxine	Lam	Poster	Tumor-Host Interactions and Disease Progression	4/17/23	1:30 PM	Section 6	9
2502	The role of high mobility group box-1 protein (HMGB1) in the microenvironment of non-small cell lung cancer	Tomohiro	Habu	Poster	Tumor-Host Interactions and Disease Progression	4/17/23	1:30 PM	Section 6	10
2503	Tumor microenvironment composition correlates with relapse in ovarian granulosa cell tumors	Eleonora	Khlebus	Poster	Tumor-Host Interactions and Disease Progression	4/17/23	1:30 PM	Section 6	11
2504	Antiarrhythmic drugs repositioning to counteract the activated phenotype of prostate cancer-associated fibroblasts	Valentina	Doldi	Poster	Tumor-Host Interactions and Disease Progression	4/17/23	1:30 PM	Section 6	12

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
2505	PYCR1 inhibition in multiple myeloma-associated stroma limits tumor growth	Inge	Oudaert	Poster	Tumor-Host Interactions and Disease Progression	4/17/23	1:30 PM	Section 6	13
2506	The influence of sex on the immune microenvironment in male and female breast cancer	Ebony	Hargrove-Wiley	Poster	Tumor-Host Interactions and Disease Progression	4/17/23	1:30 PM	Section 6	14
2507	Chronic stress promotes tumor progression and metastasis through the tumor microenvironment in triple-negative breast cancer	Chao	Zhang	Poster	Tumor-Host Interactions and Disease Progression	4/17/23	1:30 PM	Section 6	15
2508	Clinical significance of PARP7 (TIPARP) gene copy number alterations in human non-small cell and head & neck carcinomas	Viviana	Ahumada	Poster	Tumor-Host Interactions and Disease Progression	4/17/23	1:30 PM	Section 6	16
2509	Similar variant histology and immune cell infiltration in canine and human muscle-invasive bladder cancer	Karin	Allenspach	Poster	Tumor-Host Interactions and Disease Progression	4/17/23	1:30 PM	Section 6	17
2510	Pentraxin-3 associated up-regulation of genes involved in motility, angiogenesis, and inflammation in glioblastoma	Umadevi	Wesley	Poster	Tumor-Host Interactions and Disease Progression	4/17/23	1:30 PM	Section 6	18
2511	Autologous patient-derived organoid-immune cell co-culture platform for therapeutic discovery in high-grade endometrial cancer	Charlie	Chung	Poster	Tumor-Host Interactions and Disease Progression	4/17/23	1:30 PM	Section 6	19
2512	TMEM doorways are an actionable target in pancreatic adenocarcinoma	John	McAuliffe	Poster	Tumor-Host Interactions and Disease Progression	4/17/23	1:30 PM	Section 6	20
2513	Distinct cancer-intrinsic mechanisms mediate nerve recruitment/outgrowth versus perineural invasion	William	Hwang	Poster	Tumor-Host Interactions and Disease Progression	4/17/23	1:30 PM	Section 6	21
2515	DIRAS3 suppresses ovarian cancer cell growth through the inhibition of fibronectin-mediated FAK/AKT signaling	Janice	Santiago-OFarrill	Poster	Tumor-Host Interactions and Disease Progression	4/17/23	1:30 PM	Section 6	23
2516	Analysis of CLL Cellular Environment and Response (ACCER) is a novel method to understand the microenvironment in CLL	Spencer	Gibson	Poster	Tumor-Host Interactions and Disease Progression	4/17/23	1:30 PM	Section 6	24
2517	Optimizing breast cancer therapy by inhibiting the adenosine receptor and oxygen consumption	Sadna	Budhu	Poster	Tumor-Host Interactions and Disease Progression	4/17/23	1:30 PM	Section 6	25
2518	Heterogeneity of cytokine secretion in single senescent fibroblasts is impacted by ONC201 and ABT-263	Lanlan	Zhou	Poster	Tumor-Host Interactions and Disease Progression	4/17/23	1:30 PM	Section 6	26
2520	Blocking muscle wasting via deletion of the muscle specific E3 ligase, MuRF1, impedes pancreatic tumor growth	Andrew	Judge	Poster	Tumor-Host Interactions and Disease Progression	4/17/23	1:30 PM	Section 6	28
2524	Critical interactions and tumor-specific mutations of Bcl-2 transmembrane domains revealed by a novel split luciferase assay	Tobias	Beigl	Poster	Apoptosis and Bcl-2 Family Members	4/17/23	1:30 PM	Section 7	1
2525	Analyzing the role of MDMX for regulating cell death in prostate cancer cells	Ahmed	Alsarrani	Poster	Apoptosis and Bcl-2 Family Members	4/17/23	1:30 PM	Section 7	2
2526	The Bcl-2 family proteins in CLL: Effects by the cytogenetics, microenvironments and therapy	Rong	Chen	Poster	Apoptosis and Bcl-2 Family Members	4/17/23	1:30 PM	Section 7	3

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
2527	Investigation of doxorubicin interference in flow cytometry measurements of apoptosis and necrosis	Clyde	Ofner	Poster	Apoptosis and Bcl-2 Family Members	4/17/23	1:30 PM	Section 7	4
2528	New ovarian cancer approach based on sensitizing the MDM2 inhibitor by an exportin-1 inhibitor	Amal	Alzahrani	Poster	Apoptosis and Bcl-2 Family Members	4/17/23	1:30 PM	Section 7	5
2529	Necrosome translocates to lysosome to induce lysosome membrane permeabilization and subsequent necroptotic cell death	Jamila	Mammadova	Poster	Apoptosis and Bcl-2 Family Members	4/17/23	1:30 PM	Section 7	6
2530	DELE1 loss and dysfunctional integrated stress signaling in TP53 mutated AML is a novel pathway for venetoclax resistance	David	Sharon	Poster	Apoptosis and Bcl-2 Family Members	4/17/23	1:30 PM	Section 7	7
2531	FCN-683, a novel second-generation BCL-2 inhibitor, is highly potent, selective and efficacious against clinically relevant venetoclax-resistant mutations	Shu (Sophie)	Lin	Poster	Apoptosis and Bcl-2 Family Members	4/17/23	1:30 PM	Section 7	8
2532	Disrupting resistance to EGFR-specific tyrosine kinase inhibitors in TP53-mutated lung carcinoma cell lines by proteasome inhibition	Franziska	Orth	Poster	Apoptosis and Bcl-2 Family Members	4/17/23	1:30 PM	Section 7	9
2533	MAPK-driven MCL1 expression promotes osteosarcoma survival in the metastatic niche	Camille	McAloney	Poster	Apoptosis and Bcl-2 Family Members	4/17/23	1:30 PM	Section 7	10
2534	Targeting defective necroptosis in colorectal cancer to overcome therapeutic resistance	Kaylee	Ermine	Poster	Apoptosis and Bcl-2 Family Members	4/17/23	1:30 PM	Section 7	11
2535	Inhibition of oncogenic ASPP2kappa(k), a dominant-negative isoform of the tumorsuppressor ASPP2, results in reactivation of p53 in glioblastoma	Kerstin	Kampa-Schittenhelm	Poster	Apoptosis and Bcl-2 Family Members	4/17/23	1:30 PM	Section 7	12
2536	Intracellular Ctl4 overexpression promotes melanoma progression and metastasis	Hasan	Kazmi	Poster	Apoptosis and Bcl-2 Family Members	4/17/23	1:30 PM	Section 7	13
2537	Targeting acute myeloid leukemia cell death via small molecule AP-3-84 binding to the LxCxE pocket of Rb1	Avishek	Bhuniya	Poster	Apoptosis and Bcl-2 Family Members	4/17/23	1:30 PM	Section 7	14
2538	MiR-92b targets FBXW7 in GBM cells	Annelis	Sanchez-Alvarez	Poster	Apoptosis and Bcl-2 Family Members	4/17/23	1:30 PM	Section 7	15
2539	Tumor necrosis factor related apoptosis inducing ligand (TRAIL) induces cytokine release via the alternative NFKB2 pathway in triple negative breast cancer cells (TNBC) and modulates neutrophil chemotaxis	Manjari	Kundu	Poster	Apoptosis and Bcl-2 Family Members	4/17/23	1:30 PM	Section 7	16
2540	Modulation of apoptosis in pancreatic adenocarcinoma BxPC-3 cells and ductal carcinoma PANC-1 cells by aqueous extract of Bryophyllum pinnatum.	Jasmine	Cha	Poster	Apoptosis and Bcl-2 Family Members	4/17/23	1:30 PM	Section 7	17
2541	Heterogeneity of VDAC2-Bak/Bax mediated mitochondrial apoptosis can be exploited to develop effective and selective treatment against metastatic uveal melanoma	Piyush	Mishra	Poster	Apoptosis and Bcl-2 Family Members	4/17/23	1:30 PM	Section 7	18

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
2545	NNMT is a novel effector of EGFR driven glioblastoma malignancy	Lianping	Ma	Poster	Kinase Signaling	4/17/23	1:30 PM	Section 8	1
2546	Targeting of AKT/ β -catenin signaling pathways driven hepatocellular carcinoma cell lines by combined treatment of HDAC and multi-kinase inhibitors	Mohamed	Elberawi	Poster	Kinase Signaling	4/17/23	1:30 PM	Section 8	2
2547	YAP1 associates with the EPHA3 receptor tyrosine kinase to promote prostate cancer progression	Bekir	Cinar	Poster	Kinase Signaling	4/17/23	1:30 PM	Section 8	3
2548	Substrate binding, not phosphorylation, activates CBL poly-ubiquitination activity	Veronique	Baron	Poster	Kinase Signaling	4/17/23	1:30 PM	Section 8	4
2549	Targeting PI3Kinase AKT pathway and anti-apoptotic protein XIAP in chemotherapy-resistant colorectal cancer cells	Azhar	Rajabali	Poster	Kinase Signaling	4/17/23	1:30 PM	Section 8	5
2550	Growth factor-induced cell membrane macroplatforms drive protein kinase signaling for transformed cell growth	Saverio	Alberti	Poster	Kinase Signaling	4/17/23	1:30 PM	Section 8	6
2551	CASC4 drives anoikis resistance in high grade serous ovarian cancer through recycling of EGFR	Jaidev	Bapat	Poster	Kinase Signaling	4/17/23	1:30 PM	Section 8	7
2552	A novel RIP1-mediated canonical WNT signaling pathway promoting colorectal cancer metastasis	Jong Kuk	Park	Poster	Kinase Signaling	4/17/23	1:30 PM	Section 8	8
2553	Elucidation of the downstream signaling of PIK3CA genomic alterations in serous ovarian cancer	Shibo	Zhang	Poster	Kinase Signaling	4/17/23	1:30 PM	Section 8	9
2554	Phosphorylationdependent control of protein synthesis in response to inhibitors of mRNA translation and mitochondrial respiration in HeLa cancer cell line	Hamidreza	Galavi	Poster	Kinase Signaling	4/17/23	1:30 PM	Section 8	10
2555	14-3-3 and Smad2/3 are key mediators of atypical-PKCs in neuroblastoma progression	Sloan	Breedy	Poster	Kinase Signaling	4/17/23	1:30 PM	Section 8	11
2556	Phosphatase nanozyme combination with kinase inhibitor for decreasing prostate cancer cell viability	Arailym	Myrzagaliyeva	Poster	Kinase Signaling	4/17/23	1:30 PM	Section 8	12
2557	Targeting the IGF1R signaling pathway inhibits cell growth and dissemination in BCOR mutant retinoblastoma	Su-Chan	Lee	Poster	Kinase Signaling	4/17/23	1:30 PM	Section 8	13
2558	Loss of TC-PTP in keratinocytes leads to increased UVB-induced autophagy	Obed	Asare	Poster	Kinase Signaling	4/17/23	1:30 PM	Section 8	14
2559	Loss of AKT2 correlates with activation of β -catenin signaling in immortalized mouse hepatocytes	Ielyzaveta	Slarve	Poster	Kinase Signaling	4/17/23	1:30 PM	Section 8	15
2560	Post-translational modification of focal adhesion kinase (FAK) protein increases in breast cancer cells upon exposure to conditioned medium derived from in vitro and in vivo adipocytes	Noshin	Mubtasim	Poster	Kinase Signaling	4/17/23	1:30 PM	Section 8	16
2561	Computational drug repositioning identifies Akt inhibitor MK2206 binding to EZH2 as enhancer of Tazmetostat efficacy in inhibition of triple negative breast cancer proliferation	Eswar	Shankar	Poster	Kinase Signaling	4/17/23	1:30 PM	Section 8	17

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
2562	Role of MET signaling in cetuximab resistance and generation of an imaging biomarker to identify MET-driven cetuximab resistance in colorectal cancer	Bhuminder	Singh	Poster	Kinase Signaling	4/17/23	1:30 PM	Section 8	18
2563	Identifying BCLAF1 as a downstream effector of p85 β in ovarian cancer	Panpan	Wang	Poster	Kinase Signaling	4/17/23	1:30 PM	Section 8	19
2564	Targeting IGF-1/STAT3 signaling crosstalk to inhibit prostate cancer growth and metastasis	Sandeep	Sheth	Poster	Kinase Signaling	4/17/23	1:30 PM	Section 8	20
2565	Divergentnucleocytoplasmic transport influences escape from HER2-activated DCIS-like state	Lixin	Wang	Poster	Kinase Signaling	4/17/23	1:30 PM	Section 8	21
2566	Blocking the functional domain of TIP1 upregulates midkine via the β -catenin/Wnt signaling pathway	Minakshi	Saikia	Poster	Kinase Signaling	4/17/23	1:30 PM	Section 8	22
2567	Exploring novel roles of the GPCR Smoothened in AKT signaling and drug resistance	Samantha	Manuel	Poster	Kinase Signaling	4/17/23	1:30 PM	Section 8	23
2569	Investigation of the effect of chronic IL-1 exposure on breast cancer cell line response to external signaling factors	Roopal	Dhar	Poster	Kinase Signaling	4/17/23	1:30 PM	Section 8	25
2573	A novel regulation of the Wnt/ β -catenin pathway involving NLRP12 during colorectal tumorigenesis	Shahanshah	Khan	Poster	Oncogene and Tumor Suppressor Signaling in Cancer 1	4/17/23	1:30 PM	Section 9	1
2574	An exon-skipping HDAC1 novel isoform promotes colorectal carcinogenesis	Guangzheng	Deng	Poster	Oncogene and Tumor Suppressor Signaling in Cancer 1	4/17/23	1:30 PM	Section 9	2
2575	A multi-omic screening approach identifies the E3-ubiquitin ligase DCAF13 as a novel vulnerability in lung adenocarcinoma	Vinona	Wagner	Poster	Oncogene and Tumor Suppressor Signaling in Cancer 1	4/17/23	1:30 PM	Section 9	3
2577	Pre-cancerous ovarian cells harboring a familial SMARCA4 mutation acquire in vitro phenotypes associated with transformation in SSCOHT	Sonali	Joshi	Poster	Oncogene and Tumor Suppressor Signaling in Cancer 1	4/17/23	1:30 PM	Section 9	5
2578	Phosphorylation of AHR by PLK1 promotes metastasis of LUAD via upregulation of DIO2	Chaohao	Li	Poster	Oncogene and Tumor Suppressor Signaling in Cancer 1	4/17/23	1:30 PM	Section 9	6
2579	The tumor landscape is molded by quantitative and qualitative signaling differences between different oncogenic KRAS mutations	Ozgun	Le Roux	Poster	Oncogene and Tumor Suppressor Signaling in Cancer 1	4/17/23	1:30 PM	Section 9	7
2580	Nuclear receptor coactivator 3 (NCOA3) fuels oncogenic pathways in uveal melanoma	Aleksandra	Rusin	Poster	Oncogene and Tumor Suppressor Signaling in Cancer 1	4/17/23	1:30 PM	Section 9	8
2581	Fatty acid synthase regulates expression of Notum in colorectal cancer	Courtney	Kelson	Poster	Oncogene and Tumor Suppressor Signaling in Cancer 1	4/17/23	1:30 PM	Section 9	9
2582	Protein aggregation in sarcoma as a target for therapy	Sara	Sartini	Poster	Oncogene and Tumor Suppressor Signaling in Cancer 1	4/17/23	1:30 PM	Section 9	10
2583	AKT2 as the determining factor for PTEN loss-induced liver malignancy	Qi	Tang	Poster	Oncogene and Tumor Suppressor Signaling in Cancer 1	4/17/23	1:30 PM	Section 9	11

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
2584	Overcoming cetuximab resistance in colorectal cancer through inhibition of HGF processing	Vivian	Jones	Poster	Oncogene and Tumor Suppressor Signaling in Cancer 1	4/17/23	1:30 PM	Section 9	12
2585	Mutant p53 gains oncogenic functions through a cytosolic DNA response	Ge	Zhou	Poster	Oncogene and Tumor Suppressor Signaling in Cancer 1	4/17/23	1:30 PM	Section 9	13
2586	OncogenicPIK3CA promotes hematopoietic reprogramming and cell transdifferentiation developing hematopoietic malignancy	Jong Hyuk	Kim	Poster	Oncogene and Tumor Suppressor Signaling in Cancer 1	4/17/23	1:30 PM	Section 9	14
2587	AHR-WLS complex correlates with poor prognosis in B-cell precursor acute lymphoblastic leukemia	Li-Ting	Wang	Poster	Oncogene and Tumor Suppressor Signaling in Cancer 1	4/17/23	1:30 PM	Section 9	15
2589	TROP2 gene copy number variations are a hallmark of glioblastoma and MEN-2A cancers	Saverio	Alberti	Poster	Oncogene and Tumor Suppressor Signaling in Cancer 1	4/17/23	1:30 PM	Section 9	17
2590	TP53 R249S mutation confers hepatic organoids with gain-of-function (GOF) tumorigenic features through transcriptional activation of ZMIZ2	Mingjing	Xu	Poster	Oncogene and Tumor Suppressor Signaling in Cancer 1	4/17/23	1:30 PM	Section 9	18
2591	Role of Rab25 in Melanoma and its potential targeting	Samikshya	Kandel	Poster	Oncogene and Tumor Suppressor Signaling in Cancer 1	4/17/23	1:30 PM	Section 9	19
2592	Helicobacter pylori-induced FGFR4 mediates nuclear accumulation of NRF2 in gastric tumorigenesis	Nadeem	Bhat	Poster	Oncogene and Tumor Suppressor Signaling in Cancer 1	4/17/23	1:30 PM	Section 9	20
2593	A MYCN-independent mechanism mediating secretome reprogramming and metastasis in MYCN-amplified neuroblastoma	Hai-Feng	Zhang	Poster	Oncogene and Tumor Suppressor Signaling in Cancer 1	4/17/23	1:30 PM	Section 9	21
2594	Alcohol drinking inhibits NOTCH-PAX9 signaling in esophageal squamous epithelial cells	Zhaohui	Xiong	Poster	Oncogene and Tumor Suppressor Signaling in Cancer 1	4/17/23	1:30 PM	Section 9	22
2598	The DACH1 gene is frequently deleted in prostate cancer, restrains prostatic intraepithelial neoplasia, augments DNA damage repair and predicts therapy responses	Richard	Pestell	Poster	Oncogene and Tumor Suppressor Signaling in Cancer 2	4/17/23	1:30 PM	Section 10	1
2599	Targeting SETD2-inactivated cells with STF-62247 leads to cell cycle arrest	Mathieu	Johnson	Poster	Oncogene and Tumor Suppressor Signaling in Cancer 2	4/17/23	1:30 PM	Section 10	2
2600	BBOX1 is a novel tumor suppressor in kidney cancer	Chengheng	Liao	Poster	Oncogene and Tumor Suppressor Signaling in Cancer 2	4/17/23	1:30 PM	Section 10	3
2601	Lrig1 is a haplo-insufficient tumor suppressor and Lrig1-expressing cells can function as cells-of-origin of tumor development	Moyi	Wang	Poster	Oncogene and Tumor Suppressor Signaling in Cancer 2	4/17/23	1:30 PM	Section 10	4
2602	Loss of glutathione S-Transferase omega 2 is associated with PD-L1 expression and poor prognosis in lung adenocarcinoma	Ryusuke	Sumiya	Poster	Oncogene and Tumor Suppressor Signaling in Cancer 2	4/17/23	1:30 PM	Section 10	5
2603	Investigating TUSC2 for its tumor suppressive functions in glioblastoma and its role in gliomagenesis	Austin	Arrigo	Poster	Oncogene and Tumor Suppressor Signaling in Cancer 2	4/17/23	1:30 PM	Section 10	6
2604	Functional analysis of p53 codon 72 polymorphism with cysteine substitution in cancer cells	Shengliang	Zhang	Poster	Oncogene and Tumor Suppressor Signaling in Cancer 2	4/17/23	1:30 PM	Section 10	7

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
2605	LOXL3 knock out affects pathways which involve cytoskeleton regulation, proliferation and apoptosis in glioblastoma cells	Sueli	Oba-Shinjo	Poster	Oncogene and Tumor Suppressor Signaling in Cancer 2	4/17/23	1:30 PM	Section 10	8
2606	Requirement of MDM2 E3 ligase activity for regulating p53 during normal development, cell cycle regulation and genome integrity	Meenalakshmi	Chinnam	Poster	Oncogene and Tumor Suppressor Signaling in Cancer 2	4/17/23	1:30 PM	Section 10	9
2607	Homogenous TP53mut-associated tumor biology across mutation and cancer types revealed by comprehensive mRNA expression analysis	Jan	Budczies	Poster	Oncogene and Tumor Suppressor Signaling in Cancer 2	4/17/23	1:30 PM	Section 10	10
2608	Defining the function of tumor suppressor p53 arginine 181 residue in tumorigenesis	Renyta	Moses	Poster	Oncogene and Tumor Suppressor Signaling in Cancer 2	4/17/23	1:30 PM	Section 10	11
2609	Non-CpG sites preference in G:C>A:T transition of TP53 in gastric cancer of Eastern Europe (Poland, Romania and Hungary) compared to East Asian countries (China and Japan) : gastric cancer in the world, mutation spectrum revisited	Haruhiko	Sugimura	Poster	Oncogene and Tumor Suppressor Signaling in Cancer 2	4/17/23	1:30 PM	Section 10	12
2610	GNAQ/GNA11 and BAP1 mutant isogenic cell lines engineered by CRISPR/Cas9 gene editing to model ocular melanoma	Aur�lie	Fuentes-Rodriguez	Poster	Oncogene and Tumor Suppressor Signaling in Cancer 2	4/17/23	1:30 PM	Section 10	13
2611	p63 constrains cancer cell transposable element expressions and viral mimicry response to sustain esophageal cancer development and indicates therapeutic vulnerability	Bryan Cheechad	Lung	Poster	Oncogene and Tumor Suppressor Signaling in Cancer 2	4/17/23	1:30 PM	Section 10	14
2612	Mutational pattern of SWI/SNF pathway genes in lung adenocarcinoma patients reveal uneven correlation with immunotherapy sensitivity	Haimeng	Tang	Poster	Oncogene and Tumor Suppressor Signaling in Cancer 2	4/17/23	1:30 PM	Section 10	15
2613	Chronic NNAL exposure, mimicking tobacco use in humans, deactivates LKB1 and promotes tumor progression in non-small cell lung cancer	Chengguo	Xing	Poster	Oncogene and Tumor Suppressor Signaling in Cancer 2	4/17/23	1:30 PM	Section 10	16
2617	Rac and Cdc42 inhibition on macrophage function in the pancreatic tumor microenvironment	Anamaris	Torres-S�nchez	Poster	Ras-related Signaling	4/17/23	1:30 PM	Section 11	1
2618	IQGAP3 regulates intra-cellular Ras signaling and intra-tumoral malignant cycles via TGF� signaling	Mitsuhiro	Shimura	Poster	Ras-related Signaling	4/17/23	1:30 PM	Section 11	2
2619	Characterization of RAS assembly architectures in living cells	Zhiwei	Zhou	Poster	Ras-related Signaling	4/17/23	1:30 PM	Section 11	3
2620	TRIM4 is the E3 ubiquitin-ligase for TPL2/MAP3K8 and is modulated by oncogenic KRAS	Sapana	Bansod	Poster	Ras-related Signaling	4/17/23	1:30 PM	Section 11	4
2621	Characterizing MEK1/2 degradation in K-ras mutant cells	Carlos	Herrera-Montavez	Poster	Ras-related Signaling	4/17/23	1:30 PM	Section 11	5
2622	Targeting Rac/Cdc42 GTPases to overcome HER2-targeted therapy resistance	Miciely	Aponte Reyes	Poster	Ras-related Signaling	4/17/23	1:30 PM	Section 11	6
2623	Identification of KRAS suppressor genes: an ORFeome library screening	Christophe	Marcireau	Poster	Ras-related Signaling	4/17/23	1:30 PM	Section 11	7

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
2624	Assay toolkit for the discovery of new RAS pathway inhibitors	Ekaterina	Kouznetsova	Poster	Ras-related Signaling	4/17/23	1:30 PM	Section 11	8
2625	KRAS activity-mediated mechanism of castration-resistant prostate cancer progression	Taiki	Kamijima	Poster	Ras-related Signaling	4/17/23	1:30 PM	Section 11	9
2626	Rac-mediated hyper-phagocytosis causes immunodeficiency and enhances cancer cell killing	Abhinava	Mishra	Poster	Ras-related Signaling	4/17/23	1:30 PM	Section 11	10
2627	The small molecule KRAS inhibitor, TEB-17231, blocks tumor progression and overcomes KRASG12C inhibitor mediated resistance	David	Weaver	Poster	Ras-related Signaling	4/17/23	1:30 PM	Section 11	11
2628	Protein-level regulation of wild-type and mutant RIT1 by the deubiquitinase USP9X	Amanda	Riley	Poster	Ras-related Signaling	4/17/23	1:30 PM	Section 11	12
2629	Single and combined inhibition of PAK and Hippo pathway in NF2-deficient schwannoma	Dorothy	Benton	Poster	Ras-related Signaling	4/17/23	1:30 PM	Section 11	13
2633	Zanidatamab zovodotin (ZW49) induces hallmarks of immunogenic cell death and is active in patient-derived xenograft models of gastric cancer	Stuart	Barnscher	Poster	Antibody Technologies	4/17/23	1:30 PM	Section 13	1
2634	AMB302/GR1017, an antibody-drug conjugate (ADC) with topoisomerase 1 inhibitor shows therapeutic potency in orthotopic glioblastoma PDX and bladder cancer models with FGFR3-TACC3 fusion	Byeongkwi	Min	Poster	Antibody Technologies	4/17/23	1:30 PM	Section 13	2
2635	N-Myristolytransferase (NMT) inhibitors as novel potent payloads for antibody drug conjugates	Robin	Carr	Poster	Antibody Technologies	4/17/23	1:30 PM	Section 13	3
2636	Amanitin-based ADCs targeting Guanylyl cyclase C (GCC) as novel therapeutic modality for treatment of colorectal cancer	Alexandra	Braun	Poster	Antibody Technologies	4/17/23	1:30 PM	Section 13	4
2637	Novel folate receptor alpha-directed antibody-drug conjugate PRO1184 demonstrates broad antitumor activity with a promising safety profile in preclinical models	Zhu	Chen	Poster	Antibody Technologies	4/17/23	1:30 PM	Section 13	5
2638	Preclinical development of ADCT-212, a PSMA-targeted antibody-drug conjugate employing the pyrrolbenzodiazepine dimer SG2000 for PSMA-expressing cancers	Francesca	Zammarchi	Poster	Antibody Technologies	4/17/23	1:30 PM	Section 13	6
2640	An innovative site-specific dual-payload antibody drug conjugate (dpADC) combining a novel Topo1 inhibitor and an immune agonist delivers a strong immunogenic cell death (ICD) and antitumor response in vitro and in vivo	Paul	Song	Poster	Antibody Technologies	4/17/23	1:30 PM	Section 13	8
2641	ZW191, a novel FRa-targeting antibody drug conjugate bearing a topoisomerase 1 inhibitor payload	Sam	Lawn	Poster	Antibody Technologies	4/17/23	1:30 PM	Section 13	9
2642	BL-B01D1, a novel EGFR×HER3-targeting ADC, demonstrates robust anti-tumor efficacy in preclinical evaluation	Jahan	Khalili	Poster	Antibody Technologies	4/17/23	1:30 PM	Section 13	10

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
2643	BL-M07D1, a novel HER2-targeting ADC, demonstrates potent anti-tumor efficacy in preclinical pharmacodynamic models	Jahan	Khalili	Poster	Antibody Technologies	4/17/23	1:30 PM	Section 13	11
2644	BL-M02D1, a novel Trop2-targeting ADC, demonstrates robust anti-tumor efficacy in preclinical evaluation	Jahan	Khalili	Poster	Antibody Technologies	4/17/23	1:30 PM	Section 13	12
2645	A high-throughput platform for targets screening by membrane protein library	Feng	Hao	Poster	Antibody Technologies	4/17/23	1:30 PM	Section 13	13
2646	Screening the membrane proteome to determine antibody specificity and de-risk CAR-T cell development	Joseph	Rucker	Poster	Antibody Technologies	4/17/23	1:30 PM	Section 13	14
2647	Novel FGFR2 biparatopic antibodies for the treatment of cholangiocarcinoma	Saireudee	Chaturantabut	Poster	Antibody Technologies	4/17/23	1:30 PM	Section 13	15
2648	In vivo efficacy and preclinical safety profile of NN3201, an anti-cKIT antibody-drug conjugate, for treating SCLC and AML	Sung Tae	Kim	Poster	Antibody Technologies	4/17/23	1:30 PM	Section 13	16
2649	Discovery of a potent, selective, and tumor-suppressing antibody antagonist of DKK1	Linya	Wang	Poster	Antibody Technologies	4/17/23	1:30 PM	Section 13	17
2650	Pre-clinical efficacy and toxicity profile of LM-24C5: A novel CEACAM5 x 4-1BB bispecific antibody in cancer immunotherapy	Runsheng	Li	Poster	Antibody Technologies	4/17/23	1:30 PM	Section 13	18
2653	ABN501, a novel anti-claudin-3 antibody, shows potent anti-cancer activity in vitro and in vivo	Saehyung	Lee	Poster	Antibody Technologies	4/17/23	1:30 PM	Section 13	21
2654	Inhibition of lymphoma interactions with angiogenic and lymphangiogenic endothelium using α CD20-IgG1-huEndoP125A, an anti-CD20 endostatin fusion protein	Christian	Elledge	Poster	Antibody Technologies	4/17/23	1:30 PM	Section 13	22
2655	Anti-CD19 antibody-drug conjugate therapy in B cell non-Hodgkin lymphoma	Chieko	Saito	Poster	Antibody Technologies	4/17/23	1:30 PM	Section 13	23
2656	Reversible chemical modification of antibodies: A complementary approach to tuning Fc γ R binding that maintains anti-tumor activity while mitigating peripheral immune activation	Philip	Moquist	Poster	Antibody Technologies	4/17/23	1:30 PM	Section 13	24
2657	Preclinical model to evaluate the safety and efficacy of PODO83: A monoclonal antibody against podocalyxin that targets tumor growth and metastasis	Julyanne	Brassard	Poster	Antibody Technologies	4/17/23	1:30 PM	Section 13	25
2658	ZW251, a novel glypican-3-targeting antibody drug conjugate bearing a topoisomerase 1 inhibitor payload	Laurence	Madera	Poster	Antibody Technologies	4/17/23	1:30 PM	Section 13	26
2659	Anti-HER3 antibody, HMBD-001, in combination with an EGFR inhibitor effectively inhibits tumor growth in biomarker-selected pre-clinical models of squamous cell carcinomas	Weiyi	Toy	Poster	Antibody Technologies	4/17/23	1:30 PM	Section 13	27
2660	HMBD-501 - a novel Fc engineered, exatecan-based next generation HER3 targeting antibody drug conjugate shows robust efficacy and tolerability in pre-clinical solid tumor models	Suhail Ahmed Kabeer	Rasheed	Poster	Antibody Technologies	4/17/23	1:30 PM	Section 13	28

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
2661	Engineered Toxin Bodies (ETBs): Clinical stage immunotoxins with a safer and differentiated profile	Chris	Moore	Poster	Antibody Technologies	4/17/23	1:30 PM	Section 13	29
2665	Biochemical inhibition profiles of 370 wild type human kinases provide a basis for selecting alternative combinations of EGFR and VEGFR inhibitors	Nathan	Coussens	Poster	Chemotherapeutic Combinations	4/17/23	1:30 PM	Section 14	1
2666	Preclinical investigations of concomitant tumor treating fields (TTFields) with cisplatin or paclitaxel for treatment of cervical cancer	Adi	Haber	Poster	Chemotherapeutic Combinations	4/17/23	1:30 PM	Section 14	2
2667	PARG inhibition augments CHK1 inhibitor-induced replication stress and synergistically kills ovarian cancer cells	Ganesh	Acharya	Poster	Chemotherapeutic Combinations	4/17/23	1:30 PM	Section 14	3
2668	Long non-coding RNA TUG1 promotes cisplatin resistance in ovarian cancer via DNA polymerase eta	Ryosuke	Sonobe	Poster	Chemotherapeutic Combinations	4/17/23	1:30 PM	Section 14	4
2669	RRM2 inhibition synergizes with PARP inhibitor in ovarian cancer cells	Chi-Wei	Chen	Poster	Chemotherapeutic Combinations	4/17/23	1:30 PM	Section 14	5
2670	Drug combinations against Barrett's stem cells show efficacy across advanced lesions in esophageal cancer	Wa	Xian	Poster	Chemotherapeutic Combinations	4/17/23	1:30 PM	Section 14	6
2671	Imipridones ONC201 and ONC206 reduce expression of neogenin and EZH1/2 which correlate with synergy following their combination with EZH1/2 or HDAC inhibitors in treatment of DMG and other tumors	Yiqun	Zhang	Poster	Chemotherapeutic Combinations	4/17/23	1:30 PM	Section 14	7
2672	Combination of hydroxychloroquine, paricalcitol and gemcitabine modulate autophagy and anti-tumor responses in pancreatic ductal adenocarcinoma	Purnachandra Nagaraju	Ganji	Poster	Chemotherapeutic Combinations	4/17/23	1:30 PM	Section 14	8
2673	Several LSD1 inhibitors have a potential to disturb fatty acid metabolism necessary & glycolysis-inhibited pancreatic cancers to survive	Zhiheng	Zhang	Poster	Chemotherapeutic Combinations	4/17/23	1:30 PM	Section 14	9
2674	Synergistic combinations of lurbinectedin with irinotecan and ONC212 in pancreatic cancer	Tej	Tummala	Poster	Chemotherapeutic Combinations	4/17/23	1:30 PM	Section 14	10
2675	Vactosertib combined treatment with T1-44, a PRMT5 activity inhibitor, improves the survival and inhibits tumor invasion of murine pancreatic cancer model	Eunji	Hong	Poster	Chemotherapeutic Combinations	4/17/23	1:30 PM	Section 14	11
2676	Gender-associated improvement in gemcitabine's therapeutic outcome by Palmatine	Meagan	Ybarra	Poster	Chemotherapeutic Combinations	4/17/23	1:30 PM	Section 14	12
2677	ROCK inhibitors synergize with the BCL2 inhibitor venetoclax for treatment of AML	Upendarrao	Golla	Poster	Chemotherapeutic Combinations	4/17/23	1:30 PM	Section 14	13

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
2678	Combination therapy with cabozantinib and cannabidiol enhances the apoptotic cell death via phosphorylation of TP53 regulated by ER-stress in hepatocellular carcinoma	Young-Joo	Kim	Poster	Chemotherapeutic Combinations	4/17/23	1:30 PM	Section 14	14
2679	Combination of CDK 4/6 inhibitor palbociclib with rapamycin synergistically inhibits growth of hepatocellular carcinoma in preclinical models	Ankur	Tiwari	Poster	Chemotherapeutic Combinations	4/17/23	1:30 PM	Section 14	15
2680	Combination of the Rac/Cdc42 inhibitor MBQ-167 with paclitaxel reduces metastasis in triple negative breast cancer	Ailed	Cruz-Collazo	Poster	Chemotherapeutic Combinations	4/17/23	1:30 PM	Section 14	16
2681	Combination therapy of heme inhibitory protein (HeSP2) and Cyclopamine tartrate (CycT) with chemotherapeutic drugs is an effective strategy for treatment of TNBC	Parinaz Sadat	Alemi	Poster	Chemotherapeutic Combinations	4/17/23	1:30 PM	Section 14	17
2682	Targeting phosphoglycerate dehydrogenase (PHGDH) in combination with tamoxifen reduces hormone receptor positive breast cancer growth in vivo	Brian	Clem	Poster	Chemotherapeutic Combinations	4/17/23	1:30 PM	Section 14	18
2683	Investigation to explore how duocarmycin prodrugs bioactivated by cytochrome P450 enzymes can be used in combination therapy to treat breast cancer cells	Enrica	Denasio	Poster	Chemotherapeutic Combinations	4/17/23	1:30 PM	Section 14	19
2684	Synergistic efficacy of HSP90 and PI3K inhibitors in adrenocortical carcinoma	Prachi	Mishra	Poster	Chemotherapeutic Combinations	4/17/23	1:30 PM	Section 14	20
2685	Synergistic antitumor effect of oncolytic virus and cytotoxic chemotherapy in gastric cancer	Jee Hung	Kim	Poster	Chemotherapeutic Combinations	4/17/23	1:30 PM	Section 14	21
2686	The combination of Cucurbitacin B and Evodiamine inhibits cell migration and propagation, and induces apoptosis in in vitro glioma cells	Vrutti	Mehta	Poster	Chemotherapeutic Combinations	4/17/23	1:30 PM	Section 14	22
2687	The combination of temozolomide and minocycline for the treatment of glioblastoma	Marco	Arriaga	Poster	Chemotherapeutic Combinations	4/17/23	1:30 PM	Section 14	23
2688	Inhibition of CDK7 using small molecule inhibitor, TGN-1062, augments the effect of cisplatin treatment in head and neck PDX models	Trason	Thode	Poster	Chemotherapeutic Combinations	4/17/23	1:30 PM	Section 14	24
2689	Targeting the proteasome pathway in dactinomycin resistant Wilms tumors	Patricia Denise	Tiburcio	Poster	Chemotherapeutic Combinations	4/17/23	1:30 PM	Section 14	25
2690	In vivo CRISPR screen identifies SOAT1 as a chemotherapy chemosensitizing target for non-small cell lung cancer (NSCLC)	Long Shan	Li	Poster	Chemotherapeutic Combinations	4/17/23	1:30 PM	Section 14	26
2691	A triple combination of fostrox (MIV-818) with immune checkpoint and kinase inhibition shows increased anti-tumor efficacy in vivo	Fredrik	Oberg	Poster	Chemotherapeutic Combinations	4/17/23	1:30 PM	Section 14	27

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
2692	The combination of ulixertinib (ERK1/2 Inhibitor) and KRASG12C inhibition demonstrates significant efficacy in preclinical models	Deborah	Knoerzer	Poster	Chemotherapeutic Combinations	4/17/23	1:30 PM	Section 14	28
2693	Combining ulixertinib (ERK1/2 Inhibitor) with EGFR and BRAF inhibition yields significant efficacy in preclinical BRAFV600E mutant colorectal cancer models	Deborah	Knoerzer	Poster	Chemotherapeutic Combinations	4/17/23	1:30 PM	Section 14	29
2694	Blockade of the cyclooxygenase-2 prevents chemotherapy-induced cognitive impairments	Mohammad Abdur	Rashid	Poster	Chemotherapeutic Combinations	4/17/23	1:30 PM	Section 14	30
2698	Improved calcium phosphate delivery system cNaD to aim clinical application	Hirofumi	Yamamoto	Poster	Drug Delivery Systems	4/17/23	1:30 PM	Section 15	1
2699	FF-10850, a dihydrosphingomyelin (DHSM)-based novel liposomal topotecan, achieved favorable efficacy and safety in combination with platinum, PARP and immune checkpoint inhibitors	Ken	Okada	Poster	Drug Delivery Systems	4/17/23	1:30 PM	Section 15	2
2700	ORM-6151: A first-in-class CD33-antibody enabled GSPT1 degrader for AML	James	Palacino	Poster	Drug Delivery Systems	4/17/23	1:30 PM	Section 15	3
2701	pH-responsive targeted-nanoparticle releases encapsulated ERK-inhibitor effectively in the hypoxic microenvironment and sensitizes gemcitabine in pancreatic cancer cells	Debasmita	Dutta	Poster	Drug Delivery Systems	4/17/23	1:30 PM	Section 15	4
2702	GQ1001 is a next generation HER2-targeting ADC with excellent druggability, safety and potency	Lei	Huang	Poster	Drug Delivery Systems	4/17/23	1:30 PM	Section 15	5
2703	Evaluation of the effect of tumor-targeted and immunomodulating nanoparticles on the activity of cytotoxic T cells using CAR T cells as an in vitro model	Kory	Wells	Poster	Drug Delivery Systems	4/17/23	1:30 PM	Section 15	6
2705	Low-dose crystalline cytokine macrophage mediated Trojan horse immunotherapy of solid cancers	Michael	Jones	Poster	Drug Delivery Systems	4/17/23	1:30 PM	Section 15	8
2706	Therapeutic silencing of Rictor using siRNA nanoparticles to selectively block mTORC2 signaling in triple negative breast cancer	Shrusti	Patel	Poster	Drug Delivery Systems	4/17/23	1:30 PM	Section 15	9
2707	Therapeutic effects of WT1 silencing by respiratory administration of liposomal siRNA in a melanoma murine model	Martin	Ramos-Gonzalez	Poster	Drug Delivery Systems	4/17/23	1:30 PM	Section 15	10
2708	Nano-immunotherapy: efficacy of nanoconjugate QN-247 in a triple negative breast cancer (TNBC) mouse model	Tariq	Arshad	Poster	Drug Delivery Systems	4/17/23	1:30 PM	Section 15	11
2709	Leukosome-based siRNA strategy for targeting ribosomal protein L39 (RPL39) in metaplastic breast cancer	Maria	Chervo	Poster	Drug Delivery Systems	4/17/23	1:30 PM	Section 15	12
2710	Developing a novel doppel-targeting antibody-drug conjugate (ADC) for solid cancer	Ha Kyeong	Lee	Poster	Drug Delivery Systems	4/17/23	1:30 PM	Section 15	13
2711	Smart encapsulation of a MEK inhibitor into M2-9SLP/mApoE-liposomes for specific GBM targeting	Milena	Mattioli	Poster	Drug Delivery Systems	4/17/23	1:30 PM	Section 15	14
2712	Killing cancer stem cells in 72 hours can cure breast cancer	Taisun	Kim	Poster	Drug Delivery Systems	4/17/23	1:30 PM	Section 15	15

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
2713	Modulation of the blood-tumor barrier by 6-bromoindirubin acetoxime increases intra-tumoral drug accumulation and extends survival in murine glioblastoma models	Jorge	Jimenez Macias	Poster	Drug Delivery Systems	4/17/23	1:30 PM	Section 15	16
2714	Inhibiting Myc using heterofunctional polymeric degrading chimeras (HYDRACs): a novel class of compounds capable of targeted protein degradation	Max	Wang	Poster	Drug Delivery Systems	4/17/23	1:30 PM	Section 15	17
2715	Utilizing a pH sensitive peptide (pHLIP) for tumor targeted delivery of an immunogenic peptide motif	Annali	Yurkevicz	Poster	Drug Delivery Systems	4/17/23	1:30 PM	Section 15	18
2716	Further development of microRNA-34a therapeutics to target castration-resistant prostate cancer	Wen (Jess)	Li	Poster	Drug Delivery Systems	4/17/23	1:30 PM	Section 15	19
2717	A potent and highly tumor-selective KRAS inactivator for tumor targeting	Shihui	Liu	Poster	Drug Delivery Systems	4/17/23	1:30 PM	Section 15	20
2718	Co-loading of a novel PI3-Kdelta/HDAC6 dual inhibitor and navitoclax into Quatramer TM biodegradable polymeric nanoparticles synergistically inhibit growth of ER+breast cancer	Surender	Kharbanda	Poster	Drug Delivery Systems	4/17/23	1:30 PM	Section 15	21
2719	Tumor-associated macrophage reprogramming by novel nano-in-cryogel biomaterials for breast cancer immunotherapy	Sydney	Henriques	Poster	Drug Delivery Systems	4/17/23	1:30 PM	Section 15	22
2720	Enhancing oral delivery of plant-derived vesicles	Yuan	Liu	Poster	Drug Delivery Systems	4/17/23	1:30 PM	Section 15	23
2721	Sustained delivery of low-dose anti-CTLA-4 by genetically engineered encapsulated cells to the tumor microenvironment drives tumor response and prolongs survival in a colorectal cancer model	Julien	Grogg	Poster	Drug Delivery Systems	4/17/23	1:30 PM	Section 15	24
2722	Synthesis and characterization of novel small molecule drug conjugates with different payloads designed to be released in tumor microenvironment by neutrophil elastase	Hans-Georg	Lerchen	Poster	Drug Delivery Systems	4/17/23	1:30 PM	Section 15	25
2723	Treatment of gastric cancer cells with tumor treating fields (TTFields) and concomitant FOLFOX	Eyal	Dor-On	Poster	Drug Delivery Systems	4/17/23	1:30 PM	Section 15	26
2730	Antisense-oligonucleotide therapy targeting BRAF alleviates pediatric brain tumors with intractable epilepsy	Jeong Ho	Lee	Poster	Gene and Vector-based Therapy	4/17/23	1:30 PM	Section 16	1
2731	STX-001, a locally administered LNP-formulated self-replicating mRNA that encodes the therapeutic payload IL-12, induces deep systemic immune responses to solid tumors	Ryan	Sowell	Poster	Gene and Vector-based Therapy	4/17/23	1:30 PM	Section 16	2
2732	A self-replicating RNA precision medicine approach to therapeutic protein delivery of narrow therapeutic index biomolecules	Zelanna	Goldberg	Poster	Gene and Vector-based Therapy	4/17/23	1:30 PM	Section 16	3
2733	TYMS as a novel target for AAV-based therapy	Vinod	Vijayakurup	Poster	Gene and Vector-based Therapy	4/17/23	1:30 PM	Section 16	4
2734	Modulation of resting T cell status to enhance transduction and CAR T expansion following exposure to CD8-targeted fusosomes	Brian	Dolinski	Poster	Gene and Vector-based Therapy	4/17/23	1:30 PM	Section 16	5

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
2735	Development of a novel, fully human anti-CD19 chimeric antigen receptor for in vivo delivery via CD8-targeted fusosome	Jeremy	Kinder	Poster	Gene and Vector-based Therapy	4/17/23	1:30 PM	Section 16	6
2736	Locoregional modified vaccinia ankara (MVA) encoding a single-chain IL-12 achieves efficacy antitumor immune response in peritoneal carcinomatosis	Ignacio	Melero	Poster	Gene and Vector-based Therapy	4/17/23	1:30 PM	Section 16	7
2737	A gene therapy with a novel PD-L1 inhibitory peptide secretory gene inhibits the growth of colon carcinoma in mice	Masaaki	Tamura	Poster	Gene and Vector-based Therapy	4/17/23	1:30 PM	Section 16	8
2739	Genetic modification of mesothelial cells with full length membrane-bound TRAIL for ovarian cancer treatment	Er	Yue	Poster	Gene and Vector-based Therapy	4/17/23	1:30 PM	Section 16	10
2740	Safe and effective delivery of antibody fragments to the solid tumor microenvironment	Samantha	Bucktrout	Poster	Gene and Vector-based Therapy	4/17/23	1:30 PM	Section 16	11
2741	Sexual dimorphism induces differential immunomodulatory outcomes from local nanoparticle and focused ultrasound therapy in murine model of head and neck cancer	Sri Vidhya	Chandrasekar	Poster	Gene and Vector-based Therapy	4/17/23	1:30 PM	Section 16	12
2742	Small interfering RNA targeting CD24 inhibits proliferation and migration of triple-negative breast cancer cells	Yanli	Liu	Poster	Gene and Vector-based Therapy	4/17/23	1:30 PM	Section 16	13
2743	Synergistic efficacy of telomerase-specific oncolytic adenoviral therapy and histone deacetylase inhibition in human hepatocellular carcinoma	Zhong-Zhe	Lin	Poster	Gene and Vector-based Therapy	4/17/23	1:30 PM	Section 16	14
2747	Combined investigation of anti-tumor efficacy and liver safety of bispecific T cell engagers in immune-competent high-throughput co-culturing platform	Michal	Rudnik	Poster	Innovative Assay Technologies	4/17/23	1:30 PM	Section 17	1
2748	Identifying therapeutic mechanism of action and new potential patient populations using PRISM	Shiker	Nair	Poster	Innovative Assay Technologies	4/17/23	1:30 PM	Section 17	2
2749	Preclinical assessment of chimeric antigen receptor (CAR) T persistence and functionality in the disseminated NALM6-Luc human B cell acute lymphoblastic leukemia (ALL) model	David	Draper	Poster	Innovative Assay Technologies	4/17/23	1:30 PM	Section 17	3
2750	Multiplexed plate-reader based drug screening of 3D-tumoroid models	Xiaoyu	Yang	Poster	Innovative Assay Technologies	4/17/23	1:30 PM	Section 17	4
2751	ENIGMACTM discovery platform enables gene to function target validation for macrophage therapy	Luca	Cassetta	Poster	Innovative Assay Technologies	4/17/23	1:30 PM	Section 17	5
2752	Targeting intracellular tumor antigens using fully human TCR mimic antibodies derived from HLA transgenic RenMiceTM	Qingcong	Lin	Poster	Innovative Assay Technologies	4/17/23	1:30 PM	Section 17	6
2753	Engineering patient-derived tumors to enable high-throughput screening: Immuno-oncology workflows	Andrew	Tsao	Poster	Innovative Assay Technologies	4/17/23	1:30 PM	Section 17	7
2754	Transwell-grown monolayers derived from small intestinal organoids to study the effects of tight junction modulators that	Valentina	Ubertini	Poster	Innovative Assay Technologies	4/17/23	1:30 PM	Section 17	8

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
	may improve the absorption of orally-administered, anti-neoplastic drugs								
2755	Identification of novel GPX4 inhibitors using global transcriptional reporters	Timothy	Read	Poster	Innovative Assay Technologies	4/17/23	1:30 PM	Section 17	9
2756	Custom G4 DNA microarray can determine large-scale binding selectivity of small molecules and proteins to oncogene G-quadruplexes	Kristen	Huseman	Poster	Innovative Assay Technologies	4/17/23	1:30 PM	Section 17	10
2757	Combination of a fluorescent substrate-based MMP activity assay and hit pick reading/imaging procedure to screen for inhibitors of MT1-MMP activity and 3D glioma tumoroid invasion	Brad	Larson	Poster	Innovative Assay Technologies	4/17/23	1:30 PM	Section 17	11
2758	Expanding PRISM high-throughput screening capabilities to other modalities	Jacob	Smigiel	Poster	Innovative Assay Technologies	4/17/23	1:30 PM	Section 17	12
2759	Real-time cellular target engagement and protein quantification for drug discovery	Ivan	Babic	Poster	Innovative Assay Technologies	4/17/23	1:30 PM	Section 17	13
2760	Evaluation of functional heterogeneity in the potent responses of single CAR-T effector cells	Benjamin	Yellen	Poster	Innovative Assay Technologies	4/17/23	1:30 PM	Section 17	14
2762	Inhibition of murine myeloid suppressor cells increases CD8+ T cell activation in Vitro	Anita	Zaitouna	Poster	Innovative Assay Technologies	4/17/23	1:30 PM	Section 17	16
2763	Characterization of a novel immunohistochemistry (IHC) assay for CEACAM5 using a commercial antibody	Chin Leng	Cheng	Poster	Innovative Assay Technologies	4/17/23	1:30 PM	Section 17	17
2764	Application of NanoBRET target engagement cellular assay for development of inhibitors against protein kinases, RAS, and epigenetic proteins in cancer therapy	Jianghong	Wu	Poster	Innovative Assay Technologies	4/17/23	1:30 PM	Section 17	18
2765	Detection and quantification of cellular GAMP using homogenous HTS formatted bioluminescent assay	Said	Goueli	Poster	Innovative Assay Technologies	4/17/23	1:30 PM	Section 17	19
2766	Automation of linear range determination: Enzymatic progress curve applications	Earl	May	Poster	Innovative Assay Technologies	4/17/23	1:30 PM	Section 17	20
2767	Simultaneous 18F-FDG PET/ MR imaging for metastases identification in a disseminated human preclinical melanoma model	Cyril	Berthet	Poster	Innovative Assay Technologies	4/17/23	1:30 PM	Section 17	21
2768	Non-invasive detection of pancreatic adenocarcinoma using Ga-68 labelled epha2 targeting peptide	Ajay Kumar	Sharma	Poster	Innovative Assay Technologies	4/17/23	1:30 PM	Section 17	22
2769	Qualification of human tumor cell lines for inclusion in the OncoPanel™ cell-based profiling and screening service	Steven	Garner	Poster	Innovative Assay Technologies	4/17/23	1:30 PM	Section 17	23
2770	Phenotypic profiling of Aurora inhibitors using the OncoPanel™ platform	Luciano	Galdieri	Poster	Innovative Assay Technologies	4/17/23	1:30 PM	Section 17	24

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
2771	KSQ-4279 mediated USP1 inhibition induces replication associated DNA gaps that contribute to cell death	Sumeet	Nayak	Poster	Innovative Assay Technologies	4/17/23	1:30 PM	Section 17	25
2772	The development of immunotherapy agents from the indigenous herbal plants and microbes used by the tantric practitioner of Vedic Jiva Upakara Cikitsa Tantra (Vedic altruism-based medicine system) of Assam, India	Lekhika	Pathak	Poster	Innovative Assay Technologies	4/17/23	1:30 PM	Section 17	26
2773	Homologous recombination deficiency in the CCLE cell lines correlates with in vitro resistance to platinum agents and PARP inhibitors	Shiro	Takamatsu	Poster	Innovative Assay Technologies	4/17/23	1:30 PM	Section 17	27
2774	Moesin-induced adriamycin resistance through IL-6/MSN/STAT3 axis and therapeutic efficacy of atovaquone in chemotherapy resistant triple-negative breast cancer	Cheng Hyun	Lee	Poster	Innovative Assay Technologies	4/17/23	1:30 PM	Section 17	28
2778	A novel MTA-cooperative PRMT5 inhibitor, MRTX1719, stabilizes the ternary MTA-PRMT5 complex and leads to synthetic lethality in MTAP deleted cancers	Peter	Olson	Poster	Pharmacokinetics, Pharmacodynamics, and Molecular Pharmacology	4/17/23	1:30 PM	Section 18	1
2779	Identification of mechanism-based combination targets effective with the MTA-cooperative PRMT5 inhibitor MRTX1719 for the treatment of MTAP deleted cancers	Peter	Olson	Poster	Pharmacokinetics, Pharmacodynamics, and Molecular Pharmacology	4/17/23	1:30 PM	Section 18	2
2780	Unique pharmacodynamic properties conferred by differential binding to BTK, pirtobrutinib vs covalent inhibitors	Joshua	Ballard	Poster	Pharmacokinetics, Pharmacodynamics, and Molecular Pharmacology	4/17/23	1:30 PM	Section 18	3
2781	Mechanism study of surufatinib on the optimized strategy of AG plus PD-1 antibody treatment in pancreatic cancer	Song	Gao	Poster	Pharmacokinetics, Pharmacodynamics, and Molecular Pharmacology	4/17/23	1:30 PM	Section 18	4
2782	Small molecule H182 suppresses Stat3 activation in tumor cells and combines with radiation therapy to block breast tumor growth in mouse syngeneic models	Yue	Chen	Poster	Pharmacokinetics, Pharmacodynamics, and Molecular Pharmacology	4/17/23	1:30 PM	Section 18	5
2783	TET2-STAT3-CXCL5 nexus promotes triglyceride transfer from neutrophils to cancer cells to fuel lung adeno-to-squamous transdifferentiation	Yun	Xue	Poster	Pharmacokinetics, Pharmacodynamics, and Molecular Pharmacology	4/17/23	1:30 PM	Section 18	6
2784	JW-1-283 inhibits melanoma tumor growth via the stabilization of p53 pathway	Yang	Xie	Poster	Pharmacokinetics, Pharmacodynamics, and Molecular Pharmacology	4/17/23	1:30 PM	Section 18	7
2785	Carbidopa/ α -methyltryptophan as an ideal combination therapy for breast cancer	Sirin	Falconi	Poster	Pharmacokinetics, Pharmacodynamics, and Molecular Pharmacology	4/17/23	1:30 PM	Section 18	8

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
2786	Targeting oncogene and inflammation for cancer therapy	Wei	Wang	Poster	Pharmacokinetics, Pharmacodynamics, and Molecular Pharmacology	4/17/23	1:30 PM	Section 18	9
2787	Targeting Nrf2 signaling pathway by Keap1-mediated degradation in acquired gemcitabine resistant pancreatic cancer cells	Sang Kook	Lee	Poster	Pharmacokinetics, Pharmacodynamics, and Molecular Pharmacology	4/17/23	1:30 PM	Section 18	10
2788	Extracellular vesicles as a pharmacodynamic reporter in glioblastoma	Valerie	DeLuca	Poster	Pharmacokinetics, Pharmacodynamics, and Molecular Pharmacology	4/17/23	1:30 PM	Section 18	11
2789	Tumor suppressor genotype dramatically impacts lung cancer response to KRAS G12C inhibitors in vivo	Paul	McMurdie	Poster	Pharmacokinetics, Pharmacodynamics, and Molecular Pharmacology	4/17/23	1:30 PM	Section 18	12
2790	Preclinical studies of ZG19018, a novel irreversible covalent inhibitor of KRAS G12C, for the treatment of advanced non-small cell lung cancer and other solid tumors	Bing	Zhu	Poster	Pharmacokinetics, Pharmacodynamics, and Molecular Pharmacology	4/17/23	1:30 PM	Section 18	13
2791	Biomarker strategy for a phase 1 study of ORIC-944, a potent and selective allosteric PRC2 inhibitor, in patients with metastatic prostate cancer	Anneleen	Daemen	Poster	Pharmacokinetics, Pharmacodynamics, and Molecular Pharmacology	4/17/23	1:30 PM	Section 18	14
2792	Development of pharmacodynamic assays for quantifying SMARCA2 protein degradation and target gene expression in response to a SMARCA2 degrader (PRT3789)	Andrew	Moore	Poster	Pharmacokinetics, Pharmacodynamics, and Molecular Pharmacology	4/17/23	1:30 PM	Section 18	15
2793	Preclinical pharmacokinetics in cynomolgus monkeys and first in human dose prediction of DB-1303, a HER2-targeting antibody-drug conjugate	Rong	Shi	Poster	Pharmacokinetics, Pharmacodynamics, and Molecular Pharmacology	4/17/23	1:30 PM	Section 18	16
2794	A Quantitative Systems Pharmacology (QSP) model to characterize dose-dependent antitumor activity of AZD5305, PARP1 selective inhibitor, across multiple xenograft models	Mark	Albertella	Poster	Pharmacokinetics, Pharmacodynamics, and Molecular Pharmacology	4/17/23	1:30 PM	Section 18	17
2795	A food effect and esomeprazole drug-drug interaction study of RLY-4008, a highly selective FGFR2 inhibitor, in healthy subjects	Xiaoyan	Li	Poster	Pharmacokinetics, Pharmacodynamics, and Molecular Pharmacology	4/17/23	1:30 PM	Section 18	18
2796	Tumor pharmacokinetics, pharmacodynamics and efficacy analysis of WEE1 inhibitor, zn-c3 in patient-derived xenograft models of glioblastoma	Shwetal	Mehta	Poster	Pharmacokinetics, Pharmacodynamics, and Molecular Pharmacology	4/17/23	1:30 PM	Section 18	19
2797	Multicenter pharmacokinetic study of pembrolizumab for non-small cell lung cancer in older adults aged over 75 years	Yoshiro	Nakahara	Poster	Pharmacokinetics, Pharmacodynamics, and Molecular Pharmacology	4/17/23	1:30 PM	Section 18	20

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
2798	Simplifying selection and optimization of step-up dosing of subcutaneous Epcoritamab to mitigate CRS risk using repeated time-to-event modeling	Tommy	Li	Poster	Pharmacokinetics, Pharmacodynamics, and Molecular Pharmacology	4/17/23	1:30 PM	Section 18	21
2799	Pharmacodynamic biomarkers for TGFBR1 inhibition in oncology	Richard	Heinz	Poster	Pharmacokinetics, Pharmacodynamics, and Molecular Pharmacology	4/17/23	1:30 PM	Section 18	22
2800	Pharmacokinetics, bioavailability, and pharmacodynamics of oral triapine	Jan	Beumer	Poster	Pharmacokinetics, Pharmacodynamics, and Molecular Pharmacology	4/17/23	1:30 PM	Section 18	23
2801	Pharmacokinetic modeling of Vincristine and its metabolite in Kenyan pediatric cancer patients	Taylor	Cornett	Poster	Pharmacokinetics, Pharmacodynamics, and Molecular Pharmacology	4/17/23	1:30 PM	Section 18	24
2802	Development of a surrogate tissue pharmacodynamic (PD) assay for clinical use with FX-909, a novel inhibitor of the urothelial luminal lineage transcription factor peroxisome proliferator-activated receptor gamma (PPARG)	Jennifer	Mertz	Poster	Pharmacokinetics, Pharmacodynamics, and Molecular Pharmacology	4/17/23	1:30 PM	Section 18	25
2803	Pharmacokinetics and pharmacodynamics of the novel OMA1 activator BTM 3566 in a mouse model of diffuse large B-cell lymphoma	Matthew	Kostura	Poster	Pharmacokinetics, Pharmacodynamics, and Molecular Pharmacology	4/17/23	1:30 PM	Section 18	26
2804	3D printing of perfusable alveolar model for efficacy evaluation of polyisoprenylated cysteinyl amide inhibitors on lung cancer cells	Diana	Romero	Poster	Pharmacokinetics, Pharmacodynamics, and Molecular Pharmacology	4/17/23	1:30 PM	Section 18	27
2805	Pharmacogenomic platform using patient-derived cells to delineate tumor heterogeneity and therapeutic response of refractory lung cancer	Charny	Park	Poster	Pharmacokinetics, Pharmacodynamics, and Molecular Pharmacology	4/17/23	1:30 PM	Section 18	28
2806	Patient-derived cell-based pharmacogenomic platform to uncover resistance mechanisms and novel therapeutics for advanced lung cancer	Charny	Park	Poster	Pharmacokinetics, Pharmacodynamics, and Molecular Pharmacology	4/17/23	1:30 PM	Section 18	29
2810	Increasing the efficacy of KRASG12Cinhibitor therapy through the adjuvant use of FAP targeted radiotherapy in a murine model of lung cancer	Kathleen	Capaccione	Poster	Radiosensitizers and Radio-immunomodulators	4/17/23	1:30 PM	Section 19	1
2811	CDK4/6 inhibition plus radiotherapy enhances anti-tumor immunity in non-small cell lung cancer	Yan	Gong	Poster	Radiosensitizers and Radio-immunomodulators	4/17/23	1:30 PM	Section 19	2
2812	NL-201, a de novo CD25-independent IL-2Rβ agonist, synergizes with radiation to generate potent antitumor immunity	DaeYong	Lee	Poster	Radiosensitizers and Radio-immunomodulators	4/17/23	1:30 PM	Section 19	3

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
2813	Pyruvate kinase M2 confers radioresistance in head and neck cancer through reprogramming the tumor-immune microenvironment via ECM1	Yong	Teng	Poster	Radiosensitizers and Radio-immunomodulators	4/17/23	1:30 PM	Section 19	4
2814	The mutational basis of cancer's vulnerability to ionizing radiation	Mohamed	Abazeed	Poster	Radiosensitizers and Radio-immunomodulators	4/17/23	1:30 PM	Section 19	5
2815	Analyzing nuclear paraspeckle-dependent protection of unphosphorylated MicroRNA	Graham	Read	Poster	Radiosensitizers and Radio-immunomodulators	4/17/23	1:30 PM	Section 19	6
2816	BUB1 inhibition radiosensitizes triple-negative breast cancer by targeting the DNA-damage repair pathways	Sushmitha	Sriramulu	Poster	Radiosensitizers and Radio-immunomodulators	4/17/23	1:30 PM	Section 19	7
2817	Combining the RCAS/TVA retrovirus system and a conditional oncohistone H3.3K27M allele to investigate radiosensitization strategies in primary mouse models of diffuse midline glioma	Sophie	Wu	Poster	Radiosensitizers and Radio-immunomodulators	4/17/23	1:30 PM	Section 19	8
2818	Investigating TNIK as a radiosensitizing target in lung squamous cell carcinoma	Triet	Nguyen	Poster	Radiosensitizers and Radio-immunomodulators	4/17/23	1:30 PM	Section 19	9
2819	Genome-wide CRISPR screen identifies NANP as a radio-sensitizing target of GBM by regulating NF-κB pathway	Yingwen	Ding	Poster	Radiosensitizers and Radio-immunomodulators	4/17/23	1:30 PM	Section 19	10
2820	Defining the role of purine metabolism in radiation resistance in H3K27M mutant diffuse midline glioma	Erik	Peterson	Poster	Radiosensitizers and Radio-immunomodulators	4/17/23	1:30 PM	Section 19	11
2821	Mitigation of radiation-induced colon injuries in mice by oral sepiapterin (PTC923)	Vasily	Yakovlev	Poster	Radiosensitizers and Radio-immunomodulators	4/17/23	1:30 PM	Section 19	12
2822	Maximizing radiotherapy impact: a novel pre-clinical platform for screening of radiosensitizing agents in patient-derived tumor organoids	Marrit	Putker	Poster	Radiosensitizers and Radio-immunomodulators	4/17/23	1:30 PM	Section 19	13
2823	Targeting monopolar spindle kinase I (TTK) as a radiosensitizing strategy in syngeneic murine models of triple negative breast cancer (TNBC) and its implications on the tumor immune microenvironment	Kassidy	Jungles	Poster	Radiosensitizers and Radio-immunomodulators	4/17/23	1:30 PM	Section 19	14
2824	Metabolomics in radiotherapy-induced early adverse skin reactions in breast cancer patients	Alexandra	McMahon	Poster	Radiosensitizers and Radio-immunomodulators	4/17/23	1:30 PM	Section 19	15
2825	Investigation of sponge property for enhanced concurrent tumor treating fields and radiotherapy for glioblastoma	Baoying	Dai	Poster	Radiosensitizers and Radio-immunomodulators	4/17/23	1:30 PM	Section 19	16
2826	Electromagnetic fields and hyperthermia induce lysosomal permeabilization and death in different cancer cell models: in vitro and in vivo studies	Jose	Estrela	Poster	Radiosensitizers and Radio-immunomodulators	4/17/23	1:30 PM	Section 19	17
2827	Application of AZD2281 combine with radiation therapy in glioblastoma	Tsal-Lan	Liao	Poster	Radiosensitizers and Radio-immunomodulators	4/17/23	1:30 PM	Section 19	18

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
2828	Impact of sequencing of immune checkpoint blockade and targeted radionuclide therapy on murine tumor response	Caroline	Kerr	Poster	Radiosensitizers and Radio-immunomodulators	4/17/23	1:30 PM	Section 19	19
2829	Acetyl-CoA Acetyltransferase 2 confers radioresistance by inhibiting ferroptosis and enhancing the phosphorylation of AKT-S473 in esophageal squamous cell carcinoma	Heng	Jinghua	Poster	Radiosensitizers and Radio-immunomodulators	4/17/23	1:30 PM	Section 19	20
2830	Fluoxetine mediate radiosensitivity and inhibit metastasis of osteosarcoma cells via RANK/RANKL signaling	Peggy	Tan	Poster	Radiosensitizers and Radio-immunomodulators	4/17/23	1:30 PM	Section 19	21
2831	Enhanced efficacy of HDAC inhibitor panobinostat and ONC206 combined with radiation therapy against human glioblastoma cell lines without H3K27M mutation	Vida	Tajiknia	Poster	Radiosensitizers and Radio-immunomodulators	4/17/23	1:30 PM	Section 19	22
2832	Plk1 signaling as a therapeutic target for HPV- head and neck cancer	Julianna	Korns	Poster	Radiosensitizers and Radio-immunomodulators	4/17/23	1:30 PM	Section 19	23
2833	Exploring the impact of IL-17 pathway modification on radiation dermatitis and radiation therapy efficacy	Megan	Pirtle	Poster	Radiosensitizers and Radio-immunomodulators	4/17/23	1:30 PM	Section 19	24
2835	Fibroblast activation protein (FAP)-targeted radiotherapy increases tumor CD8+ T cell infiltration and enhances response to PD-1 immune checkpoint blockade	Dirk	Zboralski	Poster	Radiosensitizers and Radio-immunomodulators	4/17/23	1:30 PM	Section 19	26
2836	H2S donors as radiosensitizers for glioblastoma multiforme (GBM)	Morni	Modi	Poster	Radiosensitizers and Radio-immunomodulators	4/17/23	1:30 PM	Section 19	27
2837	A novel radiosensitizer of titanium peroxide nanoparticles (TiOxNPs) through continuous ROS generation	Ryohei	Sasaki	Poster	Radiosensitizers and Radio-immunomodulators	4/17/23	1:30 PM	Section 19	28
2838	Tumor-targeted interleukin-2 enhances the anti-cancer activity of multivalent OncoFAP radioligand therapeutics	Andrea	Galbiati	Poster	Radiosensitizers and Radio-immunomodulators	4/17/23	1:30 PM	Section 19	29
2839	Methionine restriction radiosensitizes KRAS mutant rectal cancer	Adam	Wolfe	Poster	Radiosensitizers and Radio-immunomodulators	4/17/23	1:30 PM	Section 19	30
2843	RN486, a Bruton's tyrosine kinase inhibitor, reverses multidrug resistance in ABCG2-overexpressing cancer cells	Xing-Duo	Dong	Poster	Strategies for Reversal of Drug Resistance	4/17/23	1:30 PM	Section 20	1
2844	BMP inhibition overcomes chemoresistance of prostate cancer	Jijun	Hao	Poster	Strategies for Reversal of Drug Resistance	4/17/23	1:30 PM	Section 20	2
2845	PpIX synthesis increases PDT resistant cells due to the modulating effect of EGCG on the heme synthesis pathway	Daniela	León	Poster	Strategies for Reversal of Drug Resistance	4/17/23	1:30 PM	Section 20	3
2846	The mitochondrial dynamics of breast cancer regulate P-glycoprotein expression	David	Terrero	Poster	Strategies for Reversal of Drug Resistance	4/17/23	1:30 PM	Section 20	4
2847	Concurrent inactivation of PI3K and PLK1 is synergistic and overcomes acquired resistance to PI3K inhibitors in NOTCH1MUT HNSCC	Pooja	Shah	Poster	Strategies for Reversal of Drug Resistance	4/17/23	1:30 PM	Section 20	5

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
2848	DNA replication stress and mitotic catastrophe mediate sotorasib addiction in KRASG12C-mutant cancer	Li-Wen	Chiou	Poster	Strategies for Reversal of Drug Resistance	4/17/23	1:30 PM	Section 20	6
2849	The oral SERD Elacestrant in combination with the PI3K inhibitor MEN1611 inhibits tumor growth in ER+/HER2- breast cancer in vitro and in PDX models	Alessio	Fiascarelli	Poster	Strategies for Reversal of Drug Resistance	4/17/23	1:30 PM	Section 20	7
2850	NX-5948 promotes selective, sub-nanomolar degradation of inhibitor-resistant BTK mutants	Mark	Noviski	Poster	Strategies for Reversal of Drug Resistance	4/17/23	1:30 PM	Section 20	8
2851	ALK-inhibitors as a novel potential therapy for proteasome inhibitor-resistant multiple myeloma	Lenka	Besse	Poster	Strategies for Reversal of Drug Resistance	4/17/23	1:30 PM	Section 20	9
2852	Targeting NPEPPS overcomes cisplatin resistance in patient-derived bladder cancer tumoroids	Mathijs	Scholtes	Poster	Strategies for Reversal of Drug Resistance	4/17/23	1:30 PM	Section 20	10
2853	TP-6379, an investigational TGFBR1 inhibitor, shows improvement in survival and enhances activity of standard of care in preclinical ovarian cancer models	Tetyana	Forostyan	Poster	Strategies for Reversal of Drug Resistance	4/17/23	1:30 PM	Section 20	11
2854	LncRNA UCA1 as a potential therapeutic target for drug resistance in colorectal cancer	Kyle	Doxtater	Poster	Strategies for Reversal of Drug Resistance	4/17/23	1:30 PM	Section 20	12
2855	Epithelial-mesenchymal transition profile after cisplatin-resistance induction in OSCC cell line	Dieila	De Lima	Poster	Strategies for Reversal of Drug Resistance	4/17/23	1:30 PM	Section 20	13
2856	Age-induced chronic accumulation of cortisol drives chemotherapy resistance in lung cancer	Devesh	Raizada	Poster	Strategies for Reversal of Drug Resistance	4/17/23	1:30 PM	Section 20	14
2857	Patient-derived cells (PDCs) and organoids (PDOs) as platforms for screening novel therapeutics for NSCLC	Yunjoo	Joo	Poster	Strategies for Reversal of Drug Resistance	4/17/23	1:30 PM	Section 20	15
2858	Radiotherapy and NK cell-based immunotherapy: An evolutionary double-bind	Kimberly	Luddy	Poster	Strategies for Reversal of Drug Resistance	4/17/23	1:30 PM	Section 20	16
2859	High-resolution lineage tracing for the study of cancer drug persistence at the single-cell level	Benny	Zhitomirsky	Poster	Strategies for Reversal of Drug Resistance	4/17/23	1:30 PM	Section 20	17
2863	Interferon-gamma induces NOS2 and COX2 in ER- breast cancer that drives increase metastatic potential	Yuk Sing	Cheng	Poster	Cancer-associated Immunosuppression	4/17/23	1:30 PM	Section 21	1
2864	Selective suppression of melanoma lacking IFN- γ pathway by JAK inhibition depends on T cells and host TNF signaling	Hongxing	Shen	Poster	Cancer-associated Immunosuppression	4/17/23	1:30 PM	Section 21	2
2865	IL4I1, IDO1 and other amino acid-metabolizing enzymes in high-grade serous ovarian cancer	Yvonne	Grobben	Poster	Cancer-associated Immunosuppression	4/17/23	1:30 PM	Section 21	3
2867	Ceramide-dependent mitophagy leads to metabolic reprogramming in aging T-cells associated with reduced anti-tumor T-cell functions	Mohamed Faisal	Kassir	Poster	Cancer-associated Immunosuppression	4/17/23	1:30 PM	Section 21	5
2868	A chemogenetic approach reveals a GPCR-G α s-PKA signaling axis promoting T cell dysfunction and cancer immunotherapy failure	Bryan	Yung	Poster	Cancer-associated Immunosuppression	4/17/23	1:30 PM	Section 21	6

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
2869	The role of regulatory T cells in NASH-mediated HCC development	Ming	Yang	Poster	Cancer-associated Immunosuppression	4/17/23	1:30 PM	Section 21	7
2870	Inhibition of DNA methylation and histone deacetylation synergistically reprograms M2-polarized macrophages and inhibits tumor growth by upregulating miR-7083-5p	Poongkavitha i Vadevoo	Sri Murugan	Poster	Cancer-associated Immunosuppression	4/17/23	1:30 PM	Section 21	8
2871	Spatial landscape of the tumor microenvironment in pancreatic ductal adenocarcinoma using multiplexed imaging and AI based analysis	Melinda	Angus-Hill	Poster	Cancer-associated Immunosuppression	4/17/23	1:30 PM	Section 21	9
2872	Site specific tumor microenvironments modulate the immune checkpoint inhibitors response in models of CT26 colon carcinoma	Patrick	Fadden	Poster	Cancer-associated Immunosuppression	4/17/23	1:30 PM	Section 21	10
2873	Evolution of immune cell composition and functionality as pancreatic intraepithelial neoplasia progresses to pancreatic ductal adenocarcinoma	Melissa	Lyman	Poster	Cancer-associated Immunosuppression	4/17/23	1:30 PM	Section 21	11
2874	Resolving an immune tolerogenic niche at the earliest phase of oral cancer initiation	Hulya	Taner	Poster	Cancer-associated Immunosuppression	4/17/23	1:30 PM	Section 21	12
2875	Evidence of immunosuppression in patients with breast ductal carcinoma in situ	Sedigheh	Taghinezhad-S	Poster	Cancer-associated Immunosuppression	4/17/23	1:30 PM	Section 21	13
2876	Characterization of P2X4 purinergic receptors in the prostate tumor microenvironment	Vahinipriya	Manoharan	Poster	Cancer-associated Immunosuppression	4/17/23	1:30 PM	Section 21	14
2877	Profiling of myeloid-derived suppressor cells in Pten-deficient in prostate cancer progression	Marco	De Velasco	Poster	Cancer-associated Immunosuppression	4/17/23	1:30 PM	Section 21	15
2879	Cell-autonomous Cxcl1 sustains tolerogenic circuitries and stromal inflammation via neutrophil-derived TNF in pancreatic cancer	Anna	Bianchi	Poster	Cancer-associated Immunosuppression	4/17/23	1:30 PM	Section 21	17
2880	Inhibition of HDAC6 and HDAC11 has opposite effects on inflammation and the modulation of the functional phenotype of macrophages in the tumor microenvironment	Manasa	Suresh	Poster	Cancer-associated Immunosuppression	4/17/23	1:30 PM	Section 21	18
2881	Investigating cholesterol transfer between macrophages and prostate cancer cells	Olabisi	Osunmakinde	Poster	Cancer-associated Immunosuppression	4/17/23	1:30 PM	Section 21	19
2882	Characteristic immunomodulatory role of myeloid galectin-9 in the brain tumor microenvironment	Chanju	Lee	Poster	Cancer-associated Immunosuppression	4/17/23	1:30 PM	Section 21	20
2883	Gut microbiome dysbiosis promotes immune suppression and lung cancer development	Zahraa	Rahal	Poster	Cancer-associated Immunosuppression	4/17/23	1:30 PM	Section 21	21
2884	Cancer-associated fibroblasts potentiate subcutaneous tumor growth in a novel bladder cancer mouse model with a genotype dependency	Henkel	Valentine	Poster	Cancer-associated Immunosuppression	4/17/23	1:30 PM	Section 21	22
2885	RASSF1A133Sresulting from the prevalent SNP rs2073498 is associated with Treg defects	Haonan	Xu	Poster	Cancer-associated Immunosuppression	4/17/23	1:30 PM	Section 21	23

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
2886	Investigation of tumor-intrinsic activated Wnt/B-catenin signaling in immune avoidance of HCC	Aikha Melissa	Wong	Poster	Cancer-associated Immunosuppression	4/17/23	1:30 PM	Section 21	24
2888	Hepatocytes coordinate immune evasion in cancer via release of serum amyloid A proteins	Meredith	Stone	Poster	Cancer-associated Immunosuppression	4/17/23	1:30 PM	Section 21	26
2889	Novel subset of granulocytic MDSCs as immunosuppressive regulators and therapeutic targets in gastric cancer	Takumi	Iwasawa	Poster	Cancer-associated Immunosuppression	4/17/23	1:30 PM	Section 21	27
2890	Investigating dynamic IDO-Kyn-Ahr pathway induced tumor immunosuppression using imaging modality to optimize therapeutic Intervention	Mamadou	Bah	Poster	Cancer-associated Immunosuppression	4/17/23	1:30 PM	Section 21	28
2891	Cystatin C is glucocorticoid-responsive, directs recruitment of Trem2+ macrophages and predicts failure of cancer immunotherapy	Sam	Kleeman	Poster	Cancer-associated Immunosuppression	4/17/23	1:30 PM	Section 21	29
2892	A SREBF2-dependent genetic program drives a novel immunotolerant dendritic cell population that supports cancer progression	Brent	Hanks	Poster	Cancer-associated Immunosuppression	4/17/23	1:30 PM	Section 21	30
2896	Combination of cytokines and PM21-particle stimulation results in robust expansion of memory-like Natural Killer cells with enhanced survival	Jeremiah	Oyer	Poster	Natural Killer and Natural Killer T Cell-based Cellular Therapies	4/17/23	1:30 PM	Section 22	1
2897	Overcoming barriers to the natural killer cell response against multiple myeloma: Manipulating the NKG2A/HLA-E checkpoint and CAR engineering of memory-like natural killer cells	Alice	Zhou	Poster	Natural Killer and Natural Killer T Cell-based Cellular Therapies	4/17/23	1:30 PM	Section 22	2
2898	CAT-248, an allogeneic CD70-directed CAR-NK cell therapy effectively controls CD70-positive tumor xenografts	Eugene	Choi	Poster	Natural Killer and Natural Killer T Cell-based Cellular Therapies	4/17/23	1:30 PM	Section 22	3
2899	Small molecule inhibitor of ubiquitin ligase CBL-B enhanced anti-tumor response of CAR-T and CAR-NK cell therapies	Cuiqing	Yang	Poster	Natural Killer and Natural Killer T Cell-based Cellular Therapies	4/17/23	1:30 PM	Section 22	4
2900	To develop a next generation NK therapy with deep and durable response by engineered CD16 enhancing NK cytotoxicity	Cuiqing	Yang	Poster	Natural Killer and Natural Killer T Cell-based Cellular Therapies	4/17/23	1:30 PM	Section 22	5
2902	Off-the-Shelf CAR-NK cells engineered to express calibrated release IL-15 exhibit enhanced persistence and anti-tumor activities	Chen-Ting	Lee	Poster	Natural Killer and Natural Killer T Cell-based Cellular Therapies	4/17/23	1:30 PM	Section 22	7
2903	Epigenetic modulation of NK cells to improve tumor trafficking and enhance therapeutic efficacy against osteosarcoma	Ariana	Anjier	Poster	Natural Killer and Natural Killer T Cell-based Cellular Therapies	4/17/23	1:30 PM	Section 22	8
2904	CAT-179, an allogeneic NK cell product expressing HER2-CAR, IL-15 and TGFβ dominant negative receptor, durably regresses HER2-expressing xenograft tumors in mice	Bashar	Hamza	Poster	Natural Killer and Natural Killer T Cell-based Cellular Therapies	4/17/23	1:30 PM	Section 22	9
2905	SENTI-301A, an off-the-shelf multi-armed preclinical CAR-NK cell therapy, for the treatment of GPC3 expressing tumors	Marcela	Guzman Ayala	Poster	Natural Killer and Natural Killer T Cell-based Cellular Therapies	4/17/23	1:30 PM	Section 22	10

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
2906	Memory-like differentiation, tumor targeting monoclonal antibodies, and chimeric antigen receptors enhance natural killer cell responses to head and neck cancer	Miriam	Jacobs	Poster	Natural Killer and Natural Killer T Cell-based Cellular Therapies	4/17/23	1:30 PM	Section 22	11
2907	Development of a CAR-NK cellular platform for cancer immunotherapy	Robert	Nunan	Poster	Natural Killer and Natural Killer T Cell-based Cellular Therapies	4/17/23	1:30 PM	Section 22	12
2908	TIGIT knockout enhances anti-tumor response of Natural Killer cells and prevents fratricide when combined with therapeutic ADCC-competent TIGIT antibodies	Md Faqrul	Hasan	Poster	Natural Killer and Natural Killer T Cell-based Cellular Therapies	4/17/23	1:30 PM	Section 22	13
2909	Genetically engineered Natural Killer cells as an immunotherapeutic approach for the treatment of neuroblastoma	Taylor	Croom-Perez	Poster	Natural Killer and Natural Killer T Cell-based Cellular Therapies	4/17/23	1:30 PM	Section 22	14
2910	NKG2A suppression enhances the function of primary human Natural Killer cells	Taylor	Croom-Perez	Poster	Natural Killer and Natural Killer T Cell-based Cellular Therapies	4/17/23	1:30 PM	Section 22	15
2911	Identification of novel CAR transmembrane and endodomains for improved persistence and cytotoxicity of NK cell therapies	Maddie	Williams	Poster	Natural Killer and Natural Killer T Cell-based Cellular Therapies	4/17/23	1:30 PM	Section 22	16
2912	High-throughput screening and single-cell transcriptomics identify synergies between oncology drugs and natural killer cell immunotherapy	Jonas	Bouhlal	Poster	Natural Killer and Natural Killer T Cell-based Cellular Therapies	4/17/23	1:30 PM	Section 22	17
2914	iPSC-derived CAR-NK cell therapy: nominating clinical candidate clones through integrated multi-functional analysis	Matthew	Hall	Poster	Natural Killer and Natural Killer T Cell-based Cellular Therapies	4/17/23	1:30 PM	Section 22	19
2915	Intratumoral co-injections of NK cells and neutralizing antibodies against the NKG2A inhibitory pathway achieve efficacious anti-tumor responses in a CD8 T cell and cDC1-dependent manner	Ignacio	Melero	Poster	Natural Killer and Natural Killer T Cell-based Cellular Therapies	4/17/23	1:30 PM	Section 22	20
2916	CAR-NK cells generated with CAR-RNA-LNP express high cytotoxic activity against tumor cells	Vita	Golubovskaya	Poster	Natural Killer and Natural Killer T Cell-based Cellular Therapies	4/17/23	1:30 PM	Section 22	21
2918	In vivo delivery of CD3-directed CD19-CAR lentivectors leads to the generation of CAR T and NK-like (CAR-TaNK) cells capable of complete ablation of B cells in the blood, bone marrow, and tissue of NSG-SGM3 CD34+ humanized mice	Sid	Kerkar	Poster	Natural Killer and Natural Killer T Cell-based Cellular Therapies	4/17/23	1:30 PM	Section 22	23
2919	A novel method for clinical scale production of natural killer cells from clonal master induced pluripotent stem cells with CISH knockout for next generation, off-the-shelf cancer immunotherapy	Huang	Zhu	Poster	Natural Killer and Natural Killer T Cell-based Cellular Therapies	4/17/23	1:30 PM	Section 22	24
2923	JAB-X1800: A potent immunostimulatory antibody-drug conjugate (iADC) targeting CD73	Yang	Ye	Poster	Therapeutic Antibodies 2	4/17/23	1:30 PM	Section 23	1
2924	Organoid co-cultures with autologous T cells to assess toxicity and efficacy of bispecific antibodies	Sylvia	Boj	Poster	Therapeutic Antibodies 2	4/17/23	1:30 PM	Section 23	2

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
2925	In vitro characterization of next generation therapeutic antibodies	Gemma	Moiset	Poster	Therapeutic Antibodies 2	4/17/23	1:30 PM	Section 23	3
2926	PROTECTTM, a novel trispecific antibody masking platform with integrated immune modulation displays unique activity and differentiated modes of action	Anna	von Rossum	Poster	Therapeutic Antibodies 2	4/17/23	1:30 PM	Section 23	4
2927	ITGB6 ProTriTAC™, a protease-activated T cell engager prodrug targeting Integrin-β6 for the treatment of solid tumors	S.	Lin	Poster	Therapeutic Antibodies 2	4/17/23	1:30 PM	Section 23	5
2928	TROP2 ProTriTAC™, a protease-activated T cell engager prodrug targeting TROP2 for the treatment of solid tumors	S.	Lin	Poster	Therapeutic Antibodies 2	4/17/23	1:30 PM	Section 23	6
2929	Modular peptide cargo delivery by targeting CD40 enables ligandome driven, precision immunotherapy via the Adaptable Drug Affinity Conjugate (ADAC™) technology	Sara	Mangsbo	Poster	Therapeutic Antibodies 2	4/17/23	1:30 PM	Section 23	7
2930	ADG153, a novel masked anti-CD47 IgG1 SAFEbody, demonstrates strong in vivo anti-tumor activities in preclinical solid tumor models and preferential CD47 target engagement in the tumor microenvironment	Peter	Luo	Poster	Therapeutic Antibodies 2	4/17/23	1:30 PM	Section 23	8
2931	Functional characterization of KJ-103, a novel therapeutic anti-TROP2 heavy chain-only antibody	Shugang	Yao	Poster	Therapeutic Antibodies 2	4/17/23	1:30 PM	Section 23	9
2932	Datopotamab deruxtecan (Dato-DXd) enhances antitumor response to PD-1/PD-L1 inhibitors in TROP2-expressing tumors in mice	Daisuke	Okajima	Poster	Therapeutic Antibodies 2	4/17/23	1:30 PM	Section 23	10
2933	Novel CD123xCD3 bispecific IgM antibody, IGM-2537, potently induces T-cell mediated cytotoxicity of acute myeloid leukemia cells with minimal cytokine release	Gene	Li	Poster	Therapeutic Antibodies 2	4/17/23	1:30 PM	Section 23	11
2934	BYON4228, an antagonistic SIRPα mAb with a unique and favorable preclinical profile compared to three comparator SIRPα mAbs	Timo	van den Berg	Poster	Therapeutic Antibodies 2	4/17/23	1:30 PM	Section 23	12
2935	ZW270, a conditionally masked IL-12 cytokine fusion protein displaying potent anti-tumor activity absent systemic toxicity	Nichole	Escalante	Poster	Therapeutic Antibodies 2	4/17/23	1:30 PM	Section 23	13
2936	INCA33890, a novel PD-1xTGFβR2 bispecific antibody conditionally antagonizes TGFβ signaling in primary immune cells co-expressing PD-1	Liang-Chuan	Wang	Poster	Therapeutic Antibodies 2	4/17/23	1:30 PM	Section 23	14
2937	Preclinical characterization of CBA-1535, a novel bi-specific tribody, with two binding sites to 5T4 and one site to CD3ε	Fumitake	Takizawa	Poster	Therapeutic Antibodies 2	4/17/23	1:30 PM	Section 23	15
2938	Preclinical development of a novel bispecific mAb-Trap fusion protein, IMM2902, targeting both HER2 and CD47 as cancer immunotherapy	Frank	Gan	Poster	Therapeutic Antibodies 2	4/17/23	1:30 PM	Section 23	16

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
2939	ATOR-4066, a Neo-X-Prime bispecific antibody targeting CD40 and CEA, activates myeloid cells in primary human tumors in vitro and induces anti-tumor immunity in vivo	Karin	Hägerbrand	Poster	Therapeutic Antibodies 2	4/17/23	1:30 PM	Section 23	17
2940	Use of NK humanized mouse models for the in vivo evaluation of anti-tumor NK-cell therapies	Céline	Nicolazzi	Poster	Therapeutic Antibodies 2	4/17/23	1:30 PM	Section 23	18
2941	ROR1 targeted 4-1BB costimulatory bispecific antibody, ABL102, exhibits potent in vitro and vivo antitumor activity and superior safety profile	Yangsoon	Lee	Poster	Therapeutic Antibodies 2	4/17/23	1:30 PM	Section 23	19
2942	ZW171, a T cell-engaging, bispecific antibody for the treatment of mesothelin-expressing solid tumors	Nicole	Afacan	Poster	Therapeutic Antibodies 2	4/17/23	1:30 PM	Section 23	20
2943	The structural basis for inhibition of MICA shedding and anti-tumor activity of the monoclonal anti-MICA B antibody, CLN-619	Kerry	Whalen	Poster	Therapeutic Antibodies 2	4/17/23	1:30 PM	Section 23	21
2944	Trastuzumab-deruxtecan (T-Dxd) induces superior macrophage/DC activation, antigen-presentation and anti-tumor adaptive immune responses, which can be augmented by CD47/SIRPA blockade	Li-Chung	Tsao	Poster	Therapeutic Antibodies 2	4/17/23	1:30 PM	Section 23	22
2945	Depleting hCCR8 mAb Therapy #2: Selection of candidates for the development of innovative depleting anti CCR8 therapeutic antibodies to control the immunosuppressive tumor microenvironment	Stephan	Schann	Poster	Therapeutic Antibodies 2	4/17/23	1:30 PM	Section 23	23
2946	Depleting hCCR8 mAb Therapy #1: Characterization of a broad collection of anti-hCCR8 mAbs	Stephan	Schann	Poster	Therapeutic Antibodies 2	4/17/23	1:30 PM	Section 23	24
2947	Preclinical evaluation of a novel B7-H4 targeted antibody-drug conjugate AZD8205 as a single agent and in combination with novel PARP inhibitor and checkpoint blockade	Alex	Cazes	Poster	Therapeutic Antibodies 2	4/17/23	1:30 PM	Section 23	25
2948	A humanized therapeutic antibody against S100A4 as a novel immune modulator and an inhibitor of cancer metastasis	Jia-Shiun	Leu	Poster	Therapeutic Antibodies 2	4/17/23	1:30 PM	Section 23	26
2950	CD16A shedding facilitates repetitive targeting of tumor cells by AFM13-armed NK cells	Björn	Önfelt	Poster	Therapeutic Antibodies 2	4/17/23	1:30 PM	Section 23	28
2951	NI-2901, an affinity-optimized CD47xPD-L1 bispecific antibody for dual immune checkpoint blockade	Xavier	Chauchet	Poster	Therapeutic Antibodies 2	4/17/23	1:30 PM	Section 23	29
2954	MAIT engagers: An efficacious novel modality in the field of T-cell engagers for the treatment of solid tumors	Simon	Plyte	Poster	Therapeutic Antibodies 3	4/17/23	1:30 PM	Section 24	1
2955	Anti-PD-1/IL-7v bispecific antibody promotes TCF1+ stem like CD8 T cells expansion and long-lasting in vivo efficacy	Aurore	Morello	Poster	Therapeutic Antibodies 3	4/17/23	1:30 PM	Section 24	2

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
2956	TNRX-257, a novel multifunctional biologic effectively blocks LAG3 and conditionally delivers IL2Rg/b agonism to LAG3+ cells for robust anti-tumor immunity	Rajesh	Sharma	Poster	Therapeutic Antibodies 3	4/17/23	1:30 PM	Section 24	3
2957	CD127 is expressed by acute lymphoblastic leukemias and is efficiently targeted by the IL7R-antagonist OSE-127 through macrophage-mediated antibody dependent phagocytosis	Irene	Bacelli	Poster	Therapeutic Antibodies 3	4/17/23	1:30 PM	Section 24	4
2958	BSI-508, a novel bispecific fusion molecule targeting PD1 and CD47 for cancer immunotherapy	Mark	Ma	Poster	Therapeutic Antibodies 3	4/17/23	1:30 PM	Section 24	5
2959	Novel CD38xCD3 bispecific IgM T cell engager, IGM-2644, potently kills multiple myeloma cells through complement and T cell dependent mechanisms	Keyu	Li	Poster	Therapeutic Antibodies 3	4/17/23	1:30 PM	Section 24	6
2960	The novel trifunctional anti-BCMA NK cell engager SAR'514 has potent in-vitro, in-vivo and ex-vivo anti-myeloma effect through dual NK cell engagement	Alexandre	Tang	Poster	Therapeutic Antibodies 3	4/17/23	1:30 PM	Section 24	7
2961	HLA-G-TCB (RG6353), a T cell bispecific antibody for the treatment of solid tumors in monotherapy and combination with immunomodulator agents	Meher	Majety	Poster	Therapeutic Antibodies 3	4/17/23	1:30 PM	Section 24	8
2962	ASP2138, a novel 2+1 format, claudin 18.2 x CD3 bispecific antibody, demonstrates selectivity and activity in preclinical cancer models	Taisuke	Nakazawa	Poster	Therapeutic Antibodies 3	4/17/23	1:30 PM	Section 24	9
2963	CDX-585, a novel bispecific antibody targeting PD-1 and ILT4	Lawrence	Thomas	Poster	Therapeutic Antibodies 3	4/17/23	1:30 PM	Section 24	10
2964	Targeting tumor-associated macrophages to enhance anti-tumor immunity with the Dectin-2 agonistic antibody BDC-3042	Justin	Kenkel	Poster	Therapeutic Antibodies 3	4/17/23	1:30 PM	Section 24	11
2965	LBL-033, a novel bispecific antibody targeting MUC16 and CD3, for the treatment of tumors over-expressing MUC16	Hong	Ling	Poster	Therapeutic Antibodies 3	4/17/23	1:30 PM	Section 24	12
2966	Exploring the therapeutic potential of a novel Siglec-6 targeted bispecific antibody to selectively kill leukemia cells	Jessica	Nunes	Poster	Therapeutic Antibodies 3	4/17/23	1:30 PM	Section 24	13
2967	Preclinical development of a B7-H3-targeting ADC with a novel DNA topoisomerase I inhibitor for solid tumors	Rong	Shi	Poster	Therapeutic Antibodies 3	4/17/23	1:30 PM	Section 24	14
2968	Development of anti-APP antibody targeting APP/CNTN4 axis as a novel cancer immunotherapy	Youngeun	Ha	Poster	Therapeutic Antibodies 3	4/17/23	1:30 PM	Section 24	15
2969	Development of a canine PD-L1 antibody and caninized PD-L1 mouse model: an essential translational research tool to raise the success rate of immunotherapy in humans	Wonkyung	Oh	Poster	Therapeutic Antibodies 3	4/17/23	1:30 PM	Section 24	16
2970	Overcoming mechanisms of escape from treatments for multiple myeloma with ISB 2001, a potential first-in-class trispecific BCMA and CD38 targeted T cell engager	Mario	Perro	Poster	Therapeutic Antibodies 3	4/17/23	1:30 PM	Section 24	17

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
2971	EVOLVETM: A novel T cell engager platform with integrated CD2 costimulation engineered for the treatment of immune suppressive tumors	Eric	Tam	Poster	Therapeutic Antibodies 3	4/17/23	1:30 PM	Section 24	18
2972	Preclinical characterization of SAR445877, an anti-PD-1 antibody-IL-15 mutein fusion protein with robust anti-tumor efficacy as monotherapy and in combination with PD-L1 blockade	Marie	Bernardo	Poster	Therapeutic Antibodies 3	4/17/23	1:30 PM	Section 24	19
2973	NI-3201, a PD-L1xCD28 bispecific antibody for immune checkpoint-dependent CD28 co-stimulation	Walter	Ferlin	Poster	Therapeutic Antibodies 3	4/17/23	1:30 PM	Section 24	20
2974	Targeting the oxidized form of macrophage migration inhibitory factor (oxMIF) with antibody ON203 activates the tumor microenvironment	Alexander	Schinagl	Poster	Therapeutic Antibodies 3	4/17/23	1:30 PM	Section 24	21
2976	A single administration of DNA-encoded tri-specific T cell engager (DTriTE) targeting EGFRvIII, IL13Ra2, and CD3 shows complete tumor clearance in an orthotopic challenge model of heterogeneous GBM	Daniel	Park	Poster	Therapeutic Antibodies 3	4/17/23	1:30 PM	Section 24	23
2977	A first-in-class anti-HER2/TROP2 bispecific antibody-drug conjugate (YH012) exhibits potent anti-tumor efficacy	Ellen	Zhang	Poster	Therapeutic Antibodies 3	4/17/23	1:30 PM	Section 24	24
2978	YH013, a novel EGFR x MET bispecific antibody-drug conjugate, exhibits potent antitumor efficacy	Ellen	Zhang	Poster	Therapeutic Antibodies 3	4/17/23	1:30 PM	Section 24	25
2980	HX009, a first-in-class PD1xCD47 BsAb, demonstrated anti-AML activity in PDX models	Xiaoyu	An	Poster	Therapeutic Antibodies 3	4/17/23	1:30 PM	Section 24	27
2981	Anti-tumor activity of vobramitamab duocarmazine (MGC018), an investigational duocarmycin-based anti-B7-H3 antibody-drug conjugate (ADC), in preclinical neuroblastoma models	Mirco	Ponzoni	Poster	Therapeutic Antibodies 3	4/17/23	1:30 PM	Section 24	28
2982	TriTCE CPI, next generation trispecific T cell engagers with integrated checkpoint inhibition (CPI) for the treatment of solid tumors	Maya	Poffenberger	Poster	Therapeutic Antibodies 3	4/17/23	1:30 PM	Section 24	29
2983	Tumor-specific CD28 costimulatory bispecific antibodies enhance T cell activation in solid tumors	Matthew	Dragovich	Poster	Therapeutic Antibodies 3	4/17/23	1:30 PM	Section 24	30
2987	BamQuery: a new proteogenomic tool to explore the immunopeptidome and prioritize actionable tumor antigens	Gregory	Ehx	Poster	Tumor Antigens and Antigen Presentation	4/17/23	1:30 PM	Section 25	1
2989	Colorectal cancer displays three patterns of tumor-specific MHC-II inducibility and dynamics, with implications for combining epigenetic therapy with immunotherapy	Oliver	Pickles	Poster	Tumor Antigens and Antigen Presentation	4/17/23	1:30 PM	Section 25	3
2990	Antigen presentation deficiency and mesenchymal differentiation underlie resistance to immunotherapy in the murine syngeneic CT2A tumor model	Bryan	Iorgulescu	Poster	Tumor Antigens and Antigen Presentation	4/17/23	1:30 PM	Section 25	4

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
2991	Complementarity of class I and II neoantigen mapping in MSI-high colorectal cancer in needle biopsy size tissue samples	Christopher	Below	Poster	Tumor Antigens and Antigen Presentation	4/17/23	1:30 PM	Section 25	5
2992	Conserved gene fusion ETV6/RUNX1 displays higher immunogenicity than patient-specific missense mutations within the context of HLA-A*02:01	Erin	Cygan	Poster	Tumor Antigens and Antigen Presentation	4/17/23	1:30 PM	Section 25	6
2993	Unmutated tumor antigens are abundant and contribute to tumor control in melanoma	Anca	Apavaloaei	Poster	Tumor Antigens and Antigen Presentation	4/17/23	1:30 PM	Section 25	7
2994	Hypoxia blocks the presentation of tumor antigens to CD8+ T cells	Matthew	Smith	Poster	Tumor Antigens and Antigen Presentation	4/17/23	1:30 PM	Section 25	8
2995	Cross-presented serine proteases as immunotherapy targets for lung cancer and osteosarcoma	Amber	Gibson	Poster	Tumor Antigens and Antigen Presentation	4/17/23	1:30 PM	Section 25	9
2996	CT26 neoantigen presentation and immunogenicity	Seeta	Nyayapathy	Poster	Tumor Antigens and Antigen Presentation	4/17/23	1:30 PM	Section 25	10
2997	Tumor hypoxia blocks the induction of antigen processing machinery	Alexis	Ramos	Poster	Tumor Antigens and Antigen Presentation	4/17/23	1:30 PM	Section 25	11
2998	Inhibition of a small GTPase in tumor cells enhances antigen presentation and tumor cell killing in breast cancer	Ishara	Moulana	Poster	Tumor Antigens and Antigen Presentation	4/17/23	1:30 PM	Section 25	12
2999	Hippo signaling pathway regulates cancer-cell-intrinsic MHC-II expression in melanoma	Shengqing	Gu	Poster	Tumor Antigens and Antigen Presentation	4/17/23	1:30 PM	Section 25	13
3000	A data-driven and AI-empowered systems biology model of MHC class I antigen presentation pathway	Jia	Wang	Poster	Tumor Antigens and Antigen Presentation	4/17/23	1:30 PM	Section 25	14
3001	Investigating the quantity and quality of dendritic cells in human glioblastoma tissues and in orthotopic murine xenograft and syngraft models of glioblastoma	Michael	Brown	Poster	Tumor Antigens and Antigen Presentation	4/17/23	1:30 PM	Section 25	15
3005	Pre-diagnostic methylation-based leukocyte profiles and non-small cell lung cancer risk in heavy smokers	Laurie	Grieshober	Poster	Aging, Immune Factors, and Metabolomics	4/17/23	1:30 PM	Section 27	1
3006	Metabolomic signatures of metabolic disturbance and inflammation in relation to colorectal cancer risk	Alaina	Bever	Poster	Aging, Immune Factors, and Metabolomics	4/17/23	1:30 PM	Section 27	2
3007	Psychosocial stressors and breast cancer gene expression in the Black Women's Health Study	Mollie	Barnard	Poster	Aging, Immune Factors, and Metabolomics	4/17/23	1:30 PM	Section 27	3
3008	Association between distress and the tumor immune microenvironment in women with ovarian cancer	Cassandra	Hathaway	Poster	Aging, Immune Factors, and Metabolomics	4/17/23	1:30 PM	Section 27	4
3009	Measured and genetically-predicted leukocyte telomere length and lung cancer risk in the prospective UK Biobank	Jason	Wong	Poster	Aging, Immune Factors, and Metabolomics	4/17/23	1:30 PM	Section 27	5
3010	Epigenetic age acceleration in older adults with hematologic malignancies	Ashley	Rosko	Poster	Aging, Immune Factors, and Metabolomics	4/17/23	1:30 PM	Section 27	6

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
3011	Psychosocial stress, social support, and incident breast cancer by estrogen receptor status	Wayne	Lawrence	Poster	Aging, Immune Factors, and Metabolomics	4/17/23	1:30 PM	Section 27	7
3012	Increased lung cancer risk and associated risk factors in tuberculosis survivors: a Korean population-based study	Dong Won	Park	Poster	Aging, Immune Factors, and Metabolomics	4/17/23	1:30 PM	Section 27	8
3013	The immunogenetic basis of hepatitis B virus-related hepatocellular carcinoma	Zhiwei	Liu	Poster	Aging, Immune Factors, and Metabolomics	4/17/23	1:30 PM	Section 27	9
3014	Association between HLA-KIR allele interaction combinations and density of T-cell subsets in colorectal cancer	Claire	Thomas	Poster	Aging, Immune Factors, and Metabolomics	4/17/23	1:30 PM	Section 27	10
3015	Soluble CD137 and risk of hepatocellular carcinoma: nested case-control studies in cohorts in Shanghai and Singapore	Jian-Min	Yuan	Poster	Aging, Immune Factors, and Metabolomics	4/17/23	1:30 PM	Section 27	11
3016	Cancers attributable to infectious agents in Italy	Giulia	Collatuzzo	Poster	Aging, Immune Factors, and Metabolomics	4/17/23	1:30 PM	Section 27	12
3017	Breastfeeding and ovarian cancer risk by tumor immune profiles	Jennifer	Mongiovi	Poster	Aging, Immune Factors, and Metabolomics	4/17/23	1:30 PM	Section 27	13
3018	Demographic and social patterns of average values of inflammatory markers in US adults: A 2009-2016 NHANES analysis	Marlene	Camacho-Rivera	Poster	Aging, Immune Factors, and Metabolomics	4/17/23	1:30 PM	Section 27	14
3019	Density of T cell subsets in colorectal cancer in relation to disease-specific survival	Amanda	Phipps	Poster	Aging, Immune Factors, and Metabolomics	4/17/23	1:30 PM	Section 27	15
3020	Machine learning-based cluster analysis of immune cell subtypes and breast cancer survival	Zhanwei	Wang	Poster	Aging, Immune Factors, and Metabolomics	4/17/23	1:30 PM	Section 27	16
3021	Epigenetic signatures of virus-associated cervical cancer in women living with HIV	Yinan	Zheng	Poster	Aging, Immune Factors, and Metabolomics	4/17/23	1:30 PM	Section 27	17
3022	Prospective study of circulating metabolomic signatures and breast cancer incidence among predominantly premenopausal women	Tengteng	Wang	Poster	Aging, Immune Factors, and Metabolomics	4/17/23	1:30 PM	Section 27	18
3023	Identifying colorectal cancer biomarkers using a targeted proteomics platform with extensive coverage	Justin	Harbs	Poster	Aging, Immune Factors, and Metabolomics	4/17/23	1:30 PM	Section 27	19
3024	Development of a plasma metabolomics prediction model for early detection of ovarian cancer using prospectively collected blood samples in two independent cohorts	Oana	Zeleznik	Poster	Aging, Immune Factors, and Metabolomics	4/17/23	1:30 PM	Section 27	20
3025	A pooled analysis of lung cancer metabolomics in the Cancer Prevention Studies revealing sphingomyelin (d18:0/22:0) as a potential screening biomarker	Ying	Wang	Poster	Aging, Immune Factors, and Metabolomics	4/17/23	1:30 PM	Section 27	21
3026	Dietary intakes and biliary tract cancer risk: Results from cohort studies including 638,860 Chinese and European adults	Valerie	Gunchick	Poster	Aging, Immune Factors, and Metabolomics	4/17/23	1:30 PM	Section 27	22

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
3029	Barriers to optimal breast cancer screening modalities for high-risk patients in the primary care setting	Yu Jen	Jan	Poster	Biological and Behavioral Factors in Cancer Surveillance, Prevention, and Survivorship	4/17/23	1:30 PM	Section 28	1
3030	Effect of 6 months of bazedoxifene and conjugated estrogen on measures of insulin resistance in postmenopausal women at increased risk for breast cancer	Carol	Fabian	Poster	Biological and Behavioral Factors in Cancer Surveillance, Prevention, and Survivorship	4/17/23	1:30 PM	Section 28	2
3031	Pilot study of EGFR inhibition with erlotinib in liver fibrosis for hepatocellular carcinoma prevention	Kenneth	Tanabe	Poster	Biological and Behavioral Factors in Cancer Surveillance, Prevention, and Survivorship	4/17/23	1:30 PM	Section 28	3
3032	A novel deep learning pipeline for early detection of colorectal cancer and colorectal adenoma using gut microbiome data	Nai-Shun	Liao	Poster	Biological and Behavioral Factors in Cancer Surveillance, Prevention, and Survivorship	4/17/23	1:30 PM	Section 28	4
3034	Excess weight by degree and duration and cancer risk: an individual participant data (IPD) meta - analyses of over 1.4 million participants (ABACus2 consortium)	Nadin	Hawwash	Poster	Biological and Behavioral Factors in Cancer Surveillance, Prevention, and Survivorship	4/17/23	1:30 PM	Section 28	6
3035	Phase I trial of alpha-lactalbumin vaccine in high-risk operable triple-negative breast cancer	George	Budd	Poster	Biological and Behavioral Factors in Cancer Surveillance, Prevention, and Survivorship	4/17/23	1:30 PM	Section 28	7
3036	Associations of total body fat mass and skeletal muscle index with all-cause and cancer-specific mortality in cancer survivors	Livingstone	Aduse-Poku	Poster	Biological and Behavioral Factors in Cancer Surveillance, Prevention, and Survivorship	4/17/23	1:30 PM	Section 28	8
3037	Effect of obesity on the promoter methylation of regulators of glucose catabolism and its association with prognosis in colorectal cancer	Claudia	Machicado Rivero	Poster	Biological and Behavioral Factors in Cancer Surveillance, Prevention, and Survivorship	4/17/23	1:30 PM	Section 28	9
3039	Evaluation of intra-tumoral pks+ E. coli, enterotoxigenic B. fragilis and Fusobacterium nucleatum, overall and in early onset disease, in colorectal cancer cases	Meredith	Hullar	Poster	Biological and Behavioral Factors in Cancer Surveillance, Prevention, and Survivorship	4/17/23	1:30 PM	Section 28	11
3040	A modified microbiota-accessible carbohydrates diet could change gut microbiota in patients with colorectal cancer after surgery	Boyeon	Kim	Poster	Biological and Behavioral Factors in Cancer Surveillance, Prevention, and Survivorship	4/17/23	1:30 PM	Section 28	12
3041	Gut microbiome in association with chemotherapy-induced toxicities among breast cancer patients	Sang	Nguyen	Poster	Biological and Behavioral Factors in Cancer Surveillance, Prevention, and Survivorship	4/17/23	1:30 PM	Section 28	13
3042	BXQ-350 may protect peripheral nerves from the direct cytotoxicity of chemotherapeutic agents leading to chemotherapy induced peripheral neuropathy	Nikhil	Wilkins	Poster	Biological and Behavioral Factors in Cancer Surveillance, Prevention, and Survivorship	4/17/23	1:30 PM	Section 28	14

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
3044	Integrative gut microbiome analysis of human and mouse prostate cancer	Marco	De Velasco	Poster	Biological and Behavioral Factors in Cancer Surveillance, Prevention, and Survivorship	4/17/23	1:30 PM	Section 28	16
3045	Role of CD10 negative stroma in the development of precursor lesion of endometriosis associated ovarian cancer	Huda	Atiya	Poster	Biological and Behavioral Factors in Cancer Surveillance, Prevention, and Survivorship	4/17/23	1:30 PM	Section 28	17
3046	Association of XRCC1 Arg194Trp polymorphism and XPD Lys751Gln polymorphism with biochemical parameters, severity and risk of prostate cancer in Bangladesh Population	Nafisa	Ahmed	Poster	Biological and Behavioral Factors in Cancer Surveillance, Prevention, and Survivorship	4/17/23	1:30 PM	Section 28	18
3047	Association of 16S rRNA fecal microbiome data with colorectal cancer risk: A pooled analysis	Madhawa	Gunathilake	Poster	Biological and Behavioral Factors in Cancer Surveillance, Prevention, and Survivorship	4/17/23	1:30 PM	Section 28	19
3049	Health-related quality of life among newly diagnosed young adult colorectal cancer patients: results from the ColoCare Study	Amanda	Bloomer	Poster	Biological and Behavioral Factors in Cancer Surveillance, Prevention, and Survivorship	4/17/23	1:30 PM	Section 28	21
3050	Quality control samples for future population-based microbiome studies	Semi	Zouiouich	Poster	Biological and Behavioral Factors in Cancer Surveillance, Prevention, and Survivorship	4/17/23	1:30 PM	Section 28	22
3051	Weight gain after age 35 increases the risk of breast cancer: Results from a prospective cohort study	Katherine	De la Torre	Poster	Biological and Behavioral Factors in Cancer Surveillance, Prevention, and Survivorship	4/17/23	1:30 PM	Section 28	23
3052	Patient- and clinician-reported outcomes of radiotherapy-related acute skin toxicities in a tri-racial/ethnic breast cancer population	Laura	Acosta	Poster	Biological and Behavioral Factors in Cancer Surveillance, Prevention, and Survivorship	4/17/23	1:30 PM	Section 28	24
3053	Comparative validation of neuroblastoma cell lines using flow cytometry and CyToF	Nicholas	Tastet	Poster	Biological and Behavioral Factors in Cancer Surveillance, Prevention, and Survivorship	4/17/23	1:30 PM	Section 28	25
3054	Proteomics and microRNA characterization of mammary tumor and adipose tissue-derived EVs and their combined impact on cancer cell metabolism	Ximena	Bustamante-Marin	Poster	Biological and Behavioral Factors in Cancer Surveillance, Prevention, and Survivorship	4/17/23	1:30 PM	Section 28	26
3055	Associations of the mucosal microbiome and circulating bile acids with colorectal adenoma among average-risk women	Maria	Gomez	Poster	Biological and Behavioral Factors in Cancer Surveillance, Prevention, and Survivorship	4/17/23	1:30 PM	Section 28	27
3056	Characteristics and outcomes of patients with hepatocellular carcinoma diagnosed at John Peter Smith Hospital	Madison	Hull	Poster	Biological and Behavioral Factors in Cancer Surveillance, Prevention, and Survivorship	4/17/23	1:30 PM	Section 28	28

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
3057	Second primary cancer risks for female and male breast cancer survivors	Isaac	Allen	Poster	Biological and Behavioral Factors in Cancer Surveillance, Prevention, and Survivorship	4/17/23	1:30 PM	Section 28	29
3058	Colocalization of cancer-associated biomarkers on single extracellular vesicles for early-cancer detection	Anthony	Couvillon	Poster	Biological and Behavioral Factors in Cancer Surveillance, Prevention, and Survivorship	4/17/23	1:30 PM	Section 28	30
3062	ROMO1 mediates mitochondrial function links to neuroendocrine differentiation of prostate cancer enhancement by the nuclear PKLR/MYCN/MAX complex	Yen-Nien	Liu	Poster	Endocrine-related Cancers: Treatment Resistance and Novel Targets and Therapeutics	4/17/23	1:30 PM	Section 29	1
3063	A novel mechanism for therapeutic targeting of the glucocorticoid receptor in triple negative breast cancer	Raj	Kumar	Poster	Endocrine-related Cancers: Treatment Resistance and Novel Targets and Therapeutics	4/17/23	1:30 PM	Section 29	2
3064	Exosome-based therapeutic strategy for neuroendocrine prostate cancer	Sharanjot	Saini	Poster	Endocrine-related Cancers: Treatment Resistance and Novel Targets and Therapeutics	4/17/23	1:30 PM	Section 29	3
3065	Increased longevity and quality of life with treatment with a progesterone receptor modulator in a patient with treatment resistant stage IV small cell lung cancer	Jerome	Check	Poster	Endocrine-related Cancers: Treatment Resistance and Novel Targets and Therapeutics	4/17/23	1:30 PM	Section 29	4
3067	Constitutive macropinocytosis in BRAFV600E thyroid cancer promotes response to a serum-albumin conjugate of monomethyl auristatin E	Huiyu	Hu	Poster	Endocrine-related Cancers: Treatment Resistance and Novel Targets and Therapeutics	4/17/23	1:30 PM	Section 29	6
3068	CREBBP/EP300 disruption promotes tumor progression and confers synthetic lethality in anaplastic thyroid cancers	Jacob	Haase	Poster	Endocrine-related Cancers: Treatment Resistance and Novel Targets and Therapeutics	4/17/23	1:30 PM	Section 29	7
3069	Targeting noncanonical Wnt5a signaling suppresses the neural lineage network and overcomes enzalutamide resistance in advanced prostate cancer	Shu	Ning	Poster	Endocrine-related Cancers: Treatment Resistance and Novel Targets and Therapeutics	4/17/23	1:30 PM	Section 29	8
3070	Leveraging oxysterol sulfation by SULT2B1b sulfotransferase and liver X receptor inactivation to suppress advanced prostate cancer	Bandana	Chatterjee	Poster	Endocrine-related Cancers: Treatment Resistance and Novel Targets and Therapeutics	4/17/23	1:30 PM	Section 29	9
3071	Pituitary adenylate cyclase activating polypeptide stimulates NSCLC growth by increasing HER4 tyrosine phosphorylation in a neuregulin-1 dependent manner	Terry	Moody	Poster	Endocrine-related Cancers: Treatment Resistance and Novel Targets and Therapeutics	4/17/23	1:30 PM	Section 29	10
3073	Action of thyroid hormones in sorafenib treatment of thyroid cancer	Mateo	Campos Haedo	Poster	Endocrine-related Cancers: Treatment Resistance and Novel Targets and Therapeutics	4/17/23	1:30 PM	Section 29	12

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
3074	The role of orphan nuclear receptors in breast cancer cell proliferation	Enrico	Garattini	Poster	Endocrine-related Cancers: Treatment Resistance and Novel Targets and Therapeutics	4/17/23	1:30 PM	Section 29	13
3075	Enhanced efficacy of ARV-471, a novel PROTAC® estrogen receptor degrader, in combination with targeted agents in estrogen receptor-positive (ER+) breast cancer models	Jessica	Teh	Poster	Endocrine-related Cancers: Treatment Resistance and Novel Targets and Therapeutics	4/17/23	1:30 PM	Section 29	14
3076	Autologous ECM-composed scaffolds and zebrafish PDXs for individualized theranostics in rare neuroendocrine neoplasms	Chiara	Calabrese	Poster	Endocrine-related Cancers: Treatment Resistance and Novel Targets and Therapeutics	4/17/23	1:30 PM	Section 29	15
3077	Pharmacological profiling of KSHN001034 - A novel prodrug of Fulvestrant with improved efficacy	Parva	Purohit	Poster	Endocrine-related Cancers: Treatment Resistance and Novel Targets and Therapeutics	4/17/23	1:30 PM	Section 29	16
3078	YIV-818-A enhanced apalutamide, darolutamide and enzalutamide action for prostate cancer treatment by down-regulating androgen receptor protein, inhibiting glucocorticoid receptor function and epigenetic regulation	Wing	Lam	Poster	Endocrine-related Cancers: Treatment Resistance and Novel Targets and Therapeutics	4/17/23	1:30 PM	Section 29	17
3079	Characterization of ER-AF2 inhibitors in breast cancer	Jane	Foo	Poster	Endocrine-related Cancers: Treatment Resistance and Novel Targets and Therapeutics	4/17/23	1:30 PM	Section 29	18
3080	Characterization of steroid receptor mediated activation of GLI as driving force of breast cancer growth	Shabnam	Massah	Poster	Endocrine-related Cancers: Treatment Resistance and Novel Targets and Therapeutics	4/17/23	1:30 PM	Section 29	19
3081	KDM1A/LSD1 inhibition enhances estrogen receptor beta mediated tumor suppression in ovarian cancer	Prabhakar	Venkata	Poster	Endocrine-related Cancers: Treatment Resistance and Novel Targets and Therapeutics	4/17/23	1:30 PM	Section 29	20
3082	Altered levels of corticosteroid-binding globulin: SerpinA6 and progression of prostate cancer	Sanjeev	Shukla	Poster	Endocrine-related Cancers: Treatment Resistance and Novel Targets and Therapeutics	4/17/23	1:30 PM	Section 29	21
3083	Targeting androgen receptor coregulators to enhance enzalutamide sensitivity in prostate cancer	Moray	Campbell	Poster	Endocrine-related Cancers: Treatment Resistance and Novel Targets and Therapeutics	4/17/23	1:30 PM	Section 29	22
3084	Progesterone receptor mediated crosstalk between cancer associated fibroblasts (CAFs) and ER+/PR+ breast cancer cells through CAF-secreted FGF2	Angela	Spartz	Poster	Endocrine-related Cancers: Treatment Resistance and Novel Targets and Therapeutics	4/17/23	1:30 PM	Section 29	23
3085	Role of amino acid sequences within the N terminal domain in regulating AF1-mediated glucocorticoid receptor activity	Shagufta	Khan	Poster	Endocrine-related Cancers: Treatment Resistance and Novel Targets and Therapeutics	4/17/23	1:30 PM	Section 29	24

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
3088	Identification of a novel series of MTAP-selective PRMT5 inhibitors, and first disclosure of AZ-PRMT5i-1	James	Smith	Poster	Targeted Drug Design and Development for Cancer Therapy	4/17/23	1:30 PM	Section 31	1
3089	XNW5004: a novel EZH2 inhibitor efficacious in multiple cancer xenograft models as a single agent and in combination studies	Yonghan	Hu	Poster	Targeted Drug Design and Development for Cancer Therapy	4/17/23	1:30 PM	Section 31	2
3090	Discovery of XNW9015, a potent, selective, and CNS-penetrating covalent inhibitor of CDK7 with excellent in vivo antitumor activities	Yonghan	Hu	Poster	Targeted Drug Design and Development for Cancer Therapy	4/17/23	1:30 PM	Section 31	3
3091	Discovery and development of a potent and highly selective WEE1 inhibitor IMP7068	Sui Xiong	Cai	Poster	Targeted Drug Design and Development for Cancer Therapy	4/17/23	1:30 PM	Section 31	4
3092	Optimization of deferiprone for the treatment of triple-negative breast cancer	Alexis	Johnston	Poster	Targeted Drug Design and Development for Cancer Therapy	4/17/23	1:30 PM	Section 31	5
3093	Synthesis and bioevaluation of LAT-1 efflux agonists for the treatment of pancreatic cancers	Holly	Moots	Poster	Targeted Drug Design and Development for Cancer Therapy	4/17/23	1:30 PM	Section 31	6
3094	Discovery of a Helicon TM peptide inhibitor of the beta-catenin-TCF interaction with in vivo activity	Brian	White	Poster	Targeted Drug Design and Development for Cancer Therapy	4/17/23	1:30 PM	Section 31	7
3095	Development of a novel ADAR1 inhibitor as a potent immunomodulator for the treatment of solid tumors	Aditya	Kulkarni	Poster	Targeted Drug Design and Development for Cancer Therapy	4/17/23	1:30 PM	Section 31	8
3096	Development of pyrrolopyrimidine-based ACK1 inhibitors for cancer therapeutics	Angelie	Matar	Poster	Targeted Drug Design and Development for Cancer Therapy	4/17/23	1:30 PM	Section 31	9
3098	Structure-based design rules for potent quadruplex-binding compounds based on the naphthalene diimide core	Stephen	Neidle	Poster	Targeted Drug Design and Development for Cancer Therapy	4/17/23	1:30 PM	Section 31	11
3099	Hnd-01: a potent inhibitor of wild type mutant BTK	Ahmed	Samatar	Poster	Targeted Drug Design and Development for Cancer Therapy	4/17/23	1:30 PM	Section 31	12
3100	The development of pleotropic small molecule kinase inhibitors (SKMIs) for the treatment of glioblastoma multiforme (GBM)	Alessandra	Fistrovich	Poster	Targeted Drug Design and Development for Cancer Therapy	4/17/23	1:30 PM	Section 31	13
3101	Discovery of helical sulfonyl- γ -AApeptides targeting LC3 in cancer cells	Hao	Xie	Poster	Targeted Drug Design and Development for Cancer Therapy	4/17/23	1:30 PM	Section 31	14
3102	Synthesis of N-benzoylamino-tetrahydropyridine analogues as selective COX-2 inhibitors and anti-breast cancer agents	Shasline	Gedeon	Poster	Targeted Drug Design and Development for Cancer Therapy	4/17/23	1:30 PM	Section 31	15
3103	Dual targeting MYC G-quadruplex and topoisomerase I by indenoisoquinolines for cancer therapy	Adam	Buric	Poster	Targeted Drug Design and Development for Cancer Therapy	4/17/23	1:30 PM	Section 31	16
3104	Synthesis and optimization of small molecules designed to stimulate the immune system by inducing DNA damage and blocking PD-1/PD-L1	Ana	Fraga Timiraos	Poster	Targeted Drug Design and Development for Cancer Therapy	4/17/23	1:30 PM	Section 31	17
3105	Design principle of heparanase inhibitors: A combined in vitro and in silico study	Yuzhao	Zhang	Poster	Targeted Drug Design and Development for Cancer Therapy	4/17/23	1:30 PM	Section 31	18

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
3106	Design, synthesis, and screening of niclosamide analogs as androgen receptor degraders for hepatocellular carcinoma	Jeffrey	Cheng	Poster	Targeted Drug Design and Development for Cancer Therapy	4/17/23	1:30 PM	Section 31	19
3107	Development of novel JAK2 inhibitors and PROTACs as chemical probes for the investigation of JAK2 inhibition and degradation	Briley	Humphrey	Poster	Targeted Drug Design and Development for Cancer Therapy	4/17/23	1:30 PM	Section 31	20
3109	HZ-R078: A tumor-enriched STAT3 degrader for treating T-cell lymphoma in pre-clinical models	Yizhe	Wu	Poster	Targeted Drug Design and Development for Cancer Therapy	4/17/23	1:30 PM	Section 31	22
3110	Design, synthesis, and biological evaluation of transducin β -like protein 1 (TBL1) degraders	Rui	Yang	Poster	Targeted Drug Design and Development for Cancer Therapy	4/17/23	1:30 PM	Section 31	23
3111	The Sygnature CHARMD platform - combinatorial high-throughput assembly and review of molecular degraders	Allan	Jordan	Poster	Targeted Drug Design and Development for Cancer Therapy	4/17/23	1:30 PM	Section 31	24
3115	Predicting in-depth mechanism of action of cancer drugs	Sanju	Sinha	Poster	Bioinformatics Applications in Cancer Biology 2	4/17/23	1:30 PM	Section 32	1
3116	Spatial single-cell atlas of stage III colorectal cancer	Andrew	Su	Poster	Bioinformatics Applications in Cancer Biology 2	4/17/23	1:30 PM	Section 32	2
3117	Molecular and clinical correlates of genetic ancestry in a diverse, admixed cancer dataset	Mackenzie	Postel	Poster	Bioinformatics Applications in Cancer Biology 2	4/17/23	1:30 PM	Section 32	3
3118	Predicting response to PARP inhibitors in pediatric cancer via synthetic lethal networks	Matthew	Nagy	Poster	Bioinformatics Applications in Cancer Biology 2	4/17/23	1:30 PM	Section 32	4
3119	A novel tissue resident memory T cell (TRM) signature predicts prognosis and tumor microenvironment of patients with melanoma	Chongming	Jiang	Poster	Bioinformatics Applications in Cancer Biology 2	4/17/23	1:30 PM	Section 32	5
3120	Sex differences in pediatric cancer genomics	Jieun	Oh	Poster	Bioinformatics Applications in Cancer Biology 2	4/17/23	1:30 PM	Section 32	6
3121	Exercise and tumor genomic landscapes in 2,879 patients with cancer	Brandon	Tsai	Poster	Bioinformatics Applications in Cancer Biology 2	4/17/23	1:30 PM	Section 32	7
3122	Single-cell DNA replication dynamics for genomically unstable cancer cells	Adam	Weiner	Poster	Bioinformatics Applications in Cancer Biology 2	4/17/23	1:30 PM	Section 32	8
3123	A method for quantifying circulating tumor DNA level and molecular response using methylome sequencing	Sai	Chen	Poster	Bioinformatics Applications in Cancer Biology 2	4/17/23	1:30 PM	Section 32	9
3124	Identification of sub-clonal loss of heterozygosity (LOH) in glioblastomas analyzed with spatial transcriptomics	Michelle	Webb	Poster	Bioinformatics Applications in Cancer Biology 2	4/17/23	1:30 PM	Section 32	10
3125	TCR specificity prediction of circulating T cells and TILs in personalized adoptive neoTCR T cell therapy	Tyler	Borrman	Poster	Bioinformatics Applications in Cancer Biology 2	4/17/23	1:30 PM	Section 32	11
3126	Multimodal genome-wide survey of progressing and non-progressing DCIS	Marija	Debeljak	Poster	Bioinformatics Applications in Cancer Biology 2	4/17/23	1:30 PM	Section 32	12
3127	Comprehensive proteogenomic characterization of rare kidney tumors	Yi	Hsiao	Poster	Bioinformatics Applications in Cancer Biology 2	4/17/23	1:30 PM	Section 32	13

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
3128	Using Kmerizer, a germline and somatic genotyper for immune associated complex alleles in GuardantINFINITY, for immunotherapy response prediction using cfDNA	Sante	Gnerre	Poster	Bioinformatics Applications in Cancer Biology 2	4/17/23	1:30 PM	Section 32	14
3129	Single-cell RNA sequencing of early-stage to refractory metastatic ER+ breast cancers reveal phenotypic states underlying resistance to multiple lines of therapy	Aritro	Nath	Poster	Bioinformatics Applications in Cancer Biology 2	4/17/23	1:30 PM	Section 32	15
3130	Extrachromosomal DNA in the cancerous transformation of Barrett's esophagus	Jens	Luebeck	Poster	Bioinformatics Applications in Cancer Biology 2	4/17/23	1:30 PM	Section 32	16
3131	Anaplastic transformation model in thyroid cancer revealed by single cell lineage and fate analysis	Lina	Lu	Poster	Bioinformatics Applications in Cancer Biology 2	4/17/23	1:30 PM	Section 32	17
3132	CLUMPS-PTM: Spatial clustering of post-translational modifications across cancer types	Shankara	Anand	Poster	Bioinformatics Applications in Cancer Biology 2	4/17/23	1:30 PM	Section 32	18
3133	Loss of the Y chromosome as a candidate driver in solid tumors	Meifang	Qi	Poster	Bioinformatics Applications in Cancer Biology 2	4/17/23	1:30 PM	Section 32	19
3134	Calling somatic variants from UG100 data using deep learning	Ilya	Soifer	Poster	Bioinformatics Applications in Cancer Biology 2	4/17/23	1:30 PM	Section 32	20
3135	Validation of a bioinformatic model for classifying non-tumor variants in a cell-free DNA liquid biopsy assay	Jennifer	Yen	Poster	Bioinformatics Applications in Cancer Biology 2	4/17/23	1:30 PM	Section 32	21
3136	HYENA detects non-coding genes activated by distal enhancers in cancer	Anqi	Yu	Poster	Bioinformatics Applications in Cancer Biology 2	4/17/23	1:30 PM	Section 32	22
3137	Somatic structure variants as a biomarker to predict immune checkpoint inhibitor response by generating anti-tumour antigen	Hongui	Cha	Poster	Bioinformatics Applications in Cancer Biology 2	4/17/23	1:30 PM	Section 32	23
3138	Topological analysis of spatial transcriptomics reveals different spatial interaction patterns in tumor microenvironment of lung cancer	Sungwoo	Bae	Poster	Bioinformatics Applications in Cancer Biology 2	4/17/23	1:30 PM	Section 32	24
3139	Pan-cancer splicing analysis reveals shared drivers of malignant transformation and survival	Anukana	Bhattacharjee	Poster	Bioinformatics Applications in Cancer Biology 2	4/17/23	1:30 PM	Section 32	25
3140	Computational modeling of stromal-immune cell interactions in triple-negative breast cancer	Yuhui	Wei	Poster	Bioinformatics Applications in Cancer Biology 2	4/17/23	1:30 PM	Section 32	26
3141	Epiregulon infers single-cell transcription factor activity to dissect mechanisms of lineage plasticity and drug response	Xiaosai	Yao	Poster	Bioinformatics Applications in Cancer Biology 2	4/17/23	1:30 PM	Section 32	27
3142	Enabling whole genome sequencing analysis from FFPE specimens in clinical oncology	Dylan	Domenico	Poster	Bioinformatics Applications in Cancer Biology 2	4/17/23	1:30 PM	Section 32	28
3143	A bioinformatic pipeline for identifying change-of-metabolic-function cancer mutations	Kevin	Tu	Poster	Bioinformatics Applications in Cancer Biology 2	4/17/23	1:30 PM	Section 32	29
3144	Mapping the functional interactions at the tumor-immune checkpoint interface	Behnaz	Bozorgui	Poster	Bioinformatics Applications in Cancer Biology 2	4/17/23	1:30 PM	Section 32	30

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
3148	Leveraging scale in precision oncology to measure pathway activation and detect genetic drivers in a large, real-world pan-cancer cohort	Joshua	Drews	Poster	Integrative Computational Approaches and Analyses	4/17/23	1:30 PM	Section 33	1
3149	Prediction of metabolic drug targets for cancer patients with poor prognosis by using genome-scale metabolic models and survival analyses	Sang Mi	Lee	Poster	Integrative Computational Approaches and Analyses	4/17/23	1:30 PM	Section 33	2
3150	Computational cohort discovery and coordinator-led validation to navigate potential research candidates to clinical trials	Daniel	King	Poster	Integrative Computational Approaches and Analyses	4/17/23	1:30 PM	Section 33	3
3152	Targetable public neoantigens are generated by tumor-wide cancer-specific splicing events in gliomas	Darwin	Kwok	Poster	Integrative Computational Approaches and Analyses	4/17/23	1:30 PM	Section 33	5
3153	Prediction of metabolites from cancer-associated fibroblasts that can have profound effects on cancer cells	Hae Deok	Jung	Poster	Integrative Computational Approaches and Analyses	4/17/23	1:30 PM	Section 33	6
3154	Integrating DNA damage and mutation enrichment to understand mutagenesis at transcription factor binding sites	Bo	Chi	Poster	Integrative Computational Approaches and Analyses	4/17/23	1:30 PM	Section 33	7
3155	Gene expression profiles reveal distinct regulatory activities of transcription factors GATA1 and TAL1 upon AML relapse	Chongzhi	Zang	Poster	Integrative Computational Approaches and Analyses	4/17/23	1:30 PM	Section 33	8
3156	Meta-analysis of lung cancer single-cell RNA data reveals novel gene modules associated with lineage, stage, and genetic alterations	Rui	Hong	Poster	Integrative Computational Approaches and Analyses	4/17/23	1:30 PM	Section 33	9
3157	Prediction of adverse drug reactions of anti-breast cancer drugs using machine learning	Kang	Seongmo	Poster	Integrative Computational Approaches and Analyses	4/17/23	1:30 PM	Section 33	10
3158	Checkpoint Kinase I, Cyclin E1, and Exonuclease I genes play role in the survival of lung adenocarcinoma patients	Prateek	Gupta	Poster	Integrative Computational Approaches and Analyses	4/17/23	1:30 PM	Section 33	11
3159	Next generation immuno-oncology tumor profiling using a biophysics-based biomarker to predict immunotherapy response in early-stage breast cancer	Daniel	Cook	Poster	Integrative Computational Approaches and Analyses	4/17/23	1:30 PM	Section 33	12
3160	A rapid, non-invasive test to determine HER2-low status in triple negative breast cancer (TNBC) patients	Daniel	Cook	Poster	Integrative Computational Approaches and Analyses	4/17/23	1:30 PM	Section 33	13
3161	Novel gene signature for predicting aggressive type of bladder cancer and the associated therapeutic strategies	Jim	Sheu	Poster	Integrative Computational Approaches and Analyses	4/17/23	1:30 PM	Section 33	14
3162	Genome-scale metabolic modeling suggests novel molecular targets in ER-positive breast cancer	Zachary	Mudge	Poster	Integrative Computational Approaches and Analyses	4/17/23	1:30 PM	Section 33	15
3163	Ontology guided navigation of somatic variants, mutational signatures, gene expression and histology images for pediatric cancer	Alexander	Gout	Poster	Integrative Computational Approaches and Analyses	4/17/23	1:30 PM	Section 33	16
3165	ImmuneSig: A deep learning framework to develop gene expression signature of immune checkpoint inhibitor therapy	Yang	Liu	Poster	Integrative Computational Approaches and Analyses	4/17/23	1:30 PM	Section 33	18

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
3166	CanSig: De novo discovery of shared transcriptional states in cancer single cells	Valentina	Boeva	Poster	Integrative Computational Approaches and Analyses	4/17/23	1:30 PM	Section 33	19
3167	The need for structured pathology data in matching human subjects to cancer clinical trial criteria: A methodological approach	Nalan	Yurtsever	Poster	Integrative Computational Approaches and Analyses	4/17/23	1:30 PM	Section 33	20
3168	DE-meta: Revealing tumor gene expression by meta-analysis of RNASeq and proteomics datasets	Xijun	Zhang	Poster	Integrative Computational Approaches and Analyses	4/17/23	1:30 PM	Section 33	21
3169	Decoupling the correlation between cytotoxic and exhausted T lymphocyte transcriptomic signatures in melanoma enhances immunotherapy response prediction	Binbin	Wang	Poster	Integrative Computational Approaches and Analyses	4/17/23	1:30 PM	Section 33	22
3170	Predicting the signals of adverse drug reactions on the basis of medical data	Junhyeok	Jeon	Poster	Integrative Computational Approaches and Analyses	4/17/23	1:30 PM	Section 33	23
3171	Detecting ploidy specific vulnerability to resource restriction: An integrated in vitro and in silico approach	Richard	Beck	Poster	Integrative Computational Approaches and Analyses	4/17/23	1:30 PM	Section 33	24
3172	Mapping the molecular landscape of acute myeloid leukemia enables prediction of drug response from proteogenomic data	James	Pino	Poster	Integrative Computational Approaches and Analyses	4/17/23	1:30 PM	Section 33	25
3173	Integrative structural models of oncogenic mutants within the trans- and juxta-membrane region of human epidermal growth factor receptors (HERs)	Christina	Mercado	Poster	Integrative Computational Approaches and Analyses	4/17/23	1:30 PM	Section 33	26
3174	Integrative analysis of genome-wide DNA replication origins in human cells	Mengxue	Tian	Poster	Integrative Computational Approaches and Analyses	4/17/23	1:30 PM	Section 33	27
3175	Comprehensive multi-omic characterization of hepatocellular carcinoma in Hispanic patients	Debodipta	Das	Poster	Integrative Computational Approaches and Analyses	4/17/23	1:30 PM	Section 33	28
3176	Modeling the complex multi-cellular ecosystem of the tumor microenvironment in colorectal cancer using multi-omics data	Geena	Ildefonso	Poster	Integrative Computational Approaches and Analyses	4/17/23	1:30 PM	Section 33	29
3177	Prediction of pathway-omics signature of histopathology images via attention-based deep learning in lung adenocarcinoma and squamous cell carcinoma	Han-Ru	Chen	Poster	Integrative Computational Approaches and Analyses	4/17/23	1:30 PM	Section 33	30
3181	A novel memory-like NK cell CAR targeting the proximal mesothelin domain shows promising pre-clinical activity in ovarian cancer using cell lines, patient-derived organoid tumors, and xenograft mice	Mubin	Tarannum	Poster	Adoptive Cell Therapy 2	4/17/23	1:30 PM	Section 37	1
3182	CAR T cells as micropharmacies to induce locoregional tumor vascular infarction by antigen-specific delivery of tissue factor to the tumor microenvironment	Claudia	Rossig	Poster	Adoptive Cell Therapy 2	4/17/23	1:30 PM	Section 37	2
3183	Combination of anti-EGFR antibody cetuximab with NKX101, an allogeneic NKG2D-L targeting NK cell therapy, enhances potency and in vitro cytotoxicity against solid tumors	Cynthia	Cho	Poster	Adoptive Cell Therapy 2	4/17/23	1:30 PM	Section 37	3

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
3184	"								
									Single-cell analysis of CAR T-cells helps uncover distinct functional signatures following CAR T-cell manufacturing
								"	Alfredo
Colina	Poster	Adoptive Cell Therapy 2	4/17/23	1:30 PM	Section 37	4			
3185	Development of LILRB4 biparatopic synthetic T-cell receptor and antigen receptor (STAR)-T cells for the treatment of acute myeloid leukemia (AML)	James	Pan	Poster	Adoptive Cell Therapy 2	4/17/23	1:30 PM	Section 37	5
3186	Anti-tumor effects and immunological responses by aGalCer loaded antigen presenting cell infusion in the patients with malignant tumor	Yoshinori	Ito	Poster	Adoptive Cell Therapy 2	4/17/23	1:30 PM	Section 37	6
3187	Improved anti-tumor immune functions of iPSC-derived NK cells with TGFβR2 knock-out and/or IL-15 knock-in by TALEN® editing for use alone or in combination with GPC3 Flex-NKTM bispecific antibody	An-Ping	Chen	Poster	Adoptive Cell Therapy 2	4/17/23	1:30 PM	Section 37	7

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
3188	Patient-derived TAC01-HER2 TAC T cells produced in Cocoon® Platform is highly functional in models of solid tumors	Ling	Wang	Poster	Adoptive Cell Therapy 2	4/17/23	1:30 PM	Section 37	8
3189	Pre-clinical evaluation of novel folate receptor 1 directed CAR T cells for high grade serous ovarian cancer	Christoph	Herbel	Poster	Adoptive Cell Therapy 2	4/17/23	1:30 PM	Section 37	9
3190	ALA-CART induces global transcriptional changes leading to enhanced potency and persistence of CAR T cells against both lymphoid and myeloid acute leukemias	Catherine	Danis	Poster	Adoptive Cell Therapy 2	4/17/23	1:30 PM	Section 37	10
3191	Genetically modified TGF-β dominant negative receptor and IL15 enhance Natural Killer (NK) cell mediated cytolytic activity in glioblastoma	Nethaji	Muniraj	Poster	Adoptive Cell Therapy 2	4/17/23	1:30 PM	Section 37	11
3192	Antitumor activity of ex vivo expanded tumor antigen priming cytotoxic T cells against malignant melanoma	Jonggwon	Choi	Poster	Adoptive Cell Therapy 2	4/17/23	1:30 PM	Section 37	12
3193	Developing non-exhausted tumor infiltrating lymphocytes (TILs) as a therapy for glioblastoma	Mustafa	Khasraw	Poster	Adoptive Cell Therapy 2	4/17/23	1:30 PM	Section 37	13
3194	Anti-mesothelin CAR.CIK lymphocytes are effective against ovarian cancer in 3D models of peritoneal carcinomatosis	Federica	Galvagno	Poster	Adoptive Cell Therapy 2	4/17/23	1:30 PM	Section 37	14
3195	Preclinical development of SENTI-202, an off-the-shelf logic gated CAR-NK cell therapy, for the treatment of CD33/FLT3+ hematologic malignancies including AML	Kanya	Rajangam	Poster	Adoptive Cell Therapy 2	4/17/23	1:30 PM	Section 37	15
3196	Subtype-specific targeting of cell surfaceome with CAR T therapies in small cell lung cancer	Bingnan	Zhang	Poster	Adoptive Cell Therapy 2	4/17/23	1:30 PM	Section 37	16
3197	Adoptive T cell therapy using IL-7 and IL-15 expanded HER2-specific CD4 T cells for metastatic breast cancer	Namrata	Gautam	Poster	Adoptive Cell Therapy 2	4/17/23	1:30 PM	Section 37	17
3198	Fully human CD20 and CD19 dual-targeting CAR-T cells mediate long-term remissions and protection from tumor rechallenge in vivo	Peirong	Hu	Poster	Adoptive Cell Therapy 2	4/17/23	1:30 PM	Section 37	18
3199	Development of a flow cytometry-based assay for measuring specific CAR expression on LGR5-targeting CAR-T cells	Timona	Tyllis	Poster	Adoptive Cell Therapy 2	4/17/23	1:30 PM	Section 37	19
3200	Non-engineered T cells with specific anticancer effects in KRAS-mutated colorectal cancer	Sunki	Lim	Poster	Adoptive Cell Therapy 2	4/17/23	1:30 PM	Section 37	20
3201	CB-012, an allogeneic anti-CLL-1 CAR-T cell therapy engineered with next-generation CRISPR technology to resist both the immunosuppressive tumor microenvironment and immune cell-mediated rejection, for patients with relapsed or refractory acute myeloid leukemia	Tristan	Fowler	Poster	Adoptive Cell Therapy 2	4/17/23	1:30 PM	Section 37	21
3202	NanoBIT technologies for CAR-T characterization and potency testing	Julia	Gilden	Poster	Adoptive Cell Therapy 2	4/17/23	1:30 PM	Section 37	22

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
3203	EVOcells Oncology: Tailored genetic engineering of iPSC-derived immune effector cells and combination with the right biologic therapeutics result in optimal killing of primary tumor cells from patients	Michael	Esquerré	Poster	Adoptive Cell Therapy 2	4/17/23	1:30 PM	Section 37	23
3208	Bone-derived TGF- β release is associated with cardiac dysfunction due to oxidation of SR calcium gatekeepers, Ca ²⁺ leak and mitochondrial dysfunction	Lei	Shi	Poster	Cancer Outcomes 1	4/17/23	1:30 PM	Section 38	1
3209	Metabolic characterization of radiation-induced cardiotoxicity	Sarah	Elliott	Poster	Cancer Outcomes 1	4/17/23	1:30 PM	Section 38	2
3210	Monoclonal antibodies targeting PD-1, LAG-3, and TIM-3 do not cause reproductive or endocrine toxicity in a syngeneic model of triple negative breast cancer	Payton	De La Cruz	Poster	Cancer Outcomes 1	4/17/23	1:30 PM	Section 38	3
3211	OQL025, a topical cream for the prevention of epidermal growth factor receptor inhibitor-induced skin rash	Robert	Tyler	Poster	Cancer Outcomes 1	4/17/23	1:30 PM	Section 38	4
3212	OQL06x, a gut-restricted janus kinase inhibitor to control epidermal growth factor receptor inhibitor-induced diarrhea	Robert	Tyler	Poster	Cancer Outcomes 1	4/17/23	1:30 PM	Section 38	5
3213	Association of Tumor Treating Fields (TTFields) with survival in newly diagnosed glioblastoma: A systematic review and meta-analysis	Patrick	Conlon	Poster	Cancer Outcomes 1	4/17/23	1:30 PM	Section 38	6
3214	Associations of socioeconomic status and gut microbiome with psychoneurological symptom cluster in gynecologic cancer patients	Zahra	Barandouzi	Poster	Cancer Outcomes 1	4/17/23	1:30 PM	Section 38	7
3215	Analysis of emergency department patients with known limb bone malignancies	Lauren	Ladehoff	Poster	Cancer Outcomes 1	4/17/23	1:30 PM	Section 38	8
3216	Comparative characteristics of stage I non-small cell lung cancer (NSCLC) patients segregated by quality of surgery and survival in a population-based cohort	Huibo	Shao	Poster	Cancer Outcomes 1	4/17/23	1:30 PM	Section 38	9
3217	Risk of thromboembolism in patients with non-small lung cancer (NSCLC) treated with immune check point inhibitors (ICIs) versus chemoimmunotherapy (ChemoIO)	Doaa	Attia	Poster	Cancer Outcomes 1	4/17/23	1:30 PM	Section 38	10
3218	Lifestyle intervention of food and exercise for lymphoma survivors (LIFE-L): a pilot intervention protocol for adults	Melissa	Lopez-Pentecost	Poster	Cancer Outcomes 1	4/17/23	1:30 PM	Section 38	11
3219	Development of a quality-of-life assessment module in patients with radiation dermatitis	Olivia	Allen	Poster	Cancer Outcomes 1	4/17/23	1:30 PM	Section 38	12
3220	Melanoma patients in the emergency department: Characteristics and outcomes	Henna	Hundal	Poster	Cancer Outcomes 1	4/17/23	1:30 PM	Section 38	13

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
3221	Patients with glioblastoma (GBM) treated with tumor treating fields (TTFields) therapy: post-marketing safety data over the last decade	Fabio	Iwamoto	Poster	Cancer Outcomes 1	4/17/23	1:30 PM	Section 38	14
3222	Assessment of change in HER2 status and its outcomes after neoadjuvant chemotherapy with trastuzumab and/or pertuzumab in early-stage breast cancer patients	Manasi	Godbole	Poster	Cancer Outcomes 1	4/17/23	1:30 PM	Section 38	15
3224	TTFields-prolonged the PFS of epithelioid glioblastoma patient: a case report	Yuxuan	Ding	Poster	Cancer Outcomes 1	4/17/23	1:30 PM	Section 38	17
3225	Real-world surveillance from cancer patients about their experience of comprehensive genomic profiling tests in Japan	Katsutoshi	Oda	Poster	Cancer Outcomes 1	4/17/23	1:30 PM	Section 38	18
3228	Photodynamic priming enhances immunotherapy responses overcoming oncogenic drivers in pancreatic patient derived tumor organoids	Pushpamali	De Silva	Poster	Combination Immunotherapies 1	4/17/23	1:30 PM	Section 39	1
3229	Triggering anti-tumor immune response with a nanotherapeutic that targets TLR9 and STAT3 pathways	Worapol	Ngamcherdtrakul	Poster	Combination Immunotherapies 1	4/17/23	1:30 PM	Section 39	2
3230	Tumor microenvironment modulation by immunotherapy sensitizes solid tumors to radiation	Minjeong	Kang	Poster	Combination Immunotherapies 1	4/17/23	1:30 PM	Section 39	3
3231	"								
									Temporal changes in intratumoral and systemic lymphocytes in response to short and long course

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
									radiot herapy regimens in locally advanced rectal cancer
								"	Lily
Hillson	Poster	Combination Immunotherapies 1	4/17/23	1:30 PM	Section 39	4			
3232	Combination therapy with onco-selective mRNA LNPs targets the complex immunosuppressive tumor microenvironment and is well tolerated at efficacious doses	Manfred	Kraus	Poster	Combination Immunotherapies 1	4/17/23	1:30 PM	Section 39	5
3233	A novel triple humanized B-hPD-1/hPD-L1/hCCR8 mouse model to evaluate in vivo efficacy of combination therapies	James	Jin	Poster	Combination Immunotherapies 1	4/17/23	1:30 PM	Section 39	6
3234	OCT-598, a novel EP2/EP4 dual antagonist, promotes anti-tumor immune responses in syngeneic mouse tumor models in combination with standard-of-care chemo- and immunotherapies	Youngrae	Lee	Poster	Combination Immunotherapies 1	4/17/23	1:30 PM	Section 39	7
3235	Protein kinase C is an upstream regulator of IL13Ra2 and small molecular activator enhances CAR T mediated killing	Siddharth	Subham	Poster	Combination Immunotherapies 1	4/17/23	1:30 PM	Section 39	8
3236	Optimizing mRNA vaccines and virus-mediated CAR T-cell therapy for immuno-oncology: Synthetic tools for gene modification	Ming	Yang	Poster	Combination Immunotherapies 1	4/17/23	1:30 PM	Section 39	9
3237	Dovitinib restricts EMT and promotes T cell recruitment to immune-desert gastric cancers via tumor-intrinsic IFN- γ signaling	Heng	Lu	Poster	Combination Immunotherapies 1	4/17/23	1:30 PM	Section 39	10
3238	Integrative biomarker analysis of regorafenib plus nivolumab (RegoNivo) in unresectable hepatocellular carcinoma (uHCC): A multicenter phase 2 RENOBATE trial	June-Young	Koh	Poster	Combination Immunotherapies 1	4/17/23	1:30 PM	Section 39	11
3239	Selective depletion of regulatory T cells by ALD2510, a novel IL-2-sparing anti-CD25 antibody, synergizes with PD-1 blockade in breast and gynecologic cancers	Stéphane	FATTORI	Poster	Combination Immunotherapies 1	4/17/23	1:30 PM	Section 39	12
3241	Single-cell RNA and TCR sequencing of tumor infiltrating lymphocytes identifies changes in pancreatic ductal	Joseph	Tandurella	Poster	Combination Immunotherapies 1	4/17/23	1:30 PM	Section 39	14

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
	adenocarcinomas following neoadjuvant treatment with combined anti-PD-1 blocking and anti-CD137 agonist therapy								
3242	Efficacy evaluation by novel humanized mouse models for preclinical study of ADCs combined with immunotherapy	Hongyan	Sun	Poster	Combination Immunotherapies 1	4/17/23	1:30 PM	Section 39	15
3243	Modulating the brain immune system to fight cancer in 3 dimensions	Ronit	Satchi-Fainaro	Poster	Combination Immunotherapies 1	4/17/23	1:30 PM	Section 39	16
3244	AVA-NP-695, a potent and selective ENPP1 inhibitor, abrogates tumor metastasis in 4T1 syngeneic tumor model and demonstrates strong tumor regression when combined with radiation	Aditya	Kulkarni	Poster	Combination Immunotherapies 1	4/17/23	1:30 PM	Section 39	17
3245	AXL as a therapeutic target in STK11 mutant NSCLC	Magnus	Blø	Poster	Combination Immunotherapies 1	4/17/23	1:30 PM	Section 39	18
3246	Targeting Syk reprograms tumor-associated macrophages and enhances responses to immune checkpoint blockade and radiation therapy in high-risk neuroblastoma	Shweta	Joshi	Poster	Combination Immunotherapies 1	4/17/23	1:30 PM	Section 39	19
3247	Combination therapy using PERK and PD1/PD-L1 inhibitors reprograms tumor associated macrophages and reduces tumor burden	Sushil	Kumar	Poster	Combination Immunotherapies 1	4/17/23	1:30 PM	Section 39	20
3248	Pharmacodynamic activity of epcoritamab (GEN3013; CD3xCD20) as monotherapy is maintained in combination with standard of care therapies in patients with diffuse large B-cell lymphoma	Jimin	Zhang	Poster	Combination Immunotherapies 1	4/17/23	1:30 PM	Section 39	21
3249	Circulating cytokine associations with clinical outcomes in melanoma patients treated with checkpoint inhibitors	Jiajia	Chen	Poster	Combination Immunotherapies 1	4/17/23	1:30 PM	Section 39	22
3250	Targeting CD38 on exhausted T cells overcomes resistance to cancer immunotherapy	Or-Yam	Revach	Poster	Combination Immunotherapies 1	4/17/23	1:30 PM	Section 39	23
3251	The immunostimulatory effect of 9-ING-41, a small molecule GSK-3 inhibitor, in sarcomas	William	MacDonald	Poster	Combination Immunotherapies 1	4/17/23	1:30 PM	Section 39	24
3252	TFields combined with temozolomide and immunotherapy show long-term PFS on a GBM patients with multiple negative prognostic factors	Zhiyong	Li	Poster	Combination Immunotherapies 1	4/17/23	1:30 PM	Section 39	25
3253	CD30 is a marker of activated effector regulatory T cells in solid tumors providing clinical rationale for the combination of brentuximab vedotin and PD-1 inhibitors	Ryan	Heiser	Poster	Combination Immunotherapies 1	4/17/23	1:30 PM	Section 39	26
3254	Combination of palbociclib, a potent CDK4/6 inhibitor, with anti-PD1 drug pembrolizumab treatment to promote T-cell mediated glioblastoma tumor cell death under hypoxia	Yutong	Xia	Poster	Combination Immunotherapies 1	4/17/23	1:30 PM	Section 39	27
3255	Investigate immune regulation and therapeutic efficacy via regorafenib combined with PD-L1 inhibitor in glioblastoma	Dai-Cheng	Dong	Poster	Combination Immunotherapies 1	4/17/23	1:30 PM	Section 39	28

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
3256	Entinostat enhances the efficacy of checkpoint inhibition in breast-to-lung metastases and is associated with alterations in the phenotype and function of myeloid cell populations	Edgar	Gonzalez	Poster	Combination Immunotherapies 1	4/17/23	1:30 PM	Section 39	29
3260	Potential of Type I interferon signaling leads to in vivo efficacy achieved with combination of chemotherapy and the PARP7 inhibitor RBN-2397	Jennifer	Molina	Poster	Combination Immunotherapies 2	4/17/23	1:30 PM	Section 40	1
3261	SQ3370, a doxorubicin-based click chemistry therapeutic, promotes a shift from an immunosuppressive towards a T-cell permissive tumor microenvironment in patients	Masa	Aleckovic	Poster	Combination Immunotherapies 2	4/17/23	1:30 PM	Section 40	2
3262	Single-cell spatial dynamics of the tumor-immune microenvironment of high-grade serous ovarian cancer during neoadjuvant chemotherapy	Inga-Maria	Launonen	Poster	Combination Immunotherapies 2	4/17/23	1:30 PM	Section 40	3
3263	Implications for cancer viroimmunotherapy: a new adenovirus capsid sensor	Andrew	Gillard	Poster	Combination Immunotherapies 2	4/17/23	1:30 PM	Section 40	4
3264	Sotorasib, a selective G12C K-RAS inhibitor, modulates the tumor microenvironment to promote TNF α and IFN γ signaling and augment immunotherapy response	Mohammed	Ibrahim	Poster	Combination Immunotherapies 2	4/17/23	1:30 PM	Section 40	5
3265	Temozolomide combined with ipilimumab + nivolumab enhances T cell killing of MGMT-expressing, MSS colorectal cancer cells	Lindsey	Carlsen	Poster	Combination Immunotherapies 2	4/17/23	1:30 PM	Section 40	6
3266	Classical chemotherapy modulates cytokine secretion in the MSS CRC immune microenvironment and enhances T cell killing	Lindsey	Carlsen	Poster	Combination Immunotherapies 2	4/17/23	1:30 PM	Section 40	7
3267	EGFR inhibition in EGFR-mutant lung cancer triggers the innate immune response associated with tumor immune escape	Akihiko	Shiyya	Poster	Combination Immunotherapies 2	4/17/23	1:30 PM	Section 40	8
3268	Biomarkers of drug-tolerant persistent melanoma cells in human, correlation with tumor microenvironment and response to treatment	Caroline	Robert	Poster	Combination Immunotherapies 2	4/17/23	1:30 PM	Section 40	9
3269	Reappraisal of immunologic mechanisms of hypomethylating agents in treatment of high-risk myelodysplastic syndrome and acute myeloid leukemia	Junshik	Hong	Poster	Combination Immunotherapies 2	4/17/23	1:30 PM	Section 40	10
3270	The Xerna TM TME Panel potentially predicts response to a combination of the TLR9 agonist vidutolimod and PD-1 inhibitor pembrolizumab in metastatic melanomas with prior anti-PD-1 treatment	Mark	Uhlik	Poster	Combination Immunotherapies 2	4/17/23	1:30 PM	Section 40	11
3271	Multiomic meta-analysis of differential response to PD-1 and CTLA-4 blockade in metastatic melanoma	Amy	Huang	Poster	Combination Immunotherapies 2	4/17/23	1:30 PM	Section 40	12

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
3272	Tumor treating fields combined with the PULSAR paradigm for radiotherapy and an immune checkpoint inhibitor enhances antitumor efficacy in vivo	Debabrata	Saha	Poster	Combination Immunotherapies 2	4/17/23	1:30 PM	Section 40	13
3273	Guadecitabine plus ipilimumab in unresectable melanoma: Five-year follow-up and correlation with integrated, multi-omic analysis in the NIBIT-M4 trial	Maria Fortunata	Lofiego	Poster	Combination Immunotherapies 2	4/17/23	1:30 PM	Section 40	14
3274	Novel cell-based bioassays for mono- and multi-specific antibodies targeting PD-1/PD-L1 for combination immunotherapy	Jun	Wang	Poster	Combination Immunotherapies 2	4/17/23	1:30 PM	Section 40	15
3275	Combination of talimogene laherparepvec (T-VEC) with pembrolizumab (pembro) in advanced melanoma patients following progression on a prior PD-1 inhibitor: SWOG S1607	Siwen	Hu-Lieskovan	Poster	Combination Immunotherapies 2	4/17/23	1:30 PM	Section 40	16
3277	In vivo CRISPR screening identifies PTSS1 as a potential combinatorial target to improve immune checkpoint therapy response	Jielin	Liu	Poster	Combination Immunotherapies 2	4/17/23	1:30 PM	Section 40	18
3279	Systemic immune response invoked by short-course oxaliplatin-based chemotherapy (FLOX) for efficacy of sequential immune checkpoint blockade (ICB; nivolumab) in microsatellite-stable (MSS) metastatic colorectal cancer (mCRC)	Anne	Ree	Poster	Combination Immunotherapies 2	4/17/23	1:30 PM	Section 40	20
3280	Vrd induction therapy drives memory like NK cell development in newly diagnosed multiple myeloma patients	Tao	Peng	Poster	Combination Immunotherapies 2	4/17/23	1:30 PM	Section 40	21
3281	GEN1042 (DuoBody-CD40x4-1BB) [®] in combination with PD-1 blockade reverses T-cell exhaustion in vitro	Vanessa	Spires	Poster	Combination Immunotherapies 2	4/17/23	1:30 PM	Section 40	22
3282	Regorafenib enhance PD-L1 expression via ATM activation and evaluate the therapeutic efficacy of combining PD-L1 antibody on bladder cancer	Kai-Jen	Pai	Poster	Combination Immunotherapies 2	4/17/23	1:30 PM	Section 40	23
3283	GEN1046 (DuoBody [®] -PD-L1x4-1BB) in combination with PD-1 blockade potentiates anti-tumor immunity	Michela	Capello	Poster	Combination Immunotherapies 2	4/17/23	1:30 PM	Section 40	24
3285	Targeting TBK1 to overcome resistance to cancer immunotherapy	Russell	Jenkins	Poster	Combination Immunotherapies 2	4/17/23	1:30 PM	Section 40	26
3286	B-hCD94/hNKG2A mice provide a preclinical tool for evaluating therapeutic antibodies targeting human NKG2A	Mari	Kuraguchi	Poster	Combination Immunotherapies 2	4/17/23	1:30 PM	Section 40	27
3287	A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better	Dijana	Djureinovic	Poster	Combination Immunotherapies 2	4/17/23	1:30 PM	Section 40	28
3288	A novel and defined TLR3 agonist based anticancer therapy	Dongho	Kim	Poster	Combination Immunotherapies 2	4/17/23	1:30 PM	Section 40	29
3289	Melanoma patients with high and low target expression can benefit from TCR-CD3 bispecifics through direct and indirect mechanisms of tumor control	Esra	Güç	Poster	Combination Immunotherapies 2	4/17/23	1:30 PM	Section 40	30

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
3293	CADM1 is a serum marker for small-cell lung cancer associated with poor prognosis and metastasis	Takeshi	Ito	Poster	Diagnostic and Prognostic Biomarkers 3	4/17/23	1:30 PM	Section 41	1
3294	Development and validation of an AI-based PD-L1 scoring algorithm in NSCLC samples	Daniela	Rodrigues	Poster	Diagnostic and Prognostic Biomarkers 3	4/17/23	1:30 PM	Section 41	2
3295	Plasma and tumor expression levels of progranulin osteopontin & matrix metalloproteinase 2 in colorectal cancer patients and assessment of plasma levels for diagnosis	Chandana	Herath Mudiyansele	Poster	Diagnostic and Prognostic Biomarkers 3	4/17/23	1:30 PM	Section 41	3
3296	A urine-based DNA methylation marker test to detect upper tract urothelial carcinoma: a prospective pilot study	Paolo	Piatti	Poster	Diagnostic and Prognostic Biomarkers 3	4/17/23	1:30 PM	Section 41	4
3297	Deep reactive ion etched microneedle array for in-vivo melanoma cancer monitoring via cancer exosome isolation	Scott	Smith	Poster	Diagnostic and Prognostic Biomarkers 3	4/17/23	1:30 PM	Section 41	5
3298	Two detection methods of clinical KRAS G12C mutation detection for companion diagnostics	Robert	Brown	Poster	Diagnostic and Prognostic Biomarkers 3	4/17/23	1:30 PM	Section 41	6
3299	Usefulness of protocadherin GA12 and cysteine dioxygenase type 1 methylation biomarkers in the diagnosis of lung cancer	Minhyeok	Lee	Poster	Diagnostic and Prognostic Biomarkers 3	4/17/23	1:30 PM	Section 41	7
3300	Development of a diagnostic antibody for anti-BTN1A1 therapy, a novel immune checkpoint inhibitor mutually exclusive of PD-L1/PD-1	Stephen	Yoo	Poster	Diagnostic and Prognostic Biomarkers 3	4/17/23	1:30 PM	Section 41	8
3301	Ultrasensitive compartment-free digital phenotyping of circulating extracellular vesicles for diagnosis of Ewing sarcoma	Yunjie	Wen	Poster	Diagnostic and Prognostic Biomarkers 3	4/17/23	1:30 PM	Section 41	9
3302	KLK7 expression in human tumors: A tissue microarray study on 13,447 tumors	Ronald	Simon	Poster	Diagnostic and Prognostic Biomarkers 3	4/17/23	1:30 PM	Section 41	10
3303	High homogeneity of mesothelin expression in primary and metastatic ovarian cancer	Ronald	Simon	Poster	Diagnostic and Prognostic Biomarkers 3	4/17/23	1:30 PM	Section 41	11
3304	Immune repertoire sequencing enables accurate clonality determination	Chen	Song	Poster	Diagnostic and Prognostic Biomarkers 3	4/17/23	1:30 PM	Section 41	12
3305	Clinical significance of circZKSCAN1 RNA in human hepatocellular carcinoma	Minji	Bang	Poster	Diagnostic and Prognostic Biomarkers 3	4/17/23	1:30 PM	Section 41	13
3308	Predictive biomarkers of response to immune checkpoint inhibitors in metastatic renal cell carcinoma	Takanobu	Motoshima	Poster	Diagnostic and Prognostic Biomarkers 3	4/17/23	1:30 PM	Section 41	16
3309	Genomic features, evolutionary patterns, and minimal residual disease at surgical margins as novel prognostic/predictive biomarkers in locally advanced rectal cancer	HaiMeng	Tang	Poster	Diagnostic and Prognostic Biomarkers 3	4/17/23	1:30 PM	Section 41	17
3310	Extracellular vesicles budding from stromal macrophages in the blood of metastatic non-small cell lung cancer patients correlates with poor survival	Daniel	Adams	Poster	Diagnostic and Prognostic Biomarkers 3	4/17/23	1:30 PM	Section 41	18

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
3311	Tumor cell total mRNA level predicts disease progression across multi-ethnic patient cohorts with triple-negative breast cancer	Yaoyi	Dai	Poster	Diagnostic and Prognostic Biomarkers 3	4/17/23	1:30 PM	Section 41	19
3312	Comparison of risk factors to molecular risk stratification in Chinese early-stage non-squamous non-small cell lung cancer patients	Naixin	Liang	Poster	Diagnostic and Prognostic Biomarkers 3	4/17/23	1:30 PM	Section 41	20
3313	A novel RNA aptamer-based assay for quantifying fractional occupancy of PD1 by PDL1 in formalin fixed biospecimens	Suresh	Veeramani	Poster	Diagnostic and Prognostic Biomarkers 3	4/17/23	1:30 PM	Section 41	21
3314	Circulatory altruistic stem cells as a prognostic biomarker for platinum based chemotherapy in oral cancer	Lekhika	Pathak	Poster	Diagnostic and Prognostic Biomarkers 3	4/17/23	1:30 PM	Section 41	22
3315	Evaluating biomarker potential of germline genomic factors for predicting clinical outcomes in prostate cancer	Nicole	Zeltser	Poster	Diagnostic and Prognostic Biomarkers 3	4/17/23	1:30 PM	Section 41	23
3316	Intra-tumor heterogeneity assessment of liver lesions for colorectal cancer patients on CT-scans	Ridouane	Ghermi	Poster	Diagnostic and Prognostic Biomarkers 3	4/17/23	1:30 PM	Section 41	24
3317	Expression of glucose transporter-1 in follicular lymphoma affected tumor-infiltrating immunocytes and was related to progression of disease within 24 months	Qingyuan	Zhang	Poster	Diagnostic and Prognostic Biomarkers 3	4/17/23	1:30 PM	Section 41	25
3318	Frequent loss of CACNA1C, a calcium voltage-gated channel subunit is associated with lung adenocarcinoma progression and poor prognosis	Saanvi	Dasgupta	Poster	Diagnostic and Prognostic Biomarkers 3	4/17/23	1:30 PM	Section 41	26
3319	Breath-based detection of lung cancer using exogenous volatile organic compound targeting β -glucuronidase in the tumor microenvironment	Billy	Boyle	Poster	Diagnostic and Prognostic Biomarkers 3	4/17/23	1:30 PM	Section 41	27
3320	Liquid biopsy to detect biomarkers in early-stage surgically-resected pancreatic cancer	Emmeline	Lin	Poster	Diagnostic and Prognostic Biomarkers 3	4/17/23	1:30 PM	Section 41	28
3321	Development of a CTC-based novel diagnostic technology for unresectable non-small cell lung cancer	Mami	Onishi	Poster	Diagnostic and Prognostic Biomarkers 3	4/17/23	1:30 PM	Section 41	29
3322	Diagnosis and monitoring of pediatric cancer patients using low-pass whole genome and targeted sequencing of cell-free DNA	Venkata	Yellapantula	Poster	Diagnostic and Prognostic Biomarkers 3	4/17/23	1:30 PM	Section 41	30
3326	The clinical validity of urinary pellet DNA monitoring of recurrent bladder cancer	Masakazu	Abe	Poster	Early Detection Biomarkers	4/17/23	1:30 PM	Section 42	1
3327	Proteomic profiling of extracellular vesicles in patients with biliary tract cancers	Dong Uk	Kim	Poster	Early Detection Biomarkers	4/17/23	1:30 PM	Section 42	2
3328	Using Luminex approach to develop a panel of anti-TAA autoantibodies for the detection of prostate cancer	Cuipeng	Qiu	Poster	Early Detection Biomarkers	4/17/23	1:30 PM	Section 42	3
3330	Development of a genome-wide multiomic atlas of early-stage lung cancer enables identification of novel methylation biomarkers for disease detection beyond TCGA	Revital	Knirsh	Poster	Early Detection Biomarkers	4/17/23	1:30 PM	Section 42	5

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
3331	Highly sensitive blood-based multi-cancer screening device with tiered specificity based on diagnostic workflow	Yupeng	He	Poster	Early Detection Biomarkers	4/17/23	1:30 PM	Section 42	6
3332	Reference materials for the development of assays for the detection of measurable residual disease in acute myeloid leukemia	Yves	Konigshofer	Poster	Early Detection Biomarkers	4/17/23	1:30 PM	Section 42	7
3333	Exosomal non-coding RNAs as a biomarker to improve early ovarian cancer detection	Yuliang	Cao	Poster	Early Detection Biomarkers	4/17/23	1:30 PM	Section 42	8
3334	Epigenetic immune cell markers for CLL	Janine	Jung	Poster	Early Detection Biomarkers	4/17/23	1:30 PM	Section 42	9
3335	DNA methylation markers for the surveillance of non-muscle invasive bladder cancer: Results from a prospective pilot study	Paolo	Piatti	Poster	Early Detection Biomarkers	4/17/23	1:30 PM	Section 42	10
3336	A novel clinical and biomarker model accurately predicts hepatocellular carcinoma (HCC) across racial groups	Xiyan	Xiang	Poster	Early Detection Biomarkers	4/17/23	1:30 PM	Section 42	11
3337	The impact of black raspberry as a whole food approach on DNA damage-induced by tobacco carcinogens in the oral cavity and urine of smokers	Kun-Ming	Chen	Poster	Early Detection Biomarkers	4/17/23	1:30 PM	Section 42	12
3338	Targeted serum metabolomics for noninvasive detection of colorectal neoplasia	Liam	Fitzgerald	Poster	Early Detection Biomarkers	4/17/23	1:30 PM	Section 42	13
3339	Circulating long non-coding RNA HULC as an early indicator of hepatocellular carcinoma irrespective of etiology	Joseph	George	Poster	Early Detection Biomarkers	4/17/23	1:30 PM	Section 42	14
3340	Bladder field cancerization impacts tumor development and T-cell exhaustion, and is reflected in urinary tumor DNA	Trine	Strandgaard	Poster	Early Detection Biomarkers	4/17/23	1:30 PM	Section 42	15
3341	Preliminary clinical validation of COLO eDX, a novel plasma circulating tumor DNA methylation assay for detecting colorectal cancer	Jin-Soo	Kim	Poster	Early Detection Biomarkers	4/17/23	1:30 PM	Section 42	16
3342	The dark age of single organ screening is over: CD24 is a novel universal pan-cancer blood test for early detection of cancer	Shiran	Shapira	Poster	Early Detection Biomarkers	4/17/23	1:30 PM	Section 42	17
3343	Liquid biopsy screening tool for the earlier detection of brain tumors	Ashton	Theakstone	Poster	Early Detection Biomarkers	4/17/23	1:30 PM	Section 42	18
3344	Early detection biomarkers of LncRNA H19 genotypes for determining childhood leukemia susceptibility	Chia-Wen	Tsai	Poster	Early Detection Biomarkers	4/17/23	1:30 PM	Section 42	19
3345	Tissue of origin (TOO) localization using targeted methylation biomarkers discovered by whole-genome bisulfite sequencing	Chao	Song	Poster	Early Detection Biomarkers	4/17/23	1:30 PM	Section 42	20
3346	Evaluation of a serum-based test integrating tumor tissue and gut microbiome derived metabolites for diagnosis of advanced colorectal adenoma	Xiaowei	Li	Poster	Early Detection Biomarkers	4/17/23	1:30 PM	Section 42	21
3347	Characterization of extracellular POTE-2 protein in liver cancer	Samantha	Lopez	Poster	Early Detection Biomarkers	4/17/23	1:30 PM	Section 42	22

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
3348	Unraveling new strategies for early detection of invasive cancer cells: A special focus on the nuclear and cytoskeletal architecture	Maria	Fernandes	Poster	Early Detection Biomarkers	4/17/23	1:30 PM	Section 42	23
3349	Discovery and validation of methylated DNA markers of upper tract urothelial tract cancers	John	Kisiel	Poster	Early Detection Biomarkers	4/17/23	1:30 PM	Section 42	24
3351	Identification of novel biomarkers for high grade serous ovarian cancer screening via extracellular vesicle proteomic profiling	Camille	Trinidad	Poster	Early Detection Biomarkers	4/17/23	1:30 PM	Section 42	26
3352	Development and validation of a serum microRNA-based diagnostic model for early detection of multiple cancers	Grace	Zhou	Poster	Early Detection Biomarkers	4/17/23	1:30 PM	Section 42	27
3353	Cell-free DNA (cfDNA) fragmentation profiles linked to copy number alteration analysis allows for early colorectal cancer detection	Kristi	Kruusmaa	Poster	Early Detection Biomarkers	4/17/23	1:30 PM	Section 42	28
3354	Isolation and characterization of circulating tumor cells from ductal carcinoma in situ patients using label free technology	Neha	Nagpal	Poster	Early Detection Biomarkers	4/17/23	1:30 PM	Section 42	29
3358	PLCRC-PROVENC3: assessing the prognostic value of post-surgery liquid biopsy cell-free circulating tumor DNA in stage III colon cancer patients	Carmen	Rubio-Alarcon	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 3	4/17/23	1:30 PM	Section 43	1
3359	Sensitive detection of locoregional MRD after head and neck cancer surgery	Noah	Earland	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 3	4/17/23	1:30 PM	Section 43	2
3360	Negative predictive value of circulating tumor tissue modified viral HPV DNA for identifying recurrence among patients treated for HPV-driven oropharyngeal cancer	Glenn	Hanna	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 3	4/17/23	1:30 PM	Section 43	3
3361	Clinical and genomic correlates of liquid biopsy (LB) derived variant allele frequency (VAF) in advanced NSCLC patients	Arianna	Marinello	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 3	4/17/23	1:30 PM	Section 43	4
3362	Evaluation of circulating tumor DNA kinetics as a prognostic biomarker for overall survival in metastatic castrate resistant prostate cancer using a novel methylation sequencing research assay	Christopher	Sweeney	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 3	4/17/23	1:30 PM	Section 43	5
3363	Spatial and longitudinal tumor heterogeneity in head and neck squamous cell carcinoma patients treated with primary surgery	Grégoire	Marret	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 3	4/17/23	1:30 PM	Section 43	6
3364	Combined enrichment of plasma EpCAM-positive extracellular vesicles (EVs) and circulating tumor cells (CTCs) from a single tube of cancer patient blood samples, for subsequent molecular analysis	Francesca	Fontana	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 3	4/17/23	1:30 PM	Section 43	7
3365	Circulating free HPV16 DNA as a potential biomarker for immunotherapy-based trials in HPV16+ head and neck squamous cell carcinoma	Yanan	Kuang	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 3	4/17/23	1:30 PM	Section 43	8

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
3366	A machine learning approach to determine the cellular origin of variants in liquid biopsies	Jenna	Canzoniero	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 3	4/17/23	1:30 PM	Section 43	9
3367	Tumor-derived Extracellular Vesicles as a potential PD biomarker for TEAD central pocket binder activity in liquid biopsy	Manoel	Nunes	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 3	4/17/23	1:30 PM	Section 43	10
3368	Homologous recombination deficiency (HRD) testing on cell-free tumor DNA in ascites of patients with newly diagnosed advanced epithelial ovarian cancer	Cyril	Roussel-Simonin	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 3	4/17/23	1:30 PM	Section 43	11
3369	Utility of ctDNA-based targeted methylation MRD assay for hematological malignancies	Veerendra	Munugalavadla	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 3	4/17/23	1:30 PM	Section 43	12
3370	Liquid biopsy approaches to determine tumor cell heterogeneity in advanced prostate cancer	Lina	Merkens	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 3	4/17/23	1:30 PM	Section 43	13
3371	A DNA-binding priming agent protects cell-free DNA and improves the sensitivity of liquid biopsies	Shervin	Tabrizi	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 3	4/17/23	1:30 PM	Section 43	14
3373	Deep learning for circulating tumor cell (CTC) identification with the CELLSEARCH system: achieving top human-level performance	Luca	Biasioli	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 3	4/17/23	1:30 PM	Section 43	16
3374	Circulating cell-free tumor DNA dynamics capture minimal residual disease with neoadjuvant immune checkpoint blockade plus chemoradiotherapy for patients with operable esophageal/gastroesophageal junction cancer	Blair	Landon	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 3	4/17/23	1:30 PM	Section 43	17
3375	Ultrasensitive ctDNA minimal residual disease monitoring in early NSCLC with PhasED-Seq	James	Isbell	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 3	4/17/23	1:30 PM	Section 43	18
3376	Non-small cell lung cancer (NSCLC) with higher blood tumor mutational burden (bTMB)/tissueTMB (tTMB) ratio is associated with inferior survival outcome	Leeseul	Kim	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 3	4/17/23	1:30 PM	Section 43	19
3377	Liquid biopsy analysis reveals orthologs of actionable human cancer variants in dogs	Daniel	Grosu	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 3	4/17/23	1:30 PM	Section 43	20
3378	Rapid and efficient sample preparations for cell free DNA	Zhiyang	Zeng	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 3	4/17/23	1:30 PM	Section 43	21
3379	Comprehensive circulating tumor DNA and CTC profiling of treatment naïve early-stage head and neck cancer patients reveals early signature of disease progression	Gowhar	Shafi	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 3	4/17/23	1:30 PM	Section 43	22
3380	Use of liquid biopsy for detection of pathogenic variants in cell-free tumor DNA from patients with precursor lesions and colorectal cancer	Mariana	Bisarro Dos Reis	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 3	4/17/23	1:30 PM	Section 43	23
3381	Analytical performance of an ultra-sensitive, tumor-informed liquid biopsy platform for molecular residual disease detection and clinical guidance	Rui	Chen	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 3	4/17/23	1:30 PM	Section 43	24

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
3382	Detection of CTCs using a micro-channel combined fluid dynamics and electrophoresis in colorectal cancer	Ryo	Ohta	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 3	4/17/23	1:30 PM	Section 43	25
3383	Liquid biopsy for PDL-1 status by analysis of cfRNA: Clinical data from a large community practice	Lowell	Hart	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 3	4/17/23	1:30 PM	Section 43	26
3384	Evaluation of a tumor informed MRD assay with contrived breast cancer samples	Hugh	Russell	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 3	4/17/23	1:30 PM	Section 43	27
3385	A pipeline for mRNA analysis on circulating tumor cells (CTCs) collected and stored in preservative tubes	Eleonora	Nicolo	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 3	4/17/23	1:30 PM	Section 43	28
3386	Development of next generation extracellular vesicle based urine tests for prostate cancer	Sandra	Gaston	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 3	4/17/23	1:30 PM	Section 43	29
3387	ctDNA dynamics in early stage node negative lung cancers	Jamie	Feng	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 3	4/17/23	1:30 PM	Section 43	30
3391	Dual inhibition of RAS and the IGF2/IGF1R pathways: a potential targeting strategy for RAS-mutated embryonal rhabdomyosarcoma	Dorsay	Sadeghian	Poster	Molecular Targeted Therapies 1	4/17/23	1:30 PM	Section 44	1
3392	Antitumor activity of a potent MNK inhibitor NSP-1047 in acute myeloid leukemia	Bing	Li	Poster	Molecular Targeted Therapies 1	4/17/23	1:30 PM	Section 44	2
3393	A novel targetable G3BP stress granule assembly factor 1 (G3BP1)-colony stimulating factor 1 receptor (CSF1R) fusion in acute megakaryoblastic leukemia (AMKL)	Xi	Luo	Poster	Molecular Targeted Therapies 1	4/17/23	1:30 PM	Section 44	3
3394	Simultaneous targeting of the PDZ1 and PDZ2 domains of MDA-9 inhibits melanoma metastasis	Swadesh	Das	Poster	Molecular Targeted Therapies 1	4/17/23	1:30 PM	Section 44	4
3395	Clinical impact of FGFR inhibitors on FGFR2 positive pancreatic cancer	Leah	Stein	Poster	Molecular Targeted Therapies 1	4/17/23	1:30 PM	Section 44	5
3396	Discovery of BDTX-1535, a novel 4th generation, irreversible, potent, wild type sparing EGFR MasterKey inhibitor that targets oncogenic kinase domain mutations as well as extracellular domain alterations for the treatment of NSCLC and GBM	Elizabeth	Buck	Poster	Molecular Targeted Therapies 1	4/17/23	1:30 PM	Section 44	6
3397	Evaluation of a novel two-drug combination strategy for p53-deficient colorectal and pancreatic cancers	Mohammed	Alruwaili	Poster	Molecular Targeted Therapies 1	4/17/23	1:30 PM	Section 44	7
3398	Clinical use of next-generation sequencing panel in pediatric oncology patients	Jung Yoon	Choi	Poster	Molecular Targeted Therapies 1	4/17/23	1:30 PM	Section 44	8
3399	Tumor organoid based drug sensitivity testing in ovarian cancer identifies exceptional responders to targeted therapies	Amanda	Prechtel	Poster	Molecular Targeted Therapies 1	4/17/23	1:30 PM	Section 44	9
3400	TY-2136b, a next generation ROS1/TRK/ALK inhibitor, potently inhibits kinase and cell proliferation activities of tumor cells bearing drug-dependent acquired mutations	Chengshan	Niu	Poster	Molecular Targeted Therapies 1	4/17/23	1:30 PM	Section 44	10

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
3401	Discovery of GH658, a novel tead allosteric inhibitor as a cancer therapy	Jie Jack	Li	Poster	Molecular Targeted Therapies 1	4/17/23	1:30 PM	Section 44	11
3402	In vivo efficacy of RAF/MEK clamp avutometinib (VS-6766) in combination with FAK inhibition in low grade serous ovarian cancer	Alessandro	Santin	Poster	Molecular Targeted Therapies 1	4/17/23	1:30 PM	Section 44	12
3403	Leveraging a p53 “super-tumor suppressor” to understand mechanisms of lung adenocarcinoma regression	Mengxiong	Wang	Poster	Molecular Targeted Therapies 1	4/17/23	1:30 PM	Section 44	13
3404	Single nuclei RNAseq analysis of recurrent high-grade glioma tumors from patients in the phase 0/1 ‘trigger’ trial of ribociclib plus everolimus	Nader	Sanai	Poster	Molecular Targeted Therapies 1	4/17/23	1:30 PM	Section 44	14
3405	Changes in HER3 expression associated with chemotherapy for pancreatic cancer	Tomoyuki	Satake	Poster	Molecular Targeted Therapies 1	4/17/23	1:30 PM	Section 44	15
3406	GATA2 a novel potential therapeutic target for treatment of neuroendocrine prostate cancer	Amit	Dash	Poster	Molecular Targeted Therapies 1	4/17/23	1:30 PM	Section 44	16
3407	The italian personalized medicine program PREME for high-risk neuroblastoma	Fabio	Pastorino	Poster	Molecular Targeted Therapies 1	4/17/23	1:30 PM	Section 44	17
3408	The role of obesity in promoting the LIF/LIFR signaling in triple negative breast cancer	Lois	Randolph	Poster	Molecular Targeted Therapies 1	4/17/23	1:30 PM	Section 44	18
3409	Design and characterization of highly potent and selective CDK9 heterobifunctional degraders	Mohammed	Toure	Poster	Molecular Targeted Therapies 1	4/17/23	1:30 PM	Section 44	19
3410	AVATASCAN®, a pioneer of functional precision medicine in guiding clinical decision-making	Nam-Gu	Her	Poster	Molecular Targeted Therapies 1	4/17/23	1:30 PM	Section 44	20
3411	Proof of concept study of next generation drug screening platform for glioma patients	Do-Hyun	Nam	Poster	Molecular Targeted Therapies 1	4/17/23	1:30 PM	Section 44	21
3412	Patient-derived MicroOrganoSpheres (MOS) enable precision clinical decision-making for multiple myeloma patients	Rui	Xi	Poster	Molecular Targeted Therapies 1	4/17/23	1:30 PM	Section 44	22
3413	RTK/SHP2 dependency and feedback adaptation to MEK inhibition defines sensitivity of RAS-mutant proteins to SHP2 inhibitor-based therapies	Beau	Baars	Poster	Molecular Targeted Therapies 1	4/17/23	1:30 PM	Section 44	23
3414	The pan-RAF inhibitor tovorafenib suppresses NF1-mutant glioma through upregulation of FOXO1 and triggering of oncogene-induced senescence	Lujain	Alaali	Poster	Molecular Targeted Therapies 1	4/17/23	1:30 PM	Section 44	24
3415	Preclinical characterization of a brain penetrant RAF inhibitor, BDTX-4933, targeting oncogenic BRAF Class I/II/III and RAS mutations	Yoon-Chi	Han	Poster	Molecular Targeted Therapies 1	4/17/23	1:30 PM	Section 44	25
3416	Suppression of AXL inhibits tumor growth through promotion of dendritic cell migration in lung cancer	Da-Som	Kim	Poster	Molecular Targeted Therapies 1	4/17/23	1:30 PM	Section 44	26

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
3417	Nanocage delivered engineered destabilized HER2 3UTR ARE reduced growth of primary EGFR T790M HER2 overexpressing osimertinib and trastuzumab resistant non small cell lung cancer and inhibited liver and lung metastasis in vivo	Chidiebere	Awah	Poster	Molecular Targeted Therapies 1	4/17/23	1:30 PM	Section 44	27
3418	Alterations in PIK3CA/PTEN as resistance mechanisms in lung cancer patients progressing on first-line next generation EGFR/ALK tyrosine kinase inhibitors	Giorgia	Guaitoli	Poster	Molecular Targeted Therapies 1	4/17/23	1:30 PM	Section 44	28
3419	TY-1091, a highly selective and potent second-generation RET inhibitor, demonstrates superior antitumor activity in multiple RET-mutant models	Yusheng	Wu	Poster	Molecular Targeted Therapies 1	4/17/23	1:30 PM	Section 44	29
3423	NX-2127: A first-in-class clinical stage degrader of BTK and IKZF1/3 for the treatment of patients with B cell malignancies	Jeffrey	Mihalic	Oral	New Targeted Protein Degradors: Discovery and Novel Design Strategies	4/17/23	2:30 PM	Room W224	
3424	Template-assisted covalent modification of DCAF16 enables BRD4 molecular glue degraders	Yen-Der	Li	Oral	New Targeted Protein Degradors: Discovery and Novel Design Strategies	4/17/23	2:30 PM	Room W224	
3426	Catalytic degraders effectively address kinase site mutations in EML-ALK oncogenic fusions	Jianwei	Che	Oral	New Targeted Protein Degradors: Discovery and Novel Design Strategies	4/17/23	2:30 PM	Room W224	
3427	ICP-490 is a highly potent and selective IKZF1/3 degrader with robust anti-tumor activities against multiple myeloma and non-Hodgkin's lymphoma	Davy	Ouyang	Oral	New Targeted Protein Degradors: Discovery and Novel Design Strategies	4/17/23	2:30 PM	Room W224	
3428	Discovery of a highly potent and selective dual PROTAC degrader of CDK12 and CDK13	Yu	Chang	Oral	New Targeted Protein Degradors: Discovery and Novel Design Strategies	4/17/23	2:30 PM	Room W224	
3429	Beyond cereblon IMiDs - biophysics-based discovery of novel molecular glue chemotypes	Roland	Hjerpe	Oral	New Targeted Protein Degradors: Discovery and Novel Design Strategies	4/17/23	2:30 PM	Room W224	
3431	Molecular determinants of KRAS p.G12C inhibitor efficacy in advanced NSCLC	Ferdinandos	Skoulidis	Oral	Biomarkers of Response in Novel Molecular Therapeutics	4/17/23	2:30 PM	Room W414	
3432	Ataxia-telangiectasia mutated loss of function displays variant and tissue specific differences across tumor types	Patrick	Pilie	Oral	Biomarkers of Response in Novel Molecular Therapeutics	4/17/23	2:30 PM	Room W414	
3433	Global proteomic analysis of urine using a label-free LC-MS/MS approach identifies potential biomarkers of metastatic breast cancer	Roopali	Roy	Oral	Biomarkers of Response in Novel Molecular Therapeutics	4/17/23	2:30 PM	Room W414	
3434	Selective glucocorticoid receptor modulation reveals a new role for CLEC10A in patients with solid tumors	Erkut	Borazanci	Oral	Biomarkers of Response in Novel Molecular Therapeutics	4/17/23	2:30 PM	Room W414	

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
3435	Identification of potential biomarkers of response to OMO-103, a first-in-modality pan-MYC inhibitor, in patients with advanced solid tumors	Laura	Soucek	Oral	Biomarkers of Response in Novel Molecular Therapeutics	4/17/23	2:30 PM	Room W414	
3436	Reduced p63 expression is linked to a low density of regulatory T-cells and unfavorable prognosis in muscle-invasive urothelial carcinoma of the bladder	Elena	Bady	Oral	Biomarkers of Response in Novel Molecular Therapeutics	4/17/23	2:30 PM	Room W414	
3437	Whole genome and transcriptome sequencing of a pan-cancer cohort unearths novel therapeutic avenues	Majd	Al Assaad	Oral	Biomarkers of Response in Novel Molecular Therapeutics	4/17/23	2:30 PM	Room W414	
3439	Evaluating nuclear receptor heterodimerization using live cell proximity assays: Implications for novel therapeutic approaches for hormone driven cancers	Amira	Ishag-Osman	Oral	Nuclear Receptors and Endocrine Related Cancers: New Insights into Treatment Resistance and Therapeutics Development	4/17/23	2:30 PM	Room W311 E-H	
3440	Targeting the mutant estrogen receptor in metastatic breast cancer	Karla	Parra	Oral	Nuclear Receptors and Endocrine Related Cancers: New Insights into Treatment Resistance and Therapeutics Development	4/17/23	2:30 PM	Room W311 E-H	
3441	A multivalent peptoid conjugate that inhibits therapy-resistant prostate cancer cell proliferation by modulating androgen receptor transcriptional activity	Justine	Habault	Oral	Nuclear Receptors and Endocrine Related Cancers: New Insights into Treatment Resistance and Therapeutics Development	4/17/23	2:30 PM	Room W311 E-H	
3442	FXR mediates macrophage intrinsic responses to suppress colon cancer progression	Ting	Fu	Oral	Nuclear Receptors and Endocrine Related Cancers: New Insights into Treatment Resistance and Therapeutics Development	4/17/23	2:30 PM	Room W311 E-H	
3443	Aryl hydrocarbon receptor and its ligands influence the formation of colonic tertiary lymphoid tissues	Kimberly	Allred	Oral	Nuclear Receptors and Endocrine Related Cancers: New Insights into Treatment Resistance and Therapeutics Development	4/17/23	2:30 PM	Room W311 E-H	
3444	Role of AKR1C3 in converting reservoirs of DHEA-S into potent androgens that drive prostate cancer cell growth	Andrea	Detlefsen	Oral	Nuclear Receptors and Endocrine Related Cancers: New Insights into Treatment Resistance and Therapeutics Development	4/17/23	2:30 PM	Room W311 E-H	
3445	Immune cells infiltration and activation are higher in breast cancers resistant to antiestrogen therapy	Fabiana	Napolitano	Oral	Nuclear Receptors and Endocrine Related Cancers: New Insights into Treatment Resistance and Therapeutics Development	4/17/23	2:30 PM	Room W311 E-H	

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
3447	NOS inhibition reverses epithelial-to-mesenchymal transition and synergizes with alpelisib in metaplastic breast cancer	Tejaswini	Reddy	Oral	Novel Antitumor Agents and Targets	4/17/23	2:30 PM	Room W331	
3448	Discovery of HYP-2A, a 2nd-generation KRASG12C inhibitor exhibits potent in vivo efficacy in drug resistant tumor models	Shoujun	Chen	Oral	Novel Antitumor Agents and Targets	4/17/23	2:30 PM	Room W331	
3449	Development of MRT-2359, an orally bioavailable GSPT1 molecular glue degrader, for the treatment of lung cancers with MYC-induced translational addiction	Gerald	Gavory	Oral	Novel Antitumor Agents and Targets	4/17/23	2:30 PM	Room W331	
3450	Discovery and preclinical study of novel BTK degrader HZ-Q1070	Xingguo	Liu	Oral	Novel Antitumor Agents and Targets	4/17/23	2:30 PM	Room W331	
3451	XS-04: A first-in-class dual IRAK4/BTK inhibitor for the treatment of hematological malignancies	Xiaohong	Yu	Oral	Novel Antitumor Agents and Targets	4/17/23	2:30 PM	Room W331	
3452	TNG908, a brain-penetrant MTA-cooperative PRMT5 inhibitor, is efficacious in preclinical glioblastoma models	Kimberly	Briggs	Oral	Novel Antitumor Agents and Targets	4/17/23	2:30 PM	Room W331	
3453	First disclosure of a highly potent and selective HPK1 inhibitor that rescues T cell exhaustion	Deanna	Mele	Oral	Novel Antitumor Agents and Targets	4/17/23	2:30 PM	Room W331	
3455	Transcriptional and phenotypic heterogeneity underpinning venetoclax resistance	Vakul	Mohanty	Oral	Overcoming Resistance Secondary to Genomic Alterations and Tumor Heterogeneity with Novel Strategies and Combinatorial Approaches	4/17/23	2:30 PM	Valencia BC	
3456	Synergistic drug combinations promote the development of resistance in acute myeloid leukemia	Emily	Mason-Osann	Oral	Overcoming Resistance Secondary to Genomic Alterations and Tumor Heterogeneity with Novel Strategies and Combinatorial Approaches	4/17/23	2:30 PM	Valencia BC	
3457	Characterization of acquired resistance mutations to menin inhibitors	Florian	Perner	Oral	Overcoming Resistance Secondary to Genomic Alterations and Tumor Heterogeneity with Novel Strategies and Combinatorial Approaches	4/17/23	2:30 PM	Valencia BC	
3458	Resistance to selective FGFR inhibitors in FGFR-driven urothelial cancer	Francesco	Facchinetti	Oral	Overcoming Resistance Secondary to Genomic Alterations and Tumor Heterogeneity with Novel Strategies and Combinatorial Approaches	4/17/23	2:30 PM	Valencia BC	
3459	Drug persistence pathways in ovarian cancer identified by single-cell analysis of patient samples and cell line models	Elizaveta	Leshchiner	Oral	Overcoming Resistance Secondary to Genomic Alterations and Tumor	4/17/23	2:30 PM	Valencia BC	

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
					Heterogeneity with Novel Strategies and Combinatorial Approaches				
3460	Targeting the MIF-CD74 axis to overcome resistance to tyrosine kinase inhibitors in non-small cell lung cancer	Motohiro	Izumi	Oral	Overcoming Resistance Secondary to Genomic Alterations and Tumor Heterogeneity with Novel Strategies and Combinatorial Approaches	4/17/23	2:30 PM	Valencia BC	
3461	Preclinical and clinical evaluation of the RAF/MEK clamp avutometinib (VS-6766) in combination with the mTOR inhibitor everolimus for the treatment of KRAS mutated non-small cell lung cancer	Udai	Banerji	Oral	Overcoming Resistance Secondary to Genomic Alterations and Tumor Heterogeneity with Novel Strategies and Combinatorial Approaches	4/17/23	2:30 PM	Valencia BC	
3463	Longitudinal microbiome-immune dynamics in melanoma patients treated with immune checkpoint inhibitor immunotherapy	Rebecca	Simpson	Oral	From Cancer Immunology to Immunotherapy	4/17/23	2:30 PM	Valencia A	
3464	Dynamics of resident memory (Trm) cell responses between skin and draining lymph nodes during primary and recall responses to melanoma	Cameron	Messier	Oral	From Cancer Immunology to Immunotherapy	4/17/23	2:30 PM	Valencia A	
3465	HDAC8 regulates immune escape in melanoma through increased transcription of inhibitory cytokines that increase accumulation of myeloid-derived suppressor cells (MDSCs)	Chao	Zhang	Oral	From Cancer Immunology to Immunotherapy	4/17/23	2:30 PM	Valencia A	
3466	Microbial neoantigen vectors for cancer immunotherapy	Nicholas	Arpaia	Oral	From Cancer Immunology to Immunotherapy	4/17/23	2:30 PM	Valencia A	
3467	GRWD5769: A first-in-class inhibitor of ERAP1, generating novel cancer antigens to drive de novo anti-tumor T cell responses	Peter	Joyce	Oral	From Cancer Immunology to Immunotherapy	4/17/23	2:30 PM	Valencia A	
3468	Immunoproteasome expression and checkpoint blockade response in advanced non-small cell lung cancer	Vivek	Naranbhai	Oral	From Cancer Immunology to Immunotherapy	4/17/23	2:30 PM	Valencia A	
3469	Lymph node colonization promotes distant tumor metastasis through the induction of tumor-specific immune tolerance	Nathan	Reticker-Flynn	Oral	From Cancer Immunology to Immunotherapy	4/17/23	2:30 PM	Valencia A	
3471	A function-based high-throughput discovery platform, myeloid iOTarg, identifies novel immune checkpoints of the tumor microenvironment	Tillmann	Michels	Oral	Immune Checkpoints at Tumor Beds	4/17/23	2:30 PM	Valencia D	
3472	A tumor draining lymph node CD8 T cell memory response is pivotal for a decrease in recurrence after neoadjuvant anti PD-1 therapy for NSCLC	Tatiana	Delgado Cruz	Oral	Immune Checkpoints at Tumor Beds	4/17/23	2:30 PM	Valencia D	

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
3473	High throughput screening of combination therapies to improve response to checkpoint inhibitors in solid tumors using a myelomonocytic and T cell co-culture assay	Sushil	Kumar	Oral	Immune Checkpoints at Tumor Beds	4/17/23	2:30 PM	Valencia D	
3474	Identification of the selective CBL-b inhibitors which effectively prevent T cells from exhaustion and demonstrate synergistic anti-tumor activity in combination with an anti-PD1 antibody	Renhong	Tang	Oral	Immune Checkpoints at Tumor Beds	4/17/23	2:30 PM	Valencia D	
3475	RMC-9805, a first-in-class, mutant-selective, covalent and orally bioavailable KRASG12D(ON) inhibitor, promotes cancer-associated neoantigen recognition and synergizes with immunotherapy in preclinical models	Marie	Menard	Oral	Immune Checkpoints at Tumor Beds	4/17/23	2:30 PM	Valencia D	
3476	TAK-243 increases tumor immunogenicity enhancing systemic anti-tumor immune response and tumor regression in combination with immune checkpoint inhibition in a syngeneic model of lymphoma	Richard	Klinghoffer	Oral	Immune Checkpoints at Tumor Beds	4/17/23	2:30 PM	Valencia D	
3477	Maximizing the outcome of CD226 stimulation through targeting beyond TIGIT signaling with combination and multi-specific approaches for cancer immunotherapy	Jinping	Gan	Oral	Immune Checkpoints at Tumor Beds	4/17/23	2:30 PM	Valencia D	
3479	Modeling epigenetic lesions that cause gliomas	Gilbert	Rahme	Oral	Epigenetics Mechanisms in Cancer	4/17/23	2:30 PM	Tangerine Ballroom 3-4 (WF3-4)	
3480	Modulating DNA and histone methylation as a therapeutic target for non-small cell lung cancer by shifting the composition of immune cells	Ying-Yu	Chen	Oral	Epigenetics Mechanisms in Cancer	4/17/23	2:30 PM	Tangerine Ballroom 3-4 (WF3-4)	
3481	A local tumor microenvironment acquired super-enhancer induces an oncogenic driver in colorectal carcinoma	Royce	Zhou	Oral	Epigenetics Mechanisms in Cancer	4/17/23	2:30 PM	Tangerine Ballroom 3-4 (WF3-4)	
3482	METTL3-mediated m6A modification controls splicing factor abundance and contributes to CLL progression	Yiming	Wu	Oral	Epigenetics Mechanisms in Cancer	4/17/23	2:30 PM	Tangerine Ballroom 3-4 (WF3-4)	
3483	Epigenome-wide association study of lung cancer among never-smokers in two prospective cohorts in Shanghai	Mohammad	Rahman	Oral	Epigenetics Mechanisms in Cancer	4/17/23	2:30 PM	Tangerine Ballroom 3-4 (WF3-4)	
3484	Oncohistone H2B-E76K alters gene expression & cellular phenotype in a bronchial epithelial cell line	Kimberly	Espinoza Pereira	Oral	Epigenetics Mechanisms in Cancer	4/17/23	2:30 PM	Tangerine Ballroom 3-4 (WF3-4)	

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
3485	Intrinsically disordered regions of the ARID1A/B tumor suppressors encode an interaction network within biomolecular condensates that directs mSWI/SNF chromatin remodeler complex activity	Ajinkya	Patil	Oral	Epigenetics Mechanisms in Cancer	4/17/23	2:30 PM	Tangerine Ballroom 3-4 (WF3-4)	
3487	An atlas of substrate specificities for the human tyrosine kinome	Jared	Johnson	Oral	Tyrosine Kinase and Ras Signaling	4/17/23	2:30 PM	Room W304 E-H	
3488	Truncated FGFR2 - a clinically actionable oncogene in multiple cancers	Daniel	Zingg	Oral	Tyrosine Kinase and Ras Signaling	4/17/23	2:30 PM	Room W304 E-H	
3489	TNK1 is a ubiquitin sensing kinase that can be targeted in vivo to block tumor growth	Joshua	Andersen	Oral	Tyrosine Kinase and Ras Signaling	4/17/23	2:30 PM	Room W304 E-H	
3490	IGFBP1 mediates musculoskeletal defects in colorectal cancer	Andrea	Bonetto	Oral	Tyrosine Kinase and Ras Signaling	4/17/23	2:30 PM	Room W304 E-H	
3491	Designed sensors reveal normal and oncogenic Ras signaling in endomembranes and condensates	Jason	Zhang	Oral	Tyrosine Kinase and Ras Signaling	4/17/23	2:30 PM	Room W304 E-H	
3492	The small GTPase ARF6 augments BRAFV600E-MAPK signaling in melanomagenesis	Allie	Grossmann	Oral	Tyrosine Kinase and Ras Signaling	4/17/23	2:30 PM	Room W304 E-H	
3493	Drug targeting of KRAS accumulation on the cilium inhibits its stemness driving activity	Daniel	Abankwa	Oral	Tyrosine Kinase and Ras Signaling	4/17/23	2:30 PM	Room W304 E-H	
3495	A kinome-wide CRISPR screen identifies CK1 α as a novel target to overcome enzalutamide resistance of prostate cancer	Jinghui	Liu	Oral	Molecular Pathway Discovery and Translation in Solid Tumors	4/17/23	2:30 PM	Room W304 A-D	
3496	p53 mutation biases SCJ progenitor cells towards dysplasia rather than metaplasia in Barrett's esophagus	Guodong	Lian	Oral	Molecular Pathway Discovery and Translation in Solid Tumors	4/17/23	2:30 PM	Room W304 A-D	
3497	The polyclonal path to malignant transformation in familial adenomatous polyposis	Ryan	Schenck	Oral	Molecular Pathway Discovery and Translation in Solid Tumors	4/17/23	2:30 PM	Room W304 A-D	
3498	GTP-dependent signaling links metabolism, non-homologous end joining and treatment responses in cancer and normal tissues	Weihua	Zhou	Oral	Molecular Pathway Discovery and Translation in Solid Tumors	4/17/23	2:30 PM	Room W304 A-D	
3499	Inhibition of SOS1 by MRTX0902 augments the anti-tumor response of the targeted EGFR inhibitor osimertinib in NSCLC	Shilpi	Khare	Oral	Molecular Pathway Discovery and Translation in Solid Tumors	4/17/23	2:30 PM	Room W304 A-D	
3500	A noncatalytic role for mettl1 in oncogenic translation in soft tissue sarcoma	Raja Hussain	Ali	Oral	Molecular Pathway Discovery and Translation in Solid Tumors	4/17/23	2:30 PM	Room W304 A-D	
3501	A genome-wide screen for determinants of radioresistance in head and neck cancer	Jacqueline	Law	Oral	Molecular Pathway Discovery and Translation in Solid Tumors	4/17/23	2:30 PM	Room W304 A-D	
3503	Racial disparity and roles of social determinants of health in epigenetic age acceleration among survivors of childhood cancer	Noel-Marie	Plonski	Oral	Molecular, Somatic, Social, and Geospatial Factors and Cancer Disparities	4/17/23	2:30 PM	Room W240	

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
3504	Evaluating the molecular determinants of PDAC racial health disparities	Anthony	Johansen-Sallee	Oral	Molecular, Somatic, Social, and Geospatial Factors and Cancer Disparities	4/17/23	2:30 PM	Room W240	
3505	Cancer disparities in race exposed through geospatial analysis of mutational signatures and environmental exposure	Judy	Bai	Oral	Molecular, Somatic, Social, and Geospatial Factors and Cancer Disparities	4/17/23	2:30 PM	Room W240	
3506	High-grade serous ovarian cancer somatic mutational signatures in Black and White individuals	Katherine	Lawson-Michod	Oral	Molecular, Somatic, Social, and Geospatial Factors and Cancer Disparities	4/17/23	2:30 PM	Room W240	
3507	Mosaic chromosomal alterations in blood across ancestries via whole-genome sequencing	Yasminka	Jakubek	Oral	Molecular, Somatic, Social, and Geospatial Factors and Cancer Disparities	4/17/23	2:30 PM	Room W240	
3508	Association between clonal hematopoiesis and risk of prostate cancer in a large sample of African ancestry men	Anqi	Wang	Oral	Molecular, Somatic, Social, and Geospatial Factors and Cancer Disparities	4/17/23	2:30 PM	Room W240	
3509	1,25-dihydroxyvitamin D3-mediated suppression of genes associated with cell cycle regulation and actin organization in a non-malignant African American prostate cell line	Jabril	Johnson	Oral	Molecular, Somatic, Social, and Geospatial Factors and Cancer Disparities	4/17/23	2:30 PM	Room W240	
3511	Melanoma-shed, lymph-borne CSPG4 conditions the pre-metastatic lymph node niche	Haley	du Bois	Oral	The Metastatic Niche	4/17/23	2:30 PM	Room W311 A-D	
3512	Organ-specific effects of Smad4 in metastatic pancreatic cancer	Kaloyan	Tsanov	Oral	The Metastatic Niche	4/17/23	2:30 PM	Room W311 A-D	
3513	Developing a 3D biomimetic liver metastatic niche model for pancreatic cancer	Mahsa	Pahlavanneshan	Oral	The Metastatic Niche	4/17/23	2:30 PM	Room W311 A-D	
3514	A genetic-metabolic circuit of liver-specific metastatic organotropism	Meri	Rogava	Oral	The Metastatic Niche	4/17/23	2:30 PM	Room W311 A-D	
3515	Histone demethylase KDM5D drives sex-specific differences in colorectal cancer	Jiexi	Li	Oral	The Metastatic Niche	4/17/23	2:30 PM	Room W311 A-D	
3516	Metastatic colonization requires a proliferative pause linked to vascular co-option	Pedro	García-Gómez	Oral	The Metastatic Niche	4/17/23	2:30 PM	Room W311 A-D	
3517	Multi-modal single-cell and spatial genomics reveals genomic, adaptive and microenvironmental features of human non-small cell lung cancer brain metastasis	Somnath	Tagore	Oral	The Metastatic Niche	4/17/23	2:30 PM	Room W311 A-D	
3520	Single cell-derived spheroids capture functional and genetic heterogeneity of head and neck cancer	Rana	Singh	Oral	Minisymposium: Late-breaking Research	4/17/23	2:30 PM	Room W307	
3521	CCND2 promotes proliferation in Drosha and DICER1 driven tumors	Claudette	Fraire	Poster	Pediatric Cancer 2: Biology and Therapeutics	4/18/23	9:00 AM	Section 1	1

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
3522	DICER1 Platform domain missense variants led to tumor susceptibility via failure of precursor miRNA binding	Dylan	Pelletier	Poster	Pediatric Cancer 2: Biology and Therapeutics	4/18/23	9:00 AM	Section 1	2
3523	A systematic comparison of molecular features shared by H3K27-altered diffuse midline gliomas and posterior fossa A ependymomas	Matthew	Pun	Poster	Pediatric Cancer 2: Biology and Therapeutics	4/18/23	9:00 AM	Section 1	3
3524	Pharmacological characterization of pediatric brain tumor PDX models in a single mouse trial format	Julia	Schueler	Poster	Pediatric Cancer 2: Biology and Therapeutics	4/18/23	9:00 AM	Section 1	4
3525	VGLL2-NCOA2 leverages developmental programs for pediatric sarcomagenesis	Delia	Calderon	Poster	Pediatric Cancer 2: Biology and Therapeutics	4/18/23	9:00 AM	Section 1	5
3526	The transcription factor ZEB1 shapes osteosarcoma aggressiveness by affecting tumor cell differentiation and stemness features	Caterina	Cascini	Poster	Pediatric Cancer 2: Biology and Therapeutics	4/18/23	9:00 AM	Section 1	6
3527	WNT5B drives osteosarcoma stemness, metastasis and chemoresistance	Rachel	Perkins	Poster	Pediatric Cancer 2: Biology and Therapeutics	4/18/23	9:00 AM	Section 1	7
3528	ALKBH5 promotes cancer growth by regulating ER homeostasis via UPR, autophagy, and mitochondrial function	Panneerdoss	Subbarayalu	Poster	Pediatric Cancer 2: Biology and Therapeutics	4/18/23	9:00 AM	Section 1	8
3529	EWSR1-WT1 isoform selectivity, DNA binding, and druggable targets: unpacking the biology of desmoplastic small round cell tumor	Justin	Magrath	Poster	Pediatric Cancer 2: Biology and Therapeutics	4/18/23	9:00 AM	Section 1	9
3530	Mechanisms underlying Ewing sarcoma-induced osteolysis	James	Williams	Poster	Pediatric Cancer 2: Biology and Therapeutics	4/18/23	9:00 AM	Section 1	10
3531	Discrete extracellular matrix-secreting tumor cell subpopulations remodel the Ewing sarcoma tumor microenvironment to promote invasion	Emma	Wrenn	Poster	Pediatric Cancer 2: Biology and Therapeutics	4/18/23	9:00 AM	Section 1	11
3532	Activator protein-1 (AP-1) signaling inhibits the growth of Ewing sarcoma cells in response to DNA replication stress	David	Gordon	Poster	Pediatric Cancer 2: Biology and Therapeutics	4/18/23	9:00 AM	Section 1	12
3533	Zebrafish her3knockout impacts developmental and rhabdomyosarcoma-related gene signatures	Matthew	Kent	Poster	Pediatric Cancer 2: Biology and Therapeutics	4/18/23	9:00 AM	Section 1	13
3534	Interrogating the immune microenvironment of a novel mouse model of fusion positive rhabdomyosarcoma	Erin	Resch	Poster	Pediatric Cancer 2: Biology and Therapeutics	4/18/23	9:00 AM	Section 1	14
3536	Role of Myc family proteins in fusion-positive rhabdomyosarcoma	Bishwanath	Chatterjee	Poster	Pediatric Cancer 2: Biology and Therapeutics	4/18/23	9:00 AM	Section 1	16
3537	A novel orthotopic xenograft model of spontaneous metastasis for rhabdomyosarcoma using lingual intramuscular injection	Katie	Hebron	Poster	Pediatric Cancer 2: Biology and Therapeutics	4/18/23	9:00 AM	Section 1	17
3538	Endogenous HiBiT-tagging of PAX3-FOXO1 identifies potent suppressors of PAX3-FOXO1 protein levels by high-throughput screening	Yong Yean	Kim	Poster	Pediatric Cancer 2: Biology and Therapeutics	4/18/23	9:00 AM	Section 1	18

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
3539	Indoleamine-2,3-dioxygenase 2 (IDO-2) is expressed in hepatoblastoma cells and associated with metastatic state	Lisandro	Luques	Poster	Pediatric Cancer 2: Biology and Therapeutics	4/18/23	9:00 AM	Section 1	19
3540	Reduction in cell viability of hepatoblastoma cells following inhibition of Hsp90	Ashby	Kissoondoyal	Poster	Pediatric Cancer 2: Biology and Therapeutics	4/18/23	9:00 AM	Section 1	20
3541	Tumoroid-based screening platform to test focal, chemo- and combination therapy for retinoblastoma	Irina	Sinenko	Poster	Pediatric Cancer 2: Biology and Therapeutics	4/18/23	9:00 AM	Section 1	21
3542	A stem cell model dissects detrimental effects of neuroblastoma-linked chromosomal aberrations on cell differentiation during neural crest development	Florian	Halbritter	Poster	Pediatric Cancer 2: Biology and Therapeutics	4/18/23	9:00 AM	Section 1	22
3543	Mesenchymal stromal cells and tumor-associated macrophages modulate adrenergic to mesenchymal state switching in neuroblastoma	Meng-Hua	Lee	Poster	Pediatric Cancer 2: Biology and Therapeutics	4/18/23	9:00 AM	Section 1	23
3544	ALK signaling activity stabilizes SLC3A2 protein levels in neuroblastoma tumorigenesis	Wei-Yun	Lai	Poster	Pediatric Cancer 2: Biology and Therapeutics	4/18/23	9:00 AM	Section 1	24
3545	The Yes-associated protein (YAP) regulates GD2 immunotherapy response in high-risk neuroblastoma	Adeiye	Pilgrim	Poster	Pediatric Cancer 2: Biology and Therapeutics	4/18/23	9:00 AM	Section 1	25
3550	The ENL YEATS domain links leukemic stem cell frequency and enhances YEATS inhibitor sensitivity in MLL-ENL leukemias	Hsiangyu	Hu	Poster	Pediatric Cancer 3: Genomes and Novel Tumor Models	4/18/23	9:00 AM	Section 2	1
3551	Single-cell characterization of pediatric T-cell acute lymphoblastic leukemia transcriptomes	Irina	Pushel	Poster	Pediatric Cancer 3: Genomes and Novel Tumor Models	4/18/23	9:00 AM	Section 2	2
3552	YAP-TEAD2 binding mediates therapy resistance in RAS-driven neuroblastoma	Jenny	Shim	Poster	Pediatric Cancer 3: Genomes and Novel Tumor Models	4/18/23	9:00 AM	Section 2	3
3553	Simultaneous somatic copy number alterations and single nucleotide variants detection in paired aqueous humor and tumors from retinoblastoma eyes	Liya	Xu	Poster	Pediatric Cancer 3: Genomes and Novel Tumor Models	4/18/23	9:00 AM	Section 2	4
3554	Targeting chromatin remodeling complex in pediatric cancers	Jun	Qi	Poster	Pediatric Cancer 3: Genomes and Novel Tumor Models	4/18/23	9:00 AM	Section 2	5
3555	Proteomic characterization of rhabdomyosarcoma-derived extracellular vesicles reveals a fusion-positive protein signature	Paula	Quaglietta	Poster	Pediatric Cancer 3: Genomes and Novel Tumor Models	4/18/23	9:00 AM	Section 2	6
3557	Stage-restricted osteoblasts specify signatures of osteosarcoma molecular subtypes	Jianning	Tao	Poster	Pediatric Cancer 3: Genomes and Novel Tumor Models	4/18/23	9:00 AM	Section 2	8
3558	Role of FLI portion of EWS::FLI in transcription regulation via modulation of chromatin 3D landscape in Ewing sarcoma	Ariunaa	Bayanjargal	Poster	Pediatric Cancer 3: Genomes and Novel Tumor Models	4/18/23	9:00 AM	Section 2	9
3559	Understanding Ewing sarcoma cell fate	Danh	Truong	Poster	Pediatric Cancer 3: Genomes and Novel Tumor Models	4/18/23	9:00 AM	Section 2	10
3560	Understanding alternative splicing in Ewing sarcoma progression and metastasis to inform novel therapy development	Akila	Venkataramany	Poster	Pediatric Cancer 3: Genomes and Novel Tumor Models	4/18/23	9:00 AM	Section 2	11

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
3561	Recurrent genetic alterations in epigenetic pineoblastoma subtypes	Tobias	Goschzik	Poster	Pediatric Cancer 3: Genomes and Novel Tumor Models	4/18/23	9:00 AM	Section 2	12
3562	Dissecting mechanisms underlying FOXR2-mediated gliomagenesis in diffuse midline gliomas	Jessica	Tsai	Poster	Pediatric Cancer 3: Genomes and Novel Tumor Models	4/18/23	9:00 AM	Section 2	13
3563	SWI/SNF-associated DPF1 is a unique transcriptional regulator of malignant peripheral nerve sheath tumors	Bega	Murray	Poster	Pediatric Cancer 3: Genomes and Novel Tumor Models	4/18/23	9:00 AM	Section 2	14
3564	SNAI2 enhances oncogenesis in malignant peripheral nerve sheath tumors	Hilda	Jafarah	Poster	Pediatric Cancer 3: Genomes and Novel Tumor Models	4/18/23	9:00 AM	Section 2	15
3565	Establishing a multimodal data warehousing platform to accelerate discoveries in pediatric brain tumors for the Children's Brain Tumor Network	Bailey	Farrow	Poster	Pediatric Cancer 3: Genomes and Novel Tumor Models	4/18/23	9:00 AM	Section 2	16
3566	Expansion of the Pediatric Brain Tumor Atlas: Children's Brain Tumor Network, Kids First Data Resource and Childhood Cancer Data Initiative Open Science effort	Mateusz	Koptyra	Poster	Pediatric Cancer 3: Genomes and Novel Tumor Models	4/18/23	9:00 AM	Section 2	17
3567	Cancer-epigenetic mouse models for medulloblastoma	Shilpa	Dhar	Poster	Pediatric Cancer 3: Genomes and Novel Tumor Models	4/18/23	9:00 AM	Section 2	18
3568	Developing pediatric glioblastoma microtumors with a three-dimensional bioprinter	Andee	Beierle	Poster	Pediatric Cancer 3: Genomes and Novel Tumor Models	4/18/23	9:00 AM	Section 2	19
3569	An animal model of GLI2-amplified medulloblastoma	Yanxin	Pei	Poster	Pediatric Cancer 3: Genomes and Novel Tumor Models	4/18/23	9:00 AM	Section 2	20
3570	Preservation of cellular heterogeneity in 3D and 2D cultures of pediatric solid tumors	Justina	McEvoy	Poster	Pediatric Cancer 3: Genomes and Novel Tumor Models	4/18/23	9:00 AM	Section 2	21
3571	The ITCC-P4 sustainable platform of fully characterized PDXs supports the preclinical proof-of-concept drug testing of high-risk pediatric tumor models	Aniello	Federico	Poster	Pediatric Cancer 3: Genomes and Novel Tumor Models	4/18/23	9:00 AM	Section 2	22
3572	Genomic profiling of subcutaneous patient derived xenograft models of solid childhood cancer	Funan	He	Poster	Pediatric Cancer 3: Genomes and Novel Tumor Models	4/18/23	9:00 AM	Section 2	23
3576	Molecular imaging of CD8 infiltration following combination immunotherapy in preclinical glioblastoma	Carlos	Gallegos	Poster	PET, MRI, and CT Imaging	4/18/23	9:00 AM	Section 3	1
3577	A first assessment of CD8-PET/CT with 89Zr-Crefmirlimab as predictive biomarker for response to standard of care immunotherapy in patients with solid tumors	guillaume	potdevin	Poster	PET, MRI, and CT Imaging	4/18/23	9:00 AM	Section 3	2
3578	Using a novel [68Ga]-radiolabeled peptide to detect cell surface expression of calreticulin in pancreatic adenocarcinoma	Rachael	Guenter	Poster	PET, MRI, and CT Imaging	4/18/23	9:00 AM	Section 3	3
3579	Assessment of target-mediated biodistribution of an 89Zr labeled PD-L1/4-1BB bispecific Mabcalin protein	Claudia	van Winkel	Poster	PET, MRI, and CT Imaging	4/18/23	9:00 AM	Section 3	4

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
3580	Noninvasive immuno-PET imaging of CD8+T cell behavior in tumor bearing mice models treated with SAR444245	Erwan	Jouannot	Poster	PET, MRI, and CT Imaging	4/18/23	9:00 AM	Section 3	5
3581	Differentiation of niraparib and olaparib brain penetration in healthy rhesus macaque monkeys	Mark	Groseclose	Poster	PET, MRI, and CT Imaging	4/18/23	9:00 AM	Section 3	6
3582	Differentiation of niraparib and olaparib brain penetration in a mouse brain metastatic tumor model	Mark	Groseclose	Poster	PET, MRI, and CT Imaging	4/18/23	9:00 AM	Section 3	7
3583	Novel MRI contrast system using halloysite nanotubes embedded with iron-platinum nanoparticles for the regulation of the CHST11 expression for cancer treatment	Ming-Hsien	Chan	Poster	PET, MRI, and CT Imaging	4/18/23	9:00 AM	Section 3	8
3584	Early and non-invasive detection of radiation-induced cardiotoxicity in pre-clinical and clinical models	Taylor-Jade	Higgins	Poster	PET, MRI, and CT Imaging	4/18/23	9:00 AM	Section 3	9
3585	Probing the relationship between renal carcinoma perfusion, hypoxia, and metabolism during response to VEGFR inhibition and at resistance	Qianhui	Dou	Poster	PET, MRI, and CT Imaging	4/18/23	9:00 AM	Section 3	10
3586	In vivo targeted detection and imaging of ovarian cancer by SPMR and MRI using anti-folate receptor functionalized iron oxide nanoparticles	Kathirvel	Kandasamy	Poster	PET, MRI, and CT Imaging	4/18/23	9:00 AM	Section 3	11
3587	High resolution microCT to analyze the 3D morphology of microcalcifications in benign breast disease and breast cancer biopsy tissues	Sarah	Schrup	Poster	PET, MRI, and CT Imaging	4/18/23	9:00 AM	Section 3	12
3588	Multiplex proteomics profiling with the imaging mass cytometry (IMC) identifies immune cell phenotypes associated with high NOS2/COX2 expression in ER- negative and TNBC patients	Milind	Pore	Poster	PET, MRI, and CT Imaging	4/18/23	9:00 AM	Section 3	13
3589	The use of a novel orthotopic xenograft model of fusion negative rhabdomyosarcoma to study the effect of ASAP1 on tumor progression and metastasis	Sarah	Hammoudeh	Poster	PET, MRI, and CT Imaging	4/18/23	9:00 AM	Section 3	14
3590	Targeted detection of ovarian cancer using functionalized iron oxide nanoparticles	Marie	Zhang	Poster	PET, MRI, and CT Imaging	4/18/23	9:00 AM	Section 3	15
3591	Does the metastatic immunoenvironment determine poor immunotherapy responses?	Nicole	Barth	Poster	PET, MRI, and CT Imaging	4/18/23	9:00 AM	Section 3	16
3595	Epigenetic driven IL32 expression contributes to a JNK related cell stress response in breast cancer stem cells to promote cellular invasion	Megan	Wilson	Poster	Regulation of Invasion and Migration	4/18/23	9:00 AM	Section 4	1
3596	EMG1 is an rRNA-modifying protein that contributes to breast cancer progression	Amr	Elhamamsy	Poster	Regulation of Invasion and Migration	4/18/23	9:00 AM	Section 4	2
3597	SUV420H2-mediated regulation of collective invasion in triple-negative breast cancer	Emily	Whitt	Poster	Regulation of Invasion and Migration	4/18/23	9:00 AM	Section 4	3

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
3598	Cooperative NF-KappaB and Notch1 signaling promotes a macrophage-mediated metastatic phenotype in breast cancer	Camille	Duran	Poster	Regulation of Invasion and Migration	4/18/23	9:00 AM	Section 4	4
3599	Molecular characterization of mouse colorectal cancer cell lines with high potential of peritoneal metastasis	Ayumu	Taguchi	Poster	Regulation of Invasion and Migration	4/18/23	9:00 AM	Section 4	5
3600	MET-mediated STING activation regulates EMT and NF-KB pathway in non-small cell lung cancer	Seungchan	Mun	Poster	Regulation of Invasion and Migration	4/18/23	9:00 AM	Section 4	6
3601	Tumor MK2 signaling regulates cell migration and invasion in head and neck squamous cell carcinoma	Dakota	Okwuone	Poster	Regulation of Invasion and Migration	4/18/23	9:00 AM	Section 4	7
3602	The metastasis-suppressive function of intracellular galectin-3 in melanoma	Norhan	Mohammed	Poster	Regulation of Invasion and Migration	4/18/23	9:00 AM	Section 4	8
3604	Epithelial Caveolin-1 regulates lung metastasis in advanced stages of breast cancer	Abhishek	Pandit	Poster	Regulation of Invasion and Migration	4/18/23	9:00 AM	Section 4	10
3605	Peroxiredoxin IV promotes prostate cancer malignancy through the activation of NF-kB signaling	Na	Ding	Poster	Regulation of Invasion and Migration	4/18/23	9:00 AM	Section 4	11
3606	HDAC8-mediated inhibition of EP300 drives a neural crest-like transcriptional state that increases melanoma brain metastasis	Michael	Emmons	Poster	Regulation of Invasion and Migration	4/18/23	9:00 AM	Section 4	12
3607	RNA-binding proteins are essential for EGF-induced fibronectin expression and metastasis of head and neck squamous cell carcinoma	Ting-Wei	Chang	Poster	Regulation of Invasion and Migration	4/18/23	9:00 AM	Section 4	13
3608	MLL1 regulates cytokine-driven cell migration and metastasis	Praful	Nair	Poster	Regulation of Invasion and Migration	4/18/23	9:00 AM	Section 4	14
3609	Interaction of interleukin-6/8/18 with prostate cancer cell secreted growth factors are crucial for osteoblast proliferation and differentiation	Aaron	Todman	Poster	Regulation of Invasion and Migration	4/18/23	9:00 AM	Section 4	15
3610	Prenylated PALM2 promotes the migration of esophageal squamous cancer cells through activating ezrin	Danxia	Deng	Poster	Regulation of Invasion and Migration	4/18/23	9:00 AM	Section 4	16
3611	PAUF induces migration of human pancreatic cancer cells exclusively via the TLR4/MyD88/NF-kB signaling pathway	Fen	Jiang	Poster	Regulation of Invasion and Migration	4/18/23	9:00 AM	Section 4	17
3612	KAT8/SIRT7-mediated fascin-K41 acetylation/deacetylation regulates tumor metastasis	Da-Jia	Li	Poster	Regulation of Invasion and Migration	4/18/23	9:00 AM	Section 4	18
3613	Effect of thrombomodulin and plasminogen interaction on melanoma spheroid invasion	Thi Kim Ngan	Ngo	Poster	Regulation of Invasion and Migration	4/18/23	9:00 AM	Section 4	19
3614	3D model to study migration and invasion of lung cancer	Melina	Hardt	Poster	Regulation of Invasion and Migration	4/18/23	9:00 AM	Section 4	20
3615	Targeting tumor-brain crosstalk in invasive brain metastases	Caitlyn	Mourcos	Poster	Regulation of Invasion and Migration	4/18/23	9:00 AM	Section 4	21

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
3616	Investigating proto-oncogene PBF-induced cell migration and invasion	Merve	Kocbiyik	Poster	Regulation of Invasion and Migration	4/18/23	9:00 AM	Section 4	22
3617	Investigating a role for PIKfyve in cell migration and invasion of clear cell renal cell carcinoma	Jolène	Cormier	Poster	Regulation of Invasion and Migration	4/18/23	9:00 AM	Section 4	23
3618	The role of endothelial ACKR1 in triple-negative breast cancer metastasis	Samuel	Roach	Poster	Regulation of Invasion and Migration	4/18/23	9:00 AM	Section 4	24
3619	EP4 promoted cell migration via mitochondrial biogenesis in oral cancer cells	Soichiro	Ishikawa	Poster	Regulation of Invasion and Migration	4/18/23	9:00 AM	Section 4	25
3620	N-myristoylation inhibition reduces angiogenesis and cancer cell migration	Rony	Pain	Poster	Regulation of Invasion and Migration	4/18/23	9:00 AM	Section 4	26
3621	Identification of podocalyxin-positive tumor buds in pancreatic ductal adenocarcinoma: Implications for solid tumor collective invasion	Erin	Bell	Poster	Regulation of Invasion and Migration	4/18/23	9:00 AM	Section 4	27
3622	Characterizing the metastatic potential and clonal dynamics of invasive subpopulations in TNBC cells in response to chemotherapy	Carolina	De Santiago	Poster	Regulation of Invasion and Migration	4/18/23	9:00 AM	Section 4	28
3623	MIEN1 promoter ablation provides novel evidence for colorectal cancer genome editing-based therapeutics	Payal	Ranade	Poster	Regulation of Invasion and Migration	4/18/23	9:00 AM	Section 4	29
3627	Inhibition of tumor cell-autonomous p38 MAPK suppresses IL1 α -mediated inflammatory tumor-stromal crosstalk in pancreatic adenocarcinoma	Samara	Singh	Poster	Signaling Pathways That Impact the Tumor Microenvironment	4/18/23	9:00 AM	Section 5	1
3628	RAC1 aberrations in head and neck cancer affect immune microenvironments	Helen Hoi Yin	Chan	Poster	Signaling Pathways That Impact the Tumor Microenvironment	4/18/23	9:00 AM	Section 5	2
3629	Calcium signalling and the breast cancer microenvironment	Gregory	Monteith	Poster	Signaling Pathways That Impact the Tumor Microenvironment	4/18/23	9:00 AM	Section 5	3
3630	TrkA+ sensory neurons modulate macrophage phenotype in osteosarcoma	Qizhi	Qin	Poster	Signaling Pathways That Impact the Tumor Microenvironment	4/18/23	9:00 AM	Section 5	4
3631	Infiltrating Bruton's tyrosine kinase expressed B cells effects on prostate cancer metastasis	Crystal	Byrd	Poster	Signaling Pathways That Impact the Tumor Microenvironment	4/18/23	9:00 AM	Section 5	5
3633	Exploring a novel crosstalk between hyaluronan/CD44 and ErbB-2 pathways in resistance to ErbB-2-targeted therapies in breast cancer.	Rosalia	Cordo Russo	Poster	Signaling Pathways That Impact the Tumor Microenvironment	4/18/23	9:00 AM	Section 5	7
3634	Overexpression of PLK1 activates IL4/JAK/STAT6 signaling in prostatic tumor-microenvironment	Ruixin	Wang	Poster	Signaling Pathways That Impact the Tumor Microenvironment	4/18/23	9:00 AM	Section 5	8
3635	TBK1 inhibition potentiates the efficacy of AXL-targeted therapy by modulating tumor microenvironment in aggressive breast cancers	Lan	Phi	Poster	Signaling Pathways That Impact the Tumor Microenvironment	4/18/23	9:00 AM	Section 5	9

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
3636	Liver endothelium secreted LRG1 promotes metastatic colorectal cancer growth through the HER3/RSK/EIF4B AXIS	Moeez	Rathore	Poster	Signaling Pathways That Impact the Tumor Microenvironment	4/18/23	9:00 AM	Section 5	10
3637	Extracellular matrix drives high-grade breast cancer immune suppression down-modulating PD-1 on Treg cells via the IL-23/SATB1 axis	Giovanna	Talarico	Poster	Signaling Pathways That Impact the Tumor Microenvironment	4/18/23	9:00 AM	Section 5	11
3638	Integrated single-cell and spatial analysis reveal the mechanism of KRASG12C inhibitor AMG510 in HSC-humanized NOG-EXL model	Panpan	Wang	Poster	Signaling Pathways That Impact the Tumor Microenvironment	4/18/23	9:00 AM	Section 5	12
3639	Impact of KRAS oncogenic signaling in tumorigenesis and immune evasion driven by extracellular vesicles (EVs)	Zulaida	Soto Vargas	Poster	Signaling Pathways That Impact the Tumor Microenvironment	4/18/23	9:00 AM	Section 5	13
3641	Loss of Smad4 induces SPP1 secretion and immunosuppressive myeloid cell formation in pancreatic ductal adenocarcinoma	Gilbert	Murimwa	Poster	Signaling Pathways That Impact the Tumor Microenvironment	4/18/23	9:00 AM	Section 5	15
3642	SPHK1 mediated regulation of antitumor immunity in ovarian cancer	Prachi	Gupta	Poster	Signaling Pathways That Impact the Tumor Microenvironment	4/18/23	9:00 AM	Section 5	16
3643	PTEN/STAT3 pathway in cancer-associated fibroblasts in pancreatic cancer	Samaneh	Saberi	Poster	Signaling Pathways That Impact the Tumor Microenvironment	4/18/23	9:00 AM	Section 5	17
3644	Targeting the CD51/TGF-beta pathway: a potential innovative cancer immunotherapy in T-cell lymphomas	Jérôme	Giustiniani	Poster	Signaling Pathways That Impact the Tumor Microenvironment	4/18/23	9:00 AM	Section 5	18
3645	OSM-induced LOXL2 expression hinges on upregulation of c-Myc and promotes tumor growth and metastasis, IL-1beta plays synergistic role in LOXL2 expression	Simion	Dinca	Poster	Signaling Pathways That Impact the Tumor Microenvironment	4/18/23	9:00 AM	Section 5	19
3646	New functional role of tamoxifen in breast cancer immunomodulation: role of RACK7 in activation of type I interferon signaling and CEACAM1/TIM-3-dependent immunosuppression	Shu-Ping	Wang	Poster	Signaling Pathways That Impact the Tumor Microenvironment	4/18/23	9:00 AM	Section 5	20
3647	Anti-tumor actions of neutrophils are mediated via STAT5 inhibition	Sanjana	Rajgopal	Poster	Signaling Pathways That Impact the Tumor Microenvironment	4/18/23	9:00 AM	Section 5	21
3648	MSU-42011, alone and in combination with selumetinib, reduces pERK levels in NF1 cancer cells and decreases CCL2 expression in THP-1 macrophages	Pei-Yu	Hung	Poster	Signaling Pathways That Impact the Tumor Microenvironment	4/18/23	9:00 AM	Section 5	22
3649	Elucidating the role of CXCR4-CXCL12 in the tumor microenvironment of ER+ breast cancer samples using the Akoya PhenoCycler-Fusion System	Julien	Tessier	Poster	Signaling Pathways That Impact the Tumor Microenvironment	4/18/23	9:00 AM	Section 5	23
3650	STAT1 suppresses KRAS-driven lung adenocarcinoma depending on the tumor microenvironment	Christoph	Trenk	Poster	Signaling Pathways That Impact the Tumor Microenvironment	4/18/23	9:00 AM	Section 5	24
3651	The role of caspase-1 in basal-like breast cancer and the tumor microenvironment	Wanda	Marini	Poster	Signaling Pathways That Impact the Tumor Microenvironment	4/18/23	9:00 AM	Section 5	25

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
3652	Circular RNAs repress interferon responses in the sarcoma cells and promote sarcoma growth by forging a pro-tumorigenic immune microenvironment	Jlenia	Guarnerio	Poster	Signaling Pathways That Impact the Tumor Microenvironment	4/18/23	9:00 AM	Section 5	26
3653	Oncostatin m receptor signaling reprograms tumor microenvironment for chemoresistance	Anjali	Geethadevi	Poster	Signaling Pathways That Impact the Tumor Microenvironment	4/18/23	9:00 AM	Section 5	27
3654	Olaparib combined with entinostat exerts differential effects on tumor-associated macrophages in tumors compared to ascites in syngeneic HR-proficient murine models of ovarian cancer	Vijayalaxmi	Gupta	Poster	Signaling Pathways That Impact the Tumor Microenvironment	4/18/23	9:00 AM	Section 5	28
3655	Exploring the role of FasL in the ovarian cancer tumor microenvironment	Grace	Keegan	Poster	Signaling Pathways That Impact the Tumor Microenvironment	4/18/23	9:00 AM	Section 5	29
3656	A multi-scale approach to quantitatively evaluate the SMAD signaling pathway	Ernest	Heimsath	Poster	Signaling Pathways That Impact the Tumor Microenvironment	4/18/23	9:00 AM	Section 5	30
3659	RAS drives malignancy through stem cell crosstalk with the microenvironment	Shaopeng	Yuan	Poster	Stem Cells and the Microenvironment	4/18/23	9:00 AM	Section 6	1
3660	Bone mechanics influence cancer stem cell formation in osteosarcoma	Zunaira	Shoaib	Poster	Stem Cells and the Microenvironment	4/18/23	9:00 AM	Section 6	2
3661	Extracellular vesicle derived from neural stem cells as potential vehicles of genetic information to modulate glioblastoma biology	João Pedro	de Araújo	Poster	Stem Cells and the Microenvironment	4/18/23	9:00 AM	Section 6	3
3664	Mechanism for bone marrow failure differs between acute myeloid and lymphoid leukemia	Ryan	Bertoli	Poster	Stem Cells and the Microenvironment	4/18/23	9:00 AM	Section 6	6
3665	Umbilical cord blood endothelial progenitor cell-derived extracellular vesicles control important endothelial cell functions	Houda	Haouas	Poster	Stem Cells and the Microenvironment	4/18/23	9:00 AM	Section 6	7
3666	A human skeletal muscle stem/myotube model reveals multiple signaling targets of cancer secretome in skeletal muscle	Ruizhong	Wang	Poster	Stem Cells and the Microenvironment	4/18/23	9:00 AM	Section 6	8
3671	Targeting SLC2A1 and SLC38A2-mediated metabolic shift in SMARCA4/A2-dual deficient cancer	Yemin	Wang	Poster	Cancer and Metabolism 1	4/18/23	9:00 AM	Section 7	2
3672	RNA epigenetic regulation of cholesterol metabolism in neuroblastoma	Mohit	Bansal	Poster	Cancer and Metabolism 1	4/18/23	9:00 AM	Section 7	3
3673	Plk1 phosphorylation of PHGDH to regulate serine metabolism	Xiongjian	Rao	Poster	Cancer and Metabolism 1	4/18/23	9:00 AM	Section 7	4
3674	The polyamine acetylation enzyme SAT1 drives mesenchymal features and therapeutic resistance in glioblastoma	Ayush	Rana	Poster	Cancer and Metabolism 1	4/18/23	9:00 AM	Section 7	5
3675	Targeting the mevalonate pathway, a novel anti-ferroptosis pathway, in hepatocellular carcinoma (HCC) treatment	Yiling	Chen	Poster	Cancer and Metabolism 1	4/18/23	9:00 AM	Section 7	6
3676	De novo lipogenesis and cholesterol synthesis pathways can be simultaneously targeted to induce metabolic synthetic lethality in prostate cancer	Caroline	Fidalgo Ribeiro	Poster	Cancer and Metabolism 1	4/18/23	9:00 AM	Section 7	7

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
3677	DNA damage signaling activates de novo GTP synthesis to promote chemoradiation resistance in glioblastoma	Andrew	Scott	Poster	Cancer and Metabolism 1	4/18/23	9:00 AM	Section 7	8
3678	Rewiring of amino acid metabolism in neurofibromatosis type 1-related tumors	Martina	La Spina	Poster	Cancer and Metabolism 1	4/18/23	9:00 AM	Section 7	9
3679	DNAJB1-PRKACA fusion in fibrolamellar hepatocellular carcinoma induces glutamine addiction and an immunosuppressive tumor microenvironment	Zeal	Kamdar	Poster	Cancer and Metabolism 1	4/18/23	9:00 AM	Section 7	10
3680	Multiomics analysis of triple negative breast cancer identifies potential metabolic vulnerability for overcoming the resistance of neoadjuvant therapy	Zuen	Ren	Poster	Cancer and Metabolism 1	4/18/23	9:00 AM	Section 7	11
3681	c-MAF-driven metabolic reprogramming mediates H3K27 hyperacetylation to regulate super enhancer-associated genes	Phyllis SY	Chong	Poster	Cancer and Metabolism 1	4/18/23	9:00 AM	Section 7	12
3682	Glutamine addiction of c-MAF overexpressing cells drives dysregulation of purine metabolism	Julia Sze Lynn	Lim	Poster	Cancer and Metabolism 1	4/18/23	9:00 AM	Section 7	13
3683	Activation of purine anabolism creates a therapeutic vulnerability in hepatocellular carcinoma via m6A-mediated epitranscriptomic regulation	Man-Hsin	Hung	Poster	Cancer and Metabolism 1	4/18/23	9:00 AM	Section 7	14
3685	Targeting a novel cell surface serine protease TMPRSS11B for lung cancer therapy	Hari Shankar	Sunil	Poster	Cancer and Metabolism 1	4/18/23	9:00 AM	Section 7	16
3686	Blocking fatty acid oxidation suggests a potential new therapeutic approach for pancreatic cancer	Soo-Youl	Kim	Poster	Cancer and Metabolism 1	4/18/23	9:00 AM	Section 7	17
3687	Disruption of nucleotide homeostasis confers cancer cell susceptibility to oxidative phosphorylation inhibition independently of energy depletion	Xiaohong	Zhao	Poster	Cancer and Metabolism 1	4/18/23	9:00 AM	Section 7	18
3688	Exploring metabolic vulnerabilities of metastatic prostate cancer to bone	Eleonora	Dondossola	Poster	Cancer and Metabolism 1	4/18/23	9:00 AM	Section 7	19
3689	Uncovering the metabolic vulnerabilities in activated B cell diffuse large B cell lymphoma	Satishkumar	Singh	Poster	Cancer and Metabolism 1	4/18/23	9:00 AM	Section 7	20
3693	Single-cell flux estimation analysis reveals the metabolic states of tumor-specific CD4+ T cells	Mercy	Kehinde-Ige	Poster	Cancer and Metabolism 2	4/18/23	9:00 AM	Section 8	1
3694	Metabolic response in human cervical cancer cells to modifications in bioavailable ATP	Parth	Jayaswal	Poster	Cancer and Metabolism 2	4/18/23	9:00 AM	Section 8	2
3695	Mitochondrial uncoupling reverses reductive carboxylation in cancer	Jiangbin	Ye	Poster	Cancer and Metabolism 2	4/18/23	9:00 AM	Section 8	3
3696	L-arginine depletion causes different proliferation responses in breast cancer subtypes - Relation to gene expression profiles of L-arginine metabolic pathways	Juliane	Hannemann	Poster	Cancer and Metabolism 2	4/18/23	9:00 AM	Section 8	4

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
3697	Modulation of Nicotinamide N-Methyl Transferase (NNMT) expression in TNBC is associated with altered cell membrane cholesterol levels	Woei-Yaw	Chee	Poster	Cancer and Metabolism 2	4/18/23	9:00 AM	Section 8	5
3698	Epigenetic modification induced reprogramming of PUFAs-associated metabolism during trastuzumab resistance formation of HER2-positive breast cancer	Ningjun	Duan	Poster	Cancer and Metabolism 2	4/18/23	9:00 AM	Section 8	6
3699	Involvement of p53 and KRAS in the regulation of SLC38A5 in colon cancer	Nhi	Nguyen	Poster	Cancer and Metabolism 2	4/18/23	9:00 AM	Section 8	7
3700	Isocitrate dehydrogenase 1 sustains a hybrid cytoplasmic-mitochondrial tricarboxylic acid cycle in prostate cancer	Kevin	Gonthier	Poster	Cancer and Metabolism 2	4/18/23	9:00 AM	Section 8	8
3701	Targeting wild-type IDH1 enhances chemosensitivity in pancreatic cancer	Mehrdad	Zarei	Poster	Cancer and Metabolism 2	4/18/23	9:00 AM	Section 8	9
3702	Serine promotes aggressive phenotype in renal cancer	Suman	Karki	Poster	Cancer and Metabolism 2	4/18/23	9:00 AM	Section 8	10
3703	Multimodal metabolic imaging and proteomics of radiation resistance in head and neck squamous cell carcinoma	Jesse	Ivers	Poster	Cancer and Metabolism 2	4/18/23	9:00 AM	Section 8	11
3704	The essential role of an alternate mRNA translation initiation in the regulation of breast cancer cell metabolism	Hanna	Rosenstock	Poster	Cancer and Metabolism 2	4/18/23	9:00 AM	Section 8	12
3705	L-2HG, oncometabolite-driven epigenetic and epitranscriptomic reprogramming creates metabolic vulnerability in renal cancer	Anirban	Kundu	Poster	Cancer and Metabolism 2	4/18/23	9:00 AM	Section 8	13
3706	The significance of cholesteryl ester profiles in hepatocellular carcinoma	Nazar	Rahmanov	Poster	Cancer and Metabolism 2	4/18/23	9:00 AM	Section 8	14
3707	UXS1 is a synthetic lethal target in cancer	Michelle	Cicchini	Poster	Cancer and Metabolism 2	4/18/23	9:00 AM	Section 8	15
3708	Platelet-derived microparticles modulate breast cancer malignant processes	Vanessa	Veilleux	Poster	Cancer and Metabolism 2	4/18/23	9:00 AM	Section 8	16
3709	Hyperglycemia induces metabolic reprogramming and promotes epithelial-mesenchymal transitions in pancreatic cancer: an in vitro and in vivo experiment	Zhao	Liu	Poster	Cancer and Metabolism 2	4/18/23	9:00 AM	Section 8	17
3710	Serum tryptophan metabolites mediate constitutive AHR activity in head and neck squamous cell carcinoma cells	Dhwani	Patel	Poster	Cancer and Metabolism 2	4/18/23	9:00 AM	Section 8	18
3711	Molecular and cancer-related roles of ATP-citrate lyase exon 14	Julianna	Supplee	Poster	Cancer and Metabolism 2	4/18/23	9:00 AM	Section 8	19
3715	Pharmacological targeting of circadian clock genes reveals regulatory mechanisms of E-box regulated genes in cancer	Yuanzhong	Pan	Poster	Gene Regulation in Cancer	4/18/23	9:00 AM	Section 9	1
3716	RNA N6-methyladenosine binding protein, YTHDF1 regulates DNA repair and cancer immunity in protein synthesis levels	Dongjun	Jang	Poster	Gene Regulation in Cancer	4/18/23	9:00 AM	Section 9	2
3717	Defining the mechanism of ER receptor transcription complex activity and its effect on epigenetic modulations using super resolution microscopy	Tara	Akhshi	Poster	Gene Regulation in Cancer	4/18/23	9:00 AM	Section 9	3

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
3718	FOXO1 switches protein conformations upon C-terminal domain-mediated-autoregulation dictating its transcriptional activity in cancer cell proliferation	Chia-Chan	Hsu	Poster	Gene Regulation in Cancer	4/18/23	9:00 AM	Section 9	4
3719	Targeting the eIF6 and 60S ribosomal subunit interaction interface in cancers	Kavya	Harish	Poster	Gene Regulation in Cancer	4/18/23	9:00 AM	Section 9	5
3720	Cysteine palmitoylation of astrocyte elevated gene-1/Metadherin (AEG-1/MTDH) regulates its biological and immunological activity	Maria Del Carmen	Camarena	Poster	Gene Regulation in Cancer	4/18/23	9:00 AM	Section 9	6
3721	The C1 domain of capicua has functional importance in human CIC-DUX4	Cuylar	Luck	Poster	Gene Regulation in Cancer	4/18/23	9:00 AM	Section 9	7
3722	Exploring the role of eIF4E in cancer cells with targeted protein degradation	Swee	Sharp	Poster	Gene Regulation in Cancer	4/18/23	9:00 AM	Section 9	8
3723	Identification and functional characterization of long noncoding RNAs that regulate TGF- β -Smad pathway as Smad co-factors	Masatoshi	Kitagawa	Poster	Gene Regulation in Cancer	4/18/23	9:00 AM	Section 9	9
3724	RAI2 controls polycomb-mediated repression of CDKN1A by its interaction with CtBP1	Sarah	Greimeier	Poster	Gene Regulation in Cancer	4/18/23	9:00 AM	Section 9	10
3725	ABI1 regulates STAT3 transcription through a DNA binding activity	Leszek	Kotula	Poster	Gene Regulation in Cancer	4/18/23	9:00 AM	Section 9	11
3726	Histone acetylation axis in the control of RNA Pol2 clusters	Berkley	Gryder	Poster	Gene Regulation in Cancer	4/18/23	9:00 AM	Section 9	12
3727	Development of a new All-In-One inducible lentiviral shRNA/gRNA Vector	Lipeng	Wu	Poster	Gene Regulation in Cancer	4/18/23	9:00 AM	Section 9	13
3728	A novel, simplified, streamlined workflow for high-throughput whole transcriptome RNA-seq library preparation for a variety of sample types	Chelsea	Pinegar	Poster	Gene Regulation in Cancer	4/18/23	9:00 AM	Section 9	14
3729	Targeting the writers of enhancers as a new therapeutic strategy in pediatric AML	Joanna	Yi	Poster	Gene Regulation in Cancer	4/18/23	9:00 AM	Section 9	15
3730	A new type of transcriptional reprogramming by an IRF4 mutation in lymphoma	Pierre	Cauchy	Poster	Gene Regulation in Cancer	4/18/23	9:00 AM	Section 9	16
3731	The polyamine-hypusine circuit controls an oncogenic translational program essential for malignant transformation in MYC-driven lymphoma	Shima	Nakanishi	Poster	Gene Regulation in Cancer	4/18/23	9:00 AM	Section 9	17
3733	Disconnect between APOBEC3 expressions and mutations across cancers	Diako	Ebrahimi	Poster	Gene Regulation in Cancer	4/18/23	9:00 AM	Section 9	19
3734	Neuroendocrine differentiation (ND) in sensitivity of neuroendocrine tumor (NET) cells to ONC201/TIC10 cancer therapeutic	Elizabeth	Ding	Poster	Gene Regulation in Cancer	4/18/23	9:00 AM	Section 9	20
3735	N-terminal and C-terminal elephant-to-human p53 variants and truncations alter p53 transactivation	William	Yang	Poster	Gene Regulation in Cancer	4/18/23	9:00 AM	Section 9	21

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
3736	ZBTB46/FOXA2/HIF1A transcription activator complex promotes MCTP1-regulated neuroendocrine differentiation and epithelial-to-mesenchymal transition	Vu Thuy Dung	Phan	Poster	Gene Regulation in Cancer	4/18/23	9:00 AM	Section 9	22
3737	A novel mechanism of NF- κ B activation by genotoxic chemotherapy	Arun	Rishi	Poster	Gene Regulation in Cancer	4/18/23	9:00 AM	Section 9	23
3738	A novel mechanism of STAT3 activation by genotoxic chemotherapy	Arun	Rishi	Poster	Gene Regulation in Cancer	4/18/23	9:00 AM	Section 9	24
3739	MAFG promotes melanomagenesis through the transcriptional regulation of hypoxic and immune responses	Olga	Vera	Poster	Gene Regulation in Cancer	4/18/23	9:00 AM	Section 9	25
3743	circPMS1 is a pro-metastatic circular RNA in melanoma	Florian	Karreth	Poster	Non-coding RNAs in Brain, Melanoma, Lung, and Head/Neck	4/18/23	9:00 AM	Section 10	1
3744	A circulating microRNA panel predicts recurrence and survival in early-stage lung adenocarcinoma	Koji	Kawaguchi	Poster	Non-coding RNAs in Brain, Melanoma, Lung, and Head/Neck	4/18/23	9:00 AM	Section 10	2
3745	GRAS1 long non-coding RNA binds and stabilizes NF- κ B activating protein to protect lung cancer cells from DNA damage	Colleen	McHugh	Poster	Non-coding RNAs in Brain, Melanoma, Lung, and Head/Neck	4/18/23	9:00 AM	Section 10	3
3746	Dynamic characterization of small RNAs in non small cell lung cancer exosomes under immune-checkpoint inhibitor treatments	Maria	Garrido-Barros	Poster	Non-coding RNAs in Brain, Melanoma, Lung, and Head/Neck	4/18/23	9:00 AM	Section 10	4
3747	Transcribed ultra-conserved regions (TUCRs): A first computational and molecular characterization of an understudied class of molecules in gliomas	Myron	Gibert	Poster	Non-coding RNAs in Brain, Melanoma, Lung, and Head/Neck	4/18/23	9:00 AM	Section 10	5
3748	Epstein-Barr virus BART lncRNAs induce IKZF3/Aiolos to maintain EBV latency and promote tumorigenicity in nasopharyngeal carcinoma	Songtao	He	Poster	Non-coding RNAs in Brain, Melanoma, Lung, and Head/Neck	4/18/23	9:00 AM	Section 10	6
3749	Oncogenic role of Epstein-Barr virus lnc-BARTs in EBV associated tumors	LIU	JIAYAN	Poster	Non-coding RNAs in Brain, Melanoma, Lung, and Head/Neck	4/18/23	9:00 AM	Section 10	7
3750	miR-590-3p inhibits multiple oncogenic nodes within the TGFBR2:SMAD2/3 pathway in recurrent GBM cells	Sophie	Sall	Poster	Non-coding RNAs in Brain, Melanoma, Lung, and Head/Neck	4/18/23	9:00 AM	Section 10	8
3751	Characterizing the role of the y chromosome-expressed long non-coding RNA linc-SPRY3 family in lung cancer radiation resistance	Emily	Westemeier-Rice	Poster	Non-coding RNAs in Brain, Melanoma, Lung, and Head/Neck	4/18/23	9:00 AM	Section 10	9
3752	The role of miR-200 in anaplastic thyroid cancer aggressiveness	Hugo	Huth	Poster	Non-coding RNAs in Brain, Melanoma, Lung, and Head/Neck	4/18/23	9:00 AM	Section 10	10
3753	miR-567 modulates the progression of melanoma cells and functions of macrophages	Mai-Huong	Nguyen	Poster	Non-coding RNAs in Brain, Melanoma, Lung, and Head/Neck	4/18/23	9:00 AM	Section 10	11
3754	The cell- and non-cell autonomous actions of UCA1 dysregulation in hypopharyngeal cancer	Li-Wha	Wu	Poster	Non-coding RNAs in Brain, Melanoma, Lung, and Head/Neck	4/18/23	9:00 AM	Section 10	12
3755	Dlx4os: a lncRNA associated with malignant melanocyte transformation	Miriam	Jasiulionis	Poster	Non-coding RNAs in Brain, Melanoma, Lung, and Head/Neck	4/18/23	9:00 AM	Section 10	13

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
3756	miR-145 and its gene targets as therapeutic target and prognostic biomarkers for non-small cell lung cancer	William	Cho	Poster	Non-coding RNAs in Brain, Melanoma, Lung, and Head/Neck	4/18/23	9:00 AM	Section 10	14
3757	miR-200 inhibits the activation of cancer-associated fibroblasts in lung tumor microenvironment	Inyoung	Cheon	Poster	Non-coding RNAs in Brain, Melanoma, Lung, and Head/Neck	4/18/23	9:00 AM	Section 10	15
3758	Tumor tissue and cerebrospinal fluid microRNA profiles enable the classification of brain metastasis accordingly to their origin	Dagmar	Al Tukmachi	Poster	Non-coding RNAs in Brain, Melanoma, Lung, and Head/Neck	4/18/23	9:00 AM	Section 10	16
3759	Impact of individual and combined deregulation of miR-143 and miR-506 on cytokinetic and morphometric parameters in A549 lung cancer cells	Archana	Shrestha	Poster	Non-coding RNAs in Brain, Melanoma, Lung, and Head/Neck	4/18/23	9:00 AM	Section 10	17
3760	MicroRNA-1 run down the growth and metastasis of small cell lung cancer	Parvez	Khan	Poster	Non-coding RNAs in Brain, Melanoma, Lung, and Head/Neck	4/18/23	9:00 AM	Section 10	18
3761	Mediators of RNA sorting and export in non-small cell lung cancer derived extracellular vesicles	Humna	Hasan	Poster	Non-coding RNAs in Brain, Melanoma, Lung, and Head/Neck	4/18/23	9:00 AM	Section 10	19
3762	A novel lncRNA, GTF2A1-AS1, is required for cell cycle progression and cell proliferation	Doron	Ginsberg	Poster	Non-coding RNAs in Brain, Melanoma, Lung, and Head/Neck	4/18/23	9:00 AM	Section 10	20
3763	microRNAs associated with metastatic potential in salivary gland mucoepidermoid carcinoma	Cláudia	Coutinho-Camillo	Poster	Non-coding RNAs in Brain, Melanoma, Lung, and Head/Neck	4/18/23	9:00 AM	Section 10	21
3764	Expression patterns of microRNAs and associated target genes in ulcerated primary cutaneous melanoma	Emily	Schwarz	Poster	Non-coding RNAs in Brain, Melanoma, Lung, and Head/Neck	4/18/23	9:00 AM	Section 10	22
3765	Long non-coding RNAs are dysregulated in glioblastoma and LINC00634 may affect the diffuse growth of U251-derived tumors in vivo	Marek	Vecera	Poster	Non-coding RNAs in Brain, Melanoma, Lung, and Head/Neck	4/18/23	9:00 AM	Section 10	23
3769	Intracellular miR-1290 promotes breast cancer stemness in HER2-enriched and triple-negative breast cancer	Grace	Wong	Poster	Non-coding RNAs in Breast and Gynecological/Urinary Tract Cancers and New Techniques/Technologies	4/18/23	9:00 AM	Section 11	1
3770	Hypoxia-induced circular RNA circSFMBT2 inhibits tumor malignancy in breast cancer cells	Liang-Chuan	Lai	Poster	Non-coding RNAs in Breast and Gynecological/Urinary Tract Cancers and New Techniques/Technologies	4/18/23	9:00 AM	Section 11	2
3771	PiR-hsa-4447944 promotes the progression of prostate cancer through NEFH and induces androgen-independent growth	Qiang	Peng	Poster	Non-coding RNAs in Breast and Gynecological/Urinary Tract Cancers and New Techniques/Technologies	4/18/23	9:00 AM	Section 11	3
3772	The association of androgen receptor with microRNA expression in triple-negative breast cancer	Bayan	Abu Alragheb	Poster	Non-coding RNAs in Breast and Gynecological/Urinary Tract	4/18/23	9:00 AM	Section 11	4

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
					Cancers and New Techniques/Technologies				
3773	DeMixMir: deconvolution of microRNA sequencing data from heterogeneous tumor samples	Matthew	Montierth	Poster	Non-coding RNAs in Breast and Gynecological/Urinary Tract Cancers and New Techniques/Technologies	4/18/23	9:00 AM	Section 11	5
3774	MiR-34b promotes cellular senescence and ROS generation in human cervical cancer cells	K J	Sindhu	Poster	Non-coding RNAs in Breast and Gynecological/Urinary Tract Cancers and New Techniques/Technologies	4/18/23	9:00 AM	Section 11	6
3775	Multi-omic spatial analysis with simultaneous detection of small RNAs, mRNAs and proteins using the novel RNAscope™ Plus technology	Anushka	Dikshit	Poster	Non-coding RNAs in Breast and Gynecological/Urinary Tract Cancers and New Techniques/Technologies	4/18/23	9:00 AM	Section 11	7
3776	Identification of hypoxia regulated long noncoding RNA, MARVEL in kidney cancer	Ranju	Nair	Poster	Non-coding RNAs in Breast and Gynecological/Urinary Tract Cancers and New Techniques/Technologies	4/18/23	9:00 AM	Section 11	8
3777	MicroRNA-inducible CRISPR/Cas9 for cell type-specific genome regulation in cancer	Seung Ja	Oh	Poster	Non-coding RNAs in Breast and Gynecological/Urinary Tract Cancers and New Techniques/Technologies	4/18/23	9:00 AM	Section 11	9
3778	Genome-Scale CRISPRa and CRISPRi screening for lncRNA drivers of prostate cancer progression	Simone	Weiss	Poster	Non-coding RNAs in Breast and Gynecological/Urinary Tract Cancers and New Techniques/Technologies	4/18/23	9:00 AM	Section 11	10
3779	Evaluation of anti-cancer efficacy of lipid nanoparticles containing siRNA against HPV16 E6 and E7 combined with cisplatin in xenograft model of cervical cancer	Sung Wan	Kang	Poster	Non-coding RNAs in Breast and Gynecological/Urinary Tract Cancers and New Techniques/Technologies	4/18/23	9:00 AM	Section 11	11
3780	Reciprocal regulation between DNA methyl transferase 3A and 3B and microRNAs 299-3p and -30e are the causal factors for down regulation of microRNAs targeting androgen receptors in prostate cancer	Christian	Harrs	Poster	Non-coding RNAs in Breast and Gynecological/Urinary Tract Cancers and New Techniques/Technologies	4/18/23	9:00 AM	Section 11	12
3781	NF-κB classical and alternative signaling differentially regulate miRNA expression in ovarian cancer	Brittney	Harrington	Poster	Non-coding RNAs in Breast and Gynecological/Urinary Tract	4/18/23	9:00 AM	Section 11	13

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
					Cancers and New Techniques/Technologies				
3782	Targeting cancer cells using folate conjugated to a fully modified version of miR-34a (FolamiR-34a) to produce enhanced and sustained anti-tumor activity	Shreyas	Iyer	Poster	Non-coding RNAs in Breast and Gynecological/Urinary Tract Cancers and New Techniques/Technologies	4/18/23	9:00 AM	Section 11	14
3783	Role of microRNA 28-3p in prostate cancer progression	Amritha	Sreekumar	Poster	Non-coding RNAs in Breast and Gynecological/Urinary Tract Cancers and New Techniques/Technologies	4/18/23	9:00 AM	Section 11	15
3784	miR-489 induces apoptosis and immunogenic cell death through targeting FOXM1 in triple negative breast cancer cells	Gourab	Gupta	Poster	Non-coding RNAs in Breast and Gynecological/Urinary Tract Cancers and New Techniques/Technologies	4/18/23	9:00 AM	Section 11	16
3785	Telomerase RNA component lncRNA regulates hsa-miR-320 family and promotes prostate cancer metastasis	Zodwa	Dlamini	Poster	Non-coding RNAs in Breast and Gynecological/Urinary Tract Cancers and New Techniques/Technologies	4/18/23	9:00 AM	Section 11	17
3786	In vivo miR-449b mimic-based nanotherapy suppresses growth and progression of triple-negative breast cancer	Goknur	Kara	Poster	Non-coding RNAs in Breast and Gynecological/Urinary Tract Cancers and New Techniques/Technologies	4/18/23	9:00 AM	Section 11	18
3787	miR 2355-5p regulates tumor growth and angiogenesis in VHL-inactivated clear cell renal cell carcinoma	Patric	Page	Poster	Non-coding RNAs in Breast and Gynecological/Urinary Tract Cancers and New Techniques/Technologies	4/18/23	9:00 AM	Section 11	19
3788	Profiling of microRNAs in androgen independent prostate cancer cells	Hua	Li	Poster	Non-coding RNAs in Breast and Gynecological/Urinary Tract Cancers and New Techniques/Technologies	4/18/23	9:00 AM	Section 11	20
3789	Circular RNA expression is enriched in breast cancer extracellular vesicles and is associated with chemotherapy resistance	Harrison	Ngue	Poster	Non-coding RNAs in Breast and Gynecological/Urinary Tract Cancers and New Techniques/Technologies	4/18/23	9:00 AM	Section 11	21
3793	Regulation of miR-124 expression by promoter methylation in CRC and its relationship with KITENIN expression	So-Yeon	Park	Poster	Non-coding RNAs in Gastrointestinal, Blood, and Bone Marrow Cancers	4/18/23	9:00 AM	Section 12	1

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
3794	Sensitive detection of microRNA biomarkers of pancreatic cancer using one-pot endonucleolytically exponentiated rolling circle amplification by CRISPR-Cas12a	He	Yan	Poster	Non-coding RNAs in Gastrointestinal, Blood, and Bone Marrow Cancers	4/18/23	9:00 AM	Section 12	2
3795	Deciphering the in vivo roles of a novel long non-coding RNA in chronic lymphocytic leukemia and Richter syndrome	Swati	Mohapatra	Poster	Non-coding RNAs in Gastrointestinal, Blood, and Bone Marrow Cancers	4/18/23	9:00 AM	Section 12	3
3796	Exosomes enhance the radiation sensitivity via miR-6823-5p and modulate metastases in pancreatic cancer model	Ai	Nakaoka	Poster	Non-coding RNAs in Gastrointestinal, Blood, and Bone Marrow Cancers	4/18/23	9:00 AM	Section 12	4
3797	Fecal miRNA profiles and gut metagenome composition in Lynch syndrome: results from a mouse model study and human subjects	Giulia	Francescato	Poster	Non-coding RNAs in Gastrointestinal, Blood, and Bone Marrow Cancers	4/18/23	9:00 AM	Section 12	5
3798	lncRNA LIMp27 promotes p53-defective cancer pathogenesis	Lei	Jin	Poster	Non-coding RNAs in Gastrointestinal, Blood, and Bone Marrow Cancers	4/18/23	9:00 AM	Section 12	6
3799	Regulation of p16-E2F1-CDK4/6 signaling by TRUC-16 ultraconserved long non-coding RNA	Linda	Fabris	Poster	Non-coding RNAs in Gastrointestinal, Blood, and Bone Marrow Cancers	4/18/23	9:00 AM	Section 12	7
3800	The disruption of miR-125b-SLC1A5 cascade defines the oncogenicity and differential immune profile in oral carcinoma	Ying-Chieh	Liu	Poster	Non-coding RNAs in Gastrointestinal, Blood, and Bone Marrow Cancers	4/18/23	9:00 AM	Section 12	8
3801	Identification of circular RNAs associated with the ferroptosis of pancreatic cancer cells	Jessica	Pena Paladines	Poster	Non-coding RNAs in Gastrointestinal, Blood, and Bone Marrow Cancers	4/18/23	9:00 AM	Section 12	9
3802	miR-199a and miR-199b stimulate the progression of diffuse gastric cancer through direct targeting of Frizzled-6	Jihye	Park	Poster	Non-coding RNAs in Gastrointestinal, Blood, and Bone Marrow Cancers	4/18/23	9:00 AM	Section 12	10
3803	The landscape of circular RNAs in metastatic colorectal cancer	Sidi	Zhao	Poster	Non-coding RNAs in Gastrointestinal, Blood, and Bone Marrow Cancers	4/18/23	9:00 AM	Section 12	11
3804	Linear PVT1 isoforms and circPVT1 regulate DNA damage response and immunological pathways in acute myeloid leukemia and have a potential role in the crosstalk between leukemic cells and the tumor microenvironment	Martina	Ghetti	Poster	Non-coding RNAs in Gastrointestinal, Blood, and Bone Marrow Cancers	4/18/23	9:00 AM	Section 12	12
3805	Revealing the role of microRNAs in the emergence of cancer stem cell heterogeneity during colorectal cancer progression	Molly	Lausten	Poster	Non-coding RNAs in Gastrointestinal, Blood, and Bone Marrow Cancers	4/18/23	9:00 AM	Section 12	13

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
3806	Investigating the role of miRNA-34a in the resistance of esophageal adenocarcinoma to neoadjuvant chemoradiation therapy	Christina	Cahill	Poster	Non-coding RNAs in Gastrointestinal, Blood, and Bone Marrow Cancers	4/18/23	9:00 AM	Section 12	14
3807	MicroRNA-29a synergizes with PD-1 therapy to regulate anti-tumor immunity	Xuebing	Leng	Poster	Non-coding RNAs in Gastrointestinal, Blood, and Bone Marrow Cancers	4/18/23	9:00 AM	Section 12	15
3808	MicroRNA-206 drives antitumor immunity by disrupting the communication between Kupffer cells and Tregs	Guisheng	Song	Poster	Non-coding RNAs in Gastrointestinal, Blood, and Bone Marrow Cancers	4/18/23	9:00 AM	Section 12	16
3809	Differential regulation of novel long non coding RNAs and their mechanism of action in p73 dependent manner	Chanchal	Bareja	Poster	Non-coding RNAs in Gastrointestinal, Blood, and Bone Marrow Cancers	4/18/23	9:00 AM	Section 12	17
3810	MicroRNA-483-5p inhibits cell steatosis and fibrosis by targeting PPAR α , TIMP2 and HCC cell proliferation by modulating notch signaling	Suryakant	Niture	Poster	Non-coding RNAs in Gastrointestinal, Blood, and Bone Marrow Cancers	4/18/23	9:00 AM	Section 12	18
3811	Micro-RNA induced inactivation of inflammatory cytokine signaling pathways in Waldenstrom macroglobulinemia compared to IgM-MGUS	Karan	Chohan	Poster	Non-coding RNAs in Gastrointestinal, Blood, and Bone Marrow Cancers	4/18/23	9:00 AM	Section 12	19
3812	Circular RNAs from the PAX5 oncogene are overexpressed in B-cell malignancies and modulate cancer processes	Danick	Martin	Poster	Non-coding RNAs in Gastrointestinal, Blood, and Bone Marrow Cancers	4/18/23	9:00 AM	Section 12	20
3813	Role of CDKN2B antisense RNA 1 in Epstein-Barr virus associated gastric carcinoma	Keila	Torres	Poster	Non-coding RNAs in Gastrointestinal, Blood, and Bone Marrow Cancers	4/18/23	9:00 AM	Section 12	21
3814	In CLL the U1 snRNA driver mutation alters splicing in multiple genes and pathways	Andrea	Senff-Ribeiro	Poster	Non-coding RNAs in Gastrointestinal, Blood, and Bone Marrow Cancers	4/18/23	9:00 AM	Section 12	22
3818	Isoandrographolide derivative, (3,19)-4-Bromobenzylidene-isoandrographolide induces apoptosis and causes loss of mitochondrial membrane potential in ER positive Breast cancer	Balasubramanyam	Karanam	Poster	Natural Products	4/18/23	9:00 AM	Section 13	1
3819	Naringin nanoparticles inhibit metastasis of lung cancer through TGF- β 1-smad2/3 signaling pathway	Wen	Chen	Poster	Natural Products	4/18/23	9:00 AM	Section 13	2
3820	Changes in the transcriptome of a triple negative breast cancer cell line following treatment with a water-soluble extract from the leaves of the indigenous Southern African plant Tulbaghia violacea	Zodwa	Dlamini	Poster	Natural Products	4/18/23	9:00 AM	Section 13	3
3821	Berberine and emodin synergistically suppress the EGFR signaling cascade by targeting LAMB3 in pancreatic ductal adenocarcinoma	CAIMING	XU	Poster	Natural Products	4/18/23	9:00 AM	Section 13	4

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
3822	Novel evidence for the role of the p53 signaling pathway in mediating the anticancer effects of aronia berry extract in colorectal cancer cells	Yoh	Asahi	Poster	Natural Products	4/18/23	9:00 AM	Section 13	5
3823	Therapeutic potential of plant-derived nanovesicles for neuroendocrine prostate cancer	Sharanjot	Saini	Poster	Natural Products	4/18/23	9:00 AM	Section 13	6
3824	Remodeling of anaplastic thyroid cancer cell signaling and immune landscape by natural alkaloid berberine	Tara	Jarboe	Poster	Natural Products	4/18/23	9:00 AM	Section 13	7
3825	Andrographis reverses gemcitabine-associated chemoresistance by regulating calcium signaling in pancreatic ductal adenocarcinoma	Keisuke	Okuno	Poster	Natural Products	4/18/23	9:00 AM	Section 13	8
3826	Potency of cardiac glycosides by structure in organotypic models of pancreatic and ampullary carcinomas	Md Shahadat	Hossan	Poster	Natural Products	4/18/23	9:00 AM	Section 13	9
3827	Schinus terebinthifolius extracts impair migration of BT549 triple negative breast cancer cells in vitro	Alexis	Tapanes-Castillo	Poster	Natural Products	4/18/23	9:00 AM	Section 13	10
3828	Herbal extracts from lycii radices corex and achyranthes japonica prevent multiple myeloma progression	Donghoon	Yoon	Poster	Natural Products	4/18/23	9:00 AM	Section 13	11
3829	Antioxidant and antiproliferative activities of Ipomoea cairica extracts on three breast cancer cell lines	Ayodeji	Adegoke	Poster	Natural Products	4/18/23	9:00 AM	Section 13	12
3830	The anticancer activity of a water-soluble extract from the leaves of the indigenous Southern African plant Tulbaghia violacea against a triple negative breast cancer cell line	Rodney	Hull	Poster	Natural Products	4/18/23	9:00 AM	Section 13	13
3831	The molecular composition of a water-soluble extract from the leaves of the indigenous Southern African plant Tulbaghia violacea that displays anti-cancer activity against a triple negative breast cancer cell line	Mohammed	Alaouna	Poster	Natural Products	4/18/23	9:00 AM	Section 13	14
3832	Apoptotic and cell cycle effects of triterpenes isolated from Phoradendron wattii on a chronic myelogenous leukemia cell line	Rosa	Moo-Puc	Poster	Natural Products	4/18/23	9:00 AM	Section 13	15
3833	Leonurine derivatives as a potential novel therapeutic approach to acute lymphoblastic leukemias (ALL)	Joseph	Schramm	Poster	Natural Products	4/18/23	9:00 AM	Section 13	16
3834	Antiproliferative activity of substituted chromone-2-carboxamides on MDA-MB-231 cells and their 3D pharmacophore models	Kinfe	Redda	Poster	Natural Products	4/18/23	9:00 AM	Section 13	17
3839	Discovery of GSTZ1 as a novel target for drug refractory non-small cell lung cancer by using fragment-based chemical proteomics	Yi	Liao	Poster	Structural and Chemical Biology	4/18/23	9:00 AM	Section 14	1
3840	"				High-resolution structural insights into targeting the MYC oncogene	Danzhou	Yang	Poster	Structural and

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
					G-quadruplex with the quinoline derivative PEQ"				Chemical Biology
4/18/23	9:00 AM	Section 14	2						
3841	Development of p300-targeting PROTAC degraders with enhanced selectivity and onset of degradation	Hannah	Maple	Poster	Structural and Chemical Biology	4/18/23	9:00 AM	Section 14	3
3842	Berberine recognition of the dGMP-bound PDGFR- β promoter G-quadruplex: Structural insight into specific drug targeting	Yichen	Han	Poster	Structural and Chemical Biology	4/18/23	9:00 AM	Section 14	4
3843	Potent human ClpP protease agonists with anticancer properties bind the enzyme with improved structural complementarity and alter the mitochondrial N-terminome	Walid	Houry	Poster	Structural and Chemical Biology	4/18/23	9:00 AM	Section 14	5
3844	A biophysical investigation into the binding interactions of novel anti-cancer inhibitors of atypical protein kinase C (aPKCs)	Radwan Ebna	Noor	Poster	Structural and Chemical Biology	4/18/23	9:00 AM	Section 14	6
3845	Structural mechanisms of how PTEN mutations degrade function at the membrane and life expectancy of carriers of mutations in the human brain	Hyunbum	Jang	Poster	Structural and Chemical Biology	4/18/23	9:00 AM	Section 14	7
3847	Target identification of a multi-pass transmembrane G protein coupled receptor using limited-proteolysis coupled mass spectrometry (LiP-MS)	Yuehan	Feng	Poster	Structural and Chemical Biology	4/18/23	9:00 AM	Section 14	9
3851	Targeting RET solvent-front mutants with an alkynyl nicotinamide-based inhibitor	Ujjwol	Khatri	Poster	Drug Resistance in Molecular Targeted Therapies 3	4/18/23	9:00 AM	Section 15	1
3852	IK-930, a paralog-selective novel TEAD-inhibitor, effectively attenuates drug-tolerant persister cell proliferation	Daniel	Hidalgo	Poster	Drug Resistance in Molecular Targeted Therapies 3	4/18/23	9:00 AM	Section 15	2
3853	The TWIST1-p27 signaling pathway is a critical determinant of MET TKI cell cycle arrest and resistance in MET altered non-small cell lung cancer	Vinod	Kumar	Poster	Drug Resistance in Molecular Targeted Therapies 3	4/18/23	9:00 AM	Section 15	3
3854	TNIK inhibition as a novel therapeutic in cMyc high/TTF1 low SCLC	Azusa	Tanimoto	Poster	Drug Resistance in Molecular Targeted Therapies 3	4/18/23	9:00 AM	Section 15	4
3855	Establishment and characterization of a panel of breast XPDX models representing innate or acquired resistance to trastuzumab deruxtecan (T-DXd)	Maci	DeBoer	Poster	Drug Resistance in Molecular Targeted Therapies 3	4/18/23	9:00 AM	Section 15	5
3856	Evaluation of replication protein A inhibitor, NERx329 in combination with EGFR mutant targeted therapy	Reshma	Bhowmick	Poster	Drug Resistance in Molecular Targeted Therapies 3	4/18/23	9:00 AM	Section 15	6
3857	Exploring mechanisms of resistance to elraglusib in pancreatic cancer PDX models	Taylor	Weiskittel	Poster	Drug Resistance in Molecular Targeted Therapies 3	4/18/23	9:00 AM	Section 15	7

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
3858	Exploring Exportin-1 as a therapeutic vulnerability in squamous cell carcinoma	Vidushi	Durani	Poster	Drug Resistance in Molecular Targeted Therapies 3	4/18/23	9:00 AM	Section 15	8
3859	Alterations in hormone receptors regulome following response to kinase inhibitors in lethal prostate cancer	Remi	Adelaiye-Ogala	Poster	Drug Resistance in Molecular Targeted Therapies 3	4/18/23	9:00 AM	Section 15	9
3860	ERK1/2 inhibition overcomes resistance to venetoclax in AML by altering mitochondrial metabolism	Priyanka	Sharma	Poster	Drug Resistance in Molecular Targeted Therapies 3	4/18/23	9:00 AM	Section 15	10
3861	c-MYC mediated resistance to trametinib plus hydroxychloroquine in pancreatic cancer is overcome by CDK4/6 and lysosomal inhibition	Conan	Kinsey	Poster	Drug Resistance in Molecular Targeted Therapies 3	4/18/23	9:00 AM	Section 15	11
3862	IGFBP3 promotes resistance to olaparib via modulating EGFR signaling in advanced prostate cancer	Amy	Leslie	Poster	Drug Resistance in Molecular Targeted Therapies 3	4/18/23	9:00 AM	Section 15	12
3863	Aminoflavone confers activity against aromatase inhibitor-resistant breast cancer cells in part via miR125b2-3p restoration	Eileen	Brantley	Poster	Drug Resistance in Molecular Targeted Therapies 3	4/18/23	9:00 AM	Section 15	13
3864	Targeting IL-6/STAT3 signaling in EGFR-mutant drug tolerant persister cells	Sonia	Patel	Poster	Drug Resistance in Molecular Targeted Therapies 3	4/18/23	9:00 AM	Section 15	14
3865	Multiple cancer types rapidly escape from multiple MAPK inhibitors to generate mutagenesis-prone subpopulations	Timothy	Hoffman	Poster	Drug Resistance in Molecular Targeted Therapies 3	4/18/23	9:00 AM	Section 15	15
3866	Targeting AXL can effectively inhibit c-Met-induced therapeutic resistance in renal cancer	Akash	Sabarwal	Poster	Drug Resistance in Molecular Targeted Therapies 3	4/18/23	9:00 AM	Section 15	16
3867	Chromatin modification driving sub-clonal resistance to KRAS G12C combination therapies in KRAS mutant non-small cell lung cancer	Chendi	Li	Poster	Drug Resistance in Molecular Targeted Therapies 3	4/18/23	9:00 AM	Section 15	17
3868	Aurora kinase A inhibition overcome adaptive resistance to KRAS G12C inhibitor by G1-checkpoint induced apoptosis in KRAS non-small cell lung cancer	Chendi	Li	Poster	Drug Resistance in Molecular Targeted Therapies 3	4/18/23	9:00 AM	Section 15	18
3869	Short or long-term treatment with CDK4/6 inhibitors in patients with ER+ breast cancer: characterization and comparative analysis of resistance in seventeen XPD models	Alyssa	Simonson	Poster	Drug Resistance in Molecular Targeted Therapies 3	4/18/23	9:00 AM	Section 15	19
3870	TNF-MK2 signaling drives protective autophagy following MAPK pathway inhibition in pancreatic cancer	Iftikhar Ali	Khawar	Poster	Drug Resistance in Molecular Targeted Therapies 3	4/18/23	9:00 AM	Section 15	20
3871	KRAS G12C mutant allele amplification drives resistance to sotorasib in vitro	Deanna	Mohn	Poster	Drug Resistance in Molecular Targeted Therapies 3	4/18/23	9:00 AM	Section 15	21
3872	Targeting of YAP overcomes trastuzumab-resistance and promotes immune responses in HER2-positive cancers	Kyoung-Seok	Oh	Poster	Drug Resistance in Molecular Targeted Therapies 3	4/18/23	9:00 AM	Section 15	22
3873	Candidate drug screening for TP53-mutated AML	Daehyeon	Gwak	Poster	Drug Resistance in Molecular Targeted Therapies 3	4/18/23	9:00 AM	Section 15	23

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
3874	Genomic mechanisms of resistance to tyrosine kinase inhibitors (TKIs) in HER2+ metastatic breast cancer (HER2+ MBC)	Heather	Parsons	Poster	Drug Resistance in Molecular Targeted Therapies 3	4/18/23	9:00 AM	Section 15	24
3875	Evaluation of resistance mechanisms to ARV471, an ER-targeted PROTAC	Delia	Friel	Poster	Drug Resistance in Molecular Targeted Therapies 3	4/18/23	9:00 AM	Section 15	25
3876	Kinetics of RTK activation determine ERK signaling dynamics and resistance to BRAF and MEK inhibitors	Sungsoo	Kim	Poster	Drug Resistance in Molecular Targeted Therapies 3	4/18/23	9:00 AM	Section 15	26
3877	Systematic functional and phenotypic characterization of HER2 missense mutants and their impact in ER+ metastatic breast cancer	Utthara	Nayar	Poster	Drug Resistance in Molecular Targeted Therapies 3	4/18/23	9:00 AM	Section 15	27
3878	Targeting Hippo-YAP, BRD4 and RAS-MAPK interplay in lung cancer to forestall drug resistance	Nilanjana	Chatterjee	Poster	Drug Resistance in Molecular Targeted Therapies 3	4/18/23	9:00 AM	Section 15	28
3879	SETD2 is a novel and druggable dependency in IMiD/CELMoD resistant multiple myeloma models	Sarah	Bird	Poster	Drug Resistance in Molecular Targeted Therapies 3	4/18/23	9:00 AM	Section 15	29
3882	tumor adaptations to PI3K inhibition increases and its reversibility decreases as a function of time in drug	Radha	Mukherjee	Poster	Drug Resistance in Molecular Targeted Therapies 4 / Regulation of Gene Expression in Drug Resistance	4/18/23	9:00 AM	Section 16	1
3883	Overcoming tamoxifen resistance by re-activating cAMP-Ca2+-ROS-ferroptosis axis in ER+ breast cancer	Rashedul	Alam	Poster	Drug Resistance in Molecular Targeted Therapies 4 / Regulation of Gene Expression in Drug Resistance	4/18/23	9:00 AM	Section 16	2
3884	Targeting the ARID1A mutations overcomes primary resistance to ALK inhibitors in EML4-ALK positive NSCLC	Seung Yeon	Oh	Poster	Drug Resistance in Molecular Targeted Therapies 4 / Regulation of Gene Expression in Drug Resistance	4/18/23	9:00 AM	Section 16	3
3885	A secondary Gαq mutation confers resistance to Gαq inhibitors in uveal melanoma	Xu	Chen	Poster	Drug Resistance in Molecular Targeted Therapies 4 / Regulation of Gene Expression in Drug Resistance	4/18/23	9:00 AM	Section 16	4
3886	Analysis of concomitant genetic alterations in advanced EGFR-mutated lung adenocarcinoma by targeted NGS : A multicenter prospective and real world study	In Ae	Kim	Poster	Drug Resistance in Molecular Targeted Therapies 4 / Regulation of Gene Expression in Drug Resistance	4/18/23	9:00 AM	Section 16	5
3887	ATP-binding pocket substitutions as secondary or tertiary in-cis mutations are major on-target ripretinib resistance mechanisms in gastrointestinal stromal tumor	Benjamin	Fletcher	Poster	Drug Resistance in Molecular Targeted Therapies 4 / Regulation of Gene Expression in Drug Resistance	4/18/23	9:00 AM	Section 16	6

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
3888	N-glycosylation-defective IL6 activates the SRC-YAP-SOX2 signaling to potentiate metastasis and TKI resistance in NSCLC	Chun Hua	Hung	Poster	Drug Resistance in Molecular Targeted Therapies 4 / Regulation of Gene Expression in Drug Resistance	4/18/23	9:00 AM	Section 16	7
3889	The role of CXCL1 in crosstalk between breast cancer cells with ESR1 mutations and lymphatic endothelial cells	Kideok	Jin	Poster	Drug Resistance in Molecular Targeted Therapies 4 / Regulation of Gene Expression in Drug Resistance	4/18/23	9:00 AM	Section 16	8
3890	TMPRSS2 serin protease is a novel biomarker for ER+ breast cancer patient prognosis and survival and mediates resistance to anti-estrogen treatment in ER+ breast cancer	Rumeysa	Ozyurt	Poster	Drug Resistance in Molecular Targeted Therapies 4 / Regulation of Gene Expression in Drug Resistance	4/18/23	9:00 AM	Section 16	9
3891	Epigenetic rewiring promotes antiandrogen resistance and metastasis via heterogenous oncogenic drivers in prostate cancer	Xiaoling	Li	Poster	Drug Resistance in Molecular Targeted Therapies 4 / Regulation of Gene Expression in Drug Resistance	4/18/23	9:00 AM	Section 16	10
3892	EZH2 mediated kinome reprogramming drives AR phosphorylation and activation in receptor tyrosine kinase inhibitors resistant renal carcinoma models	Christopher	Rupert	Poster	Drug Resistance in Molecular Targeted Therapies 4 / Regulation of Gene Expression in Drug Resistance	4/18/23	9:00 AM	Section 16	11
3893	KRAS G12C colon cancer resistance to vertical MAPK inhibition converges on FOS-JUN signaling through orthogonal mechanisms	Mohamad Karim	Koleilat	Poster	Drug Resistance in Molecular Targeted Therapies 4 / Regulation of Gene Expression in Drug Resistance	4/18/23	9:00 AM	Section 16	12
3894	The role of ELF3 in acquired resistance to endocrine therapy in ER-positive breast cancer	Na	Zhang	Poster	Drug Resistance in Molecular Targeted Therapies 4 / Regulation of Gene Expression in Drug Resistance	4/18/23	9:00 AM	Section 16	13
3895	New potential mechanism of mnx1-as1 in the regulation of the carboplatin chemoresistant phenotype in ovarian cancer cell lines	Tamara	Viscarra Alvarez	Poster	Drug Resistance in Molecular Targeted Therapies 4 / Regulation of Gene Expression in Drug Resistance	4/18/23	9:00 AM	Section 16	14
3896	Alteration of malignancy and histone-H3 lysine-methylation status in osteosarcoma cells which acquire methotrexate resistance in vitro	Yusuke	Aoki	Poster	Drug Resistance in Molecular Targeted Therapies 4 / Regulation of Gene Expression in Drug Resistance	4/18/23	9:00 AM	Section 16	15

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
3897	MNX1-AS1 expression is positively correlates with expression of drug efflux pumps in ovarian cancer	Kurt	Buchegger Mena	Poster	Drug Resistance in Molecular Targeted Therapies 4 / Regulation of Gene Expression in Drug Resistance	4/18/23	9:00 AM	Section 16	16
3898	Synergistic combination of the iron chelator deferasirox with cisplatin and doxorubicin chemotherapies against nonsmall cell lung carcinoma	Natalia	Ortiz Alvelo	Poster	Drug Resistance in Molecular Targeted Therapies 4 / Regulation of Gene Expression in Drug Resistance	4/18/23	9:00 AM	Section 16	17
3899	CHST11 mediated SEMA7A expression contributes to TKI resistant in lung cancer	Chien-Hsiu	Li	Poster	Drug Resistance in Molecular Targeted Therapies 4 / Regulation of Gene Expression in Drug Resistance	4/18/23	9:00 AM	Section 16	18
3900	In vivo inhibition of metastatic HER2 positive trastuzumab resistant breast cancer using engineered destabilized 3UTR ARE of HER2 improves survival outcomes	Chidiebere	Awah	Poster	Drug Resistance in Molecular Targeted Therapies 4 / Regulation of Gene Expression in Drug Resistance	4/18/23	9:00 AM	Section 16	19
3901	Identification of genomic pathways associated with resistance of NSCLC to immunotherapies containing granzyme B	Ana	Alvarez-Cienfuegos	Poster	Drug Resistance in Molecular Targeted Therapies 4 / Regulation of Gene Expression in Drug Resistance	4/18/23	9:00 AM	Section 16	20
3902	Glutathione as a potential marker of tamoxifen resistance in breast cancer	Yazan	Hamadneh	Poster	Drug Resistance in Molecular Targeted Therapies 4 / Regulation of Gene Expression in Drug Resistance	4/18/23	9:00 AM	Section 16	21
3903	Role of the miR-301a/Fra-2/GLIPR1 axis in lung cancer cisplatin resistance	Francesca	Lovat	Poster	Drug Resistance in Molecular Targeted Therapies 4 / Regulation of Gene Expression in Drug Resistance	4/18/23	9:00 AM	Section 16	22
3904	Simvastatin intensifies anti-androgen efficacy against treatment-resistant prostate cancer cells	Aino	Siltari	Poster	Drug Resistance in Molecular Targeted Therapies 4 / Regulation of Gene Expression in Drug Resistance	4/18/23	9:00 AM	Section 16	23
3905	Epigenetic priming reveals the central role of epigenetic state in the anti-tumor activity of vitamin D in pancreatic ductal adenocarcinoma	Bo	He	Poster	Drug Resistance in Molecular Targeted Therapies 4 / Regulation of Gene Expression in Drug Resistance	4/18/23	9:00 AM	Section 16	24

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
3906	The mRNA translational plasticity of small cell lung carcinoma is associated with its phenotypic transdifferentiation	Haoning	Peng	Poster	Drug Resistance in Molecular Targeted Therapies 4 / Regulation of Gene Expression in Drug Resistance	4/18/23	9:00 AM	Section 16	25
3907	Targeting adaptive resistance to EGFR and KRAS G12C inhibitors by TT125-802, a novel and specific CBP/p300 bromodomain inhibitor	Thomas	Bohnacker	Poster	Drug Resistance in Molecular Targeted Therapies 4 / Regulation of Gene Expression in Drug Resistance	4/18/23	9:00 AM	Section 16	26
3908	M6A RNA modifications regulate expression of transcripts that promote transition to cisplatin resistance in bladder cancer	Emmanuelle	Hodara	Poster	Drug Resistance in Molecular Targeted Therapies 4 / Regulation of Gene Expression in Drug Resistance	4/18/23	9:00 AM	Section 16	27
3909	THY1 regulates therapy resistance in glioblastoma recurrence	Sunita	Shankar	Poster	Drug Resistance in Molecular Targeted Therapies 4 / Regulation of Gene Expression in Drug Resistance	4/18/23	9:00 AM	Section 16	28
3913	Genomic loss of UQCR11 creates therapeutic vulnerability in triple-negative breast cancer	Samantha	Sharma	Poster	Identification of Molecular Targets 1	4/18/23	9:00 AM	Section 17	1
3914	BTK and MALT1 are critical for cell adhesion and dissemination in mantle cell lymphoma	Vivian Changying	Jiang	Poster	Identification of Molecular Targets 1	4/18/23	9:00 AM	Section 17	2
3915	RNAseq analysis reveals differentiation gene drivers as potential therapeutic targets in anaplastic thyroid cancer	Kaci	Kopec	Poster	Identification of Molecular Targets 1	4/18/23	9:00 AM	Section 17	3
3916	role of her3 v104l mutation on tumor growth and her3 stabilization	Rosalin	Mishra	Poster	Identification of Molecular Targets 1	4/18/23	9:00 AM	Section 17	4
3918	Kinase domain duplications of FGFR1 and MET are potential therapeutic targets	Chaelin	Lee	Poster	Identification of Molecular Targets 1	4/18/23	9:00 AM	Section 17	6
3919	SHP2-DDX3X complexes contribute to translational control of CD274 mRNA in KRAS-active non-small cell lung cancer	Palapoom	Wongsaengpibon	Poster	Identification of Molecular Targets 1	4/18/23	9:00 AM	Section 17	7
3920	Functional analysis of the role of RAP1GDS1 and RhoA in KRAS-driven lung adenocarcinoma	Marta	Roman Moreno	Poster	Identification of Molecular Targets 1	4/18/23	9:00 AM	Section 17	8
3921	Malic enzyme 2 identified as metabolic target in triple-negative breast cancers with increased serine biosynthesis	Mark	Slayton	Poster	Identification of Molecular Targets 1	4/18/23	9:00 AM	Section 17	9
3922	Assessing clonal evolution of myeloid neoplasms by flow cytometry guided, cell-enriched next generation sequencing	Sarah	Johnson	Poster	Identification of Molecular Targets 1	4/18/23	9:00 AM	Section 17	10
3923	Identification of membrane-expressed CAPRIN-1 as a novel and universal cancer target and generation of a therapeutic anti-CAPRIN-1 antibody TRK-950	Fumiyoshi	Okano	Poster	Identification of Molecular Targets 1	4/18/23	9:00 AM	Section 17	11

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
3924	Cooperation between mutant IL7R and TLX3 generates mixed myeloid lymphoid leukemia from thymocyte progenitors	Gisele	Rodrigues	Poster	Identification of Molecular Targets 1	4/18/23	9:00 AM	Section 17	12
3925	JunB regulates expression of HPV genes in head and neck cancer	Hina	Rehmani	Poster	Identification of Molecular Targets 1	4/18/23	9:00 AM	Section 17	13
3926	Activating missense mutations in ROS1 receptor harbor oncogenic potential and are sensitive to tyrosine kinase inhibition	Sudarshan	Iyer	Poster	Identification of Molecular Targets 1	4/18/23	9:00 AM	Section 17	14
3927	Genome-wide screening and validation of molecular targets and biomarkers for lung cancer	Yataro	Daigo	Poster	Identification of Molecular Targets 1	4/18/23	9:00 AM	Section 17	15
3928	Therapeutic targeting of NOTCH1 and neddylation pathway in T cell acute lymphoblastic leukemia	Carla	Bertulfo	Poster	Identification of Molecular Targets 1	4/18/23	9:00 AM	Section 17	16
3929	MDMX overexpression in cancer cells confers significant resistance to MDMX inhibitor XI-006 and may modulate chemosensitivity through suppressing p53 activation of pro-apoptotic factors	Andrew	George	Poster	Identification of Molecular Targets 1	4/18/23	9:00 AM	Section 17	17
3930	MCT1 as a potential target in the progression of oral premalignant dysplasia to invasive squamous cell carcinoma	Ethan	Wong	Poster	Identification of Molecular Targets 1	4/18/23	9:00 AM	Section 17	18
3931	BRD4, BRD3, NSD3, and ZNF532 fusions in histologies beyond NUT carcinomas: Investigation of a large pan-cancer cohort	Ian	Nykaza	Poster	Identification of Molecular Targets 1	4/18/23	9:00 AM	Section 17	19
3932	Targeting cyclin K in pancreatic cancer	Yi	Xiao	Poster	Identification of Molecular Targets 1	4/18/23	9:00 AM	Section 17	20
3933	RRM2 inhibition by COH29 is a potential therapeutic strategy for atypical teratoid rhabdoid tumors	Le	Hien Giang	Poster	Identification of Molecular Targets 1	4/18/23	9:00 AM	Section 17	21
3934	PRMT5 is an actionable target in CDK4/6 inhibitor-resistant ER+/Rb-deficient breast cancer	Chang-Ching	Lin	Poster	Identification of Molecular Targets 1	4/18/23	9:00 AM	Section 17	22
3935	CRISPR/Cas9 screens to identify proliferation and resistance mechanisms in uveal melanoma	Richard	Bennett	Poster	Identification of Molecular Targets 1	4/18/23	9:00 AM	Section 17	23
3936	ALK fusion oncogene driven SERPINB4 expression enhances tumor survival in NSCLC	Tzu-Po	Chuang	Poster	Identification of Molecular Targets 1	4/18/23	9:00 AM	Section 17	24
3937	An intracellular variant of zona pellucida glycoprotein 3 is expressed in cancer	Iman	Schultz	Poster	Identification of Molecular Targets 1	4/18/23	9:00 AM	Section 17	25
3938	In vivo genome-wide CRISPR screen in pancreatic ductal adenocarcinoma defines HSPE1 as a potential oncogene by acting through G2/M cell cycle arrest	Julien	Boudreault	Poster	Identification of Molecular Targets 1	4/18/23	9:00 AM	Section 17	26
3939	Inhibition of USP7 upregulates USP22 through desuppression of transcriptional activity of Sp1 in human cancer cells	Keqiang	Zhang	Poster	Identification of Molecular Targets 1	4/18/23	9:00 AM	Section 17	27
3940	Validation of TFX1, a first-in-class target for cancer metastasis	John	Ellingboe	Poster	Identification of Molecular Targets 1	4/18/23	9:00 AM	Section 17	28

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
3941	Enzymatic nitration in oncology	Arun	Kashyap	Poster	Identification of Molecular Targets 1	4/18/23	9:00 AM	Section 17	29
3942	Differential expression of a novel transport receptor, SORT1 (sortilin), in cancer versus healthy tissues that can be utilized for targeted delivery of anti-cancer drugs	Guylaine	Roy	Poster	Identification of Molecular Targets 1	4/18/23	9:00 AM	Section 17	30
3946	Radiolabeled $\alpha\beta 3$ analog 177Lu-EB-RGD is an effective therapeutic agent in thyroid cancer xenograft mouse model	Sonam	Kumari	Poster	Identification of Molecular Targets 2 / New Nonclinical Models for Targets	4/18/23	9:00 AM	Section 18	1
3947	S100A8/A9-RAGE pathway and chronic airway inflammation in cigarette smoke-induced lung carcinogenesis	Chang Dong	Yeo	Poster	Identification of Molecular Targets 2 / New Nonclinical Models for Targets	4/18/23	9:00 AM	Section 18	2
3948	DDX5 helicase resolves G-quadruplex and transactivates MYC expression	Luying	Chen	Poster	Identification of Molecular Targets 2 / New Nonclinical Models for Targets	4/18/23	9:00 AM	Section 18	3
3949	CYR61, a member of the CCN protein family, regulates IGF-1 in metastatic prostate cancer	Greisha	Ortiz-Hernandez	Poster	Identification of Molecular Targets 2 / New Nonclinical Models for Targets	4/18/23	9:00 AM	Section 18	4
3950	Sensitizing oncogenic mutant p53-expressing non-small cell lung cancer to proteasome inhibitors	Victoria	Neely	Poster	Identification of Molecular Targets 2 / New Nonclinical Models for Targets	4/18/23	9:00 AM	Section 18	5
3951	Unprecedented forward genetic screens reveal mechanisms of action, drug resistances, and hidden efficacies at amino acid resolution: combination of 5-ALA and Artesunate as a treatment option for glioblastoma multiforme	Moritz	Horn	Poster	Identification of Molecular Targets 2 / New Nonclinical Models for Targets	4/18/23	9:00 AM	Section 18	6
3952	Preclinical anti-tumor effects of MDM4/MDMX inhibitor XI-006 in breast cancer and prostate cancer cell lines mediated through reduced tumor cell migration	Arielle	De La Cruz	Poster	Identification of Molecular Targets 2 / New Nonclinical Models for Targets	4/18/23	9:00 AM	Section 18	7
3954	Evaluation of long mononucleotide repeat markers for detection of microsatellite instability	Suping	Chen	Poster	Identification of Molecular Targets 2 / New Nonclinical Models for Targets	4/18/23	9:00 AM	Section 18	9
3955	Functional evaluation of pancreatic cancer prognostic marker, LXN, utilizing multiomics analysis based on patient-derived cancer model	Chan Hee	Park	Poster	Identification of Molecular Targets 2 / New Nonclinical Models for Targets	4/18/23	9:00 AM	Section 18	10
3956	Identifying PIKfyve as potential target in clear cell renal cell carcinoma with a loss of the von Hippel-Lindau tumor suppressor gene	Sandra	Turcotte	Poster	Identification of Molecular Targets 2 / New Nonclinical Models for Targets	4/18/23	9:00 AM	Section 18	11

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
3957	Anticancer effect of novel 1,4-benzodiazepine derivatives through tubulin polymerization inhibition	Alzbeta	Srovnalova	Poster	Identification of Molecular Targets 2 / New Nonclinical Models for Targets	4/18/23	9:00 AM	Section 18	12
3958	Transcriptome analysis of Small Cell Osteosarcoma reveals an embryonic stem cell-like phenotype	Maria Antonella	Laginestra	Poster	Identification of Molecular Targets 2 / New Nonclinical Models for Targets	4/18/23	9:00 AM	Section 18	13
3959	Novel spliced isoform of the proteasome subunit ADRM1/Rpn13 promotes hepatocellular carcinoma (HCC) development through selective degradation of tumor suppressor p53	Yanmei	Sun	Poster	Identification of Molecular Targets 2 / New Nonclinical Models for Targets	4/18/23	9:00 AM	Section 18	14
3960	Therapeutic targeting of HIF-1 alpha induced CD73 expression in experimental esophageal adenocarcinoma	Md Sazzad	Hassan	Poster	Identification of Molecular Targets 2 / New Nonclinical Models for Targets	4/18/23	9:00 AM	Section 18	15
3961	Identification of lncRNAs as potential novel therapeutic targets in triple negative breast cancer	Zohaib	Rana	Poster	Identification of Molecular Targets 2 / New Nonclinical Models for Targets	4/18/23	9:00 AM	Section 18	16
3962	Development of selection-free HER4-mutated CRISPR/Cas9 knock-ins in cutaneous melanoma cell lines	Marta	Valenti	Poster	Identification of Molecular Targets 2 / New Nonclinical Models for Targets	4/18/23	9:00 AM	Section 18	17
3963	Mass spectrometry reveals a downregulation of calreticulin after neoadjuvant chemotherapy in pancreatic cancer	Michael	Stoffel	Poster	Identification of Molecular Targets 2 / New Nonclinical Models for Targets	4/18/23	9:00 AM	Section 18	18
3964	APE1 protects SMAD3 against ROC1 ubiquitin mediated degradation in esophageal adenocarcinoma cells	Farah	Ballout	Poster	Identification of Molecular Targets 2 / New Nonclinical Models for Targets	4/18/23	9:00 AM	Section 18	19
3965	KIFC1 is a therapeutic target in lung cancers with extra centrosomes	Christopher	Zhang	Poster	Identification of Molecular Targets 2 / New Nonclinical Models for Targets	4/18/23	9:00 AM	Section 18	20
3966	Targeting S100A10, a SOX9 binding protein, for the treatment of triple negative breast cancer	Yanxia	Ma	Poster	Identification of Molecular Targets 2 / New Nonclinical Models for Targets	4/18/23	9:00 AM	Section 18	21
3967	CRISPR/Cas9 screening identified novel membrane targets sensitizing hepatocellular carcinoma cells to natural killer cell-mediated cytotoxicity	James	Rong	Poster	Identification of Molecular Targets 2 / New Nonclinical Models for Targets	4/18/23	9:00 AM	Section 18	22
3968	Conophylline-target ARL6ip1 regulates Ran-mediated cellular migration and invasion in human colorectal cancer cells	Yinzhi	Lin	Poster	Identification of Molecular Targets 2 / New Nonclinical Models for Targets	4/18/23	9:00 AM	Section 18	23

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
3969	Screening of kinase inhibitors as bioenergetic metabolism modulator using the XF Real-Time ATP Rate Assay	Yoonseok	Kam	Poster	Identification of Molecular Targets 2 / New Nonclinical Models for Targets	4/18/23	9:00 AM	Section 18	24
3970	NCG-hIL15 humanized mice: an ideal model for human immune reconstitution of NK cells	Jianming	Xu	Poster	Identification of Molecular Targets 2 / New Nonclinical Models for Targets	4/18/23	9:00 AM	Section 18	25
3971	Developing cancer cell based in vitro and in vivo models with CRISPR-mediated knock-in technology for anti-tumor drug discovery	Nengwei	Xu	Poster	Identification of Molecular Targets 2 / New Nonclinical Models for Targets	4/18/23	9:00 AM	Section 18	26
3972	Novel renal cell carcinoma therapy targeting glutaminolysis	Yoshinari	Muto	Poster	Identification of Molecular Targets 2 / New Nonclinical Models for Targets	4/18/23	9:00 AM	Section 18	27
3973	Precision RNAi using synthetic shRNAmir target sites	Ralph	Neumüller	Poster	Identification of Molecular Targets 2 / New Nonclinical Models for Targets	4/18/23	9:00 AM	Section 18	28
3974	Discovery and validation of therapeutic targets in immune cells by mass spectrometry-based proteomics	Amaury	Lachaud	Poster	Identification of Molecular Targets 2 / New Nonclinical Models for Targets	4/18/23	9:00 AM	Section 18	29
3978	The growth inhibitory effect of MDV3100 on hormone receptor-positive, HER2-negative breast cancer cell lines with low DYRK2 expression	Yoshimi	Imawari	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 3	4/18/23	9:00 AM	Section 19	1
3979	Tandem peptides targeting HER2 for delivery of CD44 siRNA into HER2+ breast cancer cells in vitro	James	Kalogeros	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 3	4/18/23	9:00 AM	Section 19	2
3982	Anti-Stanniocalcin 1 antibody as a potential therapeutic strategy for liver fibrosis and hepatocellular carcinoma	Alfred Long-Hin	Suen	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 3	4/18/23	9:00 AM	Section 19	5
3983	Defining the role of FANCA in breast cancer development and cell cycle progression	Liang	Luo	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 3	4/18/23	9:00 AM	Section 19	6
3984	NB compound FOXM1 inhibitors have potent anti-cancer activity in high-grade serous ovarian carcinoma	Makenzie	Vorderbruggen	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 3	4/18/23	9:00 AM	Section 19	7
3985	S100A10 promotes HCC development and progression via transfer in extracellular vesicles and regulating their protein cargos	Lu	TIAN	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 3	4/18/23	9:00 AM	Section 19	8
3986	Novel LIPA targeted therapy for treating ovarian cancer	Alexia	Collier	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 3	4/18/23	9:00 AM	Section 19	9
3987	Targeting nucleotide synthesizing enzyme dUTPase (DUT) represents a metabolic weakness and therapeutic opportunity in liver cancer	Yue	Liu	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 3	4/18/23	9:00 AM	Section 19	10

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
3988	The role of HER3 mutations in the progression of colon cancer and modulation of drug sensitivity and resistance	Mary	Kilroy	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 3	4/18/23	9:00 AM	Section 19	11
3989	EV11 oncogenic role in non-canonical AR driven lethal prostate cancer	Surendra	Gulla	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 3	4/18/23	9:00 AM	Section 19	12
3990	Imaging molecular alterations during tucatinib response in preclinical models of HER2+ breast cancer	Patrick	Song	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 3	4/18/23	9:00 AM	Section 19	13
3991	NOS inhibition enhances docetaxel-mediated anti-tumor effect in obese mice with triple negative breast cancer	Ivonne	Uzair	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 3	4/18/23	9:00 AM	Section 19	14
3992	Elucidating reciprocal interactions between bone marrow stromal cells and a novel $\gamma\delta$ CAR T cell therapy in the context of bone metastatic prostate cancer	Jeremy	Frieling	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 3	4/18/23	9:00 AM	Section 19	15
3993	In vivo efficacy of an anti-human IL11RA antibody in B-hIL11RA mice with APAP-induced liver damage	Mari	Kuraguchi	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 3	4/18/23	9:00 AM	Section 19	16
3994	Differential regulation of hormone receptors and Ki67 in luminal breast carcinomas and tumor-adjacent mammary glands by mifepristone treatment	Leo	Saldain	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 3	4/18/23	9:00 AM	Section 19	17
3995	Trastuzumab deruxtecan, antibody-drug conjugate targeting HER2, effectively inhibits growth of patient-derived xenograft model with CIC-rearranged sarcoma	Yuki	Kojima	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 3	4/18/23	9:00 AM	Section 19	18
3996	The impact of HER3 dynamics on the efficacy of HER3-DXd, a novel HER3 directed antibody-drug conjugate	Nagiho	Komatsu	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 3	4/18/23	9:00 AM	Section 19	19
3997	Preclinical characterization of ARX517, a next-generation anti-PSMA antibody drug conjugate for the treatment of metastatic castration-resistant prostate cancer	Lillian	Skidmore	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 3	4/18/23	9:00 AM	Section 19	20
3998	Metronomic gemcitabine plus neratinib effectively inhibits the growth of human Her-2 positive breast cancer cells intracranially implanted into immunodeficient mice	Giulio	Francia	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 3	4/18/23	9:00 AM	Section 19	21
3999	Combination of T-DXd with the irreversible pan-HER TKI afatinib drives combination benefit in HER2-low gastric and lung tumors	Deepa	Bhavsar	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 3	4/18/23	9:00 AM	Section 19	22
4000	A novel pegylated bispecific antibody-drug conjugate (P-BsADC) targeting Her2+ cancers with improved efficacy and therapeutic window	Yu (Yvonne)	Wen	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 3	4/18/23	9:00 AM	Section 19	23
4004	Targeting drug-resistant acute myeloid leukemia (AML) cells using novel casein kinase II (CK2) inhibitor	Koby	Duke	Poster	Tyrosine Kinase and Phosphatase Inhibitors 1	4/18/23	9:00 AM	Section 20	1
4005	PH009-1, a highly potent and selective fourth-generation EGFR-TKI overcoming EGFR common mutations and T790M/C797S-mediated resistance in NSCLC	Feng	Gao	Poster	Tyrosine Kinase and Phosphatase Inhibitors 1	4/18/23	9:00 AM	Section 20	2

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
4006	TRX-221, a novel 4th-generation EGFR inhibitor for overcoming C797S mutation-mediated acquired resistance in NSCLC	Sumin	Lim	Poster	Tyrosine Kinase and Phosphatase Inhibitors 1	4/18/23	9:00 AM	Section 20	3
4007	Efficacy of vepafestinin in preclinical models of RET fusion-driven sarcoma models	Romel	Somwar	Poster	Tyrosine Kinase and Phosphatase Inhibitors 1	4/18/23	9:00 AM	Section 20	4
4008	TAS2940, a novel brain-penetrable pan-ERBB inhibitor, exhibits tumor regression and prolongs survival in intracranial models bearing ERBB aberrations	Kei	Oguchi	Poster	Tyrosine Kinase and Phosphatase Inhibitors 1	4/18/23	9:00 AM	Section 20	5
4009	Discovery of PLM-102, a highly potent 3rd generation FLT3 inhibitor, in drug-resistant FLT3-ITD-TKD mutated acute myeloid leukemia	Jae-Seon	Lee	Poster	Tyrosine Kinase and Phosphatase Inhibitors 1	4/18/23	9:00 AM	Section 20	6
4010	Inhibition of PERK by HC-5404 sensitizes clear cell renal cell carcinoma tumor models to anti-angiogenic tyrosine kinase inhibitors	Michael	Stokes	Poster	Tyrosine Kinase and Phosphatase Inhibitors 1	4/18/23	9:00 AM	Section 20	7
4011	Preferential cytotoxicity of ESK981 in neuroendocrine prostate cancer	Yang	Zheng	Poster	Tyrosine Kinase and Phosphatase Inhibitors 1	4/18/23	9:00 AM	Section 20	8
4012	Preclinical development of SHP2 allosteric inhibitor ICP-189	Davy	Ouyang	Poster	Tyrosine Kinase and Phosphatase Inhibitors 1	4/18/23	9:00 AM	Section 20	9
4013	Combination of BTK inhibitor orelabrutinib, anti-CD19 antibody tafasitamab, and IMiD lenalidomide for the treatment of B cell malignancies	Davy	Ouyang	Poster	Tyrosine Kinase and Phosphatase Inhibitors 1	4/18/23	9:00 AM	Section 20	10
4014	Comparative biochemical kinase activity analysis identifies rivoceranib as the most selective VEGFR-2 inhibitor compared with other TKIs with known activity against VEGFR-2	Seong	Jang	Poster	Tyrosine Kinase and Phosphatase Inhibitors 1	4/18/23	9:00 AM	Section 20	11
4015	EGFR activation via c-Jun axis promotes adaptive resistance to third generation ALK-TKI lorlatinib in ALK-rearranged non-small cell lung cancer cells	Yuki	Katayama	Poster	Tyrosine Kinase and Phosphatase Inhibitors 1	4/18/23	9:00 AM	Section 20	12
4016	Discovery of a small-molecule EGFR inhibitor that can potently target various EGFR mutants, including C797S mutant, in vitro and in vivo	Sang Kyun	Lim	Poster	Tyrosine Kinase and Phosphatase Inhibitors 1	4/18/23	9:00 AM	Section 20	13
4017	TAS2940 inhibits intracranial tumor growth and prolongs survival in HER2-aberrant and EGFR-amplified patient-derived xenograft models	Jing	Han	Poster	Tyrosine Kinase and Phosphatase Inhibitors 1	4/18/23	9:00 AM	Section 20	14
4018	BBT-207 is a broad-spectrum, highly potent, 4th generation EGFR TKI with enhanced activity to both sensitizing and treatment-emergent EGFR mutations including T790M and C797S	Jimmy	Jin	Poster	Tyrosine Kinase and Phosphatase Inhibitors 1	4/18/23	9:00 AM	Section 20	15

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
4019	Preclinical Activity of ELVN-002: A Potent, Selective, Irreversible and CNS Penetrant HER2 and pan-HER2 Mutant Small-Molecule Inhibitor for the Treatment of HER2-Driven Malignancies	Monette	Aujay	Poster	Tyrosine Kinase and Phosphatase Inhibitors 1	4/18/23	9:00 AM	Section 20	16
4020	HMPL-760 is a highly potent and selective reversible BTK inhibitor, targeting BTK and BTKC481S in B-cell malignancies	Jia	Hu	Poster	Tyrosine Kinase and Phosphatase Inhibitors 1	4/18/23	9:00 AM	Section 20	17
4021	CTS2016, a novel AXL/FLT3 inhibitor for targeting AML/MDS and solid tumors	Hui	Shi	Poster	Tyrosine Kinase and Phosphatase Inhibitors 1	4/18/23	9:00 AM	Section 20	18
4022	Preclinical intracranial activity of NVL-655 in an alectinib-resistant patient-derived model harboring EML4-ALK fusion with G1202R mutation	Anupong	Tangpeerachai kul	Poster	Tyrosine Kinase and Phosphatase Inhibitors 1	4/18/23	9:00 AM	Section 20	19
4023	Inhibiting GRP78 in non-small cell lung cancer with acquired resistance to EGFR-TKI	Jaewoo	Park	Poster	Tyrosine Kinase and Phosphatase Inhibitors 1	4/18/23	9:00 AM	Section 20	20
4024	Overcoming ALK resistance with covalent cysteine-reactive inhibitors in lung cancer	Diane	Yang	Poster	Tyrosine Kinase and Phosphatase Inhibitors 1	4/18/23	9:00 AM	Section 20	21
4027	TSN084, a multi-kinase inhibitor, overcomes acquired drug-resistant mutations of cMet, Trks, and Flt3, and displays broad activities against kinase oncotargets Axl, DDRs, and CDK8/19	Boyu	Zhong	Poster	Tyrosine Kinase and Phosphatase Inhibitors 2	4/18/23	9:00 AM	Section 21	1
4028	High-dose short-exposure of osimertinib robustly inhibits growth of patient-derived metastatic colorectal cancer organoids	Kirti	Iyer	Poster	Tyrosine Kinase and Phosphatase Inhibitors 2	4/18/23	9:00 AM	Section 21	2
4029	JIN-A04, highly effective tyrosine kinase inhibitor targeting HER2 exon 20 insertion mutations in NSCLC	Mi Ra	Yu	Poster	Tyrosine Kinase and Phosphatase Inhibitors 2	4/18/23	9:00 AM	Section 21	3
4030	Generation of profound anti-tumor immunity by AUR-109, a spectrum-selective tyrosine kinase inhibitor, either as a single agent or in combination with immune checkpoint inhibitors	Girish	Daginakatte	Poster	Tyrosine Kinase and Phosphatase Inhibitors 2	4/18/23	9:00 AM	Section 21	4
4031	In vivo studies demonstrate differences in target inhibition and anticancer efficacy between NXP900 and dasatinib in ovarian clear cell carcinoma model	Neil O.	Carragher	Poster	Tyrosine Kinase and Phosphatase Inhibitors 2	4/18/23	9:00 AM	Section 21	5
4032	Discovery of a potent, selective, and orally available SHP2 inhibitor that can penetrate blood-brain barrier	Miyeon	Kim	Poster	Tyrosine Kinase and Phosphatase Inhibitors 2	4/18/23	9:00 AM	Section 21	6
4033	Pan-exon mutant KIT inhibitor DCC-3009 demonstrates tumor regressions in preclinical gastrointestinal stromal tumor models	Bryan	Smith	Poster	Tyrosine Kinase and Phosphatase Inhibitors 2	4/18/23	9:00 AM	Section 21	7
4034	A potent and highly selective irreversible HER2 inhibitor for treating HER2-driven cancers	Chunmei	Zhao	Poster	Tyrosine Kinase and Phosphatase Inhibitors 2	4/18/23	9:00 AM	Section 21	8
4035	Preclinical activity of BAY 2927088 in HER2 mutant non-small cell lung cancer	Franziska	Siegel	Poster	Tyrosine Kinase and Phosphatase Inhibitors 2	4/18/23	9:00 AM	Section 21	9

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
4036	NMS-0963 is a novel potent, selective and orally available Syk inhibitor with promising preclinical activity in diffuse large B-cell lymphoma	Grazia	Saturno	Poster	Tyrosine Kinase and Phosphatase Inhibitors 2	4/18/23	9:00 AM	Section 21	10
4037	Doxazosin exerts anti-metastatic potential in triple-negative breast cancer via impairment of cancer stem-like features	Seongjae	Kim	Poster	Tyrosine Kinase and Phosphatase Inhibitors 2	4/18/23	9:00 AM	Section 21	11
4038	Discovery of potent and selective inhibitors of the protein tyrosine phosphatases PTPN2 and PTPN1 to trigger anti-tumor immunity through sensitization of tumor cells and activation of immune cells	Matthias	Versele	Poster	Tyrosine Kinase and Phosphatase Inhibitors 2	4/18/23	9:00 AM	Section 21	12
4039	RET overexpression is frequent in lung neuroendocrine tumors (NET) and associates with response to RET tyrosine kinase inhibitors (RET TKIs) in NET cell lines	Miguel	Molina-Vila	Poster	Tyrosine Kinase and Phosphatase Inhibitors 2	4/18/23	9:00 AM	Section 21	13
4040	Asciminib activates erythroid differentiation in K562 cell line	Hammad	Hassan	Poster	Tyrosine Kinase and Phosphatase Inhibitors 2	4/18/23	9:00 AM	Section 21	14
4041	The EML4-ALK fusion protein mediates reduced sensitivity to the combination of neratinib and dasatinib	Myra	Castel	Poster	Tyrosine Kinase and Phosphatase Inhibitors 2	4/18/23	9:00 AM	Section 21	15
4042	Role of individual HER family members and pan-HER targeting treatment strategy in NRG1 fusion positive cancer	Hibiki	Udagawa	Poster	Tyrosine Kinase and Phosphatase Inhibitors 2	4/18/23	9:00 AM	Section 21	16
4043	Stimulation of the mapk and pi3k/akt pathways in pancreatic cancer cells by polyisoprenylated cysteinyl amide inhibitors	Kweku	Oforu-Asante	Poster	Tyrosine Kinase and Phosphatase Inhibitors 2	4/18/23	9:00 AM	Section 21	17
4044	Development of UCT-01-097, a novel orally available ERK1/2 inhibitor for the treatment of ERK1/2 dependent cancers	Neil	O'Brien	Poster	Tyrosine Kinase and Phosphatase Inhibitors 2	4/18/23	9:00 AM	Section 21	18
4045	DCC-3084, a RAF dimer inhibitor, broadly inhibits BRAF class I, II, III, BRAF fusions, and RAS-driven solid tumors leading to tumor regression in preclinical models	Stacie	Bulfer	Poster	Tyrosine Kinase and Phosphatase Inhibitors 2	4/18/23	9:00 AM	Section 21	19
4049	TIDAL-01: A selected TIL process that enriches for neoantigen reactive TIL in solid tumors	Larissa	Pikor	Poster	Adoptive Cell and Natural Killer Cell Therapy	4/18/23	9:00 AM	Section 22	1
4051	Microfluidic incubation of patient derived tumor and immune cells boosts lymphocyte cytotoxic phenotype	Steven	Forsythe	Poster	Adoptive Cell and Natural Killer Cell Therapy	4/18/23	9:00 AM	Section 22	3
4052	Direct selection of PD1+ CD39+ tumor infiltrating lymphocytes (TIL) from tumor dissociates enrich for functional tumor-reactive cells	Christophe	Pedros	Poster	Adoptive Cell and Natural Killer Cell Therapy	4/18/23	9:00 AM	Section 22	4
4053	A mesothelin targeting chimeric antigen receptor macrophage (CAR-M) for solid tumor immunotherapy: pre-clinical development of CT-1119	Nicholas	Anderson	Poster	Adoptive Cell and Natural Killer Cell Therapy	4/18/23	9:00 AM	Section 22	5

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
4054	Macrophages engineered with cytokine switch receptors: Development of a modular platform for rebalancing inflammation in microenvironments	Chris	Sloas	Poster	Adoptive Cell and Natural Killer Cell Therapy	4/18/23	9:00 AM	Section 22	6
4055	CD40L stimulates melanoma infiltrating B cells and enhances ex vivo TIL expansion	Renata Ariza	Marques Rossetti	Poster	Adoptive Cell and Natural Killer Cell Therapy	4/18/23	9:00 AM	Section 22	7
4056	Intratumoral delivery of autologous tumor antigen specific CD4 Th1 cells combined with dendritic cells eradicates HER2 mammary carcinoma	Ganesan	Ramamoorthi	Poster	Adoptive Cell and Natural Killer Cell Therapy	4/18/23	9:00 AM	Section 22	8
4057	T cells co-expressing a highly potent NY-ESO-1-specific TCR and a chimeric PD1-41BB co-stimulatory switch receptor show a favorable polyfunctional profile for the treatment of solid tumors	Andrea	Coluccio	Poster	Adoptive Cell and Natural Killer Cell Therapy	4/18/23	9:00 AM	Section 22	9
4058	In vitro binding, efficacy and safety studies to support engineered T cell therapies	Gemma	Moiset	Poster	Adoptive Cell and Natural Killer Cell Therapy	4/18/23	9:00 AM	Section 22	10
4059	Developing an allogeneic iPSC derived macrophage cell therapy for oncology	Huafeng	Wang	Poster	Adoptive Cell and Natural Killer Cell Therapy	4/18/23	9:00 AM	Section 22	11
4060	Selective Neoantigens Peptide TILs (snapTILs): A next generation tumor infiltrating lymphocytes (TIL) therapy platform	Tithi	Ghosh Halder	Poster	Adoptive Cell and Natural Killer Cell Therapy	4/18/23	9:00 AM	Section 22	12
4061	Systemic autologous lymphocyte transfer can enhance tumor-infiltrating lymphocyte infiltration in glioblastoma and license co-stimulatory immunotherapy	Kirit	Singh	Poster	Adoptive Cell and Natural Killer Cell Therapy	4/18/23	9:00 AM	Section 22	13
4062	The discovery and development of a CRISPR/Cas9-engineered tumor-infiltrating lymphocytes product (GT316) as a next-generation TIL therapy	Yarong	Liu	Poster	Adoptive Cell and Natural Killer Cell Therapy	4/18/23	9:00 AM	Section 22	14
4063	Adoptive transfer of NF-kB p50 knockout immature myeloid cells shows a trend towards slower glioblastoma tumor growth in an orthotopic mouse model	Patrick	Beck	Poster	Adoptive Cell and Natural Killer Cell Therapy	4/18/23	9:00 AM	Section 22	15
4064	PD-1 blockade therapy enhances the antitumor effects of lymphodepletion and adoptive T cell transfer	Satoshi	Watanabe	Poster	Adoptive Cell and Natural Killer Cell Therapy	4/18/23	9:00 AM	Section 22	16
4065	Modulation of Trastuzumab antitumoral activity by co-culture with different T cell subtypes in 2D and 3D T cell killing assays targeting HER2+ breast cancer	Julia	Schueler	Poster	Adoptive Cell and Natural Killer Cell Therapy	4/18/23	9:00 AM	Section 22	17
4066	Lipid nanoparticle library towards development next generation genomic medicines	Samuel	Clarke	Poster	Adoptive Cell and Natural Killer Cell Therapy	4/18/23	9:00 AM	Section 22	18
4067	RNA primed SMAR-TTMcells against multiple driver mutations, all HLA's, designed for first line therapy	Alfred	Slanetz	Poster	Adoptive Cell and Natural Killer Cell Therapy	4/18/23	9:00 AM	Section 22	19
4068	Ganglioside SSEA4 in Ewing sarcoma: A marker of tumor cells with highly aggressive features and a potential immune target	Sareetha	Kailayangiri	Poster	Adoptive Cell and Natural Killer Cell Therapy	4/18/23	9:00 AM	Section 22	20

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
4070	Engineering TRAIL-expressing immune cells to target GI malignancies	Praveen	Srinivasan	Poster	Adoptive Cell and Natural Killer Cell Therapy	4/18/23	9:00 AM	Section 22	22
4071	Identification of myeloma-specific T cell receptors by functional single cell interaction analyses	Stefan	Eichmüller	Poster	Adoptive Cell and Natural Killer Cell Therapy	4/18/23	9:00 AM	Section 22	23
4072	Class I HLA-independent lysis of immunotherapy-resistant melanoma by CD8 T cells	Hongyan	Xie	Poster	Adoptive Cell and Natural Killer Cell Therapy	4/18/23	9:00 AM	Section 22	24
4073	Tunable STAT activation by synthetic pathway activators (SPAs) increases engineered T-cell potency and persistence	Beatriz	Millare	Poster	Adoptive Cell and Natural Killer Cell Therapy	4/18/23	9:00 AM	Section 22	25
4074	Cellular immunotherapy targeting kappa myeloma antigen for the treatment of multiple myeloma	Simon	Harrison	Poster	Adoptive Cell and Natural Killer Cell Therapy	4/18/23	9:00 AM	Section 22	26
4075	A modified FcγRI expressing-T cell, SolidT, enables antibody-mediated cytotoxicity to overcome the limitations of CAR-T cell therapy against solid tumors	Shahar	Dotan	Poster	Adoptive Cell and Natural Killer Cell Therapy	4/18/23	9:00 AM	Section 22	27
4076	4-1bb selection augments DC/AML fusion vaccine-educated T cells for adoptive cell therapy	Kathrine	Rallis*	Poster	Adoptive Cell and Natural Killer Cell Therapy	4/18/23	9:00 AM	Section 22	28
4077	Dual-targeted CAR-NK cell therapy: optimized CAR design to prevent antigen escape and elicit a deep and durable response in multiple myeloma	Cuiqing	Yang	Poster	Adoptive Cell and Natural Killer Cell Therapy	4/18/23	9:00 AM	Section 22	29
4078	Optimized chimeric antigen receptors (CARs) for CAR-NK cell therapies	Cuiqing	Yang	Poster	Adoptive Cell and Natural Killer Cell Therapy	4/18/23	9:00 AM	Section 22	30
4082	Impact of immunosuppressive monocytes on CART19 cell effector functions and outcomes	Kun	Yun	Poster	CAR T-cell Therapy 2	4/18/23	9:00 AM	Section 23	1
4083	In vivo efficacy of LGR5-targeting CAR-T cell therapies developed for the treatment of colorectal cancer	Dylan	McPeake	Poster	CAR T-cell Therapy 2	4/18/23	9:00 AM	Section 23	2
4084	Globo H-targeted CAR T cell cancer immunotherapy	Jiann-Shiun	Lai	Poster	CAR T-cell Therapy 2	4/18/23	9:00 AM	Section 23	4
4085	Development and in vitro validation of an LGR-5 targeting CAR-T against colorectal cancer	Veronika	Bandara	Poster	CAR T-cell Therapy 2	4/18/23	9:00 AM	Section 23	3
4086	Mitigating the CD5 CAR-CD5 interaction enhances the functionality of CD5 CAR-T cells by alleviating the T-cell fratricide	Lee	Young Ho	Poster	CAR T-cell Therapy 2	4/18/23	9:00 AM	Section 23	5
4087	Co-expression of membrane bound IL-15 enhanced anti-tumor response of CAR-T	Cuiqing	Yang	Poster	CAR T-cell Therapy 2	4/18/23	9:00 AM	Section 23	6
4088	A neovasculature-inducible CA9 CAR resistant to FASL and TGFβ mediated suppression for the treatment of ccRCC	Angela	Boroughs	Poster	CAR T-cell Therapy 2	4/18/23	9:00 AM	Section 23	7
4089	PanCAR-specific antibody-cytokine fusion proteins	John	Keane	Poster	CAR T-cell Therapy 2	4/18/23	9:00 AM	Section 23	8
4090	Regional administration of IL-12 endowed CAR T cells effectively targets systemic disease	Jackson	Gibson	Poster	CAR T-cell Therapy 2	4/18/23	9:00 AM	Section 23	9

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
4091	Engineered hypoimmune CAR T cells provide lasting tumor control in immunocompetent allogeneic humanized mice even with re-challenge	Xiaomeng	Hu	Poster	CAR T-cell Therapy 2	4/18/23	9:00 AM	Section 23	10
4092	Development of nucleotide metabolic reprogrammed CAR T cell therapy suitable for solid tumors	Yue	Hu	Poster	CAR T-cell Therapy 2	4/18/23	9:00 AM	Section 23	11
4093	Dual targeted CAR immunotherapy for neuroblastoma using $\gamma\delta$ T cells	Hunter	Jonus	Poster	CAR T-cell Therapy 2	4/18/23	9:00 AM	Section 23	12
4094	Enhanced CRISPR-Cas9 edited CAR-T cells through simultaneous inactivation of multiple T cell exhaustion pathways	Oksana	Sergeeva	Poster	CAR T-cell Therapy 2	4/18/23	9:00 AM	Section 23	13
4095	Preclinical characterization of switchable allogeneic chimeric antigen receptor T cells to support first in human clinical study in CD123-positive hematologic and lymphatic malignancies	Armin	Ehninger	Poster	CAR T-cell Therapy 2	4/18/23	9:00 AM	Section 23	14
4096	Assessing individual variability in efficacy and toxicity of autologous and allogeneic chimeric antigen receptor T-cell immunotherapy using a PBMC-humanized mouse model	Won	Lee	Poster	CAR T-cell Therapy 2	4/18/23	9:00 AM	Section 23	15
4097	Functional and translatable efficacy of CAR-T cells targeting B cell lymphomas	Robert	Nunan	Poster	CAR T-cell Therapy 2	4/18/23	9:00 AM	Section 23	16
4098	Chimeric antigen receptor (CAR) T cells overexpressing Bcl-xL increase proliferation and antitumor activity alone and in combination with BH3 mimetics	Felix	Korell	Poster	CAR T-cell Therapy 2	4/18/23	9:00 AM	Section 23	17
4099	Dual targeting of tumor cells and cancer associated fibroblasts enhances CAR T efficacy in solid tumors	Bo	Huang	Poster	CAR T-cell Therapy 2	4/18/23	9:00 AM	Section 23	18
4100	Co-stimulatory signaling boosts CAR T cell efficacy against chronic lymphocytic leukemia	Ziran	Zhao	Poster	CAR T-cell Therapy 2	4/18/23	9:00 AM	Section 23	19
4101	Control of orthotopic melanoma and breast tumor growth and metastases is achieved by alpha v beta3 CAR T cells and is augmented via PD-1 blockade	Dustin	Cobb	Poster	CAR T-cell Therapy 2	4/18/23	9:00 AM	Section 23	20
4102	attIL12-T cell therapy destructs cancer-associated fibroblasts and extracellular matrix in heterogenous osteosarcoma xenograft models	Jiemiao	Hu	Poster	CAR T-cell Therapy 2	4/18/23	9:00 AM	Section 23	21
4103	The IgG4 hinge with CD28 transmembrane domain improves VHH-based CAR T cells targeting a membrane-distal epitope of GPC1 in pancreatic cancer	Nan	Li	Poster	CAR T-cell Therapy 2	4/18/23	9:00 AM	Section 23	22
4104	Development of adoptive T-cell therapies to target heterogeneity of mCRPC	Lupita	Lopez	Poster	CAR T-cell Therapy 2	4/18/23	9:00 AM	Section 23	23

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
4105	Improvement of CD133-specific chimeric antigen receptor T cells by secreting anti-PD-L1 single-chain variable fragment against cholangiocarcinoma	Thanich	Sangsuwannuku I	Poster	CAR T-cell Therapy 2	4/18/23	9:00 AM	Section 23	24
4106	Non-autonomous enhancement of gPDL1 CAR-T annihilates TNBC development	Chia-Wei	Li	Poster	CAR T-cell Therapy 2	4/18/23	9:00 AM	Section 23	25
4107	Cytotoxic T cells armed with IL-4 receptor-targeting and PD-L1-blocking peptides inhibits lung tumor growth	Dong Gyun	Jo	Poster	CAR T-cell Therapy 2	4/18/23	9:00 AM	Section 23	26
4108	Transient epigenetic reprogramming enhances T-cell proliferation and tumor clearance	Mustafa	Turkoz	Poster	CAR T-cell Therapy 2	4/18/23	9:00 AM	Section 23	27
4112	Evaluating the survival outcomes of an anti-isoaspELAVL4 response in a small cell lung cancer mouse model	Diego	Velarde	Poster	Determinants of Immunotherapeutic Effectiveness	4/18/23	9:00 AM	Section 24	1
4113	Classification of patient-specific sensitivity to immunotherapies by ex vivo tumor testing	Lieke	Ceton	Poster	Determinants of Immunotherapeutic Effectiveness	4/18/23	9:00 AM	Section 24	2
4114	Can exosomal cargoes predict checkpoint inhibitor response in melanoma, and can we overcome drug resistance?	Pablo	Puente	Poster	Determinants of Immunotherapeutic Effectiveness	4/18/23	9:00 AM	Section 24	3
4115	KLRG1 marks tumor-infiltrating CD4 T cell subsets associated with immune escape and immunotherapy response	Casey	Ager	Poster	Determinants of Immunotherapeutic Effectiveness	4/18/23	9:00 AM	Section 24	4
4116	Modulating gut microbiota to improve intrahepatic immunity against hepatocellular cancer	Xiaogiang	Qi	Poster	Determinants of Immunotherapeutic Effectiveness	4/18/23	9:00 AM	Section 24	5
4117	Molecular insights into resistance mechanisms to therapy with T cell bispecific antibodies	Marina	Bacac	Poster	Determinants of Immunotherapeutic Effectiveness	4/18/23	9:00 AM	Section 24	6
4118	The role of microRNAs in the tumor immune microenvironment	Robert	Seitz	Poster	Determinants of Immunotherapeutic Effectiveness	4/18/23	9:00 AM	Section 24	7
4120	Depletion of tissue-resident B cells by a CD20xCD3 IgM bispecific T cell engager in cynomolgus monkeys demonstrates effective tissue penetration and potent target cell killing	Miho	Oyasu	Poster	Determinants of Immunotherapeutic Effectiveness	4/18/23	9:00 AM	Section 24	9
4121	Heterogenous cellular responses to GITR and TIGIT immunotherapy in the human gastrointestinal tumor microenvironment	Anuja	Sathe	Poster	Determinants of Immunotherapeutic Effectiveness	4/18/23	9:00 AM	Section 24	10
4122	TIL-containing patient-derived explant cultures reveal role of metformin on antigen presenting cell activation	Rita	Turpin	Poster	Determinants of Immunotherapeutic Effectiveness	4/18/23	9:00 AM	Section 24	11
4123	Rhus verniciflua Stokes (RVS) inhibits PD-1 expression and induces anticancer effects via enhancing T-cell function	Seoyoung	Kim	Poster	Determinants of Immunotherapeutic Effectiveness	4/18/23	9:00 AM	Section 24	12
4124	Targeting the clock pathway to modulate immune response in MSI-high colorectal cancer (CRC): evidence from a preclinical in vivo model	Shivani	Soni	Poster	Determinants of Immunotherapeutic Effectiveness	4/18/23	9:00 AM	Section 24	13

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
4125	Rencofilstat exerts a dominant role in synergistic anti-PD1-combination effects in a fatty liver model of hepatocellular carcinoma	Daren	Ure	Poster	Determinants of Immunotherapeutic Effectiveness	4/18/23	9:00 AM	Section 24	14
4126	Anti-tumor immunity of M9657, a conditional CD137 immune agonist, is correlated with mesothelin expression on tumor cells	Chunxiao	Xu	Poster	Determinants of Immunotherapeutic Effectiveness	4/18/23	9:00 AM	Section 24	15
4127	ANV600 is a potent, Cis-signaling, non-alpha IL-2 agonist which efficiently expands intratumoral stem-like CD8 T cells	Patrizia	Murer	Poster	Determinants of Immunotherapeutic Effectiveness	4/18/23	9:00 AM	Section 24	16
4128	AJ17 potentiates agonist CD40 antibody efficacy and attenuates agonist CD40 induced PD-L1 expression and associated toxicity in murine tumor models	Vidit	Gaur	Poster	Determinants of Immunotherapeutic Effectiveness	4/18/23	9:00 AM	Section 24	17
4129	Preclinical assessment of GlycoConnect™ ADCs with potency-modulated derivatives of PNU-159,682	Floris	van Delft	Poster	Determinants of Immunotherapeutic Effectiveness	4/18/23	9:00 AM	Section 24	18
4130	Genetically modified hematopoietic stem cells for improvement of immunotherapies against solid malignancies	Laura	Falceto Font	Poster	Determinants of Immunotherapeutic Effectiveness	4/18/23	9:00 AM	Section 24	19
4131	Long-term anti-tumor immunity induced by of HPN328, a DLL3-targeting trispecific, half-life extended T cell engager, in a preclinical immunocompetent mouse model	Banmeet	Anand	Poster	Determinants of Immunotherapeutic Effectiveness	4/18/23	9:00 AM	Section 24	20
4132	Effect of mechanical cues on T cell killing of cancer cells	Hannah	Dada	Poster	Determinants of Immunotherapeutic Effectiveness	4/18/23	9:00 AM	Section 24	21
4133	OncoTAM, a comprehensive preclinical platform to explore macrophages as key drivers of cancer progression and develop new therapies against tumor-associated-macrophages	Olivier	Duchamp	Poster	Determinants of Immunotherapeutic Effectiveness	4/18/23	9:00 AM	Section 24	22
4134	Boosting anti-tumor immunity by promoting high endothelial venule and tertiary lymphoid structure formation in solid tumors via LTBR agonism	Disi	An	Poster	Determinants of Immunotherapeutic Effectiveness	4/18/23	9:00 AM	Section 24	23
4135	A novel plasma cell-based mechanism of action of adenosine immunomodulation and A2AR antagonism	Maura	Rossetti	Poster	Determinants of Immunotherapeutic Effectiveness	4/18/23	9:00 AM	Section 24	24
4139	Functional human myeloid cells in BRGSF-HIS humanized mice enables myeloid-directed therapy assessment	Fabiane	Sônego	Poster	Developments in Anticancer Immunotherapy	4/18/23	9:00 AM	Section 25	1
4140	Oncogenic KRAS inhibition with ADT-007 primes T cell responses in pancreatic ductal adenocarcinoma	Jeremy	Foote	Poster	Developments in Anticancer Immunotherapy	4/18/23	9:00 AM	Section 25	2
4141	Effects of exercise on tumorigenesis, immune system, and the gut microbiome in a bladder carcinogen mouse model	Joseph	LaMorte	Poster	Developments in Anticancer Immunotherapy	4/18/23	9:00 AM	Section 25	3
4142	CD4 T cell-driven response to immunotherapy against mouse melanoma tumors	Amy	Erbe	Poster	Developments in Anticancer Immunotherapy	4/18/23	9:00 AM	Section 25	4
4143	Enhancing adaptive immune responses with telomerase-mediated telomere targeting therapeutics in hepatocellular carcinoma	Ann Marie	Flusche	Poster	Developments in Anticancer Immunotherapy	4/18/23	9:00 AM	Section 25	5

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
4144	Characterization of immune cell phenotypes in patient derived malignant pleural effusion treated with thioestrepton	Brian	Cunniff	Poster	Developments in Anticancer Immunotherapy	4/18/23	9:00 AM	Section 25	6
4145	Frizzled-4 expression enhances hepatocellular carcinoma progression, sorafenib resistance and suppresses anti-tumor CD8 T cell immunity	Jie	Luo	Poster	Developments in Anticancer Immunotherapy	4/18/23	9:00 AM	Section 25	7
4146	Unlocking IO drug potential by high content imaging of immune cell co-cultures with cancer organoids from diverse cancer indications	Saskia	de Man	Poster	Developments in Anticancer Immunotherapy	4/18/23	9:00 AM	Section 25	8
4147	Activated pyroptosis prior to treatment marks a potential response to immunotherapy in cancers	Huichuan	Yu	Poster	Developments in Anticancer Immunotherapy	4/18/23	9:00 AM	Section 25	9
4148	Immunophenotyping of responses to immunotherapy in syngeneic tumor models using multiplex immunofluorescence compared to multiparametric flow cytometry	Philipp	Metzger	Poster	Developments in Anticancer Immunotherapy	4/18/23	9:00 AM	Section 25	10
4149	Anti-CTLA-4 generates memory T-cells with greater expansion and functionality than anti-PD-1	Stephen	Mok	Poster	Developments in Anticancer Immunotherapy	4/18/23	9:00 AM	Section 25	11
4150	Novel preclinical model for the evaluation of cytokine release syndrome in response to CD19xCD3 bispecific antibody in humanized mice	Deep	Shah	Poster	Developments in Anticancer Immunotherapy	4/18/23	9:00 AM	Section 25	12
4151	Anti-CEACAM5 immune stimulant TLR7/8 agonist antibody drug conjugate is a potent myeloid cell activator for the treatment of CEACAM5-expressing tumors	Stephanie	Decary	Poster	Developments in Anticancer Immunotherapy	4/18/23	9:00 AM	Section 25	13
4152	Longitudinal local and peripheral immunologic changes associated with PD-L1 response in a murine breast cancer model	Ann	Hanna	Poster	Developments in Anticancer Immunotherapy	4/18/23	9:00 AM	Section 25	14
4153	SETD2 loss and ATR inhibition synergistically promote cGAS signaling and immunotherapy response in renal cell carcinoma	Xiande	Liu	Poster	Developments in Anticancer Immunotherapy	4/18/23	9:00 AM	Section 25	15
4154	mRNA-based immunotherapies to treat women's cancers	Dan	Tse	Poster	Developments in Anticancer Immunotherapy	4/18/23	9:00 AM	Section 25	16
4155	The RAF/MEK clamp avutometinib (VS-6766) induces an immunogenic tumor microenvironment and potentiates the efficacy of anti-PD-1	Jonathan	Pachter	Poster	Developments in Anticancer Immunotherapy	4/18/23	9:00 AM	Section 25	17
4156	Site specific tumor response to combination chemotherapy and immune checkpoint inhibitor in the syngeneic Pan02 pancreatic ductal adenocarcinoma model	Patrick	Fadden	Poster	Developments in Anticancer Immunotherapy	4/18/23	9:00 AM	Section 25	18
4157	Tumor context dictates reliance on TCF1 for response to immunotherapy	Giulia	Escobar	Poster	Developments in Anticancer Immunotherapy	4/18/23	9:00 AM	Section 25	19

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
4158	Selective targeting of CD122 combined with radiotherapy triggers CD8 and NK mediated immunity, abrogating metastasis in head and neck squamous cell carcinoma	Jacob	Gadwa	Poster	Developments in Anticancer Immunotherapy	4/18/23	9:00 AM	Section 25	20
4159	The COX-2/PGE2 pathway as a mediator of resistance to anti-PD-1 therapy	Shuming	Chen	Poster	Developments in Anticancer Immunotherapy	4/18/23	9:00 AM	Section 25	21
4160	Characterization of cytotoxic resilient T cells in patients with advanced cancers in response to salvage radiation therapy or chemotherapy	Haidong	Dong	Poster	Developments in Anticancer Immunotherapy	4/18/23	9:00 AM	Section 25	22
4162	T-cell metabolic profiling with bioluminescent assays	Maggie	Bach	Poster	Developments in Anticancer Immunotherapy	4/18/23	9:00 AM	Section 25	24
4163	Enhanced immune response according to different radiation fractionations in colorectal cancer cell lines	Sang Jun	Byun	Poster	Developments in Anticancer Immunotherapy	4/18/23	9:00 AM	Section 25	25
4164	Relieving immune suppressive pathways in breast cancer to improve outcomes	Amanda	Poissonnier	Poster	Developments in Anticancer Immunotherapy	4/18/23	9:00 AM	Section 25	26
4165	A systemically administered killed bacteria-based multiple immune receptor agonist for pulsed anti-tumor immunotherapy	Michael	Newman	Poster	Developments in Anticancer Immunotherapy	4/18/23	9:00 AM	Section 25	27
4166	Effects of cyproheptadine in eliciting natural killer cell-mediated immune response in bladder cancer	Himani	Kumari	Poster	Developments in Anticancer Immunotherapy	4/18/23	9:00 AM	Section 25	28
4167	Translational control of T cell exhaustion in melanoma, perspectives in therapeutics	Caroline	Robert	Poster	Developments in Anticancer Immunotherapy	4/18/23	9:00 AM	Section 25	29
4168	BALB/c-CD3EDG HuGEMTM mouse model for evaluation of CD3-targeted tumor immunotherapy	Demi	Liu	Poster	Developments in Anticancer Immunotherapy	4/18/23	9:00 AM	Section 25	30
4172	Serum PVT1 exon 9 copy number is a better predictor of positive prostate biopsy in Black and Hispanic men than serum prostate specific antigen	Emmanuel	Asante-Asamani	Poster	Cancer Screening and Health Equity	4/18/23	9:00 AM	Section 28	1
4173	Lipidome of mammographic breast density in premenopausal women	Kayla	Getz	Poster	Cancer Screening and Health Equity	4/18/23	9:00 AM	Section 28	2
4174	Incorporating continuous mammographic density into the BOADICEA breast cancer risk prediction model	Lorenzo	Ficorella	Poster	Cancer Screening and Health Equity	4/18/23	9:00 AM	Section 28	3
4175	Development of breast cancer risk assessment tool: The Korean decision aid for cancer screening (K-DACS) study	Wonyoung	Jung	Poster	Cancer Screening and Health Equity	4/18/23	9:00 AM	Section 28	4
4176	Timing of pregnancy-related factors and breast cancer risk for women across a range of absolute risk	Jasmine	McDonald	Poster	Cancer Screening and Health Equity	4/18/23	9:00 AM	Section 28	5
4177	Genetic testing for hereditary colorectal cancer syndromes in Algerian patients: A multicenter study	Farid	Cherbal	Poster	Cancer Screening and Health Equity	4/18/23	9:00 AM	Section 28	6
4178	Lysosomal storage dysfunction as a risk factor in pancreatic cancer	Hyemin	Kim	Poster	Cancer Screening and Health Equity	4/18/23	9:00 AM	Section 28	7

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
4179	Anal cancer risk factors and utilization of cancer preventive strategies in people living with HIV in Puerto Rico	Sandra	Garcia-Camacho	Poster	Cancer Screening and Health Equity	4/18/23	9:00 AM	Section 28	8
4180	Knowledge and barriers to colorectal cancer screenings in people experiencing homelessness in Central Florida	Harini	Sankar	Poster	Cancer Screening and Health Equity	4/18/23	9:00 AM	Section 28	9
4181	Geospatial heterogeneity in colorectal cancer screening among Hispanic subgroups	Robert	Buchalter	Poster	Cancer Screening and Health Equity	4/18/23	9:00 AM	Section 28	10
4182	Genetic associations with smoking relapse and proportion of follow-up in relapse throughout adulthood in pre- and post-menopausal women	Stephanie	Jones	Poster	Cancer Screening and Health Equity	4/18/23	9:00 AM	Section 28	11
4183	Employment status moderates the relationship between patient-provider communication and prostate cancer screening among Black men	Brian	Carter	Poster	Cancer Screening and Health Equity	4/18/23	9:00 AM	Section 28	12
4184	Congruent views among substance use treatment center leadership on organizational readiness to implement a tobacco-free workplace program is linked to provider uptake of non-cigarette tobacco use treatment	Brian	Carter	Poster	Cancer Screening and Health Equity	4/18/23	9:00 AM	Section 28	13
4185	Inclusive basic and advanced translational laboratory research competencies for research in cancer biology and therapeutics	Wafik	El-Deiry	Poster	Cancer Screening and Health Equity	4/18/23	9:00 AM	Section 28	14
4186	Underrepresentation of low- and middle-income country affiliated authors in NCI-supported cancer research	Linsey	Eldridge	Poster	Cancer Screening and Health Equity	4/18/23	9:00 AM	Section 28	15
4187	Development of a virtual platform to improve global access to oncology education & combat healthcare inequities	William	Wilkerson	Poster	Cancer Screening and Health Equity	4/18/23	9:00 AM	Section 28	16
4188	Multifaceted approach to engaging basic cancer scientists in community-based research	Namoonga	Mantina	Poster	Cancer Screening and Health Equity	4/18/23	9:00 AM	Section 28	17
4189	Community cancer scientist program: A model for community member advocacy for cancer research	Brooke	Hensel	Poster	Cancer Screening and Health Equity	4/18/23	9:00 AM	Section 28	18
4190	Current educational needs in the management of patients with advanced NSCLC: Results of a US case-based survey	Emily	Belcher	Poster	Cancer Screening and Health Equity	4/18/23	9:00 AM	Section 28	19
4191	Assessing performance of biomarker extraction from electronic health records: Data augmentation methods for a hierarchical self-attention network (HiSAN)	Shalini	Priya	Poster	Cancer Screening and Health Equity	4/18/23	9:00 AM	Section 28	20
4192	CervicalMethDx: A precision DNA methylation test to identify advanced disease risk in cervical cancer screening algorithms	Laura	Palmieri	Poster	Cancer Screening and Health Equity	4/18/23	9:00 AM	Section 28	21
4193	N-NOSE technology based on C. elegans olfaction. Multi-cancer early detection with high sensitivity using urine. Pancreatic-cancer-specific early detection with high sensitivity using urine	Eric	Di Luccio	Poster	Cancer Screening and Health Equity	4/18/23	9:00 AM	Section 28	22

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
4194	The FuSion Project of Pan-Cancer Early Screening in Chinese-- An integrative study by Fudan University and Singlera	Chen	Suo	Poster	Cancer Screening and Health Equity	4/18/23	9:00 AM	Section 28	23
4195	Spatially resolved single cell transcriptomic profiling in formalin-fixed paraffin-embedded (FFPE) tissues	Jiang	He	Poster	Cancer Screening and Health Equity	4/18/23	9:00 AM	Section 28	24
4200	Association between reproductive factors with lung cancer incidence and mortality: A pooled analysis of over 308,000 females in the Asia Cohort Consortium	Aesun	Shin	Poster	Descriptive Epidemiology and Environmental Risk Factors	4/18/23	9:00 AM	Section 29	1
4201	Associations of pre-diagnostic serum liver enzymes levels with lung cancer risk: results from the Southern Community Cohort Study	Shuai	Xu	Poster	Descriptive Epidemiology and Environmental Risk Factors	4/18/23	9:00 AM	Section 29	2
4202	Kidney function and risk of renal cell carcinoma	Karine	Alcala	Poster	Descriptive Epidemiology and Environmental Risk Factors	4/18/23	9:00 AM	Section 29	3
4203	A prospective study of birth weight and prostate cancer risk: extended analysis in the Health Professionals Follow-up Study	Qinran	Liu	Poster	Descriptive Epidemiology and Environmental Risk Factors	4/18/23	9:00 AM	Section 29	4
4204	Incidence of early-onset and average-onset colon cancer among Medicaid beneficiaries with and without HIV: a cohort study	Keri	Calkins	Poster	Descriptive Epidemiology and Environmental Risk Factors	4/18/23	9:00 AM	Section 29	5
4205	Profiling symptom burden of RAS and BRAF mutations in patients with colorectal cancer: Results from the ColoCare Study	Gazelle	Rouhani	Poster	Descriptive Epidemiology and Environmental Risk Factors	4/18/23	9:00 AM	Section 29	6
4206	The impact of two decades of multidisciplinary efforts to reduce the risk of recurrence from colorectal cancer - a Danish population-based registry-study	Jesper	Nors	Poster	Descriptive Epidemiology and Environmental Risk Factors	4/18/23	9:00 AM	Section 29	7
4207	Systematic review and meta-analysis of cancer incidence after blood transfusion in the general population	Youjin	Oh	Poster	Descriptive Epidemiology and Environmental Risk Factors	4/18/23	9:00 AM	Section 29	8
4208	Incidence of papillary thyroid cancer: comparison of the military with the general population by race, gender, and tumor stage/size	Julie	Bytnar	Poster	Descriptive Epidemiology and Environmental Risk Factors	4/18/23	9:00 AM	Section 29	9
4209	Cancers of unknown primary: survival by histologic type, demographic features, and treatment in the US Military Health System	Julie	Bytnar	Poster	Descriptive Epidemiology and Environmental Risk Factors	4/18/23	9:00 AM	Section 29	10
4210	Over 10 years since HPV vaccine approval, awareness of the causal link between HPV and HPV-associated cancers remains low in the US	Eric	Adjei Boakye	Poster	Descriptive Epidemiology and Environmental Risk Factors	4/18/23	9:00 AM	Section 29	11
4211	Geospatial analyses identify hot spots of late-stage cervical cancer at diagnosis in Texas	Itunu	Sokale	Poster	Descriptive Epidemiology and Environmental Risk Factors	4/18/23	9:00 AM	Section 29	12
4212	Comparison of thirty-year population-based incidence rates of invasive lobular vs ductal vs mixed breast carcinoma in Ontario, Canada	David	Lim	Poster	Descriptive Epidemiology and Environmental Risk Factors	4/18/23	9:00 AM	Section 29	13

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
4213	Comparison of benign breast disease subtypes and breast cancer risk among Hispanic and non-Hispanic white women in New Mexico	Kush	Lohani	Poster	Descriptive Epidemiology and Environmental Risk Factors	4/18/23	9:00 AM	Section 29	14
4214	Exposure to air pollution during pregnancy and risk of premenopausal breast cancer: A Swedish nation-wide cohort study including more than 1 million women	Jessica	Edlund	Poster	Descriptive Epidemiology and Environmental Risk Factors	4/18/23	9:00 AM	Section 29	15
4215	Air pollution exposure during pregnancy and risk of premenopausal breast cancer among women with a family history of cancer	Anna	Hettinger	Poster	Descriptive Epidemiology and Environmental Risk Factors	4/18/23	9:00 AM	Section 29	16
4216	Interactions of greenness with air pollution in relation to postmenopausal breast cancer risk in UK Biobank	Carmen	Smotherman	Poster	Descriptive Epidemiology and Environmental Risk Factors	4/18/23	9:00 AM	Section 29	17
4217	Cumulative environmental quality is associated with breast cancer incidence differentially by summary stage and urbanicity	Larisa	Gearhart-Serna	Poster	Descriptive Epidemiology and Environmental Risk Factors	4/18/23	9:00 AM	Section 29	18
4218	Cancer prevalence among Ohio firefighters: data from the Ohio Cancer Incidence Surveillance System (OCISS) 1996-2019	Susan	Olivo-Marston	Poster	Descriptive Epidemiology and Environmental Risk Factors	4/18/23	9:00 AM	Section 29	19
4219	Smoky coal exposure is associated with epigenetic accelerated aging	Batel	Blechter	Poster	Descriptive Epidemiology and Environmental Risk Factors	4/18/23	9:00 AM	Section 29	20
4220	Occupational pesticide use and relative leukocyte telomere length in the biomarkers of exposure and effect in agriculture study	Patricia	Erickson	Poster	Descriptive Epidemiology and Environmental Risk Factors	4/18/23	9:00 AM	Section 29	21
4221	Aflatoxin exposure in a population-based representative sample of adults in Mexico in 2018	Martin	Lajous	Poster	Descriptive Epidemiology and Environmental Risk Factors	4/18/23	9:00 AM	Section 29	22
4222	Glyphosate and AMPA exposure: Associations with dietary intake and other factors	Hannah	Park	Poster	Descriptive Epidemiology and Environmental Risk Factors	4/18/23	9:00 AM	Section 29	23
4223	A metabolomic investigation of serum perfluorooctane sulfonate and perfluorooctanoate	Jongeun	Rhee	Poster	Descriptive Epidemiology and Environmental Risk Factors	4/18/23	9:00 AM	Section 29	24
4224	University of Chicago Comprehensive Cancer Center catchment area informatics platform	Ahmed	Fadiel Metwaly	Poster	Descriptive Epidemiology and Environmental Risk Factors	4/18/23	9:00 AM	Section 29	25
4228	Replacing red and processed meat with legumes modulates gut microbiome and microbiota-related metabolites linked to gut health and cancer prevention in healthy working-aged men	Tuulia	Pietilä	Poster	Diet, Nutrition, Lifestyle, and Environment and Cancer Prevention	4/18/23	9:00 AM	Section 30	1
4229	Differential impact of rice bran based dietary interventions during inflammation-associated colorectal cancer on distinct immune infiltrates and their spatial distribution signature	Robin	Kumar	Poster	Diet, Nutrition, Lifestyle, and Environment and Cancer Prevention	4/18/23	9:00 AM	Section 30	2
4230	Transcriptomic evaluation of exercise-induced suppression of prostate cancer aggressiveness	Darpan	Patel	Poster	Diet, Nutrition, Lifestyle, and Environment and Cancer Prevention	4/18/23	9:00 AM	Section 30	3

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
4231	The anti-cancer effects of vitamin D are blocked postpartum due to suppression of vitamin D metabolism in the liver	Sarah	Bernhardt	Poster	Diet, Nutrition, Lifestyle, and Environment and Cancer Prevention	4/18/23	9:00 AM	Section 30	4
4232	Dairy product consumption across the life course and breast cancer risk	Emily	Riseberg	Poster	Diet, Nutrition, Lifestyle, and Environment and Cancer Prevention	4/18/23	9:00 AM	Section 30	5
4233	The anti-genotoxic function of Lactobacillus species in the context of bile-mediated DNA damage and inflammation in experimental models of GERD	Joshua	Bernard	Poster	Diet, Nutrition, Lifestyle, and Environment and Cancer Prevention	4/18/23	9:00 AM	Section 30	6
4234	Effects of age-diet interactions on colorectal cancer (CRC) progression in mice	Jae	Lo	Poster	Diet, Nutrition, Lifestyle, and Environment and Cancer Prevention	4/18/23	9:00 AM	Section 30	7
4235	Obesity drives inflammation and metabolic reprogramming in an orthotopic mouse model of early colon cancer	Elaine	Glenny	Poster	Diet, Nutrition, Lifestyle, and Environment and Cancer Prevention	4/18/23	9:00 AM	Section 30	8
4236	Obesity-associated endometrial cancer: Identifying the contributions of TMEM205 expression to the pathogenesis of disease	Takahiko	Sakaue	Poster	Diet, Nutrition, Lifestyle, and Environment and Cancer Prevention	4/18/23	9:00 AM	Section 30	9
4237	Social isolation induces gut dysbiosis, mitochondrial metabolic dysfunction, and infiltration of tumor immunosuppressive cells: Do they explain enhanced mammary tumorigenesis?	Fabia	Andrade	Poster	Diet, Nutrition, Lifestyle, and Environment and Cancer Prevention	4/18/23	9:00 AM	Section 30	10
4238	Specific oral microbiome is closely associated with oral potentially malignant disorders and oral squamous cell carcinoma	Mitomu	Kioi	Poster	Diet, Nutrition, Lifestyle, and Environment and Cancer Prevention	4/18/23	9:00 AM	Section 30	11
4239	Alternate-day fasting enhances the activity of anti-androgen therapy in prostate cancer models	Ricardo	Cordova	Poster	Diet, Nutrition, Lifestyle, and Environment and Cancer Prevention	4/18/23	9:00 AM	Section 30	12
4240	Tumor PD-L1 induction associated with dietary protein restriction is modulated by PERK activation	Ricardo	Cordova	Poster	Diet, Nutrition, Lifestyle, and Environment and Cancer Prevention	4/18/23	9:00 AM	Section 30	13
4241	Reducing your risk cancer-focused health events to meaningfully engage the medically underserved and diminish future cancer disparities	Melinda	Butsch Kovacic	Poster	Diet, Nutrition, Lifestyle, and Environment and Cancer Prevention	4/18/23	9:00 AM	Section 30	14
4242	High sugar food consumption and breast cancer risk in a prospective cohort study	Woo-Kyoung	Shin	Poster	Diet, Nutrition, Lifestyle, and Environment and Cancer Prevention	4/18/23	9:00 AM	Section 30	15

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
4243	Dietary flavonoids prevent colon tumor formation in ApcMin/+ mice in a microbiome- and sex-dependent manner	Jan	Claesen	Poster	Diet, Nutrition, Lifestyle, and Environment and Cancer Prevention	4/18/23	9:00 AM	Section 30	16
4244	Black soybean seed coat extract suppress intestinal tumorigenesis in APCmin mice	Yasuyuki	Shimizu	Poster	Diet, Nutrition, Lifestyle, and Environment and Cancer Prevention	4/18/23	9:00 AM	Section 30	17
4245	Effects of black raspberries extract on DNA repair capacity and metabolic activation/detoxification of the tobacco carcinogen dibenzo[def,p] in human oral cells	Yuan-Wan	Sun	Poster	Diet, Nutrition, Lifestyle, and Environment and Cancer Prevention	4/18/23	9:00 AM	Section 30	18
4246	Synergistic inhibition of prostate tumor growth and progression by the combination of curcumin and ursolic acid in HiMyc mice	Chelsea	Friedman	Poster	Diet, Nutrition, Lifestyle, and Environment and Cancer Prevention	4/18/23	9:00 AM	Section 30	19
4247	Impact of 70% ethanol intraductal injections in MNU rat models for breast cancer prevention	Erin	Zaluzec	Poster	Diet, Nutrition, Lifestyle, and Environment and Cancer Prevention	4/18/23	9:00 AM	Section 30	20
4248	Epithelial ovarian cancer causes cardiac dysfunction and myofilament dysregulation	Leslie	Ogilvie	Poster	Diet, Nutrition, Lifestyle, and Environment and Cancer Prevention	4/18/23	9:00 AM	Section 30	21
4252	CCNE1 amplification in high-grade serous ovarian cancer: analysis of the GENIE database	Shaden	Tashtoush	Poster	AACR Project GENIE Use Cases	4/18/23	9:00 AM	Section 31	1
4253	Pan-cancer analysis of XPO1 R749Q mutations across 217,570 patients reveals association with high tumor mutational burden and therapy resistance	Tulasigeri	Totiger	Poster	AACR Project GENIE Use Cases	4/18/23	9:00 AM	Section 31	2
4254	The ratio of key metabolic transcripts is a predictive biomarker of breast cancer metastasis to the lung	Deepti	Mathur	Poster	AACR Project GENIE Use Cases	4/18/23	9:00 AM	Section 31	3
4255	Concurrent KRAS and TP53 mutations in pancreatic cancer real-world data (RWD) highlight convergent tumor evolutionary patterns	Kaumudi	Bhawe	Poster	AACR Project GENIE Use Cases	4/18/23	9:00 AM	Section 31	4
4256	cBioPortal for Cancer Genomics	Ino	de Bruijn	Poster	AACR Project GENIE Use Cases	4/18/23	9:00 AM	Section 31	5
4257	Using Multilevel Regression and Poststratification (MRP) to inform estimates of biomarker prevalence for target populations of interest using linked clinico-genomic databases	Jeremy	Snider	Poster	AACR Project GENIE Use Cases	4/18/23	9:00 AM	Section 31	6
4259	Identification of anti-neoplastic therapy given before initial visit at a referral center using natural language processing applied to medical oncology initial consultation notes	Thinh	Tran	Poster	AACR Project GENIE Use Cases	4/18/23	9:00 AM	Section 31	8
4260	Understanding genomic and social determinants of cancer immunotherapy outcome across ancestry	Christopher	Fong	Poster	AACR Project GENIE Use Cases	4/18/23	9:00 AM	Section 31	9

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
4261	Genomic landscape of 2128 thyroid cancers from the aacr genie database: Implications for targeted therapies	Blessie	Nelson	Poster	AACR Project GENIE Use Cases	4/18/23	9:00 AM	Section 31	10
4262	Genomic profiling of uveal melanoma patients using the GENIE database	Shaden	Tashtoush	Poster	AACR Project GENIE Use Cases	4/18/23	9:00 AM	Section 31	11
4263	Anti-Siglec 7 antibody displays potent anti-tumor immunity and demonstrates improved tumor control in combination with anti-PD1 in ovarian cancer	Devivasha	Bordoloi	Poster	AACR Project GENIE Use Cases	4/18/23	9:00 AM	Section 31	12
4264	The genomic landscape of RET fusions in non-small cell lung cancer and the impact of co-occurring genomic alterations on the efficacy of selective RET inhibitors	Tuqa	Al Khalaf	Poster	AACR Project GENIE Use Cases	4/18/23	9:00 AM	Section 31	13
4265	Humanized 3D tumor models that are mutationally aligned with AACR GENIE patients predict IMM-1-104 activity in RAS-addicted tumors	Brett	Hall	Poster	AACR Project GENIE Use Cases	4/18/23	9:00 AM	Section 31	14
4266	Genomic landscape of prostate cancer: Bioinformatic analysis of TCGA PanCancer data by race and identification of key pathways and genes in PTEN mutation	Olumide	Arigbede	Poster	AACR Project GENIE Use Cases	4/18/23	9:00 AM	Section 31	15
4270	Prediction of cancer transcriptomes from whole-slide images with Vis-Gene	Christian	Wohlfart	Poster	Algorithms and Statistical Methods	4/18/23	9:00 AM	Section 32	1
4271	A new methodological approach to discovering biomarkers of mammographic breast density using pathway-guided lipid amalgamation	Chongliang	Luo	Poster	Algorithms and Statistical Methods	4/18/23	9:00 AM	Section 32	2
4272	Pan-cancer analysis of intra-tumor heterogeneity in 9,116 cancers using a novel regularized likelihood model	Yujie	Jiang	Poster	Algorithms and Statistical Methods	4/18/23	9:00 AM	Section 32	3
4273	Integration with benchmark data of paired bulk and single-cell RNA sequencing data substantially improves the accuracy of bulk tissue deconvolution	Shuai	Guo	Poster	Algorithms and Statistical Methods	4/18/23	9:00 AM	Section 32	4
4274	Functional dissection of complex tissue microenvironment using spatial transcriptomics data	Xinyu	Zhou	Poster	Algorithms and Statistical Methods	4/18/23	9:00 AM	Section 32	5
4275	Averon: informatics platform to discover Actionable Vulnerabilities Enabled by Rewired Oncogenic Networks	Andrey	Ivanov	Poster	Algorithms and Statistical Methods	4/18/23	9:00 AM	Section 32	6
4276	Recovering false negatives in CRISPR fitness screens with JLOE	Merve	Dede	Poster	Algorithms and Statistical Methods	4/18/23	9:00 AM	Section 32	7
4277	Measuring proliferation rates of distinct tumour clones using single-cell DNA sequencing	Olivia	Lucas	Poster	Algorithms and Statistical Methods	4/18/23	9:00 AM	Section 32	8
4278	Transcriptome-driven combination design: A computational approach	Christina	Gavazzi	Poster	Algorithms and Statistical Methods	4/18/23	9:00 AM	Section 32	9
4279	Method for identifying microsatellite instability high DNA abnormality samples	Rosalía	Aguirre-Hernández	Poster	Algorithms and Statistical Methods	4/18/23	9:00 AM	Section 32	10

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
4280	Automatic identification of cancer cell-cell interfaces at the pixel level	Jie	Zhou	Poster	Algorithms and Statistical Methods	4/18/23	9:00 AM	Section 32	11
4281	Data driven refinement of gene signatures for enrichment analysis and cell state characterization	Alexander	Wenzel	Poster	Algorithms and Statistical Methods	4/18/23	9:00 AM	Section 32	12
4282	Total RNA sequencing of frozen biopsies combined to k-mer sequence analysis identify new hallmarks of immune checkpoint therapy response in melanoma	Caroline	Robert	Poster	Algorithms and Statistical Methods	4/18/23	9:00 AM	Section 32	13
4283	scMSI: Accurately detect the sub-clonal micro-satellite instability by an integrative Bayesian model	Jiayin	Wang	Poster	Algorithms and Statistical Methods	4/18/23	9:00 AM	Section 32	14
4284	Enhancing subclonal reconstruction algorithm for resolving complex tumor phylogenies from multi-sample tumor DNA sequencing	Helena	Winata	Poster	Algorithms and Statistical Methods	4/18/23	9:00 AM	Section 32	15
4286	A statistical learning method for simultaneous copy number estimation and subclone clustering with single cell sequencing data	Feifei	Xiao	Poster	Algorithms and Statistical Methods	4/18/23	9:00 AM	Section 32	17
4287	The combination of statistical methods to compare observed and simulated data allowed to assess effectively the validity of mathematical model predictions in a context of a EGFR+ lung adenocarcinoma	Evgueni	Jacob	Poster	Algorithms and Statistical Methods	4/18/23	9:00 AM	Section 32	18
4288	Predicting DNA methylation in cervical cancer using somatic mutations in a classified mixed model prediction	Jairo	Ramos	Poster	Algorithms and Statistical Methods	4/18/23	9:00 AM	Section 32	19
4289	Long-read, assembly-based characterization of rearranged cancer karyotypes	Mikhail	Kolmogorov	Poster	Algorithms and Statistical Methods	4/18/23	9:00 AM	Section 32	20
4290	ReCorDE: A novel computational framework to discover potential combinations of anti-cancer drugs	Emily	Ghose	Poster	Algorithms and Statistical Methods	4/18/23	9:00 AM	Section 32	21
4291	Deconvolution of cell type composition in FFPE tissue: Application to benign breast disease	Yuanhang	Liu	Poster	Algorithms and Statistical Methods	4/18/23	9:00 AM	Section 32	22
4292	Gene model correction for PVRIG and TIGIT in single cell sequencing data enables accurate detection and study of its functional relevance	Zurit	Levine	Poster	Algorithms and Statistical Methods	4/18/23	9:00 AM	Section 32	23
4293	Strategies and resources for applying a quantitative multiplex IHC imaging workflow to characterize immune contexture in solid tumors	Shamilene	Sivagnanam	Poster	Algorithms and Statistical Methods	4/18/23	9:00 AM	Section 32	24
4294	Bridging the gap between targeted NGS and FISH gene-level CNV detection capabilities in hematologic malignancies	Christophe	Magnan	Poster	Algorithms and Statistical Methods	4/18/23	9:00 AM	Section 32	25
4295	Streamlining the reconstruction of subclonal evolution in DNA sequencing data	Gage	Black	Poster	Algorithms and Statistical Methods	4/18/23	9:00 AM	Section 32	26

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
4296	Fast de novo antibody structure prediction with atomic accuracy	Hui	Li	Poster	Algorithms and Statistical Methods	4/18/23	9:00 AM	Section 32	27
4297	OFFONOME: a new notion of genes' on/off	Wonyoung	Choi	Poster	Algorithms and Statistical Methods	4/18/23	9:00 AM	Section 32	28
4298	Machine learning-based model for survival prediction after immunotherapy in patients with solid tumor	Salma	Fala	Poster	Algorithms and Statistical Methods	4/18/23	9:00 AM	Section 32	29
4299	Gene expression based machine learning classifier to predict and validate cancer type in patient derived xenograft (PDX) models	Warren	Andrews	Poster	Algorithms and Statistical Methods	4/18/23	9:00 AM	Section 32	30
4303	High-throughput 3D tumoroid models for immunotherapy and drug discovery	W. Gregory	Sawyer	Poster	Integrative Cancer Systems Biology	4/18/23	9:00 AM	Section 33	1
4304	Network-based inference identifies cell state-specific drugs targeting master regulator vulnerabilities in diffuse midline glioma	Ester	Calvo Fernandez	Poster	Integrative Cancer Systems Biology	4/18/23	9:00 AM	Section 33	2
4305	Germline structural variants shape prostate cancer clinical and molecular evolution	Nicholas	Wang	Poster	Integrative Cancer Systems Biology	4/18/23	9:00 AM	Section 33	3
4306	Identifying genetic dependencies of replication stress using interpretable artificial intelligence	Akshat	Singhal	Poster	Integrative Cancer Systems Biology	4/18/23	9:00 AM	Section 33	4
4307	Integrative molecular subtypes of acute myeloid leukemia	Qianxing (Quincy)	Mo	Poster	Integrative Cancer Systems Biology	4/18/23	9:00 AM	Section 33	5
4308	Cancer as a disease of information	Adam	Goldstein	Poster	Integrative Cancer Systems Biology	4/18/23	9:00 AM	Section 33	6
4309	Early apoptotic measurements of patient-derived organoids predict patient response to therapy	Kelley	McQueeney	Poster	Integrative Cancer Systems Biology	4/18/23	9:00 AM	Section 33	7
4310	Ultra high-plex spatial proteogenomic investigation of giant cell glioblastoma multiforme immune infiltrates reveals distinct protein and RNA expression profiles	Shilah	Bonnett	Poster	Integrative Cancer Systems Biology	4/18/23	9:00 AM	Section 33	8
4311	Using multiomics analysis to identify dysregulated transcription factors in non-small cell lung cancer (NSCLC) to drive the expression of a cancer-activated synthetic biomarker	David	Suhy	Poster	Integrative Cancer Systems Biology	4/18/23	9:00 AM	Section 33	9
4312	Identification of shared mutations across many parallel human and canine cancers based on comprehensive survey of canine cancer mutations and the "caninization" of human mutations from COSMIC	William	Hendricks	Poster	Integrative Cancer Systems Biology	4/18/23	9:00 AM	Section 33	10
4313	A novel gene regulatory network model identifies master regulators in cancer	Praneeth Reddy	Sudalagunta	Poster	Integrative Cancer Systems Biology	4/18/23	9:00 AM	Section 33	11
4314	CEACAM7 an early detection biomarker for pancreatic ductal adenocarcinoma	Anupam	Dhasmana	Poster	Integrative Cancer Systems Biology	4/18/23	9:00 AM	Section 33	12
4315	Exploring the relationship of SSTR2 immunohistochemical and textural features to neuroendocrine tumor grade	Leah	Sherbansky	Poster	Integrative Cancer Systems Biology	4/18/23	9:00 AM	Section 33	13

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
4316	Identification of tertiary lymphoid structures from H&E slides using deep learning analysis of nuclear morphology is associated with favorable survival in colorectal cancer patients	Ettai	Markovits	Poster	Integrative Cancer Systems Biology	4/18/23	9:00 AM	Section 33	14
4317	Comparison of Single-Molecule Flow (SiM-Flow) and qRT-PCR for detection of plasma miR-375 and miR-1290 in metastatic castrate-resistant prostate cancer (mCRPC)	Manish	Kohli	Poster	Integrative Cancer Systems Biology	4/18/23	9:00 AM	Section 33	15
4318	Cancer cell communication with macrophages prevents T cell activation during emergence of cell cycle therapy resistance	Jason	Griffiths	Poster	Integrative Cancer Systems Biology	4/18/23	9:00 AM	Section 33	16
4319	The need for new publication standards in cancer genomics, lessons from curating COSMIC database	Alexander	Holmes	Poster	Integrative Cancer Systems Biology	4/18/23	9:00 AM	Section 33	17
4320	A novel digitally directed tissue microdissection platform integrates digital pathology with molecular analysis: Case study in metastatic colorectal cancer.	John	Butler	Poster	Integrative Cancer Systems Biology	4/18/23	9:00 AM	Section 33	18
4321	Clinical-grade early detection of esophageal cancer on data from a non-endoscopic device using deep learning	Adam	Berman	Poster	Integrative Cancer Systems Biology	4/18/23	9:00 AM	Section 33	19
4322	AI assisted detection and characterization of tertiary lymphoid structures in patients with colorectal cancer	Samantha	Burg	Poster	Integrative Cancer Systems Biology	4/18/23	9:00 AM	Section 33	20
4326	Predictive value of CXCL10 for the occurrence of immune related adverse events in patient with renal cell carcinoma	Yuji	Miura	Poster	Biomarkers of Therapeutic Benefit 4	4/18/23	9:00 AM	Section 37	1
4327	MSI cancer associated DNA (TA)n-dinucleotide repeat expansions and implications for Werner synthetic lethality	Gabriele	Picco	Poster	Biomarkers of Therapeutic Benefit 4	4/18/23	9:00 AM	Section 37	2
4329	Combined extracellular vesicle PD-L1 and radiomics as predictors of response in patients with advanced lung cancer undergoing immunotherapy	Murat	Ak	Poster	Biomarkers of Therapeutic Benefit 4	4/18/23	9:00 AM	Section 37	4
4330	A CD5 signature identifies diffuse large B-cell lymphomas (DLBCLs) sensitive to Bruton's tyrosine kinase (BTK) inhibition	Alan	Cooper	Poster	Biomarkers of Therapeutic Benefit 4	4/18/23	9:00 AM	Section 37	5
4331	Comprehensive analysis of copy number variation and sensitivity to targeted therapy in renal cell carcinoma using in-house cancer gene panel testing	Akhito	Takeuchi	Poster	Biomarkers of Therapeutic Benefit 4	4/18/23	9:00 AM	Section 37	6
4332	Characterizing cancer-associated fibroblasts in prostate cancer using Vizgen's MERSCOPETM Platform	Ben	Patterson	Poster	Biomarkers of Therapeutic Benefit 4	4/18/23	9:00 AM	Section 37	7
4333	Spatial analysis of tumor-infiltrating lymphocytes in tumor microenvironment as biomarker for immune checkpoint inhibition in biliary tract cancer	Yeong Hak	Bang	Poster	Biomarkers of Therapeutic Benefit 4	4/18/23	9:00 AM	Section 37	8
4334	Clever-1/PD-L1 ratio predicts response to Bexmarilimab, a novel macrophage-guided immunotherapy, in immune deprived cancers	Elisa	Vuorinen	Poster	Biomarkers of Therapeutic Benefit 4	4/18/23	9:00 AM	Section 37	9

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
4335	Repurposing metformin in early-stage high risk prostate cancer to avoid ADT-induced cardiovascular toxicity	Philip	Gregory	Poster	Biomarkers of Therapeutic Benefit 4	4/18/23	9:00 AM	Section 37	10
4336	Automation of proximity ligation immunoassay for interaction between PDL1 and PD1 detection in the tumor microenvironment using microfluidic based system	Agata	Zieba Wicher	Poster	Biomarkers of Therapeutic Benefit 4	4/18/23	9:00 AM	Section 37	11
4337	Predicting PD-L1 status in solid tumors using transcriptomic data and artificial intelligence algorithms	Ahmad	Charifa	Poster	Biomarkers of Therapeutic Benefit 4	4/18/23	9:00 AM	Section 37	12
4339	Development of new droplet digital PCR method for MSI assessment with automated analysis pipeline shows concordance in FFPE and plasma	Sarah	Kreston	Poster	Biomarkers of Therapeutic Benefit 4	4/18/23	9:00 AM	Section 37	14
4340	HLA-B44 motif neoepitope is associated with a favorable tumor immune microenvironment and predicts ICB response in NSCLC	Rui	Li	Poster	Biomarkers of Therapeutic Benefit 4	4/18/23	9:00 AM	Section 37	15
4341	Indoleamine 2,3-dioxygenase 1 is highly expressed in tertiary lymphoid structures and associated with improved outcome in patients with advanced non-small cell lung cancer treated with anti-PD1/PDL1 inhibitors	Jean-Philippe	Guegan	Poster	Biomarkers of Therapeutic Benefit 4	4/18/23	9:00 AM	Section 37	16
4342	Predictive precision medicine platform accurately predicts individual patient response to AML treatments to maximize outcomes	Meagan	Jacoby	Poster	Biomarkers of Therapeutic Benefit 4	4/18/23	9:00 AM	Section 37	17
4343	Development of an APC and TP53-based duplex sequencing assay to positively predict colorectal cancer response to EGFR inhibitors	Mingli	Yang	Poster	Biomarkers of Therapeutic Benefit 4	4/18/23	9:00 AM	Section 37	18
4344	Consensus genomic subtypes of gastric adenocarcinoma and their therapeutic implication	Yun Seong	Jeong	Poster	Biomarkers of Therapeutic Benefit 4	4/18/23	9:00 AM	Section 37	19
4345	Molecular pathology studies reveal PD1+ CD8 T cell density correlates with response to supraphysiological testosterone treatment in pre-treatment biopsies and MYC mRNA and protein correlate with response after treatment	Carolina	Gomes Alexandre	Poster	Biomarkers of Therapeutic Benefit 4	4/18/23	9:00 AM	Section 37	20
4346	TFF1 and TFF3 predict response to CDK4/6 inhibitors in breast cancer patients	Linjie	Luo	Poster	Biomarkers of Therapeutic Benefit 4	4/18/23	9:00 AM	Section 37	21
4347	A pivotal clinical trial of cResponse, a functional assay for cancer precision medicine	Seth	Salpeter	Poster	Biomarkers of Therapeutic Benefit 4	4/18/23	9:00 AM	Section 37	22
4348	Validation of an integrative pan-solid tumor predictor of pembrolizumab monotherapy benefit	Benjamin	Bulen	Poster	Biomarkers of Therapeutic Benefit 4	4/18/23	9:00 AM	Section 37	23
4349	C-C chemokine receptor 2-positive monocytic myeloid-derived suppressor cells predicts chemotherapeutic responses of the metastatic lesions in breast cancer patients	Serk In	Park	Poster	Biomarkers of Therapeutic Benefit 4	4/18/23	9:00 AM	Section 37	24

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
4350	Pharmacodynamic biomarkers: Evaluation of oncology drug target engagement in human plucked scalp and beard hair	Greg	Tudor	Poster	Biomarkers of Therapeutic Benefit 4	4/18/23	9:00 AM	Section 37	25
4351	Multiplex detection of G12/G13 KRAS mutations with an electrochemiluminescent hybridization assay	Annamaria	Szabolcs	Poster	Biomarkers of Therapeutic Benefit 4	4/18/23	9:00 AM	Section 37	26
4352	Leveraging deep proteome profiling of plasma- and serum-derived extracellular vesicles for melanoma biomarker discovery and disease dissection	Yuehan	Feng	Poster	Biomarkers of Therapeutic Benefit 4	4/18/23	9:00 AM	Section 37	27
4353	Utilizing scRNA sequencing to understand biomarkers of response and resistance to Sacituzumab Govetican in localized TNBC	Nicole	Peiris	Poster	Biomarkers of Therapeutic Benefit 4	4/18/23	9:00 AM	Section 37	28
4354	An exosome-based ESR1 monitoring RT-qPCR technology that rapidly and accurately detects circulating tumor acquired resistance variants at $\leq 0.1\%$ frequency in liquid biopsy samples	Sarah	Statt	Poster	Biomarkers of Therapeutic Benefit 4	4/18/23	9:00 AM	Section 37	29
4355	Prediction of cancer treatment response from histopathology images for a broad set of treatments and indications	Gal	Dinstag	Poster	Biomarkers of Therapeutic Benefit 4	4/18/23	9:00 AM	Section 37	30
4358	Glucagon-like peptide 1 agonist use and the progression of monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans with diabetes mellitus	Nikhil	Grandhi	Poster	Cancer Outcomes 2	4/18/23	9:00 AM	Section 38	1
4359	Interventions to improve pathologic nodal staging of curatively resected lung cancer: A population-based implementation study	Meredith	Ray	Poster	Cancer Outcomes 2	4/18/23	9:00 AM	Section 38	2
4360	Opioid, non-opioid, and non-pharmacological pain management in patients with a history of cancer	Oyomoare	Osazuwa-Peters	Poster	Cancer Outcomes 2	4/18/23	9:00 AM	Section 38	3
4361	The plasma proteome as a cardiovascular disease risk assessment tool in cancer survivors	Jessica	Kuzma	Poster	Cancer Outcomes 2	4/18/23	9:00 AM	Section 38	4
4363	Monocyte-specific epigenetic age acceleration and cardiomyopathy risk among survivors of childhood cancer	Cheng	Chen	Poster	Cancer Outcomes 2	4/18/23	9:00 AM	Section 38	6
4364	Cost-effectiveness analysis of abemaciclib and endocrine therapy combination for the adjuvant treatment of HR+/HER2-, node-positive, high-risk, early breast cancer	Ashna	Talwar	Poster	Cancer Outcomes 2	4/18/23	9:00 AM	Section 38	7
4365	Comorbidities at diagnosis are associated with poor outcomes among pediatric acute lymphoblastic leukemia and lymphoblastic lymphoma patients	Maua	Mosha	Poster	Cancer Outcomes 2	4/18/23	9:00 AM	Section 38	8
4367	The MD Anderson Symptom Inventory (MDASI) survey discloses persistent moderate to high-level symptoms in cancer survivors	Katherine	Gilmore	Poster	Cancer Outcomes 2	4/18/23	9:00 AM	Section 38	10
4368	Symptom network identification from anxious and depressive groups in colorectal cancer patients	Jinah	Sim	Poster	Cancer Outcomes 2	4/18/23	9:00 AM	Section 38	11
4369	The effects of primary hepatocellular carcinoma surgical resection on five year survival rates among different races	Jingwei	Song	Poster	Cancer Outcomes 2	4/18/23	9:00 AM	Section 38	12

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
4370	How much time is needed to complete quality of life assessments in oncology trials? - Metadata analysis	Jowita	Marszewska	Poster	Cancer Outcomes 2	4/18/23	9:00 AM	Section 38	13
4371	iCCaRe: Social determinants of health navigation, psycho-oncology, and emotional support for Black prostate cancer survivors: Review of current practices	Dottington	Fullwood	Poster	Cancer Outcomes 2	4/18/23	9:00 AM	Section 38	14
4372	Hierarchy of prognostic quality markers after curative-intent resection of stage IA non-small cell lung cancer	Huibo	Shao	Poster	Cancer Outcomes 2	4/18/23	9:00 AM	Section 38	15
4373	Venetoclax-based therapy in treatment-naïve and relapsed/refractory acute myeloid leukemia	Aditya	Ravindra	Poster	Cancer Outcomes 2	4/18/23	9:00 AM	Section 38	16
4374	Patient provider communication about the use of medical cannabis for cancer symptoms	Kea	Turner	Poster	Cancer Outcomes 2	4/18/23	9:00 AM	Section 38	17
4375	A bootstrapping method to optimize go/no-go decisions from single-arm, signal-finding studies in oncology	Aparna	Mohan	Poster	Cancer Outcomes 2	4/18/23	9:00 AM	Section 38	18
4376	A correlation of soluble HLA serum levels with clinical data and survival in patients with invasive breast cancer after neoadjuvant treatment	Christian	Tegeler	Poster	Cancer Outcomes 2	4/18/23	9:00 AM	Section 38	19
4377	Economic burden of lung cancer patients in the emergency department	Jayla	Hsiung	Poster	Cancer Outcomes 2	4/18/23	9:00 AM	Section 38	20
4378	Risk factors for death in the emergency department for melanoma patients	Jayla	Hsiung	Poster	Cancer Outcomes 2	4/18/23	9:00 AM	Section 38	21
4379	Survival among adults diagnosed with secondary acute myeloid leukemia	Ephrem	Sedeta	Poster	Cancer Outcomes 2	4/18/23	9:00 AM	Section 38	22
4380	Pre- and postoperative fecal microbiota and its association with complications after surgery in colon cancer patients	Dieuwertje	Kok	Poster	Cancer Outcomes 2	4/18/23	9:00 AM	Section 38	23
4381	Predictive risk factors for cancer thrombosis in gastric cancer patients	Song Ee	Park	Poster	Cancer Outcomes 2	4/18/23	9:00 AM	Section 38	24
4382	Evolution of curative-intent lung cancer surgery in a 4 eras in the population-based mid-south quality of surgical resection (MS-QSR) cohort	Raymond	Osarogiagbon	Poster	Cancer Outcomes 2	4/18/23	9:00 AM	Section 38	25
4383	Development and validation of the Lung Cancer-Health Index (LC-HI), a clinically-relevant, disease-specific patient-reported outcome measure	Anika	Varma	Poster	Cancer Outcomes 2	4/18/23	9:00 AM	Section 38	26
4384	Does progressive disease justify pembrolizumab discontinuation: a simulation analysis	Kannan	Thiagarajan	Poster	Cancer Outcomes 2	4/18/23	9:00 AM	Section 38	27
4385	Unprecedented tumor: immune interaction--clinical and drug-development implications	Farah	Mazahreh	Poster	Cancer Outcomes 2	4/18/23	9:00 AM	Section 38	28

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
4386	Comparison of cytotoxicity of anthracycline based antineoplastic drugs in breast cancer	Mitali	Singhal	Poster	Cancer Outcomes 2	4/18/23	9:00 AM	Section 38	29
4387	Total toxicity burden of FDA approved immune checkpoint inhibitors in USA	Yong	Teng	Poster	Cancer Outcomes 2	4/18/23	9:00 AM	Section 38	30
4391	Real world data and multi-genomic analysis of non-common mutations in the EGFR mutation-positive non-small cell lung cancer	Seoree	Kim	Poster	Clinical Informatics and Data Science / Retrospective Clinical Analyses 1	4/18/23	9:00 AM	Section 39	1
4392	Expression landscape of trophoblast cell surface antigen 2 (Trop-2) in breast cancer	Kai	Song	Poster	Clinical Informatics and Data Science / Retrospective Clinical Analyses 1	4/18/23	9:00 AM	Section 39	2
4393	Tumor volumetric analysis to correlate disease burden with response to dual immune checkpoint blockade in metastatic NSCLC	Muhammad	Aminu	Poster	Clinical Informatics and Data Science / Retrospective Clinical Analyses 1	4/18/23	9:00 AM	Section 39	3
4394	Feasibility analysis of querying EHR databases for cancer clinical trial criteria	Yonah	Ziemba	Poster	Clinical Informatics and Data Science / Retrospective Clinical Analyses 1	4/18/23	9:00 AM	Section 39	4
4396	TROP2 expression in non-small cell lung cancer	Peiwen	Kuo	Poster	Clinical Informatics and Data Science / Retrospective Clinical Analyses 1	4/18/23	9:00 AM	Section 39	6
4397	Chemotherapy-induced peripheral neuropathy and falls in cancer survivors relate to digital balance and gait impairments	Vrutangkumar	Shah	Poster	Clinical Informatics and Data Science / Retrospective Clinical Analyses 1	4/18/23	9:00 AM	Section 39	7
4398	Validation of an updated algorithm to identify non-small cell lung cancer (NSCLC) patients in administrative claims databases	Sandip	Patel	Poster	Clinical Informatics and Data Science / Retrospective Clinical Analyses 1	4/18/23	9:00 AM	Section 39	8
4399	Can technology improve the quality and efficiency of multidisciplinary cancer conferences?	Oporuiche	Ibekwe	Poster	Clinical Informatics and Data Science / Retrospective Clinical Analyses 1	4/18/23	9:00 AM	Section 39	9
4400	Machine learning (ML) on real-world data (RWD) of front-line (1L) metastatic castration resistance prostate cancer (mCRPC) patients for dynamic prediction of time to tx discontinuation (TTD)	Prerna	Jain	Poster	Clinical Informatics and Data Science / Retrospective Clinical Analyses 1	4/18/23	9:00 AM	Section 39	10
4401	The precision chemotherapy to improve the epithelial ovarian cancer prognosis	Youn Jin	Choi	Poster	Clinical Informatics and Data Science / Retrospective Clinical Analyses 1	4/18/23	9:00 AM	Section 39	11
4402	Survival impact of post-operative immunotherapy in resected stage III cutaneous melanomas in the checkpoint era	Garo	Hagopian	Poster	Clinical Informatics and Data Science / Retrospective Clinical Analyses 1	4/18/23	9:00 AM	Section 39	12

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
4403	The Efficacy of Immune Checkpoint Inhibitors in Advanced Biliary Tract Cancer with KRAS Mutation	Sun Young	Jeong	Poster	Clinical Informatics and Data Science / Retrospective Clinical Analyses 1	4/18/23	9:00 AM	Section 39	16
4404	Survival impact and trends of immunotherapy use in metastatic merkel cell carcinoma in the checkpoint era: analysis of a large database	Christopher	Grant	Poster	Clinical Informatics and Data Science / Retrospective Clinical Analyses 1	4/18/23	9:00 AM	Section 39	17
4405	Tumor mutational burden, as a potential predictive marker for the efficacy of immunotherapy in advanced gastric cancer	Jaeyeon	Jang	Poster	Clinical Informatics and Data Science / Retrospective Clinical Analyses 1	4/18/23	9:00 AM	Section 39	18
4406	Impact of site of metastases on response to immunotherapy in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)	Marwan	Fakih	Poster	Clinical Informatics and Data Science / Retrospective Clinical Analyses 1	4/18/23	9:00 AM	Section 39	19
4407	Clinicopathologic characteristics and mutational analysis of MYC amplified head and neck squamous cell carcinoma (HNSCC)	Thomas	Cyberski	Poster	Clinical Informatics and Data Science / Retrospective Clinical Analyses 1	4/18/23	9:00 AM	Section 39	20
4408	Provisional prognostic score for monomorphic epitheliotropic T-Cell lymphoma	Philip	Haddad	Poster	Clinical Informatics and Data Science / Retrospective Clinical Analyses 1	4/18/23	9:00 AM	Section 39	21
4409	Survival determinants of aggressive adult T-cell leukemia/lymphoma (ATLL): analysis of a pooled database	Philip	Haddad	Poster	Clinical Informatics and Data Science / Retrospective Clinical Analyses 1	4/18/23	9:00 AM	Section 39	22
4410	Determinants of progression-free and overall survival of angioimmunoblastic T-Cell lymphoma (AITL): a pooled analysis	Philip	Haddad	Poster	Clinical Informatics and Data Science / Retrospective Clinical Analyses 1	4/18/23	9:00 AM	Section 39	23
4411	Clinicopathologic determinants of survival in enteropathy-associated T-cell lymphoma (EATL): analysis of a pooled database	Philip	Haddad	Poster	Clinical Informatics and Data Science / Retrospective Clinical Analyses 1	4/18/23	9:00 AM	Section 39	24
4416	IL-1 blockade prevents cardiac toxicity and improves immunotherapy efficacy	Nilesh	Talele	Poster	Immunomodulatory Agents and Interventions	4/18/23	9:00 AM	Section 40	2
4417	Activity of novel RNA therapeutics to overcome resistance to immune checkpoint blockade	Spyro	Mousses	Poster	Immunomodulatory Agents and Interventions	4/18/23	9:00 AM	Section 40	3
4418	Heterogeneity of IFN- γ responsiveness in myeloid malignancies-implication for the possible impact on IFN- γ immunotherapy	Sawa	Ito	Poster	Immunomodulatory Agents and Interventions	4/18/23	9:00 AM	Section 40	4
4419	Use of luciferase-labeled target cells to explore immune cell killing in high throughput format in 2D and 3D co-cultures	Carla	Castro	Poster	Immunomodulatory Agents and Interventions	4/18/23	9:00 AM	Section 40	5
4420	Carbohydrate-CD11b engagement enhances differentiation of tumor-associated myeloid cells in immunotherapy of solid cancers	Mei	Zhang	Poster	Immunomodulatory Agents and Interventions	4/18/23	9:00 AM	Section 40	6

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
4421	Targeting myeloid-derived suppressor cells with actinium-225 lintuzumab, a CD33 antibody radioconjugate to enhance antitumor immunity	Amanda	Chin	Poster	Immunomodulatory Agents and Interventions	4/18/23	9:00 AM	Section 40	7
4422	Evaluation of immune response to tumor associated antigens in patients with high grade serous ovarian cancer vaccinated intradermally with DCP-001, an allogeneic, cancer cell-based vaccine	Marco	De Bruyn	Poster	Immunomodulatory Agents and Interventions	4/18/23	9:00 AM	Section 40	8
4423	XMT-2056, a HER2-targeted STING agonist antibody-drug conjugate, exhibits ADCC function that synergizes with STING pathway activation and contributes to anti-tumor responses	Jahna	Soomer-James	Poster	Immunomodulatory Agents and Interventions	4/18/23	9:00 AM	Section 40	9
4424	Immunoregulatory role of club cell secretory proteins in non-small cell lung cancer	Aakanksha Rajiv	Kapoor	Poster	Immunomodulatory Agents and Interventions	4/18/23	9:00 AM	Section 40	10
4425	GlycoConnect™ immune cell engagers (GC™-ICEs). A non-genetic approach to targeted IL-15 immunotherapy	Remon	van Geel	Poster	Immunomodulatory Agents and Interventions	4/18/23	9:00 AM	Section 40	11
4426	Removal of soluble TNF receptors as a novel form of immunotherapy for patients with advanced solid tumors	Sameera	Bilgrami	Poster	Immunomodulatory Agents and Interventions	4/18/23	9:00 AM	Section 40	12
4427	Cucurbitacin B: A promising drug candidate for targeting tumor immunosuppressive cells	Emmanuel	Anning	Poster	Immunomodulatory Agents and Interventions	4/18/23	9:00 AM	Section 40	13
4429	'Free' ISG15 acts as an immunoadjuvant to enhance CD8+ T cell-mediated anti-tumor immunity	Mariam	Oladejo	Poster	Immunomodulatory Agents and Interventions	4/18/23	9:00 AM	Section 40	15
4430	Sacituzumab-Interferon beta mutein fusion protein, ABN202 (anti Trop2-interferon beta mutein), is a potent therapeutics for Trop-2-positive urothelial cancer	Young kee	Shin	Poster	Immunomodulatory Agents and Interventions	4/18/23	9:00 AM	Section 40	16
4432	A highly differentiated A2AR inhibitor for potential use in cancer therapy	Chandregowda	Venkateshappa	Poster	Immunomodulatory Agents and Interventions	4/18/23	9:00 AM	Section 40	18
4433	Galectin-3 synergizes with CD47 to suppress phagocytosis and T cell immunity in peritoneal metastases of gastric adenocarcinoma	Yibo	Fan	Poster	Immunomodulatory Agents and Interventions	4/18/23	9:00 AM	Section 40	19
4434	A PD-1-targeted, receptor-masked IL-2 immunocytokine with maintained potential to engage endogenous IL-2Ra drives selective stimulation of PD-1+ T cells and robust anti-tumor efficacy	Jiayi	Wu	Poster	Immunomodulatory Agents and Interventions	4/18/23	9:00 AM	Section 40	20
4435	A causal modeling platform for testing lifestyle interventions on the microbiome and response to immunotherapy	Aaditya	Pallerla	Poster	Immunomodulatory Agents and Interventions	4/18/23	9:00 AM	Section 40	21
4436	A novel antibody-enabled dual precision targeted protein stabilization (TPS2) that augments anti-tumor immune response by targeting CBL-B inhibitor to exhausted T cells while blocking checkpoint molecule, PD-1	Joanne	Lim	Poster	Immunomodulatory Agents and Interventions	4/18/23	9:00 AM	Section 40	22

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
4437	BXQ-350: A novel biologic with an innovative mechanism of action targeting sphingolipid metabolism that induces cancer cell death and repolarizes the tumor microenvironment	Gilles	Tapolsky	Poster	Immunomodulatory Agents and Interventions	4/18/23	9:00 AM	Section 40	23
4438	Bypassing immune evasion in colorectal cancer by integrin inhibition-mediated downregulation of PD-L1	William	MacDonald	Poster	Immunomodulatory Agents and Interventions	4/18/23	9:00 AM	Section 40	24
4439	Negative impact of the GABA pathway on aPD(L)1 immunotherapy	Christine	Moussion	Poster	Immunomodulatory Agents and Interventions	4/18/23	9:00 AM	Section 40	25
4440	Efficacy of Gen-1, an interleukin-12 immune gene therapy, at different dose frequencies	Jean	Boyer	Poster	Immunomodulatory Agents and Interventions	4/18/23	9:00 AM	Section 40	26
4441	Bifunctional immunotherapeutic HCW9218 facilitates recruitment of immune cells from tumor draining lymph nodes to promote antitumor activity and enhance checkpoint blockade efficacy in solid tumors	Varghese	George	Poster	Immunomodulatory Agents and Interventions	4/18/23	9:00 AM	Section 40	27
4442	Dual benefit of MALT1 blockade in glioblastoma	Juliana	Hofstatter Azambuja	Poster	Immunomodulatory Agents and Interventions	4/18/23	9:00 AM	Section 40	28
4444	Targeting PI3K isoforms to improve the effectiveness of T cell mediated immunotherapy	Ritu	Bohat	Poster	Immunomodulatory Agents and Interventions	4/18/23	9:00 AM	Section 40	30
4448	Chemokine (C-X-C motif) ligand 17 promotes cutaneous squamous cell carcinoma via modulating tumor-immune evasion	Alok	Khandelwal	Poster	Inflammation, Immunity, and Cancer	4/18/23	9:00 AM	Section 41	1
4449	The expression and immune regulation of thymic stromal lymphopoietin in non-small cell lung cancer development and progression	Chung-Yu	Chen	Poster	Inflammation, Immunity, and Cancer	4/18/23	9:00 AM	Section 41	2
4450	SOX4 promotes tumor development and immune evasion via disruption of zinc homeostasis between nasopharyngeal carcinoma cells and T cells	Yuma	Yang	Poster	Inflammation, Immunity, and Cancer	4/18/23	9:00 AM	Section 41	3
4451	Developing a PROTAC-based NR4A1 degrader for melanoma cancer therapy	Rohan	Master	Poster	Inflammation, Immunity, and Cancer	4/18/23	9:00 AM	Section 41	4
4452	FASN inhibition overcomes immune evasion by upregulating MHC-I in hepatocellular carcinoma	Jiao	Huang	Poster	Inflammation, Immunity, and Cancer	4/18/23	9:00 AM	Section 41	5
4453	Neutrophil-to-lymphocyte ratio associates with intratumoral myeloid predominance and clinical outcomes of pembrolizumab in head and neck squamous cell carcinoma	Hiroki	Morimoto	Poster	Inflammation, Immunity, and Cancer	4/18/23	9:00 AM	Section 41	6
4454	Loss of CX3CL1 expression mediates immune evasion in STK11 mutated lung adenocarcinomas	Gabriela	Wright	Poster	Inflammation, Immunity, and Cancer	4/18/23	9:00 AM	Section 41	7
4455	Protein phosphatase 4 inhibition stimulates anti-tumor immunity in ovarian cancer	Remya	Raja	Poster	Inflammation, Immunity, and Cancer	4/18/23	9:00 AM	Section 41	8

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
4456	Inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX2) inhibition reprogram the tumor microenvironment and suppress tumor growth in hepatocellular carcinoma	Ronghua	Wang	Poster	Inflammation, Immunity, and Cancer	4/18/23	9:00 AM	Section 41	9
4457	Post exposure suppression of radiation pneumonitis by TRAIL pathway agonists TLY012 and ONC201	Jillian	Strandberg	Poster	Inflammation, Immunity, and Cancer	4/18/23	9:00 AM	Section 41	10
4458	Single cell landscape of multicentric Castleman disease in identical twins	Bavani	Kannan	Poster	Inflammation, Immunity, and Cancer	4/18/23	9:00 AM	Section 41	11
4459	Spatial profiling of the inflamed tumor microenvironment identifies novel prognostic subclasses in non-metastatic clear cell renal carcinoma patients	Teijo	Pellinen	Poster	Inflammation, Immunity, and Cancer	4/18/23	9:00 AM	Section 41	12
4460	Spatial profiling of immune biomarkers in resected treatment-naïve early stage lung adenocarcinoma	Sharia	Hernandez	Poster	Inflammation, Immunity, and Cancer	4/18/23	9:00 AM	Section 41	13
4461	Optimized human immunophenotyping panels enhance the flexibility for high-dimensional flow cytometry analysis with CyTOF	Lauren	Tracey	Poster	Inflammation, Immunity, and Cancer	4/18/23	9:00 AM	Section 41	14
4462	Immunoregulatory effects of NNMT-expressing cancer-associated fibroblasts	Janna	Heide	Poster	Inflammation, Immunity, and Cancer	4/18/23	9:00 AM	Section 41	15
4463	Prognostic significance of systemic inflammatory markers in recurrent or metastatic head and neck cancer patients treated with nivolumab	Hiroe	Tada	Poster	Inflammation, Immunity, and Cancer	4/18/23	9:00 AM	Section 41	16
4464	Comparison of two DTH models for T cell-mediated immunity in preclinical screen	Yingying	Cai	Poster	Inflammation, Immunity, and Cancer	4/18/23	9:00 AM	Section 41	17
4465	Evaluation of tumor draining lymph nodes in dogs with spontaneously arising osteosarcoma using single-cell sequencing	Samuel	Brill	Poster	Inflammation, Immunity, and Cancer	4/18/23	9:00 AM	Section 41	18
4466	Inhibition of ERO1a and IDO1 improves dendritic cell infiltration into pancreatic ductal adenocarcinoma	Apple	Tay	Poster	Inflammation, Immunity, and Cancer	4/18/23	9:00 AM	Section 41	19
4467	Plasmacytoid dendritic cells, prevalent in the TME of smokers, is associated with a good prognosis and treatment response of LUAD.	Yoon Soo	Chang	Poster	Inflammation, Immunity, and Cancer	4/18/23	9:00 AM	Section 41	20
4468	Tumor-derived extracellular vesicles transmit retroelement and pericentromeric RNAs to drive proinflammatory and DNA damage responses in stromal fibroblasts and immune cells	Valentina	Evdokimova	Poster	Inflammation, Immunity, and Cancer	4/18/23	9:00 AM	Section 41	21
4469	Disruption of ATG9A-dependent basal autophagy sensitizes cancer cells to innate inflammatory signaling	Dasun	Jayatunge	Poster	Inflammation, Immunity, and Cancer	4/18/23	9:00 AM	Section 41	22
4470	E-cigarette aerosol exposure increases NF-kB and modulates inflammatory markers in oral epithelial cells	Vengatesh	Ganapathy	Poster	Inflammation, Immunity, and Cancer	4/18/23	9:00 AM	Section 41	23
4471	Reprogramming “cold” NF1 malignancies into “hot” tumors for immunotherapy	Laasya	Madana	Poster	Inflammation, Immunity, and Cancer	4/18/23	9:00 AM	Section 41	24

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
4472	A mouse model for GvHD: an excellent tool for evaluating the efficacy of anti-GvHD drugs and testing mechanisms of immunoregulation	Hongyan	Sun	Poster	Inflammation, Immunity, and Cancer	4/18/23	9:00 AM	Section 41	25
4476	BI-732, a novel fourth-generation EGFR-TKI, demonstrates promising activities against the C797S-mediated EGFR-TKI resistance	Eun Ji	Lee	Poster	Molecular Targeted Therapies 2	4/18/23	9:00 AM	Section 42	1
4477	DIACC3010, optimized inhibitor of S6 kinase, combined with endocrine therapy, has potent antitumor activity in treatment-resistant ER-positive HER2-negative metastatic breast cancer	Helene	Sicard	Poster	Molecular Targeted Therapies 2	4/18/23	9:00 AM	Section 42	2
4478	Up284, A small molecule inhibitor of ADRM1 demonstrates significant anti-tumor efficacy in preclinical models of aggressive breast cancer	Balasubramanyam	Karanam	Poster	Molecular Targeted Therapies 2	4/18/23	9:00 AM	Section 42	3
4479	Targeting of eIF4A1 curtails lung metastases in triple-negative breast cancer	Shobhit	Srivastava	Poster	Molecular Targeted Therapies 2	4/18/23	9:00 AM	Section 42	4
4480	Treatment of PTEN/PI3K co-mutated endometrial adenocarcinoma with multitarget small molecule inhibitors	Ritchie	Delara	Poster	Molecular Targeted Therapies 2	4/18/23	9:00 AM	Section 42	5
4481	Vrtx153, novel small molecule inhibitor of krasg12d	Partha	Sarma	Poster	Molecular Targeted Therapies 2	4/18/23	9:00 AM	Section 42	6
4482	Discovery of GH2616, a potent and selective KIF18A inhibitor with robust in vivo efficacy in p53 mutant cancer	Jie Jack	Li	Poster	Molecular Targeted Therapies 2	4/18/23	9:00 AM	Section 42	7
4483	Distinct spatial distribution patterns of ALK-inhibitor naïve versus ALK-inhibitor treated ALK-positive NSCLC brain metastases	Tia	Cheunkarndee	Poster	Molecular Targeted Therapies 2	4/18/23	9:00 AM	Section 42	8
4484	HER3 expression after systemic therapy and clinical characteristics in patients with hepatocellular carcinoma	Mao	Okada	Poster	Molecular Targeted Therapies 2	4/18/23	9:00 AM	Section 42	9
4485	JPI-547, a novel dual inhibitor of PARP 1/2 and tankyrase 1/2 overcomes olaparib resistance in BRCA 1/2 mutant ovary and breast cancer preclinical model	Min Sil	Kang	Poster	Molecular Targeted Therapies 2	4/18/23	9:00 AM	Section 42	10
4486	Proof of principle for pharmacogenomic-guided precision oncology for pediatric malignancy	Do-Hyun	Nam	Poster	Molecular Targeted Therapies 2	4/18/23	9:00 AM	Section 42	11
4487	Effective anti-tumor effect in a rare metastatic Wilms tumor xenograft by inhibition of RAS/PI3K hyperactivation	Mohammad	Saadatzadeh	Poster	Molecular Targeted Therapies 2	4/18/23	9:00 AM	Section 42	12
4488	TY-4028: a novel, targeted therapy for non small-cell lung cancer with EGFR exon 20 or HER2 exon 20 insertion mutations	Jun	Li	Poster	Molecular Targeted Therapies 2	4/18/23	9:00 AM	Section 42	13
4489	N-Cadherin acts as a predictive biomarker for anti-FGFR therapy in KRAS wild-type NSCLC	Santiago	G. Borrego	Poster	Molecular Targeted Therapies 2	4/18/23	9:00 AM	Section 42	14
4491	TY-0584: A potent, orally available small molecule YAP/TEAD inhibitor, exhibits anti-tumor effects in vitro and in vivo	Apeng	Liang	Poster	Molecular Targeted Therapies 2	4/18/23	9:00 AM	Section 42	16

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
4492	A novel and potent FLT3 and IRAK4 dual inhibitor for the treatment of acute myeloid leukemia	Suyue	Wang	Poster	Molecular Targeted Therapies 2	4/18/23	9:00 AM	Section 42	17
4493	Sudocetaxel Zendusortide (TH1902), a peptide-drug conjugate for the treatment of sortilin-positive (SORT1+) TNBC and Her2-positive breast cancers	Cyndia	Charfi	Poster	Molecular Targeted Therapies 2	4/18/23	9:00 AM	Section 42	18
4494	Multi-specific cMet x EGFR x VEGF antibody for difficult to treat cancers	Mark	Chiu	Poster	Molecular Targeted Therapies 2	4/18/23	9:00 AM	Section 42	19
4495	A mechanistic study of the TFE3-splicing machinery gene fusions reveals a new druggable target for translocation renal cell carcinoma	Sabrina	Orsi	Poster	Molecular Targeted Therapies 2	4/18/23	9:00 AM	Section 42	20
4496	JPI-547, a dual inhibitor of PARP/Tankyrase, shows promising antitumor activity against pancreatic cancers with homologous recombination repair deficiency or Wnt-addiction	Kyoung-Seok	Oh	Poster	Molecular Targeted Therapies 2	4/18/23	9:00 AM	Section 42	21
4497	Efficacy of Jak1/2 inhibition in murine myeloproliferative neoplasms is mediated by targeting nonmalignant cells	Sivahari Prasad	Gorantla	Poster	Molecular Targeted Therapies 2	4/18/23	9:00 AM	Section 42	22
4499	The peptide-drug conjugate sudocetaxel zendusortide (TH1902) potentiates anti-tumoral activity of the anti-PD-L1 checkpoint inhibitor and induces immune cell infiltration in a B16-F10 syngeneic melanoma model	Michel	Demeule	Poster	Molecular Targeted Therapies 2	4/18/23	9:00 AM	Section 42	24
4500	Enedione derivates as a potential cancer treatment through the inhibition of COPZ1	Allana	Martins	Poster	Molecular Targeted Therapies 2	4/18/23	9:00 AM	Section 42	25
4501	Novel EHE PDX model used for drug sensitivity	Sandhya	Krishnan	Poster	Molecular Targeted Therapies 2	4/18/23	9:00 AM	Section 42	26
4502	Aptamer conjugated prostate specific membrane antigen (PSMA) targeting nanobees for prostate cancer prevention and therapy	Islam	Rady	Poster	Molecular Targeted Therapies 2	4/18/23	9:00 AM	Section 42	27
4503	Polyamine blockade therapy: A strategy to block immunosuppression in pancreatic cancer	Joseph	Goode	Poster	Molecular Targeted Therapies 2	4/18/23	9:00 AM	Section 42	28
4504	Targeting cMYC in metastatic castration resistant and neuroendocrine prostate cancer	Chidiebere	Awah	Poster	Molecular Targeted Therapies 2	4/18/23	9:00 AM	Section 42	29
4509	A pan-Canadian precision oncology program for children, adolescents and young adults with hard-to-cure cancer: The PRrecision Oncology For Young peopLE (PROFYLE) Program	Stephanie	Grover	Poster	Precision Oncology in Pediatric Cancer: From Genomics to Databases to Real World Evidence	4/18/23	9:00 AM	Section 43	1
4511	Impact of the comprehensive genomic profiling on the individual therapeutic planning in high-risk/refractory tumors: real-world precision medicine in pediatric oncology	Ondrej	Slaby	Poster	Precision Oncology in Pediatric Cancer: From Genomics to Databases to Real World Evidence	4/18/23	9:00 AM	Section 43	3
4512	My Pediatric and Adult Rare Tumor Network (MyPART): integrating longitudinal, clinical, molecular, and patient-reported outcomes for rare tumors	Karlyne	Reilly	Poster	Precision Oncology in Pediatric Cancer: From Genomics to Databases to Real World Evidence	4/18/23	9:00 AM	Section 43	4

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
4513	St. Jude Survivorship Portal: A data portal for storing, analyzing, and sharing large and complex cancer survivorship datasets	Gavriel	Matt	Poster	Precision Oncology in Pediatric Cancer: From Genomics to Databases to Real World Evidence	4/18/23	9:00 AM	Section 43	5
4514	Variations of blood DNA methylation associated with cancer treatment exposures among childhood cancer survivors of African ancestry	Qian	Dong	Poster	Precision Oncology in Pediatric Cancer: From Genomics to Databases to Real World Evidence	4/18/23	9:00 AM	Section 43	6
4515	PIONEER: harnessing multi-omics data to enhance immunotherapeutic target discovery and development	Amber	Weiner	Poster	Precision Oncology in Pediatric Cancer: From Genomics to Databases to Real World Evidence	4/18/23	9:00 AM	Section 43	7
4516	Rare high-penetrance and common low-penetrance variants associated with risk of pediatric acute lymphoblastic leukemia	Zhaoming	Wang	Poster	Precision Oncology in Pediatric Cancer: From Genomics to Databases to Real World Evidence	4/18/23	9:00 AM	Section 43	8
4517	Novel prognostic and predictive biomarker for neuroblastoma	Natarajan	Aravindan	Poster	Precision Oncology in Pediatric Cancer: From Genomics to Databases to Real World Evidence	4/18/23	9:00 AM	Section 43	9
4518	Highlighting the prenatal, natal, and early childhood risk factors of cancer: seeking better opportunities for cancer prevention	Abeer	Abd Elmoneim	Poster	Precision Oncology in Pediatric Cancer: From Genomics to Databases to Real World Evidence	4/18/23	9:00 AM	Section 43	10
4522	Pathologic complete response rate across triple negative breast cancer subtypes in the IMMUCan study	Andrea	Joaquin Garcia	Poster	Spatial Profiling, Tumor Classification, and Response Assessment	4/18/23	9:00 AM	Section 44	1
4524	Multiparametric characterization of early-stage SCLC human tumors reveals novel patient subgroups based on specific molecular to immune landscape associations	Angel	Nunez-Buiza	Poster	Spatial Profiling, Tumor Classification, and Response Assessment	4/18/23	9:00 AM	Section 44	3
4525	YAP1 in relapsed pulmonary high-grade neuroendocrine carcinomas (NEC) is associated with CDKN2A loss, intact RB1, EMT and therapeutic vulnerability to MEK1 and CDK4/6 inhibition	C. Allison	Stewart	Poster	Spatial Profiling, Tumor Classification, and Response Assessment	4/18/23	9:00 AM	Section 44	4
4526	Molecular landscape of clonal hematopoiesis in patients with lung cancer: First results of the CHIC study	Marco	Tagliamento	Poster	Spatial Profiling, Tumor Classification, and Response Assessment	4/18/23	9:00 AM	Section 44	5
4527	CD8 T cell-melanoma cell interactions in response and resistance to ipilimumab plus nivolumab: Biopsy analysis of SWOG S1616	Katie	Campbell	Poster	Spatial Profiling, Tumor Classification, and Response Assessment	4/18/23	9:00 AM	Section 44	6
4528	Evaluation of plasma circulating tumor DNA (ctDNA)-based whole genome sequencing (pWGS) and whole exome sequencing (pWES) and concordance with tumor tissue whole exome sequencing (tWES): a pilot study in patients with recurrent or metastatic head	Razvan	Cristescu	Poster	Spatial Profiling, Tumor Classification, and Response Assessment	4/18/23	9:00 AM	Section 44	7

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
	and neck squamous cell carcinoma or metastatic urothelial carcinoma								
4529	The tumor molecular landscape of nasopharyngeal carcinoma (NPC) in endemic and non endemic areas	Deborah	Lenoci	Poster	Spatial Profiling, Tumor Classification, and Response Assessment	4/18/23	9:00 AM	Section 44	8
4530	Single-cell analysis of oral squamous cell carcinoma (OSCC) from smoker vs. non-smoker patients highlights two groups of tumors with distinct immune microenvironments	Yannick	Le Meitour	Poster	Spatial Profiling, Tumor Classification, and Response Assessment	4/18/23	9:00 AM	Section 44	9
4531	Clinical translation of biomarkers for ZL-1211, an anti-CLDN18.2 antibody, in patients with advanced solid tumors from a phase I dose-escalation study	Zhen	Luo	Poster	Spatial Profiling, Tumor Classification, and Response Assessment	4/18/23	9:00 AM	Section 44	10
4532	Spatial profiling delineates tumor-T-cell dynamics in anti-PD-1-refractory melanoma treated with ipilimumab or ipilimumab plus nivolumab	Nataly	Naser Al Deen	Poster	Spatial Profiling, Tumor Classification, and Response Assessment	4/18/23	9:00 AM	Section 44	11
4533	Serum protein changes in patients with desmoid tumors responsive to the TBL1 inhibitor, tegavivint	Stephen	Horrigan	Poster	Spatial Profiling, Tumor Classification, and Response Assessment	4/18/23	9:00 AM	Section 44	12
4534	National Multidisciplinary Tumor Board improves diagnostic stratification and therapeutic management in Cancers of Unknown Primary: the French Experience	Sarah	Watson	Poster	Spatial Profiling, Tumor Classification, and Response Assessment	4/18/23	9:00 AM	Section 44	13
4535	Clinical outcomes and molecular features of different histopathologic patterns in patients with stage IB non-squamous non-small-cell lung cancer	Dongsheng	Yue	Poster	Spatial Profiling, Tumor Classification, and Response Assessment	4/18/23	9:00 AM	Section 44	14
4536	Investigating the correlation between molecular diagnostics, targeted therapies and treatment outcomes in Rosai Dorfman disease: a single-institution experience	Samuel	Reynolds	Poster	Spatial Profiling, Tumor Classification, and Response Assessment	4/18/23	9:00 AM	Section 44	15
4537	Erdheim Chester disease: A retrospective study characterizing the molecular and pathologic footprints with clinical presentation and comparative outcomes in the present era of targeted molecular targeted therapy	Sabrina	Wilcox	Poster	Spatial Profiling, Tumor Classification, and Response Assessment	4/18/23	9:00 AM	Section 44	16
4538	The heterogeneous immune and molecular landscape of endometrial cancer metastases	Matthew	Hadfield	Poster	Spatial Profiling, Tumor Classification, and Response Assessment	4/18/23	9:00 AM	Section 44	17
4539	Tumor evolution and immune microenvironment dynamics define response to neoadjuvant treatment of esophageal adenocarcinoma	Ann-Marie	Baker	Poster	Spatial Profiling, Tumor Classification, and Response Assessment	4/18/23	9:00 AM	Section 44	18

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
4540	Multiregional transcriptomics of colorectal cancers define prognostic features less vulnerable to tumor heterogeneity	Hossein	Moosavi	Poster	Spatial Profiling, Tumor Classification, and Response Assessment	4/18/23	9:00 AM	Section 44	19
4542	Development of a one-step molecular classifier for endometrial carcinoma using an amplicon-based gene panel and next generation sequencing technology	Melissa	McConechy	Poster	Spatial Profiling, Tumor Classification, and Response Assessment	4/18/23	9:00 AM	Section 44	21
4543	Identification of tumor-specific breast cancer expression subtypes and subtype-specific drug response prediction	Julie	Karam	Poster	Spatial Profiling, Tumor Classification, and Response Assessment	4/18/23	9:00 AM	Section 44	22
4544	Genomic, transcriptomic, functional, and mechanistic characterization of rhabdomyosarcoma with FUS-TFCP2 or EWSR1-TFCP2 fusions	Claudia	Scholl	Poster	Spatial Profiling, Tumor Classification, and Response Assessment	4/18/23	9:00 AM	Section 44	23
4545	Integrative immune-genomic comparison of canonical Ewing sarcoma with Ewing-like mimics identifies potential targets for personalized therapies	Zhusheng	Zhang	Poster	Spatial Profiling, Tumor Classification, and Response Assessment	4/18/23	9:00 AM	Section 44	24
4546	Comprehensive analysis using transcriptional factor based molecular subtypes and correlation to clinical outcomes in small-cell lung cancer	Sehhoon	Park	Poster	Spatial Profiling, Tumor Classification, and Response Assessment	4/18/23	9:00 AM	Section 44	25
4550	Assessing efficacy and immune-stimulatory effects of tumor-derived dendritic cell reprogramming using immuno-competent 3D tumor spheroid model	Irina	Agarkova	Poster	3D and Tissue Recombinant Models	4/18/23	1:30 PM	Section 2	1
4551	Reconstructing the metastatic tumor microenvironment of high grade serous ovarian cancer: understanding the contribution of malignant cells	Beatrice	Malacrida	Poster	3D and Tissue Recombinant Models	4/18/23	1:30 PM	Section 2	2
4552	3D-Explore platform of fresh patient tumoroids with intact TME allows assessment of the efficacy of drugs targeting the tumor stroma on ex vivo tumor immunotherapy	Seth	Currllin	Poster	3D and Tissue Recombinant Models	4/18/23	1:30 PM	Section 2	3
4553	How do shiitake and reishi mushrooms work on lung cancer? : A high throughput screening of 3D cell culture	Mihi	Yang	Poster	3D and Tissue Recombinant Models	4/18/23	1:30 PM	Section 2	4
4554	Head and neck cancer HuBiogel-embedded microtumor assay system for therapeutic efficacy testing of patient tumor specimens	Christopher	Willey	Poster	3D and Tissue Recombinant Models	4/18/23	1:30 PM	Section 2	5
4555	Aryl-hydrocarbon receptor inhibitors in combination with anticancer agents, especially proteasome pathway inhibitors, in a complex spheroid screen using patient-derived cell lines can result in greater-than additive cytotoxicity	BEVERLY	TEICHER	Poster	3D and Tissue Recombinant Models	4/18/23	1:30 PM	Section 2	6

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
4556	Matrix properties regulate 3D tumor spheroid growth and cancer drug response	Jaxson	Libby	Poster	3D and Tissue Recombinant Models	4/18/23	1:30 PM	Section 2	7
4557	3D-EXpress platform utilizing tumoroids from patients with MSS and MSI-H tumors allows rapid assessment of anti-tumor activity of immune checkpoint inhibitors and development of clinically relevant biomarkers of treatment response	Brittney	Ruedlinger	Poster	3D and Tissue Recombinant Models	4/18/23	1:30 PM	Section 2	8
4558	High-throughput, high content Imaging assay for assessing solid tumor phagocytosis in 3D spheroid model	Michal	Rudnik	Poster	3D and Tissue Recombinant Models	4/18/23	1:30 PM	Section 2	9
4559	Evaluation of T cell cytotoxicity, PD-L1 expression and phenotypic features in novel automated 3D microfluidic breast cancer co-culture platform	Ekaterina	Nikolov	Poster	3D and Tissue Recombinant Models	4/18/23	1:30 PM	Section 2	10
4560	Assay-ready tissue-engineered cancer microspheres for high-throughput screening	Yuan	Tian	Poster	3D and Tissue Recombinant Models	4/18/23	1:30 PM	Section 2	11
4561	3D Reconstructed Pancreas: A model capturing the unique tumor microenvironment and stromal architecture of pancreatic cancer	David	Draper	Poster	3D and Tissue Recombinant Models	4/18/23	1:30 PM	Section 2	12
4563	Measuring immunotherapy responses ex vivo using novel 3D culture platform: E-slice	Thomas	Gallup	Poster	3D and Tissue Recombinant Models	4/18/23	1:30 PM	Section 2	14
4564	Liquid-phase-based cell culture platform that enables polymer surface stimuli-induced generation of patient-specific glioma stem cell-like tumor spheroids	Junhyuk	Song	Poster	3D and Tissue Recombinant Models	4/18/23	1:30 PM	Section 2	15
4565	Drug screening by layered 3D co-cultured tumor model including vascularized stromal tissue	Yuki	Takahashi	Poster	3D and Tissue Recombinant Models	4/18/23	1:30 PM	Section 2	16
4566	3D cancer cell-fibroblast heterospheroids forming tumor-like microenvironments are valuable tools to study immune cell infiltration and as pre-clinical drug testing models	Boye	Nielsen	Poster	3D and Tissue Recombinant Models	4/18/23	1:30 PM	Section 2	17
4567	Transcriptomic analysis of a 3D engineered cancer model recapitulating stage-dependent heterogeneity in colorectal PDX tumors	Michael	Greene	Poster	3D and Tissue Recombinant Models	4/18/23	1:30 PM	Section 2	18
4568	Evaluating response of renal cell carcinoma to tyrosine kinase inhibitor and immune checkpoint inhibitor using a human histoculture platform	Satish	Sankaran	Poster	3D and Tissue Recombinant Models	4/18/23	1:30 PM	Section 2	19
4570	Expanding the 3D ex vivo patient tissue platform toolbox for (immuno)-oncology drug testing	Nataliia	Beztsinna	Poster	3D and Tissue Recombinant Models	4/18/23	1:30 PM	Section 2	21
4571	A novel ex vivo platform, 3D-EXpress, to rapidly assess the efficacy of KRAS targeting drugs alone and in combination with nivolumab using a biorepository of fresh patient tumoroids with intact tumor microenvironment	Jared	Ehrhart	Poster	3D and Tissue Recombinant Models	4/18/23	1:30 PM	Section 2	22

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
4572	3D-EXpress ex vivo platform using a biorepository of characterized fresh patient tumoroids allows development of rational combinations with drugs targeting DNA damage response and immune checkpoint blockade	Jared	Ehrhart	Poster	3D and Tissue Recombinant Models	4/18/23	1:30 PM	Section 2	23
4573	Evaluation of tumor treating fields (TTFields) effects at 200 kHz on a glioblastoma, an anaplastic ependymoma and an oligodendroglioma sample in a patient-derived ex vivo organoid model	Carsten	Hagemann	Poster	3D and Tissue Recombinant Models	4/18/23	1:30 PM	Section 2	24
4574	Long-term drug efficacy evaluation using stiffness-tunable scaffolds colonized by a three-dimensional tumor microenvironment	Olivier	De Wever	Poster	3D and Tissue Recombinant Models	4/18/23	1:30 PM	Section 2	25
4575	High-throughput method to analyze the cytotoxicity of CAR T cells in a 3D tumor spheroid model using image cytometry	Samir	Patel	Poster	3D and Tissue Recombinant Models	4/18/23	1:30 PM	Section 2	26
4576	3D in vitro models uncover malignant cell intrinsic and extrinsic mechanisms of CAR-T cell resistance in high grade serous ovarian cancer	Joash	Joy	Poster	3D and Tissue Recombinant Models	4/18/23	1:30 PM	Section 2	27
4577	An innovative platform to mimic the tumoral vascular microenvironment (TME) of patients with metastatic colorectal cancer (mCRC) using bioprinted hydrogel microfluidics	Nadia	Saoudi González	Poster	3D and Tissue Recombinant Models	4/18/23	1:30 PM	Section 2	28
4578	Miniaturized and multiplexed evaluation of NK cell cytotoxicity and infiltration in patient-derived sarcoma spheroids using a novel multichambered microwell chip	Valentina	Carannante	Poster	3D and Tissue Recombinant Models	4/18/23	1:30 PM	Section 2	29
4579	A three-dimensional model of glioblastoma for discovery of novel therapeutics	Viktoriia	Kriuchkovskaia	Poster	3D and Tissue Recombinant Models	4/18/23	1:30 PM	Section 2	30
4583	An essential role for Cmr2 in endothelial cell function and vascular development	Alena	Yermalovich	Poster	Advances in Angiogenesis	4/18/23	1:30 PM	Section 3	1
4584	Genetic disruption of vascular endothelial profilin-1 impacts tumor microenvironment suppressing tumorigenicity of renal cancer	David	Gau	Poster	Advances in Angiogenesis	4/18/23	1:30 PM	Section 3	2
4585	Tumor lymphangiogenesis sensitizes melanomas to the immunological effects of radiotherapy but also disrupts the local lymphatic vasculature	Anish	Mukherjee	Poster	Advances in Angiogenesis	4/18/23	1:30 PM	Section 3	3
4586	To define how the uvel melanoma-liver environment crosstalk shapes metastasis growth and therapeutic response	Sathya	Neelature Sriramareddy	Poster	Advances in Angiogenesis	4/18/23	1:30 PM	Section 3	4
4587	Vascular-derived signature imprinted by tumor microenvironment-dependent transcriptional memory predicts colon cancer prognosis	Michael	Stürzl	Poster	Advances in Angiogenesis	4/18/23	1:30 PM	Section 3	5

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
4588	Vascular regulation of T-cell exclusion in melanoma	Ha-Ram	Park	Poster	Advances in Angiogenesis	4/18/23	1:30 PM	Section 3	6
4589	Deciphering collagen-responsive mechanism in pancreatic tumor progression and immunology at single-cell resolution	Yang	Chen	Poster	Advances in Angiogenesis	4/18/23	1:30 PM	Section 3	7
4590	Anti-angiogenic mAb, anti-human VEGFR2(Cyramza) retards tumor growth in KDR (VEGFR2) humanized mice engrafted with syngeneic vs. xenograft solid tumors	Daniel	He	Poster	Advances in Angiogenesis	4/18/23	1:30 PM	Section 3	8
4591	Mechanisms of tumor-mediated endothelial cell proliferation independent of VEGF	Kevin	Sheng	Poster	Advances in Angiogenesis	4/18/23	1:30 PM	Section 3	9
4592	In vivo efficacy evaluation of anti-human VEGFR2 antibodies in humanized B-hVEGFR2 mice	Rebecca	Soto	Poster	Advances in Angiogenesis	4/18/23	1:30 PM	Section 3	10
4593	Glioblastoma tumors that respond poorly to bevacizumab therapy show upregulation of an angiogenesis gene set	Roshan	Lodha	Poster	Advances in Angiogenesis	4/18/23	1:30 PM	Section 3	11
4595	STAT-3 chemical inhibition modulates decidual-like polarization in NK cells from PCa patients and restore their anti-tumor activities	Matteo	Gallazzi	Poster	Advances in Angiogenesis	4/18/23	1:30 PM	Section 3	13
4596	BIOhabitats clinical study (NCT05375318): Histopathological analysis of vascular habitats in glioblastoma defined by perfusion MRI	María del Mar	Álvarez-Torres	Poster	Advances in Angiogenesis	4/18/23	1:30 PM	Section 3	14
4597	TIMP1 is a major contributor of the angiogenic priming of tumor associated fibroblasts in lung adenocarcinoma	Natalia	Diaz Valdivia	Poster	Advances in Angiogenesis	4/18/23	1:30 PM	Section 3	15
4598	Vitamin b1 derivative, benfotamine, prevents VEGF-induced angiogenesis	Kieran	Allowitz	Poster	Advances in Angiogenesis	4/18/23	1:30 PM	Section 3	16
4599	Blood and lymphatic endothelial cell contractility-mediated vessel permeability regulates interstitial fluid pressure and T cell infiltration in the tumor microenvironment	Yansong	Peng	Poster	Advances in Angiogenesis	4/18/23	1:30 PM	Section 3	17
4600	Phenotypic & functional diversity of tumor associated neutrophils in murine breast tumor models	Hasan	Korkaya	Poster	Advances in Angiogenesis	4/18/23	1:30 PM	Section 3	18
4601	Vitamin D supplementation attenuates resistance to anti-angiogenic therapy in colorectal cancer liver metastases	Miran	Rada	Poster	Advances in Angiogenesis	4/18/23	1:30 PM	Section 3	19
4602	Differences in tumor vascular density between smoker and non-smoker cancer patients	Shubhangi	Singh	Poster	Advances in Angiogenesis	4/18/23	1:30 PM	Section 3	20
4604	Effect of CDK 4/6 inhibition on anti-angiogenesis effect in gastric cancer	Sang Woo	Cho	Poster	Advances in Angiogenesis	4/18/23	1:30 PM	Section 3	22
4605	Chronic VEGF-C signaling exacerbates the progression of non-alcoholic steatohepatitis and hepatocarcinoma through endothelial VEGFR2 and VEGFR3	Seock-Won	Youn	Poster	Advances in Angiogenesis	4/18/23	1:30 PM	Section 3	23
4606	Heat shock proteins in immunosuppressive tumor microenvironment	Fulya	Koksalar Alkan	Poster	Advances in Angiogenesis	4/18/23	1:30 PM	Section 3	24

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
4607	TRPS1 inhibits angiogenesis in triple negative breast cancer down regulating JAG1 and TYMP genes involved in angiogenesis pathways	Liliana	Guzman	Poster	Advances in Angiogenesis	4/18/23	1:30 PM	Section 3	25
4611	Leveraging organotypic brain slice models to enhance adoptive cellular therapies	Alexandra	Reid	Poster	Evaluating Tumor Progression via 3D and Spatial Approaches	4/18/23	1:30 PM	Section 4	1
4612	Microphysiological vascularized solid liver tumor model for drug and cell therapy	Jyothsna	Vasudevan	Poster	Evaluating Tumor Progression via 3D and Spatial Approaches	4/18/23	1:30 PM	Section 4	2
4613	Inhibition of myosin II in triple-negative breast cancer cells limits macrophage recruitment in a 3D environment	Youngbin	Cho	Poster	Evaluating Tumor Progression via 3D and Spatial Approaches	4/18/23	1:30 PM	Section 4	3
4614	Investigating lymphatic vessel remodeling and anti-tumor immunity in pancreatic cancer using tumor-on-chip and mouse models	Anna	Kolarzyk	Poster	Evaluating Tumor Progression via 3D and Spatial Approaches	4/18/23	1:30 PM	Section 4	4
4615	Differential immune characteristics and anti-PD-1-induced reinvigoration capacity of tumor-infiltrating lymphocytes according to ProMisE classifier in endometrial cancer	Jung Chul	Kim	Poster	Evaluating Tumor Progression via 3D and Spatial Approaches	4/18/23	1:30 PM	Section 4	5
4616	Automated multiplex immunofluorescence enables single cell analysis of tumor stroma	François	Rivest	Poster	Evaluating Tumor Progression via 3D and Spatial Approaches	4/18/23	1:30 PM	Section 4	6
4617	A complete pipeline for high-plex spatial proteomic profiling and analysis on the cosmxtm spatial molecular imager and atomtm spatial informatics platform	Tien	Phan-Everson	Poster	Evaluating Tumor Progression via 3D and Spatial Approaches	4/18/23	1:30 PM	Section 4	7
4618	Biomarkers of functionally active tertiary lymphoid structures in human breast cancer	Doïna	Sofronii	Poster	Evaluating Tumor Progression via 3D and Spatial Approaches	4/18/23	1:30 PM	Section 4	8
4619	Spatial analysis of the immunosuppressive tumor microenvironment in brain cancer applying a novel multiplex immunofluorescence panel	Yvonne	Reiss	Poster	Evaluating Tumor Progression via 3D and Spatial Approaches	4/18/23	1:30 PM	Section 4	9
4620	Automated multiplex immunofluorescence workflow to interrogate the cellular composition of the tumor microenvironment	Vytautas	Navikas	Poster	Evaluating Tumor Progression via 3D and Spatial Approaches	4/18/23	1:30 PM	Section 4	10
4621	Distinct spatial and molecular maps in the tumour microenvironment of resistant melanoma patients treated with checkpoint inhibitor immunotherapy	James	Wilmott	Poster	Evaluating Tumor Progression via 3D and Spatial Approaches	4/18/23	1:30 PM	Section 4	11
4622	Tumor microenvironment differences between lung cancer subtypes revealed by spatial transcriptomics	Matthew	Wilkerson	Poster	Evaluating Tumor Progression via 3D and Spatial Approaches	4/18/23	1:30 PM	Section 4	12
4623	Single-cell spatial proteomic analysis of the tumor microenvironment in treatment-naive NSCLC samples with immunotherapy treatment and response data	Marie	Cumberbatch	Poster	Evaluating Tumor Progression via 3D and Spatial Approaches	4/18/23	1:30 PM	Section 4	13

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
4624	Deciphering the tumor microenvironment at single-cell resolution using a workflow combining RNA transcript and protein detection with Brightplex®, a sequential chromogenic multiplex assay	Jacques	Fieschi	Poster	Evaluating Tumor Progression via 3D and Spatial Approaches	4/18/23	1:30 PM	Section 4	14
4625	A comprehensive guided workflow for highplex imaging, tissue segmentation, and multiplex cellular phenotyping for tumor microenvironment analysis	James	Mansfield	Poster	Evaluating Tumor Progression via 3D and Spatial Approaches	4/18/23	1:30 PM	Section 4	15
4626	Spatial profiling of the tumor microenvironment in head and neck cancer identifies immune checkpoints and proteins involved in cell death signaling biomarkers of immunotherapy response	James	Mansfield	Poster	Evaluating Tumor Progression via 3D and Spatial Approaches	4/18/23	1:30 PM	Section 4	16
4627	Immune profiling of immunotherapy and adjuvant chemotherapy pretreatment NSCLC tissues by CODEX	James	Mansfield	Poster	Evaluating Tumor Progression via 3D and Spatial Approaches	4/18/23	1:30 PM	Section 4	17
4628	Profiling the tumor microenvironments of triple- and quadruple-negative breast cancers	Mahak	Bhargava	Poster	Evaluating Tumor Progression via 3D and Spatial Approaches	4/18/23	1:30 PM	Section 4	18
4629	Heterogeneity in glioblastoma tumor microenvironment: Opportunities for new therapies	Sandra	Delebecq	Poster	Evaluating Tumor Progression via 3D and Spatial Approaches	4/18/23	1:30 PM	Section 4	19
4630	Deep Immuno-profiling of syngeneic tumor mouse models for preclinical studies	Anais	Joachim	Poster	Evaluating Tumor Progression via 3D and Spatial Approaches	4/18/23	1:30 PM	Section 4	20
4631	Multiplex IHC assay to explore regional heterogeneity of FAP and inflammatory cell density in localized prostatic adenocarcinoma	Fernanda	Caramella Pereira	Poster	Evaluating Tumor Progression via 3D and Spatial Approaches	4/18/23	1:30 PM	Section 4	21
4632	Spatial whole transcriptome analysis of differential expression for biomarker discovery in colorectal cancer	Vidyodhaya	Sundaram	Poster	Evaluating Tumor Progression via 3D and Spatial Approaches	4/18/23	1:30 PM	Section 4	22
4633	Quantitative spatial profiling of NSCLC subtypes across tumor stages using 6-plex multiplex imaging technology and AI-powered phenotyping analysis	Lorcan	Sherry	Poster	Evaluating Tumor Progression via 3D and Spatial Approaches	4/18/23	1:30 PM	Section 4	23
4634	Identifying and analyzing tumor subtypes using custom morphology markers for NanoString® GeoMx® Digital Spatial Profiler	Jessica	Runyon	Poster	Evaluating Tumor Progression via 3D and Spatial Approaches	4/18/23	1:30 PM	Section 4	24
4635	Single cell definition of the immunogenic synapse between the tumorigenic schwann cells and tumor associated macrophages in Plexiform Neurofibroma	Thomas	On	Poster	Evaluating Tumor Progression via 3D and Spatial Approaches	4/18/23	1:30 PM	Section 4	25
4636	High-plex co-detection of RNA and protein to explore tumor-immune interactions utilizing RNAscope with Imaging Mass Cytometry	James	Pemberton	Poster	Evaluating Tumor Progression via 3D and Spatial Approaches	4/18/23	1:30 PM	Section 4	26
4638	Integrative spatial analysis of paired IHC and H&E images identifies Foxp3 enriched tumor-infiltrating lymphocytes associated with disease-free survival in human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma	Sumanth Reddy	Nakkireddy	Poster	Evaluating Tumor Progression via 3D and Spatial Approaches	4/18/23	1:30 PM	Section 4	28

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
4639	Single-cell immunoprofiling and spatial analysis of hormone receptor subtypes in HER2+ and HER2low breast tumors using multiplexed immunofluorescence	Anna	Juncker-Jensen	Poster	Evaluating Tumor Progression via 3D and Spatial Approaches	4/18/23	1:30 PM	Section 4	29
4640	CAF contributes to cancer progression through its immunomodulatory role within the tumor microenvironment	Muriel	Núñez	Poster	Evaluating Tumor Progression via 3D and Spatial Approaches	4/18/23	1:30 PM	Section 4	30
4644	Modeling the effects of niche specific microenvironmental changes on patient-derived organoids	Jennifer	von Schlichting	Poster	Inflammation and Tumor Progression	4/18/23	1:30 PM	Section 5	1
4645	Identification of conditionally active antibodies that selectively block CD39 activity in the acidic tumor microenvironment	F. Donelson	Smith	Poster	Inflammation and Tumor Progression	4/18/23	1:30 PM	Section 5	2
4646	Relative contribution of tumor infiltrating B cells to the tumor microenvironment assessed using an immuno-oncology focussed multi-tumor tissue microarray	Milan	Bhagat	Poster	Inflammation and Tumor Progression	4/18/23	1:30 PM	Section 5	3
4647	Potential of TIMP3 regulating the versican status in the colorectal cancer tumor microenvironment	Anna	Field	Poster	Inflammation and Tumor Progression	4/18/23	1:30 PM	Section 5	4
4648	How inherited mutations affect single cells within the tumor microenvironment in breast tumors stratified by receptor status	Dana	Pueschl	Poster	Inflammation and Tumor Progression	4/18/23	1:30 PM	Section 5	5
4649	Design and validation of ultrahigh-plex discovery panels for immuno-oncology and oncology	Yan	He	Poster	Inflammation and Tumor Progression	4/18/23	1:30 PM	Section 5	6
4650	High intratumoral levels of Notch3 increase tumorigenesis and promote an immunosuppressive TME in EGFR-mutant NSCLC	Shankar	Suman	Poster	Inflammation and Tumor Progression	4/18/23	1:30 PM	Section 5	7
4651	Comparison of the tumor and lymph node immune microenvironment in early non-small cell lung cancer through multimodal single cell sequencing	Zhanhao	Xi	Poster	Inflammation and Tumor Progression	4/18/23	1:30 PM	Section 5	8
4652	A cellular and transcriptomic dissection of the human breast for studying mechanisms of cell and tissue function	William	Hines	Poster	Inflammation and Tumor Progression	4/18/23	1:30 PM	Section 5	9
4653	Spatial architecture of tumor-infiltrating macrophagesorchestrates tumor immunity and therapeutic response	Yuanyuan	Zhang	Poster	Inflammation and Tumor Progression	4/18/23	1:30 PM	Section 5	10
4654	Differential immunomodulation following checkpoint blockade in the orthotopic ID8-luc ovarian model	Sheri	Barnes	Poster	Inflammation and Tumor Progression	4/18/23	1:30 PM	Section 5	11
4655	The prognostic significance of a 12-chemokine tertiary lymphoid structure (TLS) gene signature in uveal melanoma (UM)	Hassan	Abushukair	Poster	Inflammation and Tumor Progression	4/18/23	1:30 PM	Section 5	12
4656	Targeting macrophage PI3KGamma in aggressive prostate cancer	Kenneth	Adusei	Poster	Inflammation and Tumor Progression	4/18/23	1:30 PM	Section 5	13
4657	Topological data analysis reveals pan-cancer immune phenotypes with immune-related survival differences	Kevin	Murgas	Poster	Inflammation and Tumor Progression	4/18/23	1:30 PM	Section 5	14

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
4658	Flexible multiplexed immunofluorescent panels for accelerated identification of spatial signatures for immunotherapy checkpoint investigations	Jacob	Circelli	Poster	Inflammation and Tumor Progression	4/18/23	1:30 PM	Section 5	15
4659	Depicting ONC201/Delta-24-RGD combination for the treatment of pHGGs and DMGs reveals a therapeutic benefit and a proinflammatory tumor microenvironment remodeling	Daniel	de la Nava	Poster	Inflammation and Tumor Progression	4/18/23	1:30 PM	Section 5	16
4664	MatchR a preclinical platform of models resistant to innovative therapies	Ludovic	Bigot	Poster	Patient-Derived Xenograft Models	4/18/23	1:30 PM	Section 6	2
4665	Enhancing preclinical testing of agents in patient-derived pediatric solid tumor orthotopic xenografts with pharmacokinetics	Burgess	Freeman	Poster	Patient-Derived Xenograft Models	4/18/23	1:30 PM	Section 6	3
4666	PDX, mini-brain co-cultures and patient-derived tumor organoids: Preclinical models to study the prion protein in glioblastoma biology	Maria Clara	Souza	Poster	Patient-Derived Xenograft Models	4/18/23	1:30 PM	Section 6	4
4667	Establishment of patient-derived human cell lines using PDX mouse model for intrahepatic cholangiocarcinoma	Takashi	Matsumoto	Poster	Patient-Derived Xenograft Models	4/18/23	1:30 PM	Section 6	5
4668	In-vitro modeling of tumor-associated macrophages in glioblastoma	Hasan	Alrefai	Poster	Patient-Derived Xenograft Models	4/18/23	1:30 PM	Section 6	6
4669	A patient derived xenograft model for lung adenocarcinoma using Obagel®, a human derived hydrogel	Cecilia	Sanchez	Poster	Patient-Derived Xenograft Models	4/18/23	1:30 PM	Section 6	7
4670	True bench-to-bedside science: An international pilot study modeling hard-to-cure pediatric cancers to prioritize therapeutic intervention	Nadine	Azzam	Poster	Patient-Derived Xenograft Models	4/18/23	1:30 PM	Section 6	8
4671	MAO A, MAO B inhibitors and NMI for colon cancer therapy	Shivani	Soni	Poster	Patient-Derived Xenograft Models	4/18/23	1:30 PM	Section 6	9
4672	In-vivo tumor implantation site exhibits differential immune response in solid tumors	Rajeev	Shrimali	Poster	Patient-Derived Xenograft Models	4/18/23	1:30 PM	Section 6	10
4673	Therapeutic potential of polatuzumab vedotin for the treatment of diffuse large B-cell lymphoma	Xiangnan	Qiang	Poster	Patient-Derived Xenograft Models	4/18/23	1:30 PM	Section 6	11
4674	Patient-derived xenograft (PDX) and corresponding cell line models from glioblastoma for drug development, immunology and translational research	Jens	Hoffmann	Poster	Patient-Derived Xenograft Models	4/18/23	1:30 PM	Section 6	12
4675	Chemoresistant patient-derived xenografts to identify treatment options in breast cancer patients not responding to standard chemotherapy	Eivind Valen	Egeland	Poster	Patient-Derived Xenograft Models	4/18/23	1:30 PM	Section 6	13
4676	Deconvolution of extrinsic and intrinsic factors influencing tumor growth in solid cancer PDX models to support design, analysis and application of PDX-based pharmacology studies	Julia	Schueler	Poster	Patient-Derived Xenograft Models	4/18/23	1:30 PM	Section 6	14

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
4677	A preclinical platform of breast cancer PDX and derived cellular models as a tool for pharmacological screening and functional studies	Olivier	Déas	Poster	Patient-Derived Xenograft Models	4/18/23	1:30 PM	Section 6	15
4678	Characterization of a PDX panel covering molecular diversity of non-small cell lung cancer to accelerate the development of precision therapy	Olivier	Deas	Poster	Patient-Derived Xenograft Models	4/18/23	1:30 PM	Section 6	16
4679	Molecular pathology and BTKi pharmacology of DLBCL-PDXs	Jingjing	Wang	Poster	Patient-Derived Xenograft Models	4/18/23	1:30 PM	Section 6	17
4680	Intracranial breast cancer brain metastases (BCBM) models - stereotactic vs. intracarotid inoculation	Sigrid	Cold	Poster	Patient-Derived Xenograft Models	4/18/23	1:30 PM	Section 6	18
4681	Human Cancer Models Initiative (HCMI): A community resource of next-generation cancer models and associated data	Eva	Tonsing-Carter	Poster	Patient-Derived Xenograft Models	4/18/23	1:30 PM	Section 6	19
4682	PDCM Finder: an open global research platform for patient-derived cancer models	Zinaida	Perova	Poster	Patient-Derived Xenograft Models	4/18/23	1:30 PM	Section 6	20
4683	Developing human Ewing sarcoma in vitro models to prioritise new treatments	Elizabeth	Roundhill	Poster	Patient-Derived Xenograft Models	4/18/23	1:30 PM	Section 6	21
4684	Genomic and transcriptomic analysis of a diffuse pleural mesothelioma patient-derived xenograft library	Triparna	Sen	Poster	Patient-Derived Xenograft Models	4/18/23	1:30 PM	Section 6	22
4688	Comprehensive analysis of natural killer cell-associated markers using MultiOmyx™ immunofluorescence assay	Qingyan	Au	Poster	Single Cell and Spatial Considerations of the Tumor Microenvironment	4/18/23	1:30 PM	Section 7	1
4691	Spatially resolved transcriptomics deconvolutes histological prognostic subgroups in patients with colorectal cancer and synchronous liver metastases	Colin	Wood	Poster	Single Cell and Spatial Considerations of the Tumor Microenvironment	4/18/23	1:30 PM	Section 7	4
4692	Comparison of interassay similarity and cellular deconvolution in spatial transcriptomics data using Visum CytAssist	Mario	Rosasco	Poster	Single Cell and Spatial Considerations of the Tumor Microenvironment	4/18/23	1:30 PM	Section 7	5
4694	Single-cell analysis of glioblastoma immune contexture identifies a subset of activated and memory tumor-reactive CD8+ TILs and a Treg signature contributing to TIL irreversible dysfunction	Serena	Pellegatta	Poster	Single Cell and Spatial Considerations of the Tumor Microenvironment	4/18/23	1:30 PM	Section 7	7
4695	Expansion of the extracellular proximity labeling (ePL) technique to novel matrisome targets	Joshua	Rich	Poster	Single Cell and Spatial Considerations of the Tumor Microenvironment	4/18/23	1:30 PM	Section 7	8
4696	Characterizing CD39 and CD73 cell subtypes in the tumor microenvironment using MultiOmyx	Courtney	Todorov	Poster	Single Cell and Spatial Considerations of the Tumor Microenvironment	4/18/23	1:30 PM	Section 7	9

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
4698	Reproducibility in spatial biology: reducing variables to improve the reliability of insight generation	Lisa	Arvidson	Poster	Single Cell and Spatial Considerations of the Tumor Microenvironment	4/18/23	1:30 PM	Section 7	11
4699	Pan-cancer single-cell analysis reveals the interactions of SPP1+MMP12+ macrophages with metastasis-initiating cells that drives metastasis	Baifeng	Zhang	Poster	Single Cell and Spatial Considerations of the Tumor Microenvironment	4/18/23	1:30 PM	Section 7	12
4700	Spatial analysis of the immune microenvironment and tumor cell transition in sarcomatoid renal cell carcinoma	Allison	May	Poster	Single Cell and Spatial Considerations of the Tumor Microenvironment	4/18/23	1:30 PM	Section 7	13
4701	Spatial resolution of tumor and immune cell lineages in the hypoxic microenvironment of pancreatic ductal adenocarcinoma (PDAC)	Melinda	Angus-Hill	Poster	Single Cell and Spatial Considerations of the Tumor Microenvironment	4/18/23	1:30 PM	Section 7	14
4703	Applying spatial omics and computational integrative analyses to study drug responses and cancer immune cell interactions	Quan	Nguyen	Poster	Single Cell and Spatial Considerations of the Tumor Microenvironment	4/18/23	1:30 PM	Section 7	16
4704	Characterizing and developing the clinical grade next generation sequencing based gut microbiome assay with the bioinformatics solution	Danyi	Wang	Poster	Single Cell and Spatial Considerations of the Tumor Microenvironment	4/18/23	1:30 PM	Section 7	17
4705	Profiling of immune cell components and soluble factors in ovarian cancer ascites highlights impaired immune environment	Imane	Nafia	Poster	Single Cell and Spatial Considerations of the Tumor Microenvironment	4/18/23	1:30 PM	Section 7	18
4706	Multispectral immunofluorescence analysis of the olfactory neuroblastoma tumor immune microenvironment reveals macrophage and polymorphonuclear leukocyte stroma localization and tumor parenchyma exclusion	Riley	Larkin	Poster	Single Cell and Spatial Considerations of the Tumor Microenvironment	4/18/23	1:30 PM	Section 7	19
4707	LED photobleaching-based multiplex 3D microscopy of the tumor microenvironment	Jingtian	Zheng	Poster	Single Cell and Spatial Considerations of the Tumor Microenvironment	4/18/23	1:30 PM	Section 7	20
4708	Application of spatially resolved transcriptomics to screen multiple tumor biospecimens using tissue microarrays	Syrus	Mohabbat	Poster	Single Cell and Spatial Considerations of the Tumor Microenvironment	4/18/23	1:30 PM	Section 7	21
4709	Spatial whole transcriptome profiling of human normal liver and HCC uncovers unique insights into metabolic zonation	Andy	Nam	Poster	Single Cell and Spatial Considerations of the Tumor Microenvironment	4/18/23	1:30 PM	Section 7	22
4710	Novel 3D cytotoxicity assay to assess the impact of chimeric antigen receptor (CAR) domain design on the tumor infiltration and cytotoxicity efficacy of CAR T-cell therapies for solid tumors	Adrian	Johnston	Poster	Single Cell and Spatial Considerations of the Tumor Microenvironment	4/18/23	1:30 PM	Section 7	23

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
4712	Spatial biology of tumor-stroma assembloids reveals that nothing is lost, nothing is created, everything is reorganized	Gina	Bouchard	Poster	Single Cell and Spatial Considerations of the Tumor Microenvironment	4/18/23	1:30 PM	Section 7	25
4716	Characterization of 3D genome in nasopharyngeal carcinoma (NPC)	Dittman Lai-Shun	Chung	Poster	Chromatin Structure and Function in Cancer	4/18/23	1:30 PM	Section 8	1
4718	Analyses of epigenetic marks and mechanisms in disease: Your guide to a successful CUT&RUN assay	Angela	Guo	Poster	Chromatin Structure and Function in Cancer	4/18/23	1:30 PM	Section 8	3
4719	Alterations of chromatin structure and TGF- β signaling in ARID1A-mutated colon cancer cells	Jiwon	Kim	Poster	Chromatin Structure and Function in Cancer	4/18/23	1:30 PM	Section 8	4
4720	Chromatin conformation alterations in prostate cancer progression and formation of castration resistance	Tuomo	Virtanen	Poster	Chromatin Structure and Function in Cancer	4/18/23	1:30 PM	Section 8	5
4721	Yin Yang 1-induced long non-coding RNA DUXAP9 drives oral squamous cell carcinoma by blocking CDK1-mediated EZH2 degradation	Wei	Cao	Poster	Chromatin Structure and Function in Cancer	4/18/23	1:30 PM	Section 8	6
4722	Chronic upregulation of glucocorticoid hormones triggers chromatin remodeling in NSCLC through dynamic regulation of histone H3 chaperones	Benito	Traversa	Poster	Chromatin Structure and Function in Cancer	4/18/23	1:30 PM	Section 8	7
4723	DNA G-quadruplex facilitates MYC enhancer-promotor interaction	Dieila	De Lima	Poster	Chromatin Structure and Function in Cancer	4/18/23	1:30 PM	Section 8	8
4724	Single cell multiomic profiling of high-grade serous carcinoma	Leticia	Assad Maia Sandoval	Poster	Chromatin Structure and Function in Cancer	4/18/23	1:30 PM	Section 8	9
4725	The epigenetic determinants of BTKi efficacy in chronic lymphocytic leukemia	Zhiquan	Wang	Poster	Chromatin Structure and Function in Cancer	4/18/23	1:30 PM	Section 8	10
4726	KMT5C-dependent regulation of mesenchymal-related genes and identification of KMT5C interactome using BioID	Jihye	Son	Poster	Chromatin Structure and Function in Cancer	4/18/23	1:30 PM	Section 8	11
4727	RAS and PP2A activities converge on phosphoregulation of epigenetic complexes in cancer	Jukka	Westermarck	Poster	Chromatin Structure and Function in Cancer	4/18/23	1:30 PM	Section 8	12
4728	Biochemical and genomic approaches for high throughput drug discovery in chromatin remodeling research	Lu	Sun	Poster	Chromatin Structure and Function in Cancer	4/18/23	1:30 PM	Section 8	13
4729	LSD1 activates oncogenic super-enhancers in castration-resistant prostate cancer by forming nuclear condensates with BRD4	Mingyu	Liu	Poster	Chromatin Structure and Function in Cancer	4/18/23	1:30 PM	Section 8	14
4730	ASCL1 activates neuronal stem cell-like lineage programming through the remodeling of the chromatin landscape in prostate cancer	Shaghayegh	Nouruzi	Poster	Chromatin Structure and Function in Cancer	4/18/23	1:30 PM	Section 8	15
4731	Novel epigenetics technology for high-throughput processing of limited samples to study cancer using cavitation-based pixelated ultrasound and tagmentation-indexing ChIP-Seq	Rwik	Sen	Poster	Chromatin Structure and Function in Cancer	4/18/23	1:30 PM	Section 8	16

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
4733	Effect of KDM6A mutation in bladder cancer	Ninh	Le	Poster	Chromatin Structure and Function in Cancer	4/18/23	1:30 PM	Section 8	18
4734	BRD8-driven EP400 complex hijacks H2AZ to maintain proliferation in glioblastoma	Sherine Xueqin	Sun	Poster	Chromatin Structure and Function in Cancer	4/18/23	1:30 PM	Section 8	19
4738	Dysregulated miR-371b-5p/CSDE1/RAC1 axis is involved in pathogenesis of triple-negative breast cancer	Jong Hoon	Park	Poster	Epigenetic Mechanisms as Drivers of Tumorigenesis	4/18/23	1:30 PM	Section 9	1
4740	Molecular effects of histone deacetylase inhibitor Quisinostat on diffuse midline glioma of the pons	Danyelle	Paine	Poster	Epigenetic Mechanisms as Drivers of Tumorigenesis	4/18/23	1:30 PM	Section 9	3
4741	NUDT21 regulates PIGN through APA mechanism to affect the progression of MDS and AML	Jeffrey	Pu	Poster	Epigenetic Mechanisms as Drivers of Tumorigenesis	4/18/23	1:30 PM	Section 9	4
4742	Familial adenomatous polyposis epigenetic landscape as a precancer model of colorectal cancer	Hayan	Lee	Poster	Epigenetic Mechanisms as Drivers of Tumorigenesis	4/18/23	1:30 PM	Section 9	5
4743	Wnt/beta-catenin mediated epigenetic modifications drive age-dependent oral squamous cell carcinoma evolution	Emily	Fisher	Poster	Epigenetic Mechanisms as Drivers of Tumorigenesis	4/18/23	1:30 PM	Section 9	6
4744	Epigenetic reprogramming induced by lipids fosters mammary cell plasticity in non-transformed breast epithelial cells	Mariana	Bustamante Eduardo	Poster	Epigenetic Mechanisms as Drivers of Tumorigenesis	4/18/23	1:30 PM	Section 9	7
4745	Prostatic fluid-based cfDNA methylation profiling distinguish benign hyperplasia from prostate cancer	Hang	Dong	Poster	Epigenetic Mechanisms as Drivers of Tumorigenesis	4/18/23	1:30 PM	Section 9	8
4746	Amelioration of hemoglobinopathies by targeted deletion of zinc finger domain within BCL11A gene using CRISPR-Cas9 technology	Afsar Ali	Mian	Poster	Epigenetic Mechanisms as Drivers of Tumorigenesis	4/18/23	1:30 PM	Section 9	9
4747	NSD2 mutation drives oncogenic programming in mantle cell lymphoma	Jianping	Li	Poster	Epigenetic Mechanisms as Drivers of Tumorigenesis	4/18/23	1:30 PM	Section 9	10
4749	Effects of miR-34a-5p and miR-181b-5p silencing and induction on their potential targets in uterine leiomyosarcoma cells	Katia	Carvalho	Poster	Epigenetic Mechanisms as Drivers of Tumorigenesis	4/18/23	1:30 PM	Section 9	12
4750	TWIST2 mediated chromatin remodeling promotes fusion-negative rhabdomyosarcoma	Akansha	Shah	Poster	Epigenetic Mechanisms as Drivers of Tumorigenesis	4/18/23	1:30 PM	Section 9	13
4751	The function of bromodomain containing protein 4 (BRD44) in hematopoiesis	Francine	Nihozeko	Poster	Epigenetic Mechanisms as Drivers of Tumorigenesis	4/18/23	1:30 PM	Section 9	14
4752	Loss of the methyltransferase KMT5C drives resistance to tyrosine kinase inhibitors via H4K20me3 regulation in non-small cell lung cancer	Alejandra	Agredo	Poster	Epigenetic Mechanisms as Drivers of Tumorigenesis	4/18/23	1:30 PM	Section 9	15
4753	LSD1 mediated FOXA2/AP1 transcription program drives lineage plasticity in prostate cancer	Zifeng	Wang	Poster	Epigenetic Mechanisms as Drivers of Tumorigenesis	4/18/23	1:30 PM	Section 9	16
4754	Investigating the impact of hotspot mutations in a chromatin reader on leukemogenesis	Yiman	Liu	Poster	Epigenetic Mechanisms as Drivers of Tumorigenesis	4/18/23	1:30 PM	Section 9	17
4755	Screening non-small cell lung cancer organoids with epigenetic probes	Khadija	Jafarova	Poster	Epigenetic Mechanisms as Drivers of Tumorigenesis	4/18/23	1:30 PM	Section 9	18

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
4756	NSD1/2 histone methyltransferases regulate cell growth in HPV-negative head and neck squamous cell carcinoma (HNSCC)	Iuliia	Topchu	Poster	Epigenetic Mechanisms as Drivers of Tumorigenesis	4/18/23	1:30 PM	Section 9	19
4757	Loss of KDM5A supports KRAS-driven pancreatic cancer	Jasper	Chen	Poster	Epigenetic Mechanisms as Drivers of Tumorigenesis	4/18/23	1:30 PM	Section 9	20
4758	SETD4 transcription levels correlates with leukemic burden and SMYD2 transcription in acute lymphoblastic leukemia	Fabio	Pittella-Silva	Poster	Epigenetic Mechanisms as Drivers of Tumorigenesis	4/18/23	1:30 PM	Section 9	21
4759	Dissecting EP300 and CBP function in prostate cancer models	Kiran	Mirpuri	Poster	Epigenetic Mechanisms as Drivers of Tumorigenesis	4/18/23	1:30 PM	Section 9	22
4760	KDM4A promotes NEPC progression through regulation of MYC expression	Guocan	Wang	Poster	Epigenetic Mechanisms as Drivers of Tumorigenesis	4/18/23	1:30 PM	Section 9	23
4761	Identifying molecular targets to overcome CNS infiltration in acute lymphoblastic leukemia associated with an activating mutation of the NSD2 histone methyltransferase	Charlotte	Kaestner	Poster	Epigenetic Mechanisms as Drivers of Tumorigenesis	4/18/23	1:30 PM	Section 9	24
4762	Oncogenic over-expression of MED12 is epigenetically fostered in the core-binding factor subgroups of acute myeloid leukemia	Samrat	Roy Choudhury	Poster	Epigenetic Mechanisms as Drivers of Tumorigenesis	4/18/23	1:30 PM	Section 9	25
4763	Two epigenetically distinct cellular states in osteosarcoma are regulated by a state-specific set of transcription factors driving differential drug response	Eunice	Lopez Fuentes	Poster	Epigenetic Mechanisms as Drivers of Tumorigenesis	4/18/23	1:30 PM	Section 9	26
4764	The therapeutic potential of Inc-HLX-2-7 in group 3 medulloblastomas in children	Keisuke	Katsushima	Poster	Epigenetic Mechanisms as Drivers of Tumorigenesis	4/18/23	1:30 PM	Section 9	27
4766	Hypoxia increases the methylated histones to prevent histone clipping during Raf-induced senescence	Hyunsung	Park	Poster	Epigenetic Mechanisms as Drivers of Tumorigenesis	4/18/23	1:30 PM	Section 9	29
4771	Prevention of doxorubicin-induced cardiotoxicity by benfotiamine	Justin	Taylor	Poster	Oxidative Stress, Metabolism, and Cell Senescence	4/18/23	1:30 PM	Section 10	1
4772	β 3-adrenoceptor minimize doxorubicin effect in Ewing sarcoma by UCP2 activation	Claudia	Masi	Poster	Oxidative Stress, Metabolism, and Cell Senescence	4/18/23	1:30 PM	Section 10	2
4773	DEAD Box 1 (DDX1) protects its RNA targets in cells exposed to oxidative stress	Mansi	Garg	Poster	Oxidative Stress, Metabolism, and Cell Senescence	4/18/23	1:30 PM	Section 10	3
4774	Adaptation to chronic oxidative stress promotes metabolic rewiring to maintain redox balance in HER2+ breast tumors	Caitlynn	Mirabelli	Poster	Oxidative Stress, Metabolism, and Cell Senescence	4/18/23	1:30 PM	Section 10	4
4775	Knockout of Sod2 accelerates KrasG12D-driven formation of pancreatic cancerous lesions	Alicia	Fleming Martinez	Poster	Oxidative Stress, Metabolism, and Cell Senescence	4/18/23	1:30 PM	Section 10	5
4776	NRF2 is overexpressed in esophageal adenocarcinoma and its targeting sensitizes tumor cells to cisplatin through induction of ferroptosis and apoptosis	Dunfa	Peng	Poster	Oxidative Stress, Metabolism, and Cell Senescence	4/18/23	1:30 PM	Section 10	6
4777	Exploring ferroptosis pathway for the development of therapeutic strategy in liposarcoma	Chueh-Chuan	Yen	Poster	Oxidative Stress, Metabolism, and Cell Senescence	4/18/23	1:30 PM	Section 10	7

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
4778	Novel bioluminescence approaches for measuring fatty acid β -oxidation and production of reactive oxygen and nitrogen species	Kim	Haupt	Poster	Oxidative Stress, Metabolism, and Cell Senescence	4/18/23	1:30 PM	Section 10	8
4779	MnSOD mimetic mitoquinone mesylate (MitoQ) increases DCLK1+pancreatic cancer stem cells	Jeffrey	Perera	Poster	Oxidative Stress, Metabolism, and Cell Senescence	4/18/23	1:30 PM	Section 10	9
4780	Comparison of safety and efficacy outcomes with nonthermal plasma and tirapazamine in porcine skin and mouse melanoma models	Shoshanna	Zucker	Poster	Oxidative Stress, Metabolism, and Cell Senescence	4/18/23	1:30 PM	Section 10	10
4782	A biflavonoid TY1 induced mitochondrial oxidative stress in 5-fluorouracil-resistant colorectal cancer cells to suppress tumor progression	Ting-Yan	Jian	Poster	Oxidative Stress, Metabolism, and Cell Senescence	4/18/23	1:30 PM	Section 10	12
4783	ADO is essential for redox homeostasis in liver cancer	Marianne	Koritzinsky	Poster	Oxidative Stress, Metabolism, and Cell Senescence	4/18/23	1:30 PM	Section 10	13
4784	Multiomic landscape of evolution of Warburg effect identifies drivers of breast cancer	Rafael	Renatino Canevarolo	Poster	Oxidative Stress, Metabolism, and Cell Senescence	4/18/23	1:30 PM	Section 10	14
4785	S-nitrosylation of p53 in melanoma alters p53-DNA binding and downstream gene expression	Jordan	Winfield	Poster	Oxidative Stress, Metabolism, and Cell Senescence	4/18/23	1:30 PM	Section 10	15
4786	Imipridones induce lipid peroxidation and oxidative stress in gastrointestinal malignancies	Arielle	De La Cruz	Poster	Oxidative Stress, Metabolism, and Cell Senescence	4/18/23	1:30 PM	Section 10	16
4787	The cancer targeting synergy of tertbutylhydroquinone and a manganese porphyrin	Joseph	LaMorte	Poster	Oxidative Stress, Metabolism, and Cell Senescence	4/18/23	1:30 PM	Section 10	17
4788	Oxidative stress promotes colorectal cancer aggressiveness through transmembrane chloride intracellular channel 1 (tmCLIC1) antioxidant activity	Francesca	Cianci	Poster	Oxidative Stress, Metabolism, and Cell Senescence	4/18/23	1:30 PM	Section 10	18
4789	Spin oscillating magnetic field sOMF of oncomagnetic device selectively kills glioma cancer cells by inducing oxidative stress and DNA damage	Shashank	Hambarde	Poster	Oxidative Stress, Metabolism, and Cell Senescence	4/18/23	1:30 PM	Section 10	19
4790	Oxidation in the nucleotide pool as a novel targetable vulnerability in pancreatic ductal adenocarcinoma	Beatriz	Mateo-Victoriano	Poster	Oxidative Stress, Metabolism, and Cell Senescence	4/18/23	1:30 PM	Section 10	20
4792	Characterizing cellular senescence response to senolytic compounds using cell culture media analysis	Evelyn	Wang	Poster	Oxidative Stress, Metabolism, and Cell Senescence	4/18/23	1:30 PM	Section 10	22
4793	A role for fibroblast derived SASP factors in the activation of non-apoptotic cell death in normal mammary epithelial cells	Lisa	Hom	Poster	Oxidative Stress, Metabolism, and Cell Senescence	4/18/23	1:30 PM	Section 10	23
4794	Deciphering tumor recurrence post-therapy: Interactions between the tumor microenvironment and therapy-induced senescent glioblastoma	Valerie	DeLuca	Poster	Oxidative Stress, Metabolism, and Cell Senescence	4/18/23	1:30 PM	Section 10	24
4795	Conditionally active biologics eliminates senescence cells in cancer and aging	Jian	Chen	Poster	Oxidative Stress, Metabolism, and Cell Senescence	4/18/23	1:30 PM	Section 10	25

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
4796	Chemotherapy induced senescence drives peripheral neuropathy	Taylor	Malachowski	Poster	Oxidative Stress, Metabolism, and Cell Senescence	4/18/23	1:30 PM	Section 10	26
4797	β 3-AR blockade induces differentiation of malignant leukemia T cells in mature T lymphocytes	Francesco	Carrozzo	Poster	Oxidative Stress, Metabolism, and Cell Senescence	4/18/23	1:30 PM	Section 10	27
4801	Laurine acid enhances GEM-chemosensitivity targeting hypoxia-induced mitochondrial dysfunction and stemness in pancreatic ductal adenocarcinoma	Tadataka	Takagi	Poster	Responses to Hypoxic, Proteotoxic, and Other Novel Forms of Cell Stress	4/18/23	1:30 PM	Section 11	1
4802	Identification of critical hypoxia induced factors in castrate resistant prostate cancer	Oloruntoba	Osagie	Poster	Responses to Hypoxic, Proteotoxic, and Other Novel Forms of Cell Stress	4/18/23	1:30 PM	Section 11	2
4803	BMAL2 is a KRAS-dependent master regulator of hypoxic response in pancreatic ductal adenocarcinoma	Alvaro	Curiel Garcia	Poster	Responses to Hypoxic, Proteotoxic, and Other Novel Forms of Cell Stress	4/18/23	1:30 PM	Section 11	3
4804	p38 MAPK-dependent regulation of HIF-1 and expression of the hypoxia-inducible gene IGFBP-3 in leiomyosarcoma cells	Nuha	Haque	Poster	Responses to Hypoxic, Proteotoxic, and Other Novel Forms of Cell Stress	4/18/23	1:30 PM	Section 11	4
4806	Spry1 as a potential new hypoxia modulator in cutaneous melanoma	Barbara	Montico	Poster	Responses to Hypoxic, Proteotoxic, and Other Novel Forms of Cell Stress	4/18/23	1:30 PM	Section 11	6
4807	BACH1 proline hydroxylation regulates the hypoxia response and metastasis in triple negative breast cancer	Long	Nguyen	Poster	Responses to Hypoxic, Proteotoxic, and Other Novel Forms of Cell Stress	4/18/23	1:30 PM	Section 11	7
4808	Hypoxic HIF-1 α stabilization dependent on β 3-adrenoceptor localization in Ewing sarcoma	Amada	Pasha	Poster	Responses to Hypoxic, Proteotoxic, and Other Novel Forms of Cell Stress	4/18/23	1:30 PM	Section 11	8
4809	A novel microfluidic platform for PDAC organoid culture and drug screening	Désirée	Goubert	Poster	Responses to Hypoxic, Proteotoxic, and Other Novel Forms of Cell Stress	4/18/23	1:30 PM	Section 11	9
4810	HIF1 α is involved in radiation-induced DNA damage repair and anti-apoptotic pathways in pancreatic ductal adenocarcinoma	Kevin	Tu	Poster	Responses to Hypoxic, Proteotoxic, and Other Novel Forms of Cell Stress	4/18/23	1:30 PM	Section 11	10
4811	Oxygen tension - dependent differences in cancer cell kinome	Adedeji	Adebayo	Poster	Responses to Hypoxic, Proteotoxic, and Other Novel Forms of Cell Stress	4/18/23	1:30 PM	Section 11	11
4812	Inhibition of Smurf2 E3 ubiquitin ligase by heclin and its analogues enhances HIF-1 α expression and transcriptional activity in normoxia or hypoxia	Shuai	Zhao	Poster	Responses to Hypoxic, Proteotoxic, and Other Novel Forms of Cell Stress	4/18/23	1:30 PM	Section 11	12

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
4813	ERX-208 as a novel therapeutic for treating ovarian cancer by enhancing endoplasmic reticulum stress	Suryavathi	Viswanadhapalli	Poster	Responses to Hypoxic, Proteotoxic, and Other Novel Forms of Cell Stress	4/18/23	1:30 PM	Section 11	13
4814	Compensatory interplay of p97 segregase and HSP70 chaperone protect cancer cells from heat-induced proteotoxicity	Zdenek	Skrott	Poster	Responses to Hypoxic, Proteotoxic, and Other Novel Forms of Cell Stress	4/18/23	1:30 PM	Section 11	14
4815	TMEM9 decreases ER stress-induced misfolded proteins via lysosomal protein degradation	Dong-Han	Wi	Poster	Responses to Hypoxic, Proteotoxic, and Other Novel Forms of Cell Stress	4/18/23	1:30 PM	Section 11	15
4816	Targeting GCN2 regulation of amino acid homeostasis sensitizes prostate cancer cells to senolytic therapies	Noah	Sommers	Poster	Responses to Hypoxic, Proteotoxic, and Other Novel Forms of Cell Stress	4/18/23	1:30 PM	Section 11	16
4817	Protein aggregation promotes HSF1 activity enhancing cell survival during metastatic breast cancer colonization	Natasha	Hockaden	Poster	Responses to Hypoxic, Proteotoxic, and Other Novel Forms of Cell Stress	4/18/23	1:30 PM	Section 11	17
4818	GCN2 eIF2 kinase and p53 coordinate amino acid homeostasis and metabolism in prostate cancer	Ricardo	Cordova	Poster	Responses to Hypoxic, Proteotoxic, and Other Novel Forms of Cell Stress	4/18/23	1:30 PM	Section 11	18
4819	Mechanism of disturbance of nuclear size homeostasis in cancer cells	Changgon	Kim	Poster	Responses to Hypoxic, Proteotoxic, and Other Novel Forms of Cell Stress	4/18/23	1:30 PM	Section 11	19
4820	The disassembly of amyloid-bodies	Chloe	Kirk	Poster	Responses to Hypoxic, Proteotoxic, and Other Novel Forms of Cell Stress	4/18/23	1:30 PM	Section 11	20
4821	Exploring the role of a solid-like condensate in breast and prostate cancer	Alexander	Grunfeld	Poster	Responses to Hypoxic, Proteotoxic, and Other Novel Forms of Cell Stress	4/18/23	1:30 PM	Section 11	21
4822	Signaling pathways associated with stress factors in gastrointestinal cancers	Amayrani	Sanchez	Poster	Responses to Hypoxic, Proteotoxic, and Other Novel Forms of Cell Stress	4/18/23	1:30 PM	Section 11	22
4823	The novel miR-15a/Fra-2/IGF1R axis drives response to starvation-induced cell stress in pancreatic ductal adenocarcinoma	Gian Luca	Rampioni Vinciguerra	Poster	Responses to Hypoxic, Proteotoxic, and Other Novel Forms of Cell Stress	4/18/23	1:30 PM	Section 11	23
4824	Intracellular ferritin expression levels regulate growth and resistance to ferroptosis in pancreatic cancer cell lines	Masataka	Maruno	Poster	Responses to Hypoxic, Proteotoxic, and Other Novel Forms of Cell Stress	4/18/23	1:30 PM	Section 11	24

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
4828	Therapeutic targeting of P2X4 receptor and mitochondrial membrane potential in renal cell carcinoma	Christopher	Rupert	Poster	Role of Mitochondria and Signaling Pathways in Cancer	4/18/23	1:30 PM	Section 12	1
4829	Monitoring metabolic plasticity in the tumor microenvironment in vivo	Marissa	Howard	Poster	Role of Mitochondria and Signaling Pathways in Cancer	4/18/23	1:30 PM	Section 12	2
4830	Uncoupling protein 2 (UCP2) loss of function mediates PDAC tumor suppression by mitochondrial fusion	Ariana	Acevedo-Diaz	Poster	Role of Mitochondria and Signaling Pathways in Cancer	4/18/23	1:30 PM	Section 12	3
4831	Mitochondrial plasticity enables metabolic reprogramming and metastatic latency	Pravat	Parida	Poster	Role of Mitochondria and Signaling Pathways in Cancer	4/18/23	1:30 PM	Section 12	4
4832	Copy number amplification of OXPHOS genes drives tumor hypoxia in NSCLC	Martin	Benej	Poster	Role of Mitochondria and Signaling Pathways in Cancer	4/18/23	1:30 PM	Section 12	5
4833	Inhibiting the mitochondrial RNA degradosome complex SUV3 and PNPase increases dsRNA in the cytoplasm, triggers a viral mimicry response and kills AML cells and progenitors	Geethu	Thomas	Poster	Role of Mitochondria and Signaling Pathways in Cancer	4/18/23	1:30 PM	Section 12	6
4834	Mitochondrial ClpXP degrades serine phosphorylated protein aggregates	Yue	Feng	Poster	Role of Mitochondria and Signaling Pathways in Cancer	4/18/23	1:30 PM	Section 12	7
4835	EP4 increases the mitochondrial respiration and promotes cell migration in oral cancer	Rina	Nakakaji	Poster	Role of Mitochondria and Signaling Pathways in Cancer	4/18/23	1:30 PM	Section 12	8
4836	Fasting induces greater expression of mitochondrial proteins associated with fatty acid metabolism and non-shivering thermogenesis in brown adipose tissue of knock-in ACSS1K635Q mice	Aishani	Gargapati	Poster	Role of Mitochondria and Signaling Pathways in Cancer	4/18/23	1:30 PM	Section 12	9
4837	Inhibition of mitochondrial fission activates glycogen storage to support cell survival in colon cancer	Sumati	Hasani	Poster	Role of Mitochondria and Signaling Pathways in Cancer	4/18/23	1:30 PM	Section 12	10
4838	Exploiting mitochondrial metabolism to enhance the response to standard of care treatments in ovarian cancer	Laura	Formenti	Poster	Role of Mitochondria and Signaling Pathways in Cancer	4/18/23	1:30 PM	Section 12	11
4839	Chemotherapy alters mitochondrial metabolism in melanoma	Alexander	Loftus	Poster	Role of Mitochondria and Signaling Pathways in Cancer	4/18/23	1:30 PM	Section 12	12
4840	Dysregulation of mitochondrial function by PLK1-mediated PDHA1 phosphorylation promotes Cr(VI)-associated lung cancer progression	Qionsgi	Zhang	Poster	Role of Mitochondria and Signaling Pathways in Cancer	4/18/23	1:30 PM	Section 12	13
4841	SLC25A46 as a novel mitochondrial regulator and biomarker in breast cancer	Heather	Beasley	Poster	Role of Mitochondria and Signaling Pathways in Cancer	4/18/23	1:30 PM	Section 12	14
4842	Stress-induced mitochondrial adaptations in the polyan euploid cancer cell state	Melvin	Li	Poster	Role of Mitochondria and Signaling Pathways in Cancer	4/18/23	1:30 PM	Section 12	15
4843	Characterization of T-cell metabolic defects in chronic lymphocytic leukemia preclinical model	Wael	Gamal	Poster	Role of Mitochondria and Signaling Pathways in Cancer	4/18/23	1:30 PM	Section 12	16

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
4844	Development of an oxygen consumption rate assay for a standard plate reader	Ian	Marozas	Poster	Role of Mitochondria and Signaling Pathways in Cancer	4/18/23	1:30 PM	Section 12	17
4845	Ultra-deep sequencing of mitochondrial genome to explore the dynamic mutational changes associated with oral cavity squamous cell carcinoma progression	Alka	Singh	Poster	Role of Mitochondria and Signaling Pathways in Cancer	4/18/23	1:30 PM	Section 12	18
4846	Mitochondria packaged from platelet-derived microvesicles modulate the metabolism and mitochondrial dynamics of breast cancer cells	Vanessa	Gauvin	Poster	Role of Mitochondria and Signaling Pathways in Cancer	4/18/23	1:30 PM	Section 12	19
4847	Investigating the transcriptional regulation by estrogen-related receptor alpha (ERR α) under different metabolic conditions	Brittney	Hua	Poster	Role of Mitochondria and Signaling Pathways in Cancer	4/18/23	1:30 PM	Section 12	20
4848	Effects of cinnamon extracted under acidic conditions on proliferation of MCF7 cells	Madison	Anderson	Poster	Role of Mitochondria and Signaling Pathways in Cancer	4/18/23	1:30 PM	Section 12	21
4849	PPAR γ and FoxO1 expression and activity in aqueous cinnamon extract treated cells	Sean	Mild	Poster	Role of Mitochondria and Signaling Pathways in Cancer	4/18/23	1:30 PM	Section 12	22
4850	High salt diet induced tumor initiating stem cells mediate breast cancer progression	Lisa	Tucker	Poster	Role of Mitochondria and Signaling Pathways in Cancer	4/18/23	1:30 PM	Section 12	23
4851	Improving the efficacy of dual ERK-MAPK and autophagy inhibition as a therapeutic strategy for pancreatic ductal adenocarcinoma	Jonathan	DeLiberty	Poster	Role of Mitochondria and Signaling Pathways in Cancer	4/18/23	1:30 PM	Section 12	24
4852	Metabolomic rewiring in endocrine therapy resistant estrogen receptor positive breast cancer	Songyeon	Ahn	Poster	Role of Mitochondria and Signaling Pathways in Cancer	4/18/23	1:30 PM	Section 12	25
4853	Evaluating the role of melatonin in thyroid cancer cell (MDA-T41) apoptosis and metabolism modulation	Daniel	Sanches	Poster	Role of Mitochondria and Signaling Pathways in Cancer	4/18/23	1:30 PM	Section 12	26
4854	PKM2 Modulates hepatic macrophage regulation of NASH, ferroptosis and HCC through TGF- β signaling	Kazufumi	Ohshiro	Poster	Role of Mitochondria and Signaling Pathways in Cancer	4/18/23	1:30 PM	Section 12	27
4858	Effect of mTOR activity in peripheral blood mononuclear cells with metformin in high-risk prostate cancer patients receiving external beam radiotherapy and androgen deprivation therapy	Febin	Antony	Poster	Anticancer Approaches Targeting Signal Transduction Pathways	4/18/23	1:30 PM	Section 13	1
4859	Bi-steric mTORC1 inhibitors are superior to rapamycin and induce apoptotic cell death in tumor models with hyperactivated mTORC1	Heng	Du	Poster	Anticancer Approaches Targeting Signal Transduction Pathways	4/18/23	1:30 PM	Section 13	2
4860	PI3K inhibition sensitize cancer cells to tumor treating fields (TTFields)	Bella	Koltun	Poster	Anticancer Approaches Targeting Signal Transduction Pathways	4/18/23	1:30 PM	Section 13	3
4861	Copanlisib enhances the effectiveness of anti-PD1 therapies for colorectal cancer	Alexa	Schmitz	Poster	Anticancer Approaches Targeting Signal Transduction Pathways	4/18/23	1:30 PM	Section 13	4
4862	Investigation of the JAK/STAT signaling pathway in chemotherapy and PARP inhibitor resistant ovarian cancer	Esther	Rodman	Poster	Anticancer Approaches Targeting Signal Transduction Pathways	4/18/23	1:30 PM	Section 13	5

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
4863	PMCA inhibition induces cytotoxic calcium stress and suppression of Wnt signaling in refractory molecular subtype of gastric cancer	Saeli	Ban	Poster	Anticancer Approaches Targeting Signal Transduction Pathways	4/18/23	1:30 PM	Section 13	6
4864	ALK inhibitors downregulate the expression of death receptor 4 in ALK-mutant NSCLC cells via facilitating Fra-1 and c-Jun degradation and subsequent AP-1 suppression	Shi-Yong	Sun	Poster	Anticancer Approaches Targeting Signal Transduction Pathways	4/18/23	1:30 PM	Section 13	7
4865	Mechanisms of EGFR inhibitor sensitivity and resistance in chordoma	Daniel	Freed	Poster	Anticancer Approaches Targeting Signal Transduction Pathways	4/18/23	1:30 PM	Section 13	8
4866	Pharmacological mechanisms of osimertinib in advanced non-small lung cancer bearing the deletion exon 19 of EGFR In an original chicken chorioallantoic membrane (CAM) Model.	David	Barthelemy	Poster	Anticancer Approaches Targeting Signal Transduction Pathways	4/18/23	1:30 PM	Section 13	9
4867	Effect of FGFR3 activity on Nectin-4 expression in urothelial carcinoma	Sean	Clark-Garvey	Poster	Anticancer Approaches Targeting Signal Transduction Pathways	4/18/23	1:30 PM	Section 13	10
4868	Targeting of ERG positive prostate cancers with ERGi-USU-6 salt derivative	Binil	Eldhose	Poster	Anticancer Approaches Targeting Signal Transduction Pathways	4/18/23	1:30 PM	Section 13	11
4869	Furin and Notch signaling pathway as part of the 2OHOA landscape against glioblastoma	Victoria	Llado	Poster	Anticancer Approaches Targeting Signal Transduction Pathways	4/18/23	1:30 PM	Section 13	12
4871	Dysregulation of MYC-family proteins sensitizes cancers to NMT inhibition: identification of NMTi sensitivity and mechanism	James	Zhang	Poster	Anticancer Approaches Targeting Signal Transduction Pathways	4/18/23	1:30 PM	Section 13	14
4872	DCC-3116, a first-in-class selective ULK1/2 inhibitor of autophagy, in combination with the KIT inhibitor ripretinib induces complete regressions in GIST preclinical models	Madhumita	Bogdan	Poster	Anticancer Approaches Targeting Signal Transduction Pathways	4/18/23	1:30 PM	Section 13	15
4873	Pimavanserin suppresses glioblastoma progression by modulating the Akt/FOXO/Bim signaling axis	Manas Yogendra	Agrawal	Poster	Anticancer Approaches Targeting Signal Transduction Pathways	4/18/23	1:30 PM	Section 13	16
4874	Hyperforin induces apoptosis and inhibits invasion via inhibiting AKT/NF-KB signaling pathway in colorectal cancer cells	Ying-Tzu	Chen	Poster	Anticancer Approaches Targeting Signal Transduction Pathways	4/18/23	1:30 PM	Section 13	17
4875	The anti-tumor effects of GSK-3 β inhibitor (9-1NG-41) in ETMR and ATRT pediatric brain tumors	Divya	Gandra	Poster	Anticancer Approaches Targeting Signal Transduction Pathways	4/18/23	1:30 PM	Section 13	18
4876	A systems pharmacology approach to discover synergistic targeted therapy combinations	Cameron	Flower	Poster	Anticancer Approaches Targeting Signal Transduction Pathways	4/18/23	1:30 PM	Section 13	19
4877	Mutant or overexpressed SF3B1 facilitates endometrial cancer tumorigenesis	Pooja	Popli	Poster	Anticancer Approaches Targeting Signal Transduction Pathways	4/18/23	1:30 PM	Section 13	20
4878	Transcriptional response to rocaglate translation inhibitors in lymphoma shows cellular adaptation through induction of stress and survival pathways	Paola	Manara	Poster	Anticancer Approaches Targeting Signal Transduction Pathways	4/18/23	1:30 PM	Section 13	21
4879	Inhibition of amino acid transporters as a novel mechanism of action of the repurposed anti-cancer agent tranexamic acid	Brian	Law	Poster	Anticancer Approaches Targeting Signal Transduction Pathways	4/18/23	1:30 PM	Section 13	22

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
4880	Anti-membrane IgM monoclonal antibody, WBMP-4, induces apoptosis in B-cell malignancies by modulation of kinase expression and phosphorylation	Rachel	Welt	Poster	Anticancer Approaches Targeting Signal Transduction Pathways	4/18/23	1:30 PM	Section 13	23
4881	Anti-cancer efficacy of a novel phenothiazine derivative is independent of dopamine and serotonin receptor inhibition	Marion	Vanneste	Poster	Anticancer Approaches Targeting Signal Transduction Pathways	4/18/23	1:30 PM	Section 13	24
4882	Multi-omics analysis of mechanisms underlying sensitivity of Merkel cell carcinoma to pyrvinium pamoate	Jiawen	Yang	Poster	Anticancer Approaches Targeting Signal Transduction Pathways	4/18/23	1:30 PM	Section 13	25
4883	Pan cancer transcriptomic response to tumor treating fields (TTFields)	Moshe	Giladi	Poster	Anticancer Approaches Targeting Signal Transduction Pathways	4/18/23	1:30 PM	Section 13	26
4884	Targeted investigational oncology agents (IOA) in the NCI60: a phenotypic systems-based resource	Joel	Morris	Poster	Anticancer Approaches Targeting Signal Transduction Pathways	4/18/23	1:30 PM	Section 13	27
4885	APR-246 cytotoxic effects are TP53 independent in endometrial cancer cell lines	Camilla	Yu	Poster	Anticancer Approaches Targeting Signal Transduction Pathways	4/18/23	1:30 PM	Section 13	28
4886	PARP-1 and γ -GCS inhibitors enhance platinum sensitivity in ovarian cancer	Luxmi	Devi	Poster	Anticancer Approaches Targeting Signal Transduction Pathways	4/18/23	1:30 PM	Section 13	29
4890	A novel topoisomerase I inhibitor antibody-drug conjugate targeting CEACAM5 has potent anti-tumor activity in colorectal cancer models	Yves	Baudat	Poster	Anticancer Approaches: Antibody-Drug Conjugates, Epigenetics, and Tumor Environment	4/18/23	1:30 PM	Section 14	1
4891	Ifinatamab deruxtecan (I-DXd), a novel B7-H3-targeting antibody-drug conjugate, demonstrates efficient payload delivery into tumor through target-dependent internalization	Len	Katsumata	Poster	Anticancer Approaches: Antibody-Drug Conjugates, Epigenetics, and Tumor Environment	4/18/23	1:30 PM	Section 14	2
4892	MMAE drives immunomodulatory changes in a preclinical xenograft model that are distinct from other clinical-stage ADC payloads	Michelle	Ulrich	Poster	Anticancer Approaches: Antibody-Drug Conjugates, Epigenetics, and Tumor Environment	4/18/23	1:30 PM	Section 14	3
4893	Evaluation of bystander antitumor effect of Dato-DXd in TROP2 (+) and TROP2 (-) lung cell lines admixed tumor xenograft mouse models	Satoru	Yasuda	Poster	Anticancer Approaches: Antibody-Drug Conjugates, Epigenetics, and Tumor Environment	4/18/23	1:30 PM	Section 14	4
4894	The anti-ROR1 ADC STRO-003 demonstrates immune-modulating properties that may enhance checkpoint blockade	Andrew	McGeehan	Poster	Anticancer Approaches: Antibody-Drug Conjugates, Epigenetics, and Tumor Environment	4/18/23	1:30 PM	Section 14	5
4895	Introduction of a platform for preclinical profiling of drug conjugates: a case study with sacituzumab govitecan	Vincent	Vuaroqueaux	Poster	Anticancer Approaches: Antibody-Drug Conjugates, Epigenetics, and Tumor Environment	4/18/23	1:30 PM	Section 14	6
4896	NF1 (neurofibromatosis 1) controls microtubule dynamics and dictates sensitivity to maytansinoids	Luca	Mazzarella	Poster	Anticancer Approaches: Antibody-Drug Conjugates, Epigenetics, and Tumor Environment	4/18/23	1:30 PM	Section 14	7

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
4897	PRT543, a methyl transferase inhibitor, has potent anti-tumor activity against adenoid cystic carcinoma of salivary glands	Vasudha	Mishra	Poster	Anticancer Approaches: Antibody-Drug Conjugates, Epigenetics, and Tumor Environment	4/18/23	1:30 PM	Section 14	8
4898	Imipridones and EZH2 inhibitors induce similar changes in cytokines and regulated genes in GBM and DMG while vorinostat potentiates anti-tumor efficacy despite variability in cytokine profiles	Yiqun	Zhang	Poster	Anticancer Approaches: Antibody-Drug Conjugates, Epigenetics, and Tumor Environment	4/18/23	1:30 PM	Section 14	9
4899	Inhibition of murine tumor growth by decitabine is correlated with enhanced expression of the mouse mammary tumor virus	Jieyu	Zhang	Poster	Anticancer Approaches: Antibody-Drug Conjugates, Epigenetics, and Tumor Environment	4/18/23	1:30 PM	Section 14	10
4900	Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression	Christine	Birdwell	Poster	Anticancer Approaches: Antibody-Drug Conjugates, Epigenetics, and Tumor Environment	4/18/23	1:30 PM	Section 14	11
4901	The role of protein disulfide isomerase and copper in the paraptotic cell death of clinically investigated anticancer thiosemicarbazones	Sonja	Hager	Poster	Anticancer Approaches: Antibody-Drug Conjugates, Epigenetics, and Tumor Environment	4/18/23	1:30 PM	Section 14	12
4902	Mitochondrial and cytosolic polyglutamate synthetase in one-carbon metabolism and anti-tumor efficacy of mitochondrial-targeted antifolates	Zhanjun	Hou	Poster	Anticancer Approaches: Antibody-Drug Conjugates, Epigenetics, and Tumor Environment	4/18/23	1:30 PM	Section 14	13
4903	Levels of folate transporters impact the compartmentalization of one-carbon metabolism in the mitochondria vs cytosol providing a unique vulnerability to SHMT inhibition	Mathew	Schneider	Poster	Anticancer Approaches: Antibody-Drug Conjugates, Epigenetics, and Tumor Environment	4/18/23	1:30 PM	Section 14	14
4904	Glutamine antagonist DRP-104 enhances anti-tumor responses in KEAP1 mutant lung cancer	Ray	Pillai	Poster	Anticancer Approaches: Antibody-Drug Conjugates, Epigenetics, and Tumor Environment	4/18/23	1:30 PM	Section 14	15
4905	Anticancer activity and paraptosis induction of novel bipyridine-silver(I) compounds against resistant colorectal and ovarian cancer cell lines	Alessia	Stefanelli	Poster	Anticancer Approaches: Antibody-Drug Conjugates, Epigenetics, and Tumor Environment	4/18/23	1:30 PM	Section 14	16
4907	Atovaquone-induced increase in reactive oxygen species leads to impaired glycolytic functions in ovarian cancer cells	Nicha	Boonpattrawong	Poster	Anticancer Approaches: Antibody-Drug Conjugates, Epigenetics, and Tumor Environment	4/18/23	1:30 PM	Section 14	18
4908	Study on Ca ²⁺ -mediated regulation mechanisms on chemotherapy-induced peripheral neuropathy in multiple myeloma and non-Hodgkin lymphoma	Jinny	Park	Poster	Anticancer Approaches: Antibody-Drug Conjugates, Epigenetics, and Tumor Environment	4/18/23	1:30 PM	Section 14	19
4909	Molecular analysis of small cell lung cancer provides insights into mechanism of action underlying the novel drug combination of lurbinectedin and TIC10/ONC201	Ashley	Sanchez Sevilla Uruchurtu	Poster	Anticancer Approaches: Antibody-Drug Conjugates, Epigenetics, and Tumor Environment	4/18/23	1:30 PM	Section 14	20

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
4910	Human tumor primary culture analyses for the prediction of response to chemotherapy, targeted agents, drug combinations and metabolic inhibitors: The role of ex vivo analysis of programmed cell death in cancer therapy	Robert	Nagourney	Poster	Anticancer Approaches: Antibody-Drug Conjugates, Epigenetics, and Tumor Environment	4/18/23	1:30 PM	Section 14	21
4911	A novel C-terminal of HSP90 inhibitor NCT-547 eliminates cancer stem-like subpopulation in triple-negative breast cancer	Eunsun	Jung	Poster	Anticancer Approaches: Antibody-Drug Conjugates, Epigenetics, and Tumor Environment	4/18/23	1:30 PM	Section 14	22
4912	Anticancer activity of Hsp90 inhibitor AUY922 in nasopharyngeal carcinoma and non-small cell lung cancer cells	William	Cho	Poster	Anticancer Approaches: Antibody-Drug Conjugates, Epigenetics, and Tumor Environment	4/18/23	1:30 PM	Section 14	23
4913	Enhancer RNA profiles predict sensitivity to a novel GPX4 inhibitor	Joey	Azofeifa	Poster	Anticancer Approaches: Antibody-Drug Conjugates, Epigenetics, and Tumor Environment	4/18/23	1:30 PM	Section 14	24
4914	Role of ClpP in the anti-cancer effects of imipridone ONC201 and ONC206	Varun V.	Prabhu	Poster	Anticancer Approaches: Antibody-Drug Conjugates, Epigenetics, and Tumor Environment	4/18/23	1:30 PM	Section 14	25
4915	Sensitivity to NAMPT inhibition: In vitro and in vivo characterization in ovarian cancer	Jenny	Hong	Poster	Anticancer Approaches: Antibody-Drug Conjugates, Epigenetics, and Tumor Environment	4/18/23	1:30 PM	Section 14	26
4916	Spatial analysis of local drug induced changes in tumor microenvironment predicts effective treatment combinations in breast cancer	Zuzana	Tatarova	Poster	Anticancer Approaches: Antibody-Drug Conjugates, Epigenetics, and Tumor Environment	4/18/23	1:30 PM	Section 14	27
4917	High-frequency irreversible electroporation ablation of glioma alters extracellular vesicles and disrupts the blood-brain barrier endothelium	Kelsey	Murphy	Poster	Anticancer Approaches: Antibody-Drug Conjugates, Epigenetics, and Tumor Environment	4/18/23	1:30 PM	Section 14	28
4918	Natural compounds ursolic acid and digoxin exhibit anti-cancer effects through nuclear receptor ROR γ -dependent and -independent mechanisms	Hongye	Zou	Poster	Anticancer Approaches: Antibody-Drug Conjugates, Epigenetics, and Tumor Environment	4/18/23	1:30 PM	Section 14	29
4919	Estrogen regulates the immune microenvironment and immunotherapy response of colorectal liver metastases	Yasmine	Benslimane	Poster	Anticancer Approaches: Antibody-Drug Conjugates, Epigenetics, and Tumor Environment	4/18/23	1:30 PM	Section 14	30
4923	Prostaglandin E2 receptor EP2: A novel target for high-risk neuroblastoma	Ruida	Hou	Poster	Novel Antitumor Agents, PI3K/AKT Inhibitors, Proteasome Inhibitors, and Topoisomerases	4/18/23	1:30 PM	Section 15	1
4924	Alternative lengthening of telomeres is associated with hypersensitivity to topoisomerase 1 inhibition in glioblastoma xenograft models	Matthew	Waitkus	Poster	Novel Antitumor Agents, PI3K/AKT Inhibitors, Proteasome Inhibitors, and Topoisomerases	4/18/23	1:30 PM	Section 15	2

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
4925	Cannabidiol and Cannabis Sativa as a potential treatment in vitro prostate cancer cells silenced with RBBp6 and PC3 xenograft	Lesetja	Motadi	Poster	Novel Antitumor Agents, PI3K/AKT Inhibitors, Proteasome Inhibitors, and Topoisomerases	4/18/23	1:30 PM	Section 15	3
4926	Alpelisib in combination with trastuzumab and pertuzumab as maintenance therapy in patients with HER2+, PIK3CA-mutant advanced breast cancer: EPIK-B2 Study Part 1 safety and efficacy results	François-Clement	Bidard	Poster	Novel Antitumor Agents, PI3K/AKT Inhibitors, Proteasome Inhibitors, and Topoisomerases	4/18/23	1:30 PM	Section 15	4
4927	Exarafenib (KIN-2787) is a potent, selective pan-RAF inhibitor with activity in preclinical models of BRAF class II/III mutant and NRAS mutant melanoma	Nichol	Miller	Poster	Novel Antitumor Agents, PI3K/AKT Inhibitors, Proteasome Inhibitors, and Topoisomerases	4/18/23	1:30 PM	Section 15	5
4928	Gedatolisib, a well-tolerated pan-PI3K/mTOR inhibitor, exhibits potent therapeutic effects on gynecological cancer models regardless of their PI3K pathway mutational status	Stefano	Rossetti	Poster	Novel Antitumor Agents, PI3K/AKT Inhibitors, Proteasome Inhibitors, and Topoisomerases	4/18/23	1:30 PM	Section 15	6
4929	ICX-101, a novel MYC inhibitor, shows antitumor activity in patient-derived cells of advanced lung cancer with high MYC expression	Wonyoung	Choi	Poster	Novel Antitumor Agents, PI3K/AKT Inhibitors, Proteasome Inhibitors, and Topoisomerases	4/18/23	1:30 PM	Section 15	7
4930	Foldamers mimicking the B-DNA surface as a new class of DNA topoisomerase I inhibitors	Philippe	Pourquier	Poster	Novel Antitumor Agents, PI3K/AKT Inhibitors, Proteasome Inhibitors, and Topoisomerases	4/18/23	1:30 PM	Section 15	8
4931	Novel cancer suppressing role of REIC/DKK3 protein through a downregulation of cell surface PD-L1 in breast cancer cells	Yuma	Gohara	Poster	Novel Antitumor Agents, PI3K/AKT Inhibitors, Proteasome Inhibitors, and Topoisomerases	4/18/23	1:30 PM	Section 15	9
4932	The role of KB-S in treating pancreatic cancer	Sadia Noosrat	Boshra	Poster	Novel Antitumor Agents, PI3K/AKT Inhibitors, Proteasome Inhibitors, and Topoisomerases	4/18/23	1:30 PM	Section 15	10
4933	Duvelisib eliminates CLL B Cells, impairs CLL-supporting cells, and overcomes ibrutinib resistance in a patient-derived xenograft model	Shih-Shih	Chen	Poster	Novel Antitumor Agents, PI3K/AKT Inhibitors, Proteasome Inhibitors, and Topoisomerases	4/18/23	1:30 PM	Section 15	11
4934	CAPAC: a modular platform that can improve the safety and efficacy of existing cancer therapies	George	Coricor	Poster	Novel Antitumor Agents, PI3K/AKT Inhibitors, Proteasome Inhibitors, and Topoisomerases	4/18/23	1:30 PM	Section 15	12
4935	Cannabidiol and cannabis extract protect cells against platinum-based chemotherapy via cellular uptake	Tereza	Buchtová	Poster	Novel Antitumor Agents, PI3K/AKT Inhibitors, Proteasome Inhibitors, and Topoisomerases	4/18/23	1:30 PM	Section 15	13
4936	Activity of carfilzomib in head and neck cancer cell lines in vitro	Abdullah	Eldaly	Poster	Novel Antitumor Agents, PI3K/AKT Inhibitors, Proteasome Inhibitors, and Topoisomerases	4/18/23	1:30 PM	Section 15	14

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
4937	Immunoproteasome inhibitors for the treatment of t(4;11)-driven ALL	Alexei	Kisselev	Poster	Novel Antitumor Agents, PI3K/AKT Inhibitors, Proteasome Inhibitors, and Topoisomerases	4/18/23	1:30 PM	Section 15	15
4938	DP-9024, an investigational small molecule modulator of the integrated stress response kinase GCN2, synergizes with asparaginase therapy in leukemic tumors	Qi	Groer	Poster	Novel Antitumor Agents, PI3K/AKT Inhibitors, Proteasome Inhibitors, and Topoisomerases	4/18/23	1:30 PM	Section 15	16
4939	Combinatorial approach using covalent menin inhibitor, BMF-219, and/or covalent FLT3 inhibitor, BMF-500, with MEK or BCL2 blockade potentiates therapeutic use in AML	Daniel	Lu	Poster	Novel Antitumor Agents, PI3K/AKT Inhibitors, Proteasome Inhibitors, and Topoisomerases	4/18/23	1:30 PM	Section 15	17
4940	Proteasome and survivin inhibitors synergize to inhibit the growth of oral cancer organoids	Amir	Faisal	Poster	Novel Antitumor Agents, PI3K/AKT Inhibitors, Proteasome Inhibitors, and Topoisomerases	4/18/23	1:30 PM	Section 15	18
4941	Development of small molecule RPN13 inhibitors for treatment of glioblastoma	Yung-Nien	Chang	Poster	Novel Antitumor Agents, PI3K/AKT Inhibitors, Proteasome Inhibitors, and Topoisomerases	4/18/23	1:30 PM	Section 15	19
4942	Heme targeting and its mechanistic role in triple-negative breast cancer suppression	Eranda	Berisha	Poster	Novel Antitumor Agents, PI3K/AKT Inhibitors, Proteasome Inhibitors, and Topoisomerases	4/18/23	1:30 PM	Section 15	20
4943	SP-1-39 as a novel tubulin inhibitor overcomes taxane resistance in castration-resistant prostate cancer model	Rui	Wang	Poster	Novel Antitumor Agents, PI3K/AKT Inhibitors, Proteasome Inhibitors, and Topoisomerases	4/18/23	1:30 PM	Section 15	21
4944	Evaluating the efficacy of spermine analogue ivospemin (SBP-101) in combination with chemotherapy in ovarian cancer	Cassandra	Holbert	Poster	Novel Antitumor Agents, PI3K/AKT Inhibitors, Proteasome Inhibitors, and Topoisomerases	4/18/23	1:30 PM	Section 15	22
4945	Inhibition of wild-type PI3K α signaling is required for durable efficacy in PI3K α mutant cancer cells due to robust re-activation of wild-type PI3K α signaling	John	MacDougall	Poster	Novel Antitumor Agents, PI3K/AKT Inhibitors, Proteasome Inhibitors, and Topoisomerases	4/18/23	1:30 PM	Section 15	23
4946	TOS-358, a first-in-class covalent PI3K α inhibitor, demonstrates superior efficacy and does not induce significant hyperglycemia at efficacious doses in multiple animal models	John	MacDougall	Poster	Novel Antitumor Agents, PI3K/AKT Inhibitors, Proteasome Inhibitors, and Topoisomerases	4/18/23	1:30 PM	Section 15	24
4947	Exploration of Annamycin Organotropism to Target Primary and Metastatic Liver Cancers	Rafal	Zielinski	Poster	Novel Antitumor Agents, PI3K/AKT Inhibitors, Proteasome Inhibitors, and Topoisomerases	4/18/23	1:30 PM	Section 15	25
4948	The role of zafirlukast and isoquercetin in thiol isomerase inhibition in relation to cancer and its complications	Justine	Gelzinis	Poster	Novel Antitumor Agents, PI3K/AKT Inhibitors, Proteasome Inhibitors, and Topoisomerases	4/18/23	1:30 PM	Section 15	26

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
4949	Identification of novel regulators of response to PI3Ka inhibition in PIK3CA mutant gastric cancer	Lyla	Stanland	Poster	Novel Antitumor Agents, PI3K/AKT Inhibitors, Proteasome Inhibitors, and Topoisomerases	4/18/23	1:30 PM	Section 15	27
4950	Discovery of potent and selective CK1 α molecular degrader with a favorable safety profile for acute myeloid leukemia and solid tumors	Hyunseok	Kang	Poster	Novel Antitumor Agents, PI3K/AKT Inhibitors, Proteasome Inhibitors, and Topoisomerases	4/18/23	1:30 PM	Section 15	28
4951	Proteasome inhibitor carfilzomib induces apoptosis via downregulation of AKT pathway in HPV negative HNSCC	Woo-Jin	Jeong	Poster	Novel Antitumor Agents, PI3K/AKT Inhibitors, Proteasome Inhibitors, and Topoisomerases	4/18/23	1:30 PM	Section 15	29
4955	Kurarinone, a natural notch signaling inhibitor and modulator of breast cancer stemness	Prem	Kushwaha	Poster	Novel Targets and Pathways	4/18/23	1:30 PM	Section 16	1
4956	Discovering novel targetable pathways by combining functional and multi-omic data from primary ovarian cancer samples	Gregory	Vladimer	Poster	Novel Models of Human Cancer	4/16/23	1:30 PM	Section 2	25
4957	The targeting drug conjugate Tye1001 displayed its potent anti-tumor efficacy in lymphoma	Lichun	Sun	Poster	Novel Targets and Pathways	4/18/23	1:30 PM	Section 16	3
4959	TIC10/ONC201 activates ClpP to degrade ALAS1 while PG3 does not degrade ALAS1 in pathway to HRI, ATF4 and CHOP activation leading to tumor cell death	Xiaobing	Tian	Poster	Novel Targets and Pathways	4/18/23	1:30 PM	Section 16	5
4960	Fascin inhibitor decreases gynecological cancer cell growth through cell cycle regulation	Wanyi	Chen	Poster	Novel Targets and Pathways	4/18/23	1:30 PM	Section 16	6
4961	Novel biased PAR2 inhibitors with best-in-class properties reduce resistance to both chemotherapy and immunotherapy in oncology models	Thibaut	Brugat	Poster	Novel Targets and Pathways	4/18/23	1:30 PM	Section 16	7
4962	Discovery of cancer-specific E3 ligase ligands for targeted protein degradation	Hailong	Zhang	Poster	Novel Targets and Pathways	4/18/23	1:30 PM	Section 16	8
4963	Heme Sequestration as an effective strategy for the suppression of tumor growth and progression of SCLC	Adnin	Ashrafi	Poster	Novel Targets and Pathways	4/18/23	1:30 PM	Section 16	9
4964	SW-682: A novel TEAD inhibitor for the treatment of cancers bearing mutations in the Hippo signaling pathway	Lei	Chen	Poster	Novel Targets and Pathways	4/18/23	1:30 PM	Section 16	10
4965	Targeting the mitotic kinesin, KIF18A, in chromosomally unstable cancers	James	Joseph	Poster	Novel Targets and Pathways	4/18/23	1:30 PM	Section 16	11
4966	Targeting LIF/LIFR autocrine loops with EC359 in ovarian cancer: A novel LIFR targeted therapy	Behnam	Ebrahimi	Poster	Novel Targets and Pathways	4/18/23	1:30 PM	Section 16	12
4967	Investigating the therapeutic efficacy of EO3001 in clear cell carcinoma of the ovary	Jeffrey	Bacha	Poster	Novel Targets and Pathways	4/18/23	1:30 PM	Section 16	13

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
4968	Characterization of the clinical development candidate TNG348 as a potent and selective inhibitor of USP1 for the treatment of BRCA1/2mut cancers	Antoine	Simoneau	Poster	Novel Targets and Pathways	4/18/23	1:30 PM	Section 16	14
4969	Enhancing the efficacy of small molecule inhibitor of TRIP13 in prostate cancer using thymoquinone	Santosh	Singh	Poster	Novel Targets and Pathways	4/18/23	1:30 PM	Section 16	15
4970	TNG462 is a potential best-in-class MTA-cooperative PRMT5 inhibitor for the treatment of MTAP-deleted solid tumors	Kimberly	Briggs	Poster	Novel Targets and Pathways	4/18/23	1:30 PM	Section 16	16
4971	Identification of statins as a potential treatment for ovarian cancer	Brendan	Reilly	Poster	Novel Targets and Pathways	4/18/23	1:30 PM	Section 16	17
4972	Anti-tumor activity of Helicon inhibitors of B-catenin-TCF interaction in patient-derived xenograft models	Jonathan	Hurov	Poster	Novel Targets and Pathways	4/18/23	1:30 PM	Section 16	18
4973	Investigating the role of non-canonical NF-kappaB signaling in tumor cells and macrophages in ovarian cancer	Fiona	Yull	Poster	Novel Targets and Pathways	4/18/23	1:30 PM	Section 16	19
4974	Development of novel pyrimido-pyrazolo-quinolone derivative, IND-2 as multi-targeted inhibitor for the treatment of prostate cancer	Swapnaa	Balaji	Poster	Novel Targets and Pathways	4/18/23	1:30 PM	Section 16	20
4975	Anti-cancer effect of a probiotic bacteria-derived compound, 1,4-Dihydroxy-2-naphthoic acid in prostate cancer	Shreeja	Bitla	Poster	Novel Targets and Pathways	4/18/23	1:30 PM	Section 16	21
4976	Preclinical characterization of BGI-9004, a covalent TEAD inhibitor with exceptional anti-cancer activity and combination potential	Wolf	Wiedemeyer	Poster	Novel Targets and Pathways	4/18/23	1:30 PM	Section 16	22
4977	Development of small molecule inhibitors of protein interaction with glycosaminoglycans	Tahir	Sheikh	Poster	Novel Targets and Pathways	4/18/23	1:30 PM	Section 16	23
4978	Combination of a clinical stage-hedgehog inhibitor, GT1708, improves Venetoclax-induced apoptosis by down-regulating MCL-1 proteins in AML cells	Liandong	Ma	Poster	Novel Targets and Pathways	4/18/23	1:30 PM	Section 16	24
4979	Evaluation of heme inhibitory therapy in combination with radiation of lung cancer	Narges	Salamat	Poster	Novel Targets and Pathways	4/18/23	1:30 PM	Section 16	25
4980	Design and functional characterization of a first-in-class irreversible inhibitor of HOIL-1-interacting protein (HOIP) with selective antitumor activity against B-cell non-Hodgkin lymphoma	Gaël	Roué	Poster	Novel Targets and Pathways	4/18/23	1:30 PM	Section 16	26
4981	The potent quadruplex-binding compound QN-302 down-regulates the S100P gene in in vitro and in vivo models of pancreatic cancer: a potential therapeutic target and biomarker for PDAC	Stephen	Neidle	Poster	Novel Targets and Pathways	4/18/23	1:30 PM	Section 16	27
4982	The somatic mutation signature detected in gynecological mucosal melanoma	Zhongwu	Li	Poster	Novel Targets and Pathways	4/18/23	1:30 PM	Section 16	28

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
4983	Anaplastic thyroid cancer cells upregulate mitochondrial one-carbon metabolism to meet purine demand, eliciting a targetable vulnerability	Antonio	Di Cristofano	Poster	Novel Targets and Pathways	4/18/23	1:30 PM	Section 16	29
4984	Integrated platform enables KRAS-targeted drugs discovery	Beibei	Liu	Poster	Novel Targets and Pathways	4/18/23	1:30 PM	Section 16	30
4988	A tailored platform enables BRAF-targeted drug discovery and precision medicine	Xiangnan	Qiang	Poster	Targeting Protein Kinases and Phosphatases for Therapy 1	4/18/23	1:30 PM	Section 17	1
4989	Discovery and evaluation of ISM6466A, a novel covalent CDK12 inhibitor for the treatment of cancer	Sujata	Rao	Poster	Targeting Protein Kinases and Phosphatases for Therapy 1	4/18/23	1:30 PM	Section 17	2
4990	Dual inhibitor of ACVR1 and MEK 1/2 E6201 and PI3K/mTOR inhibitor paxalisib synergistically inhibit cell growth in DMG	Hyuk Jean	Kwon	Poster	Targeting Protein Kinases and Phosphatases for Therapy 1	4/18/23	1:30 PM	Section 17	3
4991	Phosphorylation of MERTK is required for nuclear localization in non-small cell lung cancer (NSCLC)	K.M.	Tanim	Poster	Targeting Protein Kinases and Phosphatases for Therapy 1	4/18/23	1:30 PM	Section 17	4
4992	Taxol-elevated PLK1 overcomes BETi-resistant in prostate cancer via triggering phosphorylation-dependent degradation of BRD4	Yanquan	Zhang	Poster	Targeting Protein Kinases and Phosphatases for Therapy 1	4/18/23	1:30 PM	Section 17	5
4993	Development of abbapolin inhibitors of the PLK1 PBD as potential therapeutics for prostate and other challenging cancers	Campbell	McInnes	Poster	Targeting Protein Kinases and Phosphatases for Therapy 1	4/18/23	1:30 PM	Section 17	6
4994	Crizotinib enhances the efficacy of BX-795 identified by high-throughput screening of pan-active drugs in colorectal cancer cells	Susmita	Ghosh	Poster	Targeting Protein Kinases and Phosphatases for Therapy 1	4/18/23	1:30 PM	Section 17	7
4995	Targeting PLK1 effectively suppresses growth of small cell lung cancer	John	Schmitz	Poster	Targeting Protein Kinases and Phosphatases for Therapy 1	4/18/23	1:30 PM	Section 17	8
4996	Axl inhibition sensitizes cholangiocarcinoma cells to cytotoxic chemotherapy	Shohei	Takaichi	Poster	Targeting Protein Kinases and Phosphatases for Therapy 1	4/18/23	1:30 PM	Section 17	9
4997	PLK1 promotes the metastasis and drug resistance in melanoma	Fengyi	Mao	Poster	Targeting Protein Kinases and Phosphatases for Therapy 1	4/18/23	1:30 PM	Section 17	10
4998	Selective PLK4 inhibition demonstrates synthetic lethality in TRIM37 amplified neuroblastoma and breast cancer models while less selective inhibitors do not	Siobhan	McRee	Poster	Targeting Protein Kinases and Phosphatases for Therapy 1	4/18/23	1:30 PM	Section 17	11
4999	Preclinical evaluation of MCLA-129, a bispecific antibody targeting EGFR and c-MET on solid tumor cells, in comparison with amivantamab	David J.J.	de Gorter	Poster	Targeting Protein Kinases and Phosphatases for Therapy 1	4/18/23	1:30 PM	Section 17	12
5000	MYTX-011: A novel cMET-targeting antibody drug conjugate (ADC) engineered to increase on-target uptake in and efficacy against cMET expressing tumors	Nimish	Gera	Poster	Targeting Protein Kinases and Phosphatases for Therapy 1	4/18/23	1:30 PM	Section 17	13
5003	Repurposing passenger amplifications for specific therapeutic targeting of solid cancers	Sonia	Jiménez Vázquez	Poster	Targeting Protein Kinases and Phosphatases for Therapy 1	4/18/23	1:30 PM	Section 17	16
5004	DDR-targeting small molecule inhibitor as a novel therapeutic for treating pancreatic ductal adenocarcinoma	Trong Phat	Do	Poster	Targeting Protein Kinases and Phosphatases for Therapy 1	4/18/23	1:30 PM	Section 17	17

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
5005	Targeted down regulation of FGFR1 through G-quadruplex stabilization in metastatic breast cancer	Muhammad	Safdar	Poster	Targeting Protein Kinases and Phosphatases for Therapy 1	4/18/23	1:30 PM	Section 17	18
5006	Discovery of novel heterobifunctional degraders of mutant EGFR proteins for NSCLCs harboring various EGFR mutations	Dong Hyuk	Ki	Poster	Targeting Protein Kinases and Phosphatases for Therapy 1	4/18/23	1:30 PM	Section 17	19
5009	Inhibition of TGFBR2 signaling re-sensitizes TMZ-resistant glioblastoma cells to therapy	Maya	Johnson	Poster	Targeting Protein Kinases and Phosphatases for Therapy 2	4/18/23	1:30 PM	Section 18	1
5010	Inhibition of discoidin domain receptor 1 (DDR1) as a new therapeutic strategy for osteosarcoma	Zhenfeng	Duan	Poster	Targeting Protein Kinases and Phosphatases for Therapy 2	4/18/23	1:30 PM	Section 18	2
5011	Targeting kinome reprogramming in ESR1 fusion-driven breast cancer	Xuxu	Gou	Poster	Targeting Protein Kinases and Phosphatases for Therapy 2	4/18/23	1:30 PM	Section 18	3
5012	Characterizing the functional significance of PDGFRAK385I and PDGFRAK385L extracellular domain mutations in the newly defined myxoid glioneuronal tumor	Catherine	Beach	Poster	Targeting Protein Kinases and Phosphatases for Therapy 2	4/18/23	1:30 PM	Section 18	4
5013	Effects of PP2A-activating drugs on FLT3 inhibitor resistance mediated by diverse mechanisms in acute myeloid leukemia with FLT3-ITD	Moaath	Mustafa Ali	Poster	Targeting Protein Kinases and Phosphatases for Therapy 2	4/18/23	1:30 PM	Section 18	5
5014	HPK1 gene knockout reporter cell line: an efficient drug screening system	Feng	Hao	Poster	Targeting Protein Kinases and Phosphatases for Therapy 2	4/18/23	1:30 PM	Section 18	6
5015	Wee1 inhibition and its synthetic lethal combination with Chk1 inhibition in mouse model of neuroendocrine prostate cancer	Yuzhou	Chen	Poster	Targeting Protein Kinases and Phosphatases for Therapy 2	4/18/23	1:30 PM	Section 18	7
5016	IL-6 influences PIM1 expression in renal cell carcinoma	Kimberly	Meza	Poster	Targeting Protein Kinases and Phosphatases for Therapy 2	4/18/23	1:30 PM	Section 18	8
5017	Simultaneous targeting of EphA3 on glioblastoma and tumor microenvironment to overcome resistance to CART cell therapy in brain cancer	Ekene	Ogbodo	Poster	Targeting Protein Kinases and Phosphatases for Therapy 2	4/18/23	1:30 PM	Section 18	9
5018	PROTAC degraders of CDK8/CDK19 Mediator kinases potently suppress multiple myeloma proliferation	Mengqian	Chen	Poster	Targeting Protein Kinases and Phosphatases for Therapy 2	4/18/23	1:30 PM	Section 18	10
5019	Next-generation DYRK1A inhibitors as a new therapeutic approach for the treatment of hematological malignancies	Matthew	Jarvis	Poster	Targeting Protein Kinases and Phosphatases for Therapy 2	4/18/23	1:30 PM	Section 18	11
5020	IRAK1 is a critical mediator of hyaluronic acid induced stemness	David	Standing	Poster	Targeting Protein Kinases and Phosphatases for Therapy 2	4/18/23	1:30 PM	Section 18	12
5021	Preclinical evaluation of immunomodulatory effects of aurora kinase inhibition in HPV+ cancers	Pragya	Sinha	Poster	Targeting Protein Kinases and Phosphatases for Therapy 2	4/18/23	1:30 PM	Section 18	13
5022	Atypical protein kinase C inhibitors abrogate malignant breast cancer	Nuzhat	Nowshin Oishee	Poster	Targeting Protein Kinases and Phosphatases for Therapy 2	4/18/23	1:30 PM	Section 18	14

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
5023	PFKP contributes to ovarian cancer metastasis, stemness and anchorage-independent growth via $\alpha 5$ integrin and ERK/MMP9 signaling	Ruiqian	Zhang	Poster	Targeting Protein Kinases and Phosphatases for Therapy 2	4/18/23	1:30 PM	Section 18	15
5024	Role of protein kinase C ζ and ι inhibitors on ovarian cancer cell lines in combination with cisplatin	Mahfuza	Marzan	Poster	Targeting Protein Kinases and Phosphatases for Therapy 2	4/18/23	1:30 PM	Section 18	16
5025	Reduced level of protein kinase C iota renders human glioblastoma less invasive and induces apoptosis via modulating Tak1/NF- κ B pathway	Khandker	Khalid	Poster	Targeting Protein Kinases and Phosphatases for Therapy 2	4/18/23	1:30 PM	Section 18	17
5026	Protein tyrosine phosphatase Ptpn1 knockout in mouse models drives B-cell hematological malignancies	Nupur	Nigam	Poster	Targeting Protein Kinases and Phosphatases for Therapy 2	4/18/23	1:30 PM	Section 18	18
5027	Targeting ARAF p.S214C mutation with sorafenib in non-small cell lung cancer	Carol	Lee	Poster	Targeting Protein Kinases and Phosphatases for Therapy 2	4/18/23	1:30 PM	Section 18	19
5028	The regulation of inflammatory signaling in cancer via A20 phosphorylation	Tania	Lopez Palacios	Poster	Targeting Protein Kinases and Phosphatases for Therapy 2	4/18/23	1:30 PM	Section 18	20
5029	Determining the biological function of TNK1	D	Madhusanka	Poster	Targeting Protein Kinases and Phosphatases for Therapy 2	4/18/23	1:30 PM	Section 18	21
5030	Treatment of aromatase inhibitor-resistant cells with polyisoprenylated cysteinyl amide inhibitors stimulates the mitogen-activated protein kinase pathway enzymes, impedes cell proliferation and causes cell death	Jassy Mary	Lazarte	Poster	Targeting Protein Kinases and Phosphatases for Therapy 2	4/18/23	1:30 PM	Section 18	22
5034	Targeting CXCR4 and thioredoxin reductase in high grade neuroendocrine tumors and neuroendocrine carcinomas	Melissa	Fath	Poster	Theranostics and Radionuclides / Pharmacologic Approaches	4/18/23	1:30 PM	Section 19	1
5035	Preclinical development of a ^{89}Zr -labeled human antibody as a novel immuno-PET agent for noninvasive cancer detection and monitoring response to treatment	Abhay	Singh	Poster	Theranostics and Radionuclides / Pharmacologic Approaches	4/18/23	1:30 PM	Section 19	2
5036	Single dose treatment with a novel Yttrium-90-labeled high affinity anti-B7-H3 antibody selective for the 4Ig-B7-H3 isoform provides long term survivors for established radioresistant colorectal carcinoma	Sarah	Glazer	Poster	Theranostics and Radionuclides / Pharmacologic Approaches	4/18/23	1:30 PM	Section 19	3
5037	DARPin as powerful targeting agents for radioligand therapeutics	Daniel	Steiner	Poster	Theranostics and Radionuclides / Pharmacologic Approaches	4/18/23	1:30 PM	Section 19	4
5038	Evaluation of anti-tumor immunity in response to [^{177}Lu]Lu-PSMA in a mouse model of prostate cancer	Katherine	Vallis	Poster	Theranostics and Radionuclides / Pharmacologic Approaches	4/18/23	1:30 PM	Section 19	5
5039	Development of a prostate cancer PDX model radioresistant to PSMA targeted radionuclide therapy	Carsten	Nielsen	Poster	Theranostics and Radionuclides / Pharmacologic Approaches	4/18/23	1:30 PM	Section 19	6

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
5040	Novel HER3 targeting antibody radioconjugates, 225Ac-HER3 ARC and 177Lu-HER3 ARC, exhibit potent antitumor efficacy in HER3-positive solid tumors	Denis	Beckford-Vera	Poster	Theranostics and Radionuclides / Pharmacologic Approaches	4/18/23	1:30 PM	Section 19	7
5041	TEM-1 targeted alpha therapeutic [Ac-225]-FPI-1848 induces regression in pre-clinical sarcoma xenograft models	Sean	Collens	Poster	Theranostics and Radionuclides / Pharmacologic Approaches	4/18/23	1:30 PM	Section 19	8
5042	Anti-tumor activity of RYZ101 (Ac-225 DOTATATE) in somatostatin receptor-expressing preclinical models of small-cell lung cancer	Gary	Li	Poster	Theranostics and Radionuclides / Pharmacologic Approaches	4/18/23	1:30 PM	Section 19	9
5043	Radium-223 demonstrates increased antitumor activity in combination with 177Lu-PSMA-617 in the intratibial LNCaP xenograft model of bone metastatic prostate cancer	Arne	Scholz	Poster	Theranostics and Radionuclides / Pharmacologic Approaches	4/18/23	1:30 PM	Section 19	10
5044	Antitumor activity comparison of two somatostatin receptor ligands radiolabeled with Lutetium-177 (SSO110 and DOTA-TATE) alone or combined with chemotherapy in mice bearing AR42J SST2-positive tumors	Cyril	Berthet	Poster	Theranostics and Radionuclides / Pharmacologic Approaches	4/18/23	1:30 PM	Section 19	11
5045	NTSR1-targeted alpha therapeutic [Ac-225]-FPI-2059 induces growth inhibition in a preclinical colorectal tumor model	Saleemulla	Mahammad	Poster	Theranostics and Radionuclides / Pharmacologic Approaches	4/18/23	1:30 PM	Section 19	12
5046	Cerenkov luminescence imaging of interscapular brown adipose tissue using TSPO-targeting probe to overcome off-target effect of [18F]FDG	Seok-Yong	Lee	Poster	Theranostics and Radionuclides / Pharmacologic Approaches	4/18/23	1:30 PM	Section 19	13
5047	PSMA-targeted actinium-225 conjugate (225Ac-pelgifatamab) potentiates the antitumor efficacy of darolutamide in androgen-dependent and -independent prostate cancer models	Christoph	Schatz	Poster	Theranostics and Radionuclides / Pharmacologic Approaches	4/18/23	1:30 PM	Section 19	14
5048	Combating pancreatic cancer stem cells by novel titanium peroxides nanoparticles combined with X-ray radiation	Hiroki	Kawaguchi	Poster	Theranostics and Radionuclides / Pharmacologic Approaches	4/18/23	1:30 PM	Section 19	15
5049	Pb-203 image guided Pb-212 receptor targeted alpha particle therapy for cancer - a powerful emerging paradigm	Michael	Schultz	Poster	Theranostics and Radionuclides / Pharmacologic Approaches	4/18/23	1:30 PM	Section 19	16
5050	Case report: A 17-year-old patient developed glioblastoma secondary to intracranial germ cell tumor and was stabilized with chemoradiotherapy combined with Tumor Treating Fields	Shaoqun	Li	Poster	Theranostics and Radionuclides / Pharmacologic Approaches	4/18/23	1:30 PM	Section 19	17
5051	Assessment of boron delivery peptides with angiopep-2 for boron neutron capture therapy	Qi	Liu	Poster	Theranostics and Radionuclides / Pharmacologic Approaches	4/18/23	1:30 PM	Section 19	18
5052	IB-DNQ enhances radiation induced ferroptosis in NQO1-positive cancer cells	Xiumei	Huang	Poster	Theranostics and Radionuclides / Pharmacologic Approaches	4/18/23	1:30 PM	Section 19	19
5053	A critical role for copper in enhanced radioiodide uptake in thyroid cancer cells	Katie	Brookes	Poster	Theranostics and Radionuclides / Pharmacologic Approaches	4/18/23	1:30 PM	Section 19	20
5054	The study of synergy mechanism between surufatinib and vinorelbine in the treatment of non-small cell lung cancer	Yanfang	Zheng	Poster	Theranostics and Radionuclides / Pharmacologic Approaches	4/18/23	1:30 PM	Section 19	21

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
5055	Targeting BRAFV600E/NRASQ61K-melanoma brain metastases by pharmacological intervention modulating ER/redox stress and EMT	Georg	Wondrak	Poster	Theranostics and Radionuclides / Pharmacologic Approaches	4/18/23	1:30 PM	Section 19	22
5056	ABN401 demonstrates robust anti-tumor efficacy in orthotopic PDX models of MET-driven NSCLC brain metastases in a pre-clinical study	Nirmal	Rajasekaran	Poster	Theranostics and Radionuclides / Pharmacologic Approaches	4/18/23	1:30 PM	Section 19	23
5058	Impact of dexamethasone on chemotherapy response in ovarian cancer	Annapoorna	Venkatachalam	Poster	Theranostics and Radionuclides / Pharmacologic Approaches	4/18/23	1:30 PM	Section 19	25
5059	High-throughput monitoring of proteoforms and pathways through multiplexed and customizable mass spectrometry assay panels	Yuehan	Feng	Poster	Theranostics and Radionuclides / Pharmacologic Approaches	4/18/23	1:30 PM	Section 19	26
5060	Tucatinib does not alter oxaliplatin PK or associated renal function: An OCT2 and MATE transport inhibition study	Ariel	Topletz-Erickson	Poster	Theranostics and Radionuclides / Pharmacologic Approaches	4/18/23	1:30 PM	Section 19	27
5061	Toxicological characterization and comparison of ATR inhibitors in mice	Joshua	Deppas	Poster	Theranostics and Radionuclides / Pharmacologic Approaches	4/18/23	1:30 PM	Section 19	28
5062	Small molecule superoxide dismutase mimetic avasopasem manganese for the mitigation of cisplatin induced ototoxicity	Keegan	Christensen	Poster	Theranostics and Radionuclides / Pharmacologic Approaches	4/18/23	1:30 PM	Section 19	29
5063	Optimizing benefit/risk in oncology: Review of post marketing dose optimization	Mohamed	Elmeliegy	Poster	Theranostics and Radionuclides / Pharmacologic Approaches	4/18/23	1:30 PM	Section 19	30
5067	Inhibition of CD47-SIRP α axis to enhance immunity against different molecular subtypes of breast cancer	Xingru	Ma	Poster	Combination Immunotherapies 1	4/18/23	1:30 PM	Section 21	1
5068	Nintedanib enhances antitumor effects of anti-PD-1 therapies through inhibition of immunosuppressive cells in tumor microenvironment	Ryo	Suzuki	Poster	Combination Immunotherapies 1	4/18/23	1:30 PM	Section 21	2
5069	Cancer immunotherapy based on the RNAi-based PD-L1 inhibitor, MN-siPDL1, demonstrates efficacy in preclinical pancreatic adenocarcinoma	Mozhdeh	Sojoodi	Poster	Combination Immunotherapies 1	4/18/23	1:30 PM	Section 21	3
5070	Anti-tumor activity of HPN328, a DLL3-targeting tri-specific, half-life extended T cell engager, is enhanced by combining with an anti-PD-L1 antibody in an immunocompetent mouse model	Banmeet	Anand	Poster	Combination Immunotherapies 1	4/18/23	1:30 PM	Section 21	4
5071	Olverembatinib (HQP1351) enhances antitumor effects of immunotherapy in renal cell carcinoma (RCC)	Eric	Liang	Poster	Combination Immunotherapies 1	4/18/23	1:30 PM	Section 21	5
5072	"Armed" oncolytic herpes simplex virus enables CD19 CAR-T for solid tumor cell treatment as a combination therapy	Grace	Zhou	Poster	Combination Immunotherapies 1	4/18/23	1:30 PM	Section 21	6
5073	NT219 induces tumor PD-L1 expression and potentiates anti-PD-1 efficacy	Ricardo	de Azevedo	Poster	Combination Immunotherapies 1	4/18/23	1:30 PM	Section 21	7

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
5074	Addition of MAPK inhibitors to prime and sensitize poorly differentiated thyroid cancers as a strategy to improve TSHR-CART cell therapy antitumor activity	Claudia	Manriquez Roman	Poster	Combination Immunotherapies 1	4/18/23	1:30 PM	Section 21	8
5075	Antitumor activity of liposomal formulation of eribulin combined with anti-human PD-1 antibody using hPBMC-humanized mouse models	Yuki	Niwa	Poster	Combination Immunotherapies 1	4/18/23	1:30 PM	Section 21	9
5076	Combination PancVAX neo-epitope vaccine with anti-CTLA-4 and anti-PD-1 antibodies enhances infiltration of cytotoxic T cells and mitigates T cell exhaustion in a murine model of pancreatic ductal adenocarcinoma	Jacob	Mitchell	Poster	Combination Immunotherapies 1	4/18/23	1:30 PM	Section 21	10
5077	Engineering dendritic cell-derived exosomes for brain metastases immunotherapy	Hao-Nien	Chen	Poster	Combination Immunotherapies 1	4/18/23	1:30 PM	Section 21	11
5078	Immune response markers following combination treatment with oncolytic adenovirus AMUN-003 and immune checkpoint inhibitors in a murine model of triple negative breast cancer	Weidong	Xu	Poster	Combination Immunotherapies 1	4/18/23	1:30 PM	Section 21	12
5079	Intratumoral CD40 agonist enhances the antitumor effect of anti-PD1 immunotherapy by activation of antigen-presenting cells and selective expansion of effector CD8+ T cells	Barbara	Pazdrak	Poster	Combination Immunotherapies 1	4/18/23	1:30 PM	Section 21	13
5080	TU2218, a novel ALK5/VEGFR2 dual inhibitor, overcomes tumor endothelial cell anergy and enhances anti-PD1 immunotherapy efficacy	Jihyun	Lee	Poster	Combination Immunotherapies 1	4/18/23	1:30 PM	Section 21	14
5081	Anti-tumor activity of HPN217, a BCMA-targeting tri-specific T cell engager, is enhanced by γ -secretase inhibitors in preclinical models	Patrick	Ng	Poster	Combination Immunotherapies 1	4/18/23	1:30 PM	Section 21	15
5082	Heterodimeric IL-15 (hetIL-15) immunotherapy synergizes with Fatty Acid Metabolism Modulator (FAMM) to eradicate TNBC EO771 murine tumors	Sevasti	Karaliota	Poster	Combination Immunotherapies 1	4/18/23	1:30 PM	Section 21	16
5083	Investigating the development and therapeutic potential of intra-tumoral CXCR6+ effector/effector memory T cells (TEFF/EM) in triple-negative breast cancer	Bryan Jian Wei	Lim	Poster	Combination Immunotherapies 1	4/18/23	1:30 PM	Section 21	17
5084	Targeted delivery of low-dose radiation alleviates tumor resistance to CAR-T cell therapy	Yanping	Yang	Poster	Combination Immunotherapies 1	4/18/23	1:30 PM	Section 21	18
5085	Blockade of tumor derived CSF1 promotes an immune-permissive tumor microenvironment	Maria Del Mar	Maldonado	Poster	Combination Immunotherapies 1	4/18/23	1:30 PM	Section 21	19
5086	Transcriptomic analysis in a renal cancer PDX model enables the deconvolution of additive and synergistic effects of six different standard of care compounds with anti-PD-1 treatment	Julia	Schueler	Poster	Combination Immunotherapies 1	4/18/23	1:30 PM	Section 21	20

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
5087	Combination therapy of immune checkpoint inhibitor and HIF1 α /c-MET peptide vaccine suppresses metastasis by modulating tumor microenvironment in triple-negative breast cancer	JinHwa	Hong	Poster	Combination Immunotherapies 1	4/18/23	1:30 PM	Section 21	21
5088	MDSC-targeted TFF2-MSA synergizes with PD-1 blockade therapy in diffuse-type gastric cancer	Jin	Qian	Poster	Combination Immunotherapies 1	4/18/23	1:30 PM	Section 21	22
5089	Small molecule Bax activator enhances immunotherapy against lung cancer	Xingming	Deng	Poster	Combination Immunotherapies 1	4/18/23	1:30 PM	Section 21	23
5090	TU2218, a dual inhibitor against ALK5/VEGFR2, increases anti-CTLA4 antitumor efficacy in syngeneic tumor models	Nam-Hoon	Kim	Poster	Combination Immunotherapies 1	4/18/23	1:30 PM	Section 21	24
5091	Potentiating immunogenicity of PD1 blockage with metronomic Oral CAPOX for local and liver metastasized colorectal cancer	Seong Jin	Park	Poster	Combination Immunotherapies 1	4/18/23	1:30 PM	Section 21	25
5092	Non-IL-2 blocking Treg-depleting anti-human CD25 mAb primes potent anti-tumor immunity and synergizes anti-tumor effects of anti-PD-1 in a novel hIL-2RA knockin model	Daniel	He	Poster	Combination Immunotherapies 1	4/18/23	1:30 PM	Section 21	26
5093	Chemically inducible splice-neoantigens for cancer immunotherapy	Shingo	Matsushima	Poster	Combination Immunotherapies 1	4/18/23	1:30 PM	Section 21	27
5098	B7-H3 blockade in combination with natural killer cell activity enhancers including NKTR-255 and venetoclax synergistically induces cytotoxicity in B7-H3+ AML cells	Anudishi	Tyagi	Poster	Combination Immunotherapies 2	4/18/23	1:30 PM	Section 22	1
5099	Anti-tumor effect of DA-4505, a novel AhR antagonist as an immunotherapy in the tumor microenvironment	Daewon	Cha	Poster	Combination Immunotherapies 2	4/18/23	1:30 PM	Section 22	2
5100	Combination of $\kappa\lambda$ bispecific antibodies targeting innate (CEAxCD47, NILK-2401) and adaptive immunity (CEAxCD3, NILK-2301 and CEAxCD28, NILK-3301) for next generation immunotherapy of CEA-expressing cancers	Anja	Seckinger	Poster	Combination Immunotherapies 2	4/18/23	1:30 PM	Section 22	3
5101	Inhibition of Notch reverses immunosuppression in basal-like breast cancer	Qiang	Shen	Poster	Combination Immunotherapies 2	4/18/23	1:30 PM	Section 22	4
5102	Developing CYNK-001-derived exosomes to deliver TGF- β siRNA for GBM immunotherapy enhancement	Marina	Gergues	Poster	Combination Immunotherapies 2	4/18/23	1:30 PM	Section 22	5
5104	Targeting IL-1B synergizes with PD-1 blockade for enhanced T and B cell immune responses and inhibition of early lung cancer development	Warapen	Treekitkarnmonkol	Poster	Combination Immunotherapies 2	4/18/23	1:30 PM	Section 22	7
5105	TIMP1 mediates astrocyte-dependent local immunosuppression in brain metastasis	Neibla	Priego	Poster	Combination Immunotherapies 2	4/18/23	1:30 PM	Section 22	8

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
5106	The addition of radiation therapy to simultaneous targeting of PD-1 and IL2R β enhances antigen-specific CD8 T cell anti-tumor immunity in pancreatic cancer models	Maureen	Hoen	Poster	Combination Immunotherapies 2	4/18/23	1:30 PM	Section 22	9
5107	A novel AhR inhibitor 'DA-4505' improved the anti-cancer efficacy of surgical and chemotherapy via synergistic anti-tumor effects of aPD-1	DongKwon	Kim	Poster	Combination Immunotherapies 2	4/18/23	1:30 PM	Section 22	10
5108	Overcoming roadblocks of immunotherapy in non-small cell lung cancer	Tanmoy	Saha	Poster	Combination Immunotherapies 2	4/18/23	1:30 PM	Section 22	11
5109	The anti-PD1+anti-LAG3 and anti-CTLA4+anti-PD1 combinations have non-overlapping mechanisms of action in melanoma cranial and extra cranial metastases	Manali	Phadke	Poster	Combination Immunotherapies 2	4/18/23	1:30 PM	Section 22	12
5110	Locally administered Interleukin-15 combined with cancer cell-targeted near-infrared photoimmunotherapy in a syngeneic mouse cancer model	Hiroshi	Fukushima	Poster	Combination Immunotherapies 2	4/18/23	1:30 PM	Section 22	13
5111	VentX-modulated tumor associated macrophages revert immune suppression in tumor microenvironment and promote efficacy of gemcitabine against pancreatic cancer	Joanna	Le	Poster	Combination Immunotherapies 2	4/18/23	1:30 PM	Section 22	14
5112	Immune biomarkers of clinical response after NSAID treatment in combination with vaccination targeting EGFR-COX2-CDC25B in the APC(Min/+) mouse model	Denise	Cecil	Poster	Combination Immunotherapies 2	4/18/23	1:30 PM	Section 22	15
5113	INTASYL self-delivering RNAi therapeutic dual targeting PD-1 and CTLA-4 provides synergistic antitumor efficacy in the treatment of murine colon cancer in vivo	Benjamin	Cuiffo	Poster	Combination Immunotherapies 2	4/18/23	1:30 PM	Section 22	16
5114	Development of personalized RNA-based immunotherapeutics for glioblastom	Vrunda	Trivedi	Poster	Combination Immunotherapies 2	4/18/23	1:30 PM	Section 22	17
5115	Novel humanized anti-GD2 antibody inhibits GD2-mediated immunosuppression by targeting GD2+ breast cancer stem-like cells	Vivek	Anand	Poster	Combination Immunotherapies 2	4/18/23	1:30 PM	Section 22	18
5116	Inflammasome unleashing during anti-PD-1 therapy modulates CD8+ T cell exhaustion through Th17 cells	Sofia	Russo	Poster	Combination Immunotherapies 2	4/18/23	1:30 PM	Section 22	19
5117	Combined treatment with the epigenetic drug CM272 and an anti-BCL-XL proapoptotic drug sensitizes solid tumors to immune checkpoint blockade	Yaiza	Senent	Poster	Combination Immunotherapies 2	4/18/23	1:30 PM	Section 22	20
5118	STING agonist and TLR7/8 agonist overcome anti-PD-1 resistance mediated by loss of β 2M	Li	Hua	Poster	Combination Immunotherapies 2	4/18/23	1:30 PM	Section 22	21
5119	Nano-immunotherapy targeting PD-L1, PLK1, and TLR9 for treatment of non-small cell lung cancer	Moataz	Reda	Poster	Combination Immunotherapies 2	4/18/23	1:30 PM	Section 22	22

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
5120	NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic human NSCLC in a humanized mouse model	Ismail	Meraz	Poster	Combination Immunotherapies 2	4/18/23	1:30 PM	Section 22	23
5121	TriTCE Co-stim, next generation costimulatory trispecific T cell engagers for the treatment of solid tumors	Lisa	Newhook	Poster	Combination Immunotherapies 2	4/18/23	1:30 PM	Section 22	24
5122	Electrochemotherapy and IL-12 gene electrotransfer in treatment of mast cell tumors in companion dogs	Maja	Cemazar	Poster	Combination Immunotherapies 2	4/18/23	1:30 PM	Section 22	25
5123	The anti-tumor and anti-angiogenic effects of a lipid nanoparticle suspension of an AKT-1 anti-sense oligonucleotide	Fengyang	Xie	Poster	Combination Immunotherapies 2	4/18/23	1:30 PM	Section 22	26
5124	The effect of lenvatinib in combination with chemotherapy plus immune checkpoint inhibitors on tumor microenvironments in the mouse syngeneic tumor model	Yu	Kato	Poster	Combination Immunotherapies 2	4/18/23	1:30 PM	Section 22	27
5125	Depletion of CCR8+ tumor Treg cells with SRF114 or anti-CCR8 therapy promotes robust antitumor activity and reshapes the tumor microenvironment toward a more pro-inflammatory milieu	Marisella	Panduro	Poster	Combination Immunotherapies 2	4/18/23	1:30 PM	Section 22	28
5129	Neutrophil extracellular traps induced by surgical stress regulate cancer metabolism leading to tumor growth	Tony	Haykal	Poster	Inflammation and Immunity in the Tumor Microenvironment	4/18/23	1:30 PM	Section 23	1
5130	Multi-plex cytokine profiling for mice on Bleomycin induced systemic sclerosis model	Ruiqing	Yan	Poster	Inflammation and Immunity in the Tumor Microenvironment	4/18/23	1:30 PM	Section 23	2
5131	Pulmonary influenza infection promotes the awakening of dormant metastatic breast cancer cells	Shi Biao	Chia	Poster	Inflammation and Immunity in the Tumor Microenvironment	4/18/23	1:30 PM	Section 23	3
5132	The immunomodulatory role of paracrine signaling factor VSIG4 in peritoneal cancers	Yik Yan	Chong	Poster	Inflammation and Immunity in the Tumor Microenvironment	4/18/23	1:30 PM	Section 23	4
5133	Oxazolone induced atopic dermatitis mouse model using hIL-4/hIL-4Ra double knock-in mice, a preclinical mouse model for evaluating Dupilumab biosimilars	Tao	Yang	Poster	Inflammation and Immunity in the Tumor Microenvironment	4/18/23	1:30 PM	Section 23	5
5134	PD-1/PD-L1 signalling axis, "a double-edged sword" in DSS induced colitis mouse model	Tao	Yang	Poster	Inflammation and Immunity in the Tumor Microenvironment	4/18/23	1:30 PM	Section 23	6
5135	Standardized off-the-shelf engineered NK cell therapy with improved ADCC properties to treat malignancies	Lida	Wu	Poster	Inflammation and Immunity in the Tumor Microenvironment	4/18/23	1:30 PM	Section 23	7
5136	Surgical stress promotes long-lasting protumorigenic changes in bone marrow derived progenitor cells	Hamza	Yazdani	Poster	Inflammation and Immunity in the Tumor Microenvironment	4/18/23	1:30 PM	Section 23	8
5138	Systemic agonist anti-CD40 treatment delivers precise melanoma immunotherapy within established autoimmune landscapes	Julio	Valencia	Poster	Inflammation and Immunity in the Tumor Microenvironment	4/18/23	1:30 PM	Section 23	10
5139	Chemerin suppresses prostate tumor growth by modulating the recruitment of NK and CD8+ T-cells to tumor microenvironment	Muhammad	Saeed	Poster	Inflammation and Immunity in the Tumor Microenvironment	4/18/23	1:30 PM	Section 23	11

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
5140	Combined administration of poly(I:C) and resiquimod triggers effective antitumoral response in mouse models of pancreatic adenocarcinoma	Aldo	Ummarino	Poster	Inflammation and Immunity in the Tumor Microenvironment	4/18/23	1:30 PM	Section 23	12
5141	Macrophage transcriptomic signature validation in scRNA seq and overall survival differences in urothelial carcinoma	Laura	Bukavina	Poster	Inflammation and Immunity in the Tumor Microenvironment	4/18/23	1:30 PM	Section 23	13
5142	50-parameter flow cytometry by CyTOF empowers comprehensive single-cell immune profiling of pulmonary immunosenescence in aged mice	Wenxi	Xu	Poster	Inflammation and Immunity in the Tumor Microenvironment	4/18/23	1:30 PM	Section 23	14
5144	Spatial T-cell atlas in more than 100 different tumor entities using BLEACH&STAIN	Niclas	Blessin	Poster	Inflammation and Immunity in the Tumor Microenvironment	4/18/23	1:30 PM	Section 23	16
5145	Targeting TREG1 induces innate immune response in chemoresistant small cell lung cancer	Takahiko	Murayama	Poster	Inflammation and Immunity in the Tumor Microenvironment	4/18/23	1:30 PM	Section 23	17
5146	In vitro neutrophil assays to support immuno-oncology drug development	Alanah	Pieters	Poster	Inflammation and Immunity in the Tumor Microenvironment	4/18/23	1:30 PM	Section 23	18
5147	Mice with T cells deficient in the Cytosolic Branched Chain Aminotransferase reduce the tumor burden of low and high immunogenic strains of Lymphoma	Lucas	Figuroa	Poster	Inflammation and Immunity in the Tumor Microenvironment	4/18/23	1:30 PM	Section 23	19
5148	Interrogating immuno-oncological interactions in the tumor microenvironment	Ben	Patterson	Poster	Inflammation and Immunity in the Tumor Microenvironment	4/18/23	1:30 PM	Section 23	20
5149	Age-associated remodeling of anti-tumor T cell immunity and metabolism	SeongJun	Han	Poster	Inflammation and Immunity in the Tumor Microenvironment	4/18/23	1:30 PM	Section 23	21
5150	Improvement of hematopoiesis in primary low risk MDS with the TGFBR1 investigational inhibitor TP-6379	Erika	Eksioglu	Poster	Inflammation and Immunity in the Tumor Microenvironment	4/18/23	1:30 PM	Section 23	22
5151	Enzalutamide resistance results in immunosuppressive alterations in prostate tumor immune microenvironment	Chengfei	Liu	Poster	Inflammation and Immunity in the Tumor Microenvironment	4/18/23	1:30 PM	Section 23	23
5152	Photodynamic therapy promotes immune infiltration and control of malignant pleural mesothelioma through NF-kB mediated upregulation of E-Selectin in the tumor vasculature	Louis-Emmanuel	Chriqui	Poster	Inflammation and Immunity in the Tumor Microenvironment	4/18/23	1:30 PM	Section 23	24
5153	The role of CCL22-specific CD4 T cells in modulating the immunosuppressive tumor microenvironment in ovarian cancer	Ines	Lecoq	Poster	Inflammation and Immunity in the Tumor Microenvironment	4/18/23	1:30 PM	Section 23	25
5154	The cytosolic branched chain aminotransferase is an important metabolic checkpoint of T cell function in the lymphoma microenvironment	Tanner	Wetzel	Poster	Inflammation and Immunity in the Tumor Microenvironment	4/18/23	1:30 PM	Section 23	26
5155	Targeting tumor infiltrating myeloid cells in prostate cancer	Marco	De Velasco	Poster	Inflammation and Immunity in the Tumor Microenvironment	4/18/23	1:30 PM	Section 23	27
5156	The mutagenic effects of APOBEC3A and APOBEC3B in urothelial carcinoma	Michael	Sturdivant	Poster	Inflammation and Immunity in the Tumor Microenvironment	4/18/23	1:30 PM	Section 23	28

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
5157	ATRA treatment induces an interferon response to reprogram the immunosuppressive tumor microenvironment and overcomes resistance to immune checkpoint inhibition in murine models of LKB1 deficient non small cell lung cancer	William	Crosson	Poster	Inflammation and Immunity in the Tumor Microenvironment	4/18/23	1:30 PM	Section 23	29
5161	Molecular mechanisms of early-stage lung adenocarcinoma initiation	Alice	Rodriguez-Fuguet	Poster	Modifiers of the Tumor Microenvironment	4/18/23	1:30 PM	Section 24	1
5162	Discovery of INCB098377: a potent inhibitor of phosphoinositide 3-kinase gamma (PI3K γ)	Stephen	Douglass	Poster	Modifiers of the Tumor Microenvironment	4/18/23	1:30 PM	Section 24	2
5163	Local delivery of mRNA immunotherapy encoding HPV16 antigen, IL-12, and LIGHT/TNFSF14 results in superior immunogenicity and tumor clearance in a murine model of HPV16-driven cancer	Ole Audun	Haabeth	Poster	Modifiers of the Tumor Microenvironment	4/18/23	1:30 PM	Section 24	3
5164	Liposomal Delivery of an Immunostimulatory CpG Induces Robust Antitumor Immunity and Long-Term Immune Memory by Reprogramming Tumor-Associated Macrophages	Yujin	Kim	Poster	Modifiers of the Tumor Microenvironment	4/18/23	1:30 PM	Section 24	4
5165	In vivo therapeutic validation of NRT-YHD_001, a novel macrophage checkpoint inhibitor, in liver cancer	Suk Woo	Nam	Poster	Modifiers of the Tumor Microenvironment	4/18/23	1:30 PM	Section 24	5
5166	Intratumoral delivery of mRNA encoding USP6 activates multiple immuno-stimulatory pathways simultaneously and inhibits local and distal tumor growth in murine models	Ian	Henrich	Poster	Modifiers of the Tumor Microenvironment	4/18/23	1:30 PM	Section 24	6
5167	Entinostat's modulation of myeloid derived suppressor cells through the STAT3-NF κ B-AP-1 axis decreases suppressive signaling	Aaron	Baugh	Poster	Modifiers of the Tumor Microenvironment	4/18/23	1:30 PM	Section 24	7
5168	In vitro suppressive Treg bioassays for screening of candidate therapeutics	Martijn	Vlaming	Poster	Modifiers of the Tumor Microenvironment	4/18/23	1:30 PM	Section 24	8
5169	Aurora-A kinase promotes anti-tumor immunity in high lymphocyte-infiltrated colorectal cancer	Shiang-Jie	Yang	Poster	Modifiers of the Tumor Microenvironment	4/18/23	1:30 PM	Section 24	9
5170	STING inflames NF1 malignancies for immunotherapy	Nipunika	Somatilaka	Poster	Modifiers of the Tumor Microenvironment	4/18/23	1:30 PM	Section 24	10
5171	TP-6379, an investigational TGFBR1 inhibitor, shown to remodel the tumor microenvironment and enhance anti-tumorigenic immunological responses in syngeneic mouse models of cancer	David	Kircher	Poster	Modifiers of the Tumor Microenvironment	4/18/23	1:30 PM	Section 24	11
5172	Tumor-immune microenvironmental profiling during chemo- and targeted therapy for head and neck squamous cell carcinoma	Alisa	Kimura	Poster	Modifiers of the Tumor Microenvironment	4/18/23	1:30 PM	Section 24	12
5173	BET inhibition reprograms pancreatic cancer associated fibroblasts to promote anti-tumor immunity	Trisha	Minocha	Poster	Modifiers of the Tumor Microenvironment	4/18/23	1:30 PM	Section 24	13
5174	PEGylated liposomal doxorubicin improves oral cancer response to radio-immunotherapy	Laxman	Devkota	Poster	Modifiers of the Tumor Microenvironment	4/18/23	1:30 PM	Section 24	14

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
5175	DX-002, a dual EP2 and EP4 antagonist, alters the tumor microenvironment to enhance tumor immunogenicity and responses to immune checkpoint inhibitors	Lintong	Li	Poster	Modifiers of the Tumor Microenvironment	4/18/23	1:30 PM	Section 24	15
5176	CDDO-methyl ester redirects macrophage polarization and reduces lung tumor burden in a Nrf2-dependent manner	Jess	Moerland	Poster	Modifiers of the Tumor Microenvironment	4/18/23	1:30 PM	Section 24	16
5177	Nilotinib suppresses the myofibroblastic cancer-associated fibroblast phenotype	Katherine	Johnson	Poster	Modifiers of the Tumor Microenvironment	4/18/23	1:30 PM	Section 24	17
5178	Humanized OX40/OX40L mice as a tool for evaluating novel therapeutics	James	Jin	Poster	Modifiers of the Tumor Microenvironment	4/18/23	1:30 PM	Section 24	18
5180	T cell receptor repertoire analysis revealed tissue tropism of tumor-reactive T-cell clones in cell cycle reporter mice	Mikiya	Tsunoda	Poster	Modifiers of the Tumor Microenvironment	4/18/23	1:30 PM	Section 24	20
5181	The role of Neuropilin-1 signaling in CD4 conventional T cell immune function in non-small cell lung cancer	Bitta	Kahangi	Poster	Modifiers of the Tumor Microenvironment	4/18/23	1:30 PM	Section 24	21
5182	CD47 is a promising therapeutic target in non-small cell lung cancer	Asa	Lau	Poster	Modifiers of the Tumor Microenvironment	4/18/23	1:30 PM	Section 24	22
5183	Development of an aerosol-based immunotherapy for lung cancer	Yongren	Li	Poster	Modifiers of the Tumor Microenvironment	4/18/23	1:30 PM	Section 24	23
5184	Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors	Laurent	GORVEL	Poster	Modifiers of the Tumor Microenvironment	4/18/23	1:30 PM	Section 24	24
5185	Intratumoral Escherichia is associated with response to single-agent immune checkpoint inhibition in patients with advanced non-small cell lung cancer	Arielle	Elkrief	Poster	Modifiers of the Tumor Microenvironment	4/18/23	1:30 PM	Section 24	25
5188	Interrogating the role of the immune microenvironment in the response of brain metastases to immunotherapy using new preclinical melanoma models	Amélie	Lopès	Poster	Novel Preclinical Models for Cancer Immunotherapy	4/18/23	1:30 PM	Section 25	1
5189	Comparisons of Rituximab and CD19xCD3 BiTE antitumor response across multiple humanized NSG strains engrafted with human hematopoietic stem cells	Guoxiang	Yang	Poster	Novel Preclinical Models for Cancer Immunotherapy	4/18/23	1:30 PM	Section 25	2
5190	Systematic immune-profiling of immune-deficient mouse models: A rationale to select ideal host for tumor implantation	Hervé	Luche	Poster	Novel Preclinical Models for Cancer Immunotherapy	4/18/23	1:30 PM	Section 25	3
5191	Modeling age-related changes in the tumor microenvironment in an orthotopic immunocompetent murine pancreatic cancer model - a novel approach	Morgan	Green	Poster	Novel Preclinical Models for Cancer Immunotherapy	4/18/23	1:30 PM	Section 25	4
5192	NCG-MHC-dKO mice: an excellent model for PBMC reconstitution and pharmacodynamic evaluation in the absence of GvHD	Santi	Chen	Poster	Novel Preclinical Models for Cancer Immunotherapy	4/18/23	1:30 PM	Section 25	5

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
5193	Assessing the efficacy of immune checkpoint blockade as part of a combination therapy in a zebrafish model of rhabdomyosarcoma	Eleanor	Chen	Poster	Novel Preclinical Models for Cancer Immunotherapy	4/18/23	1:30 PM	Section 25	6
5194	Humanized PD-1 knock-in mice as a model system for combination therapies with human specific PD-1 therapeutics	Holger	Weber	Poster	Novel Preclinical Models for Cancer Immunotherapy	4/18/23	1:30 PM	Section 25	7
5195	BNDG B2m KO plus mouse model is a powerful tool for immunotherapy	Hongmei	Jiang	Poster	Novel Preclinical Models for Cancer Immunotherapy	4/18/23	1:30 PM	Section 25	8
5196	Novel humanized CD36 mouse model for therapeutic studies	Rebecca	Soto	Poster	Novel Preclinical Models for Cancer Immunotherapy	4/18/23	1:30 PM	Section 25	9
5197	NCG-hIL2 mice: a novel model to support the development of T regulatory and NK cells	Jianming	Xu	Poster	Novel Preclinical Models for Cancer Immunotherapy	4/18/23	1:30 PM	Section 25	10
5199	B7-H3 & PD-L1 double-humanized BALB/c mouse: a novel animal model for preclinical studies of human B7-H3 antibodies or bispecific antibodies	Jianming	Xu	Poster	Novel Preclinical Models for Cancer Immunotherapy	4/18/23	1:30 PM	Section 25	12
5200	Novel Immuno-Oncology drugs evaluation by humanised immune cells and cancer co-inoculated models	Danyi	Wen	Poster	Novel Preclinical Models for Cancer Immunotherapy	4/18/23	1:30 PM	Section 25	13
5201	TNFR2 humanized mice: an ideal model for studying anti-TNFR2 antibodies	Huiyi	Wang	Poster	Novel Preclinical Models for Cancer Immunotherapy	4/18/23	1:30 PM	Section 25	14
5202	NCG-M humanized mice: an excellent model for human immune reconstitution of myeloid lineages	Huiyi	Wang	Poster	Novel Preclinical Models for Cancer Immunotherapy	4/18/23	1:30 PM	Section 25	15
5203	Naturally occurring colorectal cancer in rhesus macaques as model for human cancer immunotherapy: a first report on pembrolizumab ± radiotherapy	Simon	Deycmar	Poster	Novel Preclinical Models for Cancer Immunotherapy	4/18/23	1:30 PM	Section 25	16
5204	Preclinical models for translational immuno-oncology research: Rare patient-derived xenografts on humanized mice	Jens	Hoffmann	Poster	Novel Preclinical Models for Cancer Immunotherapy	4/18/23	1:30 PM	Section 25	17
5205	B6-KrasLSL-G12C mouse model for assessing the occurrence and development of lung and pancreatic cancer tumors	Erica	Trujillo	Poster	Novel Preclinical Models for Cancer Immunotherapy	4/18/23	1:30 PM	Section 25	18
5206	A novel mouse model for preclinical efficacy evaluation of anti-CD3/GPRC5D bispecific antibodies	Erica	Trujillo	Poster	Novel Preclinical Models for Cancer Immunotherapy	4/18/23	1:30 PM	Section 25	19
5207	Development of MHC I/II knock-out immunodeficient mouse strains for alleviating GvHD induced by human PBMC reconstitution	Jenna	Frame	Poster	Novel Preclinical Models for Cancer Immunotherapy	4/18/23	1:30 PM	Section 25	20
5208	Development of immunodeficient mice expressing human IL3, GM-CSF, CSF1 and THPO for improved human myeloid and lymphoid cell reconstitution	Jenna	Frame	Poster	Novel Preclinical Models for Cancer Immunotherapy	4/18/23	1:30 PM	Section 25	21
5209	Generation of humanized TREM2 mice for preclinical evaluation of therapeutics targeting tumor-associated macrophages	James	Jin	Poster	Novel Preclinical Models for Cancer Immunotherapy	4/18/23	1:30 PM	Section 25	22

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
5210	Ablation of an immunogenic human endogenous retrovirus in renal cell carcinoma cells through dual-guide CRISPR-Cas9 genome editing	Long	Chen	Poster	Novel Preclinical Models for Cancer Immunotherapy	4/18/23	1:30 PM	Section 25	23
5214	Expanding the spectrum of germline-driven cancers by leveraging population-scale targeted tumor and normal sequencing	Miika	Mehine	Poster	GWAS/Post-GWAS	4/18/23	1:30 PM	Section 26	1
5215	Clinical features of Li-Fraumeni syndrome in Korea	Ran	Song	Poster	GWAS/Post-GWAS	4/18/23	1:30 PM	Section 26	2
5216	The effect of polymorphisms in DAT1 and DRD4 on dietary intake during chemotherapy for childhood leukemia	Jing	Wen	Poster	GWAS/Post-GWAS	4/18/23	1:30 PM	Section 26	3
5217	Genome-wide interactions of processed and red meat intake on colorectal cancer risk	Joel	Sanchez Mendez	Poster	GWAS/Post-GWAS	4/18/23	1:30 PM	Section 26	4
5218	Genome-wide association study of African Americans reveals new susceptibility loci contributing to lung cancer and mechanisms of population-specific etiology	Jinyoung	Byun	Poster	GWAS/Post-GWAS	4/18/23	1:30 PM	Section 26	5
5219	Telomere length distribution, metabolic trait association, and genome-wide association study among Singaporean cohorts	Trang	Nguyen	Poster	GWAS/Post-GWAS	4/18/23	1:30 PM	Section 26	6
5220	Prediagnostic vitamin D status and colorectal cancer survival by vitamin D-binding protein isoforms in the US cohorts	Hanseul	Kim	Poster	GWAS/Post-GWAS	4/18/23	1:30 PM	Section 26	7
5221	Identifying acute lymphoblastic leukemia risk loci in latino children via admixture mapping	Jalen	Langie	Poster	GWAS/Post-GWAS	4/18/23	1:30 PM	Section 26	8
5222	Genetic variants associated with progression from monoclonal B-cell lymphocytosis (MBL) to chronic lymphocytic leukemia (CLL)	Raphael	Mwangi	Poster	GWAS/Post-GWAS	4/18/23	1:30 PM	Section 26	9
5223	Circulating lipoprotein lipids and colorectal cancer risk: A Mendelian randomization analysis from the GECCO consortium	Lili	Liu	Poster	GWAS/Post-GWAS	4/18/23	1:30 PM	Section 26	10
5224	Genome-wide interaction study of smoking and bladder cancer risk: results from the COBLAnCE cohort	Maryam	Karimi	Poster	GWAS/Post-GWAS	4/18/23	1:30 PM	Section 26	11
5225	Expression- and splicing-based multi-tissue transcriptome-wide association studies identified multiple genes for estrogen receptor-negative breast cancer	James	Li	Poster	GWAS/Post-GWAS	4/18/23	1:30 PM	Section 26	12
5226	Exome-wide association study identifies coding variant in IL17RA associated with survival in cancer patients treated with immunotherapy	Sam	Kleeman	Poster	GWAS/Post-GWAS	4/18/23	1:30 PM	Section 26	13
5227	Cross-trait genome-wide association meta-analyses of clonal hematopoiesis and solid tumor risk	Victoria	Gray	Poster	GWAS/Post-GWAS	4/18/23	1:30 PM	Section 26	14
5228	Genome-wide association study and LD score regression analysis for cholangiocarcinoma	Younghun	Han	Poster	GWAS/Post-GWAS	4/18/23	1:30 PM	Section 26	15
5229	Pathogenic germline mutations and risk of multiple myeloma	Michael	Conry	Poster	GWAS/Post-GWAS	4/18/23	1:30 PM	Section 26	16

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
5230	Comprehensive genetic analysis using clinical specimens of gastric adenocarcinoma and proximal polyposis of stomach	Chihiro	Matsumoto	Poster	GWAS/Post-GWAS	4/18/23	1:30 PM	Section 26	17
5231	Whole genome sequencing reveals significant genetic admixture in multiple myeloma patients, impacting assessment of etiology	Kylee	Maclachlan	Poster	GWAS/Post-GWAS	4/18/23	1:30 PM	Section 26	18
5232	Differential expression of stress-survival pathway genes related to Hispanic colorectal cancer disparities	Urbashi	Basnet	Poster	GWAS/Post-GWAS	4/18/23	1:30 PM	Section 26	19
5233	Germline CHEK2 variants and risk of lymphoma	Nicholas	Boddicker	Poster	GWAS/Post-GWAS	4/18/23	1:30 PM	Section 26	20
5234	Novel predictive biomarker SNPs and polygenic risk scores of immune-related genes for colorectal cancer survival in Korea	Dabin	Yun	Poster	GWAS/Post-GWAS	4/18/23	1:30 PM	Section 26	21
5235	Transcriptome-wide study of tumor samples from Peruvian women identifies dysregulated pathways in luminal tumors typically associated with more aggressive disease	Chenghuiyun	Xu	Poster	GWAS/Post-GWAS	4/18/23	1:30 PM	Section 26	22
5236	Functional analysis of variants of uncertain significance of the MSH6 mismatch repair gene	Elizabeth	Szabo	Poster	GWAS/Post-GWAS	4/18/23	1:30 PM	Section 26	23
5237	Regulation of genes located in 6q25 by an Indigenous American genetic variant in breast cancer patients from Peru	Valentina	Zavala	Poster	GWAS/Post-GWAS	4/18/23	1:30 PM	Section 26	24
5238	The functional role of promoter germline variants in breast cancer susceptibility genes	Nelly	Arroyo	Poster	GWAS/Post-GWAS	4/18/23	1:30 PM	Section 26	25
5239	Integrative analysis of 3D chromatin organization at GWAS loci identifies RAPGEF1 as a melanoma susceptibility gene	Rohit	Thakur	Poster	GWAS/Post-GWAS	4/18/23	1:30 PM	Section 26	26
5240	Validation of research cohort based penetrance estimates for multiple cancer types and multiple primary cancers on clinically ascertained families	Elissa	Dodd-Eaton	Poster	GWAS/Post-GWAS	4/18/23	1:30 PM	Section 26	27
5241	Association of polygenic risk scores with breast cancer risk among women with benign breast disease	Stacey	Winham	Poster	GWAS/Post-GWAS	4/18/23	1:30 PM	Section 26	28
5242	Do polygenic risk scores add to clinical data in predicting pancreatic cancer? a scoping review	Louise	Wang	Poster	GWAS/Post-GWAS	4/18/23	1:30 PM	Section 26	29
5243	Functional characterization of genetic loci in basal cell carcinoma	Mingyue	Li	Poster	GWAS/Post-GWAS	4/18/23	1:30 PM	Section 26	30
5247	The effect of aspirin on the transcriptional landscape of the colon	Jonathan	Downie	Poster	Dietary Derivatives and Repurposed and New Drugs for Cancer Prevention	4/18/23	1:30 PM	Section 27	1
5248	The use of reverse phase protein array (RPPA) to identify new tumor vulnerability and actionable drug targets against human cancer cell lines	Andrew	Howell	Poster	Dietary Derivatives and Repurposed and New Drugs for Cancer Prevention	4/18/23	1:30 PM	Section 27	2
5249	Polyphenon E effects MXD1 and RGS4 gene expression in PC-3 prostate cancer cells	L. Michael	Carastro	Poster	Dietary Derivatives and Repurposed and New Drugs for Cancer Prevention	4/18/23	1:30 PM	Section 27	3

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
5250	Effect of the β -blocker carvedilol in preventing DMBA-induced mammary gland tumor growth	Pabitra Kumar	Sardar	Poster	Dietary Derivatives and Repurposed and New Drugs for Cancer Prevention	4/18/23	1:30 PM	Section 27	4
5251	Skeletonema marinoi algae extract and carotenoid fucoxanthin are endowed with potential chemopreventive and angiopreventive properties for prostate cancer	Adriana	Albini	Poster	Dietary Derivatives and Repurposed and New Drugs for Cancer Prevention	4/18/23	1:30 PM	Section 27	5
5252	Salsolinol suppresses the STAT3-EMT axis in liver carcinogenesis	Hyeon Jeong	Oh	Poster	Dietary Derivatives and Repurposed and New Drugs for Cancer Prevention	4/18/23	1:30 PM	Section 27	6
5254	Topical inhibition of UV-induced PD-L1 expression and inflammatory signaling by the small molecule inhibitor BMS-202	Sally	Dickinson	Poster	Dietary Derivatives and Repurposed and New Drugs for Cancer Prevention	4/18/23	1:30 PM	Section 27	8
5255	Effect of STAT3 inhibitors, TTI-101 and SH5-07, against bladder cancer in preclinical 3D tumor models	Surya	Singh	Poster	Dietary Derivatives and Repurposed and New Drugs for Cancer Prevention	4/18/23	1:30 PM	Section 27	9
5256	Understanding HPV vaccine confidence and conspiracy beliefs across the US: Opportunities to increase cancer prevention through HPV vaccine education	Josheili	Llavona-Ortiz	Poster	Dietary Derivatives and Repurposed and New Drugs for Cancer Prevention	4/18/23	1:30 PM	Section 27	10
5257	Activation of NRF2-mediated oxidative stress response pathway by curcumin analog FLLL12: Implication for chemoprevention	A.R.M.	Amin	Poster	Dietary Derivatives and Repurposed and New Drugs for Cancer Prevention	4/18/23	1:30 PM	Section 27	11
5258	Preclinical testing of CD73 inhibitor AB680 for pancreatic cancer immunoprevention	Lincoln	Strickland	Poster	Dietary Derivatives and Repurposed and New Drugs for Cancer Prevention	4/18/23	1:30 PM	Section 27	12
5259	Bazedoxifene plus conjugated estrogen improves metabolic health and reduces mammary gland epithelial proliferation in an ovary intact rat model of obesity and breast cancer risk	Erin	Giles	Poster	Dietary Derivatives and Repurposed and New Drugs for Cancer Prevention	4/18/23	1:30 PM	Section 27	13
5260	Chemopreventive efficacy of everolimus and naproxen combination against carcinogen induced bladder cancer in F344 rats	Venkateshwar	Madka	Poster	Dietary Derivatives and Repurposed and New Drugs for Cancer Prevention	4/18/23	1:30 PM	Section 27	14
5261	Prostate specific sustained anti androgen delivery to delay early stage prostate cancer progression	Pamela	Munster	Poster	Dietary Derivatives and Repurposed and New Drugs for Cancer Prevention	4/18/23	1:30 PM	Section 27	15
5262	Avasimibe abolishes the breast cancer preventative efficacy of statin in a spontaneous mouse model of breast cancer	Anjana	Bhardwaj	Poster	Dietary Derivatives and Repurposed and New Drugs for Cancer Prevention	4/18/23	1:30 PM	Section 27	16

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
5263	Licochalcone A is a candidate for breast cancer prevention through its reprogramming of metabolic and antioxidant pathways	Atieh	Hajirahimkhan	Poster	Dietary Derivatives and Repurposed and New Drugs for Cancer Prevention	4/18/23	1:30 PM	Section 27	17
5264	Cucurbitacin D modulates the Nrf2 signaling pathway and protects against benzo[a]pyrene-induced liver injury	Shabnam	Malik	Poster	Dietary Derivatives and Repurposed and New Drugs for Cancer Prevention	4/18/23	1:30 PM	Section 27	18
5265	Investigating the role of Desmocollin-3 and immune infiltrate in bladder cancer	Sanjay	Malhotra	Poster	Dietary Derivatives and Repurposed and New Drugs for Cancer Prevention	4/18/23	1:30 PM	Section 27	19
5266	Metabolic rewiring and epigenetic reprogramming by the environmental carcinogen benzo[a]pyrene in a two-stage skin carcinogenesis mouse model and cancer interception by triterpenoid ursolic acid	Md. Shahid	Sarwar	Poster	Dietary Derivatives and Repurposed and New Drugs for Cancer Prevention	4/18/23	1:30 PM	Section 27	20
5267	Effects of polyphenon E treatment on gene expression in DU145 prostate cancer cells	Ethan	Vallebuona	Poster	Dietary Derivatives and Repurposed and New Drugs for Cancer Prevention	4/18/23	1:30 PM	Section 27	21
5268	Drug screening of non-small cell lung cancer patient-derived organoids in a microwell platform	Qiyue	Luan	Poster	Dietary Derivatives and Repurposed and New Drugs for Cancer Prevention	4/18/23	1:30 PM	Section 27	22
5269	RF-1302, a novel dual inhibitor of PIM1 and FLT3 in preclinical treatment of acute myeloid leukemia	Weiwei	Qi	Poster	Dietary Derivatives and Repurposed and New Drugs for Cancer Prevention	4/18/23	1:30 PM	Section 27	23
5270	Silibinin modulates migration and survival pathways in bone marrow mast cells via RAC2: Implications in its anti-cancer activity in basal cell carcinoma growth and progression	Neha	Mishra	Poster	Dietary Derivatives and Repurposed and New Drugs for Cancer Prevention	4/18/23	1:30 PM	Section 27	24
5271	Inhibition of ultraviolet B radiation-induced mast cell recruitment by silibinin in its efficacy against basal cell carcinoma in Ptch+/- mouse model	Rajesh	Agarwal	Poster	Dietary Derivatives and Repurposed and New Drugs for Cancer Prevention	4/18/23	1:30 PM	Section 27	25
5272	3D cell-culture strategy for screening novel agents in Fanconi anemia chemoprevention	Beverly	Wuertz	Poster	Dietary Derivatives and Repurposed and New Drugs for Cancer Prevention	4/18/23	1:30 PM	Section 27	26
5273	The E3 ubiquitin ligase SIAH2 promotes clear cell renal cell carcinoma epithelial-mesenchymal transition via regulation of SETD2 stability	Gang	Wang	Poster	Dietary Derivatives and Repurposed and New Drugs for Cancer Prevention	4/18/23	1:30 PM	Section 27	27
5277	Activation of TRPM8 channel suppresses prostate cancer growth and progression	Swapna	Asuthkar	Poster	Endocrine-related Cancers and Nuclear Receptors: Molecular Biology, Biomarkers, and Genomics	4/18/23	1:30 PM	Section 28	1

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
5278	Fbxo22 regulates estrogen signaling and suppresses tamoxifen-induced endometrial cancer	Tomohiko	Ohta	Poster	Endocrine-related Cancers and Nuclear Receptors: Molecular Biology, Biomarkers, and Genomics	4/18/23	1:30 PM	Section 28	2
5279	Molecular analysis of AMBRA1 as a candidate tumor suppressor in sporadic parathyroid adenomas	Stephanie	Chinwo	Poster	Endocrine-related Cancers and Nuclear Receptors: Molecular Biology, Biomarkers, and Genomics	4/18/23	1:30 PM	Section 28	3
5280	O-GlcNAcylation of progesterone receptor promotes mammary tumorigenesis	Harmony	Saunders	Poster	Endocrine-related Cancers and Nuclear Receptors: Molecular Biology, Biomarkers, and Genomics	4/18/23	1:30 PM	Section 28	4
5281	Role of TMEM97/Sigma-2 receptor in prostate cancer	Xiangwei	Fang	Poster	Endocrine-related Cancers and Nuclear Receptors: Molecular Biology, Biomarkers, and Genomics	4/18/23	1:30 PM	Section 28	5
5282	Mitotane induces GDF-15 expression in vitro and in vivo: A potential therapy-induced mechanism of immune escape in adrenocortical carcinoma	Isabel	Weigand	Poster	Endocrine-related Cancers and Nuclear Receptors: Molecular Biology, Biomarkers, and Genomics	4/18/23	1:30 PM	Section 28	6
5283	Glucocorticoid receptor (GR) activity alters invasive lobular breast cancer (ILC) oncogenic properties	Ishrat	Durdana	Poster	Endocrine-related Cancers and Nuclear Receptors: Molecular Biology, Biomarkers, and Genomics	4/18/23	1:30 PM	Section 28	7
5284	Recurrent Middle Eastern differentiated thyroid carcinoma has worse outcome than persistent disease	Sandeep	Parvathareddy	Poster	Endocrine-related Cancers and Nuclear Receptors: Molecular Biology, Biomarkers, and Genomics	4/18/23	1:30 PM	Section 28	8
5285	Identification of therapeutic targets in poorly differentiated carcinoma through a multimodal molecular analysis	Vanessa	Zambelli	Poster	Endocrine-related Cancers and Nuclear Receptors: Molecular Biology, Biomarkers, and Genomics	4/18/23	1:30 PM	Section 28	9
5286	Matrix metalloproteinase 14 is associated with poor survival in adrenocortical carcinoma	Liudmila	Popova	Poster	Endocrine-related Cancers and Nuclear Receptors: Molecular Biology, Biomarkers, and Genomics	4/18/23	1:30 PM	Section 28	10
5287	Is testosterone the male sex hormone responsible for increased male mortality in melanoma? In-vitro studies based on human melanoma (BLM) cell model	Pandurangan	Ramaraj	Poster	Endocrine-related Cancers and Nuclear Receptors: Molecular Biology, Biomarkers, and Genomics	4/18/23	1:30 PM	Section 28	11
5288	Single-cell multiomics reveal divergent transcriptional and epigenetic cell states in breast cancer	Aysegul	Ors	Poster	Endocrine-related Cancers and Nuclear Receptors: Molecular Biology, Biomarkers, and Genomics	4/18/23	1:30 PM	Section 28	12
5289	Proteomic profile of breast carcinomas with unbalanced levels of progesterone receptor isoforms	Andres	Elia	Poster	Endocrine-related Cancers and Nuclear Receptors: Molecular Biology, Biomarkers, and Genomics	4/18/23	1:30 PM	Section 28	13

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
5292	Characterization of androgen receptor properties and interactome in mediating transcriptional condensates in prostate cancer	Nicholas	Pinette	Poster	Endocrine-related Cancers and Nuclear Receptors: Molecular Biology, Biomarkers, and Genomics	4/18/23	1:30 PM	Section 28	16
5298	Multiplex immunoassay characterization of 48 cytokines, chemokines, and growth factors in colorectal cancer	Wen-Rong	Lie	Poster	Biological Mass Spectrometry and Systems Biology	4/18/23	1:30 PM	Section 29	2
5299	Impact of gut microbial metabolites on colon epithelium	Ru	Chen	Poster	Biological Mass Spectrometry and Systems Biology	4/18/23	1:30 PM	Section 29	3
5300	Mass spectrometry-based protein biomarker analysis in chemoimmunotherapy combinations identifies unique immune signatures in pancreatic cancer	Nigel	Beaton	Poster	Biological Mass Spectrometry and Systems Biology	4/18/23	1:30 PM	Section 29	4
5301	Detection of arginine posttranslational modifications by single-molecule protein sequencing on the Quantum-Si platform	Kenneth	Skinner	Poster	Biological Mass Spectrometry and Systems Biology	4/18/23	1:30 PM	Section 29	5
5302	Unmasking aggressive tumor profiles in lung adenocarcinomas through the molecular abundances and catalytic action of serine hydrolases	Sven	Hillinger	Poster	Biological Mass Spectrometry and Systems Biology	4/18/23	1:30 PM	Section 29	6
5303	Upregulation of the polycomb group protein SCML2 contributes to aggressive prostate cancer	Bekir	Cinar	Poster	Biological Mass Spectrometry and Systems Biology	4/18/23	1:30 PM	Section 29	7
5304	Development of a plasma biomarker panel for gastric cancer detection based on an autoimmune response signature	Rongzhang	Dou	Poster	Biological Mass Spectrometry and Systems Biology	4/18/23	1:30 PM	Section 29	8
5305	Detection and quantification of proteins using protein identification by short-epitope mapping (PrISM)	Jarrett	Egertson	Poster	Biological Mass Spectrometry and Systems Biology	4/18/23	1:30 PM	Section 29	9
5307	Imaging mass cytometry enables identification of distinct tissue phenotypes in highly autofluorescent lung and colon cancer tissues, producing consistent data across serial sections	Smriti	Kala	Poster	Biological Mass Spectrometry and Systems Biology	4/18/23	1:30 PM	Section 29	11
5308	Analysis of extracellular vesicle surface markers as small cell lung cancer biomarkers	Patricia	Ozawa	Poster	Biological Mass Spectrometry and Systems Biology	4/18/23	1:30 PM	Section 29	12
5309	Isolation and validation of small extracellular vesicles from rhabdomyosarcoma cells	Paula	Quaglietta	Poster	Biological Mass Spectrometry and Systems Biology	4/18/23	1:30 PM	Section 29	13
5310	An expanded quantitative protein expression atlas of human cancers	Han	Liang	Poster	Biological Mass Spectrometry and Systems Biology	4/18/23	1:30 PM	Section 29	14
5311	Lipidomic profiling of extracellular vesicles derived from cancer cell lines: Lipid species as potential biomarkers and cellular uptake enhancers	Ruben	Lopez Salazar	Poster	Biological Mass Spectrometry and Systems Biology	4/18/23	1:30 PM	Section 29	15
5312	Next generation quantitative proteomic analysis of urothelial lesions reveals novel diagnostic biomarkers to distinguish pathologic pitfalls and protein-protein interactions	Han Suk	Ryu	Poster	Biological Mass Spectrometry and Systems Biology	4/18/23	1:30 PM	Section 29	16

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
5313	The expression of phospho-Rb S249, N-cadherin, E-cadherin, and B-catenin as a prostate proteomic score for the risk classification of prostate cancer tumors	Sheila	Valle Cortes	Poster	Biological Mass Spectrometry and Systems Biology	4/18/23	1:30 PM	Section 29	17
5314	A peripheral blood-based glycoproteomic predictor of checkpoint inhibitor treatment benefit in advanced non-small cell lung cancer	Klaus	Lindpaintner	Poster	Biological Mass Spectrometry and Systems Biology	4/18/23	1:30 PM	Section 29	18
5315	Identification of urinary proteome signatures associated with triple-negative breast cancer	Michael	Lombardo	Poster	Biological Mass Spectrometry and Systems Biology	4/18/23	1:30 PM	Section 29	19
5319	EU-OPENSREEN - An open-access initiative in chemical biology to support anti-cancer drug discovery	Bahne	Stechmann	Poster	High-throughput Screening, Lead Identification and Optimization, and in Silico Drug Discovery	4/18/23	1:30 PM	Section 30	1
5320	The RenMice™ HiTS (Hyperimmune target specific) Platform facilitates identification of novel therapeutic antibodies for challenging targets	Li	Hui	Poster	High-throughput Screening, Lead Identification and Optimization, and in Silico Drug Discovery	4/18/23	1:30 PM	Section 30	2
5321	Large scale pan cancer drug combination screening to identify effective and actionable combinations and biomarker hypothesis	Azadeh	Bashi	Poster	High-throughput Screening, Lead Identification and Optimization, and in Silico Drug Discovery	4/18/23	1:30 PM	Section 30	3
5322	High throughput chemotherapeutic drug screening system for gastric cancer: cure-GA	Jieun	Lee	Poster	High-throughput Screening, Lead Identification and Optimization, and in Silico Drug Discovery	4/18/23	1:30 PM	Section 30	4
5323	Accelerating the drug discovery process with an automated high-throughput protein production and characterization platform for AI-driven antibody development of immunotherapy	Cheng-chi	Chao	Poster	High-throughput Screening, Lead Identification and Optimization, and in Silico Drug Discovery	4/18/23	1:30 PM	Section 30	5
5324	Drug repurposing and genetic screening strategies for effective treatment discovery in soft-tissue sarcomas	Mushriq	Al-Jazrawe	Poster	High-throughput Screening, Lead Identification and Optimization, and in Silico Drug Discovery	4/18/23	1:30 PM	Section 30	6
5326	Comparison of CAR-T cell-mediated cytotoxicity assays with suspension tumor cells using high-throughput plate-based image cytometry method	Leo	Chan	Poster	High-throughput Screening, Lead Identification and Optimization, and in Silico Drug Discovery	4/18/23	1:30 PM	Section 30	8
5327	Automated organoid alignment for clonal response characterization in pancreatic ductal adenocarcinoma	Ethan	Lin	Poster	High-throughput Screening, Lead Identification and Optimization, and in Silico Drug Discovery	4/18/23	1:30 PM	Section 30	9
5328	Novel KRAS-specific in-well lysis ELISA for high throughput screening	Hyun Min	Park	Poster	High-throughput Screening, Lead Identification and Optimization, and in Silico Drug Discovery	4/18/23	1:30 PM	Section 30	10
5329	High throughput screening strategies in the development of logic gated cell therapies	Li	Wang	Poster	High-throughput Screening, Lead Identification and Optimization, and in Silico Drug Discovery	4/18/23	1:30 PM	Section 30	11

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
5330	Cell identity, count, and viability for critical quality attributes using the Cellaca PLX image cytometer	Carolina	Franco Nitta	Poster	High-throughput Screening, Lead Identification and Optimization, and in Silico Drug Discovery	4/18/23	1:30 PM	Section 30	12
5331	DNA-encoded macrocyclic compound libraries for challenging targets	Ying	Zhang	Poster	High-throughput Screening, Lead Identification and Optimization, and in Silico Drug Discovery	4/18/23	1:30 PM	Section 30	13
5332	Characterization and comparison of acridine orange/propidium iodide and acridine/DAPI viability detection methods for cell and gene therapy development	Yongyang	Huang	Poster	High-throughput Screening, Lead Identification and Optimization, and in Silico Drug Discovery	4/18/23	1:30 PM	Section 30	14
5333	Combining chemoproteomics with machine learning identifies functionally active covalent fragments for hard-to-drug cancer drivers	Johannes	Hermann	Poster	High-throughput Screening, Lead Identification and Optimization, and in Silico Drug Discovery	4/18/23	1:30 PM	Section 30	15
5334	Targeting the KIF15-TPX2 PPI to overcome KIF11 inhibitor resistance in epithelial ovarian cancer	Benjamin	Gibbs	Poster	High-throughput Screening, Lead Identification and Optimization, and in Silico Drug Discovery	4/18/23	1:30 PM	Section 30	16
5335	circAde: a circRNA-based system for prolonged and more effective treatment of cancer	Thomas	Hansen	Poster	High-throughput Screening, Lead Identification and Optimization, and in Silico Drug Discovery	4/18/23	1:30 PM	Section 30	17
5336	Discovery of a novel activin receptor-like kinases (ALKs) inhibitor targeting TGF- β signaling pathways	Mitsuharu	Hanada	Poster	High-throughput Screening, Lead Identification and Optimization, and in Silico Drug Discovery	4/18/23	1:30 PM	Section 30	18
5337	Design, synthesis and evaluation of dual-targeted mEGFR and AURK inhibitors as anticancer agents	Dayna	Gesinski	Poster	High-throughput Screening, Lead Identification and Optimization, and in Silico Drug Discovery	4/18/23	1:30 PM	Section 30	19
5338	A novel in vitro assay to evaluate the roles of hepatic metabolism on anticancer drug safety and efficacy	Albert	Li	Poster	High-throughput Screening, Lead Identification and Optimization, and in Silico Drug Discovery	4/18/23	1:30 PM	Section 30	20
5339	4-Amino-N-phenylbenzamides as dual-targeted mEGFR and AURK inhibitors and anticancer agents	Brianne	Rogers	Poster	High-throughput Screening, Lead Identification and Optimization, and in Silico Drug Discovery	4/18/23	1:30 PM	Section 30	21
5341	Data mining of PubChem bioassay data reveals OXPHOS inhibitors with anti-cancer activity	Sejal	Sharma	Poster	High-throughput Screening, Lead Identification and Optimization, and in Silico Drug Discovery	4/18/23	1:30 PM	Section 30	23
5342	Assessment of polyphenolic secondary metabolites and small molecules against the xenobiotic metabolic and cell cycle regulatory proteins in prostate cancer	Sumit	Sheoran	Poster	High-throughput Screening, Lead Identification and Optimization, and in Silico Drug Discovery	4/18/23	1:30 PM	Section 30	24

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
5343	Evaluating the screened polyphenolics molecules as potential chemosensitizers against the oncogenic signalling proteins in lung cancer	Swati	Arora	Poster	High-throughput Screening, Lead Identification and Optimization, and in Silico Drug Discovery	4/18/23	1:30 PM	Section 30	25
5344	Novel melanoma leads demonstrate efficacy in A375 xenograft model in nude mice	Dmitriy	Minond	Poster	High-throughput Screening, Lead Identification and Optimization, and in Silico Drug Discovery	4/18/23	1:30 PM	Section 30	26
5345	The application of CDK16 inhibitors in the treatment of triple-negative breast cancer	Haihua	Xiao	Poster	High-throughput Screening, Lead Identification and Optimization, and in Silico Drug Discovery	4/18/23	1:30 PM	Section 30	27
5346	Discovery of new targeted protein degraders using DNA-encoded chemistry	Yan	Yu	Poster	High-throughput Screening, Lead Identification and Optimization, and in Silico Drug Discovery	4/18/23	1:30 PM	Section 30	28
5347	Selective targeting deacetylase 3 (HDAC3) and HDAC8 by PROTACs	Yufeng	Xiao	Poster	High-throughput Screening, Lead Identification and Optimization, and in Silico Drug Discovery	4/18/23	1:30 PM	Section 30	29
5348	Targeting MEK, alone and in combination with BRAF, in metastatic BRAFK601E-mutated melanoma	Sin Ting	Chow	Poster	High-throughput Screening, Lead Identification and Optimization, and in Silico Drug Discovery	4/18/23	1:30 PM	Section 30	30
5352	Targeting DNA methylation in T cells to improve the efficacy of immunotherapy	Pengtao	Dang	Poster	Artificial Intelligence and Machine/Deep Learning 1	4/18/23	1:30 PM	Section 31	1
5353	Graph representation learning of tumor topology from spatial imaging data	Nicholas	Ceglia	Poster	Artificial Intelligence and Machine/Deep Learning 1	4/18/23	1:30 PM	Section 31	2
5354	Prediction of OncotypeDX high risk group for chemotherapy benefit in breast cancer by deep learning analysis of hematoxylin and eosin-stained whole slide images	Gil	Shamai	Poster	Artificial Intelligence and Machine/Deep Learning 1	4/18/23	1:30 PM	Section 31	3
5355	Elraglusib response prediction and mechanistic discovery using iterative machine learning	Joseph	McDermott	Poster	Artificial Intelligence and Machine/Deep Learning 1	4/18/23	1:30 PM	Section 31	4
5356	Collaborating to ensure data-driven drug discovery on the Cancer Genomics Cloud: Realizing the possibilities for MoDaC and ATOM	Dennis	Dean	Poster	Artificial Intelligence and Machine/Deep Learning 1	4/18/23	1:30 PM	Section 31	5
5357	Estrogen receptor gene expression prediction from H&E-stained whole slide images	Ronnachai	Jaroensri	Poster	Artificial Intelligence and Machine/Deep Learning 1	4/18/23	1:30 PM	Section 31	6
5358	Digital SP263 PD-L1 tumor cell scoring in non-small cell lung cancer achieves comparable outcome prediction to manual pathology scoring	Hen	Prizant	Poster	Artificial Intelligence and Machine/Deep Learning 1	4/18/23	1:30 PM	Section 31	7
5359	Translating state-of-the-art deep learning predictions of treatment efficacy to clinical practice	Gustavo	Arango-Argoty	Poster	Artificial Intelligence and Machine/Deep Learning 1	4/18/23	1:30 PM	Section 31	8

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
5360	Improved identification of CHIP mutations from cell-free DNA without matched normal samples using machine learning	Gustavo	Arango-Argoty	Poster	Artificial Intelligence and Machine/Deep Learning 1	4/18/23	1:30 PM	Section 31	9
5361	Deep learning models capture high dimensional features for cell morphology analysis	Kevin	Jacobs	Poster	Artificial Intelligence and Machine/Deep Learning 1	4/18/23	1:30 PM	Section 31	10
5362	AI-enabled novel workflow to evaluate T-cell activity in vitro using 3D spheroid models	Zhisong	Tong	Poster	Artificial Intelligence and Machine/Deep Learning 1	4/18/23	1:30 PM	Section 31	11
5363	MicroArray-based MethylationToActivity: Advancing biological knowledges from DNA methylation profiles of patient tumors	Karissa	Dieseldorff Jones	Poster	Artificial Intelligence and Machine/Deep Learning 1	4/18/23	1:30 PM	Section 31	12
5364	Language modeling of peptide-HLA interactions achieves state-of-the-art performance on prediction of peptide presentation by HLA Class II	Ankur	Dhanik	Poster	Artificial Intelligence and Machine/Deep Learning 1	4/18/23	1:30 PM	Section 31	13
5365	Extracting novel knowledge from scientific literature to build a web portal for cancer researchers to keep up with the latest scientific discoveries	Jinfeng	Zhang	Poster	Artificial Intelligence and Machine/Deep Learning 1	4/18/23	1:30 PM	Section 31	14
5366	Constructing the largest-scale biomedical knowledge graph using all PubMed articles and its application in automated knowledge discovery	Jinfeng	Zhang	Poster	Artificial Intelligence and Machine/Deep Learning 1	4/18/23	1:30 PM	Section 31	15
5367	Deep neural networks using protein-protein network information predict multiple myeloma survival	Jiening	Zhu	Poster	Artificial Intelligence and Machine/Deep Learning 1	4/18/23	1:30 PM	Section 31	16
5368	AI-enabled prediction of lung cancer specific hot spot gene alterations from histology images	Gowhar	Shafi	Poster	Artificial Intelligence and Machine/Deep Learning 1	4/18/23	1:30 PM	Section 31	17
5369	Detection of ERG:TMPRSS2 gene fusion in prostate cancer from histopathology slides using attention-based deep learning	Mohamed	Omar	Poster	Artificial Intelligence and Machine/Deep Learning 1	4/18/23	1:30 PM	Section 31	18
5370	New oncology target identification and validation platform combining artificial intelligence and preclinical pharmacology	Olivier	Duchamp	Poster	Artificial Intelligence and Machine/Deep Learning 1	4/18/23	1:30 PM	Section 31	19
5371	Modeling single-cell dynamics using stochastic generative models based on neural differential equations	Michael	Vinyard	Poster	Artificial Intelligence and Machine/Deep Learning 1	4/18/23	1:30 PM	Section 31	20
5372	Supervised manifold learning and classification; application to expression data visualization and cancer prediction	James	Webber	Poster	Artificial Intelligence and Machine/Deep Learning 1	4/18/23	1:30 PM	Section 31	21
5373	Autoencoder-based multimodal prediction of survival for non-small cell lung cancer	Natasha	Markuzon	Poster	Artificial Intelligence and Machine/Deep Learning 1	4/18/23	1:30 PM	Section 31	22
5374	Why only focus on the tumor?: The crucial role of the extra-tumor environment to predict poor responders for locally advanced rectal cancer	Rumi	Shin	Poster	Artificial Intelligence and Machine/Deep Learning 1	4/18/23	1:30 PM	Section 31	23
5375	Learned phenotypic embeddings enable scalable imputation of high-content molecular data elucidating prognostic chromatin signatures	Christopher	Probert	Poster	Artificial Intelligence and Machine/Deep Learning 1	4/18/23	1:30 PM	Section 31	24

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
5376	Protein structure-based modeling to improve MHC class I epitope predictions	Karen	Anderson	Poster	Artificial Intelligence and Machine/Deep Learning 1	4/18/23	1:30 PM	Section 31	25
5377	An integrative prognostic machine learning model in mantle cell lymphoma	Holly	Hill	Poster	Artificial Intelligence and Machine/Deep Learning 1	4/18/23	1:30 PM	Section 31	26
5379	Deep learning enables label-free tracking of heterogeneous subpopulations	Tyler	Jost	Poster	Artificial Intelligence and Machine/Deep Learning 1	4/18/23	1:30 PM	Section 31	28
5380	Systematic evaluation and comparison of drug response prediction models: a case study of prediction generalization across cell lines datasets	Alexander	Partin	Poster	Artificial Intelligence and Machine/Deep Learning 1	4/18/23	1:30 PM	Section 31	29
5381	A broad-use deep learning model based on multi-dimensional morphology to identify and characterize tumor cell heterogeneity	Emilie	Schneider	Poster	Artificial Intelligence and Machine/Deep Learning 1	4/18/23	1:30 PM	Section 31	30
5387	Discovery of plasma protein biomarkers associated with overall survival in R/R DLBCL patients treated with loncastuximab tesirine	Francesco	Vallania	Poster	Artificial Intelligence and Machine/Deep Learning 2	4/18/23	1:30 PM	Section 32	3
5388	A unified computational pathology method to quantify HER2 expression from raw IHC and IF images in breast cancer	Nicolas	Brieu	Poster	Artificial Intelligence and Machine/Deep Learning 2	4/18/23	1:30 PM	Section 32	4
5389	Micron-resolution spatial analysis near the tumor-stromal border reveals a distinct density distribution of tumor-infiltrating lymphocytes and related genomic features	Chan-Young	Ock	Poster	Artificial Intelligence and Machine/Deep Learning 2	4/18/23	1:30 PM	Section 32	5
5390	Robust prediction of pan-cancer immune checkpoint blockade response using machine learning	Tianguen	Chang	Poster	Artificial Intelligence and Machine/Deep Learning 2	4/18/23	1:30 PM	Section 32	6
5391	Machine learning of cancer type and tissue of origin from proteomes of 1,277 human tissue samples and 975 cancer cell lines	Zhaoxiang	Cai	Poster	Artificial Intelligence and Machine/Deep Learning 2	4/18/23	1:30 PM	Section 32	7
5392	Universal immunohistochemistry positivity classification of cancer cells across multiple cancer types and antibodies using artificial intelligence	Chan-Young	Ock	Poster	Artificial Intelligence and Machine/Deep Learning 2	4/18/23	1:30 PM	Section 32	8
5393	Comparison of deep learning approaches applied to hematoxylin and eosin-stained whole slide images from women with benign breast disease to predict risk of developing invasive breast cancer	Monjoy	Saha	Poster	Artificial Intelligence and Machine/Deep Learning 2	4/18/23	1:30 PM	Section 32	9
5394	Detecting pulmonary malignancy against benign nodules using non-invasive cfDNA fragmentomics assay	Shun	Xu	Poster	Artificial Intelligence and Machine/Deep Learning 2	4/18/23	1:30 PM	Section 32	10
5395	Improving survival prediction using flexible late fusion machine learning framework for multi-omics data integration	Natasha	Markuzon	Poster	Artificial Intelligence and Machine/Deep Learning 2	4/18/23	1:30 PM	Section 32	11
5396	Early detection of ovarian cancer using mRNA sample data to investigate the correlation of specific gene mutations with ovarian cancer	Zahra	Saghaie	Poster	Artificial Intelligence and Machine/Deep Learning 2	4/18/23	1:30 PM	Section 32	12

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
5397	Prediction of conversion surgery completion following neoadjuvant modified FOLFIRINOX in borderline resectable and locally advanced pancreatic adenocarcinoma: machine learning algorithm analysis	Hyunseok	Yoon	Poster	Artificial Intelligence and Machine/Deep Learning 2	4/18/23	1:30 PM	Section 32	13
5398	Optimization generator app (OpGen) for radiotherapy treatment planning using case-based reasoning	Reza	Reiazi	Poster	Artificial Intelligence and Machine/Deep Learning 2	4/18/23	1:30 PM	Section 32	14
5399	Deep learning-based ensemble model using H&E images for the prediction of KRAS G12C mutations in non-small cell lung cancer	Sehhoon	Park	Poster	Artificial Intelligence and Machine/Deep Learning 2	4/18/23	1:30 PM	Section 32	15
5400	Predicting disease progression in inoperable localized NSCLC patients using cfDNA fragmentomics assay	Yin	Yang	Poster	Artificial Intelligence and Machine/Deep Learning 2	4/18/23	1:30 PM	Section 32	16
5401	Computational cancer cell gene expression deconvolution from tumor bulk RNA-seq via the machine learning algorithm Helenus	Krystle	Nomie	Poster	Artificial Intelligence and Machine/Deep Learning 2	4/18/23	1:30 PM	Section 32	17
5402	Using computer vision to resolve proliferative dynamics within therapeutic responses in large scale screens of patient derived models	Madhavi	Kannan	Poster	Artificial Intelligence and Machine/Deep Learning 2	4/18/23	1:30 PM	Section 32	18
5403	Predicting cancer cell response to TEAD auto-palmitoylation inhibitor using bulk RNA-seq data and a random-forest based algorithm	Tracy	Tang	Poster	Artificial Intelligence and Machine/Deep Learning 2	4/18/23	1:30 PM	Section 32	19
5404	Predicting protein receptor status from H&E-stained images in breast cancer	Geongyu	Lee	Poster	Artificial Intelligence and Machine/Deep Learning 2	4/18/23	1:30 PM	Section 32	20
5405	An ML-based tool for predicting tissue of origin for cancer of unknown primary (CUP) based on genomic and transcriptomic data	Nara	Shin	Poster	Artificial Intelligence and Machine/Deep Learning 2	4/18/23	1:30 PM	Section 32	21
5406	A deep learning enabled digital pathology platform for characterization of cancer-associated thrombosis of ovarian cancer	Ju Young	Ahn	Poster	Artificial Intelligence and Machine/Deep Learning 2	4/18/23	1:30 PM	Section 32	22
5407	A pan-cancer PDX histology image repository with genomic and pathological annotations for deep learning analysis	Brian	White	Poster	Artificial Intelligence and Machine/Deep Learning 2	4/18/23	1:30 PM	Section 32	23
5408	AI powered-platform to predict gene modifications from prostate and breast cancer whole slide images	Wei	Huang	Poster	Artificial Intelligence and Machine/Deep Learning 2	4/18/23	1:30 PM	Section 32	24
5409	NuKit: a deep learning platform for histopathological Images	Ching-Nung	Lin	Poster	Artificial Intelligence and Machine/Deep Learning 2	4/18/23	1:30 PM	Section 32	25
5410	Predictive biomarker discovery method to bridge the gap between preclinical disease model dose-response and clinical trials	Kirill	Pevzner	Poster	Artificial Intelligence and Machine/Deep Learning 2	4/18/23	1:30 PM	Section 32	26
5411	Efficient development of prognostic tests for detecting cancer risk using proteomic technology	Yolanda	Hagar	Poster	Artificial Intelligence and Machine/Deep Learning 2	4/18/23	1:30 PM	Section 32	27

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
5412	Redefined chronic inflammatory responses as prognostic markers in glioma: an explainable artificial intelligence model	Debajyoti	Chowdhury	Poster	Artificial Intelligence and Machine/Deep Learning 2	4/18/23	1:30 PM	Section 32	28
5413	AIVE, an artificial intelligence protein miner based on omics data to discover new cancer druggable candidates	Dongwan	Hong	Poster	Artificial Intelligence and Machine/Deep Learning 2	4/18/23	1:30 PM	Section 32	29
5414	Automated detection of high-grade urothelial carcinoma from urine cytology slides using attention-based deep learning	Mohamed	Omar	Poster	Artificial Intelligence and Machine/Deep Learning 2	4/18/23	1:30 PM	Section 32	30
5418	AI-driven image analysis enables simplified, label-free cytotoxicity screening	Gillian	Lovell	Poster	Artificial Intelligence: From Pathomics to Radiomics	4/18/23	1:30 PM	Section 33	1
5420	Deep learning-based mapping of tertiary lymphoid structure scores from H&E images of renal cell carcinoma trained by spatial transcriptomics data	Seungho	Cook	Poster	Artificial Intelligence: From Pathomics to Radiomics	4/18/23	1:30 PM	Section 33	3
5421	Constructing the largest-scale knowledge graph using all PubMed abstracts and its application for highly specific and accurate knowledge retrieval	Jinfeng	Zhang	Poster	Artificial Intelligence: From Pathomics to Radiomics	4/18/23	1:30 PM	Section 33	4
5422	Machine learning models identify key histological features of renal cell carcinoma subtypes	Samuel	Vilchez	Poster	Artificial Intelligence: From Pathomics to Radiomics	4/18/23	1:30 PM	Section 33	5
5423	AI powered quantification of mitotic rate in H&E stained tissue detects significant differences between treatment groups of preclinical pancreas cancer xenografts	Sharon	Ruane	Poster	Artificial Intelligence: From Pathomics to Radiomics	4/18/23	1:30 PM	Section 33	6
5424	A deep learning approach (AI) which accurately identifies breast tumor cells, tumor infiltrating lymphocytes (TILs) and fibroblasts from H&E slides	Luiz Augusto	Zillmann da Silva	Poster	Artificial Intelligence: From Pathomics to Radiomics	4/18/23	1:30 PM	Section 33	7
5425	Analysis of cancer patients' molecular and clinical data using artificial intelligence and machine learning approaches	Ali	Firooz	Poster	Artificial Intelligence: From Pathomics to Radiomics	4/18/23	1:30 PM	Section 33	8
5426	Multi-omic characterization and predictive features of advanced ovarian cancer patients in a large phase III cohort	Cyril	Ramathal	Poster	Artificial Intelligence: From Pathomics to Radiomics	4/18/23	1:30 PM	Section 33	9
5427	Improving non-small cell lung cancer segmentation on a challenging dataset	Yi	Wei	Poster	Artificial Intelligence: From Pathomics to Radiomics	4/18/23	1:30 PM	Section 33	10
5428	Skeletal muscle gauge prediction by a machine learning model in patients with colorectal cancer	Jeonghyun	Kang	Poster	Artificial Intelligence: From Pathomics to Radiomics	4/18/23	1:30 PM	Section 33	11
5429	Using machine learning to predict tissue of origin from somatic mutation features	Andrea	Giorni	Poster	Artificial Intelligence: From Pathomics to Radiomics	4/18/23	1:30 PM	Section 33	12
5430	Improved colorectal cancer survival prediction with deep learning-based WSI analysis on PETACC8 and PRODIGE13 cohorts	Paul	Jacob	Poster	Artificial Intelligence: From Pathomics to Radiomics	4/18/23	1:30 PM	Section 33	13
5431	3D multiplexed tissue imaging reconstruction and optimized region-of-interest (ROI) selection through deep learning model of channels embedding	Young Hwan	Chang	Poster	Artificial Intelligence: From Pathomics to Radiomics	4/18/23	1:30 PM	Section 33	14

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
5432	Validation of spatial gene expression patterns predicted by deep convolutional neural networks from breast cancer histopathology images	Liuliu	Pan	Poster	Artificial Intelligence: From Pathomics to Radiomics	4/18/23	1:30 PM	Section 33	15
5433	Representation learning for histological profiling of lung squamous premalignant lesions and tumors	Jennifer	Beane	Poster	Artificial Intelligence: From Pathomics to Radiomics	4/18/23	1:30 PM	Section 33	16
5434	Machine-learning-based epigenetic detection of early-stage lung cancers using the EpiCheck liquid biopsy platform	Dvir	Netanely	Poster	Artificial Intelligence: From Pathomics to Radiomics	4/18/23	1:30 PM	Section 33	17
5435	Correlating and combining computational radiomics, deep radiomics and transcriptomics data in soft-tissue sarcomas (STS) patients highlight complementary prognostic information	Antoine	Italiano	Poster	Artificial Intelligence: From Pathomics to Radiomics	4/18/23	1:30 PM	Section 33	18
5436	Developing artificial intelligence algorithms to predict response to neoadjuvant chemotherapy in HER2-positive breast cancer	Zaibo	Li	Poster	Artificial Intelligence: From Pathomics to Radiomics	4/18/23	1:30 PM	Section 33	19
5437	Vision transformers for breast cancer human epidermal growth factor receptor 2 (HER2) expression staging without immunohistochemical (IHC) staining	Gelan	Ayana	Poster	Artificial Intelligence: From Pathomics to Radiomics	4/18/23	1:30 PM	Section 33	20
5438	The combination of artificial intelligence and BLEACH&STAIN multiplex fluorescence immunohistochemistry facilitates automated prostate and breast cancer detection	Niclas	Blessin	Poster	Artificial Intelligence: From Pathomics to Radiomics	4/18/23	1:30 PM	Section 33	21
5439	Deep understanding of medication events from clinical narratives is essential to building a holistic picture of cancer patient medication history	Neehar	Mukne	Poster	Artificial Intelligence: From Pathomics to Radiomics	4/18/23	1:30 PM	Section 33	22
5440	Deep-learning model for tumor type classification enables enhanced clinical decision support in cancer diagnosis	Madison	Darmofal	Poster	Artificial Intelligence: From Pathomics to Radiomics	4/18/23	1:30 PM	Section 33	23
5441	Cell cycle arrest status predicted from H&E stained images using deep learning	Christina	Aigner	Poster	Artificial Intelligence: From Pathomics to Radiomics	4/18/23	1:30 PM	Section 33	24
5442	SlideQC: An AI-based tool for automated quality control of whole-slide digital pathology images	Daniela	Rodrigues	Poster	Artificial Intelligence: From Pathomics to Radiomics	4/18/23	1:30 PM	Section 33	25
5443	Pathomics reveals the molecular and immune evolution from lung preneoplasia to invasive adenocarcinoma	Pingjun	Chen	Poster	Artificial Intelligence: From Pathomics to Radiomics	4/18/23	1:30 PM	Section 33	26
5444	Integrated analysis of gene expression signatures and AI-based detection of tertiary lymphoid structures and stromal tumor-infiltrating lymphocytes in breast cancer H&E samples	Ekaterina	Postovalova	Poster	Artificial Intelligence: From Pathomics to Radiomics	4/18/23	1:30 PM	Section 33	27
5445	Segmentation-free analysis of multiplexed images with unbiased spatial analytics and explainable AI for predicting disease outcomes	Filippo	Pullara	Poster	Artificial Intelligence: From Pathomics to Radiomics	4/18/23	1:30 PM	Section 33	28

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
5446	Immune phenotypes classified by deep learning-based H&E tissue analyzer demonstrate distinct immune landscape and transcriptomic features in ovarian cancer	Horyun	Choi	Poster	Artificial Intelligence: From Pathomics to Radiomics	4/18/23	1:30 PM	Section 33	29
5447	Artificial intelligence (AI)-based classification of stromal subtypes reveals associations between stromal composition and prognosis in NSCLC	Fedaa	Najdawi	Poster	Artificial Intelligence: From Pathomics to Radiomics	4/18/23	1:30 PM	Section 33	30
5451	Multiplex immunofluorescence for cancer research	Patrick	Savickas	Poster	Biomarkers of Therapeutic Benefit 5	4/18/23	1:30 PM	Section 37	1
5452	Complimentary use of DNA- and RNA-based NGS assays optimizes detection of clinically relevant translocations for comprehensive genomic profiling	Michelle	Shiller	Poster	Biomarkers of Therapeutic Benefit 5	4/18/23	1:30 PM	Section 37	2
5453	Individualized risk stratification in newly diagnosed multiple myeloma	Francesco	Maura	Poster	Biomarkers of Therapeutic Benefit 5	4/18/23	1:30 PM	Section 37	3
5454	Peripheral blood biomarkers in Phase II study of pembrolizumab in combination with oral binimetinib in patients with unresectable locally advanced or metastatic triple-negative breast cancer	Saranya	Chumsri	Poster	Biomarkers of Therapeutic Benefit 5	4/18/23	1:30 PM	Section 37	4
5455	Large-scale cancer genomic analysis reveals significant disparities between microsatellite instability and tumor mutational burden	Jungyoon	Choi	Poster	Biomarkers of Therapeutic Benefit 5	4/18/23	1:30 PM	Section 37	5
5456	Application of a multiplex urinalysis test for predicting treatment response in patients with BCG unresponsive bladder cancer: a pilot study	Hideki	Furuya	Poster	Biomarkers of Therapeutic Benefit 5	4/18/23	1:30 PM	Section 37	6
5457	Prevalence of "low" HER2 expression is frequent in breast cancer but also in cancers of other origin: A tissue microarray study on 131 tumor types	Maximilian	Lennartz	Poster	Biomarkers of Therapeutic Benefit 5	4/18/23	1:30 PM	Section 37	7
5458	TONSL is an immortalizing oncogene of the chromosome 8q24.3 amplicon and new therapeutic target in breast cancer	Aditi	Khatpe	Poster	Biomarkers of Therapeutic Benefit 5	4/18/23	1:30 PM	Section 37	8
5459	Association between stomatitis and treatment efficacy with novel TROP2-directed antibody drug conjugate (ADC), datopotamab deruxtecan, in patients with metastatic cancer	Rachel	Abelman	Poster	Biomarkers of Therapeutic Benefit 5	4/18/23	1:30 PM	Section 37	9
5460	Novel immunohistochemistry-based predictive and prognostic tests for hormone receptor-positive breast cancer	Anuraag	Shrivastav	Poster	Biomarkers of Therapeutic Benefit 5	4/18/23	1:30 PM	Section 37	10
5461	Gain early insights from single cell RNA-sequencing of clinical trial needle biopsy cores	Thomas	Gallup	Poster	Biomarkers of Therapeutic Benefit 5	4/18/23	1:30 PM	Section 37	11
5462	Elevated creatine phosphokinase (CPK) as a strong predictor of aumolertinib (Au) treatment response in patients (pts) with advanced non-small cell lung cancer (NSCLC): post-hoc analysis of AENEAS	Jiawei	Wei	Poster	Biomarkers of Therapeutic Benefit 5	4/18/23	1:30 PM	Section 37	12

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
5463	The PD-L1 protein expression in Chinese patients with recurrent or metastatic head and neck squamous cell carcinoma: A multi-center retrospective study	Jianming	Ying	Poster	Biomarkers of Therapeutic Benefit 5	4/18/23	1:30 PM	Section 37	13
5464	Predictive biomarkers for PD-1 and PD-L1 checkpoint inhibitor response in NSCLC: An analysis of clinical trial and real-world data	Jehad	Charo	Poster	Biomarkers of Therapeutic Benefit 5	4/18/23	1:30 PM	Section 37	14
5465	Immune cell dynamics of patients and mice with hepatocellular carcinoma treated with anti-PD-L1 plus anti-CTLA-4 combination therapy	Yuta	Myojin	Poster	Biomarkers of Therapeutic Benefit 5	4/18/23	1:30 PM	Section 37	15
5466	Functional status of tumor-associated macrophages impacts clinical outcome of durvalumab in patients with advanced NSCLC as revealed by proteomics mass spectrometry	Anna	Hansen	Poster	Biomarkers of Therapeutic Benefit 5	4/18/23	1:30 PM	Section 37	16
5467	Single-cell analysis of CD34-enriched blood cells reveals early prognostic markers of myelodysplastic syndromes	Zohar	Shipony	Poster	Biomarkers of Therapeutic Benefit 5	4/18/23	1:30 PM	Section 37	17
5468	Which are the clinicopathological characteristics useful to define the metastatic breast cancer patients that will respond to CDK4/6 inhibitors and hormone therapy? An Italian real-world experience	Sara	Bravaccini	Poster	Biomarkers of Therapeutic Benefit 5	4/18/23	1:30 PM	Section 37	18
5469	Characterization of CCNE1 amplifications and associated genomic features in ovarian and uterine cancers	Sunantha	Sethuraman	Poster	Biomarkers of Therapeutic Benefit 5	4/18/23	1:30 PM	Section 37	19
5470	Identification of gene amplification based signature as predictors for chemotherapy in squamous cell carcinoma of the lung	Yuan	Tang	Poster	Biomarkers of Therapeutic Benefit 5	4/18/23	1:30 PM	Section 37	20
5471	Integrating tumor-intrinsic and immunological factors to identify immunogenic breast cancers from a low-risk cohort; results from the randomized SweBCG91RT trial	Axel	Stenmark Tullberg	Poster	Biomarkers of Therapeutic Benefit 5	4/18/23	1:30 PM	Section 37	21
5472	Utilizing response in immune checkpoint inhibitor treated cohorts improves clinical applicability of neoantigen immunogenicity predictions	Rachel Marty	Pyke	Poster	Biomarkers of Therapeutic Benefit 5	4/18/23	1:30 PM	Section 37	22
5473	Genomic profiling of chemotherapy-related clonal hematopoiesis in patients with high-grade serous ovarian cancer	Emine	Bayraktar	Poster	Biomarkers of Therapeutic Benefit 5	4/18/23	1:30 PM	Section 37	23
5474	Combined use of MRI and TAM analysis in GB monitoring	Carolina	Giordano	Poster	Biomarkers of Therapeutic Benefit 5	4/18/23	1:30 PM	Section 37	24
5475	Improved prediction of immunotherapy responses by constitutive neoantigen load and LINE-1 methylation	Hyo Eun	Bang	Poster	Biomarkers of Therapeutic Benefit 5	4/18/23	1:30 PM	Section 37	25
5476	Veracyte Biopharma Atlas for colorectal cancer: Combining multi-parameter approach and machine learning to capture the complexity of the tumor immune contexture	laurent	vanhille	Poster	Biomarkers of Therapeutic Benefit 5	4/18/23	1:30 PM	Section 37	26

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
5477	An investigation to study differential gene expression of lung cancer cells, tumor associated macrophages, and bone marrow derived mesenchymal stems cells in the tumor microenvironment	Hirendra	Banerjee	Poster	Biomarkers of Therapeutic Benefit 5	4/18/23	1:30 PM	Section 37	27
5479	A six-protein signature predicts response and survival in patients with advanced cutaneous melanoma treated with immunotherapy	Qing	Zhong	Poster	Biomarkers of Therapeutic Benefit 5	4/18/23	1:30 PM	Section 37	29
5483	Combined inhibition of CDK4/6 and AKT is highly active against the luminal androgen receptor (LAR) subtype of triple negative breast cancer (TNBC)	Maria del Rosario	Chica-Parrado	Poster	Combination Therapies for Cancer	4/18/23	1:30 PM	Section 38	1
5484	Synergistic antitumor activity of nab-sirolimus in combination with KRAS inhibitors (KRASis) sotorasib and adagrasib in KRAS G12C NSCLC and bladder cancer xenografts	Shihe	Hou	Poster	Combination Therapies for Cancer	4/18/23	1:30 PM	Section 38	2
5485	Clinical evaluation of a functional combinatorial precision medicine platform reveals combination-specific sub-populations in t-cell lymphoma	Edward	Chow	Poster	Combination Therapies for Cancer	4/18/23	1:30 PM	Section 38	3
5486	Combining bromodomain and extraterminal (BET) protein inhibitor treatment with standard MAPK inhibitors improved MAPK signaling inhibition in colorectal cancer	Hey Min	Lee	Poster	Combination Therapies for Cancer	4/18/23	1:30 PM	Section 38	4
5487	Synergy between FAK and PI3K inhibitors in cervical and pancreatic cancer cells	Chuan-Hsiang	Huang	Poster	Combination Therapies for Cancer	4/18/23	1:30 PM	Section 38	5
5489	Synergistic activity of SCD1 blockade in combination with tyrosine kinase inhibitors lenvatinib and cabozantinib in hepatocellular carcinoma (HCC)	Justyna	Gleba	Poster	Combination Therapies for Cancer	4/18/23	1:30 PM	Section 38	7
5490	Combination of the PI3k inhibitor Paxalisib with the nucleoside analog Gemcitabine over-activates the integrated stress response and induces atypical teratoid/rhabdoid tumor cell death	Tyler	Findlay	Poster	Combination Therapies for Cancer	4/18/23	1:30 PM	Section 38	8
5492	Determining effects of the CD206 positive M2 macrophage depleting engineered exosome in combination with anti PD1 therapy in breast tumor	Mahrma	Parvin	Poster	Combination Therapies for Cancer	4/18/23	1:30 PM	Section 38	10
5493	Novel strategy to make KRAS targeted therapies more effective for PDAC treatment	Sheema	Khan	Poster	Combination Therapies for Cancer	4/18/23	1:30 PM	Section 38	11
5494	Preclinical combination of ONC201 with radiotherapy and Temozolomide in a GBM mouse orthotopic model results in reduced tumor burden and prolonged survival	Lanlan	Zhou	Poster	Combination Therapies for Cancer	4/18/23	1:30 PM	Section 38	12
5495	Combination therapy with poly (ADP-ribose) polymerase inhibitor in endometrial cancer	Conway	Xu	Poster	Combination Therapies for Cancer	4/18/23	1:30 PM	Section 38	13

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
5496	Glutaminase inhibition induces replication stress in ovarian cancer cells and inhibition of replication checkpoint causes synthetic lethality	Pamela	Luna	Poster	Combination Therapies for Cancer	4/18/23	1:30 PM	Section 38	14
5497	Venetoclax and dinaciclib elicit synergistic preclinical efficacy against high-risk B-cell leukemia	Ernesto	Diaz-Flores	Poster	Combination Therapies for Cancer	4/18/23	1:30 PM	Section 38	15
5498	SHP2 inhibition enhances antitumor effect of mirdametininib in a pediatric brain tumor model bearing CDC42SE2BRAF fusion by rewiring the proteome and phosphoproteome landscape	Nur	Damayanti	Poster	Combination Therapies for Cancer	4/18/23	1:30 PM	Section 38	16
5499	Synergistic effects of the combination of ERK1/2 with EGFR, KRASG12C, CDK4/6, and PD-L1 inhibition for cancer treatment	Bing	Hou	Poster	Combination Therapies for Cancer	4/18/23	1:30 PM	Section 38	17
5500	Patient-derived organotypic cultures (PDOCs) from melanoma metastases as a precision medicine test to improve patient management	Antonella	Bresin	Poster	Combination Therapies for Cancer	4/18/23	1:30 PM	Section 38	18
5501	Vertical inhibition of the MAPK pathway with D3S-002, a potent and selective ERK1/2 inhibitor, to improve anti-tumor activity of and overcome resistance to KRAS G12C inhibitors	Jing	Zhang	Poster	Combination Therapies for Cancer	4/18/23	1:30 PM	Section 38	19
5502	Androgen blockade confers sensitivity to PIKfyve inhibition in prostate cancer	Yuanyuan	Qiao	Poster	Combination Therapies for Cancer	4/18/23	1:30 PM	Section 38	20
5503	Targeting CDK12-mediated DNA damage response to overcome cisplatin resistance in human urothelial carcinoma	Jun-Ren	Dong	Poster	Combination Therapies for Cancer	4/18/23	1:30 PM	Section 38	21
5504	A tumor-promoting senescent secretome triggered by platinum chemotherapy exploits a targetable TGFβR1/Akt-mTOR axis in lung cancer	Daniel	Muñoz-Espín	Poster	Combination Therapies for Cancer	4/18/23	1:30 PM	Section 38	22
5505	Combination nitazoxanide and auranofin treatment has synergistic anticancer activity in anaplastic thyroid cancer and act by enhanced activation of multiple cell death pathways	Chandrayee	Ghosh	Poster	Combination Therapies for Cancer	4/18/23	1:30 PM	Section 38	23
5506	Circulating immature neutrophils early detect hyperprogressive disease upon first-line PD-1/PD-L1 inhibitors in non-small cell lung cancer patients selecting best candidates for platinum-based chemotherapy and PD-1/PD-L1 inhibitors combinations	Roberto	Ferrara	Poster	Combination Therapies for Cancer	4/18/23	1:30 PM	Section 38	24
5507	A potential combinatorial treatment strategy to overcome olaparib resistance in high-grade ovarian cancer	Jie	Bao	Poster	Combination Therapies for Cancer	4/18/23	1:30 PM	Section 38	25
5508	Artesunate increases enzalutamide efficacy in advanced prostate cancer	Xinyi	Wang	Poster	Combination Therapies for Cancer	4/18/23	1:30 PM	Section 38	26
5509	The PI3K inhibitor Paxalisib combines synergistically with the MEK inhibitor Mirdametininib to target atypical teratoid/rhabdoid tumors	Kristen	Malebranche	Poster	Combination Therapies for Cancer	4/18/23	1:30 PM	Section 38	27

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
5510	TAS102 synergizes with regorafenib against colorectal and gastric cancer cells	Jun	Zhang	Poster	Combination Therapies for Cancer	4/18/23	1:30 PM	Section 38	28
5511	Investigating Wee1 and Myt1 combined inhibition as a potential cancer therapeutic strategy	Sargun	Sokhi	Poster	Combination Therapies for Cancer	4/18/23	1:30 PM	Section 38	29
5512	TIC10/ONC201 in combination with ceralasertib exhibits potent synergy in high grade serous ovarian cancer cells	Maryam	Ghandali	Poster	Combination Therapies for Cancer	4/18/23	1:30 PM	Section 38	30
5516	Identifying DNA methylation biomarkers in Brazilian women of African descent	Lisette	Delgado-Cruzata	Poster	Community-based Research and Biobanking Research	4/18/23	1:30 PM	Section 39	1
5517	Pegaspargase is a viable option in elderly adults with acute lymphoblastic leukemia	Yosef Joseph Rene	Amel Riazat-Kesh	Poster	Community-based Research and Biobanking Research	4/18/23	1:30 PM	Section 39	2
5518	Use of antihypertensive drugs and the risk of cancer, findings of a population-based cohort study in Shanghai	Li	Xie	Poster	Community-based Research and Biobanking Research	4/18/23	1:30 PM	Section 39	3
5519	Biobanking of gastric organoid models from a racially diverse cohort for gastric cancer interception	Priya	Alagesan	Poster	Community-based Research and Biobanking Research	4/18/23	1:30 PM	Section 39	4
5520	Research Ready graphic-style story to support future research participation among adolescents	Lauren	Bates	Poster	Community-based Research and Biobanking Research	4/18/23	1:30 PM	Section 39	5
5521	Racial and ethnic disparities for intravascular large B-cell lymphoma: A Surveillance, Epidemiology, and End Results (SEER) database analysis with emphasis on Hispanics.	Daniela	Urueta Portillo	Poster	Community-based Research and Biobanking Research	4/18/23	1:30 PM	Section 39	6
5522	Does physician-patient language concordance increase clinical trial enrollment in breast cancer patients?: A real-life study in a majority-minority population	Daniela	Urueta Portillo	Poster	Community-based Research and Biobanking Research	4/18/23	1:30 PM	Section 39	7
5523	Impact of COVID-19 on longitudinal breast cancer research studies involving TNBC patients	Esther	Kong	Poster	Community-based Research and Biobanking Research	4/18/23	1:30 PM	Section 39	8
5524	Persistent patient barriers to genomic testing in ambulatory oncology	Nadine	McCleary	Poster	Community-based Research and Biobanking Research	4/18/23	1:30 PM	Section 39	9
5525	Community cancer research advocates: Helping underrepresented minority groups become research ready	Sarah	Been	Poster	Community-based Research and Biobanking Research	4/18/23	1:30 PM	Section 39	10
5526	State-of-the-art biobanking of gastroesophageal adenocarcinoma samples: Integrating non-viable biospecimens with 3D and 2D cell models and their characterization, validation, and utilization of cell models for precision oncology	Mingyang Iris	Kong	Poster	Community-based Research and Biobanking Research	4/18/23	1:30 PM	Section 39	11
5527	Undergraduate cancer research scholars' community field experiences encourage community engagement to curb future disparities in the cancer workforce	Melinda	Butsch Kovacic	Poster	Community-based Research and Biobanking Research	4/18/23	1:30 PM	Section 39	12
5528	Palliative and end of life care utilization in Asian and White patients with stage IV lung cancer	Xiao	Hu	Poster	Community-based Research and Biobanking Research	4/18/23	1:30 PM	Section 39	13

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
5529	Lung cancer clinical trials in Latin America: A 20-year analysis	Thomas	Knapp	Poster	Community-based Research and Biobanking Research	4/18/23	1:30 PM	Section 39	14
5530	A community led approach to addressing disparities in pancreatic cancer care for Native Americans in Oregon	Grace	McCarthy	Poster	Community-based Research and Biobanking Research	4/18/23	1:30 PM	Section 39	15
5531	Early detection of cancer disparity and treatment resistance in TNBC	Amy	Tang	Poster	Community-based Research and Biobanking Research	4/18/23	1:30 PM	Section 39	16
5532	Increasing racial and ethnic diversity of phase 1 solid tumor clinical trials through enrollment at a safety net hospital	Varun	Roy	Poster	Community-based Research and Biobanking Research	4/18/23	1:30 PM	Section 39	17
5533	Providing culturally responsible health care to Pacific Islander communities: The creation of a cultural competency training for healthcare professionals	Mark	Willingham Jr.	Poster	Community-based Research and Biobanking Research	4/18/23	1:30 PM	Section 39	18
5534	“Simply ask and explain”: perspectives from Black patients with lung cancer on strategies to address racial disparities in biospecimen research participation	Marjory	Charlot	Poster	Community-based Research and Biobanking Research	4/18/23	1:30 PM	Section 39	19
5535	Research team perspectives on engaging Black patients with cancer in biospecimen research	Marjory	Charlot	Poster	Community-based Research and Biobanking Research	4/18/23	1:30 PM	Section 39	20
5536	Landscape and analysis of ERBB2 amplification and short variant mutations in large-scale Chinese patients with colorectal cancer	Ming	Quan	Poster	Community-based Research and Biobanking Research	4/18/23	1:30 PM	Section 39	21
5537	Prognostic impact of sarcopenia in patients with metastatic castration sensitive prostate cancer	Hiroaki	Iwamoto	Poster	Community-based Research and Biobanking Research	4/18/23	1:30 PM	Section 39	22
5538	Prevalence of factors serving as common cancer clinical trial eligibility criteria by race and ethnicity	Yayi	Zhao	Poster	Community-based Research and Biobanking Research	4/18/23	1:30 PM	Section 39	23
5539	Assessing knowledge, vaccine hesitancy, and completion rates of free HPV vaccination in uninsured/underinsured low-income patients	Hiram	Diaz	Poster	Community-based Research and Biobanking Research	4/18/23	1:30 PM	Section 39	24
5540	Spouse caregivers of patients with glioblastoma report unmet needs throughout the disease trajectory	Laurie	Minns	Poster	Community-based Research and Biobanking Research	4/18/23	1:30 PM	Section 39	25
5544	Association of circulating markers of gut barrier damage and inflammation with colorectal neoplasia stage	Flavia	Genua	Poster	Diagnostic and Prognostic Biomarkers 4	4/18/23	1:30 PM	Section 40	1
5545	Assessing LGR5 expression levels on colorectal cancer tissue samples for use in LGR5-targeting CAR-T cell therapy clinical trial	Veronika	Bandara	Poster	Diagnostic and Prognostic Biomarkers 4	4/18/23	1:30 PM	Section 40	2
5546	Urine metabolomic biomarkers discovery for bladder cancer diagnostics	Andrew	Schwab	Poster	Diagnostic and Prognostic Biomarkers 4	4/18/23	1:30 PM	Section 40	3
5547	Evaluation of two clinically focused targeted NGS systems for liquid biopsy testing shows a high level of concordance in resulting actionable mutations	Sarah	Kreston	Poster	Diagnostic and Prognostic Biomarkers 4	4/18/23	1:30 PM	Section 40	4

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
5548	Clinical management and decision making in early ER-positive breast cancers through improved prognosis and pathway directed molecular profiling	Jane	Bayani	Poster	Diagnostic and Prognostic Biomarkers 4	4/18/23	1:30 PM	Section 40	5
5549	Normalized platelet splicing junction count is a novel biomarker for diagnosis of ovarian tumors	Eunyong	Ahn	Poster	Diagnostic and Prognostic Biomarkers 4	4/18/23	1:30 PM	Section 40	6
5550	Sociodemographic disparities in access to biomarker testing in patients with advanced colorectal cancer	Saad	Sabbagh	Poster	Diagnostic and Prognostic Biomarkers 4	4/18/23	1:30 PM	Section 40	7
5551	Cancer associated PSA-glycoforms as prostate cancer markers	Hannu	Koistinen	Poster	Diagnostic and Prognostic Biomarkers 4	4/18/23	1:30 PM	Section 40	8
5552	MAGE-A3 and MAGE-A4 protein show co-expression in tumor of lung, bladder, and colon cancer	Rachel	Gonzalez	Poster	Diagnostic and Prognostic Biomarkers 4	4/18/23	1:30 PM	Section 40	9
5553	Diagnostic aqueous humor proteome predicts metastatic potential in uveal melanoma	Chen-Ching	Peng	Poster	Diagnostic and Prognostic Biomarkers 4	4/18/23	1:30 PM	Section 40	10
5554	Mammaglobin-A expression is highly specific for tumors derived from the breast, the female genital tract and salivary gland tumors	Ronald	Simon	Poster	Diagnostic and Prognostic Biomarkers 4	4/18/23	1:30 PM	Section 40	11
5555	Altered p53/p16 expression is linked to urothelial carcinoma progression but is unrelated to prognosis in muscle-invasive tumors	Elena	Bady	Poster	Diagnostic and Prognostic Biomarkers 4	4/18/23	1:30 PM	Section 40	12
5556	Lemur tyrosine kinase 3 serves as a predictor of patient outcome and a target for the treatment of ovarian cancer	Ghassan	Saed	Poster	Diagnostic and Prognostic Biomarkers 4	4/18/23	1:30 PM	Section 40	13
5557	Patterns of oncogene co-expression at single cell resolution influence survival in diffuse large B-cell lymphoma	Michal	Hoppe	Poster	Diagnostic and Prognostic Biomarkers 4	4/18/23	1:30 PM	Section 40	14
5558	Understanding the molecular mechanism of tumor budding and its relationship with tumor microenvironment in colorectal cancer	Phimmada	Hatthakarnkul	Poster	Diagnostic and Prognostic Biomarkers 4	4/18/23	1:30 PM	Section 40	15
5559	Exploratory analysis of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) PIK3CA mutated (mut) advanced breast cancer (aBC) treated with taselisib (TAS) and/or fulvestrant (FUL) reveals increased CCNE2 expression with poor outcome to placebo (PBO) + FUL but not TAS + FUL in SANDPIPER	Radia	Johnson	Poster	Diagnostic and Prognostic Biomarkers 4	4/18/23	1:30 PM	Section 40	16
5560	Prognostic effect of co-mutations on patients with NPM1+ acute myeloid leukemia (AML) enrolled in the Connect® Myeloid registry	Jaroslav	Maciejewski	Poster	Diagnostic and Prognostic Biomarkers 4	4/18/23	1:30 PM	Section 40	17
5561	Molecular imaging of calcification and soft tissue defines prognosis of DCIS to invasive breast cancer	Jayakrupakar	Nallala	Poster	Diagnostic and Prognostic Biomarkers 4	4/18/23	1:30 PM	Section 40	18
5562	Prevalence and prognostic significance of malnutrition in patients with brain metastasis	Zheran	Liu	Poster	Diagnostic and Prognostic Biomarkers 4	4/18/23	1:30 PM	Section 40	19

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
5563	Androgen receptor (AR) is frequently found in human cancers and inversely linked to patient outcome in breast and renal cell carcinomas	Tim	Mandelkow	Poster	Diagnostic and Prognostic Biomarkers 4	4/18/23	1:30 PM	Section 40	20
5564	SerpinE2: A potential biomarker for urological cancers	Ruusu-Maaria	Kovanen	Poster	Diagnostic and Prognostic Biomarkers 4	4/18/23	1:30 PM	Section 40	21
5567	Circulating bacterial DNA is a non-invasive biomarker for early recurrence of NSCLC patients	Haiming	Chen	Poster	Diagnostic and Prognostic Biomarkers 4	4/18/23	1:30 PM	Section 40	24
5569	Quantification of tumor-associated vasculature as an imaging biomarker for monitoring the response of triple-negative breast cancer to neoadjuvant chemotherapy	Chengyue	Wu	Poster	Diagnostic and Prognostic Biomarkers 4	4/18/23	1:30 PM	Section 40	26
5570	Development of prognostic index based on twenty-three genes for predicting superficial-to-invasive progression of non-muscle invasive bladder cancer patients	Seon-Kyu	Kim	Poster	Diagnostic and Prognostic Biomarkers 4	4/18/23	1:30 PM	Section 40	27
5571	FoxP3 absolute quantification to build an effective risk model for cancer patient survival	Adele	Ponzoni	Poster	Diagnostic and Prognostic Biomarkers 4	4/18/23	1:30 PM	Section 40	28
5572	A COX-2-based pro-tumourigenic inflammatory signature predicts poor outcome in early-stage non-small cell lung cancer	Victoria	Fife	Poster	Diagnostic and Prognostic Biomarkers 4	4/18/23	1:30 PM	Section 40	29
5573	Use of circulating tumor DNA (ctDNA) for early assessment of treatment response in patients with non-small cell lung cancer (NSCLC): A real-world (RW) analysis incorporating baseline ctDNA level and molecular response	Sean	Gordon	Poster	Diagnostic and Prognostic Biomarkers 4	4/18/23	1:30 PM	Section 40	30
5577	Detection of RAS mutations in colorectal cancer patients using DNA from extracellular vesicles	Sho	Kuriyama	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 4	4/18/23	1:30 PM	Section 41	1
5578	Analytical validation of an NGS-based, personalized and tumor-informed liquid biopsy assay for detecting minimal residual disease (MRD) with high sensitivity and specificity	Wei	Gao	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 4	4/18/23	1:30 PM	Section 41	2
5579	Single cell characterization of circulating plasma cells and BCMA levels in patients with multiple myeloma	Sonia Maryam	Setayesh	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 4	4/18/23	1:30 PM	Section 41	3
5580	Circulating tumor DNA (ctDNA) identifies genomic alterations associated with resistance to Nivolumab in combination with other agents in metastatic castration-resistant prostate cancer from the CheckMate 9KD trial	Justin	David	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 4	4/18/23	1:30 PM	Section 41	4
5581	Single-cell genomic analysis of patient-derived circulating tumor cells in pancreatic cancer	Harrison	Ball	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 4	4/18/23	1:30 PM	Section 41	5
5582	Liquid biopsy-based comprehensive genomic profiling reveal mutational landscape in real-world patients with unresectable NSCLC	Haoran	Tang	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 4	4/18/23	1:30 PM	Section 41	6

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
5583	Pre-radiotherapy ctDNA risk-stratifies non-small cell lung cancer patients with oligometastatic disease	Nicholas	Semenkovich	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 4	4/18/23	1:30 PM	Section 41	7
5584	Analysis of cell free DNA to predict outcome to Bevacizumab combination therapy in metastatic colorectal cancer patients	Ian	Miller	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 4	4/18/23	1:30 PM	Section 41	8
5585	Tissue based next generation sequence is more accurate than ctDNA to detected pathogenic variants in MTAP wild type tumors	Andre	De Souza	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 4	4/18/23	1:30 PM	Section 41	9
5587	Ultra-deep targeted sequencing of cell-free DNA and patient-matched white blood cells for treatment response evaluation in patients with metastatic colorectal cancer	Iris	van 't Erve	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 4	4/18/23	1:30 PM	Section 41	11
5588	Methylated ctDNA dynamics correspond with clinical tumor load in metastatic lung cancer patients on therapy	Patrick	Ye	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 4	4/18/23	1:30 PM	Section 41	12
5589	The effect of morphine-based perioperative analgesia on circulating tumor cells dissemination in colorectal cancer patients	Pavel	Stejskal	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 4	4/18/23	1:30 PM	Section 41	13
5590	Liquid biopsy testing in metastatic or advanced breast cancer patients during the COVID-19 pandemic	Benjamin	Furman	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 4	4/18/23	1:30 PM	Section 41	14
5591	Circulating tumor DNA for recurrence prediction and efficacy analysis in the ICONIC trial of peri-operative FLOT and avelumab (PD-L1) in localized esophago-gastric adenocarcinoma	Marco	Gerlinger	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 4	4/18/23	1:30 PM	Section 41	15
5592	Expansion and characterization on ALK positive NSCLC circulating tumor cells isolated using a size based inertial microfluidic Labyrinth device	Yuru	Chen	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 4	4/18/23	1:30 PM	Section 41	16
5593	Clonal mutation burden and evolutionary dynamics analysis in metastatic gastro-esophageal adenocarcinoma (GEA) by error corrected whole-exome circulating tumor DNA sequencing	Neil	McCafferty	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 4	4/18/23	1:30 PM	Section 41	17
5594	Association of circulating cell-free DNA and prostate cancer risk groups in patients undergoing proton therapy	Andrew	Bass	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 4	4/18/23	1:30 PM	Section 41	18
5595	Serial monitoring of circulating tumor cells and circulating tumor DNA in metastatic lobular breast cancer identifies intra-tumor heterogeneity and precision and immuno-oncology biomarkers of therapeutic importance	Andi	Cani	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 4	4/18/23	1:30 PM	Section 41	19
5596	Cell free DNA levels and fragmentation patterns in different liquid biopsy analytes (blood, urine and vaginal fluid) in cervical cancer patients	Sarah Tadhg	Ferrier	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 4	4/18/23	1:30 PM	Section 41	20
5597	Enhanced detection and classification of cell-free DNA alterations through matched normal analyses with PGDx elio™ plasma complete	Kenneth	Valkenburg	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 4	4/18/23	1:30 PM	Section 41	21

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
5598	Microfluidic isolation and capture of circulating tumor cells and clusters from mouse blood	Celine	Macaraniag	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 4	4/18/23	1:30 PM	Section 41	22
5599	An introduction of a highly sensitive circulating tumor DNA monitoring system for minimal residual disease detection using a library of 1000 digital PCR probes	Satoshi	Nishizuka	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 4	4/18/23	1:30 PM	Section 41	23
5600	Utility of circulating tumor DNA and transcriptomic profiling in predicting outcome in muscle invasive bladder cancer patients	Sia	Lindskrog	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 4	4/18/23	1:30 PM	Section 41	24
5601	Oncomine™ dx express CE-IVD liquid biopsy assay for non-small cell lung cancer: Performance review and analytical validation	Nicholas	Siepert	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 4	4/18/23	1:30 PM	Section 41	25
5602	Markers of hypoxic cells: Testing a pre-clinical detection assay	Beatriz	Zayas	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 4	4/18/23	1:30 PM	Section 41	26
5603	Functional studies on viable circulating tumor cells (v-CTCs) and frequent expression of PD-L1 on v-CTCs in pancreatic cancer	Masahiro	Tanemura	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 4	4/18/23	1:30 PM	Section 41	27
5604	Circulating tumor DNA for predicting peritoneal only disease recurrence in colon cancer	Kevin	Chang	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 4	4/18/23	1:30 PM	Section 41	28
5605	Ambient storage and stabilization of proteins and cell-free nucleic acids in whole blood samples	Nicholas	George	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 4	4/18/23	1:30 PM	Section 41	29
5606	Dynamics of sequence and structural cell-free DNA landscapes in small-cell lung cancer during systemic therapy	Lavanya	Sivapalan	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 4	4/18/23	1:30 PM	Section 41	30
5610	[18F]FluorThanatrace ([18F]FTT) PET Imaging of PARP-inhibitor drug-target engagement as a biomarker of response in ovarian cancer	Sarah	Gitto	Poster	New Approaches in Radiodiagnostics and Theranostics	4/18/23	1:30 PM	Section 42	1
5611	LAG-3 PET imaging in patients with cancer before immune checkpoint inhibitor therapy	Pim	van de Donk	Poster	New Approaches in Radiodiagnostics and Theranostics	4/18/23	1:30 PM	Section 42	2
5612	Shape features of extra-nodal lesions on positron emission tomography identifies responders to CAR-T-cell therapy	Yoganand	Balagurunathan	Poster	New Approaches in Radiodiagnostics and Theranostics	4/18/23	1:30 PM	Section 42	3
5613	Tumor glucose metabolism profiles detected via [18F]-FDG PET/CT correlate with the immune landscape in soft-tissue sarcomas	Antoine	Italiano	Poster	New Approaches in Radiodiagnostics and Theranostics	4/18/23	1:30 PM	Section 42	4
5614	Genomic aberrations in circulating tumor DNA (ctDNA) and clinical outcomes from [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer (mCRPC)	Heidi	Fettke	Poster	New Approaches in Radiodiagnostics and Theranostics	4/18/23	1:30 PM	Section 42	5
5615	Novel trop-2-targeted NIR-II fluorescence imaging technique for accurate determination of breast conserving surgery margin in vivo and human fresh tissue	Weiling	Chen	Poster	New Approaches in Radiodiagnostics and Theranostics	4/18/23	1:30 PM	Section 42	6
5616	Optical metabolic imaging of treatment-naive human NSCLC to determine long-term outcome	Paola	Monterroso Diaz	Poster	New Approaches in Radiodiagnostics and Theranostics	4/18/23	1:30 PM	Section 42	7

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
5617	A novel DNA double-strand breaks biosensor based on fluorescence resonance energy transfer	Jung-Soo	Suh	Poster	New Approaches in Radiodiagnostics and Theranostics	4/18/23	1:30 PM	Section 42	8
5618	Multi-institutional validation of a radiomics-based artificial intelligence method for predicting response to PD-1/PD-L1 immune checkpoint inhibitor (ICI) therapy in stage IV NSCLC	Petr	Jordan	Poster	New Approaches in Radiodiagnostics and Theranostics	4/18/23	1:30 PM	Section 42	9
5619	Radiomics-based machine learning models to predict progression and biomarker status in non-small cell lung cancer (NSCLC) patients treated with immunotherapy	Young Kwang	Chae	Poster	New Approaches in Radiodiagnostics and Theranostics	4/18/23	1:30 PM	Section 42	10
5620	Radiogenomic analysis in the patients with primary brain tumor using dual time point 18F-FET PET/CT	Dong Yun	Lee	Poster	New Approaches in Radiodiagnostics and Theranostics	4/18/23	1:30 PM	Section 42	11
5621	Multi-parametric MRI maps regional heterogeneity of high grade glioma phenotypes	Matthew	Flick	Poster	New Approaches in Radiodiagnostics and Theranostics	4/18/23	1:30 PM	Section 42	12
5622	Integrative cross-platform characterisation of mammographic screen-detected breast cancer	Alison	Cheung	Poster	New Approaches in Radiodiagnostics and Theranostics	4/18/23	1:30 PM	Section 42	13
5626	Multimic spatial profiling of the tumor immune microenvironment at single cell resolution	Niyati	Jhaveri	Poster	Spatial Proteomics and Transcriptomics 1	4/18/23	1:30 PM	Section 43	1
5627	Spatial protein profiling by cyclic immunofluorescence to interpret and improve bulk tumor-based predictor of response to chemotherapy with bevacizumab in neoadjuvant breast cancer treatment	Mads	Haugen	Poster	Spatial Proteomics and Transcriptomics 1	4/18/23	1:30 PM	Section 43	2
5629	Spatial genomics and proteomics enable multimodal analyses of oral SCC clonal heterogeneity and interactions with tumor microenvironment	Ines	Sequeira	Poster	Spatial Proteomics and Transcriptomics 1	4/18/23	1:30 PM	Section 43	4
5630	Robust spatial biomarker discovery through multi-platform multiplex image analysis of breast cancer clinical cohorts	Jennifer	Eng	Poster	Spatial Proteomics and Transcriptomics 1	4/18/23	1:30 PM	Section 43	5
5631	Expanding tools for multiplex mRNA imaging in spatialomics through the ViewRNA tissue assay kits	Nancie	Mooney	Poster	Spatial Proteomics and Transcriptomics 1	4/18/23	1:30 PM	Section 43	6
5632	Evaluating a novel molecular biomarker of angioinvasive lung adenocarcinoma with spatial transcriptomics	Dylan	Steiner	Poster	Spatial Proteomics and Transcriptomics 1	4/18/23	1:30 PM	Section 43	7
5633	Analysis of the immune microenvironment and tumor-infiltrating immune cells across different solid tumors by combined spatial transcriptomics and proteomics	Andreas	Bosio	Poster	Spatial Proteomics and Transcriptomics 1	4/18/23	1:30 PM	Section 43	8
5635	Joint secondary transcriptomic analysis of triple negative breast cancer offers a window into new therapeutic possibilities and biomarkers	Naomi	Rapier-Sharman	Poster	Spatial Proteomics and Transcriptomics 1	4/18/23	1:30 PM	Section 43	10
5636	Multiplex digital spatial profiling (DSP) of proteins in the tumor microenvironment in response to GSK-3 inhibition by 9-ING-41	Kelsey	Huntington	Poster	Spatial Proteomics and Transcriptomics 1	4/18/23	1:30 PM	Section 43	11

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
	(elraglusib) correlates with novel immunostimulatory effects observed in vivo								
5637	Path to the holy grail of spatial biology: Spatial single-cell whole transcriptomes using 6000-plex spatial molecular imaging on FFPE tissue	Shanshan	He	Poster	Spatial Proteomics and Transcriptomics 1	4/18/23	1:30 PM	Section 43	12
5638	Total-sync ultra-content microscopic opto-biotinylation enables high-sensitivity hypothesis-free subcellular protein discovery	Jung-Chi	Liao	Poster	Spatial Proteomics and Transcriptomics 1	4/18/23	1:30 PM	Section 43	13
5639	High throughput spatially resolved laser-activated cell sorting links the genomic molecules with its spatial information	Sumin	Lee	Poster	Spatial Proteomics and Transcriptomics 1	4/18/23	1:30 PM	Section 43	14
5640	Identifying pathophysiological features of mouse tumors using imaging mass cytometry	Qanber	Raza	Poster	Spatial Proteomics and Transcriptomics 1	4/18/23	1:30 PM	Section 43	15
5641	Single cell spatial molecular imaging of 76-plex proteins in clinical cancer samples in response to personalized treatment	Zachary	Lewis	Poster	Spatial Proteomics and Transcriptomics 1	4/18/23	1:30 PM	Section 43	16
5642	Validation of a novel multiplex immuno-fluorescence panel for the spatial analysis of the tumor microenvironment	François	Rivest	Poster	Spatial Proteomics and Transcriptomics 1	4/18/23	1:30 PM	Section 43	17
5643	High-spatial-resolution multi-omics analysis of cancer tissues	Robert	Pinard	Poster	Spatial Proteomics and Transcriptomics 1	4/18/23	1:30 PM	Section 43	18
5644	Spatially resolved transcriptomics points to distinct malignant cell populations within primary and castration resistant prostate cancer	Antti	Kiviaho	Poster	Spatial Proteomics and Transcriptomics 1	4/18/23	1:30 PM	Section 43	19
5646	Spatial transcriptomic profiling of the human and mouse retina prepared with CryoJane Tape Transfer System using GeoMx and CosMx spatial analysis	Charles	Glaser	Poster	Spatial Proteomics and Transcriptomics 1	4/18/23	1:30 PM	Section 43	21
5647	Single cell, multiomic spatial phenotyping of immunotherapy responses in head and neck cancer	HaYeun	Ji	Poster	Spatial Proteomics and Transcriptomics 1	4/18/23	1:30 PM	Section 43	22
5648	Single cell spatial phenotyping of bladder tumors with a novel mechanism of NKG2A and HLA-E mediated resistance to BCG immunotherapy	Dmytro	Klymyshyn	Poster	Spatial Proteomics and Transcriptomics 1	4/18/23	1:30 PM	Section 43	23
5652	IL-19 blockade reprograms glioblastoma immunosuppressive microenvironment and overcomes chemo-resistance as revealed by single-cell transcriptome analyses	Gilbert	Lee	Poster	Therapeutic Antibodies, Including Engineered Antibodies	4/18/23	1:30 PM	Section 44	1
5653	LCB97, an antibody drug conjugate (ADC) targeting a novel tumor antigen for the treatment of multiple solid tumors	Changsik	Park	Poster	Therapeutic Antibodies, Including Engineered Antibodies	4/18/23	1:30 PM	Section 44	2
5654	A therapeutic humanized anti-carcinoma monoclonal antibody (mAb) NEO-201 can also target human granulocytic myeloid-derived suppressor cells (gMDSCs) and regulatory T (Tregs) cells	Massimo	Fantini	Poster	Therapeutic Antibodies, Including Engineered Antibodies	4/18/23	1:30 PM	Section 44	3

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
5655	preclinical development of a novel anti-tslpr bispecific antibody 1b7/cd3 targeting crlf2-rearranged ph-like b-all	Ze	Tian	Poster	Therapeutic Antibodies, Including Engineered Antibodies	4/18/23	1:30 PM	Section 44	4
5657	HK010, a novel anti-PDL1×CD137 bispecific antibody, exhibits potent anti-tumor immunity and low toxicity	Liangwei	Li	Poster	Therapeutic Antibodies, Including Engineered Antibodies	4/18/23	1:30 PM	Section 44	6
5658	MG-Ig (molecularly grafted immunoglobulin): An alternative platform for production of bispecific antibodies	Donglin	Liu	Poster	Therapeutic Antibodies, Including Engineered Antibodies	4/18/23	1:30 PM	Section 44	7
5659	Targeting solid cancers with a cancer-specific monoclonal antibody to surface expressed aberrant O-glycosylated proteins	Mikkel	Aasted	Poster	Therapeutic Antibodies, Including Engineered Antibodies	4/18/23	1:30 PM	Section 44	8
5660	IGM-7354, an immunocytokine with IL-15 fused to an anti-PD-L1 IgM, induces NK and CD8+ T cell mediated cytotoxicity of PD-L1-positive tumor cells	Thierry	Giffon	Poster	Therapeutic Antibodies, Including Engineered Antibodies	4/18/23	1:30 PM	Section 44	9
5661	Pre-clinical development of a dopamine receptor 2, PD-1, and CD47 trispecific antibody for the treatment of solid tumors	Shugang	Yao	Poster	Therapeutic Antibodies, Including Engineered Antibodies	4/18/23	1:30 PM	Section 44	10
5662	Early unwanted immunogenicity assessment of immuno oncology drugs	Sofie	Pattyn	Poster	Therapeutic Antibodies, Including Engineered Antibodies	4/18/23	1:30 PM	Section 44	11
5663	Discovery and characterization of anti-LILRB2 antibody SPX-104	Anthony	Haight	Poster	Therapeutic Antibodies, Including Engineered Antibodies	4/18/23	1:30 PM	Section 44	12
5664	A novel immunotherapy for relapsed/refractory acute lymphoblastic leukemia (ALL)	Uksha	Saini	Poster	Therapeutic Antibodies, Including Engineered Antibodies	4/18/23	1:30 PM	Section 44	13
5665	HX301 (ON1232580) a novel kinase inhibitor with potent activity against CSF1R and FLT3, shows strong anti-AML activity in defined preclinical models	Xiaoyu	An	Poster	Therapeutic Antibodies, Including Engineered Antibodies	4/18/23	1:30 PM	Section 44	14
5666	NAV-003, a full-length IgG1 bispecific antibody targeting a unique mesothelin epitope and CD3 to improve cytotoxicity against humoral immunosuppressed tumors	Luigi	Grasso	Poster	Therapeutic Antibodies, Including Engineered Antibodies	4/18/23	1:30 PM	Section 44	15
5667	CYT-303 FLEX-NKTM engager dose response efficacy mechanisms in HCC tumor model and safety in cynomolgus monkey toxicology studies support clinical evaluation in hepato-cellular carcinoma	Vishal	Khairnar	Poster	Therapeutic Antibodies, Including Engineered Antibodies	4/18/23	1:30 PM	Section 44	16
5668	Using clinical utility index (CUI) to determine the optimal biological dose of a nonfucosylated anti-TIGIT antibody: A proposed alternative to maximum tolerated dose (MTD)	Gabriela	Patilea-Vrana	Poster	Therapeutic Antibodies, Including Engineered Antibodies	4/18/23	1:30 PM	Section 44	17
5671	MB201, a CD8+ T cell-selective anti-PD-L1 x IL-2 variant fusion protein, exhibits a potent anti-tumor efficacy without peripheral toxicity	Bom	Park	Poster	Therapeutic Antibodies, Including Engineered Antibodies	4/18/23	1:30 PM	Section 44	20
5672	Comparative mouse pharmacokinetics of matched- and unmatched-isotype anti-PD-L1 antibodies	Breanna	Demestichas	Poster	Therapeutic Antibodies, Including Engineered Antibodies	4/18/23	1:30 PM	Section 44	21

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
5673	Characterization of AB598, a therapeutic anti-human CD39 antibody for the treatment of cancer	Amy	Anderson	Poster	Therapeutic Antibodies, Including Engineered Antibodies	4/18/23	1:30 PM	Section 44	22
5674	Anti-CCR8-based bispecific antibodies engineered to preferentially eliminate tumor-infiltrating regulatory T cells: leaving effectors unharmed	Andy	Tsun	Poster	Therapeutic Antibodies, Including Engineered Antibodies	4/18/23	1:30 PM	Section 44	23
5675	Discovery and development of an asymmetric IgG-like bispecific antibody targeting EGFR and c-MET, engineered through H-H and H-L chain charge-based heterodimerization	Andy	Tsun	Poster	Therapeutic Antibodies, Including Engineered Antibodies	4/18/23	1:30 PM	Section 44	24
5676	SGN-BB228, a CD228-directed costimulatory antibody anticalin® bispecific provides potent and conditional 4-1BB costimulation to T cells in vivo and in an in vitro model of T cell exhaustion	Ryan	Heiser	Poster	Therapeutic Antibodies, Including Engineered Antibodies	4/18/23	1:30 PM	Section 44	25
5677	MB101, a novel PD-L1 x CD3 targeted bispecific antibody, exhibits potent tumor-killing efficacy with minimal off-tumor toxicity	Suna	Kim	Poster	Therapeutic Antibodies, Including Engineered Antibodies	4/18/23	1:30 PM	Section 44	26
5679	Tetra-specific antibody GNC-035: guidance and navigation control (GNC) molecule development for treatment of ROR1+ malignancies	Jahan	Khalili	Poster	Therapeutic Antibodies, Including Engineered Antibodies	4/18/23	1:30 PM	Section 44	28
5680	Tetra-specific antibody GNC-039: guidance and navigation control (GNC) molecule development for treatment of EGFRvIII+ malignancies	Jahan	Khalili	Poster	Therapeutic Antibodies, Including Engineered Antibodies	4/18/23	1:30 PM	Section 44	29
5681	Tetra-specific antibody GNC-038: guidance and navigation control (GNC) molecule development for treatment of CD19+ malignancies	Jahan	Khalili	Poster	Therapeutic Antibodies, Including Engineered Antibodies	4/18/23	1:30 PM	Section 44	30
5693	Cancer cells subvert fibroblast function to promote a growth factor enriched tumor microenvironment in endocrine therapy resistant ER+ breast cancer	Jason	Griffiths	Oral	Clinical Applications of Artificial Intelligence and Mathematical Oncology	4/18/23	2:30 PM	Valencia BC	
5694	Adaptive treatment scheduling of PARP inhibitors in ovarian cancer: Using mathematical modeling to assess clinical feasibility and estimate potential benefits	Maximilian	Strobl	Oral	Clinical Applications of Artificial Intelligence and Mathematical Oncology	4/18/23	2:30 PM	Valencia BC	
5695	Deep learning risk prediction model of distant recurrence from H&E endometrial cancer slides	Sarah	Fremont	Oral	Clinical Applications of Artificial Intelligence and Mathematical Oncology	4/18/23	2:30 PM	Valencia BC	
5696	A prognostic machine learning model for early breast cancer which combines clinical and genetic data in patients treated with neo/adjuvant chemotherapy	Aidan (Amanzhol)	Kubeyev	Oral	Clinical Applications of Artificial Intelligence and Mathematical Oncology	4/18/23	2:30 PM	Valencia BC	
5697	Predicting response to PD-L1 inhibition in NSCLC using a quantitative systems pharmacology model guided by immunogenomic data	Hanwen	Wang	Oral	Clinical Applications of Artificial Intelligence and Mathematical Oncology	4/18/23	2:30 PM	Valencia BC	

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
5698	A multicenter study validated an integrated deep learning model for precision malignancy risk assessment and reducing unnecessary biopsies in BI-RADS 4 cases	Chika	Ezeana	Oral	Clinical Applications of Artificial Intelligence and Mathematical Oncology	4/18/23	2:30 PM	Valencia BC	
5699	Development and validation of a quantitative systems pharmacology model for prediction of preclinical efficacy of PARP inhibitors rucaparib and talazoparib combined with the ATR inhibitor gartisertib (M4344)	Nathalie	Dupuy	Oral	Clinical Applications of Artificial Intelligence and Mathematical Oncology	4/18/23	2:30 PM	Valencia BC	
5701	Predictive biomarker models of immunotherapy response in patients with metastatic melanoma: genomic, transcriptomic, and immune profiles from the Personalised Immunotherapy Program (PIP)	James	Wilmott	Oral	Immune-based Biomarkers for Prognostic and Predictive Benefit	4/18/23	2:30 PM	Valencia A	
5702	Ovarian cancer tumor microenvironment and atezolizumab (atezo) clinical activity: IMagyn050 sub-study	Venkatesh	Krishnan	Oral	Immune-based Biomarkers for Prognostic and Predictive Benefit	4/18/23	2:30 PM	Valencia A	
5703	The immune cell state atlas analysis predicts therapeutic benefits with immune checkpoint inhibitors	Tingyi	Li	Oral	Immune-based Biomarkers for Prognostic and Predictive Benefit	4/18/23	2:30 PM	Valencia A	
5704	An integrated immune signature predictive of adjuvant immunotherapeutic benefits for high-risk melanoma	Ahmad	Tarhini	Oral	Immune-based Biomarkers for Prognostic and Predictive Benefit	4/18/23	2:30 PM	Valencia A	
5705	Digital pathology based prognostic & predictive biomarkers in metastatic non-small cell lung cancer	Assaf	Amitai	Oral	Immune-based Biomarkers for Prognostic and Predictive Benefit	4/18/23	2:30 PM	Valencia A	
5706	ImmunoPROFILE: A prospective implementation of clinically validated, quantitative immune cell profiling test identifies tumor-infiltrating CD8+ and PD-1+ cell densities as prognostic biomarkers across a 2,023 patient pan-cancer cohort treated with different therapies	James	Lindsay	Oral	Immune-based Biomarkers for Prognostic and Predictive Benefit	4/18/23	2:30 PM	Valencia A	
5707	Tumor and immune determinants of response to anti-BCMA CAR T-cell therapy in multiple myeloma using cell-free DNA	Mia	Carleton	Oral	Immune-based Biomarkers for Prognostic and Predictive Benefit	4/18/23	2:30 PM	Valencia A	
5709	Whole genome error-corrected sequencing for sensitive circulating tumor DNA cancer monitoring	Alexandre	Cheng	Oral	Increasing the Clinical Utility of Cell-Free DNA Testing	4/18/23	2:30 PM	Valencia D	
5710	Detection and monitoring of t(11;14) in liquid biopsies from patients with relapsed/refractory multiple myeloma treated with venetoclax-based regimens	Jeremy	Ross	Oral	Increasing the Clinical Utility of Cell-Free DNA Testing	4/18/23	2:30 PM	Valencia D	
5711	Blood-based early detection of non-small cell lung cancer using orphan noncoding RNAs	Babak	Alipanahi	Oral	Increasing the Clinical Utility of Cell-Free DNA Testing	4/18/23	2:30 PM	Valencia D	
5712	Anti-TIGIT antibody tiragolumab leverages myeloid cells and regulatory T cells to improve PD-L1 checkpoint blockade	Namrata	Patil	Oral	Increasing the Clinical Utility of Cell-Free DNA Testing	4/18/23	2:30 PM	Valencia D	
5713	Assessing the real-world utility of cell-free microbial DNA in diagnosing early-stage lung cancer	Gregory	Sepich-Poore	Oral	Increasing the Clinical Utility of Cell-Free DNA Testing	4/18/23	2:30 PM	Valencia D	

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
5714	Cell-free DNA fragmentation profiling for monitoring therapeutic response in metastatic colorectal cancer	Bahar	Alipanahi	Oral	Increasing the Clinical Utility of Cell-Free DNA Testing	4/18/23	2:30 PM	Valencia D	
5715	Circulating tumor DNA in colorectal cancer patients with resectable liver metastases: Preliminary results of the MIRACLE study	Lissa	Wullaert	Oral	Increasing the Clinical Utility of Cell-Free DNA Testing	4/18/23	2:30 PM	Valencia D	
5717	Bridging the gap between clinical-omics and machine learning to improve cancer treatment	Chang In	Moon	Oral	The Next Wave of Precision Oncology: New Drugs, Databases, and Analytics to Refine Care	4/18/23	2:30 PM	Room W414	
5718	Additivity predicts the clinical efficacy of most approved combination therapies for advanced cancer	Adam	Palmer	Oral	The Next Wave of Precision Oncology: New Drugs, Databases, and Analytics to Refine Care	4/18/23	2:30 PM	Room W414	
5719	Clinical response to the PDGFR α inhibitor avapritinib in high-grade glioma patients	Kallen	Schwark	Oral	The Next Wave of Precision Oncology: New Drugs, Databases, and Analytics to Refine Care	4/18/23	2:30 PM	Room W414	
5720	Combination therapies in matched 3D in vitro and in vivo preclinical models of rare and recalcitrant cancers from the National Cancer Institute's Patient-Derived Models Repository	Thomas	Dexheimer	Oral	The Next Wave of Precision Oncology: New Drugs, Databases, and Analytics to Refine Care	4/18/23	2:30 PM	Room W414	
5721	Automated annotation for large-scale clinicogenomic models of lung cancer treatment response and overall survival	Justin	Jee	Oral	The Next Wave of Precision Oncology: New Drugs, Databases, and Analytics to Refine Care	4/18/23	2:30 PM	Room W414	
5722	The mutational signatures of 100,477 targeted sequenced tumors	Bin	Zhu	Oral	The Next Wave of Precision Oncology: New Drugs, Databases, and Analytics to Refine Care	4/18/23	2:30 PM	Room W414	
5723	An in vivo pharmacogenomics platform replicates and extends biomarkers of therapy response identified via causal inference analysis of clinical data	Michael	Rosen	Oral	The Next Wave of Precision Oncology: New Drugs, Databases, and Analytics to Refine Care	4/18/23	2:30 PM	Room W414	
5725	The USP1 inhibitor I-138 kills BRCA1-deficient tumor cells and overcomes PARP inhibitor resistance	Alexandre Andre	Da Costa	Oral	Molecular Targets	4/18/23	2:30 PM	Tangerine Ballroom 3-4 (WF3-4)	
5726	Pan-cancer proteogenomics expands the landscape of therapeutic targets	Jonathan	Lei	Oral	Molecular Targets	4/18/23	2:30 PM	Tangerine Ballroom 3-4 (WF3-4)	
5727	Identification of synthetic lethal vulnerabilities in cancers with loss of function mutations in NOTCH	Deli	Hong	Oral	Molecular Targets	4/18/23	2:30 PM	Tangerine Ballroom 3-4 (WF3-4)	

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
5728	Inhibition of TACC3 blocks the growth of highly aggressive breast cancers with centrosome amplification	Ozge	Saatci	Oral	Molecular Targets	4/18/23	2:30 PM	Tangerine Ballroom 3-4 (WF3-4)	
5729	Imiquilines for pancreatic cancer: first-in-class potent and synergistic inhibitors of microtubule polymerisation	Kevin	Bigot	Oral	Molecular Targets	4/18/23	2:30 PM	Tangerine Ballroom 3-4 (WF3-4)	
5730	Targeting intrinsically disordered protein β II-spectrin prevents metabolic syndrome and hepatocellular carcinoma on a sex-based bias	Xiaochun	Yang	Oral	Molecular Targets	4/18/23	2:30 PM	Tangerine Ballroom 3-4 (WF3-4)	
5731	Apoptosis Inducing Agent 1 enhances cancer therapy-induced apoptosis by direct interaction with BAX and BAK	Xingping	Qin	Oral	Molecular Targets	4/18/23	2:30 PM	Tangerine Ballroom 3-4 (WF3-4)	
5733	Combining KRASG12C(ON) inhibition with SHP2 and immune checkpoint blockade to enhance anti-tumor immunity and overcome development of resistance in lung cancer	Miriam	Molina-Arcas	Oral	New Tricks for Known Targets: Novel Approaches to Inhibit Oncogenic Signaling	4/18/23	2:30 PM	Room W224	
5734	Designing RAF and MEK inhibitor combinations based on their biochemical properties to effectively target MAPK-driven cancers	Ana	Orive-Ramos	Oral	New Tricks for Known Targets: Novel Approaches to Inhibit Oncogenic Signaling	4/18/23	2:30 PM	Room W224	
5735	Novel KRAS G12D degrader ASP3082 demonstrates in vivo, dose-dependent KRAS degradation, KRAS pathway inhibition, and antitumor efficacy in multiple KRAS G12D-mutated cancer models	Takeyuki	Nagashima	Oral	New Tricks for Known Targets: Novel Approaches to Inhibit Oncogenic Signaling	4/18/23	2:30 PM	Room W224	
5736	AZD9592: An EGFR-cMET bispecific antibody-drug conjugate (ADC) targeting key oncogenic drivers in non-small-cell lung cancer (NSCLC) and beyond	Frank	Comer	Oral	New Tricks for Known Targets: Novel Approaches to Inhibit Oncogenic Signaling	4/18/23	2:30 PM	Room W224	
5737	Evaluation of the relationship between target expression and in vivo anti-tumor efficacy of AZD9592, an EGFR/c-MET targeted bispecific antibody drug conjugate	Lara	McGrath	Oral	New Tricks for Known Targets: Novel Approaches to Inhibit Oncogenic Signaling	4/18/23	2:30 PM	Room W224	
5738	A pan-ras mRNA vaccine elicits specific immune responses and inhibits tumor growth in the mouse model of colon cancer	Dong	Shen	Oral	New Tricks for Known Targets: Novel Approaches to Inhibit Oncogenic Signaling	4/18/23	2:30 PM	Room W224	
5739	Targeting WEE1 to improve the therapy of KRAS G12C mutant non-small cell lung cancer	Gaku	Yamamoto	Oral	New Tricks for Known Targets: Novel Approaches to Inhibit Oncogenic Signaling	4/18/23	2:30 PM	Room W224	
5741	Harnessing macrophages, while protecting T cells, enhances anti-tumor efficacy	Sean	Yamada-Hunter	Oral	New Opportunities for Combinatorial Immunotherapies	4/18/23	2:30 PM	Tangerine Ballroom 2 (WF2)	

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
5742	Pharmacologic modulation of RNA splicing enhances anti-tumor immunity	James	Thomas	Oral	New Opportunities for Combinatorial Immunotherapies	4/18/23	2:30 PM	Tangerine Ballroom 2 (WF2)	
5743	Reprogramming myeloid cells by JAK inhibition to enhance checkpoint blockade immunotherapy	Jaroslav	Zak	Oral	New Opportunities for Combinatorial Immunotherapies	4/18/23	2:30 PM	Tangerine Ballroom 2 (WF2)	
5744	Decreasing toxicity of immunocytokines by transient and selective inhibition of their intracellular signaling activation	Giulia	Rotta	Oral	New Opportunities for Combinatorial Immunotherapies	4/18/23	2:30 PM	Tangerine Ballroom 2 (WF2)	
5745	Proposing the best MET inhibitor to improve anti-PD-1 efficacy in HCC	Ricardo	de Azevedo	Oral	New Opportunities for Combinatorial Immunotherapies	4/18/23	2:30 PM	Tangerine Ballroom 2 (WF2)	
5746	Flexible tumor-specific cytokine and antigen delivery through the T-SIGn vector platform enables effective CAR-T cell therapy against solid tumors	Maria Stella	Sasso	Oral	New Opportunities for Combinatorial Immunotherapies	4/18/23	2:30 PM	Tangerine Ballroom 2 (WF2)	
5747	A novel combination therapy of arenavirus vectors and PD1-IL2v strongly potentiates tumor specific T cell responses resulting in synergistic anti-tumor efficacy	Judith	Strauss	Oral	New Opportunities for Combinatorial Immunotherapies	4/18/23	2:30 PM	Tangerine Ballroom 2 (WF2)	
5749	Core transcriptional regulatory circuitry in AML	Maxim	Pimkin	Oral	Gene Regulation and Transcription Factors in Cancer	4/18/23	2:30 PM	Room W311 A-D	
5750	The mutational landscape of ultraconserved elements in human cancers	Recep	Bayraktar	Oral	Gene Regulation and Transcription Factors in Cancer	4/18/23	2:30 PM	Room W311 A-D	
5751	Single-cell epigenomic analysis reveals an important role of the receptor kinase Ror2 in the erosion of cellular identity during pancreatic carcinogenesis	Simone	Benitz	Oral	Gene Regulation and Transcription Factors in Cancer	4/18/23	2:30 PM	Room W311 A-D	
5752	Enhancer amplification defines lineage addiction in human lung adenocarcinoma	John	Pulice	Oral	Gene Regulation and Transcription Factors in Cancer	4/18/23	2:30 PM	Room W311 A-D	
5753	RUNX3 disrupts MYC/MAX complex and promotes MYC degradation	Yoshiaki	Ito	Oral	Gene Regulation and Transcription Factors in Cancer	4/18/23	2:30 PM	Room W311 A-D	
5754	Determining the regulatory logic of breast cancer cells using single-cell multi-omics	Hector	Franco	Oral	Gene Regulation and Transcription Factors in Cancer	4/18/23	2:30 PM	Room W311 A-D	
5755	TP63 fusions drive enhancer rewiring, lymphomagenesis, and dependence on EZH2	Gongwei	Wu	Oral	Gene Regulation and Transcription Factors in Cancer	4/18/23	2:30 PM	Room W311 A-D	
5757	Breast cancer diagnosis and treatment associated with acceleration of biological aging over time in a racially diverse cohort of women	Jacob	Kresovich	Oral	Survivorship and Biomarkers of Prognosis	4/18/23	2:30 PM	Room W307	

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
5758	Regular aspirin use, breast tumor characteristics and long-term breast cancer survival	Cheng	Peng	Oral	Survivorship and Biomarkers of Prognosis	4/18/23	2:30 PM	Room W307	
5759	Accelerated cardiac aging in adolescent and young adult cancer survivors previously treated with cardiotoxic therapy	Michelle	Hildebrandt	Oral	Survivorship and Biomarkers of Prognosis	4/18/23	2:30 PM	Room W307	
5760	Molecular, immune, and microbial profiles of early-onset, intermediate-onset, and later-onset CRCs	Tomotaka	Ugai	Oral	Survivorship and Biomarkers of Prognosis	4/18/23	2:30 PM	Room W307	
5761	Bayesian estimation of a semi-parametric recurrent event model with competing outcomes for personalized risk prediction among cancer survivors	Nam	Nguyen	Oral	Survivorship and Biomarkers of Prognosis	4/18/23	2:30 PM	Room W307	
5762	New perspective on racial disparities in prostate cancer: identification of new molecular subsets using whole-mount radical prostatectomy	Wei	Zhao	Oral	Survivorship and Biomarkers of Prognosis	4/18/23	2:30 PM	Room W307	
5763	Risk factors, trends, and disparities in HPV-associated subsequent malignant neoplasms among adolescent and young adult cancer survivors	Judy	Ou	Oral	Survivorship and Biomarkers of Prognosis	4/18/23	2:30 PM	Room W307	
5765	Promoter DNA methylation patterns in oral, laryngeal, and oropharyngeal anatomical regions are associated with tumor differentiation, nodal involvement, and survival in Latinos	Rafael	Guerrero-Preston	Oral	Behavioral and Biological Opportunities to Improve Cancer Prevention, Early Detection, and Disparities	4/18/23	2:30 PM	Room W304 E-H	
5766	Prospective evaluation of cell-free DNA fragmentomes for lung cancer detection	Victor	Velculescu	Oral	Behavioral and Biological Opportunities to Improve Cancer Prevention, Early Detection, and Disparities	4/18/23	2:30 PM	Room W304 E-H	
5767	Pan-viral response in African Americans and European Americans with hepatocellular carcinoma	Theresa	Ewa	Oral	Behavioral and Biological Opportunities to Improve Cancer Prevention, Early Detection, and Disparities	4/18/23	2:30 PM	Room W304 E-H	
5768	Genetic screening in a tertiary medical center identifies carriers of cancer predisposition diseases that would be missed by clinical guidelines	Niloy Jewel	Samadder	Oral	Behavioral and Biological Opportunities to Improve Cancer Prevention, Early Detection, and Disparities	4/18/23	2:30 PM	Room W304 E-H	
5769	Disparities in uptake of levonorgestrel-releasing intrauterine system (LNG-IUS): implications for uterine cancer primary prevention	Paul	Yeh	Oral	Behavioral and Biological Opportunities to Improve Cancer Prevention, Early Detection, and Disparities	4/18/23	2:30 PM	Room W304 E-H	

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/ Section	Board Num
									single-cell tumor micro-environment atlas predictive of immunotherapy response
								"	Francesca
Lodi	Oral	Spatial Considerations of the 3D Tumor Microenvironment	4/18/23	2:30 PM	Tangerine Ballroom 1 (WF1)				
5786	Spatial relationships in the tumor microenvironment predict response to immune checkpoint inhibitors in urothelial and head and neck cancer	Alberto	Gil-Jimenez	Oral	Spatial Considerations of the 3D Tumor Microenvironment	4/18/23	2:30 PM	Tangerine Ballroom 1 (WF1)	
5787	Modelling the spatial heterogeneity of CD45-positive tumor infiltrating lymphocytes in early-stage, estrogen receptor-positive breast cancer	Zak	Kinsella	Oral	Spatial Considerations of the 3D Tumor Microenvironment	4/18/23	2:30 PM	Tangerine Ballroom 1 (WF1)	
5788	Single-cell and spatial transcriptomic mapping of human renal cell carcinoma brain metastases uncovers actionable immune-resistance targets	Elshad	Hasanov	Oral	Spatial Considerations of the 3D Tumor Microenvironment	4/18/23	2:30 PM	Tangerine Ballroom 1 (WF1)	
5791	Autophagy & PIM1 kinase inhibition in breast cancer stem cells & bulk cancer cells attenuates breast cancer & metastasis	Kanakaraju	Manupati	Poster	Cancer Stem Cells and Therapeutic Resistance	4/19/23	9:00 AM	Section 1	1
5792	The novel therapeutic diiminoquinone exhibits anticancer effects on human prostate cancer cells in 2D and 3D in vitro models	Wassim	Abou-Kheir	Poster	Cancer Stem Cells and Therapeutic Resistance	4/19/23	9:00 AM	Section 1	2
5793	Met confers radioresistance-associated aggressiveness through enhancing PLXDC2-mediated cancer stem cell plasticity	Yong	Teng	Poster	Cancer Stem Cells and Therapeutic Resistance	4/19/23	9:00 AM	Section 1	3

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
5794	Targeting CD133+/CD90+ liver cancer stem cells by piperlongumine: A novel strategy for liver cancer treatment	Basma	Abdelaziz	Poster	Cancer Stem Cells and Therapeutic Resistance	4/19/23	9:00 AM	Section 1	4
5795	Leukemic stem cells confer ferroptosis resistance in aggressive blood cancer	Nunki	Hassan	Poster	Cancer Stem Cells and Therapeutic Resistance	4/19/23	9:00 AM	Section 1	5
5797	NTX301, a novel DNA hypomethylating agent, targets lipid metabolism in ovarian cancer	Yinu	Wang	Poster	Cancer Stem Cells and Therapeutic Resistance	4/19/23	9:00 AM	Section 1	7
5798	Ex vivo culturing of primary AML cells facilitates the study of developmental therapeutics	Satyam	Patel	Poster	Cancer Stem Cells and Therapeutic Resistance	4/19/23	9:00 AM	Section 1	8
5799	SPINK1-induced tumor plasticity provides a therapeutic window for chemotherapy in hepatocellular carcinoma	Stephanie	Ma	Poster	Cancer Stem Cells and Therapeutic Resistance	4/19/23	9:00 AM	Section 1	9
5800	Anti-metastatic potential of pitavastatin in triple-negative breast cancer via targeting breast cancer stem-like properties and STAT3 signaling	Dongmi	Ko	Poster	Cancer Stem Cells and Therapeutic Resistance	4/19/23	9:00 AM	Section 1	10
5801	Inhibition of muscarinic acetylcholine receptors in glioma stem cells blocks tumor progression	Sumyuktha	Anand	Poster	Cancer Stem Cells and Therapeutic Resistance	4/19/23	9:00 AM	Section 1	11
5802	The impact of tumor-treating fields on cancer stem-like cells isolated from the sub-ventricular zone of glioblastoma patients	Yamhilette	Licon Munoz	Poster	Cancer Stem Cells and Therapeutic Resistance	4/19/23	9:00 AM	Section 1	12
5804	Targeting methyl donor synthesis inhibits platinum-induced enrichment of ovarian cancer stem cells	Shu	Zhang	Poster	Cancer Stem Cells and Therapeutic Resistance	4/19/23	9:00 AM	Section 1	14
5805	Ebastine targets cancer stem cell-like properties and metastasis in triple-negative breast cancer by binding focal adhesion kinase	Juyeon	Seo	Poster	Cancer Stem Cells and Therapeutic Resistance	4/19/23	9:00 AM	Section 1	15
5806	Kinase library screening identifies IGF-1R/PI3K/AKT axis as a crucial pathway for survival of intrahepatic cholangiocarcinoma cells with stemness characteristics	Chotirat	Rattanasinchai	Poster	Cancer Stem Cells and Therapeutic Resistance	4/19/23	9:00 AM	Section 1	16
5807	mTOR regulates stem cells of glioblastoma by altering the self-renewal and proliferation	Meena	Jhanwar-Uniyal	Poster	Cancer Stem Cells and Therapeutic Resistance	4/19/23	9:00 AM	Section 1	17
5808	Integrin-linked kinase regulates Wnt transcriptional activity in platinum resistant ovarian cancer stem cells	Rula	Atwani	Poster	Cancer Stem Cells and Therapeutic Resistance	4/19/23	9:00 AM	Section 1	18
5809	Tracking cancer stem cell expression of pancreatic and ampullary cancer organoids in response to chemotherapy	Eleanor	Riedl	Poster	Cancer Stem Cells and Therapeutic Resistance	4/19/23	9:00 AM	Section 1	19
5810	The effects of retinoid agents and retinoic acid receptor genotype on proliferation, differentiation, and stem cells in colorectal cancer	Victoria	Hunsu	Poster	Cancer Stem Cells and Therapeutic Resistance	4/19/23	9:00 AM	Section 1	20
5811	Epigenetic regulation of chromosomal instability in triple-negative breast cancer	Yang	Bai	Poster	Cancer Stem Cells and Therapeutic Resistance	4/19/23	9:00 AM	Section 1	21
5815	Nucleus positioning and composition dictate the invasion performance of E-cadherin mutant cells	Joana	Figueiredo	Poster	Cell Adhesion and Cell Signaling in Cancer and Drug Resistance	4/19/23	9:00 AM	Section 2	1

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
5816	Tensin1 tension sensor reveals novel features associated with actomyosin, focal adhesion dynamics, and mechanosensitivity	Yoon-Kwan	Jang	Poster	Cell Adhesion and Cell Signaling in Cancer and Drug Resistance	4/19/23	9:00 AM	Section 2	2
5817	LKB1 overcomes RAS pathway-mediated loss of epithelial integrity	Topi	Tervonen	Poster	Cell Adhesion and Cell Signaling in Cancer and Drug Resistance	4/19/23	9:00 AM	Section 2	3
5818	Cadherin complexes recruit PIWIL2 to suppress pro-tumorigenic transformation	Alyssa	Risner	Poster	Cell Adhesion and Cell Signaling in Cancer and Drug Resistance	4/19/23	9:00 AM	Section 2	4
5819	Src inhibitor suppresses rab11 mediated collective cell migration in colon cancer cells	Wei-Ting	Chao	Poster	Cell Adhesion and Cell Signaling in Cancer and Drug Resistance	4/19/23	9:00 AM	Section 2	5
5820	Chloroquine inhibited Rab11 mediated E-cadherin transport in collective colon cell migration in Dasatinib resistant cells	Xiang-Ling	Hou	Poster	Cell Adhesion and Cell Signaling in Cancer and Drug Resistance	4/19/23	9:00 AM	Section 2	6
5821	Synergism of FAK and ROS1 inhibitors in the treatment of CDH1-deficient cancers mediated by FAK-YAP-TRX signaling	Jiaming	Gao	Poster	Cell Adhesion and Cell Signaling in Cancer and Drug Resistance	4/19/23	9:00 AM	Section 2	7
5822	YAP inhibition via targeting MAP3K3-dependent lysosomal degradation pathway overcomes BRAF and CDK4/6 inhibitor resistance	Won-Ji	Ryu	Poster	Cell Adhesion and Cell Signaling in Cancer and Drug Resistance	4/19/23	9:00 AM	Section 2	8
5823	Uncovering the mechanisms of matrix metalloproteinase-3 (MMP-3) in the cisplatin resistance of ovarian cancer	Mariela	Rivera-Serrano	Poster	Cell Adhesion and Cell Signaling in Cancer and Drug Resistance	4/19/23	9:00 AM	Section 2	9
5824	Human ovarian cancer cell seeding density as a mechanism of cisplatin resistance associated with expression of anti-apoptotic and autophagy proteins	Thomas	Brown	Poster	Cell Adhesion and Cell Signaling in Cancer and Drug Resistance	4/19/23	9:00 AM	Section 2	10
5825	TM4SF19 regulates oxidative stress-dependent YAP transcription in HNSCC	Eunbie	Shin	Poster	Cell Adhesion and Cell Signaling in Cancer and Drug Resistance	4/19/23	9:00 AM	Section 2	11
5828	Distinct immunosuppressive tumor microenvironment modulates small cell lung carcinoma neuroendocrine phenotypic plasticity and heterogeneity	Parth	Desai	Poster	Crosstalk between Cancer Cells, Immune Cells, and Fibroblasts	4/19/23	9:00 AM	Section 3	1
5829	Differential expression of PD-L1 and PD-L2 is associated with M2 tumor-associated macrophages and tumor differentiation in non-small cell lung cancer	Ryota	Sumitomo	Poster	Crosstalk between Cancer Cells, Immune Cells, and Fibroblasts	4/19/23	9:00 AM	Section 3	2
5830	Presence of androgens improves efficacy of PD1 blockade	María Elena	Vargas-Delgado	Poster	Crosstalk between Cancer Cells, Immune Cells, and Fibroblasts	4/19/23	9:00 AM	Section 3	3
5831	CD200R signaling contributes to unfavorable tumor microenvironment through regulating production of chemokines by tumor associated macrophages	Cho-Hao	Lin	Poster	Crosstalk between Cancer Cells, Immune Cells, and Fibroblasts	4/19/23	9:00 AM	Section 3	4
5832	Integrin α 5 mediates the direct heterocellular interaction between cancer cells and cancer-associated fibroblasts and promotes peritoneal metastasis of diffuse-type gastric carcinoma	Hideki	Yamaguchi	Poster	Crosstalk between Cancer Cells, Immune Cells, and Fibroblasts	4/19/23	9:00 AM	Section 3	5

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
5833	Crosstalk between cancer-associated fibroblasts and CD8 T cells leads to improved T cell activation in head and neck cancer	Diana	Graves	Poster	Crosstalk between Cancer Cells, Immune Cells, and Fibroblasts	4/19/23	9:00 AM	Section 3	6
5834	The pro-tumoral function of cancer-associated mesothelial cells	Maeva	Chauvin	Poster	Crosstalk between Cancer Cells, Immune Cells, and Fibroblasts	4/19/23	9:00 AM	Section 3	7
5835	Targeting discoidin domain receptor 1 (DDR1) reverses glioma immune suppression by remodeling collagen fiber architecture	Syed	Faisal	Poster	Crosstalk between Cancer Cells, Immune Cells, and Fibroblasts	4/19/23	9:00 AM	Section 3	8
5836	Non-invasive quantification of fibroblast activation protein (FAP) cleaved type III collagen in serum reflects FAP activity and has biomarker potential in non-small cell lung cancer	Rasmus	Pedersen	Poster	Crosstalk between Cancer Cells, Immune Cells, and Fibroblasts	4/19/23	9:00 AM	Section 3	9
5838	Cancer-associated fibroblasts drive spheroid formation and pleural dissemination in non-small cell lung cancer	Masayoshi	Ohki	Poster	Crosstalk between Cancer Cells, Immune Cells, and Fibroblasts	4/19/23	9:00 AM	Section 3	11
5839	Novel stroma-derived prostate cancer subtypes are associated with risk of clinical progression	Martin	Rasmussen	Poster	Crosstalk between Cancer Cells, Immune Cells, and Fibroblasts	4/19/23	9:00 AM	Section 3	12
5840	Normal fibroblasts, cancer-associated fibroblasts, and their senescent counterparts exert varying effects on tumorigenic potential and ABT-263 sensitivity of gastric cancer cells	Francesca	Di Cristofano	Poster	Crosstalk between Cancer Cells, Immune Cells, and Fibroblasts	4/19/23	9:00 AM	Section 3	13
5841	Exploring the role of versican in immune exclusion within triple negative breast cancer	Priyanka	Hirani	Poster	Crosstalk between Cancer Cells, Immune Cells, and Fibroblasts	4/19/23	9:00 AM	Section 3	14
5842	Determining the tumor supportive and inhibitory capabilities of cancer associated fibroblast subpopulations in central nervous system metastasis	Thomas	Simon	Poster	Crosstalk between Cancer Cells, Immune Cells, and Fibroblasts	4/19/23	9:00 AM	Section 3	15
5843	miR-224 activates cancer-associated fibroblasts to promote cancer cell invasion in lung tumor microenvironment	Seonyeong	Oh	Poster	Crosstalk between Cancer Cells, Immune Cells, and Fibroblasts	4/19/23	9:00 AM	Section 3	16
5844	Fibroblasts play an immunoregulatory role in lung cancer through exosome secretion and by controlling extracellular matrix composition	Luca	Roz	Poster	Crosstalk between Cancer Cells, Immune Cells, and Fibroblasts	4/19/23	9:00 AM	Section 3	17
5845	Periostin secreted by cancer-associated fibroblasts promotes cancer progression and drug resistance in non-small cell lung cancer	Mao	Yoshikawa	Poster	Crosstalk between Cancer Cells, Immune Cells, and Fibroblasts	4/19/23	9:00 AM	Section 3	18
5847	The splanchnic mesenchyme is the main tissue origin of fibroblasts in the pancreas during homeostasis and tumorigenesis	Lu	Han	Poster	Crosstalk between Cancer Cells, Immune Cells, and Fibroblasts	4/19/23	9:00 AM	Section 3	20
5848	Identification of mechanosensitive cancer associated fibroblasts in pancreatic cancer	Reginald	Hill	Poster	Crosstalk between Cancer Cells, Immune Cells, and Fibroblasts	4/19/23	9:00 AM	Section 3	21
5849	SMAD3 in tumor associated fibroblasts drives enhanced fibroblast accumulation in lung adenocarcinoma through increased migration	Natalia	Diaz Valdivia	Poster	Crosstalk between Cancer Cells, Immune Cells, and Fibroblasts	4/19/23	9:00 AM	Section 3	22

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
5850	Development and characterization of patient-derived pancreatic fibroblasts to study CAF heterogeneity	Nidhi	Dwivedi	Poster	Crosstalk between Cancer Cells, Immune Cells, and Fibroblasts	4/19/23	9:00 AM	Section 3	23
5851	Cancer associated fibroblast crosstalk through VEGF increases tumor cell proliferation in human pancreatic ductal adenocarcinoma	Samantha	Guinn	Poster	Crosstalk between Cancer Cells, Immune Cells, and Fibroblasts	4/19/23	9:00 AM	Section 3	24
5852	Vimentin content associated with shear wave speed in hepatocellular carcinoma: Non-invasive identification of more aggressive tumor phenotypes.	Andrea	Cortes	Poster	Crosstalk between Cancer Cells, Immune Cells, and Fibroblasts	4/19/23	9:00 AM	Section 3	25
5854	Suppression of phosphorylated focal adhesion kinase+ (pFAK+) fibroblasts and C-X-C chemokine receptor type 4 (CXCR4) expressing granulocytes is associated with exceptional clinical outcomes in pancreatic ductal adenocarcinoma (PDAC)	John	Davelaar	Poster	Crosstalk between Cancer Cells, Immune Cells, and Fibroblasts	4/19/23	9:00 AM	Section 3	27
5855	Spatial transcriptomics deciphers the cellular society of advanced colorectal cancer	Masahiro	Hashimoto	Poster	Crosstalk between Cancer Cells, Immune Cells, and Fibroblasts	4/19/23	9:00 AM	Section 3	28
5860	ZEB1-driven reconstruction of the hyaluronan network establishes a pro-metastatic microenvironment in lung adenocarcinoma.	Sieun	Lee	Poster	Immunotherapy and Cellular Interactions in the Tumor Microenvironment	4/19/23	9:00 AM	Section 4	2
5861	Tumor cell-intrinsic factors promoting fibrotic tumor microenvironment in gastric cancer	Takashi	Semba	Poster	Immunotherapy and Cellular Interactions in the Tumor Microenvironment	4/19/23	9:00 AM	Section 4	3
5862	ABCB5 knockdown suppresses tumor-intrinsic expression of immune checkpoint regulators PD-1 and PD-L1 in hepatocellular carcinoma (HCC)	Chun	Yeung	Poster	Immunotherapy and Cellular Interactions in the Tumor Microenvironment	4/19/23	9:00 AM	Section 4	4
5863	Blockade of tumor glucocorticoid production inhibits Treg function and tumor growth	Shizuka	Otsuka	Poster	Immunotherapy and Cellular Interactions in the Tumor Microenvironment	4/19/23	9:00 AM	Section 4	5
5864	An angiogenic target of immune exclusion with checkpoint blockade in melanoma	Saba	Tabasum	Poster	Immunotherapy and Cellular Interactions in the Tumor Microenvironment	4/19/23	9:00 AM	Section 4	6
5865	Combinatorial activity of amivantamab and pembrolizumab in head and neck squamous cell carcinoma and lung squamous cell carcinoma expressing wild-type EGFR and MET	Sun Min	Lim	Poster	Immunotherapy and Cellular Interactions in the Tumor Microenvironment	4/19/23	9:00 AM	Section 4	7
5866	Mavoxifafor enhances apoptosis of tumor cells treated with ibrutinib or venetoclax in diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia	Chi	Nguyen	Poster	Immunotherapy and Cellular Interactions in the Tumor Microenvironment	4/19/23	9:00 AM	Section 4	8

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
5867	Multimodal analysis of glioblastoma identifies the additional function of CXCL12 for modulating GBM resistance and immunosuppressive microenvironment	Chan-Chuan	Liu	Poster	Immunotherapy and Cellular Interactions in the Tumor Microenvironment	4/19/23	9:00 AM	Section 4	9
5868	Uncovering key microenvironmental features for immunotherapy response at the subclonal level in pancreatic cancer	Er-Yen	Yen	Poster	Immunotherapy and Cellular Interactions in the Tumor Microenvironment	4/19/23	9:00 AM	Section 4	10
5869	The concordant disruption of B7/CD28 immune regulators predicts the prognosis of oral carcinoma	Sih-Rou	Chang	Poster	Immunotherapy and Cellular Interactions in the Tumor Microenvironment	4/19/23	9:00 AM	Section 4	11
5870	T-cell factor-4 variants regulate PD-L1 expression in liver cancer cells	Hironori	Koga	Poster	Immunotherapy and Cellular Interactions in the Tumor Microenvironment	4/19/23	9:00 AM	Section 4	12
5871	Pan-cancer myeloid cell analysis at the single cell level reveals the influence of distinct organ sites in myeloid cell phenotypes and support targeting S100A4 to reverse immune suppression	Nourhan	Abdelfattah	Poster	Immunotherapy and Cellular Interactions in the Tumor Microenvironment	4/19/23	9:00 AM	Section 4	13
5872	Spatial immunophenotypes contribute to predict survival of triple-negative breast cancer assessed as Miller-Payne grade 4 and N0 after neoadjuvant therapy	Qingyuan	Zhang	Poster	Immunotherapy and Cellular Interactions in the Tumor Microenvironment	4/19/23	9:00 AM	Section 4	14
5873	LDH inhibition boosts effector T cells while destabilizing regulatory T cells and improves responses to CTLA-4 blockade	Svena	Verma	Poster	Immunotherapy and Cellular Interactions in the Tumor Microenvironment	4/19/23	9:00 AM	Section 4	15
5874	HSF1 downregulation of CCL5 reduces CD8 T cell trafficking in breast cancer	Curteisha	Jacobs	Poster	Immunotherapy and Cellular Interactions in the Tumor Microenvironment	4/19/23	9:00 AM	Section 4	16
5875	Rab37 mediates intracellular trafficking and membrane presentation of PD-1 in T cells to foster an immunosuppressive microenvironment in lung cancer	Yi-Ching	Wang	Poster	Immunotherapy and Cellular Interactions in the Tumor Microenvironment	4/19/23	9:00 AM	Section 4	17
5876	Sorafenib and Lenvatinib induce vascular responses in patient derived HCC on-Chip models	Désirée	Goubert	Poster	Immunotherapy and Cellular Interactions in the Tumor Microenvironment	4/19/23	9:00 AM	Section 4	18
5877	Intratumoral lymphocyte networks harbor TCF1+ PD1+ progenitor CD8 T cells in lung cancer	Megan	Burger	Poster	Immunotherapy and Cellular Interactions in the Tumor Microenvironment	4/19/23	9:00 AM	Section 4	19
5879	Defining the cancer Immunogram using multimodal analysis to guide immunotherapy in diffuse large B cell lymphoma	Michael	Mattie	Poster	Immunotherapy and Cellular Interactions in the Tumor Microenvironment	4/19/23	9:00 AM	Section 4	21

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
5880	The role of SOAT1 on CD8+T cells-mediated immune response in ovarian cancer	Jiangnan	He	Poster	Immunotherapy and Cellular Interactions in the Tumor Microenvironment	4/19/23	9:00 AM	Section 4	22
5881	PERIO-01: Initial safety experience and immunologic effects of a Class C TLR9 agonist using pressure- enabled drug delivery in a phase 1 trial of hepatic arterial infusion of SD-101 +/- checkpoint inhibition in metastatic uveal melanoma	Sapna	Patel	Poster	Immunotherapy and Cellular Interactions in the Tumor Microenvironment	4/19/23	9:00 AM	Section 4	23
5882	Prevention of antibiotic-induced dysbiosis in human volunteers by DAV132 and preservation of responsiveness to anti-PD-1 demonstrated by transplantation of human feces into tumor-bearing mice	Meriem	Messaoudene	Poster	Immunotherapy and Cellular Interactions in the Tumor Microenvironment	4/19/23	9:00 AM	Section 4	24
5883	Computational analysis of immune synapses in melanoma tumor microenvironment	Zichao	Liu	Poster	Immunotherapy and Cellular Interactions in the Tumor Microenvironment	4/19/23	9:00 AM	Section 4	25
5884	Targeting T regulatory cells to intercept progression from preinvasive to invasive lung adenocarcinoma using a novel KRAS-driven murine model	Mitchell	Martin	Poster	Immunotherapy and Cellular Interactions in the Tumor Microenvironment	4/19/23	9:00 AM	Section 4	26
5885	A pathway-centric approach to characterising tumour heterogeneity and cell diversity across multiple cancer types	Leiam	Colbert	Poster	Immunotherapy and Cellular Interactions in the Tumor Microenvironment	4/19/23	9:00 AM	Section 4	27
5886	Targeting IDO1 and TDO2 is crucial for the modulation of immune effector in platinum resistant non-small cell lung cancer	Sydney	Spector	Poster	Immunotherapy and Cellular Interactions in the Tumor Microenvironment	4/19/23	9:00 AM	Section 4	28
5890	Distinct differences in microbial enrichment and diversity identified between gastric and gastroesophageal junction adenocarcinoma	Miseker	Abate	Poster	Interactions Between the Microbiome, Cancer Cells, and Tumor Stromal Components	4/19/23	9:00 AM	Section 5	1
5891	Identification of intratumor pathogens from single-cell RNA sequencing, cellular dysfunction and immune response	Laura	Bukavina	Poster	Interactions Between the Microbiome, Cancer Cells, and Tumor Stromal Components	4/19/23	9:00 AM	Section 5	2
5892	Microbial diversity and composition according to short-term postoperative complication status in colorectal cancer patients	Hyeree	Park	Poster	Interactions Between the Microbiome, Cancer Cells, and Tumor Stromal Components	4/19/23	9:00 AM	Section 5	3
5893	Suppression of anti-tumor immunity by the Fusobacterium nucleatum protease fusolisin	Amjad	Shhadeh	Poster	Interactions Between the Microbiome, Cancer Cells, and Tumor Stromal Components	4/19/23	9:00 AM	Section 5	4

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
5894	Changes in the gut microbiota associated with oncolytic virotherapy efficacy in a gastric cancer murine model	Natalie	Melendez-Vazquez	Poster	Interactions Between the Microbiome, Cancer Cells, and Tumor Stromal Components	4/19/23	9:00 AM	Section 5	5
5895	Analysis of microbiome in gastric MALT lymphoma	Seungjoo	Yoo	Poster	Interactions Between the Microbiome, Cancer Cells, and Tumor Stromal Components	4/19/23	9:00 AM	Section 5	6
5896	Identification of microbial biomarkers to predict recurrence of oral squamous cell carcinoma	Wei-Ni	Lyu	Poster	Interactions Between the Microbiome, Cancer Cells, and Tumor Stromal Components	4/19/23	9:00 AM	Section 5	7
5898	Gut microbiota-derived metabolism of 5-fluorouracil affects drug efficacy	Despoina	Chrysostomou	Poster	Interactions Between the Microbiome, Cancer Cells, and Tumor Stromal Components	4/19/23	9:00 AM	Section 5	9
5900	Tolerance to colibactin correlates with response to chemotherapeutic agents in colorectal cancer	Alberto	Sogari	Poster	Interactions Between the Microbiome, Cancer Cells, and Tumor Stromal Components	4/19/23	9:00 AM	Section 5	11
5901	Microbiome and genomic profiling in rectal adenocarcinoma	David	Hein	Poster	Interactions Between the Microbiome, Cancer Cells, and Tumor Stromal Components	4/19/23	9:00 AM	Section 5	12
5903	Comparison of the tissue and gut microbiome in extrahepatic cholangiocarcinoma patients and healthy liver donors	Sora	Kang	Poster	Interactions Between the Microbiome, Cancer Cells, and Tumor Stromal Components	4/19/23	9:00 AM	Section 5	14
5904	Intra-tumor microbes identified by RNAseq associated with response to immune checkpoint blockade in metastatic melanoma	Caroline	Wheeler	Poster	Interactions Between the Microbiome, Cancer Cells, and Tumor Stromal Components	4/19/23	9:00 AM	Section 5	15
5905	Enterotoxigenic Bacteroides fragilis, a colon microbe, dysregulates polyamine catabolism to promote breast cancer progression	Deeptashree	Nandi	Poster	Interactions Between the Microbiome, Cancer Cells, and Tumor Stromal Components	4/19/23	9:00 AM	Section 5	16
5906	Gut microbiota signatures are associated with immunotherapy induced cognitive decline and neurotoxicity	Anik	Banerjee	Poster	Interactions Between the Microbiome, Cancer Cells, and Tumor Stromal Components	4/19/23	9:00 AM	Section 5	17
5907	The tumor microbiome associates with features of the tumor microenvironment, treatment outcomes, and histologies: A national collaboration of the exORIENT Consortium	Daniel	Spakowicz	Poster	Interactions Between the Microbiome, Cancer Cells, and Tumor Stromal Components	4/19/23	9:00 AM	Section 5	18
5908	Specific gut microbial community is associated with specific cancer types: A strategy for cancer detection and prevention	Ekansh	Mittal	Poster	Interactions Between the Microbiome, Cancer Cells, and Tumor Stromal Components	4/19/23	9:00 AM	Section 5	19

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
5909	Characterization of the lung cancer microbiome using whole genome sequencing	John	McElderry	Poster	Interactions Between the Microbiome, Cancer Cells, and Tumor Stromal Components	4/19/23	9:00 AM	Section 5	20
5910	Prospective platform to define microbiome correlates of metastasis and therapy resistance in early onset and average onset gastrointestinal cancers	Melissa	Lumish	Poster	Interactions Between the Microbiome, Cancer Cells, and Tumor Stromal Components	4/19/23	9:00 AM	Section 5	21
5912	Bitter taste receptors link between microbiome dysbiosis and programmed cell death in oral squamous cell carcinoma	Byeong-Oh	Hwang	Poster	Interactions Between the Microbiome, Cancer Cells, and Tumor Stromal Components	4/19/23	9:00 AM	Section 5	23
5913	Semi-supervised analysis of myeloid and T cell behavior in ex vivo ovarian tumor slices reveals changes in cell motility after treatments	Florian	Laforets	Poster	Interactions Between the Microbiome, Cancer Cells, and Tumor Stromal Components	4/19/23	9:00 AM	Section 5	24
5914	Colorectal cancer attributes and outcomes according to Fusobacterium nucleatum enrichment and presence	Courtney	Hill	Poster	Interactions Between the Microbiome, Cancer Cells, and Tumor Stromal Components	4/19/23	9:00 AM	Section 5	25
5915	Exploring the impact of microbiome in the response of combined radiation with immune checkpoint blockade in muscle invasive bladder cancer (MIBC)	Eva	Michaud	Poster	Interactions Between the Microbiome, Cancer Cells, and Tumor Stromal Components	4/19/23	9:00 AM	Section 5	26
5916	Weight loss intervention triggered gut microbiota modulation can positively impact obesity associated endocrine therapy resistance	Sheetal	Parida	Poster	Interactions Between the Microbiome, Cancer Cells, and Tumor Stromal Components	4/19/23	9:00 AM	Section 5	27
5917	Development of a medium-to-high throughput organoid-bacteria co-culture platform for the assessment of host pathogen interaction	Eider	Valle-Encinas	Poster	Interactions Between the Microbiome, Cancer Cells, and Tumor Stromal Components	4/19/23	9:00 AM	Section 5	28
5918	Interrogating host-intratumoral microbial interactions in pancreatic cancer	Vidhi	Chandra	Poster	Interactions Between the Microbiome, Cancer Cells, and Tumor Stromal Components	4/19/23	9:00 AM	Section 5	29
5919	The significant role of HMGB1 in mesothelial cells in contributing to the mesothelioma development induced by asbestos	Haining	Yang	Poster	Interactions Between the Microbiome, Cancer Cells, and Tumor Stromal Components	4/19/23	9:00 AM	Section 5	30
5923	The genetic landscape of metastatic breast cancer reflected in circulating tumor DNA	Stephanie	Kavan	Poster	Methods to Measure Clonal Evolution	4/19/23	9:00 AM	Section 6	1
5924	Intratumor heterogeneity in thyroid cancer progression	Vincenzo Davide	Pantina	Poster	Methods to Measure Clonal Evolution	4/19/23	9:00 AM	Section 6	2
5925	Prevalence of clonal hematopoiesis in patients with monoclonal gammopathy of undetermined significance	Gurbakhash	Kaur	Poster	Methods to Measure Clonal Evolution	4/19/23	9:00 AM	Section 6	3

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
5926	High dimensional morphology analysis reveals new insights in melanoma cell heterogeneity	Manisha	Ray	Poster	Methods to Measure Clonal Evolution	4/19/23	9:00 AM	Section 6	4
5927	Leveraging single cell RNA profiling to uncover intra-tumor heterogeneity across cytogenetic subgroups in acute myeloid leukemia	Hussein	Abbas	Poster	Methods to Measure Clonal Evolution	4/19/23	9:00 AM	Section 6	5
5928	Prevalence of clonal hematopoiesis in neuroendocrine tumor patients prior to lutetium 177 dotatate therapy (Lu177): A prospective trial of 36 patients	Yael	Kusne	Poster	Methods to Measure Clonal Evolution	4/19/23	9:00 AM	Section 6	6
5929	Individual organoid level analyses reveal hidden tumor molecular heterogeneity	Shirsa	Udgata	Poster	Methods to Measure Clonal Evolution	4/19/23	9:00 AM	Section 6	7
5930	Single day workflow for high-quality whole genome analysis of thousands of single cells	Jay	West	Poster	Methods to Measure Clonal Evolution	4/19/23	9:00 AM	Section 6	8
5931	Characterizing tumor heterogeneity through bulk and single cell analysis of patient derived bladder cancer models	Ziyu	Chen	Poster	Methods to Measure Clonal Evolution	4/19/23	9:00 AM	Section 6	9
5932	Clonal mapping phylogenetic and transcriptomic analysis of an M36 PDX amputation lung metastatic osteosarcoma model	Sylvester	Jusu	Poster	Methods to Measure Clonal Evolution	4/19/23	9:00 AM	Section 6	10
5933	Trimodal molecular analysis in single cells of a primary breast cancer cohort with ResolveOME™ amplification	Jon	Zawistowski	Poster	Methods to Measure Clonal Evolution	4/19/23	9:00 AM	Section 6	11
5934	Tracking T cell clonal dynamics across time and space in metastatic colorectal cancer	Ann-Marie	Baker	Poster	Methods to Measure Clonal Evolution	4/19/23	9:00 AM	Section 6	12
5935	Phenotype profiling of tumor microenvironment in EGFR mutant lung adenocarcinoma with multi-omics data	You Won	Lee	Poster	Methods to Measure Clonal Evolution	4/19/23	9:00 AM	Section 6	13
5940	Enhanced mast cell abundance is associated with the enrichment of CCR2+ cytotoxic T cells and favorable prognosis in lung adenocarcinoma.	Fan	Fan	Poster	Tumor-Stromal Cell (Including Immune Cell) Interactions and Therapy Responses	4/19/23	9:00 AM	Section 7	1
5941	Sequencing of targeted- and immune-therapy: delineating time dependent changes in both melanoma cells and the immune microenvironment	Karen	Sheppard	Poster	Tumor-Stromal Cell (Including Immune Cell) Interactions and Therapy Responses	4/19/23	9:00 AM	Section 7	2
5942	Mechanism and role of neutrophil recruitment in head and neck squamous cell carcinoma	Kulsoom	Ghias	Poster	Tumor-Stromal Cell (Including Immune Cell) Interactions and Therapy Responses	4/19/23	9:00 AM	Section 7	3
5943	Plasma cell repertoire in the lung cancer tumor microenvironment	Akshay	Patel	Poster	Tumor-Stromal Cell (Including Immune Cell) Interactions and Therapy Responses	4/19/23	9:00 AM	Section 7	4
5944	Relief of chromosomal instability-induced cGAS-STING signaling sensitizes STK11-mutant non-small cell lung cancer to immune checkpoint blockade	Lindsay	Caprio	Poster	Tumor-Stromal Cell (Including Immune Cell) Interactions and Therapy Responses	4/19/23	9:00 AM	Section 7	5

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
5945	Transcriptional analysis of TME in MC38 colon carcinoma model following checkpoint inhibition	Priyanka	Singh	Poster	Tumor-Stromal Cell (Including Immune Cell) Interactions and Therapy Responses	4/19/23	9:00 AM	Section 7	6
5946	OBI-999, an anti-Globo H antibody drug conjugate, exhibits synergistic anti-tumor effect in combination with pembrolizumab	Wan-Fen	Li	Poster	Tumor-Stromal Cell (Including Immune Cell) Interactions and Therapy Responses	4/19/23	9:00 AM	Section 7	7
5947	Tumor cells escape cell death after radiotherapy by senescence - a mechanism that can be counteracted with zinc oxide nanoparticles	Nadine	Wiesmann	Poster	Tumor-Stromal Cell (Including Immune Cell) Interactions and Therapy Responses	4/19/23	9:00 AM	Section 7	8
5948	MAGE-A3 expression with MMR-MSH6 screening suggests MAGE-A3 as a potential target for microsatellite-stable colorectal cancer	Jina	Yom	Poster	Tumor-Stromal Cell (Including Immune Cell) Interactions and Therapy Responses	4/19/23	9:00 AM	Section 7	9
5949	Modulate TAM infiltration at cancer-immune interface by targeting at monocyte migration	Wenxuan	Du	Poster	Tumor-Stromal Cell (Including Immune Cell) Interactions and Therapy Responses	4/19/23	9:00 AM	Section 7	10
5950	Ccr2+ monocyte derived macrophages influence trajectories of acquired therapy resistance in BRAF-mutant melanoma	Dahihm	Kim	Poster	Tumor-Stromal Cell (Including Immune Cell) Interactions and Therapy Responses	4/19/23	9:00 AM	Section 7	11
5951	The correlation between single nucleotide polymorphism of chemokine receptor and ligand and infiltrating immune cells on tumor microenvironment of gastric cancer	Sunjoo	Yoon	Poster	Tumor-Stromal Cell (Including Immune Cell) Interactions and Therapy Responses	4/19/23	9:00 AM	Section 7	12
5952	Pyroptotic adipocytes contribute to chemoresistance in advanced stage ovarian cancer	Chang-Ni	Lin	Poster	Tumor-Stromal Cell (Including Immune Cell) Interactions and Therapy Responses	4/19/23	9:00 AM	Section 7	13
5953	Reshaping the tumor microenvironment: new application of tamoxifen in triple negative breast cancer immunomodulation	Pony	Lee	Poster	Tumor-Stromal Cell (Including Immune Cell) Interactions and Therapy Responses	4/19/23	9:00 AM	Section 7	14
5954	Germline epitopes modulate immune surveillance informing breast cancer subtypes	Kathleen	Houlahan	Poster	Tumor-Stromal Cell (Including Immune Cell) Interactions and Therapy Responses	4/19/23	9:00 AM	Section 7	15
5955	In Silico dissection of immune infiltrate signatures that are detected by DetermalO, a predictor of response to immune therapy	Robert	Seitz	Poster	Tumor-Stromal Cell (Including Immune Cell) Interactions and Therapy Responses	4/19/23	9:00 AM	Section 7	16
5956	Tumor-infiltrating neutrophil progenitors impair homologous DNA repair and promote sensitivity to PARP-inhibition	Arianna	Calcinotto	Poster	Tumor-Stromal Cell (Including Immune Cell) Interactions and Therapy Responses	4/19/23	9:00 AM	Section 7	17

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
5957	Chemotherapy-induced extracellular matrix remodeling in HGSOC	Panoraia	Kotantaki	Poster	Tumor-Stromal Cell (Including Immune Cell) Interactions and Therapy Responses	4/19/23	9:00 AM	Section 7	18
5958	Analysis of MDSCs as a diagnostic and therapeutic target for gastric cancer	Suguru	Yamauchi	Poster	Tumor-Stromal Cell (Including Immune Cell) Interactions and Therapy Responses	4/19/23	9:00 AM	Section 7	19
5959	Dissecting the stromal drivers of gastroesophageal adenocarcinoma chemoresistance	Kulsum	Tai	Poster	Tumor-Stromal Cell (Including Immune Cell) Interactions and Therapy Responses	4/19/23	9:00 AM	Section 7	20
5960	Identification and validation of sarcoma cellular ecosystems associated with prognosis and predictive of immunotherapy response	Everett	Moding	Poster	Tumor-Stromal Cell (Including Immune Cell) Interactions and Therapy Responses	4/19/23	9:00 AM	Section 7	21
5961	Inhibition of AURKA destabilizes glioblastoma primary cilia and sensitizes cells to tumor treating fields (TTFields) in vitro and ex vivo	Matthew	Sarkisian	Poster	Tumor-Stromal Cell (Including Immune Cell) Interactions and Therapy Responses	4/19/23	9:00 AM	Section 7	22
5962	NUC-7738 causes reduction of soluble and exosome-associated PD-L1 in melanoma cell lines and patients	Mustafa	Elshani	Poster	Tumor-Stromal Cell (Including Immune Cell) Interactions and Therapy Responses	4/19/23	9:00 AM	Section 7	23
5963	Germline variant positive melanoma patients exhibit an enhanced inflammatory microenvironment	Alan	Shen	Poster	Tumor-Stromal Cell (Including Immune Cell) Interactions and Therapy Responses	4/19/23	9:00 AM	Section 7	24
5964	Context-dependent induction of interferon signaling by CD11b agonists supports anti-tumor immunity in mouse models and human cancer patients	Xiuting	Liu	Poster	Tumor-Stromal Cell (Including Immune Cell) Interactions and Therapy Responses	4/19/23	9:00 AM	Section 7	25
5965	B2M loss of heterozygosity in melanoma is associated with increased numbers of activated NK cells and higher expression of the NK cell inhibitory ligand, HLA-G	Mildred	Galvez	Poster	Tumor-Stromal Cell (Including Immune Cell) Interactions and Therapy Responses	4/19/23	9:00 AM	Section 7	26
5966	Cathepsin S mediates interleukin 7 to sculpture the tumor immunity in head and neck cancer	Yung-Chieh	Chang	Poster	Tumor-Stromal Cell (Including Immune Cell) Interactions and Therapy Responses	4/19/23	9:00 AM	Section 7	27
5967	Advanced patient-derived lung tumoroids to identify limiting factors for oncolytic virotherapy	Le	Hélène	Poster	Tumor-Stromal Cell (Including Immune Cell) Interactions and Therapy Responses	4/19/23	9:00 AM	Section 7	28
5968	Leukemia inhibitory factor regulates macrophage immune response in head and neck squamous cell carcinoma	Yun Hua	Sui	Poster	Tumor-Stromal Cell (Including Immune Cell) Interactions and Therapy Responses	4/19/23	9:00 AM	Section 7	29

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
5972	CDK1 bridges NF-κB and b-catenin signaling in response to H. pylori infection in gastric tumorigenesis	Marwah	Al-Mathkour	Poster	Cyclin-dependent Kinases and Cyclin-dependent Kinase Inhibitors	4/19/23	9:00 AM	Section 9	1
5973	The brain penetrant CDK4/6 Inhibitor, PRT3645, is highly effective in combination with other targeted therapies in preclinical models of NSCLC, CRC, and HER2-positive breast cancer	Yue	Zou	Poster	Cyclin-dependent Kinases and Cyclin-dependent Kinase Inhibitors	4/19/23	9:00 AM	Section 9	2
5974	Synergistic activity of the CDK4/6 antagonist narazaciclib (ON123300) with irreversible BTK inhibition in ibrutinib-resistant mantle cell lymphoma	Nuria	Profitos-Peleja	Poster	Cyclin-dependent Kinases and Cyclin-dependent Kinase Inhibitors	4/19/23	9:00 AM	Section 9	3
5975	Discovery of mechanisms that modulate the hippo pathway and CDK6 expression in CDK4/6 inhibitor resistant breast cancer cells	Jiun-l	Lai	Poster	Cyclin-dependent Kinases and Cyclin-dependent Kinase Inhibitors	4/19/23	9:00 AM	Section 9	4
5977	Evaluation of the potential combination regimens for q901, a clinical stage selective cdk7 inhibitor, as a DNA damage repair inhibitor	Donghoon	Yu	Poster	Cyclin-dependent Kinases and Cyclin-dependent Kinase Inhibitors	4/19/23	9:00 AM	Section 9	6
5978	Cyclin dependent kinase 9 inhibitor AZD4573 induces cell death through DNA damage accumulation in breast cancer cells in vitro	Minyoung	Lee	Poster	Cyclin-dependent Kinases and Cyclin-dependent Kinase Inhibitors	4/19/23	9:00 AM	Section 9	7
5979	TY-0540, a highly potent CDK2/4/6 inhibitor, attenuates acquired resistance against CDK4/6 inhibition	Meihua	Li	Poster	Cyclin-dependent Kinases and Cyclin-dependent Kinase Inhibitors	4/19/23	9:00 AM	Section 9	8
5980	Identification of CDK15 activating cyclins by a recombinant co-expression approach	Daniel	Mueller	Poster	Cyclin-dependent Kinases and Cyclin-dependent Kinase Inhibitors	4/19/23	9:00 AM	Section 9	9
5981	TY-2699a is a highly potent CDK7 inhibitor to abolish dysfunctional tumor cell cycle for clinical development	Shengli	Dong	Poster	Cyclin-dependent Kinases and Cyclin-dependent Kinase Inhibitors	4/19/23	9:00 AM	Section 9	10
5982	A potent and selective CDK8 inhibitor ABM-3249 with excellent efficacies in multiple in vivo cancer models	Chen	Chen	Poster	Cyclin-dependent Kinases and Cyclin-dependent Kinase Inhibitors	4/19/23	9:00 AM	Section 9	11
5983	The secretome produced by senescent gastric cancer cells can lead to different paracrine effects depending on the status of autophagy	Claudio A.	Valenzuela	Poster	Cyclin-dependent Kinases and Cyclin-dependent Kinase Inhibitors	4/19/23	9:00 AM	Section 9	12
5984	CDK9 inhibition as a potential therapeutic strategy in Ewing sarcoma	Yuta	Matsumura	Poster	Cyclin-dependent Kinases and Cyclin-dependent Kinase Inhibitors	4/19/23	9:00 AM	Section 9	13
5985	Cyclin dependent kinase 9 (CDK9) inhibition increased efficacy of programmed cell death protein 1 (PD-1) blockade for hepatocellular carcinoma (HCC) through decreasing programmed death-ligand 1 (PD-L1) expression	Ching-Tso	Chen	Poster	Cyclin-dependent Kinases and Cyclin-dependent Kinase Inhibitors	4/19/23	9:00 AM	Section 9	14
5987	Differential targets engaged by narazaciclib in comparison to the approved CDK4/6 inhibitors contribute to enhanced inhibition of tumor cell growth	Petros	Kechagioglou	Poster	Cyclin-dependent Kinases and Cyclin-dependent Kinase Inhibitors	4/19/23	9:00 AM	Section 9	16
5988	A non-canonical CDK9 complex mediates endocycling in polyan euploid cancer cell (PACC) state	Cheng-fan	Lee	Poster	Cyclin-dependent Kinases and Cyclin-dependent Kinase Inhibitors	4/19/23	9:00 AM	Section 9	17

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
5989	Targeting RRM2 & cell cycle for breast cancer treatment	Nahid	Sultana	Poster	Cyclin-dependent Kinases and Cyclin-dependent Kinase Inhibitors	4/19/23	9:00 AM	Section 9	18
5990	Druggable CRISPR/Cas9 screen identifies Cyclin E1 (CCNE1) as a key mediator of sensitivity to CDK4/6 inhibition in non-small cell lung cancer (NSCLC)	Matthew	Bott	Poster	Cyclin-dependent Kinases and Cyclin-dependent Kinase Inhibitors	4/19/23	9:00 AM	Section 9	19
5991	Development and characterization of a novel CDK4/6 inhibitor for the treatment of CDK4/6 dependent cancers	Neil	O'Brien	Poster	Cyclin-dependent Kinases and Cyclin-dependent Kinase Inhibitors	4/19/23	9:00 AM	Section 9	20
5992	Cells rapidly adapt to CDK2 inhibitors via plasticity of the CDK2/4/6-Rb-E2F axis	Lotte	Watts	Poster	Cyclin-dependent Kinases and Cyclin-dependent Kinase Inhibitors	4/19/23	9:00 AM	Section 9	21
5993	Dissecting the role of CDK4 in liposarcoma	Silvia	Vanni	Poster	Cyclin-dependent Kinases and Cyclin-dependent Kinase Inhibitors	4/19/23	9:00 AM	Section 9	22
5994	INX-315, a potent and selective CDK2 inhibitor, demonstrates robust antitumor activity in CCNE1-amplified cancers	Alec	Trub	Poster	Cyclin-dependent Kinases and Cyclin-dependent Kinase Inhibitors	4/19/23	9:00 AM	Section 9	23
5999	Comparative and integrative analysis of transcriptomic and epigenome wide DNA methylation changes in African American prostate cancer	Bernard	Kwabi-Addo	Poster	DNA Methylation Changes in Cancer	4/19/23	9:00 AM	Section 10	2
6000	Distinct HOX gene family DNA methylation profiles in histologically normal skin dependent on dermoscopic pattern of adjacent nevi	Mitchell	Stark	Poster	DNA Methylation Changes in Cancer	4/19/23	9:00 AM	Section 10	3
6001	Epigenetic regulation of BARD1 confers resistance to anti-VEGF therapy in ovarian cancer	Emine	Bayraktar	Poster	DNA Methylation Changes in Cancer	4/19/23	9:00 AM	Section 10	4
6002	Characterizing dynamic landscape of DNA methylation in ovarian high-grade serous carcinoma	Alexandra	Lahtinen	Poster	DNA Methylation Changes in Cancer	4/19/23	9:00 AM	Section 10	5
6003	Study of secondary epimutations in cis of the promoter in germline tumor suppressor genes as a cause of hereditary breast and ovarian cancer	Miguel	Ruiz De La Cruz	Poster	DNA Methylation Changes in Cancer	4/19/23	9:00 AM	Section 10	6
6004	DNA methylation diagnostics for upper urinary tract urothelial carcinoma using newly developed high-performance liquid chromatography	Mao	Fujimoto	Poster	DNA Methylation Changes in Cancer	4/19/23	9:00 AM	Section 10	7
6005	Promoter methylation occurs at high frequencies regardless of mutation status of tumor-associated genes in oral malignancies	Masanobu	Abe	Poster	DNA Methylation Changes in Cancer	4/19/23	9:00 AM	Section 10	8
6006	RNA m6A methylation relay the oncogenic flow from DNA methylation to gene expression of ANKRD13B	Huichuan	Yu	Poster	DNA Methylation Changes in Cancer	4/19/23	9:00 AM	Section 10	9
6007	p16 epimutation modulates the tumor microenvironment and promotes malignancy of Apc-mutant colon cancer	Li	Yang	Poster	DNA Methylation Changes in Cancer	4/19/23	9:00 AM	Section 10	10
6008	Antibody validation for clinical pharmacodynamic assay reveals cross-reactivity of commercial DNMT3B clones	Gabriel	Benton	Poster	DNA Methylation Changes in Cancer	4/19/23	9:00 AM	Section 10	11

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
6009	An end-to-end workflow for improved methylation detection	Lydia	Bonar	Poster	DNA Methylation Changes in Cancer	4/19/23	9:00 AM	Section 10	12
6010	Targeting p16 epimutation during lung cancer progression for anticancer therapy	Xiaomin	Chen	Poster	DNA Methylation Changes in Cancer	4/19/23	9:00 AM	Section 10	13
6011	Methylation profiling reveals the role of PRC2 in regulating DNA methylome changes in malignant peripheral nerve sheath tumors	Christopher	Stehn	Poster	DNA Methylation Changes in Cancer	4/19/23	9:00 AM	Section 10	14
6012	Comparison of pre-analytical methods for DNA methylation analysis of cfDNA	Miljana	Tanic	Poster	DNA Methylation Changes in Cancer	4/19/23	9:00 AM	Section 10	15
6013	DNA methylation-based inflammation score is associated with hepatocellular carcinoma among people living with HIV	Kyeezu	Kim	Poster	DNA Methylation Changes in Cancer	4/19/23	9:00 AM	Section 10	16
6014	Cancer risk diagnosis by epimutation burden: a multicenter prospective study	Harumi	Yamada	Poster	DNA Methylation Changes in Cancer	4/19/23	9:00 AM	Section 10	17
6015	Methylation synthetic lethality: CHFR methylation and KRAS inhibition in gastric cancers	Hideyuki	Takeshima	Poster	DNA Methylation Changes in Cancer	4/19/23	9:00 AM	Section 10	18
6016	A comprehensive analysis of gut microbiome mediated epigenetic regulation of intestinal stem cells	Robert	Peery	Poster	DNA Methylation Changes in Cancer	4/19/23	9:00 AM	Section 10	19
6017	Exposure-related DNA methylation and gene expression changes in mammary glands of Sprague Dawley rats treated with lorcaserin	Volodymyr	Tryndyak	Poster	DNA Methylation Changes in Cancer	4/19/23	9:00 AM	Section 10	20
6018	Sequencing of 5-hydroxymethylcytosine to single base resolution	Louise	Williams	Poster	DNA Methylation Changes in Cancer	4/19/23	9:00 AM	Section 10	21
6019	Characteristics and impact of DNA methylation on prognosis in hepatitis B virus-related follicular lymphoma	Qingyuan	Zhang	Poster	DNA Methylation Changes in Cancer	4/19/23	9:00 AM	Section 10	22
6021	Genetic and epigenetic features OF KMT2D, CREBBP, ATM, TSC2 and GNAS in uterine leiomyosarcomas	Katia	Carvalho	Poster	DNA Methylation Changes in Cancer	4/19/23	9:00 AM	Section 10	24
6022	The importance of DNA methylation to breast cancer cell phenotype and its role in the anticancer activity of withaferin-A	Andrew	Brane	Poster	DNA Methylation Changes in Cancer	4/19/23	9:00 AM	Section 10	25
6023	Plasma methylome landscape across the spectrum of prostate cancer progression, and differentially methylated region (DMR) based biomarkers of hormonal therapy failure in metastatic hormone-sensitive prostate cancer	Manish	Kohli	Poster	DNA Methylation Changes in Cancer	4/19/23	9:00 AM	Section 10	26
6024	Precancerous nature of intestinal metaplasia with accelerated DNA methylation along with altered epigenomic landscape	Chihiro	Takeuchi	Poster	DNA Methylation Changes in Cancer	4/19/23	9:00 AM	Section 10	27
6028	Cancer-selective metabolic vulnerabilities in MYC-amplified medulloblastoma	William	Gwynne	Poster	Metabolism and Metabolomics of Cancer	4/19/23	9:00 AM	Section 11	1
6029	Multi-omic landscape of squamous cell lung cancer	Paul	Stewart	Poster	Metabolism and Metabolomics of Cancer	4/19/23	9:00 AM	Section 11	2

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
6031	KYNU upregulation is a prominent feature of NRF2-activated cancers and is associated with tumor immunosuppression and poor prognosis	Ricardo	Leon Letelier	Poster	Metabolism and Metabolomics of Cancer	4/19/23	9:00 AM	Section 11	4
6032	Exploiting metabolic vulnerabilities of ovarian cancer with upregulated succinate dehydrogenase	Magdalena	Bieniasz	Poster	Metabolism and Metabolomics of Cancer	4/19/23	9:00 AM	Section 11	5
6033	RA123, a new GLS1 allosteric inhibitor demonstrates in vitro and in vivo activity in multiple myeloma models	Christophe	Henry	Poster	Metabolism and Metabolomics of Cancer	4/19/23	9:00 AM	Section 11	6
6034	Detection of potassium channel (KCN) gene expression, often multiple and pH sensitive, in cancer genomic landscapes, as low to mid level genes of interest, suggests potassium transmembrane flow may enable proton efflux in a Goldilocks manner	Marie	Beckner	Poster	Metabolism and Metabolomics of Cancer	4/19/23	9:00 AM	Section 11	7
6035	Glutaminase inhibitors block metabolic switch in prostate cancer and prevents anti-androgen treatment resistance	Hirak	Basu	Poster	Metabolism and Metabolomics of Cancer	4/19/23	9:00 AM	Section 11	8
6036	Functional antibodies against multi span transmembrane proteins - revisiting the Warburg effect in cancer cells	Siret	Tahk	Poster	Metabolism and Metabolomics of Cancer	4/19/23	9:00 AM	Section 11	9
6037	Identification of collateral lethal targets in cancers using integrated machine learning and flux analysis platform for personalized metabolic therapy	Abhinav	Achreja	Poster	Metabolism and Metabolomics of Cancer	4/19/23	9:00 AM	Section 11	10
6038	KDM2B regulates Serine-Glycine-One Carbon (SGOC) metabolism by targeting the SGOC enzyme genes via a combination of direct and indirect epigenetic mechanisms	Evangelia	Chavdoula	Poster	Metabolism and Metabolomics of Cancer	4/19/23	9:00 AM	Section 11	11
6039	ELOVL5 affects prostate cancer cell proliferation and modulates the AR pathway	Silvia	Rodrigues	Poster	Metabolism and Metabolomics of Cancer	4/19/23	9:00 AM	Section 11	12
6040	The CHST11-CP-iron axis contributes to NSCLC stemness	Li-Jie	Li	Poster	Metabolism and Metabolomics of Cancer	4/19/23	9:00 AM	Section 11	13
6041	Investigating metabolic dependencies of group 3 medulloblastoma	Derek	Dang	Poster	Metabolism and Metabolomics of Cancer	4/19/23	9:00 AM	Section 11	14
6042	Targeting metabolic vulnerabilities in MET-driven lung cancer brain metastases	Kasey	Cargill	Poster	Metabolism and Metabolomics of Cancer	4/19/23	9:00 AM	Section 11	15
6043	Manipulation of mitochondrial metabolism, through SIRT3 agonists, in a novel immunoreactive melanoma organoids model	Azza	El-derby	Poster	Metabolism and Metabolomics of Cancer	4/19/23	9:00 AM	Section 11	16
6044	Identification and molecular characterization of cancer cells survived under glucose starvation	Elimelech	Nesher	Poster	Metabolism and Metabolomics of Cancer	4/19/23	9:00 AM	Section 11	17
6045	Role of PP2A methylation on methionine dependence of cancer	Anna	Andronicos	Poster	Metabolism and Metabolomics of Cancer	4/19/23	9:00 AM	Section 11	18
6046	Enhanced Acod1 expression in cancer cells promotes immune evasion	James	Schofield	Poster	Metabolism and Metabolomics of Cancer	4/19/23	9:00 AM	Section 11	19

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
6047	ZFTA-RELA fusion aberrantly drives glutamine metabolism in lethal pediatric ependymomas	Siva Kumar	Natarajan	Poster	Metabolism and Metabolomics of Cancer	4/19/23	9:00 AM	Section 11	20
6048	OGT/CDK5/ACSS2 axis regulates breast cancer brain metastatic growth	Emily	Esquea	Poster	Metabolism and Metabolomics of Cancer	4/19/23	9:00 AM	Section 11	21
6049	Exogenous serine promotes cancer stem cells in oral squamous cell carcinoma	Stacy	Jankowski	Poster	Metabolism and Metabolomics of Cancer	4/19/23	9:00 AM	Section 11	22
6050	Analysis of diverse metabolic pathways using bioluminescent cell-based assays	Donna	Leippe	Poster	Metabolism and Metabolomics of Cancer	4/19/23	9:00 AM	Section 11	23
6051	Dissecting unique metabolic vulnerabilities in triple-negative breast cancer metastasis	Divya	Ramchandani	Poster	Metabolism and Metabolomics of Cancer	4/19/23	9:00 AM	Section 11	24
6052	Metabolic consequences of casein kinase 2 α inhibition in lymphoid leukemia	Diwakar	Bastihalli Tukaramrao	Poster	Metabolism and Metabolomics of Cancer	4/19/23	9:00 AM	Section 11	25
6053	Sulfation is required for prostate cancer xenograft tumor formation but is dispensable for cell viability in vitro	Ko-Chien	Chen	Poster	Metabolism and Metabolomics of Cancer	4/19/23	9:00 AM	Section 11	26
6054	Weight specific effects of hyaluronic acid on glioblastoma's energy metabolism and bio-molecular content	Ashwin	Bale	Poster	Metabolism and Metabolomics of Cancer	4/19/23	9:00 AM	Section 11	27
6055	Polyaneuploid cancer cells are metabolically active and utilize lipid droplets to survive toxic stress	Laurie	Kostecka	Poster	Metabolism and Metabolomics of Cancer	4/19/23	9:00 AM	Section 11	28
6056	A nested case-control study of untargeted plasma metabolomics and lung cancer risk among never-smoking women in the prospective Shanghai Women's Health Study	Mohammad	Rahman	Poster	Metabolism and Metabolomics of Cancer	4/19/23	9:00 AM	Section 11	29
6057	Association of liver cancer and chronic liver disease with urinary glyphosate and its metabolites in Thailand	Daxesh	Patel	Poster	Metabolism and Metabolomics of Cancer	4/19/23	9:00 AM	Section 11	30
6062	Viral genome structure correlates with patterns of somatic alteration in human papillomavirus associated head and neck squamous cell carcinoma	Jeremiah	Holt	Poster	Multi-omics Tumor Profiling	4/19/23	9:00 AM	Section 12	2
6063	Genomic characterization of non-small cell lung cancer (NSCLC) brain metastasis (BM) patients identifies novel alterations associated with tropisms and disease progression	Henry	Walch	Poster	Multi-omics Tumor Profiling	4/19/23	9:00 AM	Section 12	3
6064	Patient-partnered research enables germline characterization of angiosarcoma predisposition genes	Hoyin	Chu	Poster	Multi-omics Tumor Profiling	4/19/23	9:00 AM	Section 12	4
6065	Patterns of dysregulated coding and noncoding gene expression in high-grade serous ovarian carcinomas	Brett	Reid	Poster	Multi-omics Tumor Profiling	4/19/23	9:00 AM	Section 12	5
6066	Genomic analysis of end-stage renal disease	Kosuke	Ieiri	Poster	Multi-omics Tumor Profiling	4/19/23	9:00 AM	Section 12	6
6067	Characterizing the landscape of rare structural variant events in newly diagnosed multiple myeloma	Monika	Chojnacka	Poster	Multi-omics Tumor Profiling	4/19/23	9:00 AM	Section 12	7

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
6068	Methylomic, transcriptomic and immune profiles of high grade serous ovarian cancer among Black and non-Hispanic White women	Hao	Huang	Poster	Multi-omics Tumor Profiling	4/19/23	9:00 AM	Section 12	8
6069	Genomic and transcriptomic characterization of medullary thyroid cancer	Seong Eun	Lee	Poster	Multi-omics Tumor Profiling	4/19/23	9:00 AM	Section 12	9
6070	Comprehensive real-world-data based molecular profiling and mapping of non-squamous NSCLC patients to immune-checkpoint-inhibitor biomarkers	Andreas	Kloetgen	Poster	Multi-omics Tumor Profiling	4/19/23	9:00 AM	Section 12	10
6071	Whole-exome RNA sequencing of metastatic synovial sarcomas reveals heterogeneous transcriptomic profile and targetable co-alterations: Cohort study from the French Sarcoma Group	Helene	Vanacker	Poster	Multi-omics Tumor Profiling	4/19/23	9:00 AM	Section 12	11
6072	Chromosomal aneuploidy, whole-genome doubling and mutational signatures in NCI PDMR models	Li	Chen	Poster	Multi-omics Tumor Profiling	4/19/23	9:00 AM	Section 12	12
6073	Distinct subtype of multiple myeloma revealed by whole genome and transcriptome sequencing	Sheehyun	Kim	Poster	Multi-omics Tumor Profiling	4/19/23	9:00 AM	Section 12	13
6074	Germline and somatic genomic profiling of urothelial carcinoma	Bing-Jian	Feng	Poster	Multi-omics Tumor Profiling	4/19/23	9:00 AM	Section 12	14
6075	Comprehensive genomic characterization of early-stage bladder cancer from 438 patients by whole genome- and exome sequencing	Frederik	Prip	Poster	Multi-omics Tumor Profiling	4/19/23	9:00 AM	Section 12	15
6076	Compartment-specific multiomic characterisation of ovarian carcinosarcoma	Robert	Hollis	Poster	Multi-omics Tumor Profiling	4/19/23	9:00 AM	Section 12	16
6077	Comprehensive multi-omic characterization of genetic changes associated with sinonasal squamous cell carcinoma progression	Alka	Singh	Poster	Multi-omics Tumor Profiling	4/19/23	9:00 AM	Section 12	17
6079	Comprehensive characterization of FBXW7 mutational and clinicopathological profiles in human colorectal cancers	Haimeng	Tang	Poster	Multi-omics Tumor Profiling	4/19/23	9:00 AM	Section 12	19
6080	Comprehensive profiling of pathogenic/likely pathogenic large genomic rearrangements in pan cancer samples	Haimeng	Tang	Poster	Multi-omics Tumor Profiling	4/19/23	9:00 AM	Section 12	20
6081	Integrative genomic analysis of primary prostate tumors and corresponding lymph node metastases	Carlos	Moreno	Poster	Multi-omics Tumor Profiling	4/19/23	9:00 AM	Section 12	21
6082	Assessing difference in the tumor and immune microenvironment of BRCA1/2 mutated versus BRCA wild type high grade serous ovarian cancers	Jing	Qian	Poster	Multi-omics Tumor Profiling	4/19/23	9:00 AM	Section 12	22
6083	Extensive epigenetic and transcriptomic donor-specific differences observed in iPSC derived allogenic NK (iNK) cells	Rohith	Srivas	Poster	Multi-omics Tumor Profiling	4/19/23	9:00 AM	Section 12	23
6084	The Osteosarcoma and Leiomyosarcoma Count Me In Projects of the Cancer Moonshot funded PE-CGS Network directly engage patient participants in genomics research	Katherine	Janeway	Poster	Multi-omics Tumor Profiling	4/19/23	9:00 AM	Section 12	24

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
6085	Molecular profile by next generation sequencing in papillary thyroid carcinoma, Colombian Cohort at Fundacion Santa fe de Bogota University Hospital	Sebastián	González	Poster	Multi-omics Tumor Profiling	4/19/23	9:00 AM	Section 12	25
6086	PALB2 germline mutations in a large cohort Middle Eastern breast-ovarian cancer patients	Rong	Bu	Poster	Multi-omics Tumor Profiling	4/19/23	9:00 AM	Section 12	26
6087	Mutation and co-mutation landscape of ERBB2 alterations in advanced NSCLC	Lingzhi	Hong	Poster	Multi-omics Tumor Profiling	4/19/23	9:00 AM	Section 12	27
6088	Charting new cancer dependencies with patient derived organoids	James	Neiswender	Poster	Multi-omics Tumor Profiling	4/19/23	9:00 AM	Section 12	28
6089	Identification of novel YAP/TAZ pathway regulators in the triple-negative breast cancer cell line MDA-MB231 using single-cell CRISPR screening	Jan	Naujoks	Poster	Multi-omics Tumor Profiling	4/19/23	9:00 AM	Section 12	29
6093	IDE161, a potential first-in-class clinical candidate PARG inhibitor, selectively targets homologous-recombination-deficient and PARP inhibitor resistant breast and ovarian tumors	Mike	White	Poster	Targeting DNA Damage Response and Novel Pathways	4/19/23	9:00 AM	Section 13	1
6094	Longitudinal analysis of PARP inhibitor and platinum resistance in BRCA1/2m breast cancer using liquid biopsy	Stephen	Pettitt	Poster	Targeting DNA Damage Response and Novel Pathways	4/19/23	9:00 AM	Section 13	2
6095	A DNA damaging agent affects BRCA2 exon 3-skipping	Jordan	Werner	Poster	Targeting DNA Damage Response and Novel Pathways	4/19/23	9:00 AM	Section 13	3
6096	BRCA1-BARD1 ubiquitylates histones for genome maintenance	Wenjing	Li	Poster	Targeting DNA Damage Response and Novel Pathways	4/19/23	9:00 AM	Section 13	4
6097	Determination of BRCA2 deletion status by copy number estimation using next generation sequencing to predict prognosis of clinically localized prostate cancer	Makoto	Sumitomo	Poster	Targeting DNA Damage Response and Novel Pathways	4/19/23	9:00 AM	Section 13	5
6098	Genome wide CRISPR screen reveals genetic vulnerabilities of next generation PARP1 inhibitor AZD5305	Ling	Yin	Poster	Targeting DNA Damage Response and Novel Pathways	4/19/23	9:00 AM	Section 13	6
6100	The Fanconi Anemia pathway protein complex FANCI/FANCD2 couples the DNA damage response to R-loop regulation through SRSF1-mediated mRNA export	Anne	Olazabal-Herrero	Poster	Targeting DNA Damage Response and Novel Pathways	4/19/23	9:00 AM	Section 13	8
6101	PUM3 is a novel R-loop regulator and is essential for efficient DNA damage repair	Wayne	Miles	Poster	Targeting DNA Damage Response and Novel Pathways	4/19/23	9:00 AM	Section 13	9
6102	Targeting BARD1 slows PDAC growth in vitro and in vivo and sensitizes cells to DNA damaging agents	Sohum	Patel	Poster	Targeting DNA Damage Response and Novel Pathways	4/19/23	9:00 AM	Section 13	10
6103	Genomic instability delays cell death in PDAC after simultaneous double strand breaks	Selina Shiqing	Teh	Poster	Targeting DNA Damage Response and Novel Pathways	4/19/23	9:00 AM	Section 13	11
6104	Prognostic and therapeutic impact of a homologous recombination repair protein TONSL in cancer stem cells	Sukjoon	Yoon	Poster	Targeting DNA Damage Response and Novel Pathways	4/19/23	9:00 AM	Section 13	12

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
6105	Unravelling the mechanistic basis of chromoplexy, a mutational process driving early cancer genome evolution	Nataliia	Serbyn	Poster	Targeting DNA Damage Response and Novel Pathways	4/19/23	9:00 AM	Section 13	13
6106	Epigenetic-miRNA regulatory circuit confers ovarian cancer chemoresistance through RAD18-mediated DNA damage tolerance and repair signaling	Tasmin Rahman	Omy	Poster	Targeting DNA Damage Response and Novel Pathways	4/19/23	9:00 AM	Section 13	14
6107	Novel roles for AMBRA1 in regulating DNA double-strand breaks	Tarek	Abbas	Poster	Targeting DNA Damage Response and Novel Pathways	4/19/23	9:00 AM	Section 13	15
6108	Novel functional dSTRIDE-HR assays to report on the status of homologous recombination repair in cancer cells	Kamil	Solarczyk	Poster	Targeting DNA Damage Response and Novel Pathways	4/19/23	9:00 AM	Section 13	16
6109	Multi-site evaluation of novel BRCA1/2 reference materials including large genomic rearrangements	Dana	Ruminski Lowe	Poster	Targeting DNA Damage Response and Novel Pathways	4/19/23	9:00 AM	Section 13	17
6110	Multi-site evaluation of FFPE homologous recombination deficiency reference materials	Dana	Ruminski Lowe	Poster	Targeting DNA Damage Response and Novel Pathways	4/19/23	9:00 AM	Section 13	18
6111	Design of a small molecule screening assay to detect DNA trapping of PARP1/2	Veronique	Baron	Poster	Targeting DNA Damage Response and Novel Pathways	4/19/23	9:00 AM	Section 13	19
6112	Automated scoring to assess RAD51-mediated homologous recombination in patient-derived tumor organoids of ovarian cancers	Lucie	Thorel	Poster	Targeting DNA Damage Response and Novel Pathways	4/19/23	9:00 AM	Section 13	20
6113	Predictive value of HRD testing on the response to PARP inhibitors in ovarian cancer preclinical models	Giulia	Dellavedova	Poster	Targeting DNA Damage Response and Novel Pathways	4/19/23	9:00 AM	Section 13	21
6114	Race-associated base excision repair defects alter the DNA damage landscape in prostate cancer	Kimiko	Krieger	Poster	Targeting DNA Damage Response and Novel Pathways	4/19/23	9:00 AM	Section 13	22
6115	Comprehensive DNA repair landscape analysis reveals novel small cell lung cancer biology	Benjamin	Morris	Poster	Targeting DNA Damage Response and Novel Pathways	4/19/23	9:00 AM	Section 13	23
6116	Ablation of mitotic checkpoint kinase BUB1 sensitizes lung adenocarcinoma to different classes of chemotherapy, radiation, and chemo-radiation	Shivani	Thoidingjam	Poster	Targeting DNA Damage Response and Novel Pathways	4/19/23	9:00 AM	Section 13	24
6117	Dose, dose rate, and linear energy transfer influence tumor immunologic and DNA damage response following alpha- and beta-emitting radionuclides	Julia	Sheehan-Klenk	Poster	Targeting DNA Damage Response and Novel Pathways	4/19/23	9:00 AM	Section 13	25
6121	UCP2 inhibitor eradicates cancer stem-like population in trastuzumab-resistant HER2-positive breast cancer	Minsu	Park	Poster	Apoptosis and Growth Factor Receptors as Therapeutic Targets	4/19/23	9:00 AM	Section 15	1
6122	Targeting mutant p53 and KRAS for novel pancreatic cancer therapy by combination treatment of simvastatin and imipridones	Xiaobing	Tian	Poster	Apoptosis and Growth Factor Receptors as Therapeutic Targets	4/19/23	9:00 AM	Section 15	2
6123	Characterization of the synergistic tumor cytotoxicity of agonistic DR5 IgM antibody IGM-8444 with chemotherapeutic agents	Beatrice	Wang	Poster	Apoptosis and Growth Factor Receptors as Therapeutic Targets	4/19/23	9:00 AM	Section 15	3

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
6124	Recombinant apurinic/aprimidinic endonuclease-1/redox factor-1 plus acetylsalicylic acid combination therapy inhibits tumorigenesis in an orthotopic xenograft murine model of triple-negative breast cancer	Yu Ran	Lee	Poster	Apoptosis and Growth Factor Receptors as Therapeutic Targets	4/19/23	9:00 AM	Section 15	4
6125	Induction and modulation of apoptosis in pancreatic ductal carcinoma PANC-1 cells by Chinese medicinal herbs Scutellaria barbata and Oldenlandia diffusa	MinSeo	Kang	Poster	Apoptosis and Growth Factor Receptors as Therapeutic Targets	4/19/23	9:00 AM	Section 15	5
6126	Antitumor effect of Iso-mukaadial acetate in MCF-7 human cancer xenograft models	Portia	Raphela-Choma	Poster	Apoptosis and Growth Factor Receptors as Therapeutic Targets	4/19/23	9:00 AM	Section 15	6
6127	MDM2 inhibition in combination with MEK inhibition in pre-clinical models of lung adenocarcinomas with MDM2 amplification	Arielle	Elkrief	Poster	Apoptosis and Growth Factor Receptors as Therapeutic Targets	4/19/23	9:00 AM	Section 15	7
6128	Deubiquitinating enzyme Inhibitor PR-619 induces endoplasmic reticulum stress-related apoptosis in human chondrosarcoma	Kuan-Lin	Kuo	Poster	Apoptosis and Growth Factor Receptors as Therapeutic Targets	4/19/23	9:00 AM	Section 15	8
6129	The proapoptotic peptide PEP-010 is efficient on several models of different tumor origins and it can be monitored by pharmacodynamic biomarker candidates in clinical practice	Diego	Germini	Poster	Apoptosis and Growth Factor Receptors as Therapeutic Targets	4/19/23	9:00 AM	Section 15	9
6130	Cancer sensitivity to therapy is constrained by apoptosis regulation in cells of origin	Kristopher	Sarosiek	Poster	Apoptosis and Growth Factor Receptors as Therapeutic Targets	4/19/23	9:00 AM	Section 15	10
6131	Extracellular vesicles containing p53 of xenogeneic origin as a therapeutic strategy	Alex	Tendler	Poster	Apoptosis and Growth Factor Receptors as Therapeutic Targets	4/19/23	9:00 AM	Section 15	11
6132	Impact of treatment with agents targeting different members of HER family, CDKs and downstream cell signaling molecules on growth and migration of stomach cancer cells.	Tina	Al-Janaby	Poster	Apoptosis and Growth Factor Receptors as Therapeutic Targets	4/19/23	9:00 AM	Section 15	12
6133	Growth response and migration of brain cancer cell lines to treatment with agents targeting different members of the HER family, CDKs and other signalling pathways	Ermira	Mulliqi	Poster	Apoptosis and Growth Factor Receptors as Therapeutic Targets	4/19/23	9:00 AM	Section 15	13
6134	Exploiting the oncogenic state of colorectal cancer for therapeutic development	Felipe	de Sousa e Melo	Poster	Apoptosis and Growth Factor Receptors as Therapeutic Targets	4/19/23	9:00 AM	Section 15	14
6135	Dynamics of ligand-induced epidermal growth factor receptor internalization in cancer cell lines	Mandy	Smeets	Poster	Apoptosis and Growth Factor Receptors as Therapeutic Targets	4/19/23	9:00 AM	Section 15	15
6139	Clinical implication of EZH2 inhibitors in hepatocellular carcinoma	Bo Hwa	Sohn	Poster	Cell Death Pathways and Treatment / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes	4/19/23	9:00 AM	Section 16	1

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
6140	Caspase-3 mediated cleavage of GSDME enhances the antitumor efficacy of HER2-targeted therapy in HER2-positive gastric cancer	Qiuyun	Luo	Poster	Cell Death Pathways and Treatment / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes	4/19/23	9:00 AM	Section 16	2
6141	Mechanisms by which Mito-Ionidamine inhibits EGFR mutant lung cancer	Katherine	Weh	Poster	Cell Death Pathways and Treatment / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes	4/19/23	9:00 AM	Section 16	3
6142	Inhibition of both MAPK and AKT pathways overcomes resistance of NRAS-mutant melanoma stem cells to apoptosis	Ryvan	Alobaidi	Poster	Cell Death Pathways and Treatment / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes	4/19/23	9:00 AM	Section 16	4
6143	Novel multiplexed assays of ferroptosis, pyroptosis and necroptosis biomarkers for translational studies	William	Herrick	Poster	Cell Death Pathways and Treatment / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes	4/19/23	9:00 AM	Section 16	5
6144	Polyploidization enables initial survival of chemotherapy but a progressively increased susceptibility to ferroptosis	Luke	Loftus	Poster	Cell Death Pathways and Treatment / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes	4/19/23	9:00 AM	Section 16	6
6145	Alternative splicing of GSDMB modulates killer lymphocyte-triggered pyroptosis	Zhibin	Zhang	Poster	Cell Death Pathways and Treatment / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes	4/19/23	9:00 AM	Section 16	7
6146	Tumor suppressor p73 primes extrinsic apoptosis via transcriptional activation of DR5 and c-FLIP	Shengliang	Zhang	Poster	Cell Death Pathways and Treatment / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes	4/19/23	9:00 AM	Section 16	8

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
6147	MCL1 inhibitor PRT1419 demonstrates anti-tumor activity in PBRM1-altered clear cell renal cancer and synergizes with standard of care agents	Norman	Fultang	Poster	Cell Death Pathways and Treatment / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes	4/19/23	9:00 AM	Section 16	9
6148	Disulfide isomerases AGR2, ERp44, and PDIA1 maintain death receptor 5 in an auto-inhibited, monomeric form	Brian	Law	Poster	Cell Death Pathways and Treatment / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes	4/19/23	9:00 AM	Section 16	10
6149	STAT3 activation promotes invasiveness and cancer stemness in lung cancer	Sai Fung	Yeung	Poster	Cell Death Pathways and Treatment / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes	4/19/23	9:00 AM	Section 16	11
6150	AZD0466, a dual BCL-2/XL targeting nanomedicine, is active in small cell lung cancer models	Courtney	Andersen	Poster	Cell Death Pathways and Treatment / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes	4/19/23	9:00 AM	Section 16	12
6151	Loss of GPR54 inhibits tumor growth by suppressing AKT/DDC signaling pathway in KRAS-mutant non-small cell lung cancer	Seo Yeon	Lee	Poster	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 2	4/17/23	9:00 AM	Section 20	30
6152	Exploiting ferroptosis in mutant BAP1 uveal melanoma	Camille	Cunanan	Poster	Cell Death Pathways and Treatment / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes	4/19/23	9:00 AM	Section 16	14
6153	Triple negative breast cancer targeted by Ophiobolin A: Epithelial-mesenchymal transition take the lead	Santhalakshmi	Ranganathan	Poster	Cell Death Pathways and Treatment / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes	4/19/23	9:00 AM	Section 16	15
6154	Imipramine induces apoptosis and inhibits metastasis via suppression of EGFR signaling pathway in bladder cancer	Tsai Lin	Lo	Poster	Cell Death Pathways and Treatment / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes	4/19/23	9:00 AM	Section 16	16

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
6155	Lurbinectedin exhibits combinatorial activity with BCL2/BCL2L1 inhibitors in vitro and in vivo by modulation of MCL1 expression	Kedar	Vaidya	Poster	Cell Death Pathways and Treatment / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes	4/19/23	9:00 AM	Section 16	17
6156	MALT1 protease inhibition overcomes BTK inhibitor resistance and shows synergistic activity with venetoclax in models of B cell lymphoma and leukemia	William	Pappano	Poster	Cell Death Pathways and Treatment / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes	4/19/23	9:00 AM	Section 16	18
6157	USP7 is a promising therapeutic target for neuroblastoma	Christophe	Le Clorennec	Poster	Cell Death Pathways and Treatment / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes	4/19/23	9:00 AM	Section 16	19
6158	BGB-24714, a novel oral IAP antagonist, displayed significant anti-tumor activities in preclinical models as a monotherapy and in combination with paclitaxel	Jie	Li	Poster	Cell Death Pathways and Treatment / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes	4/19/23	9:00 AM	Section 16	20
6160	Targeting RNA N6-methyladenosine methyltransferase, METTL3 activates p53 and apoptosis pathways in osteosarcoma cells	Seungjae	Shin	Poster	Cell Death Pathways and Treatment / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes	4/19/23	9:00 AM	Section 16	22
6161	Targeting endogenous and therapy-induced dependence on BCL-XL in high grade serous ovarian carcinoma	Lissah	Johnson	Poster	Cell Death Pathways and Treatment / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes	4/19/23	9:00 AM	Section 16	23
6162	High resolution detection of HER2 copy number variation in admixed breast cancer cell lines and HER2+ FFPE donor tissue using a digital PCR multigene reference panel	Tyler	Landrith	Poster	Cell Death Pathways and Treatment / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes	4/19/23	9:00 AM	Section 16	24
6163	Fusion landscape in acute leukemias: A submerged world of not routinely characterized transcripts	Anna	Ferrari	Poster	Cell Death Pathways and Treatment / Molecular	4/19/23	9:00 AM	Section 16	25

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
					Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes				
6164	NF-κB and NRF2 signaling pathways affect prognosis in HPV-associated head and neck cancer	Aditi	Kothari	Poster	Cell Death Pathways and Treatment / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes	4/19/23	9:00 AM	Section 16	26
6165	Identification of biomarkers of early onset colorectal cancer from transcriptome and whole genome data	Yejin	Ha	Poster	Cell Death Pathways and Treatment / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes	4/19/23	9:00 AM	Section 16	27
6166	TBL1, a multifunctional transcriptional regulator, is highly expressed in osteosarcoma and correlates with activated beta catenin	Kimberly	Holloway	Poster	Cell Death Pathways and Treatment / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes	4/19/23	9:00 AM	Section 16	28
6167	Targeting TBL1 with tegavivint promotes anti-tumor and immunomodulatory responses in preclinical models of hepatocellular carcinoma	Kimberly	Holloway	Poster	Cell Death Pathways and Treatment / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes	4/19/23	9:00 AM	Section 16	29
6168	Implementation and adoption of a web tool to support precision diagnostic and treatment decisions for patient with myelodysplastic syndromes	Elli	Papaemmanuil	Poster	Cell Death Pathways and Treatment / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes	4/19/23	9:00 AM	Section 16	30
6172	Characterization of a novel series of highly selective PARP1 inhibitors	Alan	Wise	Poster	DNA Damage Response	4/19/23	9:00 AM	Section 17	1
6173	AKT1 prevents aberrant R-loops accumulation via regulating DHX9 and suppresses transcription-replication collision in PARP inhibitor-resistant ovarian cancer	Tzu-Ting	Huang	Poster	DNA Damage Response	4/19/23	9:00 AM	Section 17	2
6174	ATX-101, a peptide drug targeting PCNA, enhances the effect of gemcitabine in liposarcoma and leiomyosarcoma	Elgilda	Musi	Poster	DNA Damage Response	4/19/23	9:00 AM	Section 17	3
6175	CDK8 inhibition potentiates the efficacy of niraparib in homologous recombination proficient cancer cell lines	Karen	Simon-Crevatis	Poster	DNA Damage Response	4/19/23	9:00 AM	Section 17	4

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
6176	Enhancing treatment efficacy of glioblastoma cell lines by adding tumor treating fields (TTFields) to temozolomide and lomustine	Adi	Haber	Poster	DNA Damage Response	4/19/23	9:00 AM	Section 17	5
6177	ATRN-119 and ATRN-W1051: Novel and potentially well tolerated ATR and WEE1 inhibitors for targeted cancer treatment	Oren	Gilad	Poster	DNA Damage Response	4/19/23	9:00 AM	Section 17	6
6178	A novel second-generation nano-fluoropyrimidine to treat metastatic colorectal cancer and overcome 5-fluorouracil resistance	Naresh	Sah	Poster	DNA Damage Response	4/19/23	9:00 AM	Section 17	7
6179	Comparative study of Polθ helicase and polymerase inhibitor biochemical and cellular potency	Johanna	Ahlskog	Poster	DNA Damage Response	4/19/23	9:00 AM	Section 17	8
6180	Antitumor activity of the ATR inhibitor Elimusertib in patient-derived xenograft models with DNA damage response pathway alterations	Kaushik	Varadarajan	Poster	DNA Damage Response	4/19/23	9:00 AM	Section 17	9
6181	Dynamic changes in monocyte and reticulocyte counts predict mechanism-based anemia development and recovery during ATR inhibitor treatment in phase I/II trials	Natalie	Ngoi	Poster	DNA Damage Response	4/19/23	9:00 AM	Section 17	10
6182	Tumor treating fields (TTFields) concomitant with PARP inhibitors or carboplatin for treatment of ovarian cancer cell lines	Eyal	Dor-On	Poster	DNA Damage Response	4/19/23	9:00 AM	Section 17	11
6183	PARP inhibitors preferentially sensitize splicing factor mutant myeloid neoplasms	Dang	Nguyen	Poster	DNA Damage Response	4/19/23	9:00 AM	Section 17	12
6184	Pre-clinical study of SYX3759, a novel PARG inhibitor for the treatment of homologous recombination deficient malignancies	Song	Shi	Poster	DNA Damage Response	4/19/23	9:00 AM	Section 17	13
6185	Debio 0123 is a selective WEE1 inhibitor that effectively penetrates the brain and demonstrates anti-tumor activity in preclinical models of glioblastoma	Luke	Piggott	Poster	DNA Damage Response	4/19/23	9:00 AM	Section 17	14
6186	Patient-derived tumor organoids with p53 mutations, and not wild-type p53, demonstrate synergistic sensitivity to treatment with temozolomide in combination with talazoparib PARP inhibitor	Florencia	Madorsky Rowdo	Poster	DNA Damage Response	4/19/23	9:00 AM	Section 17	15
6187	The combination of Trifluridine/Tipiracil and a WEE1 inhibitor is an effective and tolerable candidate strategy against ESCC	Hoang Trang	Nguyen Vu	Poster	DNA Damage Response	4/19/23	9:00 AM	Section 17	16
6188	Exportin 1 inhibition synergizes with lurbinectedin by altering the response to DNA damage in neuroendocrine lung tumors	Esther	Redin Resano	Poster	DNA Damage Response	4/19/23	9:00 AM	Section 17	17
6189	Targeting DNA damage responsive pathways in cancer therapy	Junjie	Chen	Poster	DNA Damage Response	4/19/23	9:00 AM	Section 17	18
6190	Polymerase theta inhibition activates the cGAS-STING pathway and cooperates with immune checkpoint blockade in BRCA-deficient cancers	Jeffrey	Patterson-Fortin	Poster	DNA Damage Response	4/19/23	9:00 AM	Section 17	19

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
6191	Temozolomide-associated DNA damage processes related to glioblastoma-immune interactions	Elizabeth	Choe	Poster	DNA Damage Response	4/19/23	9:00 AM	Section 17	20
6192	MSI2 regulates DNA damage response signaling and tumor progression in murine NSCLC	Igor	Bychkov	Poster	DNA Damage Response	4/19/23	9:00 AM	Section 17	21
6194	A bifunctional inhibitor of PARP and HDAC enzymes with activity in Ewing sarcoma 3D spheroid and metastasis models	John	Langlands	Poster	DNA Damage Response	4/19/23	9:00 AM	Section 17	23
6195	Assessing replication stress as an actionable therapeutic opportunity in chordoma	Nindo	Punturi	Poster	DNA Damage Response	4/19/23	9:00 AM	Section 17	24
6199	Proteasome inhibitors induce DNA damage and mitotic catastrophe in acute lymphoblastic leukemia via autophagy-mediated degradation of WEE1	Chun-fung	Sin	Poster	DNA Repair / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes / Others	4/19/23	9:00 AM	Section 18	1
6200	PARP1 hyperactivation by the decoy oligodeoxynucleotide OX425 mediates DNA repair abrogation and unleashes the anti-tumor immune response	Vlada	Zakharova	Poster	DNA Repair / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes / Others	4/19/23	9:00 AM	Section 18	2
6201	Identification of SP-002, a highly selective USP1 inhibitor effectively inhibits HRD tumor growth and displays low hematotoxicity risk	Renhong	Tang	Poster	DNA Repair / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes / Others	4/19/23	9:00 AM	Section 18	3
6202	6-Phosphofructo-2-kinase in regulating DNA damage and repair in EGFR-driven lung cancer	Nadiia	Lypova	Poster	DNA Repair / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes / Others	4/19/23	9:00 AM	Section 18	4
6203	CTC1-STN1-TEN1 (CST) complex-independent roles for STN1 in DNA double-strand break repair in pancreatic ductal adenocarcinoma	Changxian	Shen	Poster	DNA Repair / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes / Others	4/19/23	9:00 AM	Section 18	5
6204	DNA-PK inhibition augment the cancer specific cytotoxicity of mitotic MTH1 inhibitor OXC-101	Kumar	Sanjiv	Poster	DNA Repair / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes / Others	4/19/23	9:00 AM	Section 18	6
6205	Visualizing dynamics of long non-coding RNA TUG1 in live glioblastoma cells	Ayaka	Minematsu	Poster	DNA Repair / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes / Others	4/19/23	9:00 AM	Section 18	7

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
6206	Combined inhibition of AXL and ATR enhances replication stress, cell death and immune response in small cell lung cancer	Kavya	Ramkumar	Poster	DNA Repair / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes / Others	4/19/23	9:00 AM	Section 18	8
6208	Targeting DNA polymerase theta and ATM leads to synergistic killing of mantle cell lymphoma cells	Jithma	Abeykoon	Poster	DNA Repair / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes / Others	4/19/23	9:00 AM	Section 18	10
6209	O6-methylguanine as the junction of MGMT and PARP1-mediated repair pathways	Raushan	Kurmasheva	Poster	DNA Repair / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes / Others	4/19/23	9:00 AM	Section 18	11
6210	Combination of M1774 and niraparib can overcome ATR and PARP inhibitor resistance in BRCA1 mutated ovarian cancer models	Jie	Hao	Poster	DNA Repair / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes / Others	4/19/23	9:00 AM	Section 18	12
6211	Development and validation of a novel sSTRIDE-MMR functional assay to study the efficiency of MMR inhibitors	Magdalena	Kordon-Kiszala	Poster	DNA Repair / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes / Others	4/19/23	9:00 AM	Section 18	13
6212	Inhibition of ATM-dependent checkpoint control and DNA double-strand break repair enhances the efficacy of ATR inhibitors	Brian	Elenbaas	Poster	DNA Repair / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes / Others	4/19/23	9:00 AM	Section 18	14
6213	Disruption of XPF function by HPV promotes alternative end joining and sensitivity to cisplatin in HNSCC	Qi	Liu	Poster	DNA Repair / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes / Others	4/19/23	9:00 AM	Section 18	15
6214	FANCA promotes transcription-coupled homologous recombination by catalyzing R-loops formation	Fang	Li	Poster	DNA Repair / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes / Others	4/19/23	9:00 AM	Section 18	16
6215	Peposertib, a DNA-PK inhibitor, enhances the antitumor efficacy of anthracyclines in triple-negative breast cancer models in vitro and in vivo	Joachim	Albers	Poster	DNA Repair / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes / Others	4/19/23	9:00 AM	Section 18	17

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
6216	Pre-ribosomal RNA mediates HR repair via the BRCA1/BARD1 complex	Duo	Wu	Poster	DNA Repair / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes / Others	4/19/23	9:00 AM	Section 18	18
6217	Inhibiting ataxia-telangiectasia mutated and RAD3-related (ATR) by BAY 1895344 overcomes chemoresistance to oxaliplatin and promotes synergistic anti-tumor effect in pancreatic cancer	Hye Won	Shon	Poster	DNA Repair / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes / Others	4/19/23	9:00 AM	Section 18	19
6218	NKX3.1 immunohistochemistry and methylome profiling in mesenchymal chondrosarcoma: additional diagnostic value for a well defined disease?	Baptiste	Ameline	Poster	DNA Repair / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes / Others	4/19/23	9:00 AM	Section 18	20
6219	Endogenous human retroviruses in epithelial ovarian cancers: An exploratory analysis	Jill	Allredge	Poster	DNA Repair / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes / Others	4/19/23	9:00 AM	Section 18	21
6220	Development of a mutation profiling NGS assay to facilitate clinical decisions in hematologic malignancies.	Grant	Hogg	Poster	DNA Repair / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes / Others	4/19/23	9:00 AM	Section 18	22
6221	Support for targeted therapy selection in triple negative breast cancer patients using aberrant signal transduction pathway activity profiles	Diederick	Keizer	Poster	DNA Repair / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes / Others	4/19/23	9:00 AM	Section 18	23
6222	Clinical impact of p53 and AXL immunostaining on the efficacy of immune checkpoint inhibitor-based therapy after osimertinib treatment in patients with epidermal growth factor mutant non-small cell lung cancer	Kenji	Morimoto	Poster	DNA Repair / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes / Others	4/19/23	9:00 AM	Section 18	24
6223	Evaluating peroxiredoxins 1-6 and their potential as prognostic biomarkers for uterine corpus endometrial carcinoma	Calli	Davison-Versagli	Poster	DNA Repair / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes / Others	4/19/23	9:00 AM	Section 18	25
6224	Exploring the integration of CMS subtyping and other omics in colorectal cancer classification and its reflection in stool miRNome and metagenome for non-invasive precision medicine	Amedeo	Gagliardi	Poster	DNA Repair / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes / Others	4/19/23	9:00 AM	Section 18	26

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
6225	SERPINB3 promotes the aggressive basal-like/squamous subtype and correlates with poor prognosis in pancreatic ductal adenocarcinoma through metabolic reprogramming	Yuuki	Ohara	Poster	DNA Repair / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes / Others	4/19/23	9:00 AM	Section 18	27
6226	Therapeutic vulnerability of MTAP-deleted nasopharyngeal carcinoma by MAT2A inhibitors	Kwok Wai	Lo	Poster	DNA Repair / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes / Others	4/19/23	9:00 AM	Section 18	28
6227	Tumor cell heterogeneity may cause treatment failure of GPA33-targeted therapy in colorectal cancer	Teresa	Börding	Poster	DNA Repair / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes / Others	4/19/23	9:00 AM	Section 18	29
6231	Activation of GCN2 by HC-7366 results in significant antitumor efficacy as monotherapy and in combination with multiple standard of care agents in various solid cancer models	Feven	Tameire	Poster	DNA-reactive Agents, HDAC and Methyltransferase Inhibitors, and Tubulin Agents	4/19/23	9:00 AM	Section 19	1
6232	Ulipristal acetate, a selective progesterone receptor modulator, induces cell death via inhibition of STAT3/CCL2 signaling pathway in uterine sarcoma	Jae Ryoung	Hwang	Poster	DNA-reactive Agents, HDAC and Methyltransferase Inhibitors, and Tubulin Agents	4/19/23	9:00 AM	Section 19	2
6233	Omacetaxine reduces c-MYC expression and demonstrates antitumor effects in osteosarcoma	Kristen	Farrell	Poster	DNA-reactive Agents, HDAC and Methyltransferase Inhibitors, and Tubulin Agents	4/19/23	9:00 AM	Section 19	3
6234	Targeting integrin alpha V beta 5 heterodimer stability using a novel small molecular inhibitor for tumor suppression	Nicole	Mattson	Poster	DNA-reactive Agents, HDAC and Methyltransferase Inhibitors, and Tubulin Agents	4/19/23	9:00 AM	Section 19	4
6235	Discovery of novel HDAC6 inhibitors that enhance proteasomal activity to boost antigen presentation and trigger anti-myeloma T-cell immunity	Priyanka	Rana	Poster	DNA-reactive Agents, HDAC and Methyltransferase Inhibitors, and Tubulin Agents	4/19/23	9:00 AM	Section 19	5
6236	Stelletin B induces apoptosis and autophagy in human bladder cancer RT112 cells	Mei-Chuan	Chen	Poster	DNA-reactive Agents, HDAC and Methyltransferase Inhibitors, and Tubulin Agents	4/19/23	9:00 AM	Section 19	6
6237	Small molecule screen identifies pyrimethamine as an inhibitor of NRF2-driven esophageal hyperplasia	chorlada	Paiboonrungruang	Poster	DNA-reactive Agents, HDAC and Methyltransferase Inhibitors, and Tubulin Agents	4/19/23	9:00 AM	Section 19	7
6238	ABM-2752, a potent and selective HPK1 inhibitor with excellent efficacies as a single agent or in combination with a PD-1 antibody	Chen	Chen	Poster	DNA-reactive Agents, HDAC and Methyltransferase Inhibitors, and Tubulin Agents	4/19/23	9:00 AM	Section 19	8

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
6239	PM534 is a novel microtubule-destabilizing agent with high affinity and potent antineoplastic properties	Maria Ángela	Oliva	Poster	DNA-reactive Agents, HDAC and Methyltransferase Inhibitors, and Tubulin Agents	4/19/23	9:00 AM	Section 19	9
6240	The potent quadruplex-binding compound QN-302 shows anti-tumor activity as a monotherapy in an orthotopic in vivo model of pancreatic cancer	Stephen	Neidle	Poster	DNA-reactive Agents, HDAC and Methyltransferase Inhibitors, and Tubulin Agents	4/19/23	9:00 AM	Section 19	10
6241	LP-184, an acylfulvene class small molecule therapeutic, is synthetically lethal in DNA damage repair deficient cancers	Aditya	Kulkarni	Poster	DNA-reactive Agents, HDAC and Methyltransferase Inhibitors, and Tubulin Agents	4/19/23	9:00 AM	Section 19	11
6242	Inhibition of BIRC5/survivin by LQZ-7I inhibits neuroblastoma growth while hemizyosity of BIRC5 does not: implications for therapy of neuroblastoma	Carmen	Dorneburg	Poster	DNA-reactive Agents, HDAC and Methyltransferase Inhibitors, and Tubulin Agents	4/19/23	9:00 AM	Section 19	12
6243	The novel antitubulin agent PM534 exhibits potent antitumoral and antiangiogenic properties in vitro and in vivo	Marta	Martínez Diez	Poster	DNA-reactive Agents, HDAC and Methyltransferase Inhibitors, and Tubulin Agents	4/19/23	9:00 AM	Section 19	13
6244	Design, synthesis, and structure-activity relationships of substituted pyrido[3,2-d]pyrimidines as microtubule targeting agents and anti-cancer agents	Yesha	Shah	Poster	DNA-reactive Agents, HDAC and Methyltransferase Inhibitors, and Tubulin Agents	4/19/23	9:00 AM	Section 19	14
6245	Selective HDAC6 inhibition by ITF3756 modifies the landscape of gene and protein expression in human monocytes: Possible identification of a specific biomarker signature	Christian	Steinkuhler	Poster	DNA-reactive Agents, HDAC and Methyltransferase Inhibitors, and Tubulin Agents	4/19/23	9:00 AM	Section 19	15
6246	The MTA-cooperative PRMT5 inhibitor AM-9747 exhibits robust antitumor activity in combination with clinically relevant chemotherapies and targeted agents in MTAP null tumor models	Katherine	Slemmons	Poster	DNA-reactive Agents, HDAC and Methyltransferase Inhibitors, and Tubulin Agents	4/19/23	9:00 AM	Section 19	16
6247	Lurbinectedin shows potent activity in all four molecular subtypes of small cell lung cancer (SCLC) and POU2F3 and SLFN11 are biomarkers for a better response	Eva Maria	Garrido-Martin	Poster	DNA-reactive Agents, HDAC and Methyltransferase Inhibitors, and Tubulin Agents	4/19/23	9:00 AM	Section 19	17
6248	Inhibiting β -catenin in AML by targeting DDX5	WEI	NI	Poster	DNA-reactive Agents, HDAC and Methyltransferase Inhibitors, and Tubulin Agents	4/19/23	9:00 AM	Section 19	18
6249	Low Bcl-2 is a robust biomarker of sensitivity to nab-paclitaxel in Ewing sarcoma	Angel	Carcaboso	Poster	DNA-reactive Agents, HDAC and Methyltransferase Inhibitors, and Tubulin Agents	4/19/23	9:00 AM	Section 19	19
6251	High expression level of GSK3 β in basal triple negative breast cancer: Effects of the HDAC inhibitor, vorinostat	Beverly	Lyn-Cook	Poster	DNA-reactive Agents, HDAC and Methyltransferase Inhibitors, and Tubulin Agents	4/19/23	9:00 AM	Section 19	21

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
6252	HDAC inhibition increases Ewing sarcoma sensitivity to chemotherapy	Kaitlyn	Smith	Poster	DNA-reactive Agents, HDAC and Methyltransferase Inhibitors, and Tubulin Agents	4/19/23	9:00 AM	Section 19	22
6253	SP-3164, a novel molecular glue degrader with activity in preclinical models of multiple myeloma	Aundrietta	Duncan	Poster	DNA-reactive Agents, HDAC and Methyltransferase Inhibitors, and Tubulin Agents	4/19/23	9:00 AM	Section 19	23
6254	The discovery and preclinical characterization of the SAM-competitive PRMT5 inhibitor UCT-000445	Martina	McDermott	Poster	DNA-reactive Agents, HDAC and Methyltransferase Inhibitors, and Tubulin Agents	4/19/23	9:00 AM	Section 19	24
6255	Anti-proliferative effect of two copper complexes against medulloblastoma cells	Hope	Fiadjoe	Poster	DNA-reactive Agents, HDAC and Methyltransferase Inhibitors, and Tubulin Agents	4/19/23	9:00 AM	Section 19	25
6256	Inhibition of class IIa HDACs potentiates MYC inhibitor-driven cytotoxicity by inducing MYC depletion and oxidative stress in non-small cell lung cancer	Jina	Park	Poster	DNA-reactive Agents, HDAC and Methyltransferase Inhibitors, and Tubulin Agents	4/19/23	9:00 AM	Section 19	26
6257	Developing HDAC inhibitors as immunomodulators	Sean	Colligan	Poster	DNA-reactive Agents, HDAC and Methyltransferase Inhibitors, and Tubulin Agents	4/19/23	9:00 AM	Section 19	27
6258	The discovery and preclinical characterization of the potent covalent KRASG12C inhibitor UCT-001024	Tristin	Rose	Poster	DNA-reactive Agents, HDAC and Methyltransferase Inhibitors, and Tubulin Agents	4/19/23	9:00 AM	Section 19	28
6259	Novel inhibitors of StAR related lipid transfer protein 5 inhibitors target plasma membrane lipid raft growth signaling	Shoja	Hajira	Poster	DNA-reactive Agents, HDAC and Methyltransferase Inhibitors, and Tubulin Agents	4/19/23	9:00 AM	Section 19	29
6263	Lysine-specific histone demethylase 1A (KDM1A/LSD1) inhibition attenuates DNA double-strand break repair and augments efficacy of temozolomide in glioblastoma	Salvador	Alejo	Poster	Epigenetics	4/19/23	9:00 AM	Section 20	1
6264	NUV-868, a novel BD2-selective BET inhibitor, in combination with enzalutamide or olaparib, inhibits growth of solid tumor xenografts	Hitisha	Patel	Poster	Epigenetics	4/19/23	9:00 AM	Section 20	2
6266	Group 3 medulloblastoma transcriptional networks are selectively sensitive to EP300 and CBP bromodomain inhibition	Noha	Shendy	Poster	Epigenetics	4/19/23	9:00 AM	Section 20	4
6267	A novel and potent EZH1/2 dual inhibitor, HM97662 demonstrates antitumor activity in T-cell lymphoma	Heesun	Moon	Poster	Epigenetics	4/19/23	9:00 AM	Section 20	5
6268	TT125-802 is a potent and highly selective CBP/p300 bromodomain inhibitor for the treatment of castration resistant prostate cancer and haematological malignancies	Sara	Laudato	Poster	Epigenetics	4/19/23	9:00 AM	Section 20	6

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
6269	JBI-778, a novel brain-penetrant small molecule PRMT5 inhibitor for treatment of cancer	Dhanalakshmi	Sivanandhan	Poster	Epigenetics	4/19/23	9:00 AM	Section 20	7
6270	Combination therapy with selective SMARCA2 (BRM) degraders for treatment of SMARCA4 (BRG1)-deficient cancers	Michael	Hulse	Poster	Epigenetics	4/19/23	9:00 AM	Section 20	8
6271	Discovery of BR1733 for the treatment of SWI/SNF deficient or highly vascularized solid tumor	Hailong	Zhang	Poster	Epigenetics	4/19/23	9:00 AM	Section 20	9
6272	AZ-PRMT5i-1: A potent MTAP-selective PRMT5 inhibitor with pharmacodynamic and monotherapy anti-tumor activity in MTAP-deleted tumours	James	Lynch	Poster	Epigenetics	4/19/23	9:00 AM	Section 20	10
6273	CTS3157, a novel MTA-cooperative PRMT5 inhibitor for targeting MTAP-deleted human tumors	Long	Wang	Poster	Epigenetics	4/19/23	9:00 AM	Section 20	11
6274	Preclinical characterization of the BET inhibitor, INCB057643, in combination with ruxolitinib for treatment of myeloproliferative neoplasms (MPN)	Gaurang	Trivedi	Poster	Epigenetics	4/19/23	9:00 AM	Section 20	12
6275	DW91170: A novel potent EZH1/2 dual inhibitor for lymphoma treatment	Doc-Gyun	Jeong	Poster	Epigenetics	4/19/23	9:00 AM	Section 20	13
6276	SKL27969, an oral selective PRMT5 inhibitor, sensitizes the effect of DNA-damaging agents in preclinical models of multiple solid tumors	Mijin	Moon	Poster	Epigenetics	4/19/23	9:00 AM	Section 20	14
6277	Selective and orally bioavailable SMARCA2 targeted degraders induce synthetic lethality in SMARCA4- deficient solid tumor	Koichi	Ito	Poster	Epigenetics	4/19/23	9:00 AM	Section 20	15
6278	Combination therapeutic strategy with type I PRMT inhibition in cancer treatment	Hui	Shi	Poster	Epigenetics	4/19/23	9:00 AM	Section 20	16
6279	CTS2190, a next-generation epigenetic inhibitor for targeting type I PRMT deregulated human tumors	Hui	Shi	Poster	Epigenetics	4/19/23	9:00 AM	Section 20	17
6281	OTX-015 inhibits proliferation and migration in ARID1A-mutated bladder cancer	Ryan	Kemper	Poster	Epigenetics	4/19/23	9:00 AM	Section 20	19
6282	EP102: Pharmacological inhibition of METTL3 arrests tumor progression and prolongs survival in CDX and PDX models of AML	Graeme	Fraser	Poster	Epigenetics	4/19/23	9:00 AM	Section 20	20
6283	Evaluating the potency of a first-in-class covalent antagonist of the H3K9me3 reader protein MPP8 in bladder cancer	Stephany	Gonzalez Tineo	Poster	Epigenetics	4/19/23	9:00 AM	Section 20	21
6284	SUV420H1 as a novel target in HPV-negative head and neck squamous cell carcinoma	Arfa	Moshiri	Poster	Epigenetics	4/19/23	9:00 AM	Section 20	22
6285	Preclinical efficacy of CDK7 inhibitor-based combinations in cellular models of advanced myeloproliferative neoplasms (MPN)	Christopher	Mill	Poster	Epigenetics	4/19/23	9:00 AM	Section 20	23
6286	Targeting Polycomb Repressive Complex 1 with small-molecule inhibitors as a potential therapeutic approach to combat leukemia	Miranda	Simes	Poster	Epigenetics	4/19/23	9:00 AM	Section 20	24

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
6287	Selective CBP degradation shows superior potency and differentiated biological activity compared to small molecule inhibitors	Laura	La Bonte	Poster	Epigenetics	4/19/23	9:00 AM	Section 20	25
6288	Discovery and characterization of potent, selective CBP degraders	Laura	La Bonte	Poster	Epigenetics	4/19/23	9:00 AM	Section 20	26
6289	Enhancer reprogramming by novel SMARCA2 degrading PROTACs underlies therapeutic utility in SMARCA4 mutant tumors	Nicholas	Blazanin	Poster	Epigenetics	4/19/23	9:00 AM	Section 20	27
6290	Characterizing antitumor responses to EXS-74539, a novel, reversible LSD1 inhibitor with potential in small-cell lung cancer	Andrew	Payne	Poster	Epigenetics	4/19/23	9:00 AM	Section 20	28
6294	CXCR5 is a very promising drug target for the development of antibody-drug conjugates to treat patients with lymphoma	Tibor	Schomber	Poster	Growth Factor Receptors as Therapeutic Targets	4/19/23	9:00 AM	Section 21	1
6295	Belzupacap sarotalocan, an investigational virus-like drug conjugate, preferentially binds cancer cell glycosaminoglycans associated with the epithelial to mesenchymal transition	Nathan	Fons	Poster	Growth Factor Receptors as Therapeutic Targets	4/19/23	9:00 AM	Section 21	2
6296	Preclinical study of a novel anti-CLEC12A antibody-drug conjugate with a glucuronide-protected pyrrolobenzodiazepine payload	Jinwon	Jung	Poster	Growth Factor Receptors as Therapeutic Targets	4/19/23	9:00 AM	Section 21	3
6297	Rationale for the development of a differentiated Trop2 ADC	Satyajit	Mitra	Poster	Growth Factor Receptors as Therapeutic Targets	4/19/23	9:00 AM	Section 21	4
6298	A novel topoisomerase I inhibitor based anti-ICAM-1 antibody drug conjugate for the treatment of hematologic malignancies and solid tumors	Oi Kwan	Wong	Poster	Growth Factor Receptors as Therapeutic Targets	4/19/23	9:00 AM	Section 21	5
6299	ZB131 antibody-drug conjugates induce potent antitumor activity	Samantha	Perez	Poster	Growth Factor Receptors as Therapeutic Targets	4/19/23	9:00 AM	Section 21	6
6300	Therapeutic potential of EO-3021/SYSA1801, a Claudin18.2 antibody-drug conjugate, for the treatment of CLDN18.2-expressing cancers	Thomas	O'Hare	Poster	Growth Factor Receptors as Therapeutic Targets	4/19/23	9:00 AM	Section 21	7
6301	Post-translational modifications regulate sensitivity to Polatuzumab Vedotin in DLBCL	Sean	Corcoran	Poster	Growth Factor Receptors as Therapeutic Targets	4/19/23	9:00 AM	Section 21	8
6302	Identification of OASEP1 as a biomarker and therapeutic target for oral cancer	Atsushi	Takano	Poster	Growth Factor Receptors as Therapeutic Targets	4/19/23	9:00 AM	Section 21	9
6304	Preclinical development of a next generation antibody drug conjugate (ADC) targeting B7-H3 for treatment of solid tumors	Jian	Xu	Poster	Growth Factor Receptors as Therapeutic Targets	4/19/23	9:00 AM	Section 21	11
6305	Bispecific claudin 18.2 and GPRC5D antibodies with potent cell-killing activity for cancer therapeutics	Ileine	Sanchez	Poster	Growth Factor Receptors as Therapeutic Targets	4/19/23	9:00 AM	Section 21	12
6306	Pharmacological deuteration of SCID mice using the water-isotopologue deuterium oxide (D2O) inhibits tumor growth in bioluminescent models of human malignant melanoma and pancreatic ductal adenocarcinoma	Georg	Wondrak	Poster	Growth Factor Receptors as Therapeutic Targets	4/19/23	9:00 AM	Section 21	13

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
6307	A novel pegylated bispecific antibody-drug conjugate (P-BsADCpb- adc) targeting cancers co-expressing PD-L1 and CD47	Shumin	Liu	Poster	Growth Factor Receptors as Therapeutic Targets	4/19/23	9:00 AM	Section 21	14
6308	Preclinical development of ABBV-319: a CD19-targeting glucocorticoid receptor modulator (GRM) agonist antibody-drug conjugate (ADC) for the treatment of B-cell malignancies	Chewei	Chang	Poster	Growth Factor Receptors as Therapeutic Targets	4/19/23	9:00 AM	Section 21	15
6309	Anti-tumor efficacy of SI-B001, a novel EGFR×HER3 bispecific antibody, against EGFR-driven epithelial tumors alone or in combination with paclitaxel and carboplatin	Jahan	Khalili	Poster	Growth Factor Receptors as Therapeutic Targets	4/19/23	9:00 AM	Section 21	16
6310	Phylogenetic conservation of primate Trop-2 underscores favorable pharmacokinetics and lack of toxicity of the cancer- selective Hu2G10 anti-Trop-2	Saverio	Alberti	Poster	Growth Factor Receptors as Therapeutic Targets	4/19/23	9:00 AM	Section 21	17
6311	ABBV-400: An ADC delivering a novel topoisomerase 1 inhibitor to c-Met-positive solid tumors	Regina	Reilly	Poster	Growth Factor Receptors as Therapeutic Targets	4/19/23	9:00 AM	Section 21	18
6312	Targeting HSPG is more efficient than using soluble heparin for interfering with cancer cell adhesion and migration	Luisa	Bracci	Poster	Growth Factor Receptors as Therapeutic Targets	4/19/23	9:00 AM	Section 21	19
6313	IND-enabling studies for GrB-Fc-IT4: in vivo efficacy, pharmacokinetics, schedule optimization and maximum tolerated dose	Ana	Alvarez- Cienfuegos	Poster	Growth Factor Receptors as Therapeutic Targets	4/19/23	9:00 AM	Section 21	20
6314	Novel granzyme B-based fusion constructs targeting FR α on liquid and solid tumors	Ana	Alvarez- Cienfuegos	Poster	Growth Factor Receptors as Therapeutic Targets	4/19/23	9:00 AM	Section 21	21
6315	Human granzyme B fusions targeting VEGFR on tumor cells and activated vasculature	Khalid	Mohamedali	Poster	Growth Factor Receptors as Therapeutic Targets	4/19/23	9:00 AM	Section 21	22
6316	In vitro and in vivo studies of human granzyme B fusion constructs targeting mesothelin	Khalid	Mohamedali	Poster	Growth Factor Receptors as Therapeutic Targets	4/19/23	9:00 AM	Section 21	23
6317	Targeting cell-surface CEA with a novel human fusion construct delivers the serine protease granzyme B to solid tumor cells	Khalid	Mohamedali	Poster	Growth Factor Receptors as Therapeutic Targets	4/19/23	9:00 AM	Section 21	24
6318	Preclinical characterization of ARX305, a next-generation anti- CD70 antibody drug conjugate for the treatment of CD70- expressing cancers	Lillian	Skidmore	Poster	Growth Factor Receptors as Therapeutic Targets	4/19/23	9:00 AM	Section 21	25
6319	Mechanism of anti-EGFR antibody endostatin fusion protein action on inhibition of vasculogenic mimicry and tumor cell motility in triple negative breast cancer	Ankita	Sankar	Poster	Growth Factor Receptors as Therapeutic Targets	4/19/23	9:00 AM	Section 21	26
6320	CUSP06/AMT-707, a new CDH6-targeting antibody-drug conjugate, demonstrates potent antitumor activity in preclinical models	Wei	Lu	Poster	Growth Factor Receptors as Therapeutic Targets	4/19/23	9:00 AM	Section 21	27

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
6321	HMPL-453, a highly selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays potent activity in FGFR-altered tumor models	Jia	Hu	Poster	Growth Factor Receptors as Therapeutic Targets	4/19/23	9:00 AM	Section 21	28
6325	A novel EGFR x MUC1 bispecific antibody-drug conjugate, BSA01, targets MUC1 transmembrane cleavage products and improves tumor selectivity	Frank	An	Poster	Anticancer Immunotherapeutics	4/19/23	9:00 AM	Section 22	1
6326	Discovery & preclinical evaluation of BPB-101: A novel triple functional bi-specific antibody targeting GARP-TGF β complex/SLC, free TGF- β and PD-L1	Wenxin	Xu	Poster	Anticancer Immunotherapeutics	4/19/23	9:00 AM	Section 22	2
6327	Intratumoral administration of ultra high-concentration nitric oxide (UNO) is more efficacious than anti-PD1 therapy in 4T1 tumor-bearing mice	Yana	Epshtein	Poster	Anticancer Immunotherapeutics	4/19/23	9:00 AM	Section 22	3
6328	An off-the-shelf Twin BiTE combination therapy controls heterogenous glioblastoma and shapes immune response	Filippo	Rossignoli	Poster	Anticancer Immunotherapeutics	4/19/23	9:00 AM	Section 22	4
6329	Preclinical study of CD19 detection methods using monoclonal antibodies post tafasitamab treatment	Kristina	Ilieva	Poster	Anticancer Immunotherapeutics	4/19/23	9:00 AM	Section 22	5
6330	Countering antidrug antibodies to programmed cell death-1 blockade in mouse Pten-null prostate cancer	Marco	De Velasco	Poster	Anticancer Immunotherapeutics	4/19/23	9:00 AM	Section 22	6
6331	The anti-tumor activity of HSP-90 therapeutic cancer vaccine (AST-021p) combine with TLR2/3 agonist in a MMTV-neu transgenic model	Jee Hyun	Choi	Poster	Anticancer Immunotherapeutics	4/19/23	9:00 AM	Section 22	7
6332	A humanized anti-cd40 antibody with anti-tumor pharmacological activity and cynomolgus monkey safety	Zhenyu	Li	Poster	Anticancer Immunotherapeutics	4/19/23	9:00 AM	Section 22	8
6333	Repurposing NSAIDs for chemo-immunotherapy: mechanisms beyond COX inhibition	Ogacheko	Okoko	Poster	Anticancer Immunotherapeutics	4/19/23	9:00 AM	Section 22	9
6334	VBI-002, a CD47xICAM-1 bispecific antibody for the treatment of hepatocellular carcinoma, melanoma and non-small cell lung cancers	Oi Kwan	Wong	Poster	Anticancer Immunotherapeutics	4/19/23	9:00 AM	Section 22	10
6335	Developing anti-IL-22 therapeutics for inflammation and cancer	Christina	Wheeler	Poster	Anticancer Immunotherapeutics	4/19/23	9:00 AM	Section 22	11
6336	Heterodimeric Fc-fused IL12 shows potent antitumor activity and low toxicity	Yang	Huang	Poster	Anticancer Immunotherapeutics	4/19/23	9:00 AM	Section 22	12
6337	Tri-specific CD3 x HER2 x HER2 antibodies in 1:2 format recognizing two different epitopes on HER2 demonstrate selective activity on human cancer cells with high HER2 expression	Jie	Zhang	Poster	Anticancer Immunotherapeutics	4/19/23	9:00 AM	Section 22	13
6338	Development of a novel MSLN \times 4-1BB bispecific antibody	Liangwei	Li	Poster	Anticancer Immunotherapeutics	4/19/23	9:00 AM	Section 22	14

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
6339	BCA101, a novel tumor-targeted bifunctional fusion antibody simultaneously inhibiting EGFR and TGF- β signaling with potential for durable tumor growth inhibition	Pradip	Nair	Poster	Anticancer Immunotherapeutics	4/19/23	9:00 AM	Section 22	15
6340	Preclinical development of a monoclonal antibody targeting CD24 as cancer immunotherapy	Fan	Zhang	Poster	Anticancer Immunotherapeutics	4/19/23	9:00 AM	Section 22	16
6341	Preclinical development of a monoclonal antibody targeting CD70 as cancer immunotherapy	Fan	Zhang	Poster	Anticancer Immunotherapeutics	4/19/23	9:00 AM	Section 22	17
6342	Preclinical safety & pharmacokinetics of AFVT-2101, a tetravalent FR α x CD16A bispecific innate cell engager for the treatment of solid tumors	Eric	Gaukel	Poster	Anticancer Immunotherapeutics	4/19/23	9:00 AM	Section 22	18
6343	7E1, a novel blocking antibody targeting human anti-Müllerian-hormone-receptor II (AMHRII), elicits potent anti-tumor activity in vivo	Qingcong	Lin	Poster	Anticancer Immunotherapeutics	4/19/23	9:00 AM	Section 22	19
6344	Recombinant Immunotoxin exhibited targeted killing of Trop2 overexpressing tumour cells lines	Dennis	Dogbey	Poster	Anticancer Immunotherapeutics	4/19/23	9:00 AM	Section 22	20
6345	Non-clinical pharmacology of HX009, a novel FIC PD1xCD47 BsAb	Henry	Li	Poster	Anticancer Immunotherapeutics	4/19/23	9:00 AM	Section 22	21
6346	Discovery of HX011, a novel OX40 mAb, for potential cancer immunotherapy	Henry	Li	Poster	Anticancer Immunotherapeutics	4/19/23	9:00 AM	Section 22	22
6347	Preliminary results of an exploratory phase I clinical trial of anchored canine interleukin-12 (cANK-101) in dogs with advanced oral malignant melanoma	Matheus Moreno	Passos Barbosa	Poster	Anticancer Immunotherapeutics	4/19/23	9:00 AM	Section 22	23
6348	ABN202 (α EGFR-interferon- β mutein), a potent antibody-cytokine fusion protein for the treatment of EGFR-positive non-small cell lung cancer	Saehyung	Lee	Poster	Anticancer Immunotherapeutics	4/19/23	9:00 AM	Section 22	24
6350	Monoclonal antibody against BST2 isoform: potential tool for diagnostic and cancer therapy	Laura	Bover	Poster	Anticancer Immunotherapeutics	4/19/23	9:00 AM	Section 22	26
6351	Reversal of dysfunctional CIK cells after the exposure to resistant cholangiocarcinoma cells through chemical perturbation of resistant gene signature	Adisak	Wongkajornsilp	Poster	Anticancer Immunotherapeutics	4/19/23	9:00 AM	Section 22	27
6352	Combination treatment with recombinant murine IL-12 and anti-PD-1 antibody enhanced anti-tumor efficacy through the activation of cytotoxic T cell response	San-Chi	Chen	Poster	Anticancer Immunotherapeutics	4/19/23	9:00 AM	Section 22	28
6353	Combination of poly- γ -glutamic acid with anti PD-L1 blockade leads to improved anti-tumor activity in murine models	Jae-Pyung	Jang	Poster	Anticancer Immunotherapeutics	4/19/23	9:00 AM	Section 22	29
6354	A new tumor-bearing humanized mouse model to evaluate the efficacy of bispecific T cell engager and monoclonal checkpoint antibodies	Li-Chin	Yao	Poster	Anticancer Immunotherapeutics	4/19/23	9:00 AM	Section 22	30

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
6357	Generation of a mutant SIRPa fusion protein with highly-improved affinity and favorable safety profile	Renhong	Tang	Poster	Immune Checkpoints	4/19/23	9:00 AM	Section 23	1
6358	CLEC-1 inhibitory myeloid checkpoint blockade enhances antitumor responses and tumor phagocytosis by macrophages	Vanessa	Gauttier	Poster	Immune Checkpoints	4/19/23	9:00 AM	Section 23	2
6359	Structural insights into Siglec-15 reveal glycosylation dependency for interaction with T cells through integrin CD11b	Asis	Palazon	Poster	Immune Checkpoints	4/19/23	9:00 AM	Section 23	3
6361	A preclinical model of acquired anti-PD-1 resistance is responsive to SEA-TGT, an effector-function enhanced anti-TIGIT monoclonal antibody	David	Gruber	Poster	Immune Checkpoints	4/19/23	9:00 AM	Section 23	5
6362	Overcoming resistance to immunotherapy due to loss of antigen presentation	Brian	Miller	Poster	Immune Checkpoints	4/19/23	9:00 AM	Section 23	6
6363	Short-term exposure of cancer cells to ultra-high concentrations nitric oxide induces PDL-1 upregulation	Yana	Epshtein	Poster	Immune Checkpoints	4/19/23	9:00 AM	Section 23	7
6365	TRIM21 is a novel endogenous partner of the inhibitory myeloid checkpoint CLEC-1 involved in tumor antigen cross-presentation	Irene	Bacelli	Poster	Immune Checkpoints	4/19/23	9:00 AM	Section 23	9
6366	NB002, a novel therapeutic antibody targeting unique epitope on TIM-3 presenting potent antitumor activity	Yu	Zhang	Poster	Immune Checkpoints	4/19/23	9:00 AM	Section 23	10
6367	BSI-507, a first-in-class bispecific antibody targeting PD1 and PVRIG for cancer immunotherapy	Xiaodong	Liu	Poster	Immune Checkpoints	4/19/23	9:00 AM	Section 23	11
6368	Preclinical pharmacology and safety studies of ZG005: an anti-PD-1/TIGIT bispecific mAb in a phase I clinical trial for advanced tumors	Bing	Zhu	Poster	Immune Checkpoints	4/19/23	9:00 AM	Section 23	12
6369	Modulation of tumor microenvironment with TIM-3 blockade improves survival in diffuse midline glioma models	Iker	Ausejo-Mauleon	Poster	Immune Checkpoints	4/19/23	9:00 AM	Section 23	13
6370	Cell-based luminescent reporter bioassays for immunotherapies targeting macrophage effector functions	Gopal	Krishnan	Poster	Immune Checkpoints	4/19/23	9:00 AM	Section 23	14
6371	Identification of a lymphocyte activation gene-3-binding peptides using phage displayed-peptide libraries for cancer immunotherapy	Seok-Min	Lee	Poster	Immune Checkpoints	4/19/23	9:00 AM	Section 23	15
6372	In situ detection of various activated immune checkpoints via next-generation proximity ligation assays in tumor tissue	Ka I	Au leong	Poster	Immune Checkpoints	4/19/23	9:00 AM	Section 23	16
6373	P-selectin glycoprotein ligand-1 modulates the functions of human T cells and macrophages in vitro	Jun	Guan	Poster	Immune Checkpoints	4/19/23	9:00 AM	Section 23	17
6374	The role of myeloid cell-expressed PVRL2 in high-grade serous ovarian cancer	Kosuke	Murakami	Poster	Immune Checkpoints	4/19/23	9:00 AM	Section 23	18
6375	Transcriptomic signatures in melanoma lymph node metastasis that relate to immune oncology treatment	Matias	Bustos	Poster	Immune Checkpoints	4/19/23	9:00 AM	Section 23	19

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
6376	Discovery and preclinical characterization of dual antagonist antibodies targeting both LILRB1 and LILRB2 that enhance innate and adaptive anti-cancer immune responses	Meghan	Zuck	Poster	Immune Checkpoints	4/19/23	9:00 AM	Section 23	20
6377	A translatable tumor-killing platform with robust sensitivity towards immune checkpoint inhibitor targeted therapeutics	Louise	Brackenbury	Poster	Immune Checkpoints	4/19/23	9:00 AM	Section 23	21
6378	An in vitro human CD8 T cell exhaustion model for the functional screening of immune checkpoint inhibitors	Roberto	Carrio	Poster	Immune Checkpoints	4/19/23	9:00 AM	Section 23	22
6380	Ultrasensitive detection of circulating human PD-1 and PD-L1 using Single Molecule Counting (SMC) technology	Wen-Rong	Lie	Poster	Immune Checkpoints	4/19/23	9:00 AM	Section 23	24
6381	Quantitative multiplex analysis of soluble and cellular immune checkpoint proteins in response to interferon gamma across multiple murine tumor models	Wen-Rong	Lie	Poster	Immune Checkpoints	4/19/23	9:00 AM	Section 23	25
6382	Activation of transcription factors, p65 and NFATc1, mediated by WNT5a, induces up-regulation of novel immune checkpoint CNTN4 expression	Bu-Nam	Jeon	Poster	Immune Checkpoints	4/19/23	9:00 AM	Section 23	26
6384	ATG-034, an LILRB4 antagonist antibody, reinvigorates dendritic cells and prevents tumor progression	Bing	Hou	Poster	Immune Checkpoints	4/19/23	9:00 AM	Section 23	28
6388	High dose acetaminophen with n-acetylcysteine rescue inhibits M2 polarization of tumor associated macrophages.	Alexander	Neuwelt	Poster	Immune Mechanisms Mediated by Other Therapies	4/19/23	9:00 AM	Section 24	1
6389	Differential role of CD8 cells and CD4 cells in anti-tumor immunity triggered by tumor cell apoptosis using HSVtk/GCV system	Sho	Umegaki	Poster	Immune Mechanisms Mediated by Other Therapies	4/19/23	9:00 AM	Section 24	2
6390	N17350 is an emerging therapeutic modality that selectively kills cancer cells and stimulates anti-tumor immunity	Ravindra	Gujar	Poster	Immune Mechanisms Mediated by Other Therapies	4/19/23	9:00 AM	Section 24	3
6391	Development of a novel strategy for cancer immunotherapy based on tumor immunogenicity improvement by HLA-drug interaction	Takeshi	Susukida	Poster	Immune Mechanisms Mediated by Other Therapies	4/19/23	9:00 AM	Section 24	4
6392	Combination of pulsed electric field, immunotherapy and cisplatin significantly prolongs survival in an orthotopic breast cancer mouse model	Chiara	Pastori	Poster	Immune Mechanisms Mediated by Other Therapies	4/19/23	9:00 AM	Section 24	5
6395	Atovaquone promotes release of damage-associated molecular patterns from epithelial ovarian cancer cells	Mayra	Betancourt Ponce	Poster	Immune Mechanisms Mediated by Other Therapies	4/19/23	9:00 AM	Section 24	8
6396	BET inhibition alleviates T-cell dysfunction in chronic lymphocytic leukemia	Audrey	Smith	Poster	Immune Mechanisms Mediated by Other Therapies	4/19/23	9:00 AM	Section 24	9
6397	Eribulin acts as an immune adjuvant to enhance the antitumor efficacy of STING agonists in triple-negative breast cancer models	Leila	Takahashi-Ruiz	Poster	Immune Mechanisms Mediated by Other Therapies	4/19/23	9:00 AM	Section 24	10
6398	Targeting ENPP1 to boost anti-tumor immunity during PARP inhibition	Jie	Li	Poster	Immune Mechanisms Mediated by Other Therapies	4/19/23	9:00 AM	Section 24	11

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
6399	Hyperthermic intrathoracic chemotherapy (HITOC) improves malignant pleural mesothelioma control through a tumor specific cytotoxic immune response	Sabrina	Cavin	Poster	Immune Mechanisms Mediated by Other Therapies	4/19/23	9:00 AM	Section 24	12
6400	Synergistic combination of NCX 4040 and napabucasin induces immunogenic activation via upregulation of mitochondrial oxidative stress and STAT3 inhibition in cadmium transformed and metastatic prostate cancer cells	Nishtha	Pathak	Poster	Immune Mechanisms Mediated by Other Therapies	4/19/23	9:00 AM	Section 24	13
6401	HMGB1 release predicts chemotherapy combinatorial efficacy with TIM-3 blockade	Alexis	Onimus	Poster	Immune Mechanisms Mediated by Other Therapies	4/19/23	9:00 AM	Section 24	14
6402	The effects of cytotoxic chemotherapy on colorectal cancer immunogenicity	Pietro Paolo	Vitiello	Poster	Immune Mechanisms Mediated by Other Therapies	4/19/23	9:00 AM	Section 24	15
6403	A self-replicating RNA precision medicine approach to overcoming resistance to endocrine therapy in ER+BC	Zelanna	Goldberg	Poster	Immune Mechanisms Mediated by Other Therapies	4/19/23	9:00 AM	Section 24	16
6404	Clinical scenario of immune checkpoint inhibitor treatment in metastatic nasopharyngeal carcinoma	Cheng-Lung	Hsu	Poster	Immune Mechanisms Mediated by Other Therapies	4/19/23	9:00 AM	Section 24	17
6406	Radiation and STING activation limit tumor development and modulate the immune environment via distinct mechanisms	Kay	Shigemori	Poster	Immune Mechanisms Mediated by Other Therapies	4/19/23	9:00 AM	Section 24	19
6407	Radionuclide-specific effects of ⁹⁰ Y-, ¹⁷⁷ Lu-, or ²²⁵ Ac-NM600 targeted radionuclide therapy on tumor immunomodulation and enhanced immunotherapy response in syngeneic murine tumors	Thanh Phuong	Nguyen	Poster	Immune Mechanisms Mediated by Other Therapies	4/19/23	9:00 AM	Section 24	20
6408	Anti-tumor immunity evolved by novel titanium peroxide nanoparticles (TiOxNPs) as a radiosensitizer and PD-1 blockade	Yoshiko	Fujita	Poster	Immune Mechanisms Mediated by Other Therapies	4/19/23	9:00 AM	Section 24	21
6409	Non-redundant mechanisms of immune resistance to radiotherapy converge on innate immunity	Anthony	Nguyen	Poster	Immune Mechanisms Mediated by Other Therapies	4/19/23	9:00 AM	Section 24	22
6410	Deciphering the role of MyD88 signaling pathway in regulating type I IFN-mediated responses to radiation therapy in solid tumors	Aanchal Preet	Kaur	Poster	Immune Mechanisms Mediated by Other Therapies	4/19/23	9:00 AM	Section 24	23
6414	Concomitant anti-tumor immunity and checkpoint blockade responses are restored by depletion of CD62L expressing cells	Jose-Alejandro	Guevara-Patino	Poster	Immunotherapy Strategies and Mechanisms	4/19/23	9:00 AM	Section 25	1
6415	CD25-targeted aptamer-drug conjugate (CD25-ApDC) depletes and blocks regulatory T cells selectivel	Daekyun	Lee	Poster	Immunotherapy Strategies and Mechanisms	4/19/23	9:00 AM	Section 25	2
6416	Statins inhibit onco-dimerization of 4Ig-B7-H3	Margie	Sutton	Poster	Immunotherapy Strategies and Mechanisms	4/19/23	9:00 AM	Section 25	3
6417	Deciphering aberrant STING pathway and exploring oncolytic viruses therapy in low grade serous ovarian carcinoma	Almira	Zhantuyakova	Poster	Immunotherapy Strategies and Mechanisms	4/19/23	9:00 AM	Section 25	4
6418	xWU-NK-101 as salvage therapy post immune checkpoint blockade (ICB)	Tom	Leedom	Poster	Immunotherapy Strategies and Mechanisms	4/19/23	9:00 AM	Section 25	5

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
6420	Harnessing immune responses in prostate MMRd tumors treated with immune checkpoint blockade	Marcel	Arias Badia	Poster	Immunotherapy Strategies and Mechanisms	4/19/23	9:00 AM	Section 25	7
6421	Molecular profiles and single cell analysis identify immunogenic pancreatic ductal adenocarcinoma (iPDAC)	Wungki	Park	Poster	Immunotherapy Strategies and Mechanisms	4/19/23	9:00 AM	Section 25	8
6422	Combined TGFβ/PD-L1 blockade enhances systemic antitumor immunity in head and neck cancer	Magdalena	Rainey	Poster	Immunotherapy Strategies and Mechanisms	4/19/23	9:00 AM	Section 25	9
6423	Targeting an autophagy regulator augments antitumor immunity and immunotherapy	Yi	Bao	Poster	Immunotherapy Strategies and Mechanisms	4/19/23	9:00 AM	Section 25	10
6424	Immune characteristics and anti-PD-1-induced reinvigoration capacity of tumor-infiltrating lymphocytes in ovarian clear cell carcinoma relative to high-grade serous ovarian carcinoma	Junsik	Park	Poster	Immunotherapy Strategies and Mechanisms	4/19/23	9:00 AM	Section 25	11
6425	Functional roles of enhancers in immune microenvironment & immunotherapy response	Kunal	Rai	Poster	Immunotherapy Strategies and Mechanisms	4/19/23	9:00 AM	Section 25	12
6427	Selective-HDAC inhibitor relieves the suppressive immune microenvironment in the brain to impede breast cancer brain metastasis	Shao-Ping	Yang	Poster	Immunotherapy Strategies and Mechanisms	4/19/23	9:00 AM	Section 25	14
6428	Targeting SMARCA1 as a therapeutic strategy to enhance cGAS/STING signaling in gastric cancer	Po-Yen	Hsu	Poster	Immunotherapy Strategies and Mechanisms	4/19/23	9:00 AM	Section 25	15
6429	A surrogate to the anti-IL1RAP antibody nadunolimab induces tumor microenvironment changes to the metastatic lung and reduces metastatic lesions in mouse models of metastatic cancer	Elin	Jaensson Gyllenbäck	Poster	Immunotherapy Strategies and Mechanisms	4/19/23	9:00 AM	Section 25	16
6430	Single-cell transcriptomic and epigenomic landscapes of innate and adaptive immune cells in metastatic melanoma treated with immunotherapy	Jiekun	Yang	Poster	Immunotherapy Strategies and Mechanisms	4/19/23	9:00 AM	Section 25	17
6431	Targeting Rab7-mediated STING degradation to amplify therapeutic STING agonism in TNBC	Yuqing	Zhang	Poster	Immunotherapy Strategies and Mechanisms	4/19/23	9:00 AM	Section 25	18
6432	Glutamine antagonist prodrug JHU083 reprograms immunosuppressive tumor-associated macrophages (TAMs) to drive tumor immunity in urologic cancers	Fan	Shen	Poster	Immunotherapy Strategies and Mechanisms	4/19/23	9:00 AM	Section 25	19
6433	A novel bacterial strain, CJRB-101, induces anti-cancer effects by repolarization of M2 to CXCL9 and CXCL10 dual expressing M1 macrophages in humanized non-small cell lung cancer mice models	Arim	Min	Poster	Immunotherapy Strategies and Mechanisms	4/19/23	9:00 AM	Section 25	20
6434	A precision probiotic therapeutic promotes a more efficacious type I immune response and limits breast cancer growth in mice	Denise	Cecil	Poster	Immunotherapy Strategies and Mechanisms	4/19/23	9:00 AM	Section 25	21
6435	BCG008, a human Siglec-15 blocking antibody, displays potent anti-tumor activity in Siglec-15-humanized mice	Zhaoxue	Yu	Poster	Immunotherapy Strategies and Mechanisms	4/19/23	9:00 AM	Section 25	22

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
6436	1C3, a novel non-blocking anti-human TNFR2 antibody, promotes effector T cell responses and demonstrates potent anti-tumor activity	Zhaoxue	Yu	Poster	Immunotherapy Strategies and Mechanisms	4/19/23	9:00 AM	Section 25	23
6437	Development of therapeutic vaccines against ovarian cancer	Leslie	Hesnard	Poster	Immunotherapy Strategies and Mechanisms	4/19/23	9:00 AM	Section 25	24
6438	Next-generation pan-cancer immunotherapy with patient-derived APC	Zhen	Bian	Poster	Immunotherapy Strategies and Mechanisms	4/19/23	9:00 AM	Section 25	25
6439	Actin remodeling, inhibitory ligand polarization and small vesicle recruitment hinder effective anti-tumor immunity by shaping the tumor cell side of the immune synapse	Andrea Michela	Biolato	Poster	Immunotherapy Strategies and Mechanisms	4/19/23	9:00 AM	Section 25	26
6440	Targeting TCTP reverses the multi-malignant phenotypes of immune-refractory tumor cells	Hyo-Jung	Lee	Poster	Immunotherapy Strategies and Mechanisms	4/19/23	9:00 AM	Section 25	27
6442	Role of TWEAK-Fn14 axis in driving immunosuppression in glioblastoma multiforme	Angad	Beniwal	Poster	Immunotherapy Strategies and Mechanisms	4/19/23	9:00 AM	Section 25	29
6447	Carotenoid and tocopherol intake in relation to pancreatic cancer risk in a population-based case-control study	Jianjun	Zhang	Poster	Diet, Alcohol, Tobacco Use, and Other Lifestyle Factors	4/19/23	9:00 AM	Section 26	1
6448	Processed, red, and white meat consumption and breast composition in a prospective cohort study of Chilean girls	Claire	Kim	Poster	Diet, Alcohol, Tobacco Use, and Other Lifestyle Factors	4/19/23	9:00 AM	Section 26	2
6449	Association between dietary one-carbon metabolism-related nutrients and the risk of colorectal cancer: Findings from the Singapore Chinese Health Study	Yen	Pham	Poster	Diet, Alcohol, Tobacco Use, and Other Lifestyle Factors	4/19/23	9:00 AM	Section 26	3
6450	Fatty acid intake as potential risk factor of colorectal cancer: A multicenter case control study in Iran	Monireh Sadat	Seyyedsalehi	Poster	Diet, Alcohol, Tobacco Use, and Other Lifestyle Factors	4/19/23	9:00 AM	Section 26	4
6451	Dietary medium-chain fatty acids and risk of incident colorectal cancer in a predominantly low-income population: a report from the Southern Community Cohort Study (SCCS)	Lei	Fan	Poster	Diet, Alcohol, Tobacco Use, and Other Lifestyle Factors	4/19/23	9:00 AM	Section 26	5
6452	A plasma metabolomic signature of healthy lifestyles and risk of colorectal cancer in the UK Biobank	Fangcheng	Yuan	Poster	Diet, Alcohol, Tobacco Use, and Other Lifestyle Factors	4/19/23	9:00 AM	Section 26	6
6453	Lifestyle and environmental factors in relation to colorectal cancer risk and survival by colibactin tumor mutational signature status	Claire	Thomas	Poster	Diet, Alcohol, Tobacco Use, and Other Lifestyle Factors	4/19/23	9:00 AM	Section 26	7
6454	Metabolic obesity phenotype and risk of obesity-related cancers in the women's health initiative	Prasoon	Karra	Poster	Diet, Alcohol, Tobacco Use, and Other Lifestyle Factors	4/19/23	9:00 AM	Section 26	8
6456	Association of dietary inflammatory and insulinemic potential with risk of liver cancer and chronic liver disease mortality	Xinyuan	Zhang	Poster	Diet, Alcohol, Tobacco Use, and Other Lifestyle Factors	4/19/23	9:00 AM	Section 26	10
6457	Blood magnesium level is associated with liver cancer risk in a prospective cohort of liver cirrhosis patients	Xinyuan	Zhang	Poster	Diet, Alcohol, Tobacco Use, and Other Lifestyle Factors	4/19/23	9:00 AM	Section 26	11

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
6458	Maternal and paternal alcohol exposures program higher incidence of hepatocellular carcinoma in offspring	Alison	Basel	Poster	Diet, Alcohol, Tobacco Use, and Other Lifestyle Factors	4/19/23	9:00 AM	Section 26	12
6459	Developed and persistent dyslipidemia is associated with increased risk of gastric cancer in a prospective study	Dan	Huang	Poster	Diet, Alcohol, Tobacco Use, and Other Lifestyle Factors	4/19/23	9:00 AM	Section 26	13
6460	Smoking initiation at young age increases risk of gastric cancer among Korean men	Hwi-Won	Lee	Poster	Diet, Alcohol, Tobacco Use, and Other Lifestyle Factors	4/19/23	9:00 AM	Section 26	14
6461	Excess risk due to smoking and modifying effect of quitting on bladder cancer incidence: the multiethnic cohort	David	Bogumil	Poster	Diet, Alcohol, Tobacco Use, and Other Lifestyle Factors	4/19/23	9:00 AM	Section 26	15
6462	Cigarette smoking reduction and lung cancer risk in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study	Daniela	Gutiérrez-Torres	Poster	Diet, Alcohol, Tobacco Use, and Other Lifestyle Factors	4/19/23	9:00 AM	Section 26	16
6463	Persistence of smoking mutational signatures in the non-small cell lung cancer genome	Colin	Lindsay	Poster	Diet, Alcohol, Tobacco Use, and Other Lifestyle Factors	4/19/23	9:00 AM	Section 26	17
6464	Antidepressant use and lung cancer risk and mortality: A meta-analysis of observational studies	Eunkyung	Lee	Poster	Diet, Alcohol, Tobacco Use, and Other Lifestyle Factors	4/19/23	9:00 AM	Section 26	18
6465	Associations of early menopause and hormone therapy with lung health and mortality among female never and ever smokers from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial	Tessa	Flores	Poster	Diet, Alcohol, Tobacco Use, and Other Lifestyle Factors	4/19/23	9:00 AM	Section 26	19
6468	Association of food groups and dietary pattern with breast cancer risk: A systematic review and meta-analysis	Sangah	Shin	Poster	Diet, Alcohol, Tobacco Use, and Other Lifestyle Factors	4/19/23	9:00 AM	Section 26	22
6469	Associations between serum iron levels and breast cancer tumor size	Ann	Von Holle	Poster	Diet, Alcohol, Tobacco Use, and Other Lifestyle Factors	4/19/23	9:00 AM	Section 26	23
6470	Coffee and tea consumption, coffee-related metabolites, and breast cancer risk in US Women	Andrea	Romanos-Nanclares	Poster	Diet, Alcohol, Tobacco Use, and Other Lifestyle Factors	4/19/23	9:00 AM	Section 26	24
6471	Tattooing and risk of hematologic cancer: A population-based case-control study in Utah	Rachel	McCarty	Poster	Diet, Alcohol, Tobacco Use, and Other Lifestyle Factors	4/19/23	9:00 AM	Section 26	25
6472	Self-reported knowledge of Δ 9-tetrahydrocannabinol (THC) and cannabidiol (CBD) potency in cannabis products among cancer patients and survivors: Results from a survey of cannabis consumers at an NCI-designated cancer center	Michelle	Goulette	Poster	Diet, Alcohol, Tobacco Use, and Other Lifestyle Factors	4/19/23	9:00 AM	Section 26	26
6473	Association of sun-seeking behaviors with indoor tanning habit in US females	Bojung	Seo	Poster	Diet, Alcohol, Tobacco Use, and Other Lifestyle Factors	4/19/23	9:00 AM	Section 26	27
6474	Stress-related sick leave and subsequent cancer risk: A Swedish national register study of 516 678 cancer cases	Sai San Moon	Lu	Poster	Diet, Alcohol, Tobacco Use, and Other Lifestyle Factors	4/19/23	9:00 AM	Section 26	28
6475	Compatibility of chatbot-based mobile and paper-based FFQs in participants with colorectal or gastric cancer screening	Eui Yeon	Lim	Poster	Diet, Alcohol, Tobacco Use, and Other Lifestyle Factors	4/19/23	9:00 AM	Section 26	29

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
6480	Mortality in patients with monoclonal gammopathy of undetermined significance: an analysis of National Health and Nutrition Examination Survey	Mengmeng	Ji	Poster	Novel Factors Associated with Cancer Mortality	4/19/23	9:00 AM	Section 27	1
6481	Systematic review of the literature: tertiary prevention in leukemia patients	Nikita	Manyak	Poster	Novel Factors Associated with Cancer Mortality	4/19/23	9:00 AM	Section 27	2
6482	CLDN18.2 expression is associated with clinicopathological features and prognosis of Chinese patients with digestive system cancers: a retrospective analysis	Chong	XiaoYi	Poster	Novel Factors Associated with Cancer Mortality	4/19/23	9:00 AM	Section 27	3
6483	The association between food deserts, food swamps, and obesity-related cancer mortality in the United States: the new epidemic	Malcolm	Bevel	Poster	Novel Factors Associated with Cancer Mortality	4/19/23	9:00 AM	Section 27	4
6484	Impact of time between last childbirth and diagnosis of early-onset breast cancer on survival in germline BRCA1/2 carriers	Zhenzhen	Zhang	Poster	Novel Factors Associated with Cancer Mortality	4/19/23	9:00 AM	Section 27	5
6485	Oxidative phosphorylation-associated radiomic feature and survival of women with serous ovarian cancer	Christelle	Colin-Leitzinger	Poster	Novel Factors Associated with Cancer Mortality	4/19/23	9:00 AM	Section 27	6
6486	Single nucleotide polymorphisms that predict serum cholesterol as a prostate cancer prognostic factor - a Mendelian randomization study	Teemu	Murtola	Poster	Novel Factors Associated with Cancer Mortality	4/19/23	9:00 AM	Section 27	7
6487	Association between telomere length and overall survival in lung cancer patients: a mendelian randomization study	Ting	Zhai	Poster	Novel Factors Associated with Cancer Mortality	4/19/23	9:00 AM	Section 27	8
6488	Correlation of availability of primary care physicians and colorectal cancer-related mortality in the United States: Do racial disparities exist?	Udhayvir	Grewal	Poster	Novel Factors Associated with Cancer Mortality	4/19/23	9:00 AM	Section 27	9
6489	Marital status, living arrangement, and overall survival among individuals with advanced prostate cancer in the IRONMAN cohort	Naiyu	Chen	Poster	Novel Factors Associated with Cancer Mortality	4/19/23	9:00 AM	Section 27	10
6490	Post-diagnosis statin use and survival among head and neck cancer patients: A cohort study in the US military health system	Jie	Lin	Poster	Novel Factors Associated with Cancer Mortality	4/19/23	9:00 AM	Section 27	11
6491	Temporal changes in circulating sex hormones and aromatase activity and associations with lung cancer survival in postmenopausal women	Yingya	Zhao	Poster	Novel Factors Associated with Cancer Mortality	4/19/23	9:00 AM	Section 27	12
6492	Body mass index characterization of patients undergoing neoadjuvant chemotherapy for breast cancer: Correlation with survival	Sangeetha	Prabhakaran	Poster	Novel Factors Associated with Cancer Mortality	4/19/23	9:00 AM	Section 27	13
6493	Ethnic disparities in breast cancer survival in Guam	Grazyna	Badowski	Poster	Novel Factors Associated with Cancer Mortality	4/19/23	9:00 AM	Section 27	14
6494	Postdiagnosis adherence to American Cancer Society cancer prevention guidelines and mortality among survivors of obesity-related cancers	Ying	Wang	Poster	Novel Factors Associated with Cancer Mortality	4/19/23	9:00 AM	Section 27	15

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
6495	The relationship between inflammatory diet score and cancer-specific outcomes: Systematic review and meta-analysis	Eric	Han	Poster	Novel Factors Associated with Cancer Mortality	4/19/23	9:00 AM	Section 27	16
6496	Exposure phenotype risk scores (E-PRS) and prostate cancer aggressiveness in the Michigan Genomics Initiative (MGI)	Xinman	Zhang	Poster	Novel Factors Associated with Cancer Mortality	4/19/23	9:00 AM	Section 27	17
6497	Availability of healthcare providers and its association with survival outcomes in non-Hodgkin lymphoma in the United States	Shiva Jashwanth	Gaddam	Poster	Novel Factors Associated with Cancer Mortality	4/19/23	9:00 AM	Section 27	18
6498	Association of lifestyle related risk factors with multiple myeloma mortality rates in the United States	Shiva Jashwanth	Gaddam	Poster	Novel Factors Associated with Cancer Mortality	4/19/23	9:00 AM	Section 27	19
6499	Towards a combined immunohistochemistry-based subtyping of ovarian endometrioid carcinoma	Brooke	Jorgensen	Poster	Novel Factors Associated with Cancer Mortality	4/19/23	9:00 AM	Section 27	20
6503	A case of stage IIA anal squamous cell carcinoma (SCC) diagnosed using a multi-cancer early detection (MCED) test	David	Myers	Poster	Early Detection and Molecular Markers of Prevention	4/19/23	9:00 AM	Section 28	1
6504	Germline genetically predicted body mass index is associated with endometrial cancer somatic transcriptomic, immune, and mutational signatures in The Cancer Genome Atlas	George	Richenberg	Poster	Early Detection and Molecular Markers of Prevention	4/19/23	9:00 AM	Section 28	2
6505	ColoScape test: a molecular assay to detect early-stage colorectal cancer in plasma cell-free DNA	Hiromi	Tanaka	Poster	Early Detection and Molecular Markers of Prevention	4/19/23	9:00 AM	Section 28	3
6506	Early colorectal cancer detection with a spectroscopic liquid biopsy	James	Cameron	Poster	Early Detection and Molecular Markers of Prevention	4/19/23	9:00 AM	Section 28	4
6507	E3 ubiquitin-protein ligase, tetratricopeptide repeat domain 3 (TTC3), H4 clustered histone 5 (H4C5), and epithelial cell adhesion molecule (EpCAM) are novel urine-enriched liquid biopsy biomarkers to detect prostate cancer in men	Ranjan	Perera	Poster	Early Detection and Molecular Markers of Prevention	4/19/23	9:00 AM	Section 28	5
6508	Eclipse, an automated CRISPR platform for the large-scale generation of cell models	Teddy	Lin	Poster	Early Detection and Molecular Markers of Prevention	4/19/23	9:00 AM	Section 28	6
6509	Panel of CD-34, CD-105 & vimentin in immunohistochemical & histomorphometric analysis for prognostic evaluation of oral potentially malignant lesions	Saravanan	SP	Poster	Early Detection and Molecular Markers of Prevention	4/19/23	9:00 AM	Section 28	7
6510	REM-DREAMing: Low-cost digital microfluidic analysis of DNA methylation heterogeneity for enhanced, liquid biopsy-based detection of early-stage lung cancer	Yang	Zhao	Poster	Early Detection and Molecular Markers of Prevention	4/19/23	9:00 AM	Section 28	8
6511	Optimizing an in vitro toolbox to interrogate pancreatic tumorigenesis from a patient-derived intraductal papillary mucinous neoplasm sample	Raymond	Paranal	Poster	Early Detection and Molecular Markers of Prevention	4/19/23	9:00 AM	Section 28	9
6512	Label-free autofluorescence imaging reveals different metabolic responses to adverse growth conditions between normal and breast cancer cells lines	Katherine	Junkins	Poster	Early Detection and Molecular Markers of Prevention	4/19/23	9:00 AM	Section 28	10

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
6513	Single cell and spatial profiling reveal molecular and immune evolution from precancers to invasive lung adenocarcinomas in genetic and carcinogen-induced mouse models	Bo	Zhu	Poster	Early Detection and Molecular Markers of Prevention	4/19/23	9:00 AM	Section 28	11
6514	Liquid biopsy for lung cancer based on extracellular vesicles	Juan	Hinestrosa	Poster	Early Detection and Molecular Markers of Prevention	4/19/23	9:00 AM	Section 28	12
6515	Pancreatic ductal adenocarcinoma (PDAC) early detection	Juan	Hinestrosa	Poster	Early Detection and Molecular Markers of Prevention	4/19/23	9:00 AM	Section 28	13
6516	Comparison study between a ketogenic diet and a high-fat diet on pancreatic cancer incidence in mice	Tarek	Bacha	Poster	Early Detection and Molecular Markers of Prevention	4/19/23	9:00 AM	Section 28	14
6518	Time course genomic characterization reveals progressive accumulation of mutations during tumor development in a Lynch syndrome mouse model	Yurong	Song	Poster	Early Detection and Molecular Markers of Prevention	4/19/23	9:00 AM	Section 28	16
6519	Haploinsufficiency for BRCA2 leads to common fragile site instability in human mammary epithelial cells	Mihriban	Karaayvaz	Poster	Early Detection and Molecular Markers of Prevention	4/19/23	9:00 AM	Section 28	17
6520	Combination of serum human satellite RNA and miR-21 levels as a biomarker for diagnosis of pancreatic cancer	Takahiro	Seimiya	Poster	Early Detection and Molecular Markers of Prevention	4/19/23	9:00 AM	Section 28	18
6521	Subtype-specific molecular signatures of field cancerization in patients with sporadic breast cancer	Anjana	Bhardwaj	Poster	Early Detection and Molecular Markers of Prevention	4/19/23	9:00 AM	Section 28	19
6522	Improved detection of low frequency mutations in ovarian and endometrial cancers by utilizing a highly accurate sequencing platform	Jiannis	Ragoussis	Poster	Early Detection and Molecular Markers of Prevention	4/19/23	9:00 AM	Section 28	20
6523	A case of stage I HPV-mediated oropharyngeal squamous cell carcinoma (SCC) diagnosed using a multi-cancer early detection (MCED) test	Jason	Carey	Poster	Early Detection and Molecular Markers of Prevention	4/19/23	9:00 AM	Section 28	21
6524	Single-cell transcriptomic analysis reveals immune landscape in the malignant transformation of normal lung to lung adenocarcinoma in genetic murine models	Hong	Chen	Poster	Early Detection and Molecular Markers of Prevention	4/19/23	9:00 AM	Section 28	22
6525	Colon cancer screening and treatment with engineered probiotics	Candice	Gurbatri	Poster	Early Detection and Molecular Markers of Prevention	4/19/23	9:00 AM	Section 28	23
6526	Investigation levels of trace elements in breast cancer types using laser spectroscopic techniques	Ola	Ahmed	Poster	Early Detection and Molecular Markers of Prevention	4/19/23	9:00 AM	Section 28	24
6527	Fusion genes as novel putative biomarkers for head and neck squamous cell carcinomas	Yabdiel	Ramos Valerio	Poster	Early Detection and Molecular Markers of Prevention	4/19/23	9:00 AM	Section 28	25
6528	HPV status and epigenetic profiling of saliva from a cancer-free population	Mariana	Brait	Poster	Early Detection and Molecular Markers of Prevention	4/19/23	9:00 AM	Section 28	26
6529	Early life liver proteomic signature and minerals mitigation of liver injury	Muhammad	Aslam	Poster	Early Detection and Molecular Markers of Prevention	4/19/23	9:00 AM	Section 28	27

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
6530	Preferential low frequency allele enrichment with lower sequencing depth requirement using KAPA HyperPETE specialized primer designs	Florence	Crary-Dooley	Poster	Early Detection and Molecular Markers of Prevention	4/19/23	9:00 AM	Section 28	28
6531	Point of care test for cervical cancer screening	Samrin	Habbani	Poster	Early Detection and Molecular Markers of Prevention	4/19/23	9:00 AM	Section 28	29
6535	Identification of coding and non-coding genes associated with survival outcomes in uterine cancer	Enrique	Ramos	Poster	Bioinformatics Applications in Cancer Biology 3	4/19/23	9:00 AM	Section 30	1
6537	Single cell transcriptomics uncovers cellular and molecular differences in PBMCs of responders and non-responders to the MUC1 cancer vaccine given in the preventative setting	Daniel	Yuan	Poster	Bioinformatics Applications in Cancer Biology 3	4/19/23	9:00 AM	Section 30	3
6538	Development and refinement of functional gene expression signatures as a computational tool for comprehensive characterization of transcriptomic data	Elena	Ocheredko	Poster	Bioinformatics Applications in Cancer Biology 3	4/19/23	9:00 AM	Section 30	4
6539	Application of optical genome mapping to identify samples with homologous recombination deficiency	Andy Wing Chun	Pang	Poster	Bioinformatics Applications in Cancer Biology 3	4/19/23	9:00 AM	Section 30	5
6540	Multiscale protein networks: de novo aberrant protein interactions and oncogenic regulators in seven cancer types	Won Min	Song	Poster	Bioinformatics Applications in Cancer Biology 3	4/19/23	9:00 AM	Section 30	6
6541	Geometry of gene expression network reveals potential novel indicator in Ewing sarcoma	Rena	Elkin	Poster	Bioinformatics Applications in Cancer Biology 3	4/19/23	9:00 AM	Section 30	7
6542	Detection of androgen receptor splice variants from clinical sequencing	Suhyun	Hwangbo	Poster	Bioinformatics Applications in Cancer Biology 3	4/19/23	9:00 AM	Section 30	8
6543	Comparative analysis of immune landscape according to EGFR mutation and tumor PD-L1 proportion scores in non-small cell lung cancer at single cell resolution	Kyoung-Ho	Pyo	Poster	Bioinformatics Applications in Cancer Biology 3	4/19/23	9:00 AM	Section 30	9
6544	Identification of epigenetic regulatory networks associated with the basal-like breast cancer subtype	Larissa	Okano	Poster	Bioinformatics Applications in Cancer Biology 3	4/19/23	9:00 AM	Section 30	10
6545	Investigating secondary findings in a pediatric cancer cohort: preliminary findings	Safa	Majeed	Poster	Bioinformatics Applications in Cancer Biology 3	4/19/23	9:00 AM	Section 30	11
6546	Peritoneal microenvironment promotes appendiceal adenocarcinoma tumor formation in PDX models	Vinay	Pattalachinti	Poster	Bioinformatics Applications in Cancer Biology 3	4/19/23	9:00 AM	Section 30	12
6547	Features of the TCR repertoire associate with patient's clinical and molecular characteristics in acute myeloid leukemia	Mateusz	Pospiech	Poster	Bioinformatics Applications in Cancer Biology 3	4/19/23	9:00 AM	Section 30	13
6548	Bioinformatic characterization of dendritic and T cell subpopulations in the tumor microenvironment across different cancer types by single-cell RNA-Seq analysis	Yamil	Mahmoud	Poster	Bioinformatics Applications in Cancer Biology 3	4/19/23	9:00 AM	Section 30	14

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
6549	Investigating the effects of density and frequency-dependent selection on subpopulations of cancer cells defined by copy number	Thomas	Veith	Poster	Bioinformatics Applications in Cancer Biology 3	4/19/23	9:00 AM	Section 30	15
6551	HiTAIC: Hierarchical tumor artificial intelligence classifier traces tissue of origin and tumor type in primary and metastasized tumors using DNA methylation data	Ze	Zhang	Poster	Bioinformatics Applications in Cancer Biology 3	4/19/23	9:00 AM	Section 30	17
6552	ZEB1-AS1 lncRNA prevents ZEB1 suppression and leads to tumor progression in undifferentiated AML subtype	Stefano	Percio	Poster	Bioinformatics Applications in Cancer Biology 3	4/19/23	9:00 AM	Section 30	18
6553	The development of homologous recombination repair deficiency (HRD) score methodology using WES data and its application in patient-derived xenograft models	Jixin	Wang	Poster	Bioinformatics Applications in Cancer Biology 3	4/19/23	9:00 AM	Section 30	19
6554	Prediction of MET amplification from H&E images in non small cell lung cancer using self-supervised deep learning and its role in clinical trial enrollment	Chaitanya	Parmar	Poster	Bioinformatics Applications in Cancer Biology 3	4/19/23	9:00 AM	Section 30	20
6555	Integrated bioinformatics analysis identified ASNS and DDIT3 as the therapeutic target in castration resistance prostate cancer	Yong Hyun	Park	Poster	Bioinformatics Applications in Cancer Biology 3	4/19/23	9:00 AM	Section 30	21
6556	A gene signature of DNA damage response pathway is predictive of patient clinical outcomes and is associated with tumor immune microenvironment of lung adenocarcinoma	Xiaoli	Zhang	Poster	Bioinformatics Applications in Cancer Biology 3	4/19/23	9:00 AM	Section 30	22
6557	A 6-microbial signature risk score for overall survival prediction in hepatocellular carcinoma: a machine learning approach	Nour	Al-Bzour	Poster	Bioinformatics Applications in Cancer Biology 3	4/19/23	9:00 AM	Section 30	23
6558	Defining differentiation States in well-differentiated and de-differentiated liposarcoma	Danh	Truong	Poster	Bioinformatics Applications in Cancer Biology 3	4/19/23	9:00 AM	Section 30	24
6559	Model constructed by ferroptosis-related genes and m6A genes predicts the sensitivity to different drug treatments	Mengyuan	Liu	Poster	Bioinformatics Applications in Cancer Biology 3	4/19/23	9:00 AM	Section 30	25
6560	Identification of distinct patterns in diffuse large B-cell lymphoma through alternative splicing analysis	Sanyeowool	An	Poster	Bioinformatics Applications in Cancer Biology 3	4/19/23	9:00 AM	Section 30	26
6561	Specific binding mode of RNA binding protein FAM120A to lncRNA	Kenichiro	Kawai	Poster	Bioinformatics Applications in Cancer Biology 3	4/19/23	9:00 AM	Section 30	27
6562	Comparative analysis of blood-based tumor fraction estimation in 300 cancer patients	Chao	Dai	Poster	Bioinformatics Applications in Cancer Biology 3	4/19/23	9:00 AM	Section 30	28
6563	Glioma stem cell index recapitulates grade, IDH mutation status and correlates with survival of glioma patients	Tathiane	Malta	Poster	Bioinformatics Applications in Cancer Biology 3	4/19/23	9:00 AM	Section 30	29
6564	Biomarker discovery in triple negative breast cancer using RNA-sequencing analysis	Jenna	Poulsen	Poster	Bioinformatics Applications in Cancer Biology 3	4/19/23	9:00 AM	Section 30	30
6568	Extended support for model organisms: The next frontier for the molecular signatures database	Anthony	Castanza	Poster	Databases, Platforms, and Tools	4/19/23	9:00 AM	Section 31	1

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
6569	ClinGen Somatic and CIViC collaborate to comprehensively evaluate somatic variants in cancer	Jason	Saliba	Poster	Databases, Platforms, and Tools	4/19/23	9:00 AM	Section 31	2
6570	Integrative pan-cancer genomic and transcriptomic analyses of refractory metastatic cancer	Daniel	Gautheret	Poster	Databases, Platforms, and Tools	4/19/23	9:00 AM	Section 31	3
6571	Mammonc-DB: A web based user-friendly tool for comprehensive multi-omics data analysis in breast cancer	Santhosh Kumar	Karthikeyan	Poster	Databases, Platforms, and Tools	4/19/23	9:00 AM	Section 31	4
6572	A lung cancer cell line explorer	Ling	Cai	Poster	Databases, Platforms, and Tools	4/19/23	9:00 AM	Section 31	5
6573	Drug Combo: A unique resource for efficient phase 1 trial design with manually curated MTD and DLT	Lei	Wang	Poster	Databases, Platforms, and Tools	4/19/23	9:00 AM	Section 31	6
6574	Systematic analysis of the predictive gene expression signatures of immunotherapies across multiple cancer types using IOSig	Samuel	Coleman	Poster	Databases, Platforms, and Tools	4/19/23	9:00 AM	Section 31	7
6575	LinkedOmicsKB: A web portal to explore pan-cancer molecular and phenotype associations	Sara	Savage	Poster	Databases, Platforms, and Tools	4/19/23	9:00 AM	Section 31	8
6576	Gabriella Miller Kids First Data Resource Center (KFDR): Empowering discovery across germline and somatic variation in pediatric cancer	David	Higgins	Poster	Databases, Platforms, and Tools	4/19/23	9:00 AM	Section 31	9
6577	CARMEN: A pan-HLA and pan-cancer proteogenomic database on antigen presentation to support cancer immunotherapy	Ashwin Adrian	Kallor	Poster	Databases, Platforms, and Tools	4/19/23	9:00 AM	Section 31	10
6578	reVUE: repository for variants with unexpected effects	Ino	de Bruijn	Poster	Databases, Platforms, and Tools	4/19/23	9:00 AM	Section 31	11
6579	Accelerating de-identification of images with cloud services to support data sharing in cancer research	Benjamin	Kopchick	Poster	Databases, Platforms, and Tools	4/19/23	9:00 AM	Section 31	12
6580	A machine learning-based pipeline and web server ImmuneMirror for neoantigen prediction	Wei	Dai	Poster	Databases, Platforms, and Tools	4/19/23	9:00 AM	Section 31	13
6581	SLKB: Synthetic lethality knowledge base for gene combination double knockout experiments	Birkan	Gökbağ	Poster	Databases, Platforms, and Tools	4/19/23	9:00 AM	Section 31	14
6582	A path to sustainability for the National Cancer Institute's Cancer Research Data Commons	Juergen	Klenk	Poster	Databases, Platforms, and Tools	4/19/23	9:00 AM	Section 31	15
6584	Potential carcinogenic effects of electronic nicotine delivery systems through epigenetic reprogramming in oral, brain, and lung stem cells	Jayanta	Das	Poster	Databases, Platforms, and Tools	4/19/23	9:00 AM	Section 31	17
6585	OncoKB, MSK's precision oncology knowledge base	Moriah	Nissan	Poster	Databases, Platforms, and Tools	4/19/23	9:00 AM	Section 31	18
6586	Updates to UALCAN, a comprehensive cancer proteogenomic data analysis platform for discovery research	Darshan	Shimoga Chandrashekar	Poster	Databases, Platforms, and Tools	4/19/23	9:00 AM	Section 31	19
6587	Method to increase performance of genome-wide association study using imputation for Asian ancestry	GangPyo	Ryu	Poster	Databases, Platforms, and Tools	4/19/23	9:00 AM	Section 31	20
6588	Systems biology-based drug repositioning and biomarker discovery for Thai liver fluke-associated cholangiocarcinoma	Somponnat	Sampattavanich	Poster	Databases, Platforms, and Tools	4/19/23	9:00 AM	Section 31	21

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
6590	Undergraduate e-mentoring in cancer research: The ACE scholars program	Cristina	Baciu	Poster	Databases, Platforms, and Tools	4/19/23	9:00 AM	Section 31	23
6591	A universal atlas of cellular and oncogenic phenotypes	Corey	Weistuch	Poster	Databases, Platforms, and Tools	4/19/23	9:00 AM	Section 31	24
6592	An AI platform for vascular and fibrosis analysis of pathology images	Yawen	Zheng	Poster	Databases, Platforms, and Tools	4/19/23	9:00 AM	Section 31	25
6596	Genomic and proteome analysis using preoperative cell free DNA and extracellular vesicles of lung cancer patients	Hayato	Koba	Poster	Integrative Spatial and Temporal Multi-omics of Cancer	4/19/23	9:00 AM	Section 32	1
6597	A multi-omics classifier achieves high sensitivity and specificity for pancreatic ductal adenocarcinoma in a case-control study of 146 subjects	Brian	Koh	Poster	Integrative Spatial and Temporal Multi-omics of Cancer	4/19/23	9:00 AM	Section 32	2
6598	The development of a tumor-agnostic liquid biopsy assay for minimal residual disease detection and monitoring in cancers	Giancarlo	Bonora	Poster	Integrative Spatial and Temporal Multi-omics of Cancer	4/19/23	9:00 AM	Section 32	3
6599	Neomer and fragmentation profiles of cell-free DNA with low-pass whole genome sequencing to predict prostate cancer biopsy outcomes	Haimeng	Tang	Poster	Integrative Spatial and Temporal Multi-omics of Cancer	4/19/23	9:00 AM	Section 32	4
6600	The nRichDX [®] revolution sample prep system enables recovery of more amplifiable copies and more cancer fraction detection from cfDNA as evaluated on the MassARRAY [®] System	Nafiseh	Jafari	Poster	Integrative Spatial and Temporal Multi-omics of Cancer	4/19/23	9:00 AM	Section 32	5
6601	Analytical validation of a robust integrated genomic and epigenomic liquid biopsy for biomarker discovery, therapy selection, and response monitoring	Brett	Kennedy	Poster	Integrative Spatial and Temporal Multi-omics of Cancer	4/19/23	9:00 AM	Section 32	6
6602	Refining liquid biopsy: generating more information from cell free DNA	Joanna	Holbrook	Poster	Integrative Spatial and Temporal Multi-omics of Cancer	4/19/23	9:00 AM	Section 32	7
6603	BRCA1 promoter methylation in sporadic breast cancer patients detected by liquid biopsy	Jennifer	Yen	Poster	Integrative Spatial and Temporal Multi-omics of Cancer	4/19/23	9:00 AM	Section 32	8
6604	Analytical development and validation of a personalized hybrid capture based assay for high sensitivity monitoring minimal residual disease (MRD)	Xiaoqiang	Wang	Poster	Integrative Spatial and Temporal Multi-omics of Cancer	4/19/23	9:00 AM	Section 32	9
6605	Automated isolation and identification of circulating rare cells from blood samples using a label-free rare cell isolation platform - the Genesis System with Celselect Slide technology	Yoon-Tae	Kang	Poster	Integrative Spatial and Temporal Multi-omics of Cancer	4/19/23	9:00 AM	Section 32	10
6606	Biomarker discovery in non-small-cell lung cancer enabled by deep multi-omics profiling of proteins, metabolites, transcripts, and genes in blood	Manway	Liu	Poster	Integrative Spatial and Temporal Multi-omics of Cancer	4/19/23	9:00 AM	Section 32	11
6607	Dried blood spot (DBS) sample analysis for drug and metabolomic profiling in oncology clinical trials: Cost-effective decentralized sampling modality for precision oncology	Megan	Showalter	Poster	Integrative Spatial and Temporal Multi-omics of Cancer	4/19/23	9:00 AM	Section 32	12

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
6608	High-sensitivity detection of specific ultra low-frequency somatic mutations for minimal residual disease monitoring	Tong	Liu	Poster	Integrative Spatial and Temporal Multi-omics of Cancer	4/19/23	9:00 AM	Section 32	13
6609	Detection of rare mutations, copy number variation, and DNA methylation in the same template DNA molecules	Yuxuan	Wang	Poster	Integrative Spatial and Temporal Multi-omics of Cancer	4/19/23	9:00 AM	Section 32	14
6610	Increasing blood volumes to detect minimal residual disease in neoadjuvant-treated early breast cancer patients	Alfonso	Alba-Bernal	Poster	Integrative Spatial and Temporal Multi-omics of Cancer	4/19/23	9:00 AM	Section 32	15
6611	Harnessing the power of multiomics from a single sample to explore tumor heterogeneity and advancing immuno-oncology research	Bhagyashree	Birla	Poster	Integrative Spatial and Temporal Multi-omics of Cancer	4/19/23	9:00 AM	Section 32	16
6612	Data-driven hallmarks of cancer as a new paradigm for precision medicine: multi-omics and functional profiling in acute myeloid leukemia	Tom	Erkers	Poster	Integrative Spatial and Temporal Multi-omics of Cancer	4/19/23	9:00 AM	Section 32	17
6613	Label-free multimodal multiphoton microscopy for predicting DNA damage response in patient derived non-small cell lung cancer organoids	Terrence	Roh	Poster	Integrative Spatial and Temporal Multi-omics of Cancer	4/19/23	9:00 AM	Section 32	18
6614	Spatial transcriptomic driven mechanistic model to investigate and predict pathogenesis of oligodendroglioma	Sandhya	Prabhakaran	Poster	Integrative Spatial and Temporal Multi-omics of Cancer	4/19/23	9:00 AM	Section 32	19
6615	Novel digital pathology tools for exploring role of myeloid cells in modulating next generation immunotherapies	Richard	Van Krieken	Poster	Integrative Spatial and Temporal Multi-omics of Cancer	4/19/23	9:00 AM	Section 32	20
6616	Development of a high-throughput image processing pipeline for multiplex immunofluorescence whole slide images at scale	Waleed	Tahir	Poster	Integrative Spatial and Temporal Multi-omics of Cancer	4/19/23	9:00 AM	Section 32	21
6617	Gleason score 6 often coexists with Gleason score 7 adenocarcinoma within 3D z-levels of a prostate biopsy	Xavier	Farré	Poster	Integrative Spatial and Temporal Multi-omics of Cancer	4/19/23	9:00 AM	Section 32	22
6618	Longitudinal, multimodal profiling of metastatic ER+ breast cancer on CDK4/6 inhibitor therapy	Allison	Creason	Poster	Integrative Spatial and Temporal Multi-omics of Cancer	4/19/23	9:00 AM	Section 32	23
6619	Virtual staining enabled combined morphological and spatial transcriptomic analysis of individual malignant B cells and local tumor microenvironments	Michael	Kallen	Poster	Integrative Spatial and Temporal Multi-omics of Cancer	4/19/23	9:00 AM	Section 32	24
6620	Identification of crosstalk signaling between brain-tumor niche and reactive human cytomegalovirus in brain metastases	Hong	Zhao	Poster	Integrative Spatial and Temporal Multi-omics of Cancer	4/19/23	9:00 AM	Section 32	25
6621	Simulating the distortion of clonal fractions in ctDNA due to spatially heterogenous selection	Thomas	Rachman	Poster	Integrative Spatial and Temporal Multi-omics of Cancer	4/19/23	9:00 AM	Section 32	26
6622	Developing spatial molecular correlates of response to immunotherapy in kidney cancer	Anupama	Reddy	Poster	Integrative Spatial and Temporal Multi-omics of Cancer	4/19/23	9:00 AM	Section 32	27
6623	Spatial organization of tumor-infiltrating lymphocytes (TILs) is prognostic for survival in triple negative breast cancer (TNBC)	Sahil	Patel	Poster	Integrative Spatial and Temporal Multi-omics of Cancer	4/19/23	9:00 AM	Section 32	28

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
6624	3D assessment of the lung cancer microenvironment using multi-resolution open-top light-sheet microscopy	Alexandra	Alvarsson	Poster	Integrative Spatial and Temporal Multi-omics of Cancer	4/19/23	9:00 AM	Section 32	29
6625	Mathematical modeling of single-cell data reveals the key role of stochasticity - not fitness - in determining the clonal origins of relapse in childhood leukemia	Virginia	Turati	Poster	Integrative Spatial and Temporal Multi-omics of Cancer	4/19/23	9:00 AM	Section 32	30
6629	Genomic and immunophenotypic landscape of acquired resistance to PD-(L)1 blockade in non-small cell lung cancer	Biagio	Ricciuti	Poster	Immune Checkpoints	4/19/23	9:00 AM	Section 38	1
6630	Flow cytometry immunophenotyping using commercial antibodies to maximize detection of PD-1 in immuno-oncology (I-O) clinical studies with anti-PD-1 check point inhibitors	Angelina	Bisconte	Poster	Immune Checkpoints	4/19/23	9:00 AM	Section 38	2
6631	Association between poliovirus receptor (PVR) expression in tumor and exclusion of immune cells expressing T cell immunoreceptor with Ig and ITIM domain (TIGIT) from tumor area	Sara	Moore	Poster	Immune Checkpoints	4/19/23	9:00 AM	Section 38	3
6632	Simultaneous comparison of response to two different anti-PD1 drugs in the same patient using a human tumor histo-culture platform	Satish	Sankaran	Poster	Immune Checkpoints	4/19/23	9:00 AM	Section 38	4
6633	T regulatory cell subsets in colorectal cancer: friends or foes	Eyad	Elkord	Poster	Immune Checkpoints	4/19/23	9:00 AM	Section 38	5
6634	Digital and spacial characterization of PD-L1 expression and IVD assay performance in the immune landscape of head and neck squamous cell carcinoma: A multimodal approach	Clara	Troccoli	Poster	Immune Checkpoints	4/19/23	9:00 AM	Section 38	6
6635	Lipid and glycolipid antigen presentation faults as a mechanism of resistance to immune checkpoint therapy in poorly immunogenic melanomas	Carlos	Figueiredo	Poster	Immune Checkpoints	4/19/23	9:00 AM	Section 38	7
6636	Metformin suppresses tumor immune evasion through downregulation of PD-L1 expression in cancer cells and PD-1 expression in NK cells and T cells	Su Hwan	Park	Poster	Immune Checkpoints	4/19/23	9:00 AM	Section 38	8
6637	Transcriptomic biomarkers of immunotherapy response in solid tumors	Balazs	Gyorffy	Poster	Immune Checkpoints	4/19/23	9:00 AM	Section 38	9
6638	Pulsed electric fields combined with anti-PD1 prolongs survival and triggers an adaptive immune response in an IO-non-responsive orthotopic mouse model	Ebtesam	Nafie	Poster	Immune Checkpoints	4/19/23	9:00 AM	Section 38	10
6639	Preclinical characterization and clinical biomarker studies with RP3, a novel oncolytic immunotherapy expressing a fusogenic protein, a human anti-CTLA-4 antibody, hCD40L and h4-1BBL	Praveen	Bommareddy	Poster	Immune Checkpoints	4/19/23	9:00 AM	Section 38	11
6641	ATG-031, a first-in-class humanized anti-CD24 antibody, demonstrates potent in vivo efficacy and repolarizes tumor-associated macrophages in the TME	Bing	Hou	Poster	Immune Checkpoints	4/19/23	9:00 AM	Section 38	13

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
6642	Rapid tissue donation identifies LAG3 as a potential therapeutic target for ALK fusion positive lung cancer	Hilal	Ozakinci	Poster	Immune Checkpoints	4/19/23	9:00 AM	Section 38	14
6643	Immune checkpoint reporter cell lines based on the protein profiling of ATCC cell lines for cancer immunotherapy drug screening	Hyeyoun	Chang	Poster	Immune Checkpoints	4/19/23	9:00 AM	Section 38	15
6644	Investigating the effect of immune checkpoint inhibitors (ICI) on ovarian function in young patients with melanoma	Ashley	Hickman	Poster	Immune Checkpoints	4/19/23	9:00 AM	Section 38	16
6645	A systematic approach for detection of tumor genomic alterations which alter the immune microenvironment	Raven	Vella	Poster	Immune Checkpoints	4/19/23	9:00 AM	Section 38	17
6646	Inhibition of HuR/CD147/IL-6 axis enhances anti-PD1 immunotherapy response in cancer	Qi	Zhang	Poster	Immune Checkpoints	4/19/23	9:00 AM	Section 38	18
6647	Dostarlimab shows dose-dependent immune activation of the tumor microenvironment in a patient-derived NSCLC explant model similar to pembrolizumab	Giovanna	Bergamini	Poster	Immune Checkpoints	4/19/23	9:00 AM	Section 38	19
6648	Prediction of anti-PD-1 efficacy based on immune marker densities and their spatial distribution in colorectal cancer	Bahar	Saberzadeh-Ardestani	Poster	Immune Checkpoints	4/19/23	9:00 AM	Section 38	20
6649	Prevalence and spatial interplay of mononuclear phagocyte and lymphocyte subpopulations in 49 carcinoma entities in respect to its TIM3, PD-1, PD-L1 and CTLA-4 expression using BLEACH&STAIN	Niclas	Blessin	Poster	Immune Checkpoints	4/19/23	9:00 AM	Section 38	21
6650	Cell-based assay to support development and characterization of new drugs in immuno-oncology	Mohammad	Haque	Poster	Immune Checkpoints	4/19/23	9:00 AM	Section 38	22
6651	MoA-based potency bioassays for immunotherapy programs targeting the TIGIT/CD112R/CD96 axis	Steven	Edenson	Poster	Immune Checkpoints	4/19/23	9:00 AM	Section 38	23
6652	Overcoming immune resistance in DNA mismatch repair deficient tumors	Guillaume	Mestrallet	Poster	Immune Checkpoints	4/19/23	9:00 AM	Section 38	24
6653	Analysis of selective response of anti-PD-L1 treatment in huPBMC-NCG mice reconstituted with different donors	Hongyan	Sun	Poster	Immune Checkpoints	4/19/23	9:00 AM	Section 38	25
6654	Association PD-L1 overexpression with immune checkpoint inhibitor effect in triple-negative breast cancer	A Young	Park	Poster	Immune Checkpoints	4/19/23	9:00 AM	Section 38	26
6655	A real world analysis: Impact of clinical trial eligibility criteria on clinical outcomes among patients with advanced non-small cell lung cancer (aNSCLC) receiving second line (2L) immune checkpoint inhibitor (ICI) therapy	Hina	Mohammed	Poster	Immune Checkpoints	4/19/23	9:00 AM	Section 38	27
6656	Expression pattern and clinicopathological implication of B7 family immune checkpoints, VTCN1 and HHLA2, in non-small cell lung cancer	Sojung	Lim	Poster	Immune Checkpoints	4/19/23	9:00 AM	Section 38	28

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
6657	Phase I trial of first-in-class anti-PVR mAb NTX1088: Restoration of DNAM1 expression as MOA for enhanced antitumor immunity	Pini	Tsukerman	Poster	Immune Checkpoints	4/19/23	9:00 AM	Section 38	29
6658	Prevalence of PD-L1 expression and its correlation with tumor biomarkers in the Chinese muscle invasive urothelial bladder carcinoma patients	Yu	Fan	Poster	Immune Checkpoints	4/19/23	9:00 AM	Section 38	30
6662	Studying immune responses against human endogenous retroviruses in immune checkpoint blockade-treated lung adenocarcinoma	Khaled	Sanber	Poster	Immune Monitoring and Responses to Therapy	4/19/23	9:00 AM	Section 39	1
6663	Immunostimulatory gene therapy targeting CD40/4-1BB in combination with chemotherapy induces an inflammatory gene profile in tumors from patients with advanced disease	Jessica	Wenthe	Poster	Immune Monitoring and Responses to Therapy	4/19/23	9:00 AM	Section 39	2
6664	Comprehensive immunoprofiling of peripheral blood reveals five conserved immunotypes with implications for immunotherapy in cancer patients	Michael	Goldberg	Poster	Immune Monitoring and Responses to Therapy	4/19/23	9:00 AM	Section 39	3
6665	A spatiotemporal cell atlas of human gastric malignancy reveals mechanisms underlying metastasis and immunotherapy response	Yikai	Luo	Poster	Immune Monitoring and Responses to Therapy	4/19/23	9:00 AM	Section 39	4
6666	Multispectral imaging to detect immune phenotypes in pre and post therapy breast cancer patient specimens	Navi	Mehra	Poster	Immune Monitoring and Responses to Therapy	4/19/23	9:00 AM	Section 39	5
6667	Pan-cancer assessment of tumour and peripheral T-cell receptor repertoire dynamics in patients treated with immune checkpoint inhibitors	Shirin	Soleimani	Poster	Immune Monitoring and Responses to Therapy	4/19/23	9:00 AM	Section 39	6
6668	Immune infiltrate co-occurrence and neoantigen similarity are prognostic factors in early stage NSCLC	Charles	Abbott	Poster	Immune Monitoring and Responses to Therapy	4/19/23	9:00 AM	Section 39	7
6669	Antigen features are associated with response and survival after neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer	Wolfgang	Beckabir	Poster	Immune Monitoring and Responses to Therapy	4/19/23	9:00 AM	Section 39	8
6670	Association between circulating CD4 memory T cell levels and severe immune-related adverse events in melanoma patients treated with immune checkpoint blockade	Abul	Usmani	Poster	Immune Monitoring and Responses to Therapy	4/19/23	9:00 AM	Section 39	9
6671	Simplifying high-parameter phenotypic and functional characterization of cancer immune cells	Deeqa	Mahamed	Poster	Immune Monitoring and Responses to Therapy	4/19/23	9:00 AM	Section 39	10
6673	Simultaneous detection of IGH VDJ rearrangements and JH translocations via Ring-Seq, a novel multiplex PCR technology for targeted sequencing of translocations with novel gene partners or breakpoints	Timothy	Looney	Poster	Immune Monitoring and Responses to Therapy	4/19/23	9:00 AM	Section 39	12
6675	Integration of associations of immune profiles in peripheral blood and tumor microenvironment with bladder cancer outcomes	Ji-Qing	Chen	Poster	Immune Monitoring and Responses to Therapy	4/19/23	9:00 AM	Section 39	14

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
6676	Exploratory biomarker analyses in phase 1 study of regorafenib, ipilimumab, and nivolumab (RIN) in chemotherapy resistant microsatellite stable (MSS) metastatic colorectal cancer (mCRC)	Jian	Ye	Poster	Immune Monitoring and Responses to Therapy	4/19/23	9:00 AM	Section 39	15
6677	Preliminary immune correlates from BCA101 trial show favorable modulation of tumor immune microenvironment	Patrick	Lizotte	Poster	Immune Monitoring and Responses to Therapy	4/19/23	9:00 AM	Section 39	16
6681	XNA increases assay sensitivity in sanger sequencing, qPCR, NGS and CRISPR mutant screening	Wei	Liu	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 5	4/19/23	9:00 AM	Section 40	1
6682	A patient-specific, tumor-informed, circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) assay in surgical patients with biliary tract cancer	Tianqiang	Song	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 5	4/19/23	9:00 AM	Section 40	2
6683	Genetic alterations of circulating tumor DNA in advanced pancreatic cancer patients receiving 5-fluorouracil based chemotherapy	SooBeen	Heo	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 5	4/19/23	9:00 AM	Section 40	3
6684	Detection of PD-L1, HER2 and EGFR on circulating tumor cells in carcinoma patients	Jayant	Khandare	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 5	4/19/23	9:00 AM	Section 40	4
6685	Targeted liquid biopsy mutation profiling and genome-wide cfDNA copy-number landscape in 3000 samples from six major cancer indications	Billie	Gould	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 5	4/19/23	9:00 AM	Section 40	5
6686	Tumor suppressor miRNA-665 based serum biomarker for detecting pancreatobiliary cancer	Shuichi	Mitsunaga	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 5	4/19/23	9:00 AM	Section 40	6
6687	Prevalence of four major gene mutation classes in a survey of ctDNA recovery from early and advanced stage NSCLC	Claire	Gould	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 5	4/19/23	9:00 AM	Section 40	7
6688	Development of a liquid biopsy cfDNA assay for detection of multiple HPV types in cervical neoplasias	Harriet	Wikman	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 5	4/19/23	9:00 AM	Section 40	8
6689	Whole genome cell-free tumor DNA mutational signatures from blood for early detection of recurrence of low stage lung adenocarcinoma	Matija	Snuderl	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 5	4/19/23	9:00 AM	Section 40	9
6690	Monitoring response and resistance to EGFR inhibition with circulating tumor DNA in a non-small cell lung cancer patient-derived xenograft	Long	Do	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 5	4/19/23	9:00 AM	Section 40	10
6691	Paired comparison of routine molecular screening of patient samples with advanced non-small cell lung cancer in circulating cell-free DNA using OncoBEAM™ EGFR V2, targeted next-generation sequencing Plasma-SeqSense™ Solid Cancer IVD Kit and custom-validated NGS assay	Lea	Payen-Gay	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 5	4/19/23	9:00 AM	Section 40	11
6692	Identification of circulating tumor cells based on machine learning	Jae Hyuk	Lee	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 5	4/19/23	9:00 AM	Section 40	12

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
6693	Stability of urinary cell-free DNA and detection of T790M variant	Ivonne	Nel	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 5	4/19/23	9:00 AM	Section 40	13
6694	Evaluation of a multi-omics approach to molecular residual disease detection	Brady	Culver	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 5	4/19/23	9:00 AM	Section 40	14
6695	Utility of circulating tumor DNA in breast cancer clinical research and practice: systematic review and meta-analysis	Xuezheng	Sun	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 5	4/19/23	9:00 AM	Section 40	15
6696	Genomic alterations associated with early-onset and late-onset colorectal cancer	Eric	Lander	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 5	4/19/23	9:00 AM	Section 40	16
6697	Deep learning algorithm for cancer detection using multimodal characteristics of whole methylome sequencing of cf-DNA	Juntae	Park	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 5	4/19/23	9:00 AM	Section 40	17
6698	Combinatorial genomic and epigenomic cell-free DNA analysis of high-risk metastatic castration resistant prostate cancer reveals prognostic liquid biopsy signatures	Pradeep	Chauhan	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 5	4/19/23	9:00 AM	Section 40	18
6699	What are the characteristics of mutations to use as targets in tumor-informed ctDNA analysis?	Marijana	Nesic	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 5	4/19/23	9:00 AM	Section 40	19
6700	Characterizing circulating tumor DNA release kinetics and fragment length in a chemotherapy resistant model of esophageal adenocarcinoma	Alexandra	Bartolomucci	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 5	4/19/23	9:00 AM	Section 40	20
6701	6-color Crystal Digital PCR for the high-plex detection of 10 ESR1 mutations in breast cancer	Stavroula	Smilkou	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 5	4/19/23	9:00 AM	Section 40	21
6702	The clinical characteristics and outcomes of NSCLC patients with genomic alterations detected by blood-based NGS ctDNA assay	Hsin-Yi	Wang	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 5	4/19/23	9:00 AM	Section 40	22
6703	Objective qualification of cell-free DNA by applying the cfDNA quality metric	Annika	Dorn	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 5	4/19/23	9:00 AM	Section 40	23
6704	A digital-PCR primer/probe library for pan-cancer ctDNA monitoring established from public databases for somatic mutations	Hayato	Hiraki	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 5	4/19/23	9:00 AM	Section 40	24
6705	Molecular detection of circulating cancer cells with cancer stem cell or mesenchymal characteristics in esophageal squamous cell carcinoma	Zhen	Tan	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 5	4/19/23	9:00 AM	Section 40	25
6706	Co-culture of circulating tumor cells (CTCs)-derived 3D organoids and autologous cytotoxic CD8+ T cells: A new functional precision oncology platform	Lanlan	Zhou	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 5	4/19/23	9:00 AM	Section 40	26
6707	Optimization of miRNA isolation from plasma biopsies of proton therapy prostate cancer patients	Johnny	Velasquez	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 5	4/19/23	9:00 AM	Section 40	27

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
6709	Utility of RNA sequencing for transcriptome analysis of small extracellular vesicles derived from blood sera of colorectal cancer patients	Tana	Machackova	Poster	Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 5	4/19/23	9:00 AM	Section 40	29
6713	Myc-regulated miR17, 20a modulate RANK expression in osteosarcoma	Bikesh	Nirala	Poster	Preclinical Therapies and Clinical Observations in Pediatric Oncology	4/19/23	9:00 AM	Section 41	1
6714	ALCAM promotes neuroblastoma proliferation, migration, and immune evasion	Jarrett	Lindsay	Poster	Preclinical Therapies and Clinical Observations in Pediatric Oncology	4/19/23	9:00 AM	Section 41	2
6715	CLIC1 and CLIC4 ion channels as bioelectric targets for tumor treating fields in pediatric high-grade glioma	Stuart	Smith	Poster	Preclinical Therapies and Clinical Observations in Pediatric Oncology	4/19/23	9:00 AM	Section 41	3
6716	Preclinical evaluation of nano-liposomal irinotecan in pediatric solid tumor patient-derived xenografts	Elizabeth	Stewart	Poster	Preclinical Therapies and Clinical Observations in Pediatric Oncology	4/19/23	9:00 AM	Section 41	4
6717	Extracellular vesicles in diagnostic retinoblastoma aqueous humor correlate with disease stage and clinical outcome: a pilot study	Sarah	Pike	Poster	Preclinical Therapies and Clinical Observations in Pediatric Oncology	4/19/23	9:00 AM	Section 41	5
6718	Exploiting metabolic vulnerabilities of pediatric rhabdomyosarcoma with novelnicotinamide phosphoribosyltransferase (NAMPT) inhibitor OT-82	Grace	McKay-Corkum	Poster	Preclinical Therapies and Clinical Observations in Pediatric Oncology	4/19/23	9:00 AM	Section 41	6
6720	Using proteasome inhibition to hyperactivate the integrated stress response in aggressive pediatric brain tumors	Orlandi	Novak	Poster	Preclinical Therapies and Clinical Observations in Pediatric Oncology	4/19/23	9:00 AM	Section 41	8
6721	β 3-adrenergic receptor correlates with tumor growth and progression in neuroblastoma	Alessia	Boaretto	Poster	Preclinical Therapies and Clinical Observations in Pediatric Oncology	4/19/23	9:00 AM	Section 41	9
6722	RNAScope in situ hybridization as a novel approach for the spatiotemporal assessment of RD3 mRNA expression in neuroblastoma	Natarajan	Aravindan	Poster	Preclinical Therapies and Clinical Observations in Pediatric Oncology	4/19/23	9:00 AM	Section 41	10
6723	Application of in vitro drug screening of circulating tumor cells in pediatric glioma therapy	Yen-Lin	Liu	Poster	Preclinical Therapies and Clinical Observations in Pediatric Oncology	4/19/23	9:00 AM	Section 41	11
6725	Targeting urea cycle dysfunction to prevent and treat osteosarcoma	Rachel	Offenbacher	Poster	Preclinical Therapies and Clinical Observations in Pediatric Oncology	4/19/23	9:00 AM	Section 41	13
6726	Effectiveness of irinotecan plus trabectedin in a desmoplastic small round cell tumor patient-derived xenograft	Valentina	Doldi	Poster	Preclinical Therapies and Clinical Observations in Pediatric Oncology	4/19/23	9:00 AM	Section 41	14
6727	Therapeutic targeting of BET bromodomain proteins increases DNA damage and potentiates salvage therapy in osteosarcoma xenografts derived from patients with replication stress signatures	Niknam	Riyahi	Poster	Preclinical Therapies and Clinical Observations in Pediatric Oncology	4/19/23	9:00 AM	Section 41	15
6728	Osteosarcoma patient-derived xenografts derived from naive and pretreated metastatic patients with high-risk CDK4/6 hyperactivation signatures are sensitive to dual inhibition of CDK4/6 and PI3K/mTOR	Farinaz	Barghi	Poster	Preclinical Therapies and Clinical Observations in Pediatric Oncology	4/19/23	9:00 AM	Section 41	16

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
6729	Urea cycle metabolism is disturbed in Fibrolamellar carcinoma	Mahsa	Shirani	Poster	Preclinical Therapies and Clinical Observations in Pediatric Oncology	4/19/23	9:00 AM	Section 41	17
6730	Preclinical testing of lestaurtinib (CEP701) as a single and combination agent for the treatment of Ewing sarcoma	Stefan	Zöllner	Poster	Preclinical Therapies and Clinical Observations in Pediatric Oncology	4/19/23	9:00 AM	Section 41	18
6731	Gut microbiome associated with the psychoneurological symptom cluster among children with solid tumors receiving chemotherapy	Jinbing	Bai	Poster	Preclinical Therapies and Clinical Observations in Pediatric Oncology	4/19/23	9:00 AM	Section 41	19
6732	Identifying novel combination therapies for Ewing sarcoma	Maria Ana Isabel	De Los Santos	Poster	Preclinical Therapies and Clinical Observations in Pediatric Oncology	4/19/23	9:00 AM	Section 41	20
6733	Targeting Sp1 in Ewing sarcoma: a multi-approach method for the utilization of mithramycin	Christoffer	Lambring	Poster	Preclinical Therapies and Clinical Observations in Pediatric Oncology	4/19/23	9:00 AM	Section 41	21
6734	Identification of the novel TENM3-ALK fusion in an AYA case with ALK rearranged neuroblastoma	Mitsuteru	Hiwatari	Poster	Preclinical Therapies and Clinical Observations in Pediatric Oncology	4/19/23	9:00 AM	Section 41	22
6735	Identifying the role of novel driver TREX subcomplex in medulloblastoma growth and progression	Shahad	Abdulsahib	Poster	Preclinical Therapies and Clinical Observations in Pediatric Oncology	4/19/23	9:00 AM	Section 41	23
6736	Suppression of antigen presentation is a hallmark of pediatric rhabdomyosarcoma	David	Milewski	Poster	Preclinical Therapies and Clinical Observations in Pediatric Oncology	4/19/23	9:00 AM	Section 41	24
6737	Exposure-response and age subgroup analyses to support body-weight (BW) dosing of brentuximab vedotin (BV) in newly diagnosed high-risk classical Hodgkin lymphoma (cHL) in children and young adults (aged 2-21 years [y]): A randomized children's oncology group phase 3 trial (AHOD1331)	Zufei	Zhang	Poster	Preclinical Therapies and Clinical Observations in Pediatric Oncology	4/19/23	9:00 AM	Section 41	25
6741	Number of prescription drugs and overall survival in metastatic castrate resistant prostate cancer	Carley	Pickett	Poster	Retrospective Clinical Analyses 2	4/19/23	9:00 AM	Section 42	1
6742	Genomic profiling and sites of metastasis in non-small cell lung cancer (NSCLC)	Ji	Lin	Poster	Retrospective Clinical Analyses 2	4/19/23	9:00 AM	Section 42	2
6743	Clinical outcomes with pembrolizumab-based therapies in relapsed/refractory NSCLC after definitive chemoradiation and durvalumab	Lukas	Delasos	Poster	Retrospective Clinical Analyses 2	4/19/23	9:00 AM	Section 42	3
6744	Cell-free DNA detection of alterations in the MAPK pathway in metastatic hormone receptor positive breast cancer: A multi-institutional analysis of incidence and clinical outcomes	Arielle	Medford	Poster	Retrospective Clinical Analyses 2	4/19/23	9:00 AM	Section 42	4
6745	Prognostic indicators and outcomes of hepatocellular carcinoma (HCC) in an Appalachian population	Michelle	Hartzell	Poster	Retrospective Clinical Analyses 2	4/19/23	9:00 AM	Section 42	5
6746	Academic facility is associated with improved survival in patients with leiomyosarcoma: a national cancer database analysis	Steven	Stanley	Poster	Retrospective Clinical Analyses 2	4/19/23	9:00 AM	Section 42	6
6747	Sites of metastases prior to systemic treatment influence progression patterns and survival in stage IV melanoma patients	Ismael	Vergara	Poster	Retrospective Clinical Analyses 2	4/19/23	9:00 AM	Section 42	7

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
6749	Histiocytic sarcoma descriptors and clinicopathologic determinants of survival: Analysis of a pooled database	Philip	Haddad	Poster	Retrospective Clinical Analyses 2	4/19/23	9:00 AM	Section 42	9
6750	Primary effusion lymphoma descriptors and clinicopathologic determinants of survival: Analysis of a pooled database	Philip	Haddad	Poster	Retrospective Clinical Analyses 2	4/19/23	9:00 AM	Section 42	10
6751	Provisional prognostic score for primary effusion lymphoma	Philip	Haddad	Poster	Retrospective Clinical Analyses 2	4/19/23	9:00 AM	Section 42	11
6752	Patient (pt) characteristics, diagnostic journey, and cancer enrichment among pts with nonspecific signs and/or symptoms (s/sx) in the US community oncology setting: a real-world retrospective study	Christopher	Benton	Poster	Retrospective Clinical Analyses 2	4/19/23	9:00 AM	Section 42	12
6753	Non-HIV cryptococcal patients with hematological malignancies: A retrospective analysis of a ten-year study from a Peruvian oncologic center	Kelly	Meza	Poster	Retrospective Clinical Analyses 2	4/19/23	9:00 AM	Section 42	13
6754	Clinical characteristics, real-world treatment patterns, and clinical outcomes among patients with previously treated metastatic or unresectable EGFR-mutated non-small cell lung cancer in the United States	Jie	Meng	Poster	Retrospective Clinical Analyses 2	4/19/23	9:00 AM	Section 42	14
6755	The impact of renin-angiotensin system inhibitors on survival outcomes of pancreatic adenocarcinoma patients	Cheng-Wei	Chou	Poster	Retrospective Clinical Analyses 2	4/19/23	9:00 AM	Section 42	15
6756	Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric cancer who previously treated with first-line nivolumab plus chemotherapy	Youngkyung	Jeon	Poster	Retrospective Clinical Analyses 2	4/19/23	9:00 AM	Section 42	16
6757	Identification of predictive factors for early relapse in patients with unresectable stage III NSCLC receiving consolidation durvalumab after concurrent chemoradiation	Hye Seon	Kang	Poster	Retrospective Clinical Analyses 2	4/19/23	9:00 AM	Section 42	17
6762	Tumor immune microenvironment & genomic features of non-small cell lung carcinomas in patients with HIV (PWH)	Kishu	Ranjan	Poster	Spatial Proteomics and Transcriptomics 2	4/19/23	9:00 AM	Section 43	2
6763	Spatial profiling of cancer-associated fibroblasts in non-small cell lung cancer	Yunhe	Liu	Poster	Spatial Proteomics and Transcriptomics 2	4/19/23	9:00 AM	Section 43	3
6764	Multi-parametric comparison of scRNA-seq with CITE-seq and ultrahigh-plex spatial phenotyping of proteins in FFPE head and neck tumor biopsies: An opportunity to generate uniquely comprehensive multi-omic single cell datasets to investigate the tumor microenvironment.	Bernard	Fox	Poster	Spatial Proteomics and Transcriptomics 2	4/19/23	9:00 AM	Section 43	4
6765	Spatial insights into tumor immune evasion illuminated with 1000-plex RNA profiling with CosMx Spatial Molecular Imager	Claire	Williams	Poster	Spatial Proteomics and Transcriptomics 2	4/19/23	9:00 AM	Section 43	5
6766	Pan-cancer characterization of tumor-immune interactions using spatially resolved transcriptomics	Guangsheng	Pei	Poster	Spatial Proteomics and Transcriptomics 2	4/19/23	9:00 AM	Section 43	6

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
6767	Cancer-associated fibroblasts promote T-cell exclusion and resistance to immunotherapy in non-small cell lung cancer with tertiary lymphoid structures	Florent	Peyraud	Poster	Spatial Proteomics and Transcriptomics 2	4/19/23	9:00 AM	Section 43	7
6768	The potential predictive role of spatial phenotyping in non-small cell lung cancer	Ning	Ma	Poster	Spatial Proteomics and Transcriptomics 2	4/19/23	9:00 AM	Section 43	8
6769	Precise spatial multiplexing of protein biomarkers for immune profiling in tissue samples with chip cytometry	Karen	Kwarta	Poster	Spatial Proteomics and Transcriptomics 2	4/19/23	9:00 AM	Section 43	9
6770	Spatial characterization of immune microenvironment from early onset metastatic colorectal cancer (EOmCRC) showed a dual prognostic role for IDO1 expression	Raghavendar	Nagaraju	Poster	Spatial Proteomics and Transcriptomics 2	4/19/23	9:00 AM	Section 43	10
6771	Interrogating the tumor-immune landscape with a novel automated RNAscope™ assay for multiplexed detection of RNA and protein	Anushka	Dikshit	Poster	Spatial Proteomics and Transcriptomics 2	4/19/23	9:00 AM	Section 43	11
6772	Powerful background reduction in fluorescent tissue stains with an improved proximity-based technology for detection of protein-protein interactions	Doroteya	Raykova	Poster	Spatial Proteomics and Transcriptomics 2	4/19/23	9:00 AM	Section 43	12
6773	Spatial dynamics of cytotoxic T lymphocyte exhaustion in reactive and tumoral tissue	Maxim	De Schepper	Poster	Spatial Proteomics and Transcriptomics 2	4/19/23	9:00 AM	Section 43	13
6774	The development of a spatial metabolic map of immunotherapy sensitive and resistant cutaneous skin carcinoma	Niyati	Jhaveri	Poster	Spatial Proteomics and Transcriptomics 2	4/19/23	9:00 AM	Section 43	14
6775	Combination of spatial transcriptomics and multiplex IHC as valuable multi-omics tool for biomarker discovery	Nicole	Kerstedt	Poster	Spatial Proteomics and Transcriptomics 2	4/19/23	9:00 AM	Section 43	15
6776	Spatial transcriptomics of response to tepotinib treatment in a patient with NSCLC	Manon A.	Simard	Poster	Spatial Proteomics and Transcriptomics 2	4/19/23	9:00 AM	Section 43	16
6777	Digital Spatial Profiler highlights a T and B cells inflamed tumor microenvironment in brain metastases derived from melanoma vs. non-melanoma solid tumors	Alberto	Mendoza-Valderrey	Poster	Spatial Proteomics and Transcriptomics 2	4/19/23	9:00 AM	Section 43	17
6778	Spatial analysis of genomic signatures on colorectal cancer pathogenesis using the GeoMx® Digital Spatial Profiler	Xiang	Li	Poster	Spatial Proteomics and Transcriptomics 2	4/19/23	9:00 AM	Section 43	18
6779	Spatial and single-nucleus transcriptomics of human glioblastoma	Yue	Hao	Poster	Spatial Proteomics and Transcriptomics 2	4/19/23	9:00 AM	Section 43	19
6780	Characterization of immunological heterogeneity in the tumor microenvironment by integrated analyses using single cell RNAseq, spatial RNAseq and multiplex IHC	Seul	Lee	Poster	Spatial Proteomics and Transcriptomics 2	4/19/23	9:00 AM	Section 43	20
6781	Spatial omics using spatially-resolved laser-activated cell sorting for cancer biomarker discovery	Amos	Lee	Poster	Spatial Proteomics and Transcriptomics 2	4/19/23	9:00 AM	Section 43	21

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
6782	Spatial transcriptomics of serous tubal intraepithelial carcinoma and its putative precursor lesions	Rahul	Krishnan	Poster	Spatial Proteomics and Transcriptomics 2	4/19/23	9:00 AM	Section 43	22
6785	Dendritic cell/myeloma fusion vaccine with lenalidomide maintenance following autologous hematopoietic cell transplant induced T cell activation and expansion	Giulia	Cheloni	Poster	Vaccines	4/19/23	9:00 AM	Section 44	1
6786	NT-I7 as an adjuvant to DNA neoantigen vaccination enhances and prolongs neoantigen-specific anti-tumor immunity	Michael	Chen	Poster	Vaccines	4/19/23	9:00 AM	Section 44	2
6787	Vaccinia virus harboring TRAIL (vTRAIL) for in vivo lung cancer therapy	So Young	Yoo	Poster	Vaccines	4/19/23	9:00 AM	Section 44	3
6788	hNIS imaging data from a first-in-human trial of the oncolytic virus CF33-hNIS-antiPD-L1 in patients with triple negative breast cancer	Jamie	Rand	Poster	Vaccines	4/19/23	9:00 AM	Section 44	4
6789	The oncolytic virus VET3-TGI both blocks TGF-beta signaling and activates type 2 IFN responses, resulting in potent therapeutic responses in multiple mouse models	Ravikumar	Muthuswamy	Poster	Vaccines	4/19/23	9:00 AM	Section 44	5
6790	The peptide vaccine revived in cancer immunotherapy: a novel peptide vaccine platform for effective cancer immunotherapy	SeungHwan	Lee	Poster	Vaccines	4/19/23	9:00 AM	Section 44	6
6791	Inovative in vivo (in ovo) CAM model to predict efficacy and mode of action of a new antitumor vaccine stc-1010 on human colorectal adenocarcinoma	Philippe	Fornies	Poster	Vaccines	4/19/23	9:00 AM	Section 44	7
6792	Targeting immunosuppressive adenosine to enhance vaccinia virus renal cancer oncolysis in vivo	Valery	Chavez	Poster	Vaccines	4/19/23	9:00 AM	Section 44	8
6793	In vivo effects and molecular mechanisms of Minnelide mediated enhancement of measles virus oncolysis in human colorectal cancer	Valery	Chavez	Poster	Vaccines	4/19/23	9:00 AM	Section 44	9
6794	SETD2 loss in renal cell carcinoma generates peptides from aberrantly translated retained introns	Marya	Kozinova	Poster	Vaccines	4/19/23	9:00 AM	Section 44	10
6796	PoxSTG, a novel chimeric poxvirus with improved oncolytic potency	Philippe	Erbs	Poster	Vaccines	4/19/23	9:00 AM	Section 44	12
6797	Oncolytic virotherapy with non-human viruses to improve anti-myeloma effect	Valentina	Marchica	Poster	Vaccines	4/19/23	9:00 AM	Section 44	13
6798	CD8 α + dendritic cells potentiate the antitumor and immune activities against murine ovarian cancers	Shin-Wha	Lee	Poster	Vaccines	4/19/23	9:00 AM	Section 44	14
6799	A porous silicon particle based particulate anti-cancer vaccine for immunotherapy	Junhua	Mai	Poster	Vaccines	4/19/23	9:00 AM	Section 44	15
6800	Unique autologous cancer vaccine comprised of irradiated whole tumor cells and MBTA (rWTC-MBTA) triggers antitumor immune response to prevent metastasis	Juan	Ye	Poster	Vaccines	4/19/23	9:00 AM	Section 44	16

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
CT001	A personalized cancer vaccine, mRNA-4157, combined with pembrolizumab versus pembrolizumab in patients with resected high-risk melanoma: Efficacy and safety results from the randomized, open-label Phase 2 mRNA-4157-P201/Keynote-942 trial	Jeffrey	Weber	Oral	Harnessing the Immune System in the Clinic	4/16/23	12:45 PM	Chapin Theater	
CT002	KEYMAKER-U02 substudy 02C: Neoadjuvant pembrolizumab (pembro) + vibostolimab (vibo) or gebasaxturev (geba) or pembro alone followed by adjuvant pembro for stage IIIB-D melanoma	Reinhard	Dummer	Oral	Harnessing the Immune System in the Clinic	4/16/23	12:45 PM	Chapin Theater	
CT003	IMbrave050: Phase 3 study of adjuvant atezolizumab + bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation	Pierce	Chow	Oral	Harnessing the Immune System in the Clinic	4/16/23	12:45 PM	Chapin Theater	
CT004	Intratumoral (IT) MEDI1191 + durvalumab (D): Update on the first-in-human study in advanced solid tumors	Eduardo	Castañón	Oral	Harnessing the Immune System in the Clinic	4/16/23	12:45 PM	Chapin Theater	
CT005	AEGEAN: A phase 3 trial of neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC	John	Heymach	Oral	Harnessing the Immune System in the Clinic	4/16/23	12:45 PM	Chapin Theater	
CT006	First-in-class, first-in-human phase 1 trial of VT3989, an inhibitor of yes-associated protein (YAP)/transcriptional enhancer activator domain (TEAD), in patients (pts) with advanced solid tumors enriched for malignant mesothelioma and other tumors with neurofibromatosis 2 (NF2) mutations	Timothy	Yap	Oral	Hope for Rare Cancers: Novel Targeted and Immunotherapy Agents	4/16/23	3:30 PM	W Hall A2-3	
CT007	Phase 2-3 trial of pegargiminase plus chemotherapy versus placebo plus chemotherapy in patients with non-epithelioid pleural mesothelioma	Peter	Szlosarek	Oral	Hope for Rare Cancers: Novel Targeted and Immunotherapy Agents	4/16/23	3:30 PM	W Hall A2-3	
CT008	Pembrolizumab (pembro) in combination with gemcitabine and cisplatin (gem/cis) for advanced biliary tract cancer (BTC): Phase 3 KEYNOTE-966 study	Robin	Kelley	Oral	Hope for Rare Cancers: Novel Targeted and Immunotherapy Agents	4/16/23	3:30 PM	W Hall A2-3	
CT009	S1512: High response rate with single agent anti-PD-1 in patients with metastatic desmoplastic melanoma	Kari	Kendra	Oral	Hope for Rare Cancers: Novel Targeted and Immunotherapy Agents	4/16/23	3:30 PM	W Hall A2-3	
CT011	A phase 1 multicenter study (TRAVERSE) evaluating the safety and efficacy of ALLO-316 following conditioning regimen in pts with advanced or metastatic clear cell renal cell carcinoma (ccRCC)	Samer	Srouf	Oral	Promising Novel Antitumor Strategies in Early Phase Clinical Trials	4/17/23	10:15 AM	W Hall A2-3	
CT012	Clinical activity of MCLA-158 (petosemtamab), an IgG1 bispecific antibody targeting EGFR and LGR5, in advanced head and neck squamous cell cancer (HNSCC)	Ezra	Cohen	Oral	Promising Novel Antitumor Strategies in Early Phase Clinical Trials	4/17/23	10:15 AM	W Hall A2-3	

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
CT013	Safety and efficacy from the phase 1/2 first-in-human study of REGN5459, a BCMA×CD3 bispecific antibody with low CD3 affinity, in patients with relapsed/refractory multiple myeloma	Attaya	Suvannasankha	Oral	Promising Novel Antitumor Strategies in Early Phase Clinical Trials	4/17/23	10:15 AM	W Hall A2-3	
CT014	Phase I dose-escalation study of fractionated dose 225Ac J591 for metastatic castration resistant prostate cancer	Jones	Nauseef	Oral	Promising Novel Antitumor Strategies in Early Phase Clinical Trials	4/17/23	10:15 AM	W Hall A2-3	
CT016	Clinical and translational findings of pemigatinib in previously treated solid tumors with activating FGFR1-3 alterations in the FIGHT-207 study	Jordi	Rodon	Oral	Novel Biomarker-driven Molecularly Targeted Therapy Trials	4/18/23	10:15 AM	Chapin Theater	
CT017	Pan-mutant and isoform selective PI3Kα inhibitor, RLY-2608, demonstrates selective targeting in a first-in-human study of PIK3CA-mutant solid tumor patients, ReDiscover trial	Andreas	Varkaris	Oral	Novel Biomarker-driven Molecularly Targeted Therapy Trials	4/18/23	10:15 AM	Chapin Theater	
CT018	Safety and efficacy of three PARP inhibitors (PARPi) combined with the ataxia telangiectasia- and Rad3-related kinase inhibitor (ATRI) camonsertib in patients (pts) with solid tumors harboring DNA damage response (DDR) alterations	Timothy	Yap	Oral	Novel Biomarker-driven Molecularly Targeted Therapy Trials	4/18/23	10:15 AM	Chapin Theater	
CT019	Phase I/II study of the PARP inhibitor olaparib and ATR inhibitor ceralasertib in children with advanced malignancies: Arm N of the AcSé-ESMART trial	Susanne	Gatz	Oral	Novel Biomarker-driven Molecularly Targeted Therapy Trials	4/18/23	10:15 AM	Chapin Theater	
CT021	Assessing clinical and pharmacodynamic (PD) profiles of patients (pts) with chronic lymphocytic leukemia (CLL) on ialalumab (VAY736) + ibrutinib	Janghee	Woo	Oral	Novel Clinical Trials for Hematological Malignancies	4/16/23	3:00 PM	Valencia A	
CT022	Five-year efficacy and safety of tafasitamab in patients with relapsed or refractory DLBCL: Final results from the phase II L-MIND study	Nagesh	Kalakonda	Oral	Novel Clinical Trials for Hematological Malignancies	4/16/23	3:00 PM	Valencia A	
CT023	Phase 1 trial of CD19/CD20 bispecific chimeric antigen receptor-engineered naïve/memory T cells for relapsed or refractory non-Hodgkin lymphoma	Benjamin	Puliafito	Oral	Novel Clinical Trials for Hematological Malignancies	4/16/23	3:00 PM	Valencia A	
CT024	REDIRECT: A Phase 2 study of AFM13 in patients with CD30-positive relapsed or refractory (R/R) peripheral T cell lymphoma (PTCL)	Won Seog	Kim	Oral	Novel Clinical Trials for Hematological Malignancies	4/16/23	3:00 PM	Valencia A	
CT025	NMS-03592088, a novel, potent FLT3, KIT and CSF1R inhibitor with activity in FLT3 positive acute myeloid leukemia patients with prior FLT3 inhibitor experience	Antonio	Curti	Oral	Novel Clinical Trials for Hematological Malignancies	4/16/23	3:00 PM	Valencia A	
CT026	A first-in-human phase 1 study of LY3410738, a covalent inhibitor of mutant IDH, in advanced myeloid malignancies	Courtney	DiNardo	Oral	Novel Clinical Trials for Hematological Malignancies	4/16/23	3:00 PM	Valencia A	

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
CT028	A first-in-human phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumors	Yonina	Murciano-Goroff	Oral	Targeting the KRAS Pathway in the Clinic	4/17/23	2:30 PM	Chapin Theater	
CT029	Phase Ib study of GDC-6036 in combination with cetuximab in patients with colorectal cancer (CRC) with KRAS G12C mutation	Jayesh	Desai	Oral	Targeting the KRAS Pathway in the Clinic	4/17/23	2:30 PM	Chapin Theater	
CT030	Phase I study of IBI351 (GFH925) monotherapy in patients with advanced solid tumors: Updated results of the phase I study	Qing	Zhou	Oral	Targeting the KRAS Pathway in the Clinic	4/17/23	2:30 PM	Chapin Theater	
CT031	A first-in-human, phase 1a/1b, open-label, dose-escalation and expansion study to investigate the safety, pharmacokinetics, and antitumor activity of the RAF dimer inhibitor BGB-3245 in patients with advanced or refractory tumors	Alison	Schram	Oral	Targeting the KRAS Pathway in the Clinic	4/17/23	2:30 PM	Chapin Theater	
CT032	Trials in progress: a global phase 1/1b clinical trial evaluating exarafenib (KIN-2787), a highly selective pan-RAF inhibitor, in adult patients with BRAF-altered solid tumors and NRAS mutant melanoma	Alexander	Spira	Oral	Targeting the KRAS Pathway in the Clinic	4/17/23	2:30 PM	Chapin Theater	
CT033	Safety, pharmacokinetics, and antitumor activity findings from a phase 1b, open-label, dose-escalation and expansion study investigating RAF dimer inhibitor lifirafenib in combination with MEK inhibitor mirdametinib in patients with advanced or refractory solid tumors	Benjamin	Solomon	Oral	Targeting the KRAS Pathway in the Clinic	4/17/23	2:30 PM	Chapin Theater	
CT034	GLIMMER-01: initial results from a phase 1 dose escalation trial of a first-in-class bi-sialidase (E-602) in solid tumors	Jason	Luke	Oral	Novel Immunotherapy Combination Clinical Trials	4/18/23	2:30 PM	Chapin Theater	
CT035	Addition of Salmonella-IL2 to FOLFIRINOX for metastatic stage 4 pancreatic cancer nearly doubles median survival	Daniel	Saltzman	Oral	Novel Immunotherapy Combination Clinical Trials	4/18/23	2:30 PM	Chapin Theater	
CT036	Safety and immunogenicity of a first-in-human mutant KRAS long peptide vaccine combined with ipilimumab/nivolumab in resected pancreatic cancer: Preliminary analysis from a phase I study	Saurav	Halдар	Oral	Novel Immunotherapy Combination Clinical Trials	4/18/23	2:30 PM	Chapin Theater	
CT037	Nivolumab plus ipilimumab vs chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma: CheckMate 649 biomarker analyses	Yelena	Janjigian	Oral	Novel Immunotherapy Combination Clinical Trials	4/18/23	2:30 PM	Chapin Theater	
CT038	Comprehensive molecular characterization of clinical response to durvalumab plus pazopanib combination in patients with advanced soft tissue sarcomas: A phase 2 clinical trial	Hyo Song	Kim	Oral	Novel Immunotherapy Combination Clinical Trials	4/18/23	2:30 PM	Chapin Theater	
CT039	Immunomodulatory effects of ceralasertib in combination with durvalumab in patients with NSCLC and progression on anti-PD-(L)1 treatment (HUDSON, NCT03334617)	Sonia	Iyer	Oral	Novel Immunotherapy Combination Clinical Trials	4/18/23	2:30 PM	Chapin Theater	

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
CT040	A first-in-human phase 1 trial of IO-108, an antagonist antibody targeting LILRB2 (ILT4), as monotherapy and in combination with pembrolizumab in adult patients with advanced relapsed or refractory solid tumors: Dose escalation study	Matthew	Taylor	Oral	Novel Immunotherapy Combination Clinical Trials	4/18/23	2:30 PM	Chapin Theater	
CT043	Feasibility study to evaluate performance of the LUM Imaging System for intraoperative detection of residual tumor in breast cancer patients receiving and not receiving neoadjuvant therapy	Jorge	Ferrer	Poster	Phase II and Phase III Clinical Trials in Progress	4/17/23	9:00 AM	Section 46	1
CT044	KGOG2031 A phase II trial of repeated high dose luteal hormone therapy for intrauterine recurrence following fertility preserving therapy for atypical endometrial hyperplasia or endometrial cancer	Min Kyu	Kim	Poster	Phase II and Phase III Clinical Trials in Progress	4/17/23	9:00 AM	Section 46	2
CT045	A randomized phase II trial of TG4001 plus avelumab versus avelumab alone in recurrent/metastatic (R/M) human papilloma virus (HPV)-16 positive anogenital cancers	Maud	Brandely	Poster	Phase II and Phase III Clinical Trials in Progress	4/17/23	9:00 AM	Section 46	3
CT046	A randomized, phase 2 study of pembrolizumab plus chemotherapy with or without anti-immunoglobulin-like transcript 4 monoclonal antibody MK-4830 as neoadjuvant treatment for high-grade serous ovarian cancer	Jung-Yun	Lee	Poster	Phase II and Phase III Clinical Trials in Progress	4/17/23	9:00 AM	Section 46	4
CT047	A phase 2 study of ipatasertib in combination with pembrolizumab for first line treatment of recurrent or metastatic squamous cell cancer of the head and neck	Jacob	Thomas	Poster	Phase II and Phase III Clinical Trials in Progress	4/17/23	9:00 AM	Section 46	5
CT048	A Phase II trial of JDQ443 in KRAS G12C-mutated NSCLC with PD-L1 expression <1% or PD-L1 expression ≥1% and an STK11 co-mutation	Colin	Lindsay	Poster	Phase II and Phase III Clinical Trials in Progress	4/17/23	9:00 AM	Section 46	6
CT049	VELOCITY-Lung: A phase 2 study evaluating safety and efficacy of sacituzumab govitecan (SG) + zimberelimab (zim) + etrumadenant (etruma) in patients (pts) with advanced or metastatic non-small cell lung cancer (mNSCLC) progressing on or after platinum (PT)-based chemotherapy and checkpoint inhibitors (CPI)	Anjali	Rohatgi	Poster	Phase II and Phase III Clinical Trials in Progress	4/17/23	9:00 AM	Section 46	7
CT050	A phase 2, multi-center, open-label, dose-finding study evaluating telomere targeting agent THIO sequenced with cemiplimab in patients with advanced NSCLC	Mihail	Obrocea	Poster	Phase II and Phase III Clinical Trials in Progress	4/17/23	9:00 AM	Section 46	8
CT051	Double lung transplant registry aimed for lung-limited malignancies (DREAM) - a prospective registry study of bilateral lung transplantation for medically refractory cancers confined to the lungs	Liam Il-Young	Chung	Poster	Phase II and Phase III Clinical Trials in Progress	4/17/23	9:00 AM	Section 46	9

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
CT052	A phase 1/2 randomized study of imvotamab monotherapy and in combination with loncastuximab tesirine in relapsed/refractory non-Hodgkin lymphomas	Catherine	Diefenbach	Poster	Phase II and Phase III Clinical Trials in Progress	4/17/23	9:00 AM	Section 46	10
CT053	Merlin_001: a prospective registry study of a primary melanoma gene-signature to predict sentinel node (SN) status and determine its prognostic value for more accurate staging of SN-negative melanoma patients	Tina	Hieken	Poster	Phase II and Phase III Clinical Trials in Progress	4/17/23	9:00 AM	Section 46	11
CT054	Phase 2 study to assess the efficacy, safety, and tolerability of the GDF-15 inhibitor ponesimomab in patients with cancer cachexia	Jeffrey	Crawford	Poster	Phase II and Phase III Clinical Trials in Progress	4/17/23	9:00 AM	Section 46	12
CT055	PAVO: A phase-II, open label, single arm study of niraparib in patients with locally advanced/metastatic PALB2 mutated tumors	Tian	Zhang	Poster	Phase II and Phase III Clinical Trials in Progress	4/17/23	9:00 AM	Section 46	13
CT056	A multicenter, open-label phase 1/2 trial evaluating the safety, tolerability, and efficacy of MORAb-202, a folate-receptor-alpha-targeting antibody-drug conjugate in patients with selected tumor types	Robert	Wenham	Poster	Phase II and Phase III Clinical Trials in Progress	4/17/23	9:00 AM	Section 46	14
CT057	Phase 2, multicenter open-label basket trial of nab-sirolimus for patients with inactivating alterations in TSC1 or TSC2 (PRECISION I)	Jordi	Rodon Ahnert	Poster	Phase II and Phase III Clinical Trials in Progress	4/17/23	9:00 AM	Section 46	15
CT058	TROPION-PanTumor03: Phase 2, multicenter study of datopotamab deruxtecan (Dato-DXd) as monotherapy and in combination with anticancer agents in patients (pts) with advanced/metastatic solid tumors	Funda	Meric-Bernstam	Poster	Phase II and Phase III Clinical Trials in Progress	4/17/23	9:00 AM	Section 46	16
CT059	StrataPATHTM: a multicohort, non-randomized, open-label phase 2 trial to explore efficacy and safety of FDA-approved cancer therapies in novel biomarker-guided patient population	Kat	Kwiatkowski	Poster	Phase II and Phase III Clinical Trials in Progress	4/17/23	9:00 AM	Section 46	17
CT060	ACTION: A randomized phase 3 study of dordaviprone (ONC201) in patients with newly diagnosed H3 K27M-mutant diffuse glioma	Joshua	Allen	Poster	Phase II and Phase III Clinical Trials in Progress	4/17/23	9:00 AM	Section 46	18
CT061	TRIDENT phase 3 study (EF-32): First-line Tumor Treating Fields (TTFields; 200 kHz) therapy concomitant with chemo-radiation, followed by maintenance TTFields/temozolomide in newly diagnosed glioblastoma	Suriya	Jeyapalan	Poster	Phase II and Phase III Clinical Trials in Progress	4/17/23	9:00 AM	Section 46	19
CT062	GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma	Ingo	Mellinghoff	Poster	Phase II and Phase III Clinical Trials in Progress	4/17/23	9:00 AM	Section 46	20
CT063	A Phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/ HER2- advanced breast cancer	Hyo	Han	Poster	Phase II and Phase III Clinical Trials in Progress	4/17/23	9:00 AM	Section 46	21

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
	previously treated with a CDK4/6 inhibitor plus a non-steroidal aromatase inhibitor (VIKTORIA-1)								
CT064	Phase III study to evaluate the efficacy and safety of GLSI-100 (GP2 + GM-CSF) in breast cancer patients with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy, Flamingo-01	Snehal	Patel	Poster	Phase II and Phase III Clinical Trials in Progress	4/17/23	9:00 AM	Section 46	22
CT065	Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer (HER2CLIMB-05, trial in progress)	Ciara	O'Sullivan	Poster	Phase II and Phase III Clinical Trials in Progress	4/17/23	9:00 AM	Section 46	23
CT066	HERTHENA-Lung02: A randomized Phase 3 study of patritumab deruxtecan vs platinum-based chemotherapy in locally advanced or metastatic EGFR-mutated NSCLC after progression with a third-generation EGFR tyrosine kinase inhibitor	Balazs	Halmos	Poster	Phase II and Phase III Clinical Trials in Progress	4/17/23	9:00 AM	Section 46	24
CT067	Pembrolizumab with and without sacituzumab govitecan as first-line treatment for metastatic non-small-cell lung cancer (NSCLC) with PD-L1 TPS \geq 50%: phase 3 KEYNOTE-D46/EVOKE-03 study	Mor	Moskovitz	Poster	Phase II and Phase III Clinical Trials in Progress	4/17/23	9:00 AM	Section 46	25
CT068	CASCADE-LUNG: validation of a blood-based assay that evaluates cell-free DNA fragmentation patterns to detect lung cancer	Julie	Barta	Poster	Phase II and Phase III Clinical Trials in Progress	4/17/23	9:00 AM	Section 46	26
CT069	Randomized phase 3 study (STARBOARD) evaluating encorafenib (enco) + binimetinib (bini) + pembrolizumab (pembro) for first-line treatment of unresectable locally advanced or metastatic BRAF V600-mutant melanoma	Dirk	Schadendorf	Poster	Phase II and Phase III Clinical Trials in Progress	4/17/23	9:00 AM	Section 46	27
CT070	Double-blind placebo-controlled trial of AL102 for treatment of progressing desmoid tumors: the RINGSIDE phase 3 study design	Mrinal	Gounder	Poster	Phase II and Phase III Clinical Trials in Progress	4/17/23	9:00 AM	Section 46	28
CT073	Efficacy of novel oral SERD elacestrant in fulvestrant-refractory hormone receptor-positive (HR+) breast cancer: a translational investigation	Taronish	Dubash	Poster	Phase III and Pediatric Clinical Trials	4/17/23	9:00 AM	Section 47	1
CT075	Updated overall survival outcomes from a randomized, double-blind phase III study of sintilimab versus placebo in combination with chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma (ORIENT-15)	Lin	Shen	Poster	Phase III and Pediatric Clinical Trials	4/17/23	9:00 AM	Section 47	3
CT076	Randomized, global, phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-306): China subgroup analysis	Xiaohong	Wu	Poster	Phase III and Pediatric Clinical Trials	4/17/23	9:00 AM	Section 47	4

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
CT077	Association of tumor mutational burden (TMB) and clinical outcomes with tislelizumab versus chemotherapy in esophageal cell carcinoma (ESCC) from RATIONALE-302	Jingwen	Shi	Poster	Phase III and Pediatric Clinical Trials	4/17/23	9:00 AM	Section 47	5
CT078	First-line treatment with sintilimab (sin) vs placebo in combination with chemotherapy (chemo) in patients (pts) with unresectable gastric or gastroesophageal junction (G/GEJ) cancer: Final overall survival (OS) results from the randomized, phase III ORIENT-16 trial	Jianming	Xu	Poster	Phase III and Pediatric Clinical Trials	4/17/23	9:00 AM	Section 47	6
CT079	Efficacy and safety of sintilimab (anti-PD-1 mAb) for advanced cervical cancer: Results from a Phase II trial	Qinglei	Gao	Poster	Phase III and Pediatric Clinical Trials	4/17/23	9:00 AM	Section 47	7
CT080	Tremelimumab (T) + durvalumab (D) + chemotherapy (CT) in 1L metastatic NSCLC: Outcomes by blood tumor mutational burden (bTMB) in POSEIDON	Solange	Peters	Poster	Phase III and Pediatric Clinical Trials	4/17/23	9:00 AM	Section 47	8
CT081	Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) vs chemo in Chinese patients (pts) with resectable NSCLC in CheckMate 816	Mark	Awad	Poster	Phase III and Pediatric Clinical Trials	4/17/23	9:00 AM	Section 47	9
CT082	Next-generation sequencing (NGS) and cytokine assessment from a phase III study of copanlisib in combination with rituximab in patients with indolent non-Hodgkin lymphoma (iNHL) - associations with survival endpoints	Shalini	Chaturvedi	Poster	Phase III and Pediatric Clinical Trials	4/17/23	9:00 AM	Section 47	10
CT083	Tumor-agnostic efficacy and safety of dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: ROAR basket study	Vivek	Subbiah	Poster	Phase III and Pediatric Clinical Trials	4/17/23	9:00 AM	Section 47	11
CT084	Targeted intra-arterial gemcitabine vs. continuation of IV gemcitabine plus nab-paclitaxel following Induction with sequential IV gemcitabine plus nab-paclitaxel and radiotherapy for unresectable locally advanced pancreatic cancer (TIGeR-PaC) - phase III trial interim analysis	Michael	Pishvaian	Poster	Phase III and Pediatric Clinical Trials	4/17/23	9:00 AM	Section 47	12
CT085	A phase 2/3, multicenter trial of lenzilumab and azacitidine in chronic myelomonocyt---ic leukemia: The PREACH-M trial	Devendra	Hiwase	Poster	Phase III and Pediatric Clinical Trials	4/17/23	9:00 AM	Section 47	13
CT086	H3.3-K27M neoantigen vaccine elicits CD4+ and CD8+ T cells immunity and improved prognosis against diffuse intrinsic pontine glioma	Yang	Zhang	Poster	Phase III and Pediatric Clinical Trials	4/17/23	9:00 AM	Section 47	14
CT087	Phase I/II study of the WEE1 inhibitor adavosertib in combination with carboplatin in children with advanced malignancies: arm C of the AcSé-ESMART trial	Susanne	Gatz	Poster	Phase III and Pediatric Clinical Trials	4/17/23	9:00 AM	Section 47	15

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
CT088	Phase I/II study of the PARP inhibitor olaparib in combination with irinotecan in children with advanced malignancies: arm D of the AcSé-ESMART trial	Susanne	Gatz	Poster	Phase III and Pediatric Clinical Trials	4/17/23	9:00 AM	Section 47	16
CT089	Molecular-guided therapy for the treatment of patients with relapsed and refractory childhood cancers: a Beat Childhood Cancer Research Consortium trial	Giselle	Saulner Sholler	Poster	Phase III and Pediatric Clinical Trials	4/17/23	9:00 AM	Section 47	17
CT090	PEPN2011: a phase 1/2 study of tegavivint in children, adolescents, and young adults with recurrent or refractory solid tumors, including lymphomas and desmoid tumors: a report from the pediatric early phase clinical trials network	Sarah	Whittle	Poster	Phase III and Pediatric Clinical Trials	4/17/23	9:00 AM	Section 47	18
CT093	Preliminary evidence of antitumor activity of Ipatasertib (Ipat) and Atezolizumab (A) in glioblastoma (GBM) patients (pts) with PTEN loss in the Phase 1 Ice-CAP trial (NCT03673787)	Juanita	Lopez	Poster	First-in-Human Phase I Clinical Trials 1	4/17/23	1:30 PM	Section 45	1
CT094	Phase I dose-escalation study evaluating the safety and tolerability of ginisortamab (UCB6114), a first-in-class anti-gremlin-1 monoclonal antibody (mAb), as monotherapy in advanced solid tumors	Debashis	Sarker	Poster	First-in-Human Phase I Clinical Trials 1	4/17/23	1:30 PM	Section 45	2
CT095	Update: a phase 1/2, open-label study to assess safety, tolerability, biodistribution, radiation dosimetry and PET imaging characteristics of [18F]FPyGal in comparison to in-vitro diagnostic for the assessment of senescence in oncological patients (NCT04536454)	Lars	Zender	Poster	First-in-Human Phase I Clinical Trials 1	4/17/23	1:30 PM	Section 45	3
CT096	Phase 1 study of RO7119929 (TLR7 agonist prodrug) in patients (pts) with advanced primary or metastatic liver cancers	Changhoon	Yoo	Poster	First-in-Human Phase I Clinical Trials 1	4/17/23	1:30 PM	Section 45	4
CT097	First report of preliminary safety, efficacy, and pharmacokinetics of C-CAR031 (GPC3-specific TGFβRIIDN CAR-T) in patients with advanced HCC	Tingbo	Liang	Poster	First-in-Human Phase I Clinical Trials 1	4/17/23	1:30 PM	Section 45	5
CT098	A first-in-human phase 1 study of LY3410738, a covalent inhibitor of mutant IDH, in advanced IDH-mutant cholangiocarcinoma and other solid tumors	Jordi	Rodon	Poster	First-in-Human Phase I Clinical Trials 1	4/17/23	1:30 PM	Section 45	6
CT099	First-in-human study of ALF501, polypeptide PSMA-targeted chimeric antigen receptor engineered natural killer cells) for castration-resistant prostate cancer	Lida	Wu	Poster	First-in-Human Phase I Clinical Trials 1	4/17/23	1:30 PM	Section 45	7
CT100	A new therapeutic cancer vaccine inducing multifunctional immunity, artificial adjuvant vector cells	Shin-ichiro	Fujii	Poster	First-in-Human Phase I Clinical Trials 1	4/17/23	1:30 PM	Section 45	8
CT101	Phase I study of the T-cell receptor-like antibody Hu8F4 in patients with advanced hematologic malignancies	Tapan	Kadia	Poster	First-in-Human Phase I Clinical Trials 1	4/17/23	1:30 PM	Section 45	9

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
CT102	Interim results of a first-in-human, dose escalation and expansion study of PLB-1004, an irreversible inhibitor of exon 20 insertion mutations in patients with non-small cell lung cancer	Kevin	Schaab	Poster	First-in-Human Phase I Clinical Trials 1	4/17/23	1:30 PM	Section 45	10
CT103	A phase 1 first-in-human study of MEM-288 oncolytic virus in solid tumors including non-small cell lung cancer (NSCLC): impact on tumor and systemic T cell immunity	Andreas	Saltos	Poster	First-in-Human Phase I Clinical Trials 1	4/17/23	1:30 PM	Section 45	11
CT104	MC1R imaging and histology in the targeted imaging of melanoma for alpha-particle radiotherapy (TIMAR1) trial	Brenna	Marks	Poster	First-in-Human Phase I Clinical Trials 1	4/17/23	1:30 PM	Section 45	12
CT105	Preliminary results from the Phase I part of a first-in-human Phase I/II study of HH2853, an EZH1/2 inhibitor, in patients with relapsed/refractory non-Hodgkin lymphomas or advanced solid tumors	Lin	Shen	Poster	First-in-Human Phase I Clinical Trials 1	4/17/23	1:30 PM	Section 45	13
CT107	Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid Tumors	Blessie	Nelson	Poster	First-in-Human Phase I Clinical Trials 1	4/17/23	1:30 PM	Section 45	15
CT108	First-in-patient study of the GDF-15 inhibitor ponesegromab in patients with cancer and cachexia: Safety, tolerability, and exploratory measures of efficacy	Jeffrey	Crawford	Poster	First-in-Human Phase I Clinical Trials 1	4/17/23	1:30 PM	Section 45	16
CT109	First-in-class first-in-human phase 1 trial and translational study of the mono(ADP-ribose) polymerase-7 (PARP7) inhibitor RBN-2397 in patients with selected advanced solid tumors	Timothy	Yap	Poster	First-in-Human Phase I Clinical Trials 1	4/17/23	1:30 PM	Section 45	17
CT110	Safety and anti-tumor activity of a novel Treg depleter RG6292, as a single agent and in combination with atezolizumab in patients with solid tumors	Valentina	Gambardella	Poster	First-in-Human Phase I Clinical Trials 1	4/17/23	1:30 PM	Section 45	18
CT113	Safety and efficacy of Tumor Treating Fields (TTFields) combined with bevacizumab and systemic chemotherapy in recurrent GBM	Wenbin	Li	Poster	Phase I Clinical Trials in Progress	4/17/23	1:30 PM	Section 46	1
CT114	Data from first-in-human study of EXS21546, an A2A receptor antagonist, now progressing into phase 1 in RCC/NSCLC	Nieves	Diaz	Poster	Phase I Clinical Trials in Progress	4/17/23	1:30 PM	Section 46	2
CT115	Treatment of skin tumors with intratumoral interleukin 12 gene electrotransfer in the head and neck region: A phase I clinical trial	Gregor	Sersa	Poster	Phase I Clinical Trials in Progress	4/17/23	1:30 PM	Section 46	3
CT116	First-in-human study of AZD8853, an anti-growth and differentiation factor 15 (GDF15) antibody, in patients (pts) with advanced/metastatic solid tumors	Benedito	Carneiro	Poster	Phase I Clinical Trials in Progress	4/17/23	1:30 PM	Section 46	4
CT117	Synergism between inhibitors of the EGFR-RAS-RAF-MEK pathway and the WNT pathway	Michael	An	Poster	Phase I Clinical Trials in Progress	4/17/23	1:30 PM	Section 46	5

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
CT118	A phase I/II trial of a CXCR1/2 inhibitor in combination with anti-PD-1 for circulating tumor DNA (ctDNA) positive & refractoryRAS-mutated microsatellite stable (MSS) colorectal cancer	Benny	Johnson	Poster	Phase I Clinical Trials in Progress	4/17/23	1:30 PM	Section 46	6
CT119	A first-in-human phase 1 study of LOXO-435, a potent, highly isoform-selective FGFR3 inhibitor in advanced solid tumors with FGFR3 alterations (trial in progress)	Gopa	Iyer	Poster	Phase I Clinical Trials in Progress	4/17/23	1:30 PM	Section 46	7
CT120	The randomized phase 1/2 LITESPARK-024 study of belzutifan with or without palbociclib in patients with advanced renal cell carcinoma (RCC)	David	McDermott	Poster	Phase I Clinical Trials in Progress	4/17/23	1:30 PM	Section 46	8
CT121	ARX517, an anti-PSMA ADC targeting mCRPC resistant or refractory to standard therapies: A phase 1 dose escalation and dose expansion study (ARX517-2011, NCT04662580)	Darryl	L'Heureux	Poster	Phase I Clinical Trials in Progress	4/17/23	1:30 PM	Section 46	9
CT122	A phase 1/2 open-label, multicenter, dose escalation and expansion study of AVB-001, an intraperitoneally administered, cell-generated, human IL-2 immunotherapy in patients with platinum-resistant, high-grade, serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube	Shannon	Westin	Poster	Phase I Clinical Trials in Progress	4/17/23	1:30 PM	Section 46	10
CT123	Trial in progress: First-in-human immunotherapy-trio for advanced head and neck squamous cell carcinoma	Bernard	Fox	Poster	Phase I Clinical Trials in Progress	4/17/23	1:30 PM	Section 46	11
CT124	A first-in-clinic phase 1 study of GSK3745417 STING agonist in relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndrome	Pau	Montesinos	Poster	Phase I Clinical Trials in Progress	4/17/23	1:30 PM	Section 46	12
CT125	A Phase 1 study to evaluate the safety and tolerability of a combination autologous CD19 CAR T cell therapy (SYNCAR-001) and orthogonal IL-2 (STK-009) in subjects with relapsed or refractory CD19 expressing hematologic malignancies (NCT05665062)	Alex	Azrilevich	Poster	Phase I Clinical Trials in Progress	4/17/23	1:30 PM	Section 46	13
CT126	An open-label, first-in-human study of BAY2927088 in patients with advanced non-small cell lung cancer (NSCLC) harboring an EGFR and/or HER2 mutation	Daniel	Tan	Poster	Phase I Clinical Trials in Progress	4/17/23	1:30 PM	Section 46	14
CT127	A phase 1 study to assess BDTX-1535, an oral EGFR inhibitor, in patients with glioblastoma or non-small cell lung cancer	Melissa	Johnson	Poster	Phase I Clinical Trials in Progress	4/17/23	1:30 PM	Section 46	15
CT128	Phase 1 study of HSK29116, a Bruton tyrosine kinase (BTK) proteolysis-targeting chimera (PROTAC) agent, in patients with relapsed or refractory B-cell malignancies	Jianyong	Li	Poster	Phase I Clinical Trials in Progress	4/17/23	1:30 PM	Section 46	16
CT129	Trial in progress: ATHENA-1 - a phase 1, open-label, first-in-human study to assess safety and tolerability of REGN5837 in	John	Baird	Poster	Phase I Clinical Trials in Progress	4/17/23	1:30 PM	Section 46	17

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
	combination with odronextamab in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphomas								
CT130	An open label, dose escalation, phase 1 study of AT101, a novel CD19-directed CAR-T cell therapy targeting a membrane-proximal epitope of CD19, in patients with relapsed or refractory B cell non-Hodgkin lymphoma	Marco	Ruella	Poster	Phase I Clinical Trials in Progress	4/17/23	1:30 PM	Section 46	18
CT131	Initial preclinical and clinical experience of autologous engineered monocytes in T cell lymphoma patients	Michele	Gerber	Poster	Phase I Clinical Trials in Progress	4/17/23	1:30 PM	Section 46	19
CT132	Trial in progress: A phase 1/2 study of ASP1570, a novel inhibitor of DGK ζ , in participants with locally advanced or metastatic solid tumors who have progressed on, or are ineligible for, all available standard therapies	Jason	Luke	Poster	Phase I Clinical Trials in Progress	4/17/23	1:30 PM	Section 46	20
CT133	Trial in progress: a multicenter phase 1/1b dose escalation study of WTX-124 as a monotherapy and in combination with pembrolizumab in patients with selected advanced or metastatic solid tumors	Sameer	Chopra	Poster	Phase I Clinical Trials in Progress	4/17/23	1:30 PM	Section 46	21
CT134	Non-viral mesothelin-targeted CAR-T cells armored with IFN γ -induced secretion of PD-1 nanobody in treatment of malignant mesothelioma in phase I clinical trial	Wenfeng	Xu	Poster	Phase I Clinical Trials in Progress	4/17/23	1:30 PM	Section 46	22
CT135	A pilot clinical study of orotecan (oral irinotecan HCl, VAL-413) in patients with recurrent pediatric solid tumors	Jeffrey	Bacha	Poster	Phase I Clinical Trials in Progress	4/17/23	1:30 PM	Section 46	23
CT136	An open-label phase I/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy and in combination in patients with advanced hematological malignancies	Kristopher	Frese	Poster	Phase I Clinical Trials in Progress	4/17/23	1:30 PM	Section 46	24
CT137	ENLIGHTen-01: a phase 1 study of fluorescein-specific (FITC-E2)-car T cells in combination with folate-fluorescein (UB-TT170) for osteosarcoma	Catherine	Albert	Poster	Phase I Clinical Trials in Progress	4/17/23	1:30 PM	Section 46	25
CT139	The STELLAR trial: A phase II/III study of high-dose intermittent sunitinib in patients with recurrent glioblastoma	Jorien	Janssen	Poster	Phase II Clinical Trials 1	4/17/23	1:30 PM	Section 47	1
CT141	Combination of hormone therapy, GnRH agonist, and immunotherapy enhance immune activation in premenopausal ER+/HER2- metastatic breast cancer patients: Results of biomarker analysis from a pilot phase II study	I-Chun	Chen	Poster	Phase II Clinical Trials 1	4/17/23	1:30 PM	Section 47	3
CT142	TALAVE: Induction talazoparib (tala) followed by combined tala and avelumab in patients (pts) with advanced breast cancer (ABC)	Filipa	Lynce	Poster	Phase II Clinical Trials 1	4/17/23	1:30 PM	Section 47	4
CT143	Whole cell antigen presenting immune stimulating cells (Bria-IMT) for the treatment of metastatic breast cancer	Giuseppe	Del Priore	Poster	Phase II Clinical Trials 1	4/17/23	1:30 PM	Section 47	5

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
CT144	Randomized phase II trial of preoperative fulvestrant with or without enzalutamide for ER+/Her2- breast cancer	Jennifer	Richer	Poster	Phase II Clinical Trials 1	4/17/23	1:30 PM	Section 47	6
CT145	Olaparib +/- atezolizumab in patients with BRCA-mutated (BRCAmt) locally advanced unresectable or metastatic (advanced) breast cancer: an open-label, multicenter, randomized phase II trial	Kristina	Fanucci	Poster	Phase II Clinical Trials 1	4/17/23	1:30 PM	Section 47	7
CT146	Trifluridine/tipiracil (FTD/TPI) and oxaliplatin as induction chemotherapy (IC) in resectable esophageal and gastroesophageal junction adenocarcinoma (EGAC): Preliminary results from a phase II study	Sarbajit	Mukherjee	Poster	Phase II Clinical Trials 1	4/17/23	1:30 PM	Section 47	8
CT147	A phase II study of neoadjuvant immune checkpoint inhibitor IMC-001 (anti-PD-L1 antibody) in patients with resectable upper gastrointestinal cancers (Neo-Chance Study)	Sook Ryun	Park	Poster	Phase II Clinical Trials 1	4/17/23	1:30 PM	Section 47	9
CT148	Efficacy, safety, and biomarker analysis of combined MEK (Cobimetinib) and PD-L1 (Atezolizumab) inhibition (COTEZO) in advanced small bowel adenocarcinoma (SBA)	Nicholas	Hornstein	Poster	Phase II Clinical Trials 1	4/17/23	1:30 PM	Section 47	10
CT149	BOLD-100-001 (TRIO039): a phase 1b/2a dose-escalation study of BOLD-100 in combination with FOLFOX chemotherapy in patients with pre-treated advanced colorectal cancer: interim efficacy, safety and tolerability analysis	Jim	Pankovich	Poster	Phase II Clinical Trials 1	4/17/23	1:30 PM	Section 47	11
CT150	Result of an open-label phase 2 trial of dual TORC1/TORC2 inhibitor onatasertib (ATG-008) in HBV+ advanced hepatocellular carcinoma (HCC) subjects who have received at least one prior line of systemic therapy (TORCH)	Shukui	Qin	Poster	Phase II Clinical Trials 1	4/17/23	1:30 PM	Section 47	12
CT151	A phase II study of optimized individualized adaptive radiation therapy for hepatocellular carcinoma	Daniel	Herr	Poster	Phase II Clinical Trials 1	4/17/23	1:30 PM	Section 47	13
CT152	A multicenter Phase II study of savolitinib in patients with MET-amplified gastroesophageal junction adenocarcinomas or gastric cancer	Lin	Shen	Poster	Phase II Clinical Trials 1	4/17/23	1:30 PM	Section 47	14
CT153	Pemigatinib in Chinese patients with advanced/metastatic or surgically unresectable cholangiocarcinoma including FGFR2 fusion or rearrangement: Updated overall survival from an open-label, single-arm, multicenter Phase II study	Guoming	Shi	Poster	Phase II Clinical Trials 1	4/17/23	1:30 PM	Section 47	15
CT154	Combination of cinrebafusp alfa with ramucirumab and paclitaxel is well tolerated and elicits encouraging clinical activity in patients with HER2-positive gastric/gastroesophageal junction (GEJ) adenocarcinoma	Geoffrey	Ku	Poster	Phase II Clinical Trials 1	4/17/23	1:30 PM	Section 47	16

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
CT155	Long term results and ctDNA correlatives for CAPOX BETR: A multi-center phase II trial of capecitabine, oxaliplatin, bevacizumab and trastuzumab for previously untreated HER2 positive metastatic gastroesophageal adenocarcinoma	Harshabad	Singh	Poster	Phase II Clinical Trials 1	4/17/23	1:30 PM	Section 47	17
CT156	MCLA-158 (petosemtamab), an IgG1 bispecific antibody targeting EGFR and LGR5, in advanced gastric/esophageal adenocarcinoma (GEA)	Marc	Díez García	Poster	Phase II Clinical Trials 1	4/17/23	1:30 PM	Section 47	18
CT157	Combination of nivolumab with standard of care in the management of grade group 5 prostate cancer: Interim analysis of a phase II trial	John Michael	Bryant	Poster	Phase II Clinical Trials 1	4/17/23	1:30 PM	Section 47	19
CT158	BrUOG360: A phase Ib/II study of copanlisib combined with rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC)	Matthew	Hadfield	Poster	Phase II Clinical Trials 1	4/17/23	1:30 PM	Section 47	20
CT159	CYCLONE 1: abemaciclib in men with heavily pretreated metastatic castration-resistant prostate cancer (mCRPC)	Neeraj	Agarwal	Poster	Phase II Clinical Trials 1	4/17/23	1:30 PM	Section 47	21
CT160	Phase 1b/2a clinical trial of the oral BET inhibitor PLX2853 as monotherapy for ARID1A mutated gynecologic cancers and in combination with carboplatin for platinum resistant ovarian cancer	Elizabeth	Swisher	Poster	Phase II Clinical Trials 1	4/17/23	1:30 PM	Section 47	22
CT161	A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the non-epithelial ovarian tumor cohort	Young Kwang	Chae	Poster	Phase II Clinical Trials 1	4/17/23	1:30 PM	Section 47	23
CT162	A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the clear cell ovarian, endometrial, cervical cancer cohorts	Young Kwang	Chae	Poster	Phase II Clinical Trials 1	4/17/23	1:30 PM	Section 47	24
CT163	A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the small cell carcinoma of the ovary, hypercalcemic type cohort	Young Kwang	Chae	Poster	Phase II Clinical Trials 1	4/17/23	1:30 PM	Section 47	25
CT164	Tisotumab vedotin (TV) in squamous cell carcinoma of head and neck (SCCHN): interim analysis from innovaTV 207	Beatriz	Cirauqui	Poster	Phase II Clinical Trials 1	4/17/23	1:30 PM	Section 47	26
CT165	Phase II study of nivolumab and ipilimumab for treatment of metastatic/recurrent adenoid cystic carcinoma (ACC) of all anatomic sites of origin and other malignant salivary gland tumors	Richard	Duan	Poster	Phase II Clinical Trials 1	4/17/23	1:30 PM	Section 47	27
CT166	Similar outcomes regardless of post-randomization treatment with ibrutinib or ibrutinib + venetoclax in the phase 2 CAPTIVATE study of first-line ibrutinib + venetoclax in CLL	Tanya	Siddiqi	Poster	Phase II Clinical Trials 1	4/17/23	1:30 PM	Section 47	28

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
CT167	Efficacy of pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in Richter transformation: Results from the phase 1/2 BRUIN study	Joanna	Rhodes	Poster	Phase II Clinical Trials 1	4/17/23	1:30 PM	Section 47	29
CT169	Bioplatin (NTPX-07) as an oral nano platinum in patients of advanced stage malignancy: Outcomes of a phase I clinical trial	Eeshani	Bendale	Poster	First-in-Human Phase I Clinical Trials 2	4/18/23	9:00 AM	Section 45	1
CT170	Initial safety and feasibility results from a first-in-human clinical trial evaluating a novel magnetic hyperthermia approach for the treatment of metastatic solid tumors	Sarah	Kraus	Poster	First-in-Human Phase I Clinical Trials 2	4/18/23	9:00 AM	Section 45	2
CT171	A first-in-human phase I study of the ATM inhibitor M4076 in patients with advanced solid tumors (DDRiver Solid Tumors 410): Part 1A results	Lillian	Siu	Poster	First-in-Human Phase I Clinical Trials 2	4/18/23	9:00 AM	Section 45	3
CT172	A phase 1, open-label, dose-escalation study of PRT1419, a selective induced myeloid leukemia cell differentiation protein (MCL-1) inhibitor, in patients (pts) with advanced/metastatic solid tumors	Gerald	Falchook	Poster	First-in-Human Phase I Clinical Trials 2	4/18/23	9:00 AM	Section 45	4
CT173	A phase 1, open-label, multicenter, dose-escalation study of PRT2527, a cyclin-dependent kinase 9 (CDK9) inhibitor, in adult patients (pts) with advanced solid tumors	Jason	Henry	Poster	First-in-Human Phase I Clinical Trials 2	4/18/23	9:00 AM	Section 45	5
CT174	First-in-class anti-CD200R1 antibody 23ME-00610 in patients with advanced solid malignancies: Phase 1 results	Shivaani	Kummar	Poster	First-in-Human Phase I Clinical Trials 2	4/18/23	9:00 AM	Section 45	6
CT175	Safety, tolerability, pharmacokinetics, and antitumor activity of SHR-A1811 in HER2-expressing/mutated advanced solid tumors: A global phase 1, multi-center, first-in-human study	Herui	Yao	Poster	First-in-Human Phase I Clinical Trials 2	4/18/23	9:00 AM	Section 45	7
CT176	Pharmacokinetic/pharmacodynamic (PK/PD) relationships of the novel Treg depleter RG6292 in Phase Ia and Ib studies in patients with solid tumors	Tamara	Tanos	Poster	First-in-Human Phase I Clinical Trials 2	4/18/23	9:00 AM	Section 45	8
CT177	A phase I, first in human study of CBA-1205, glycoengineered humanized anti-DLK-1 monoclonal antibody in patients with advanced solid tumors	Masafumi	Ikeda	Poster	First-in-Human Phase I Clinical Trials 2	4/18/23	9:00 AM	Section 45	9
CT178	GQ1001: A next generation HER2-targeting ADC that exhibits promising early clinical efficacy with excellent tolerance in a multi-center, Phase Ia study	Charlotte	Lemech	Poster	First-in-Human Phase I Clinical Trials 2	4/18/23	9:00 AM	Section 45	10
CT179	First-in-human study of ICT01, an anti-BTN3A activating monoclonal antibody in combination with low dose IL-2 in patients with advanced solid tumors (EVICTION-2 study)	Katrien	Lemmens	Poster	First-in-Human Phase I Clinical Trials 2	4/18/23	9:00 AM	Section 45	11
CT180	Activation of innate and adaptive immune response with a clinical stage TLR7 agonist prodrug PRTX007	Curtis	Scribner	Poster	First-in-Human Phase I Clinical Trials 2	4/18/23	9:00 AM	Section 45	12

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
CT181	A first-in-human (FIH) phase 1 study of SHR-A1921, a TROP-2 targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors	Jie	Wang	Poster	First-in-Human Phase I Clinical Trials 2	4/18/23	9:00 AM	Section 45	13
CT182	OXC-101 shows favorable safety profile in first in human phase 1 trial in patients with advanced solid cancer	Jeffrey	Yachnin	Poster	First-in-Human Phase I Clinical Trials 2	4/18/23	9:00 AM	Section 45	14
CT184	Preliminary dose escalation results of ERAS-601 in combination with cetuximab in FLAGSHP-1: a phase I study of ERAS-601, a potent and selective SHP2 inhibitor, in patients with previously treated advanced or metastatic solid tumors	Meredith	McKean	Poster	First-in-Human Phase I Clinical Trials 2	4/18/23	9:00 AM	Section 45	16
CT185	First in human dose-escalation trial with the c-MET targeting antibody-drug conjugate BYON3521	N.	Kotecki	Poster	First-in-Human Phase I Clinical Trials 2	4/18/23	9:00 AM	Section 45	17
CT188	A phase Ib study of sapacitabine (sapa) and olaparib (ola) in patients (pts) with BRCA1/2-mutated (BRCA1/2m) metastatic breast cancer (MBC)	Filipa	Lynce	Poster	Phase I Clinical Trials 1	4/18/23	9:00 AM	Section 46	1
CT189	A phase I study of BAT1006, a novel anti-HER2 antibody, in patients with locally advanced/metastatic solid tumors	Bert	Thomas	Poster	Phase I Clinical Trials 1	4/18/23	9:00 AM	Section 46	2
CT190	Oncolytic virus TG6002 safety and activity after intrahepatic artery administration in patients with liver-dominant metastatic colorectal cancer	Adel	Samson	Poster	Phase I Clinical Trials 1	4/18/23	9:00 AM	Section 46	3
CT192	Phase 1, open-label, single-dose study to evaluate the effect of hepatic impairment on the pharmacokinetics and safety of futibatinib in adult subjects	Ling	Gao	Poster	Phase I Clinical Trials 1	4/18/23	9:00 AM	Section 46	5
CT193	Final results from a phase I study to evaluate the safety and efficacy of a telomerase-specific oncolytic adenovirus (OBP-301) with pembrolizumab in patients with advanced solid tumors (EPOC1505)	Takashi	Kojima	Poster	Phase I Clinical Trials 1	4/18/23	9:00 AM	Section 46	6
CT194	ETCTN 10388: a first in human phase I trial of triapine and lutetium Lu 177 DOTATATE in well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs)	Aman	Chauhan	Poster	Phase I Clinical Trials 1	4/18/23	9:00 AM	Section 46	7
CT195	Interim safety results from SEPION/AIO-PAK-0118: A multicenter, Phase I/II study of sequential epigenetic and immune targeting in combination with nab-paclitaxel/gemcitabine in patients with advanced pancreatic ductal adenocarcinoma	Jens	Siveke	Poster	Phase I Clinical Trials 1	4/18/23	9:00 AM	Section 46	8
CT196	A phase I clinical trial of oncolytic adenovirus mediated suicide and interleukin-12 gene therapy in patients with recurrent prostate cancer	Shyam	Nyati	Poster	Phase I Clinical Trials 1	4/18/23	9:00 AM	Section 46	9

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
CT197	Profiling of tumor infiltrating T cells in malignant pleural/peritoneal mesothelioma (MPM) and ovarian cancer patients as part of a Phase 1 clinical trial of gavo-cel (TC-210)	Munisha	Smalley	Poster	Phase I Clinical Trials 1	4/18/23	9:00 AM	Section 46	10
CT198	Immunomodulatory effects of the ATR inhibitor ceralasertib in a window of opportunity biomarker trial in patients with head and neck squamous cell carcinoma	Gemma	Jones	Poster	Phase I Clinical Trials 1	4/18/23	9:00 AM	Section 46	11
CT199	Rescuing response to ICI by blocking the type-2 immune axis in patients with NSCLC progressing on immunotherapy: A phase 1b/2 trial of dupilumab administered with checkpoint blockade	Thomas	Marron	Poster	Phase I Clinical Trials 1	4/18/23	9:00 AM	Section 46	12
CT200	Updated PFS & OS from the phase 1b study of TQB2450 alone/with Anlotinib in previously treated advanced non-small cell lung cancer	Baohui	Han	Poster	Phase I Clinical Trials 1	4/18/23	9:00 AM	Section 46	13
CT201	HS-10365, a highly potent and selective RET tyrosine kinase inhibitor, demonstrates robust activity in RET fusion positive NSCLC patients	Jiawei	Wei	Poster	Phase I Clinical Trials 1	4/18/23	9:00 AM	Section 46	14
CT202	Xevinapant plus avelumab in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC): Phase 1b dose-expansion results and exploratory biomarker analyses	Glenwood	Goss	Poster	Phase I Clinical Trials 1	4/18/23	9:00 AM	Section 46	15
CT203	Updated data from the Phase I Beamion Lung 1 trial of the HER2 tyrosine kinase inhibitor (TKI), BI 1810631, as monotherapy in patients (pts) with advanced/metastatic solid tumors with HER2 aberrations	John	Heymach	Poster	Phase I Clinical Trials 1	4/18/23	9:00 AM	Section 46	16
CT204	Safety, tolerability, pharmacokinetics, and efficacy of SHR-A1811, an antibody-drug conjugate, in patients with advanced HER2-mutant non-small cell lung cancer (NSCLC): a multicenter, open-label, phase 1/2 study	Shun	Lu	Poster	Phase I Clinical Trials 1	4/18/23	9:00 AM	Section 46	17
CT205	Safety and preliminary activity of naptumomab estafenatox (NAP) and durvalumab in patients with advanced or metastatic solid tumors: interim results from a phase 1b trial	Ilana	Lorber	Poster	Phase I Clinical Trials 1	4/18/23	9:00 AM	Section 46	18
CT206	A phase I study of binimetinib, a MEK inhibitor, in combination with pembrolizumab in patients with advanced non-small cell lung cancer (NSCLC)	Christopher	Theriau	Poster	Phase I Clinical Trials 1	4/18/23	9:00 AM	Section 46	19
CT207	Phase I trial of vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 (VSV-IFN β -TYRP1) in metastatic ocular melanoma	Katherine	Smith	Poster	Phase I Clinical Trials 1	4/18/23	9:00 AM	Section 46	20

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
CT208	Tebotelimab, a PD-1/LAG-3 bispecific antibody, in patients with untreated, unresectable, recurrent or metastatic, mucosal melanoma: An open-label, single-arm, Phase 1 study	Si	Lu	Poster	Phase I Clinical Trials 1	4/18/23	9:00 AM	Section 46	21
CT212	A ctDNA-directed, multi-center phase II study of molecular response adaptive immuno-chemotherapy in patients with non-small cell lung cancer: Analysis of Stage 1 of CCTG BR.36	Valsamo	Anagnostou	Poster	Phase II Clinical Trials 2	4/18/23	9:00 AM	Section 47	2
CT213	Biomarker analysis from Phase 1/2 study of tusamitamab ravtansine (SAR408701) in patients with advanced non-small cell lung cancer (NSCLC)	Anas	Gazzah	Poster	Phase II Clinical Trials 2	4/18/23	9:00 AM	Section 47	3
CT214	Preliminary efficacy of telisotuzumab vedotin (Teliso-V) treatment in the 2L/3L setting in MET gene amplified (MET Amp), c-Met protein overexpressing (c-Met OE), non-squamous, non-small cell lung cancer (NSQ NSCLC): Retrospective analysis of LUMINOSITY	Elysa	Noon	Poster	Phase II Clinical Trials 2	4/18/23	9:00 AM	Section 47	4
CT215	Efficacy and safety of adjuvant (adj) atezolizumab (atezo) from the Phase 2 LCMC3 study	David	Carbone	Poster	Phase II Clinical Trials 2	4/18/23	9:00 AM	Section 47	5
CT216	Response to first-line (1L) pembrolizumab (pembro) + chemotherapy (chemo) in non-small cell lung cancer (NSCLC) by blood tumor mutational burden (bTMB): the phase 2 KEYNOTE-782 trial	Jair	Bar	Poster	Phase II Clinical Trials 2	4/18/23	9:00 AM	Section 47	6
CT217	3-year update of neoadjuvant atezolizumab + chemotherapy in patients with resectable non-small cell lung cancer	Brian	Henick	Poster	Phase II Clinical Trials 2	4/18/23	9:00 AM	Section 47	7
CT218	A phase II trial of niraparib plus dostarlimab in relapsed small cell lung cancer and other high-grade neuroendocrine carcinomas	Carl	Gay	Poster	Phase II Clinical Trials 2	4/18/23	9:00 AM	Section 47	8
CT219	Efficacy and safety of Low dose radiotherapy (LDRT) concurrent Atezolizumab (Atezo) plus chemotherapy as first line (1L) therapy for ES-SCLC: Primary analysis of Phase II MATCH study	Lin	Zhou	Poster	Phase II Clinical Trials 2	4/18/23	9:00 AM	Section 47	9
CT221	Phase II of frontline maintenance rucaparib in combination with nivolumab in ES SCLC	Aman	Chauhan	Poster	Phase II Clinical Trials 2	4/18/23	9:00 AM	Section 47	11
CT222	Multimodal mechanism of action of the GSK-3 inhibitor 9-ING-41 (elraglusib) includes an immunomodulatory component: preliminary results from the 1801 phase 1/2 trial	Taylor	Weiskittel	Poster	Phase II Clinical Trials 2	4/18/23	9:00 AM	Section 47	12
CT223	Long-term survival follow-up of tebentafusp in previously treated metastatic uveal melanoma (mUM)	Joseph	Sacco	Poster	Phase II Clinical Trials 2	4/18/23	9:00 AM	Section 47	13
CT224	mRNA-4157, a personalized cancer vaccine, in combination with pembrolizumab, demonstrates trend for improved recurrence free survival compared to pembrolizumab alone in adjuvant melanoma patients across tumor mutational burden subgroups	Ryan	Sullivan	Poster	Phase II Clinical Trials 2	4/18/23	9:00 AM	Section 47	14

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
CT225	Surufatinib plus toripalimab for first-line treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 positive expression: A multicenter, single-arm phase 2 study	Ying	Cheng	Poster	Phase II Clinical Trials 2	4/18/23	9:00 AM	Section 47	15
CT226	Crizotinib (C) in patients (pts) with solid tumors with MET amplification (amp) or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study	Kathryn	Mileham	Poster	Phase II Clinical Trials 2	4/18/23	9:00 AM	Section 47	16
CT227	Interim results of a phase 1b/2 study of ADG126 (a masked anti-CTLA-4 SAFEbody®) monotherapy and in combination with toripalimab (an anti-PD-1 antibody) in patients (pts) with advanced / metastatic solid tumors	Jiping	Zha	Poster	Phase II Clinical Trials 2	4/18/23	9:00 AM	Section 47	17
CT228	Concordance between tissue and circulating tumor DNA (ctDNA) testing for neurotrophic tyrosine receptor kinase (NTRK) gene fusions in larotrectinib (laro) clinical trials	Erin	Rudzinski	Poster	Phase II Clinical Trials 2	4/18/23	9:00 AM	Section 47	18
CT229	CRESTONE: A Phase 2 study of seribantumab in adult patients with neuregulin-1 (NRG1) fusion positive locally advanced or metastatic solid tumors	Tejas	Patil	Poster	Phase II Clinical Trials 2	4/18/23	9:00 AM	Section 47	19
CT231	Temsirolimus (T) in patients (pts) with solid tumors with PTEN mutation (mut): results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study	Gina	Grantham	Poster	Phase II Clinical Trials 2	4/18/23	9:00 AM	Section 47	21
CT232	Safety, efficacy, and tolerability of FHND9041 capsules as first-line treatment in patients with EGFR sensitive mutations or second/third-line treatment in patients with T790M+ advanced non-small cell lung cancer (NSCLC): results from a phase I/II single-arm, multi-center, open-label study	Yongqiang	Zhu	Poster	Phase II Clinical Trials 2	4/18/23	9:00 AM	Section 47	22
CT233	Initial results of a phase 1b/2 study of ADG126 (a masked anti-CTLA-4 SAFEbody®) in combination with pembrolizumab (an anti-PD-1 antibody) in patients with advanced/metastatic solid tumors	Jiping	Zha	Poster	Phase II Clinical Trials 2	4/18/23	9:00 AM	Section 47	23
CT234	A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors	Ecaterina	Dumbrava	Poster	Phase II Clinical Trials 2	4/18/23	9:00 AM	Section 47	24
CT235	A phase I/II clinical study of an oncolytic adenovirus expressing the immunostimulatory transgenes TMZ-CD40L and 4-1BBL in advanced solid malignancies	Amanda	Hahn	Poster	Phase II Clinical Trials 2	4/18/23	9:00 AM	Section 47	25
CT238	Pharmacokinetic analyses and immunophenotyping of patients treated with Nelmastobart (hSTC810), a novel immune checkpoint inhibitor	Stephen	Yoo	Poster	Phase I and First-in-Human Clinical Trials in Progress	4/18/23	1:30 PM	Section 46	1

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
CT240	On-going phase 1A clinical trial for AG01 an first-in-class anti-progranulin (GP88) monoclonal antibody in patients with advanced malignancies	Ginette	Serrero	Poster	Phase I and First-in-Human Clinical Trials in Progress	4/18/23	1:30 PM	Section 46	3
CT241	A phase 1, first-in-human (FIH) study of autologous anti-HER2 chimeric antigen receptor macrophage (CAR-M) in participants (pt) with HER2 overexpressing solid tumors	Yara	Abdou	Poster	Phase I and First-in-Human Clinical Trials in Progress	4/18/23	1:30 PM	Section 46	4
CT242	A phase I study of ruxolitinib in combination with abemaciclib for patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis	Jan	Bewersdorf	Poster	Phase I and First-in-Human Clinical Trials in Progress	4/18/23	1:30 PM	Section 46	5
CT243	Clinical trial simulation to inform dose selection of zilurgisertib, an ALK2 inhibitor, in patients with anemia due to myelofibrosis (MF)	Yan-ou	Yang	Poster	Phase I and First-in-Human Clinical Trials in Progress	4/18/23	1:30 PM	Section 46	6
CT244	Phase 1/2 study of PRO1184, a novel folate receptor alpha-directed antibody-drug conjugate, in patients with locally advanced and/or metastatic solid tumors	Justin	Call	Poster	Phase I and First-in-Human Clinical Trials in Progress	4/18/23	1:30 PM	Section 46	7
CT245	Clinical development of a novel form of interleukin-12 with extended pharmacokinetics	Richard	Kenney	Poster	Phase I and First-in-Human Clinical Trials in Progress	4/18/23	1:30 PM	Section 46	8
CT246	An open-label, single-center, phase 0, microdose study to demonstrate delivery of TTX-MC138-NODAGA-Cu64 to radiographically confirmed metastases in subjects with advanced solid tumors	Susan	Duggan	Poster	Phase I and First-in-Human Clinical Trials in Progress	4/18/23	1:30 PM	Section 46	9
CT247	A Phase 1/2a, multicenter, open-label, non-randomized first-in-human study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of DB-1303 in patients with advanced/metastatic solid tumors	Yang	Qiu	Poster	Phase I and First-in-Human Clinical Trials in Progress	4/18/23	1:30 PM	Section 46	10
CT248	First in human trial of DB1305 in patients with advanced malignant solid tumors	Yang	Qiu	Poster	Phase I and First-in-Human Clinical Trials in Progress	4/18/23	1:30 PM	Section 46	11
CT249	A study to evaluate the safety and tolerability of the covalent phosphoinositide-3-kinase (PI3K)-alpha Inhibitor, TOS-358, in adult subjects with select solid tumors	Ovid	Trifan	Poster	Phase I and First-in-Human Clinical Trials in Progress	4/18/23	1:30 PM	Section 46	12
CT250	An open-label, phase 1a/b study of AB248, a CD8+ selective IL-2 mutein fusion protein, alone or in combination with pembrolizumab in patients with advanced solid tumors	Elizabeth	Buchbinder	Poster	Phase I and First-in-Human Clinical Trials in Progress	4/18/23	1:30 PM	Section 46	13
CT251	Phase 1/2 study of HST-1011, an oral CBL-B inhibitor, alone and in combination with anti-PD1 in patients with advanced solid tumors	Amanda	Redig	Poster	Phase I and First-in-Human Clinical Trials in Progress	4/18/23	1:30 PM	Section 46	14
CT252	A modular, open-label, phase I/II study to evaluate the safety, tolerability, pharmacokinetics and efficacy of EP0031, a next	Andrew	Gianoukakis	Poster	Phase I and First-in-Human Clinical Trials in Progress	4/18/23	1:30 PM	Section 46	15

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/ Section	Board Num
	generation selective RET inhibitor, in patients with advanced RET-altered malignancies								
CT253	Phase 1/2 study of the safety, pharmacokinetics, and preliminary clinical activity of BT7480 in patients with nectin-4 associated advanced malignancies	Thomas	Evans	Poster	Phase I and First-in-Human Clinical Trials in Progress	4/18/23	1:30 PM	Section 46	16
CT254	Trial in progress: a first-in-human, phase 1, multicenter dose escalation and dose expansion study of WTX-330 in adult patients with advanced or metastatic solid tumors or non-Hodgkin lymphoma	Sameer	Chopra	Poster	Phase I and First-in-Human Clinical Trials in Progress	4/18/23	1:30 PM	Section 46	17
CT255	ELU-FR α -1: a study to evaluate ELU001 in patients with solid tumors that overexpress folate receptor alpha (FR α)	Wen Wee	Ma	Poster	Phase I and First-in-Human Clinical Trials in Progress	4/18/23	1:30 PM	Section 46	18
CT256	Modi-1, anti-citrullinated neopeptide vaccine alone and combined with checkpoint inhibitors in patients with head and neck, breast, renal and ovarian carcinoma: protocol for the ModiFY phase I/II basket clinical trial	Lindy	Durrant	Poster	Phase I and First-in-Human Clinical Trials in Progress	4/18/23	1:30 PM	Section 46	19
CT257	First-in-human phase 1 studies of PTPN2/1 inhibitors ABBV-CLS-484 and ABBV-CLS-579 in locally advanced or metastatic tumors	Patricia	LoRusso	Poster	Phase I and First-in-Human Clinical Trials in Progress	4/18/23	1:30 PM	Section 46	20
CT258	A phase 1 / 2 study of JK08, an IL-15 antibody fusion protein targeting CTLA-4, in patients with advanced solid tumors	Naimish	Pandya	Poster	Phase I and First-in-Human Clinical Trials in Progress	4/18/23	1:30 PM	Section 46	21
CT261	A Phase 1, open-label, dose-escalation study of selinexor plus ruxolitinib in patients with treatment-naïve myelofibrosis	Haris	Ali	Poster	Phase I Clinical Trials 2	4/18/23	1:30 PM	Section 47	1
CT262	Durable responses following anti-TIGIT (BMS-986207) and anti-LAG3 (BMS-980616) in combination with pomalidomide in relapsed myeloma: MMRF MyCheckpoint trial	Hearn	Cho	Poster	Phase I Clinical Trials 2	4/18/23	1:30 PM	Section 47	2
CT263	A phase Ib dose-expansion study of porustobart, an anti-CTLA-4 heavy chain only monoclonal antibody, in combination with toripalimab in patients with advanced high-grade neuroendocrine neoplasms (NENs)	Humphrey	Gardner	Poster	Phase I Clinical Trials 2	4/18/23	1:30 PM	Section 47	3
CT264	Taking sotorasib with an acidic beverage improves sotorasib exposure for subjects on omeprazole	Natasha	Strydom	Poster	Phase I Clinical Trials 2	4/18/23	1:30 PM	Section 47	4
CT265	Phase 1 dose-escalation study of SGN-TGT monotherapy in patients with advanced malignancies	Andres	Forero-Torres	Poster	Phase I Clinical Trials 2	4/18/23	1:30 PM	Section 47	5
CT266	Chinese race and origin have no clinically meaningful effect on tiragolumab and atezolizumab pharmacokinetics and safety in patients with advanced solid tumors	Colby	Shemesh	Poster	Phase I Clinical Trials 2	4/18/23	1:30 PM	Section 47	6
CT267	ENB-003, an ETBR antagonist, in combination with pembrolizumab for advanced solid tumor: The ENBolden trial	Sumayah	Jamal	Poster	Phase I Clinical Trials 2	4/18/23	1:30 PM	Section 47	7

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
CT268	Targeting replication stress and chemotherapy resistance with a combination of sacituzumab govitecan and berzosertib: A phase I clinical trial	Melissa	Abel	Poster	Phase I Clinical Trials 2	4/18/23	1:30 PM	Section 47	8
CT269	A highly sensitive and specific PARylation assay confirms significant and durable target engagement by AZD5305 in patients	Benedetta	Lombardi	Poster	Phase I Clinical Trials 2	4/18/23	1:30 PM	Section 47	9
CT270	Immunogenicity of PGV_001 neoantigen vaccine in a Phase-I clinical trial, across various types of cancers in adjuvant setting	Mansi	Saxena	Poster	Phase I Clinical Trials 2	4/18/23	1:30 PM	Section 47	10
CT271	Translational analyses of ATR inhibitor M1774 in a Phase I study in patients with solid tumors (DDRiver Solid Tumors 301)	Anthony	Tolcher	Poster	Phase I Clinical Trials 2	4/18/23	1:30 PM	Section 47	11
CT272	Pharmacodynamic and immunophenotyping analyses of ATR inhibitor M1774 in a Phase I study in patients with solid tumors (DDRiver Solid Tumors 301)	Anthony	Tolcher	Poster	Phase I Clinical Trials 2	4/18/23	1:30 PM	Section 47	12
CT273	Evaluation of the effect of rivoceranib on the pharmacokinetics of cytochrome P450 enzyme substrates in healthy volunteers	Janelle	Weyer	Poster	Phase I Clinical Trials 2	4/18/23	1:30 PM	Section 47	13
CT274	Individualized APC targeting VB10.NEO cancer vaccines induce broad neoepitope-specific CD8 T cell responses in patients with advanced or metastatic solid tumors: interim results from a phase 1/2a trial	Kushi	Kushekhar	Poster	Phase I Clinical Trials 2	4/18/23	1:30 PM	Section 47	14
CT275	Phase 1 clinical update of allogeneic invariant natural killer T cells (iNKTs), agenT-797, alone or in combination with pembrolizumab or nivolumab in patients with advanced solid tumors	Benedito	Carneiro	Poster	Phase I Clinical Trials 2	4/18/23	1:30 PM	Section 47	15
CT276	Preliminary analysis of pharmacokinetic (PK) and target engagement biomarkers from a first in human phase 1 study of immunomodulatory aryl hydrocarbon receptor (AhR) inhibitor BAY2416964	Kyriakos	Papadopoulos	Poster	Phase I Clinical Trials 2	4/18/23	1:30 PM	Section 47	16
CT278	ERBB2 amplification detected in ctDNA as a surrogate for tumor tissue FISH analysis of HER2 status in a phase 1 study with zanidatamab for the treatment of locally advanced or metastatic HER2 expressing cancers	Diana	Shpektor	Poster	Phase I Clinical Trials 2	4/18/23	1:30 PM	Section 47	18
LB001	Encapsulation of IL-12 with an ultra pH-sensitive nanoparticle platform improves tolerability and promotes antitumor response in mice	Tian	Zhao	Poster	Late-Breaking Research: Chemistry	4/16/23	1:30 PM	Section 34	1
LB002	Extracellular vesicle loading of proteolysis targeting chimeras for targeted therapeutic delivery	Nina	Erwin	Poster	Late-Breaking Research: Chemistry	4/16/23	1:30 PM	Section 34	2
LB003	BI 907828: A highly potent MDM2-p53 antagonist suitable for intermittent dose schedules	Andreas	Gollner	Poster	Late-Breaking Research: Chemistry	4/16/23	1:30 PM	Section 34	3

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
LB004	Ultra-sensitive targeted DNA panel for very low-frequency mutation detection in circulating cell-free DNA	Zhong	Wu	Poster	Late-Breaking Research: Chemistry	4/16/23	1:30 PM	Section 34	4
LB005	Insights of renal cell carcinoma from multiomic perspective	Aron	Bartha	Poster	Late-Breaking Research: Chemistry	4/16/23	1:30 PM	Section 34	5
LB006	Interactome analysis identifies signaling pathways activated by ETV6-NTRK3 oncogenic gene fusions	Markku	Varjosalo	Poster	Late-Breaking Research: Chemistry	4/16/23	1:30 PM	Section 34	6
LB009	Notch4 inhibition by a novel neutralizing antibody reduces tumor progression and increases macrophage recruitment within the tumor microenvironment	Katherine	Alexander	Poster	Late-Breaking Research: Experimental and Molecular Therapeutics 1	4/16/23	1:30 PM	Section 35	1
LB010	LY6K depletion modulates TGF- β and EGF signaling	Young	Yang	Poster	Late-Breaking Research: Experimental and Molecular Therapeutics 1	4/16/23	1:30 PM	Section 35	2
LB011	Development of novel protein drug conjugates (PDCs) for the selective targeting of ALPP/ALPPL2 expressing tumors	Graham	Cotton	Poster	Late-Breaking Research: Experimental and Molecular Therapeutics 1	4/16/23	1:30 PM	Section 35	3
LB012	Claudin-1 is a driver and therapeutic target for cholangiocarcinoma	Emilie	Crouchet	Poster	Late-Breaking Research: Experimental and Molecular Therapeutics 1	4/16/23	1:30 PM	Section 35	4
LB013	Integrated in vivo functional screens and multi-omics analyses identify alpha-2,3-sialylation as essential for melanoma survival	Praveen	Agrawal	Poster	Late-Breaking Research: Experimental and Molecular Therapeutics 1	4/16/23	1:30 PM	Section 35	5
LB014	Targeting Stearoyl-coA desaturase (SCD) as a therapeutic strategy in STK11/KEAP1 co-mutant non-small cell lung cancer	Utsav	Sen	Poster	Late-Breaking Research: Experimental and Molecular Therapeutics 1	4/16/23	1:30 PM	Section 35	6
LB015	Bi-steric mTORC1-selective inhibitors activate 4EBP1, suppress MYC, restore anti-tumor immunity, and cooperate with immune checkpoint inhibition to elicit tumor regression	Wadie	Mahauad-Fernandez	Poster	Late-Breaking Research: Experimental and Molecular Therapeutics 1	4/16/23	1:30 PM	Section 35	7
LB016	Immunotherapeutic potential of ST316, a peptide antagonist of β -catenin	Claudio	Scuoppo	Poster	Late-Breaking Research: Experimental and Molecular Therapeutics 1	4/16/23	1:30 PM	Section 35	8
LB017	Potential role of kinesin family member C1 (KIFC1) in melanoma	Davis	Mau	Poster	Late-Breaking Research: Experimental and Molecular Therapeutics 1	4/16/23	1:30 PM	Section 35	9
LB018	Therapeutic efficacy of inhibition of specific sirtuins against melanoma in BrafV600E/PtenNULL and PDX models	Karla	Anaya Aldrete	Poster	Late-Breaking Research: Experimental and Molecular Therapeutics 1	4/16/23	1:30 PM	Section 35	10

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
LB019	DUSP4 overexpression exerts anti-tumor effects in vivo in pancreatic cancer xenografts in nu/nu mice	Chandra	Singh	Poster	Late-Breaking Research: Experimental and Molecular Therapeutics 1	4/16/23	1:30 PM	Section 35	11
LB021	KN-052, a novel PDL1/OX40 bispecific antibody, exhibits potent antitumor efficacy	Ting	Xu	Poster	Late-Breaking Research: Experimental and Molecular Therapeutics 1	4/16/23	1:30 PM	Section 35	13
LB022	A novel first-in-class USP19 inhibitor for the treatment of cancer-induced muscle atrophy	Natalie	Page	Poster	Late-Breaking Research: Experimental and Molecular Therapeutics 1	4/16/23	1:30 PM	Section 35	14
LB023	Discovery, development and characterization of potent and selective USP11 inhibitors	Forum	Kayastha	Poster	Late-Breaking Research: Experimental and Molecular Therapeutics 1	4/16/23	1:30 PM	Section 35	15
LB024	Pharmacokinetics of a novel viscoelastic suspension of trastuzumab biosimilar for high-concentration, low-volume subcutaneous injection	Rick	Fitch	Poster	Late-Breaking Research: Experimental and Molecular Therapeutics 1	4/16/23	1:30 PM	Section 35	16
LB025	First disclosure of AZD5335, a TOP1i-ADC targeting low and high FR α -expressing ovarian cancer with superior preclinical activity vs FR α -MTI ADC	Marco	Gymnopoulos	Poster	Late-Breaking Research: Experimental and Molecular Therapeutics 1	4/16/23	1:30 PM	Section 35	17
LB026	Porcine brain-derived hydrogel carriers for intratumoral administration of cellular immunotherapies enhances anti-tumor potential in post-resection GBM	Meghan	Logun	Poster	Late-Breaking Research: Experimental and Molecular Therapeutics 1	4/16/23	1:30 PM	Section 35	18
LB027	In vivo delivery of novel CD89 fusion receptor to myeloid cells by mRNA activates anti-tumor immunity	Thomas	Prod'homme	Poster	Late-Breaking Research: Experimental and Molecular Therapeutics 1	4/16/23	1:30 PM	Section 35	19
LB028	Reprogramming of tumor-infiltrating immune cells using a tumor-associated macrophage-targeted TLR7 agonist	John Victor	Napoleon	Poster	Late-Breaking Research: Experimental and Molecular Therapeutics 1	4/16/23	1:30 PM	Section 35	20
LB029	AWT030: a first-in-class bi-functional IL-21 fusion protein selectively activates tumor infiltrated CD8 T cells and suppresses Treg cells	Fan	Ye	Poster	Late-Breaking Research: Experimental and Molecular Therapeutics 1	4/16/23	1:30 PM	Section 35	21
LB030	SHR-A1921, a novel TROP-2 ADC with an optimized design and well-balanced profile between efficacy and safety	Linda	Zhao	Poster	Late-Breaking Research: Experimental and Molecular Therapeutics 1	4/16/23	1:30 PM	Section 35	22
LB031	SHR-A1811, a novel anti-HER2 ADC with superior bystander effect, optimal DAR and favorable safety profiles	Linda	Zhao	Poster	Late-Breaking Research: Experimental and Molecular Therapeutics 1	4/16/23	1:30 PM	Section 35	23

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
									wide association study identifies susceptibility loci and genes for lung cancer risk
								"	Tianying
Zhao	Poster	Late-Breaking Research: Molecular/Cellular Biology and Genetics 1	4/16/23	1:30 PM	Section 36	12			
LB046	Characterizing the role of inflammation-induced epigenetic alterations in modulating the immune microenvironment during lung cancer initiation	Na	Wang	Poster	Late-Breaking Research: Molecular/Cellular Biology and Genetics 1	4/16/23	1:30 PM	Section 36	13
LB048	AR-targeted linked-read sequencing reveals complex AR structural variants in CRPC tumors	Andrej	Zivanovic	Poster	Late-Breaking Research: Molecular/Cellular Biology and Genetics 1	4/16/23	1:30 PM	Section 36	15
LB049	ALKBH5 emerges as a novel regulator of the BCR pathway	Anirban	Roychowdhury	Poster	Late-Breaking Research: Molecular/Cellular Biology and Genetics 1	4/16/23	1:30 PM	Section 36	16
LB052	Electronic nicotine delivery system (ENDS) use among LatinX youth in low-resource communities: Implications for policy and regulation	Marcelo	Sleiman	Poster	Science and Health Policy / Regulatory Science and Policy	4/16/23	1:30 PM	Section 26	17

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
LB054	Establishment of an infrastructure for rapid pandemic response at the Frederick National Laboratory	Nancy	Roche	Poster	COVID-19 and Cancer	4/16/23	1:30 PM	Section 29	17
LB056	Crowdsourcing rare cancer research in the Hack4NF GENIE-NF tumor identification and classification challenge	Robert	Allaway	Oral	Advancing Cancer Research Through an International Cancer Registry: AACR Project GENIE Use Cases	4/16/23	3:00 PM	Room W230	
LB058	A transcriptome-wide gene expression outlier analysis pinpoints therapeutic vulnerabilities in colorectal cancer	Gaia	Grasso	Poster	Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 1	4/17/23	9:00 AM	Section 34	1
LB059	DNA damage and somatic mutations in mammalian cells after irradiation with a nail polish dryer	Maria	Zhivagui	Poster	Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 1	4/17/23	9:00 AM	Section 34	2
LB060	Integrated analysis of transcriptomics and kinase activity data for better characterization of cancer models	Simar	Pal Singh	Poster	Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 1	4/17/23	9:00 AM	Section 34	3
LB061	Proteomic-based stemness score measure oncogenic dedifferentiation and enable the identification of druggable targets	Maciej	Wiznerowicz	Poster	Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 1	4/17/23	9:00 AM	Section 34	4
LB062	Identifying novel targets for CAR-T therapies from single cell RNA-sequencing data	Sanna	Madan	Poster	Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 1	4/17/23	9:00 AM	Section 34	5
LB063	An integrated transomics approach reveals significant differences between EGFR inhibitors with the potential to identify novel targets to overcome EGFR resistance	Christopher	Nicholson	Poster	Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 1	4/17/23	9:00 AM	Section 34	6
LB064	Using a genomic only approach to a radiation-age association for supplementing differentiation amongst lung diseases and cancer using PMBCs	Nathan	Ruprecht	Poster	Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 1	4/17/23	9:00 AM	Section 34	7
LB065	Interface-guided phenotyping of coding variants	Kivilcim	Ozturk	Poster	Late-Breaking Research: Bioinformatics, Computational	4/17/23	9:00 AM	Section 34	8

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
					Biology, Systems Biology, and Convergent Science 1				
LB066	Machine learning algorithm for drug discovery targeting new co-transcription factors of HIF1A	Yuxiang	Zhang	Poster	Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 1	4/17/23	9:00 AM	Section 34	9
LB067	A confident and operator-independent deep segmentation model to measure residual tumor volume in the follow-up MRIs for glioblastoma	Kang Lin	Hsieh	Poster	Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 1	4/17/23	9:00 AM	Section 34	10
LB069	Predictive modeling of drug sensitivity based on the genetic dependency	Bicna	Song	Poster	Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 1	4/17/23	9:00 AM	Section 34	12
LB070	Predicting distant recurrences in invasive breast carcinoma patients using their clinicopathological profiles	Shrey	Sukhadia	Poster	Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 1	4/17/23	9:00 AM	Section 34	13
LB071	A phenomics platform combining imaging and artificial intelligence for rapid validation and advancement of novel oncology targets	Jenny	Rudnick	Poster	Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 1	4/17/23	9:00 AM	Section 34	14
LB073	NCI's broad-use collections: Accelerating discovery process by improving access to individual-level genomics and other -omics data	Freddie	Pruitt	Poster	Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 1	4/17/23	9:00 AM	Section 34	16
LB074	Towards the next generation cancer dependency map	Kirsty	Wienand	Poster	Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 1	4/17/23	9:00 AM	Section 34	17
LB075	Cancers adapt to their mutational load by buffering protein misfolding stress	Christina	Curtis	Poster	Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 1	4/17/23	9:00 AM	Section 34	18
LB076	A novel spatial trajectory inference method for detecting regional breast cancer progression from spatial transcriptomics data	Duy	Pham	Poster	Late-Breaking Research: Bioinformatics, Computational	4/17/23	9:00 AM	Section 34	19

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
					Biology, Systems Biology, and Convergent Science 1				
LB077	Analysis of indel and structural variant error profiles in deep next generation sequencing data	Quang	Tran	Poster	Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 1	4/17/23	9:00 AM	Section 34	20
LB078	pbfusion: Detecting gene-fusion and other transcriptional abnormalities using PacBio HiFi data	Zev	Kronenberg	Poster	Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 1	4/17/23	9:00 AM	Section 34	21
LB079	An end-to-end Visium spatial transcriptomics computational pipeline for generating low-code interactive reports of spatial insights	Steven	Hamel	Poster	Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 1	4/17/23	9:00 AM	Section 34	22
LB080	SAVANA: a computational method to characterize structural variation in human cancer genomes using nanopore sequencing	Hillary	Elrick	Poster	Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 1	4/17/23	9:00 AM	Section 34	23
LB081	Concurrent characterization of somatic nucleotide mutations, 5mC, and 5hmC methylation in clinical research samples using a single nanopore sequencing assay	Sergey	Aganezov	Poster	Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 1	4/17/23	9:00 AM	Section 34	24
LB082	The CytoR1: a standardized dielectrophoretic platform for label free sorting	Dean	Thomas	Poster	Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 1	4/17/23	9:00 AM	Section 34	25
LB085	Antitumor activity of AZD0754, a dnTGFbRII armored STEAP2 targeted CAR-T therapy, in preclinical models of prostate cancer	Emily	Bosco	Poster	Late-Breaking Research: Immunology 1	4/17/23	9:00 AM	Section 35	1
LB087	IFN-gamma targets tumor vascular endothelial cells, causing impaired perfusion and tumor growth suppression in adoptive T cell therapy	Qiaoya	Lin	Poster	Late-Breaking Research: Immunology 1	4/17/23	9:00 AM	Section 35	3
LB089	ACE2016: an off-the-shelf EGFR-targeting $\gamma\delta$ T cell therapy against EGFR-expressing solid tumors	Hao-Kang	Li	Poster	Late-Breaking Research: Immunology 1	4/17/23	9:00 AM	Section 35	5
LB090	IL-18 secreting chimeric antigen receptor T cells targeting glypican-3 show superior persistence and antitumor immunity against hepatocellular carcinoma	Joseph	Jeong	Poster	Late-Breaking Research: Immunology 1	4/17/23	9:00 AM	Section 35	6

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
LB091	Design, characterization and preclinical validation of a combinatorial CAR-based immunotherapy against colorectal cancer with HER2 amplification	Enzo	Medico	Poster	Late-Breaking Research: Immunology 1	4/17/23	9:00 AM	Section 35	7
LB092	Identification of target antigens for logic-gated CAR-T therapeutics for the treatment of clear cell renal cell carcinoma: conditional targeting of CA9 with a PSMA PrimeR	Samuel	Williams	Poster	Late-Breaking Research: Immunology 1	4/17/23	9:00 AM	Section 35	8
LB093	Engineering tumor infiltrating lymphocytes from sarcoma and colorectal tumors with membrane bound IL-15 for IL-2 independent expansion and enhanced cytotoxicity against autologous tumor cell lines	Zheng	Ao	Poster	Late-Breaking Research: Immunology 1	4/17/23	9:00 AM	Section 35	9
LB094	Arginine pre-conditioning improves T-cell potency and metabolic fitness measured by real-time impedance and seahorse assays	Mark	Garner	Poster	Late-Breaking Research: Immunology 1	4/17/23	9:00 AM	Section 35	10
LB095	Hybrid TCR-CAR design surpasses conventional CARs and patient-derived TCRs in targeting an ultra-low-density neoantigen	Brian	Mog	Poster	Late-Breaking Research: Immunology 1	4/17/23	9:00 AM	Section 35	11
LB096	IL15-engineered tumor infiltrating lymphocytes (cytoTIL15TM) exhibit activity against autologous tumor cells from multiple solid tumor indications without IL2	Kyle	Pedro	Poster	Late-Breaking Research: Immunology 1	4/17/23	9:00 AM	Section 35	12
LB097	Armored bicistronic CAR T cells with dominant-negative TGF- β receptor II to alleviate antigenic heterogeneity and suppressive immune microenvironment in glioblastoma	Nannan	Li	Poster	Late-Breaking Research: Immunology 1	4/17/23	9:00 AM	Section 35	13
LB098	Combination of a PD-1/CTLA-4 bispecific antibody with orally active PD-L1 inhibitor MAX-10181 effectively increased the percentage of tumors inhibited in animal model study	Yuguang	Wang	Poster	Late-Breaking Research: Immunology 1	4/17/23	9:00 AM	Section 35	14
LB099	Organoid-based drug efficacy evaluation model for immunotherapy	Boeun	Lee	Poster	Late-Breaking Research: Immunology 1	4/17/23	9:00 AM	Section 35	15
LB100	Understanding how IL-2 cytokine synergizes with PD-1 therapy during chronic viral infection	Masao	Hashimoto	Poster	Late-Breaking Research: Immunology 1	4/17/23	9:00 AM	Section 35	16
LB101	Cell-generated IL12 combined with PD-1 inhibition produces local and abscopal immune activation to eradicate metastatic melanoma and pancreatic cancer	Amanda	Nash	Poster	Late-Breaking Research: Immunology 1	4/17/23	9:00 AM	Section 35	17
LB102	Hexyl-(cuban-1-yl-methyl)-biguanide (HCB) suppresses N-glycosylation of immune checkpoint proteins B7-H3 and B7-H4, reverses tumor hypoxia, decreases intratumoral regulatory T cells, and increases intratumoral CD8+ T cells in the ovarian dependent ER+HER2- SSM2ucd mammary cancer allograft model	Zhijun	Guo	Poster	Late-Breaking Research: Immunology 1	4/17/23	9:00 AM	Section 35	18

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
LB104	Preclinical evaluation of the role of Galectin-1 in tumor immune evasion associated mechanisms using a highly selective Galectin-1 small molecule inhibitor	Ian	Holyer	Poster	Late-Breaking Research: Immunology 1	4/17/23	9:00 AM	Section 35	20
LB107	A precision DNA methylation test to triage HPV positive women before referral to colposcopy-driven biopsies or ablative treatment in cervical cancer screening clinics worldwide	Laura	Palmieri	Poster	Late-Breaking Research: Prevention, Early Detection, and Interception	4/17/23	9:00 AM	Section 36	1
LB109	Network analysis of gut microbiome throughout a whole foods based high fiber dietary intervention reveals complex community dynamics in melanoma survivors	Daniel	Mousavi	Poster	Late-Breaking Research: Prevention, Early Detection, and Interception	4/17/23	9:00 AM	Section 36	3
LB110	Racial and ethnic disparities associated with the intratumor microbiome in female cancers	Daniel	John	Poster	Late-Breaking Research: Prevention, Early Detection, and Interception	4/17/23	9:00 AM	Section 36	4
LB111	Epigenetic mechanism underlying pathogenesis of skin photo-damage and actinic keratoses	Mahendra	Kashyap	Poster	Late-Breaking Research: Prevention, Early Detection, and Interception	4/17/23	9:00 AM	Section 36	5
LB112	Increasing clinical trials diversity through Community Research Registry (CoRR): The Community Champions for clinical trials program	Folakemi	Odedina	Poster	Late-Breaking Research: Prevention, Early Detection, and Interception	4/17/23	9:00 AM	Section 36	6
LB113	Bio-printed 3D cell models and high-content imaging for testing anti-cancer compounds	Zhisong	Tong	Poster	Late-Breaking Research: Prevention, Early Detection, and Interception	4/17/23	9:00 AM	Section 36	7
LB114	Colon cancer preventive efficacy of ONC201 and naproxen alone or in combination in FAP relevant PIRC rat model	Chinthalapally	Rao	Poster	Late-Breaking Research: Prevention, Early Detection, and Interception	4/17/23	9:00 AM	Section 36	8
LB115	Simultaneous whole-body ultrasound contrast imaging: a novel high throughput preclinical platform for targeted molecular imaging studies	Arutselvan	Natarajan	Poster	Late-Breaking Research: Prevention, Early Detection, and Interception	4/17/23	9:00 AM	Section 36	9
LB118	Evidence of tumor response in orbital lesions treated with tebentafusp in metastatic uveal melanoma patients	Marcus	Butler	Poster	Late-Breaking Research: Clinical Research 1 / Endocrinology	4/17/23	1:30 PM	Section 34	1
LB119	Recurrence score for recurrence over survival outcome in the landmark TAILORx trial	Sherry	Yang	Poster	Late-Breaking Research: Clinical Research 1 / Endocrinology	4/17/23	1:30 PM	Section 34	2
LB121	BrainChild-03: Intraventricular B7-H3 CAR T cells for recurrent/refractory central nervous system tumors and non-pontine diffuse midline glioma in children and young adults	Nicholas	Vitanza	Poster	Late-Breaking Research: Clinical Research 1 / Endocrinology	4/17/23	1:30 PM	Section 34	4
LB122	Arima-HiC sequencing accurately detects clinically-relevant structural variants in pediatric leukemia samples	Anthony	Schmitt	Poster	Late-Breaking Research: Clinical Research 1 / Endocrinology	4/17/23	1:30 PM	Section 34	5

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
LB123	Poorer outcomes in EGFR L858R-driven NSCLC treated with osimertinib may be addressed with novel combination of BLU-945 and osimertinib	Yasir	Elamin	Poster	Late-Breaking Research: Clinical Research 1 / Endocrinology	4/17/23	1:30 PM	Section 34	6
LB126	RELA fusion-positive ependymoma and diffuse midline glioma treated with VAL-083 under expanded access - case reports	Carlos	Kamiya-Matsuoka	Poster	Late-Breaking Research: Clinical Research 1 / Endocrinology	4/17/23	1:30 PM	Section 34	9
LB127	VAL-083 in patients with recurrent glioblastoma treated under expanded access program	Carlos	Kamiya-Matsuoka	Poster	Late-Breaking Research: Clinical Research 1 / Endocrinology	4/17/23	1:30 PM	Section 34	10
LB129	Survival of most commonly diagnosed second primary cancers among adult cancer survivors	Hyuna	Sung	Poster	Late-Breaking Research: Clinical Research 1 / Endocrinology	4/17/23	1:30 PM	Section 34	12
LB130	Single-cell multiomics analysis of myelodysplastic syndrome predicts clinical response to DNA methylation inhibitor therapy	Manel	Esteller	Poster	Late-Breaking Research: Clinical Research 1 / Endocrinology	4/17/23	1:30 PM	Section 34	13
LB131	Association between epigenetic heterogeneity of esophageal adenocarcinoma and response to first-line immunochemotherapy in LUD2015-005 Trial	Phil	Xie	Poster	Late-Breaking Research: Clinical Research 1 / Endocrinology	4/17/23	1:30 PM	Section 34	14
LB132	In silico mutant neoantigen prediction - a promising avenue for target identification in human adrenocortical carcinoma	Laura-Sophie	Landwehr	Poster	Late-Breaking Research: Clinical Research 1 / Endocrinology	4/17/23	1:30 PM	Section 34	15
LB133	An orally bioavailable degrader targeting androgen receptor and the splice variant in castration resistant prostate cancer	Chiu-Lien	Hung	Poster	Late-Breaking Research: Clinical Research 1 / Endocrinology	4/17/23	1:30 PM	Section 34	16
LB134	Targeting coactivators to inhibit ESR1 fusion-driven breast cancer growth	Charles	Foulds	Poster	Late-Breaking Research: Clinical Research 1 / Endocrinology	4/17/23	1:30 PM	Section 34	17
LB137	Ovulatory years prior to menopause and postmenopausal endogenous hormone levels	Daniel	Cramer	Poster	Late-Breaking Research: Population Sciences	4/17/23	1:30 PM	Section 35	1
LB138	The conception of an Oncology Neurodiversity Work Group to address cancer disparity for individuals with autism and intellectual or developmental disability (IDD) at the Sidney Kimmel Cancer Center	Avnish	Bhatia	Poster	Late-Breaking Research: Population Sciences	4/17/23	1:30 PM	Section 35	2
LB139	Factors associated with clinical trial participation among female cancer survivors in Maryland	Avonne	Connor	Poster	Late-Breaking Research: Population Sciences	4/17/23	1:30 PM	Section 35	3
LB140	Inequity in cancer crowdfunding among LGBTQ+ cancer survivors	Echo	Warner	Poster	Late-Breaking Research: Population Sciences	4/17/23	1:30 PM	Section 35	4
LB142	Metabolically defined body size phenotypes in relation to subsequent colorectal cancer risk	Linda	Vidman	Poster	Late-Breaking Research: Population Sciences	4/17/23	1:30 PM	Section 35	6
LB143	Improving treatment outcomes: a digital solution for remote patient monitoring of stomatitis for patients receiving Dato-DXd	Rebecca	Wray	Poster	Late-Breaking Research: Population Sciences	4/17/23	1:30 PM	Section 35	7
LB144	The nationwide population-based cohort study on the risk of immune-mediated diseases and risk of cancer in KOREA	Jiyeong	Youn	Poster	Late-Breaking Research: Population Sciences	4/17/23	1:30 PM	Section 35	8

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
LB145	The relationship of socio-behavioral factors to the symptom experience of Asian American breast cancer survivors: a structural equation model	Seo Yun	Kim	Poster	Late-Breaking Research: Population Sciences	4/17/23	1:30 PM	Section 35	9
LB146	Imaging surveillance practice patterns among older adults with stage I/II non-small cell lung cancer	Meghann	Wheeler	Poster	Late-Breaking Research: Population Sciences	4/17/23	1:30 PM	Section 35	10
LB147	The mediating effects of socio-behavioral factors on the needs for help among Asian American breast cancer survivors	Seo Yun	Kim	Poster	Late-Breaking Research: Population Sciences	4/17/23	1:30 PM	Section 35	11
LB150	Endothelial protein kinase D1 signaling induces development of aggressive cancer stem-like cells for breast cancer progression and lung metastasis	Bin	Ren	Poster	Late-Breaking Research: Tumor Biology 1	4/17/23	1:30 PM	Section 36	1
LB151	Exploring the tumor microenvironment in a spatial context with SpaCET	Beibei	Ru	Poster	Late-Breaking Research: Tumor Biology 1	4/17/23	1:30 PM	Section 36	2
LB153	Inhibiting BRD4 as a proposed alternative therapeutic strategy for HPV16-associated head and neck squamous cell carcinoma	Dhruthi	Suresh	Poster	Late-Breaking Research: Tumor Biology 1	4/17/23	1:30 PM	Section 36	4
LB154	Circ0003039 interacts with calreticulin to inhibit the progression of hepatocellular carcinoma by suppressing wnt/beta-catenin signaling pathway	Yue-Ning	Wang	Poster	Late-Breaking Research: Tumor Biology 1	4/17/23	1:30 PM	Section 36	5
LB155	In vivo imaging of vascular pathology in mouse orthotopic glioma model using functional ultrasound	Jussi	Rytkönen	Poster	Late-Breaking Research: Tumor Biology 1	4/17/23	1:30 PM	Section 36	6
LB156	Identified the ISG15 mediated extracellular vesicles drives ovarian cancer progression and metastasis: extracellular vesicular ISG15 is a potential biomarker and therapeutic target	Kalpana Deepa Priya	Dorayappan	Poster	Late-Breaking Research: Tumor Biology 1	4/17/23	1:30 PM	Section 36	7
LB157	Cereblon inhibits prostate cancer progression and metastasis by negatively regulating 6PGD	Steve	Cho	Poster	Late-Breaking Research: Tumor Biology 1	4/17/23	1:30 PM	Section 36	8
LB158	Rapid cancer cell perineural invasion utilizes amoeboid migration	Qi	Wang	Poster	Late-Breaking Research: Tumor Biology 1	4/17/23	1:30 PM	Section 36	9
LB159	Deregulation of CTC-associated RPL/RPS protein expression inhibits melanoma brain metastasis	Tetiana	Bowley	Poster	Late-Breaking Research: Tumor Biology 1	4/17/23	1:30 PM	Section 36	10
LB160	Mdm2 regulates metastasis and associated cellular processes through modulation of Sprouty4 in a p53-independent manner	Rafaela	Muniz de Queiroz	Poster	Late-Breaking Research: Tumor Biology 1	4/17/23	1:30 PM	Section 36	11
LB161	Single cell bioprinted cell circuits for the systematic assessment of cell-cell communication in the early tumor microenvironment	Haylie	Helms	Poster	Late-Breaking Research: Tumor Biology 1	4/17/23	1:30 PM	Section 36	12
LB162	A multiplex organoid avatar drug testing platform for precision medicine	Phillip	Buckhaults	Poster	Late-Breaking Research: Tumor Biology 1	4/17/23	1:30 PM	Section 36	13
LB163	A microfluidic platform for developing circulating tumor cells (CTCs) organoids for precision medicine in pancreatic cancer	Yu	Zhang	Poster	Late-Breaking Research: Tumor Biology 1	4/17/23	1:30 PM	Section 36	14

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
LB164	Entinostat restores sensitivity to olaparib in two in vitro models of PARPi resistant ovarian cancer cells	Bisiayo	Fashemi	Poster	Late-Breaking Research: Tumor Biology 1	4/17/23	1:30 PM	Section 36	15
LB165	A novel PDX-based 2-stage screening platform can identify active drug combinations against KRAS-mutated colorectal cancer	Alexey	Sorokin	Poster	Late-Breaking Research: Tumor Biology 1	4/17/23	1:30 PM	Section 36	16
LB168	Efficacy analysis of the DeepNeo neoantigen prediction tool for antitumor vaccine development	Suhwan	Chang	Poster	Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 2	4/18/23	9:00 AM	Section 34	1
LB169	Machine learning-based approach for glioblastoma drug repurposing on real-world patient data	Ko-Hong	Lin	Poster	Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 2	4/18/23	9:00 AM	Section 34	2
LB170	Artificial intelligence-assisted morphology-based detection and enrichment of malignant effusion tumor cells as a method for molecular profiling	Manisha	Ray	Poster	Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 2	4/18/23	9:00 AM	Section 34	3
LB171	WSI based prediction of TP53 mutations identifies aggressive disease phenotype in prostate cancer	Marija	Pizurica	Poster	Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 2	4/18/23	9:00 AM	Section 34	4
LB172	Improved T-cell and B-cell receptor repertoire profiling and immunophenotyping for biomarker discovery	Alex	Chenchik	Poster	Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 2	4/18/23	9:00 AM	Section 34	5
LB173	A bioinformatics approach to determine the potential benefit of blocking both Galectin-1 and Galectin-3 in cancer	Ian	Holyer	Poster	Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 2	4/18/23	9:00 AM	Section 34	6
LB174	Diabetes-associated breast cancer is molecularly distinct and shows DNA repair deficiency	Gatikrushna	Panigrahi	Poster	Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 2	4/18/23	9:00 AM	Section 34	7
LB175	Ploidy as a predictive biomarker for gemcitabine sensitivity in triple-negative breast cancers	Vural	Tagal	Poster	Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 2	4/18/23	9:00 AM	Section 34	8

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
LB176	Interrogating the single cell immune checkpoint inhibition atlas to decipher ICI response mechanisms	Janusz	Dutkowski	Poster	Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 2	4/18/23	9:00 AM	Section 34	9
LB177	Tumor sideomics: spatial characteristics and functional deregulation in colorectal cancer	S. Stephen	Yi	Poster	Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 2	4/18/23	9:00 AM	Section 34	10
LB178	Cell free RNA for prediction of PDAC in de novo symptomatic patients presenting for EUS-FNA	Rowan	Callahan	Poster	Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 2	4/18/23	9:00 AM	Section 34	11
LB179	Automated viable circulating tumor cell (CTC) isolation enables efficient single-cell multi-omics analysis in a clinical setting	Yipeng	Wang	Poster	Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 2	4/18/23	9:00 AM	Section 34	12
LB180	SPOC, A highly multiplexed platform to study the kinetics of hundreds of biomolecular interactions: applications for early cancer detection	Rebecca	Cook	Poster	Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 2	4/18/23	9:00 AM	Section 34	13
LB181	Infer cancer cell gene dependency in multiple myeloma using causal AI in-silico patient model	Yaoyu	Wang	Poster	Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 2	4/18/23	9:00 AM	Section 34	14
LB182	Targeting arginine methylation for improved therapy in triple negative breast cancer	Nidhi	Sahni	Poster	Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 2	4/18/23	9:00 AM	Section 34	15
LB183	Network biology approach reveals multiple non-essential helper genes to target cancer cell lethality	S. Stephen	Yi	Poster	Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 2	4/18/23	9:00 AM	Section 34	16
LB187	Case report: APN401, a novel cancer therapy using Cbl-b silenced autologous PBMCs, induced stable disease in two patients with advanced solid tumors	Mario	Kuttke	Poster	Late-Breaking Research: Clinical Research 2	4/18/23	9:00 AM	Section 35	2

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
LB188	Discovery and development of fully human TACI/BCMA bispecific armored CAR for the treatment of relapsed/refractory multiple myeloma	Garima	Agrahari	Poster	Late-Breaking Research: Clinical Research 2	4/18/23	9:00 AM	Section 35	3
LB192	MTL-CEBPA in combination with pembrolizumab converts an immune desert to an inflamed TME in solid tumors resistant to checkpoint blockade	Nagy	Habib	Poster	Late-Breaking Research: Clinical Research 2	4/18/23	9:00 AM	Section 35	7
LB194	A small molecular-weight anti-lag-3 peptide inhibits colon tumor growth	Mohammed	Alahmari	Poster	Late-Breaking Research: Clinical Research 2	4/18/23	9:00 AM	Section 35	9
LB195	Immunotherapies that repolarize macrophages and CD4 T cells enhance the effect of chemotherapy in high-grade serous ovarian cancer	Samar	Elorbany	Poster	Late-Breaking Research: Clinical Research 2	4/18/23	9:00 AM	Section 35	10
LB196	NOUS-PEV, a personalized cancer immunotherapy targeting neoantigens, induces long lasting, tumor infiltrating memory T cells	Elisa	Scarselli	Poster	Late-Breaking Research: Clinical Research 2	4/18/23	9:00 AM	Section 35	11
LB197	A pooled mutant KRAS peptide vaccine activates polyfunctional T cell responses in patients with resected pancreatic cancer	Amanda	Huff	Poster	Late-Breaking Research: Clinical Research 2	4/18/23	9:00 AM	Section 35	12
LB198	A first-in-human, open-label, multicenter study of intratumoral SAR441000 (mixture of cytokine encoding mRNAs), as monotherapy and in combination with cemiplimab in patients with advanced solid tumors	Oliver	Bechter	Poster	Late-Breaking Research: Clinical Research 2	4/18/23	9:00 AM	Section 35	13
LB199	A personalized neoantigen vaccine is well tolerated and induces specific T-cell immune response in patients with resected melanoma	Daniela	Kleine-Kohlbrecher	Poster	Late-Breaking Research: Clinical Research 2	4/18/23	9:00 AM	Section 35	14
LB200	Indoximod or ibrutinib/indoximod based clinical chemo-immunotherapy drives conversion of extra-tumoral circulating stem-like precursor CD8+ T cells into clonally expanded, rejuvenated effector cells	Theodore	Johnson	Poster	Late-Breaking Research: Clinical Research 2	4/18/23	9:00 AM	Section 35	15
LB201	A novel combination of Listeria-based immunotherapy and repurposed drug combats colorectal cancer	Shreyas	Gaikwad	Poster	Late-Breaking Research: Clinical Research 2	4/18/23	9:00 AM	Section 35	16
LB202	Obesity-trained C1q+ macrophages compromise T cell anti-tumor immunity	Tao	Zhang	Poster	Late-Breaking Research: Clinical Research 2	4/18/23	9:00 AM	Section 35	17
LB203	Targeted inhibition of IRAK-4 with CA-4948 (emavusertib) sensitizes metastatic brain melanoma to anti-PD-1 immune checkpoint blockade	Christina	von Roemeling	Poster	Late-Breaking Research: Clinical Research 2	4/18/23	9:00 AM	Section 35	18
LB205	Feasibility and immunogenicity of adjuvant TG4050, a patient tailored cancer vaccine in head and neck and ovarian cancer	Kaidre	Bendjama	Poster	Late-Breaking Research: Clinical Research 2	4/18/23	9:00 AM	Section 35	20

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
LB208	A potent macrophage switching drug D-4559 reduces tumor GROWTH in a hepatocellular carcinoma mouse model	Naze	Avci	Poster	Late-Breaking Research: Immunology 2	4/18/23	9:00 AM	Section 36	1
LB209	An ADC composed of daratumumab and lenalidomide is extremely powerful in killing multiple myeloma cells	Yueh-Hsiang	Yu	Poster	Late-Breaking Research: Immunology 2	4/18/23	9:00 AM	Section 36	2
LB210	RenNano [®] mice: A heavy-chain-only antibody platform for the generation of nanobody therapeutics	Li	Hui	Poster	Late-Breaking Research: Immunology 2	4/18/23	9:00 AM	Section 36	3
LB211	Discovery of RenNano [®] -derived human heavy-chain-only antibodies that cross the blood-brain barrier	Li	Hui	Poster	Late-Breaking Research: Immunology 2	4/18/23	9:00 AM	Section 36	4
LB212	BCG022: A novel bispecific antibody-drug conjugate targeting HER3 and MET	Ellen	Zhang	Poster	Late-Breaking Research: Immunology 2	4/18/23	9:00 AM	Section 36	5
LB213	Identification of DM004, a first-in-class anti-5T4/MET bispecific antibody-drug conjugate	Qingcong	Lin	Poster	Late-Breaking Research: Immunology 2	4/18/23	9:00 AM	Section 36	6
LB214	A first-in-class bispecific antibody-drug conjugate (DM002) targeting HER3 and the juxtamembrane domain of MUC1	Qingcong	Lin	Poster	Late-Breaking Research: Immunology 2	4/18/23	9:00 AM	Section 36	7
LB215	A first-in-class anti-TROP2/EGFR bispecific antibody-drug conjugate, DM001, exhibits potent anti-tumor efficacy	Ellen	Zhang	Poster	Late-Breaking Research: Immunology 2	4/18/23	9:00 AM	Section 36	8
LB216	Discovery of BCG033, a novel anti-PTK7 x TROP2 bispecific antibody-drug conjugate with promising efficacy against triple-negative breast cancer	Ellen	Zhang	Poster	Late-Breaking Research: Immunology 2	4/18/23	9:00 AM	Section 36	9
LB217	A novel bispecific LILRB4/CD3 antibody with potent killing of monocytic acute myeloid leukemia cells	X.Charlene	Liao	Poster	Late-Breaking Research: Immunology 2	4/18/23	9:00 AM	Section 36	10
LB218	Developing a bispecific anti-ROR1 antibody drug conjugate for hematological and solid tumor treatment	Xiaobei	Zhao	Poster	Late-Breaking Research: Immunology 2	4/18/23	9:00 AM	Section 36	11
LB219	Inducing significant and efficient tumor growth inhibition vs trastuzumab deruxtecan with low drug-load topoisomerase 1 inhibitor ADC using novel peptide linkers for payload conjugation	Isabella	Attinger-Toller	Poster	Late-Breaking Research: Immunology 2	4/18/23	9:00 AM	Section 36	12
LB220	S095029: a novel clinical-stage Fc-silenced NKG2A-blocking antibody with best-in-class potential	Maria	Melander	Poster	Late-Breaking Research: Immunology 2	4/18/23	9:00 AM	Section 36	13
LB221	Novel peptide linker-based nectin-4 targeting ADC shows improved tolerability with long-lasting anti-tumor efficacy at low doses	Isabella	Attinger-Toller	Poster	Late-Breaking Research: Immunology 2	4/18/23	9:00 AM	Section 36	14
LB222	An mRNA-based cancer vaccine multi-targeting KRAS mutations inhibits tumor growth by increasing immune response in KRAS mutant LL/2 mouse model	Seung-Hyun	Shin	Poster	Late-Breaking Research: Immunology 2	4/18/23	9:00 AM	Section 36	15
LB223	Intratumoral administration of modified vaccinia Ankara expressing a tumor associated antigen and the costimulatory	Cigdem	Atay Langbein	Poster	Late-Breaking Research: Immunology 2	4/18/23	9:00 AM	Section 36	16

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
	molecules IL-12 and 4-1BBL induces potent systemic long-term immune responses against murine tumors								
LB224	STC-1010 a new therapeutic vaccine promotes tumor cell death	George	Alzeeb	Poster	Late-Breaking Research: Immunology 2	4/18/23	9:00 AM	Section 36	17
LB226	FGFR2 modulates ALK inhibition response in high-risk neuroblastoma	Perla	Pucci	Poster	Late-Breaking Research: Experimental and Molecular Therapeutics 2	4/18/23	1:30 PM	Section 34	1
LB227	Leveraging novel Dato-DXd resistance models to inform biomarker discovery and rational combinations to combat drug resistance	Anna	Przybyla	Poster	Late-Breaking Research: Experimental and Molecular Therapeutics 2	4/18/23	1:30 PM	Section 34	2
LB228	Replication stress activates the DNA damage response and contributes to lapatinib resistance in HER2-positive SK-BR-3 cells	So Hyeon	Kim	Poster	Late-Breaking Research: Experimental and Molecular Therapeutics 2	4/18/23	1:30 PM	Section 34	3
LB229	Tinengotinib, a novel fibroblast growth factor receptor (FGFR) inhibitor, is potent against resistance mutations in FGFR1/2/3	Xiaoyan	Qiang	Poster	Late-Breaking Research: Experimental and Molecular Therapeutics 2	4/18/23	1:30 PM	Section 34	4
LB230	Critical role for DAXX in triple negative breast cancer	Clodia	Osipo	Poster	Late-Breaking Research: Experimental and Molecular Therapeutics 2	4/18/23	1:30 PM	Section 34	5
LB231	Overcoming KRAS G12C inhibitor resistance with a chaperone-mediated protein degrader (CHAMP)	Ines	Pulido Endrino	Poster	Late-Breaking Research: Experimental and Molecular Therapeutics 2	4/18/23	1:30 PM	Section 34	6
LB232	Targeting MEK activity in pancreatic tumors resistant to the combination of 5FU, irinotecan, and oxaliplatin promotes response to immunotherapy	Thao	Pham	Poster	Late-Breaking Research: Experimental and Molecular Therapeutics 2	4/18/23	1:30 PM	Section 34	7
LB233	Preclinical analysis identifies predictive biomarker and potential pathways of resistance to lurbinectedin treatment in small cell lung cancer	Subhamoy	Chakraborty	Poster	Late-Breaking Research: Experimental and Molecular Therapeutics 2	4/18/23	1:30 PM	Section 34	8
LB234	Activation of the integrated stress response by the developmental HSF1 pathway inhibitor NXP800	Marissa	Powers	Poster	Late-Breaking Research: Experimental and Molecular Therapeutics 2	4/18/23	1:30 PM	Section 34	9
LB235	Mechanistic studies on VNLG-152R-mediated tumor inhibition of triple negative breast cancer	Elizabeth	Thomas	Poster	Late-Breaking Research: Experimental and Molecular Therapeutics 2	4/18/23	1:30 PM	Section 34	10
LB236	ST101, a peptide antagonist of novel I/O target CEBP β , reprograms MDSCs and promotes an immunoactive tumor microenvironment	Jim	Rotolo	Poster	Late-Breaking Research: Experimental and Molecular Therapeutics 2	4/18/23	1:30 PM	Section 34	11

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
LB237	Functional characterisation of TRACERx reveals mechanisms of NSCLC evolution	Wei-Ting	Lu	Poster	Late-Breaking Research: Experimental and Molecular Therapeutics 2	4/18/23	1:30 PM	Section 34	12
LB238	Image-based phenotypic profiling of a chemogenomic screening library identifies novel targets of known inhibitors	Kenji	Tanabe	Poster	Late-Breaking Research: Experimental and Molecular Therapeutics 2	4/18/23	1:30 PM	Section 34	13
LB239	Downregulation of spliceosomal proteins hnRNPH1 and H2 in WM266-4 melanoma cells induces immune signaling	Maab	Sultan	Poster	Late-Breaking Research: Experimental and Molecular Therapeutics 2	4/18/23	1:30 PM	Section 34	14
LB242	Characterizing the fate<tissue distribution and excretion route> of cancer vaccine lipoplex-RNA following intravenous injection of 14C-DOTMA-lipoplex-mRNA in mice	Victor	Yip	Poster	Late-Breaking Research: Experimental and Molecular Therapeutics 2	4/18/23	1:30 PM	Section 34	17
LB245	ONM-501, a dual-activating polyvalent STING agonist, enhances tumor retention and demonstrates favorable preclinical safety profile	Zirong	Chen	Poster	Late-Breaking Research: Experimental and Molecular Therapeutics 2	4/18/23	1:30 PM	Section 34	20
LB246	Enfortumab vedotin, a nectin-4-directed antibody-drug conjugate, demonstrates compelling antitumor activity in non-muscle invasive bladder cancer models which predicts minimal systemic exposure when administered by intravesical instillation in patients	Devra	Olson	Poster	Late-Breaking Research: Experimental and Molecular Therapeutics 2	4/18/23	1:30 PM	Section 34	21
LB249	A genome-scale CROP-seq screen reveals mediators of T cell signaling	Henrik	Schmidt	Poster	Late-Breaking Research: Molecular/Cellular Biology and Genetics 2	4/18/23	1:30 PM	Section 35	1
LB250	Multiplex screening of PBMCs with DNA barcoded peptide exchanged MHC trimers to identify peptide-specific paired VDJ TCRs at single cell level	Marc	Delcommenne	Poster	Late-Breaking Research: Molecular/Cellular Biology and Genetics 2	4/18/23	1:30 PM	Section 35	2
LB251	Blocking genomic instability delays acquired resistance to MAPK inhibitor therapy in melanoma	Gatien	Moriceau	Poster	Late-Breaking Research: Molecular/Cellular Biology and Genetics 2	4/18/23	1:30 PM	Section 35	3
LB252	HPV integration events are heterogenous, clonally selected and associated with spatially distinct transcriptomic profiles in aggressive HPV positive oropharyngeal squamous cell carcinoma	Wenjin	Gu	Poster	Late-Breaking Research: Molecular/Cellular Biology and Genetics 2	4/18/23	1:30 PM	Section 35	4
LB253	Long-read single-cell sequencing of liver cancer	Jian-Hua	Luo	Poster	Late-Breaking Research: Molecular/Cellular Biology and Genetics 2	4/18/23	1:30 PM	Section 35	5
LB254	Accurate detection of low frequency AML-associated mutations in vitro using Duplex Sequencing with enzymatic fragmentation	Elizabeth	Schmidt	Poster	Late-Breaking Research: Molecular/Cellular Biology and Genetics 2	4/18/23	1:30 PM	Section 35	6

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
LB255	Benchmarking NGS integration site analysis methods in support of long-term safety monitoring of gene therapy products	Jeffrey	Otto	Poster	Late-Breaking Research: Molecular/Cellular Biology and Genetics 2	4/18/23	1:30 PM	Section 35	7
LB258	Therapeutic advantage of targeting lysosome as signaling hub for metabolic conditions in malignant gliomas	Yongwei	Jing	Poster	Late-Breaking Research: Molecular/Cellular Biology and Genetics 2	4/18/23	1:30 PM	Section 35	10
LB259	Distinct microRNA signature and suppression of ZFP36L1 define ASCL1-positive lung adenocarcinoma	Naoya	Miyashita	Poster	Late-Breaking Research: Molecular/Cellular Biology and Genetics 2	4/18/23	1:30 PM	Section 35	11
LB260	Assessing the suitability of our exosomal small ncRNAs to serve as biomarkers for breast cancer & elucidating the relationship of exosomal ncRNAs and cancer cells from t-47d and hc1143 cell lines	Ken	Kobayashi	Poster	Late-Breaking Research: Molecular/Cellular Biology and Genetics 2	4/18/23	1:30 PM	Section 35	12
LB261	The Akt-IWS1 signaling axis regulates microRNA activity	Niki	Christodoulou	Poster	Late-Breaking Research: Molecular/Cellular Biology and Genetics 2	4/18/23	1:30 PM	Section 35	13
LB262	HSK38008: An oral AR-V7 degrader for metastatic castration-resistant prostate cancer	Ju	Wang	Poster	Late-Breaking Research: Molecular/Cellular Biology and Genetics 2	4/18/23	1:30 PM	Section 35	14
LB263	An in vivo unbiased screen identifies clathrin adaptor protein complex-2 as a novel tumor suppressor	Seth	Zimmerman	Poster	Late-Breaking Research: Molecular/Cellular Biology and Genetics 2	4/18/23	1:30 PM	Section 35	15
LB267	Nitric oxide suppression by secreted frizzled-related protein 2 drives retinoblastoma	Yuzuru	Shiio	Poster	Late-Breaking Research: Tumor Biology 2	4/18/23	1:30 PM	Section 36	1
LB269	Inhibition Of C-C chemokine receptor 7 extends survival rate in murine model of T-cell acute lymphoblastic leukemia	Charlotte	Vines	Poster	Late-Breaking Research: Tumor Biology 2	4/18/23	1:30 PM	Section 36	3
LB270	LINGO2-microRNA cluster controls oral cancer stemness ability and cancer progression	Wei-Min	Chang	Poster	Late-Breaking Research: Tumor Biology 2	4/18/23	1:30 PM	Section 36	4
LB272	Spatial cellular architecture predicts prognosis in glioblastoma	Yuanning	Zheng	Poster	Late-Breaking Research: Tumor Biology 2	4/18/23	1:30 PM	Section 36	6
LB273	An emerging paradigm of heterogeneous midkine expression in thyroid cancer	Dimitra	Anastasiadou	Poster	Late-Breaking Research: Tumor Biology 2	4/18/23	1:30 PM	Section 36	7
LB274	Senescent cells develop PDK4-dependent hypercatabolism and form an acidic microenvironment to drive cancer resistance	Yu	Sun	Poster	Late-Breaking Research: Tumor Biology 2	4/18/23	1:30 PM	Section 36	8
LB275	Transcriptomic reversal analysis yields cytokines and drugs mediating tumor microenvironmental reprogramming during cancer progression and therapy response	Vishaka	Gopalan	Poster	Late-Breaking Research: Tumor Biology 2	4/18/23	1:30 PM	Section 36	9

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
LB277	β 1-integrin and CD44 may both be required in modulating traction force transmission in collagen-hyaluronic acid hydrogels	Brian	Cheung	Poster	Late-Breaking Research: Tumor Biology 2	4/18/23	1:30 PM	Section 36	11
LB278	IL-12 immunotherapy prevents hepatocellular carcinoma in a murine NAFLD induced cirrhosis model	Mozhdeh	Sojoodi	Poster	Late-Breaking Research: Tumor Biology 2	4/18/23	1:30 PM	Section 36	12
LB279	Targeting microglial metabolic rewiring synergizes with immune checkpoint blockade therapy for glioblastoma	Shengtao	Zhou	Poster	Late-Breaking Research: Tumor Biology 2	4/18/23	1:30 PM	Section 36	13
LB281	HIRA suppression is a mechanism of chemotherapy resistance in ovarian cancer	Maya	Yasukawa	Poster	Late-Breaking Research: Tumor Biology 2	4/18/23	1:30 PM	Section 36	15
LB282	RUNX2 is a master transcription factor that determines the identity of cancer-associated fibroblast subtypes with abnormal activation in the tumor microenvironment	So-Young	Yeo	Poster	Late-Breaking Research: Tumor Biology 2	4/18/23	1:30 PM	Section 36	16
LB283	ARC2-001 inhibits cancer-associated fibroblast-dependent cancer stem cell populations by disrupting cancer-stroma interactions.	Keun-Woo	Lee	Poster	Late-Breaking Research: Tumor Biology 2	4/18/23	1:30 PM	Section 36	17
LB284	CLAUDIN-1 targeting antibody ALE.C04 drives single activity and restores anti-PD1 efficacy in solid tumors	Alberto	Toso	Poster	Late-Breaking Research: Tumor Biology 2	4/18/23	1:30 PM	Section 36	18
LB285	Single cell characterization of the adjacent primed tissues and metastatic microenvironment of adrenocortical carcinoma reveals profound molecular and cellular reprograms that dictate metastatic progression and disease outcome	Mohd Omar	Sikder	Poster	Late-Breaking Research: Tumor Biology 2	4/18/23	1:30 PM	Section 36	19
LB288	Biomarker analysis from AMPECT correlating response to nab-sirolimus with TSC1 and TSC2 inactivating alterations	Lee	Cranmer	Poster	Late-Breaking Research: Clinical Research 3	4/19/23	9:00 AM	Section 34	1
LB289	Longitudinal ctDNA levels and clinical outcomes of first-line (1L) tislelizumab (TIS) + chemotherapy (chemo) treatment for advanced non-small cell lung cancer (NSCLC) in the RATIONALE-304 and 307 studies	Wanyu	He	Poster	Late-Breaking Research: Clinical Research 3	4/19/23	9:00 AM	Section 34	2
LB290	Intracranial, intratumoral drug-releasing microdevices in patients with high grade gliomas may identify biomarkers of drug activity and predict tumor response to systemic chemotherapy	Oliver	Jonas	Poster	Late-Breaking Research: Clinical Research 3	4/19/23	9:00 AM	Section 34	3
LB291	Uncovering gene fusions with 3D genomics: from clinical validation to actionable insights for undiagnosable solid tumors	Anthony	Schmitt	Poster	Late-Breaking Research: Clinical Research 3	4/19/23	9:00 AM	Section 34	4
LB292	GCC2 on small extracellular vesicles for the early diagnosis of lung adenocarcinoma: A multicenter trial	Byeong Hyeon	Choi	Poster	Late-Breaking Research: Clinical Research 3	4/19/23	9:00 AM	Section 34	5
LB293	The evolution of MRD assays: Moving beyond the tumor-Informed bespoke NGS panel	Paul	Labrousse	Poster	Late-Breaking Research: Clinical Research 3	4/19/23	9:00 AM	Section 34	6
LB294	Baseline and on-treatment plasma-based genomics as a predictor of outcome in SAVANNAH: Savolitinib + osimertinib in EGFRm MET overexpressed/amplified NSCLC post-osimertinib	Ryan	Hartmaier	Poster	Late-Breaking Research: Clinical Research 3	4/19/23	9:00 AM	Section 34	7

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
LB296	Clinical validation of a liquid biopsy microRNA assay for diagnosis and risk stratification of invasive cutaneous melanoma	Ryan	Van Laar	Poster	Late-Breaking Research: Clinical Research 3	4/19/23	9:00 AM	Section 34	9
LB297	Analytical validation of a tissue-free, multi-cancer, post-diagnosis cancer research test that uses cell-free DNA methylation profiling	Mohini	Desai	Poster	Late-Breaking Research: Clinical Research 3	4/19/23	9:00 AM	Section 34	10
LB298	Molecular phenotype classification of metastatic prostate cancer by cell-free DNA methylation analysis	Mohamed	Adil	Poster	Late-Breaking Research: Clinical Research 3	4/19/23	9:00 AM	Section 34	11
LB299	Identification of key regulators for nuclear protein export inhibitor and chemotherapy combination in pancreatic cancer using spatial genomics approach	Md. Hafiz	Uddin	Poster	Late-Breaking Research: Clinical Research 3	4/19/23	9:00 AM	Section 34	12
LB301	Molecular pharmacology and broad synergy of the novel ATR inhibitor M1774 with DNA damaging anticancer agents	Ukhyun	Jo	Poster	Late-Breaking Research: Clinical Research 3	4/19/23	9:00 AM	Section 34	14
LB302	Radiotherapy exposure and baseline gut microbiota predict clinical outcomes of fruquintinib plus sintilimab in microsatellite-stable metastatic colorectal cancer	Min	Jin	Poster	Late-Breaking Research: Clinical Research 3	4/19/23	9:00 AM	Section 34	15
LB303	Tumor microenvironment modulation by SERPINE1 increases radioimmunotherapy in murine model of gastric cancer	Javeria	Zaheer	Poster	Late-Breaking Research: Clinical Research 3	4/19/23	9:00 AM	Section 34	16
LB304	Mechanisms of cell death escape in glioblastoma	Mike	Westhoff	Poster	Late-Breaking Research: Clinical Research 3	4/19/23	9:00 AM	Section 34	17
LB311	Increased potency of CD8-targeted fusosomes enhances CAR gene delivery to resting primary T cells	Jesse	Green	Poster	Late-Breaking Research: Experimental and Molecular Therapeutics 3	4/19/23	9:00 AM	Section 35	2
LB313	EGFRVIII-targeted alpha therapy shows significant therapeutic efficacy as both a single-agent and in combination with standard of care against preclinical GBM models	Julie	Metcalf	Poster	Late-Breaking Research: Experimental and Molecular Therapeutics 3	4/19/23	9:00 AM	Section 35	4
LB314	Epigenetic regulator Menin-MLL1 maintains cancer stem cells and promotes neuroblastoma growth	Saurabh	Agarwal	Poster	Late-Breaking Research: Experimental and Molecular Therapeutics 3	4/19/23	9:00 AM	Section 35	5
LB315	Inhibition of FGFR4 with futibatinib combined with inhibition of IGF1R, Src family kinases, or AKT is synergistic against rhabdomyosarcoma	Jerry	Wu	Poster	Late-Breaking Research: Experimental and Molecular Therapeutics 3	4/19/23	9:00 AM	Section 35	6
LB316	A next-generation KRASG12C inhibitor ABSK071 demonstrated broad synergy with other therapeutic agents in KRASG12C mutated cancer models	Haiyan	Ying	Poster	Late-Breaking Research: Experimental and Molecular Therapeutics 3	4/19/23	9:00 AM	Section 35	7
LB317	Discovery and characterization of a next-generation FGFR inhibitor overcoming FGFR resistant mutations	Haiyan	Ying	Poster	Late-Breaking Research: Experimental and Molecular Therapeutics 3	4/19/23	9:00 AM	Section 35	8

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
LB318	SB-4826, a first-in-class oral, covalent inhibitor of SUMO E1 that induces IFN signaling and inhibits tumor growth as monotherapy and in combination with immune checkpoint blockade	Jude	Canon	Poster	Late-Breaking Research: Experimental and Molecular Therapeutics 3	4/19/23	9:00 AM	Section 35	9
LB319	IAG933, a selective and orally efficacious YAP1/WWTR1(TAZ)-panTEAD protein-protein interaction inhibitor with pre-clinical activity in monotherapy and combinations	Tobias	Schmelzle	Poster	Late-Breaking Research: Experimental and Molecular Therapeutics 3	4/19/23	9:00 AM	Section 35	10
LB320	Discovery and characterization of QTX3034, a potent, selective, and orally bioavailable allosteric KRAS inhibitor	Yang	Zhang	Poster	Late-Breaking Research: Experimental and Molecular Therapeutics 3	4/19/23	9:00 AM	Section 35	11
LB321	Discovery and characterization of QTX3046, a potent, selective, and orally bioavailable non-covalent KRASG12D inhibitor	Elizabeth	Vo	Poster	Late-Breaking Research: Experimental and Molecular Therapeutics 3	4/19/23	9:00 AM	Section 35	12
LB322	Antitumor activity of 1st-in-class pan-RAS inhibitor ADT-1004 in mouse models of pancreatic ductal adenocarcinoma	Yulia	Maxuitenko	Poster	Late-Breaking Research: Experimental and Molecular Therapeutics 3	4/19/23	9:00 AM	Section 35	13
LB323	Inhibition of ENPP1 using small molecule, SR-8541A, enhances the effect of checkpoint inhibition in cancer models	Alexis	Weston	Poster	Late-Breaking Research: Experimental and Molecular Therapeutics 3	4/19/23	9:00 AM	Section 35	14
LB324	BB3008, a potent and selective small molecular HPK1 inhibitor effective in multiple syngeneic tumor models	Xingmin	Zhang	Poster	Late-Breaking Research: Experimental and Molecular Therapeutics 3	4/19/23	9:00 AM	Section 35	15
LB326	Combined inhibition of BRD4 and FAK1 as a novel therapeutic strategy for neurofibromatosis type 2 related schwannomas	Maria	Gonzalez	Poster	Late-Breaking Research: Experimental and Molecular Therapeutics 3	4/19/23	9:00 AM	Section 35	17
LB327	Discovery and characterization of ABSK112, a next-generation and potential best-in-class EGFR Exon20 mutant inhibitor with superior selectivity and brain penetration ability	Mei	Ning	Poster	Late-Breaking Research: Experimental and Molecular Therapeutics 3	4/19/23	9:00 AM	Section 35	18
LB328	Discovery & characterization of a next-generation FGFR4 inhibitor overcoming resistant mutations	Haiyan	Ying	Poster	Late-Breaking Research: Experimental and Molecular Therapeutics 3	4/19/23	9:00 AM	Section 35	19
LB329	A potent and selective small molecule inhibitor of CSF-1R ABSK021 demonstrates strong efficacy in preclinical models of osteosarcoma	Nannan	Zhang	Poster	Late-Breaking Research: Experimental and Molecular Therapeutics 3	4/19/23	9:00 AM	Section 35	20
LB330	FHND5071: a selective RET inhibitor with unique pharmacokinetic profile	Yongqiang	Zhu	Poster	Late-Breaking Research: Experimental and Molecular Therapeutics 3	4/19/23	9:00 AM	Section 35	21

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
LB333	Cytokine affinity tuning using the AlphaSeq platform to generate targeted immuno-oncology therapeutics	Ryan	Swanson	Poster	Late-Breaking Research: Immunology 3	4/19/23	9:00 AM	Section 36	1
LB335	Establishment of the effective dose of the STAT3 inhibitor WP1066 used in combination with STING activation for reprogramming the preclinical glioma microenvironment	Shashwat	Tripathi	Poster	Late-Breaking Research: Immunology 3	4/19/23	9:00 AM	Section 36	3
LB336	pH-sensitive polymeric micelles loading IL-12 profoundly inflame the tumor microenvironment to eradicate cold tumors	Horacio	Cabral	Poster	Late-Breaking Research: Immunology 3	4/19/23	9:00 AM	Section 36	4
LB337	Inhibition of the E3 ligase CBL-B enhances the effector function and proliferation of natural killer cells	Yilin	Qi	Poster	Late-Breaking Research: Immunology 3	4/19/23	9:00 AM	Section 36	5
LB338	A novel class of T cell-activators targeting germline encoded TCR β chains promotes antitumor activity in PD1-refractory models through expansion of a clonally enriched effector memory T cell subset	Jacques	Moisan	Poster	Late-Breaking Research: Immunology 3	4/19/23	9:00 AM	Section 36	6
LB339	PARP inhibition reprograms CD8 T cells, enhancing their function and generation of prolonged memory, leading to greater anti-tumor immune response	Wael	Traboulsi	Poster	Late-Breaking Research: Immunology 3	4/19/23	9:00 AM	Section 36	7
LB340	Spur cell-delivered peptide antigen generates T cell immunity to eradicate mouse KRASG12D spontaneous lung cancer	Ke	Zen	Poster	Late-Breaking Research: Immunology 3	4/19/23	9:00 AM	Section 36	8
LB341	Single-cell CRISPR screens in primary human T cells identify regulators of Th2 cell skewing	Henrik	Schmidt	Poster	Late-Breaking Research: Immunology 3	4/19/23	9:00 AM	Section 36	9
LB343	Antitumor and metabolomic evaluation of immune checkpoint inhibition in diet-induced obese mice	Michael	Boice	Poster	Late-Breaking Research: Immunology 3	4/19/23	9:00 AM	Section 36	11
LB344	Complement-mediated signaling during cross-presentation of tumor antigen augments T cell responses	Caryn	Bird	Poster	Late-Breaking Research: Immunology 3	4/19/23	9:00 AM	Section 36	12
LB346	Mapping of shared tumor antigen reactivity with nanoparticle encapsulated mRNA in prostate cancer patients	Elena	Montauti	Poster	Late-Breaking Research: Immunology 3	4/19/23	9:00 AM	Section 36	14
LB347	A lung-mimicking synthetic metastatic niche reveals N1 neutrophils drive breast cancer metastatic dormancy in the lungs	Jing	Wang	Poster	Late-Breaking Research: Immunology 3	4/19/23	9:00 AM	Section 36	15
LB348	A controlled high fiber dietary intervention alters metabolome and gut microbiome in melanoma survivors	Yan	Jiang	Poster	Late-Breaking Research: Immunology 3	4/19/23	9:00 AM	Section 36	16
LB349	The use of PBMC humanized mice to test the efficacy and safety of antibody and cell-based cancer immunotherapeutics	Destanie	Rose	Poster	Late-Breaking Research: Immunology 3	4/19/23	9:00 AM	Section 36	17
LB350	Novel mouse model to study HPV associated pathologies	Xue	Li	Poster	Late-Breaking Research: Immunology 3	4/19/23	9:00 AM	Section 36	18
LB351	A novel mouse model to interrogate the functional relationship between protein synthesis and antigen presentation in cancer	Alex	Jaeger	Poster	Late-Breaking Research: Immunology 3	4/19/23	9:00 AM	Section 36	19

Pres Num	Abstract Title	Pres First	Pres Last	Pres Type	Session Title	Date	Time	Room/Section	Board Num
LB352	KRAS inhibition enhances immunogenicity of KRASG12C colorectal cancer	Jun	Tian	Poster	Late-Breaking Research: Immunology 3	4/19/23	9:00 AM	Section 36	20
LB353	The switch from cap-dependent to cap-independent translation reshapes the immunopeptidome of lung cancer	Anika	Ali	Poster	Late-Breaking Research: Immunology 3	4/19/23	9:00 AM	Section 36	21
LB354	9p arm loss is an important predictor of immune evasion in several human cancers	Joy	Bianchi	Poster	Late-Breaking Research: Immunology 3	4/19/23	9:00 AM	Section 36	22
LB357	CRISPR-Cas9 targeting of somatic mutations selectively kills cancer cells	Kirsten	Bowland	Oral	Minisymposium: Late-breaking Research	4/17/23	2:30 PM	Room W307	
LB358	Efficacy of a functional precision medicine approach in relapsed/refractory pediatric cancer patients: Results from a prospective clinical study	Diana	Azzam	Oral	Minisymposium: Late-breaking Research	4/17/23	2:30 PM	Room W307	
LB360	Type-1 interferon sensing is critical for CD8+ resident memory (TRM) cell generation in tumor-draining lymph nodes	Nikhil	Khatwani	Oral	Minisymposium: Late-breaking Research	4/17/23	2:30 PM	Room W307	
LB361	Li-Fraumeni syndrome-associated dimer-forming mutant p53 promotes transactivation-independent mitochondrial cell death	Joshua	Choe	Oral	Minisymposium: Late-breaking Research	4/17/23	2:30 PM	Room W307	
LB362	Epigenome-wide DNA methylation alterations precede diagnosis since birth and affect prognosis of pediatric B-cell acute lymphoblastic leukemia	Zdenko	Herceg	Oral	Minisymposium: Late-breaking Research	4/17/23	2:30 PM	Room W307	
LB363	Patient-derived iPSCs faithfully represent the genetic diversity and cellular architecture of human acute myeloid leukemia	Eirini	Papapetrou	Oral	Minisymposium: Late-breaking Research	4/17/23	2:30 PM	Room W307	